Class / Patent application number | Description | Number of patent applications / Date published |
435700100 | Using tissue cell culture to make a protein or polypeptide | 88 |
20080199879 | Method of Assaying Alzheimer's Disease and Diagnostic Reagent - The present invention is intended to devise a process of measuring β-amyloid in a biological sample such as blood and to apply the process to diagnosis of Alzheimer's disease. | 08-21-2008 |
20080199880 | SPIN ARRAY METHOD - An improvement in heterogeneous immunoassays to significantly reduce assay time, from as much as 50% up to 90% of what used to be typical assay times. The improvement involves rotating the captured substrate during incubation times for antigen capture and during incubation times for sample labeling. | 08-21-2008 |
20080199881 | MN Gene and Protein - Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular contacts. The MN protein binding site is a therapeutic target that can be blocked by organic or inorganic molecules, preferably organic molecules, more preferably proteins/polypeptides that specifically bind to that site. Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Vectors are provided that encode the variable domains of MN-specific antibodies and a flexible linker polypeptide separating those domains. Further vectors are disclosed that encode a cytotoxic protein/polypeptide operatively linked to the MN gene promoter, and which vectors preferably further encode a cytokine. The MN gene promoter is characterized, and the binding site for a repressor of MN transcription is disclosed. | 08-21-2008 |
20080199882 | METHOD FOR DETECTION OF BIOMARKERS FOR EXPOSURE TO STACHYBOTRYS - A method of determining exposure of an individual to a macrocyclic trichothecene comprises isolating a sample of at least a portion of a naturally occurring protein from an individual, and detecting a reaction of the sample with a macrocyclic trichothecene. The macrocyclic trichothecene may be a product of | 08-21-2008 |
20080206780 | Antibody Libraries - The invention relates to a composition comprising a plurality of antibody fragments, each comprising a framework region having a murine VH14 heavy chain and a murine VK2 light chain, or homologues thereof, each antibody fragment further comprising at least one different CDR. | 08-28-2008 |
20080206781 | Assay and kit for drug efflux transporter activity - The present invention relates to high-throughput cell-based assays for real-time monitoring of multi-resistant drug protein activity. The present invention is an improvement over existing assays in that in addition to a fluorescent drug efflux probe as an indicator of MDR protein activity, the instant assays provide an o-tolidine-based dye for quenching extracellular fluorescence of the probe. | 08-28-2008 |
20080206782 | Methods for Determining the Bivalency of Protein and Antibody Therapeutics - The invention provides methods and kits for detecting or quantitating intact bivalent antibody molecules in a sample and distinguishing those molecules from monovalent fragments. | 08-28-2008 |
20080213793 | ANTIBODIES THAT BIND RECEPTOR PROTEIN DESIGNATED 2F1 - 2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation. | 09-04-2008 |
20080213794 | SCREENING FOR GESTATIONAL DISORDERS - The invention relates to methods and compositions for identifying subjects having, or predisposed to having, gestational diabetes, preeclampsia, and gestational hypertension. The methods are applicable to urine and/or blood samples and can be conducted prior to the third trimester of pregnancy. | 09-04-2008 |
20080213795 | DNA sequences encoding peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes - The invention discloses isolated DNA sequences encoded by polypeptides characterized by the presence in their structure of one or more sequences bearing all or part of the one or more T epitopes, and possibly other epitopes, particularly B epitopes, characteristic of proteins resulting from the infectious activity of | 09-04-2008 |
20080213796 | GFP-SNAP25 Fluorescence Release Assay for Botulinum Toxin Protease Activity - The present invention provides a nucleic acid molecule which contains a nucleotide sequence encoding a SNAP-25 substrate which includes (i) a green fluorescent protein; (ii) a first partner of an affinity couple; and (iii) a portion of SNAP-25 that includes a BoNT/A, BoNT/C1 or BoNT/E recognition sequence containing a cleavage site, where the cleavage site intervenes between the green fluorescent protein and the first partner of the affinity couple. Further provided herein is a nucleic acid molecule which contains a nucleotide sequence encoding a tagged toxin substrate which includes (i) a fluorescent protein; (ii) a first partner of an affinity couple; and (iii) a clostridial toxin recognition sequence containing a cleavage site, where the cleavage site intervenes between the fluorescent protein and the first partner of the affinity couple. | 09-04-2008 |
20080213797 | IMMUNOASSAYS EXHIBITING A REDUCTION IN PROZONE PHENOMENA - The present invention relates to immunoassays for detecting or quantifying at least one analyte of interest in a test sample. Specifically, the immunoassays of the present invention exhibit a reduction in prozone phenomena. | 09-04-2008 |
20080220440 | Waveguide sensors optimized for discrimination against non-specific binding - A system for interferometrically detecting the present of bound material using a wave propagating waveguide and the influence on propagation time of bound material in the proximity of the waveguide. The waveguide layer thickness and the radiation wavelength λ are selected so that the effects on phase difference between the two radiations applied in the beam are minimal in the region directly adjacent the surface of the waveguide, so as to unmask the influence of the more distant bound materials. | 09-11-2008 |
20080220441 | Advanced drug development and manufacturing - X-ray fluorescence (XRF) spectrometry has been used for detecting binding events and measuring binding selectivities between chemicals and receptors. XRF may also be used for estimating the therapeutic index of a chemical, for estimating the binding selectivity of a chemical versus chemical analogs, for measuring post-translational modifications of proteins, and for drug manufacturing. | 09-11-2008 |
20080220442 | Difference detection methods using isoelectric focusing chips - The present invention provides an isoelectric focusing difference detection method, as well as an isoelectric focusing chip and device. The method entails labeling proteins in the first sample with a first label, and labeling proteins in the second sample with a second, different label, wherein each label has ionic and pH characteristics whereby, upon isoelectric focusing, relative migration of a protein labeled with the first label is substantially the same as relative migration of the same protein labeled with the second label. The samples are subjected to isoelectric focusing to produce a pattern of separated proteins from both samples, which is then detected to compare the protein composition of the samples. The method can be carried with a novel isoelectric focusing chip including a substrate comprising a channel for carrying out isolectric focusing. The substrate includes a non-fluorescent or low-fluorescence material in a detection region of the channel, facilitating direct detection of the pattern of separated proteins, which makes the chip particularly useful for clinical applications, including use disease diagnosis and monitoring. | 09-11-2008 |
20080220443 | Methods of Screening for Modulators of h2-Calponin Activity - The invention provides methods for identifying modulators of mammalian, e.g., human, h2-calponin, the calponin isoform of relatively neutral pI. H2-calponin exerts an effect on the migration and proliferation of a variety of muscle (smooth muscle) and non-muscle cells and is an actin filament-associated regulatory protein influencing the structure of the actin cytoskeleton. Modulators of the activity levels of this protein are useful in preventing, ameliorating, or treating a variety of diseases, disorders or conditions characterized by aberrant cell migration and/or cell proliferation. | 09-11-2008 |
20080227110 | Human Genes, Sequences and Expression Products - Human polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for therapeutic purposes. Antagonists against such polypeptides and their use as a therapeutic are also disclosed. Also disclosed are diagnostic methods for detecting disease which utilize the sequences and polypeptides. | 09-18-2008 |
20080227111 | REAGENT KIT AND METHOD FOR MEASURING HCV ANTIBODY - A reagent kit for measuring an HCV antibody is described herein. This reagent comprises a first and second reagents. The first reagent comprises an HCV synthetic peptide antigen which has a solid phase binding site. The second reagent comprises a solid phase. On the solid phase is immobilized a binding substance and/or an HCV recombinant HCV antigen. The binding substance can bind to the solid phase binding site. | 09-18-2008 |
20080227112 | Global polyclonal antibodies, process for depleting commonly shared proteins by same, devices using same - A method for removing abundance proteins from a biological sample comprises passing the biological sample through a support. The support is coated with an avian polyclonal antibody. The avian polyclonal antibody is capable of binding to substantially all proteins in the biological sample with concentrations higher than a predetermined value. The method for removing abundance proteins from a biological sample further comprises collecting the pass-through fractions of the biological sample. | 09-18-2008 |
20080227113 | Methods, Antibodies and Kits for Detecting Cerebrospinal Fluid in a Sample - The present disclosure relates to detection of the presence or absence of cerebrospinal fluid (CSF) in a sample, in particular to the analysis of the CSF protein lipocalin-type prostaglandin D2 synthase (L-PGDS). The present disclosure provides assays for the analysis of L-PGDS indicating the presence or absence of CSF in a sample. | 09-18-2008 |
20080233594 | Method For Detecting An At Least Bivalent Analyte Using Two Affinity Reactants - A method for the determination of an analyte which is a) present in a liquid sample 1 suspected of containing the analyte, and b) at least bivalent with respect to simultaneous affinity binding of at least two binding structures BSs. The method comprises formation of an affinity complex that comprises the analyte and an affinity reactant 1 that is immobilized to a solid phase. The method comprises the steps of: (i) providing a microfluidic flow path that comprises a reaction cavity containing a solid phase to which affinity reactant 1 is immobilized, (ii) providing sample 1 upstream of the cavity and flowing it through the cavity for the formation of the affinity complex under flow conditions, (iii) measuring the amount of complex formed in the solid phase by a) incorporating an analytically detectable and soluble affinity reactant 2 that comprises a binding structure BS into the complex subsequent to step (ii), and b) measuring the amount of affinity reactant 2 incorporated. | 09-25-2008 |
20080233595 | METHOD FOR DIAGNOSING INTERTILITY - The invention relates to methods for diagnosing conditions characterized by altered expression of a pregnancy related serine protease (PRSP) protein in a mammal. Such conditions include infertility caused by an inability to achieve or sustain embryo implantation, an inability to sustain a pregnancy, early abortion, insufficient placentation, pre-eclampsia, or intrauterine growth restriction. The methods include detecting expression of PRSP, such as SEQ ID NP33. Detection may be accomplished using a PRSP-specific antibody. | 09-25-2008 |
20080233596 | CHIMERIC HUMAN T1R1 TASTE RECEPTOR POLYPEPTIDES AND COMPOSITIONS CONTAINING SAME - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed. | 09-25-2008 |
20080241850 | Method of Protein Measurement - The present invention relates to a technique of measuring a protein based on a degree of coloring in a liquid sample mixed with a protein measurement indicator. In the present invention, information reflecting creatinine concentration in the liquid sample is obtained, and then an influence quantity caused by creatinine to the protein concentration measurement is eliminated based on the information. | 10-02-2008 |
20080241851 | Cartilage intermediate layer protein 2 C1 and its use to differentiate osteoarthritis from rheumatoid arthritis and non-disease conditions - A method for differentiation of osteoarthritis from rheumatoid arthritis and non-disease conditions in a sample, comprising measuring in the sample the concentration of human cartilage intermediate layer protein 2(CILP-2) in body fluids and more specifically, measuring in the sample the concentration of the N-terminal part of CILP-2 (2C1) or fragments thereof. | 10-02-2008 |
20080241852 | Compositions, kits, and methods for identification, assessment, prevention, and therapy of endometriosis - The invention relates to newly discovered marker polypeptides associated with endometriosis. Compositions, kits, and methods for detecting, characterizing, preventing, and treating endometriosis are provided. | 10-02-2008 |
20080241853 | MICROTITER SPIN ARRAY - An improvement in heterogeneous immunoassays in microtiter plates to significantly reduce assay time, from as much as 50% up to 90% of what used to be typical assay times. The improvement involves the rotation of the liquid in a microtiter plate and during incubation times for antigen capture and during incubation times for sample labeling. This is accomplished through the insertion of fluted cylindrical stirrers in each well, and the use of a conventional, commercially available, microtiter vortexer. | 10-02-2008 |
20080241854 | KITS AND METHODS FOR EVALUATING HAIR - The invention relates to kits and methods for analyzing hair, particularly for determining the amount of damage to hair, including placing hair into a solution containing at least one metal ion so that an amount of the metal ion is attached to the hair, removing the hair from the solution, determining the amount of metal ion attached to the hair, and determining the amount of damage to the hair based upon the amount of metal ion attached to the hair. | 10-02-2008 |
20080241855 | Method for simultaneously detecting an antigen of, and an antibody against, an infectious microorganism - The invention relates to a method for detecting, in vitro, an infection with a microorganism, such as the hepatitis C virus, in a biological sample, by simultaneously detecting an antigen of this microorganism and the antibodies against this same antigen, and also to the reagents and kits implementing this method. | 10-02-2008 |
20080241856 | Glycoproteomic probes for fluorescent imaging of fucosylated glycans in vivo - The disclosure provides a method of labeling of cellular glycans bearing azide groups via a fluorescent labeling technique based on Cu(I)-catalyzed [3+2]cycloaddition (click activation) of a probe comprising an alkynyl group. The method entails generating a fluorescent probe from a nonfluorescent precursor, 4-ethynyl-N-ethyl-1,8-naphthalimide, by Cu(I)-catalyzed [3+2]cycloaddition of the alkyne group of the probe with an azido-modified sugar. The disclosure further provides a method of incorporating an azido-containing fucose analog into glycoconjugates via the fucose salvage pathway. The disclosure provides a method of fluorescent visualization of fucosylated cells by flow cytometry when cells treated with 6-azidofucose are labeled with the click-activated fluorogenic probe or biotinylated alkyne. A method of visualizing the intracellular localization of fucosylated glycoconjugates by fluorescence microscopy is also disclosed. | 10-02-2008 |
20080241857 | Netrin receptors - The invention provides methods and compositions relating to vertebrate UNC-5 proteins which function as receptor proteins for netrins, a family of cell guidance proteins. The proteins may be produced recombinantly from transformed host cells from the disclosed vertebrate UNC-5 encoding nucleic acid or purified from human cells. The invention provides specific hybridization probes and primers capable of specifically hybridizing with the disclosed vertebrate unc-5 gene, vertebrate UNC-5-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry. | 10-02-2008 |
20080248485 | Radiolabeled 3-[3- (Benzoyl-Amido) Benzyloxy] Aspartic Acid Derivative and Method of Producing the Same - The present invention provides a radiolabeled ligand which is highly selective and potent for glutamate transporters and is usable in specifically detecting the glutamate transporter. | 10-09-2008 |
20080248486 | Type Pept1 Protein Assay - The present invention relates to a type PepT1 protein assay and in particular a process for identifying a substrate and/or a modulator of the PepT1 protein. | 10-09-2008 |
20080248487 | MODULATION OF PROTEIN FUNCTIONALITIES - New methods for the rational identification of molecules capable of interacting with specific naturally occurring proteins are provided, in order to yield new pharmacologically important compounds and treatment modalities. Broadly, the method comprises the steps of identifying a switch control ligand forming a part of a particular protein of interest, and also identifying a complemental switch control pocket forming a part of the protein and which interacts with said switch control ligand. The ligand interacts in vivo with the pocket to regulate the conformation and biological activity of the protein such that the protein assumes a first conformation and a first biological activity upon the ligand-pocket interaction, and assumes a second, different conformation and biological activity in the absence of the ligand-pocket interaction. Next, respective samples of said protein in the first and second conformations are provided, and these are screened against one or more candidate molecules by contacting the molecules and the samples. Thereupon, small molecules which bind with the protein at the region of the pocket maybe identified. Novel protein-modulator adducts and methods of altering protein activity are also provided. | 10-09-2008 |
20080248488 | Platelet-Derived Microparticles as a Novel Diagnosis Maker for a Cardiovascular Disease - The present invention relates to a diagnosis maker for a cardiovascular disease comprising platelet-derived microparticles. The present invention also relates to a method for diagnosing a cardiovascular disease in a subject with symptoms of cardiovascular disease or suspected of having cardiovascular disease, wherein said method comprises: (a) obtaining a sample from said subject; (b) reacting an antibody to platelet-derived microparticles or a fragment thereof with a biological sample; (c) detecting a presence or an absence of the platelet-derived microparticles or a fragment thereof in said sample; and (d) diagnosing cardiovascular disease in said subject having said symptoms when said platelet-derived microparticles or a fragment thereof are detected in said sample. | 10-09-2008 |
20080248489 | METHODS AND COMPOSITIONS FOR DIRECTED MICROWAVE CHEMISTRY - The present invention concerns a novel means by which specific chosen reactions can be accelerated through the use of a new type of artificial enzyme. The invention allows specific reactions to occur at an accelerated rate, even in the presence of other non-chosen molecules, which may be very similar in structure to the chosen reactant. The reactions may be stoichiometric or catalytic. | 10-09-2008 |
20080248490 | Reagents for the detection of protein phosphorylation in Leukemia signaling pathways - The invention discloses nearly 288 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Adaptor/Scaffold proteins, Cytoskeletal proteins, Cellular Metabolism enzymes, G Protein/GTPase Activating/Guanine Nucleotide Exchange Factor proteins, Immunoglobulin Superfamily proteins, Inhibitor proteins, Lipid Kinases, Nuclear DNA Repair/RNA Binding/Transcription proteins, Serine/Threonine Protein Kinases, Tyrosine Kinases, Protein Phosphatases, and Translation/Transporter proteins. | 10-09-2008 |
20080248491 | BIOMARKER FRAGMENTS FOR THE DETECTION OF HUMAN BNP - The present invention relates among other things to a composition comprising at least two (2) human BNP fragments, wherein each of the human BNP fragments of the composition are cross-linked to at least one of the other human BNP fragments of the composition. | 10-09-2008 |
20080254479 | Methods and Kits For Predicting Risk For Preterm Labor - The invention is directed to kits and methods that allow one to predict the risk for preterm labor in a pregnant woman. The inventors have discovered that various extracellular matrix components can be detected in cervical secretions. The quantification of certain extracellular matrix proteins found within cervical secretions can be used as a diagnostic for the biomechanical state of the cervix, which indicates whether preterm labor is likely. Some extracellular matrix components that can be found in cervical secretions include hyaluronic acid, thrombospondins and matrix metalloproteinases. | 10-16-2008 |
20080254480 | MICROCYTOXICITY ASSAY BY PRE-LABELING TARGET CELLS - The standard or original microcytotoxicity assay (OMCA) has significant advantages over other cytotoxicity assays, since it is able to detect both cell necrosis and apoptosis and it is simpler, safer, more practical, and more economical. OMCA has serious weaknesses, however, such as low accuracy, low selectivity, and low sensitivity. These drawbacks are ameliorated or eliminated by pre-labeling of target cell nuclei, for instance, with 5-bromo2′-deoxyuridine. This improved microcytotoxicity assay (IMCA) is readily adapted to a wide range of applications, such as screening of cytotoxicity drug candidates, selecting an anticancer cytotoxic therapy, detecting abnormalities including reduced tumor cell killing ability of NK cells in cancer patients, predicting outcome of cytokine therapy and immunotherapy, determining effectiveness of cytokine therapy and immunotherapy in follow up studies following treatment, determining effectiveness of anticancer cytotoxic therapy during and following therapy and ascertaining cytotoxic T cell activity during anticancer vaccination therapy. | 10-16-2008 |
20080254481 | METHODS AND KITS FOR DETECTING PROSTATE CANCER BIOMARKERS - Provided herein are novel autoantibody biomarkers, and panels for detecting autoantibody biomarkers for prostate cancer, and methods and kits for detecting these biomarkers in the serum of individuals suspected of having prostate cancer. | 10-16-2008 |
20080254482 | AUTOIMMUNE DISEASE BIOMARKERS - Provided herein are novel panels of biomarkers for the diagnosis of autoimmune diseases, and methods and kits for detecting these biomarkers in samples of individuals suspected of having an autoimmune disease. Also provided are methods of monitoring the progression of an autoimmune disease and methods of monitoring the efficacy and side effects of a treatment for an autoimmune disease. | 10-16-2008 |
20080254483 | In Vitro Method for Diagnosing and Monitoring Renal Cell Carcinoma (Rcc) Using Mmp-7 as Humoral Biomarker for Rcc - The present invention relates to the use of matrix metalloproteinase 7 (MMP-7) and/or its precursors and fragments with MMP-7 immunoreactivity, or of circulating anti-MMP-7 antibodies, as humoral biomarkers in diagnostic in vitro methods for the detection, early detection, monitoring and/or prognosis of renal cell carcinoma (RCC) in human patients. | 10-16-2008 |
20080254484 | Preparation of Deallergenized Proteins and Permuteins - Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding. | 10-16-2008 |
20080261232 | Use of Precursors of Enkephalins and/or Their Fragments in Medical Diagnostics - The invention relates to the diagnosis of disease based on the presence of biochemical components in human or animal body fluids, tissues and/or biomaterials. More specifically the invention relates to the use of precursors of enkephalins and/or its fragments isolated from body fluids, tissues or other biomaterials as a marker peptide for detection of a number of diseases/disorders including diseases/disorders of the central nervous system, neurodegenerative diseases, Parkinson's disease, Alzheimer's disease, Huntington's disease, ischemia including myocardiac ishcemica, schizophrenia, disease/disorders of the immune system, diseases/conditions of pain, chronic pain, migraine, tension type headache, tumor diseases/cancer including lymphoblastic leukaemia, malignant brain tumors, adenomas, in particular human pituitary adenomas, disorders of the blood brain barrier, multiple sclerosis, inflammation, chronic arthritis, infectious diseases, bacterial and viral infections, in particular infections of Gram-positive bacteria, borna diseases virus infections, peritonitis, intoxication, AIDS, stress, trauma comprising head trauma, infarction, in particular cerebral infarction, heart and cardiovascular diseases including coronary heart disease, bone and skin disorders, malaria chronic/obstructive pulmonary disease and cerebral damage. The invention further provides antibodies that bind to proenkephalin and its fragments. In accordance with the invention, a kit useful for the above mentioned diagnosis is also provided. | 10-23-2008 |
20080261233 | Assessment of Biological Activity of Hepatocyte Growth Factor (Hgf) - In the present invention the methods for recognition of biologically active hepatocyte growth factor efficient for using in therapeutic components are presented. The biological activity can be determined using: i) an in vitro model of restitution of damaged cells, and/or ii) affinity measurements or epitope mapping using SPR, with the C-met receptor, anti-HGF antibodies or polysaccharides such as dextran, and/or iii) an animal model of hair growth rates. By these methods the activity of HGF in body secretions can be evaluated as well. | 10-23-2008 |
20080261234 | Peptides and their use in assays for cardiovascular disease - A peptide having affinity for oxidised low density lipoprotein, in cyclised or multimeric form is useful in an enzyme immunosolvent assay, to detect oxLDL which is a marker of coronary heart disease. | 10-23-2008 |
20080261235 | Novel Green and Orange Fluorescent Labels and Their Uses - The present invention provides novel fluorescent compounds and covalent attachment chemistries which facilitate the use of these compounds as labels for ultrasensitive and quantitative fluorescent detection of low levels of biomolecules. In a preferred embodiment, the fluorescent labels of this invention are novel derivatives of the hydroxy-pyrene trisulpbonic and disulphonic acids which may be used in any assay in which radioisotopes, colored dyes or other fluorescent molecules are currently used. Thus, for example, any assay using labeled antibodies, proteins, oligonucleotides or lipids, including fluorescent cell sorting, fluorescence microscopy (including dark-field microscopy), fluorescence polarization assays, ligand, receptor binding assays, receptor activation assays and diagnostic assays can benefit from use of the compounds disclosed herein. | 10-23-2008 |
20080261236 | FGF21 upregulates expression of GLUT-1 in a beta Klotho-dependent manner - A method is provided to identify a modulator of βKlotho-dependant glucose transporter-1 (GLUT-1) upregulation that specifically modulates interaction of βKlotho and an FGFR. | 10-23-2008 |
20080268459 | Anti-Lewis Y Anti-Idiotypic Antibodies and Uses Thereof - This invention provides anti-idiotype antibodies specific for Anti-Lewis Y monoclonal antibodies. The present invention also directed against an ELISA screening method of mAbs produced by hybridoma clones for specific binding to the variable regions of hu3S193 and the ability of the anti-idiotypic mAB to inhibit hu3S193 binding to Lewis Y antigen. Additionally, the present invention provides a hybridoma capable of producing an anti-idiotype antibody specific for anti-Lewis Y monoclonal antibody. A further aspect of the invention is to provide a hybridoma, which is specific for anti-Lewis Y monoclonal antibody selected from the group consisting of LMH-1, LMH-2, LMH-3, or LMH-4. The present invention is also directed against a method to detect HAMA, HACA and HAHA responses using the antibody of the invention. | 10-30-2008 |
20080268460 | Assays to Identify Irreversibly Binding Inhibitors of Receptor Tyrosine Kinases - The present invention relates to a method of identifying an inhibitor of a receptor tyrosine kinase that irreversibly binds to the kinase. Specifically, the method comprises using a variety of assays, either alone or in combination, to identify compounds that irreversibly bind to tyrosine kinases. More specifically, there are four assays, which are novel variations of a basic enzyme assay and identify irreversible binding inhibitors. | 10-30-2008 |
20080268461 | Method of Measuring Cholesterol in Remnant-Like Lipoproteins - There are provided a method and reagent for measuring cholesterol in remnant-like lipoprotein in a sample with high sensitivity by more simple operation. The method for measuring cholesterol in remnant-like lipoprotein uses a cholesterol esterase, in which the activity ratio of a lipoprotein lipase to a cholesterol esterase (lipoprotein lipase activity/cholesterol esterase activity) is from 12 to 7000 in a method for measuring cholesterol in the lipoprotein by measuring hydrogen peroxide or a reduced coenzyme obtained by allowing the cholesterol esterase and a cholesterol oxidase or a cholesterol dehydrogenase to act on a test sample containing a lipoprotein. | 10-30-2008 |
20080268462 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use - A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaryl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, a thiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels. | 10-30-2008 |
20080268463 | Methods for Prognosis and Diagnosis of Chronic Prostatitis/Pelvic Pain Syndrome and Interstitial Cystitis - We have discovered that levels of specific protein biomarkers present in urine samples of subjects correlate with the presence, or absence of, chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in men or interstitial cystitis (IC) in women. These protein biomarkers are cortitropin releasing hormone (CRH), dehydroepiandrosterone (DHEA), neuropeptide Y (NPY) and Galanin. Accordingly, the invention is directed to methods for diagnosis of CP/CPPS and IC by monitoring the levels of at least one of these proteins in urine, as well as to diagnostic kits designed for diagnosis of CP/CPPS and IC. | 10-30-2008 |
20080268464 | Process And Device For Determining The Activity Of Enzymes In Liquids, Or The Concentration And/Or Activity Of Inhibitors In Liquids - A process and device are disclosed to determine the activity of enzymes in liquids in a largely automatic manner. The device for carrying out this process has a column ( | 10-30-2008 |
20080274473 | Amyloid binding assays - Provided herein are amyloid-binding assays that simulate in situ brain conditions by combining binders with various A-beta species on mammalian brain tissue. In general the amyloid-binding assays comprise the steps of (a) contacting a mammalian brain tissue sample with at least one A-beta species; (b) applying a putative binder to the brain tissue sample; and (c) determining whether the putative binder binds to the A-beta species. | 11-06-2008 |
20080274474 | Authentication Method and System for Authenticating Security Documents, Security Document and Security Element - An authentication system for authenticating security documents contains at least an enzyme and a substrate and any co-enzymes and/or co-factors needed, capable of an enzymatic conversion. This conversion leads to a detectable change. The security-document contains at least one of the enzyme and the substrate. According to the invention the genetic information for the enzyme is derived from an extremophilic micro-organism. A security document for use in the authentication system and method is also described. | 11-06-2008 |
20080274475 | HLA-E BINDING - The invention relates to a method of testing a compound for biological activity, which method comprises providing cells expressing one of the CD94/NKG2 family of receptors, contacting the cells with recombinant HLA-E under binding conditions in the presence of the test compound, and determining whether the presence of the compound affects the binding of HLA-E to the cells. The HLA-E property of binding to CD94/NKG2 receptors on NK cells and a subset of CD8+ T cells is useful for targeting CD94/NKG2+ cells for a variety of purposes such as identification, isolation, killing or inactivation. | 11-06-2008 |
20080280305 | Assays for Detecting Hiv-1 Tat Protein in Hiv-1 Infection - A method for detecting or measuring HIV-1 Transactivating (Tat) protein in a biological sample comprising contacting the biological sample with an amount of a basic protein effective to reduce interference with binding between anti-HIV-1 Tat Epitope 2 ligand and Tat that is caused by acidic components within the sample or reagents. A more accurate detection and measurement of the amount of HIV-1 Tat in the sample is obtained by binding between the anti-Epitope 2 antibody and the Tat in the sample when the interference is neutralized. A diagnostic kit for use in practicing the method contains these components. | 11-13-2008 |
20080280306 | Immunoassay For Determining The Release Of Neurotensin Into The Circulation - The invention relates to an immunodiagnostic method for determining the release of neurotensin into the circulation of mammals based on the selective determination of an immunoreactivity of the N-terminal portion of a mammal proneurotensin (PNT immunoreactivity) m a serum or plasma sample of a mammal; this immunoreactivity is not neurotensin or neuromedin immunoreactivity. | 11-13-2008 |
20080280307 | Chimeric Recombinant Antigens of Toxoplasma Gondii - The invention described herein relates to a method for combining antigen fragments of | 11-13-2008 |
20080280308 | G protein coupled receptor signaling modulation - This invention relates to methods for identifying peptides and other compounds which block or enhance G protein coupled receptor mediated signaling with high affinity and specificity and/or which stabilize a particular conformer of a G protein coupled receptor. Assays, methods of treatment and other methods developed in conjunction with these methods also are disclosed. | 11-13-2008 |
20080286802 | SYSTEM AND METHOD FOR LARGE SCALE DETECTION OF HAZARDOUS MATERIALS IN THE MAIL OR IN OTHER OBJECTS - A system and method that enables early detection of hazardous materials, such as explosives and biological materials, in the early phases of mail handling or processing. | 11-20-2008 |
20080286803 | Method for the Functional Determination of Mannan-Binding-Lectin Associated Serine Proteases (Masps) and Complexes Thereof - This invention relates to the field of determining, assaying or quantifying activity of components of the complement system. More particularly, the invention relates to methods for detecting the presence or level of activity in a sample of mannan-binding-lectin associated serine proteases (MASPs) or complexes of such proteases with lectins and to detection of the particular lectins themselves. Provided is a method for determining the activity of a MASP in a sample, comprising incubating the sample with a pro-urokinase comprising at its activation site the consensus sequence Arg/Leu/Gly-Yyy-Arg/Lys-Ile/Leu/Val-Zzz-Gly-Gly cleavable by a MASP, wherein Yyy can be any amino acid and Zzz is preferably an aliphatic amino acid, and determining proteolytic activation of said pro-urokinase. | 11-20-2008 |
20080286804 | MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC METHODS - The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma. | 11-20-2008 |
20080293073 | Methods for Assessing CDK5 Activation and Function - As described herein, signaling events occurring in neurons or at neuronal synapses have been identified that involve Cdk5 and various other molecules which bind to, are activated by, and/or activate Cdk5. Of particular relevance are interactions that stimulate calpain cleavage of p35 into p25, which binds Cdk5 in pathologic states. Assays to identify modulators of these interactions are provided. | 11-27-2008 |
20080293074 | Hemoglobin Derivative Measurement Method, and Reagent Composition, Measurement Kit, Analysis Device and Analysis System for Use in the Method - A sample solution including blood components is processed with a denaturalization reagent comprising a nonionic surface-activating agent and an oxidizing agent to denaturalize a hemoglobin derivative in the sample solution, and thereafter, an immunoassay is performing utilizing an antibody that is specific to a denaturalized site of the hemoglobin derivative to measure the amount of the hemoglobin derivative in the sample. Therefore, when performing assay of hemoglobin derivative, denaturalization of hemoglobin can be performed speedily and reliably while minimizing adverse effects of the denaturalization reagent on immune reaction. | 11-27-2008 |
20080293075 | Method and Composition for Analyzing A Carbohydrate Polymer - Disclosed is a method for characterizing carbohydrate polymer by identifying at least two binding agents that bind to the carbohydrate polymer. Binding is preferably determined by contacting the carbohydrate polymer with substrate that contains a plurality of first saccharide-binding agents affixed at predetermined locations on the substrate. The carbohydrate polymer is allowed to contact the substrate under conditions that allow for formation of a first complex between the first saccharide-binding agent and the carbohydrate polymer. A second saccharide-binding agent, which preferably includes a label, is also contacted with the carbohydrate polymer under conditions that allow for formation of a second complex between the second binding agent and the first complex. Identification of the first and second binding agent allows for characterization of the polysaccharide. | 11-27-2008 |
20080305493 | Determining Cancer-Linked Genes and Therapeutic Targets Using Molecular Cytogenetic Methods - Methods for identifying antineoplastic agents by using their ability to modify expression of specific genes or the biological activity of polypeptides encoded by such genes, wherein said genes are located in specific chromosomal regions, called amplicons, or regions of interest, and the presence of such amplified regions within a cancerous cell, are disclosed. Also described are methods for diagnosing cancerous, or potentially cancerous, conditions using these methods. Also encompassed are methods involving determining the modulated expression of the genes in these regions of interest (ROIs), or amplicons, as pharmacodynamic/pharmacogenetic/surrogate markers and/or for patient profiling prior to accrual for clinical trials/treatments based on the identification of these genes as validated gene/drug targets in various cancer tissue types. | 12-11-2008 |
20080305494 | Chemokine Ccl18 as a Biomarker - The invention relates to a diagnostic tool, e.g. to the chemokine CCL | 12-11-2008 |
20080305495 | Methods for determining the redox status of proteins - A method for determining the redox status of a protein sample, the method comprising the steps of: a) contacting the sample with a first label adapted to bind to at least one reduced cysteine group therein; b) contacting the sample with a reducing agent to reduce at least one oxidized cysteine group therein; c) contacting the sample with a second label adapted to bind to any reduced cysteine groups produced in step (b); and d) determining the ratio of the signal from the first label to the signal from the second label wherein the ratio indicates the redox status. | 12-11-2008 |
20080311588 | NEUROGENIN - The invention relates to novel neurogenin proteins, nucleic acids and antibodies. | 12-18-2008 |
20080311589 | METHOD OF HIGH-THROUGHPUT SCREENING OF MOLECULES AND COMPOUNDS FOR THEIR EFFECTS ON BIOLOGICAL AND CHEMICAL PROCESSES - The present invention provides a system for high-throughput analysis of chemical compounds. Assays are performed in a high density platform, and compounds having pre-determined desirable effects are identified. Preferably, the compounds have biological effects, more preferably, the assays and detection are performed on whole cells. | 12-18-2008 |
20080318245 | NANOTUBE STRUCTURES HAVING A SURFACTANT BILAYER INNER WALL COATING - Nanotubes and nanotube array structures comprise (a) a nanotube having an inner wall portion; and (b) a bilayer coating formed on the inner wall portions, with the bilayer coating comprised of surfactants. A secondary compound such as a protein, peptide or nucleic acid may be associated with the bilayer coating. The structures are useful for, among other things, affinity purification, catalysis, and as biochips. | 12-25-2008 |
20080318246 | Deeply quenched enzyme sensors - Sensors for detecting enzyme activity are provided that include a substrate module comprising a substrate for the enzyme of interest and a fluorescent label, a quencher, and a detection module. The detection module binds to the substrate module either before or after the enzyme acts on the substrate and sequesters the label from the quencher, resulting in an increased signal from the label. Sensors for detecting enzyme activity are also provided that include a substrate for the enzyme, a label, and a quencher that quenches the label. Action of the enzyme on the substrate results in a conformational change that relieves quenching. Sensors for detecting protein-protein interactions are also provided that include a quencher and a labeled first polypeptide. Binding of the first polypeptide to a second polypeptide sequesters the label from the quencher, resulting in an increased signal from the label. Methods using the sensors to detect enzyme activity and to screen for compounds affecting enzyme activity or to detect protein-protein interactions and to screen for compounds affecting protein-protein interactions, respectively, are also described. | 12-25-2008 |
20080318247 | Biomarker for cardiac transplant rejection - The invention provides a method of diagnosing a disease or disorder featuring an abnormal level of a ring-containing molecule in a tissue. In one embodiment, a method of diagnosing organ transplant rejection is provided. | 12-25-2008 |
20080318248 | Compositions and Methods of Screening Apoproteins - The present invention is directed to compositions and methods of screening apoproteins for the elucidation of modulators of metalation of apoproteins. | 12-25-2008 |
20090004670 | METHODS FOR FABRICATING SURFACE ENHANCED FLUORESCENT (SEF) NANOPARTICLES AND THEIR APPLICATIONS IN BIOASSAYS - Embodiments of the invention relate to SEF nanoparticles with increased fluorescence, methods of making SEF nanoparticles, and their application in various bioassays for the detection of target bioanalytes. One embodiment includes the SEF nanoparticle itself, a second embodiment includes the fabrication of SEF nanoparticles, a third embodiment includes methods of using SEF nanoparticles in biodetection assays. A final embodiment includes kits to be used in the fabrication of SEF nanoparticles. | 01-01-2009 |
20090004671 | Marker Protein For Use In Diagnosis Of Pancreatic Cancer - Disclosed herein are a pancreatic carcinoma marker protein that is a blood protein having a molecular weight of 28,080±15, 17,272±9, 17,253±9, 8,766±5, or 14,779±8 (m/z) and a method for detecting pancreatic carcinoma using the marker protein as an indicator. | 01-01-2009 |
20090004672 | 17867, A NOVEL HUMAN AMINOPEPTIDASE - The present invention relates to a newly identified human aminopeptidase. The invention also relates to polynucleotides encoding the aminopeptidase. The invention further relates to methods using the aminopeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in aminopeptidase-related disorders. The invention further relates to drug-screening methods using the aminopeptidase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the aminopeptidase polypeptides and polynucleotides. The invention further relates to procedures for producing the aminopeptidase polypeptides and polynucleotides. | 01-01-2009 |
20090004673 | Method for Determining Condition of Disseminated Intravascular Coagulation - A method for determining a condition of disseminated intravascular coagulation (DIC), by analyzing the amount and/or enzyme activity of a von Willebrand factor (vWF)-cleaving protease (ADAMTS13) (preferably also the amount of vWF) in a patient suffering from DIC, and a kit for determining a condition of DIC, comprising an antibody or a fragment thereof which specifically binds to ADAMTS13, are disclosed. According to the present invention, a differential diagnosis of patients with thrombotic thrombocytopenic purpura (TTP) can be carried out from among patients with DIC, which could not be distinguished on the basis of only clinical findings or known markers. | 01-01-2009 |
20090011425 | Incubation Device for Serology and Histology Slides - This application relates to an incubation device for serology or histology supports. It also relates to any apparatus comprising one such device, and to the use of said apparatuses and/or devices in analysis or diagnosis methods. | 01-08-2009 |
20090011426 | Methods of Diagnosis and Treatment of M.Tuberculosis Infection and Reagents Therefor - The present invention provides diagnostic, prognostic and therapeutic reagents for infection of an animal subject such as a human by | 01-08-2009 |
20090011427 | ASSAYS FOR PREIMPLANTATION FACTOR AND PREIMPLANTATION FACTOR PEPTIDES - The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytometry assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled anti-lymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (i) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate. | 01-08-2009 |
20090011428 | Fluid Membrane-Based Ligand Display System for Live Cell Assays and Disease Diagnosis Applications - A supported membrane based, strategy for the presentation of soluble signaling molecules to living cells is described. In this system, the fluidity of the supported membrane enables localized enrichment of ligand density in a configuration reflecting cognate receptor distribution on the cell surface. Display of a ligand in non-fluid supported membranes produces significantly less cell adhesion and spreading, thus demonstrating that this technique provides a means to control functional soluble ligand exposure in a surface array format. Furthermore, this technique can be applied to tether natively membrane-bound signaling molecules such as ephrin A1 to a supported lipid bilayer. Such a surface can modulate the spreading behavior of metastatic human breast cancer cells displaying ligands and biomolecules of choice. The SLB microenvironment provides a versatile platform that can be tailored to controllably and functionally present a multitude of cell signaling events in a parallel surface array format. | 01-08-2009 |
20090011429 | Diagnosis of Pre-Eclampsia - The present invention relates to a method of predicting pre-eclampsia (PE). The present invention also relates to a diagnostic kit for performing a method of predicting PE. In particular, the method determining the level of two or more markers selected from placenta growth factor (P1GF), plasminogen activator inhibitor-1 (PAI-1), plasminogen activator inhibitor-2 (PAI-2) and leptin. | 01-08-2009 |
20090017466 | SEPARATION-FREE ASSAY METHOD - This invention relates to a separation-free assay method employing a binding partner label and a nonspecifically binding label, wherein a signal from said binding partner label or said nonspecifically binding label is measured in a binding event, said method comprising the use of a) two or more binding partners, and a directly luminescent binding partner label adsorbed and/or covalently coupled to at least one of said binding partners; and b) said nonspecifically binding label, wherein i) said nonspecifically binding label is able to affect the signal of said binding partner label, or ii) said binding partner label is able to affect the signal of said nonspecifically binding label; and wherein at least one of said binding partners is a mobile binding partner and at least one other of said binding partners is a labeled ligand. | 01-15-2009 |
20090023155 | Polyelectrolyte multilayer films at liquid-liquid interfaces and methods for providing and using same - The present invention is directed to methods for providing a polyelectrolyte multilayer film at a liquid-liquid interface. Such methods include steps of sequentially-depositing layers of cationic and anionic polyelectrolytes at a liquid-liquid interface that is formed between immiscible first and second liquids whereby a polyelectrolyte multilayer film is provided at the liquid-liquid interface. In certain preferred embodiments, the first liquid is an aqueous solution and the second liquid is a liquid crystal. In alternative embodiments, the first liquid is an aqueous solution and the second liquid is an oil. The invention further encompasses polyelectrolyte multilayer films provided by the disclosed methods as well as applications utilizing such materials. | 01-22-2009 |
20090023156 | Methods and reagents for quantifying analytes - The present invention relates to methods and reagents for quantifying analytes. More specifically, the present invention related to methods and reagents for measuring one or more analytes present in a sample. | 01-22-2009 |
20090023157 | Proteome epitope tags and methods of use thereof in protein modification analysis - Disclosed are methods for reliably detecting the presence of proteins, especially proteins with various post-translational modifications (phosphorylation, glycosylation, methylation, acetylation, etc.) in a sample by the use of one or more capture agents that recognize and interact with recognition sequences uniquely characteristic of a set of proteins (Proteome Epitope Tags, or PETs) in the sample. Arrays comprising these capture agents or PETs are also provided. | 01-22-2009 |
20090023158 | Compositions and Methods for Identifying Substrate Specificity of Inhibitors of Gamma Secretase - The invention provides assays and methods for determining the substrate specificity of gamma secretase inhibitors and for identifying substrate-selective (and substrate isoform-selective) inhibitors of gamma secretase. The invention provides assays and methods for determining whether a compound inhibits gamma secretase in a site specific or substrate specific manner. The invention provides isolated polypeptide sequences comprising modified gamma secretase substrates, and polynucleotide sequences encoding the polypeptide sequences. The invention also provides compounds that inhibit gamma secretase, pharmaceutical compositions comprising such compounds, and methods of treating Alzheimer's disease using such compounds. | 01-22-2009 |
20090029387 | METHOD FOR EFFECTIVELY MEASURING THE ACTIVITY OF CYTOTOXIC T LYMPHOCYTES IN HUMAN AND OUT-BRED ANIMALS - A method for measuring the activity of cytotoxic T lymphocytes (CTLs) includes preparing peripheral blood mononuclear cells (PBMCs) from blood of an animal; preparing mature dendritic cells by isolating monocytes from the PBMCs, differentiating the monocytes into dendritic cells for presenting an antigen molecule and pulsing dendritic cells with the antigen molecule to obtain the mature dendritic cells; preparing the CTLs as an effector cell by stimulating the PBMCs with the mature dendritic cells to activate and amplify the CTLs; preparing target cells by pulsing the PBMCs, monocytes or B cells with a cytoplasmic transduction peptide (CTP)-antigen complex generated by linking the antigen molecule of step (b) to the CTP; treating the target cells with the effector cells; and analyzing the lysis of the target cells. In addition, a kit for measuring the activity of cytotoxic T lymphocytes is provided. | 01-29-2009 |
20090029388 | Detection of Antibodies - The present invention relates to a method for detecting antibodies against a target antigen in a sample which comprises contacting the sample with labelled target antigen, subjecting the sample to immunoprecipitation to precipitate antibodies in the sample and detecting the presence of antibodies against the target antigen in the sample by means of the presence of labelled target antigen in the immunoprecipitate, wherein the labelled target antigen is a fusion protein comprising the target antigen and a fluorescent protein label and the presence of labelled target antigen in the immunoprecipitate is detected by means of the fluorescence of the fluorescent label. The method is particularly suitable for use where the target antigen is an autoantigen and can also be used to identify autoantigens implicated in a particular autoimmune disorder by screening serum samples from patients with a clinical phenotype indicative or suggestive of an autoimmune disorder and suitable controls. The target protein may be from the cys-loop acetyl choline receptor ion channel gene superfamily, the voltage-gated calcium, sodium or potassium ion channel gene superfamily, the glutamate receptor gene family, a receptor tyrosine kinase, or other membrane associated channels such as aquaporin gene family. | 01-29-2009 |
20090029389 | FLUORESCENT METAL ION INDICATORS WITH LARGE STOKES SHIFTS - The present invention provides fluorogenic compounds for the detection of target metal ions wherein the compounds exhibit a Stokes shift greater than 50 nm and the detectable signal is modulated by photoinduced electron transfer (PET). The present compounds consist of three functional elements, the ion sensing moiety (chelating moiety), the reporter moiety (fluorophore or fluorescent protein) and spacer or linker between the sensing and reporter moieties of the present compound that allows for PET upon binding of a metal ion and excitation by an appropriate wavelength. | 01-29-2009 |
20090035783 | FLUORESCENT PROTEINS AND USES THEREOF - A fluorescent sensor and methods for producing and using the fluorescent sensor. Such fluorescent sensors have broad applicability in characterizing cells and organisms, in detecting or measuring various cellular parameters, and in detecting or measuring protein-protein/peptide interactions. | 02-05-2009 |
20090035784 | NPC1L1 AND NPC1L1 INHIBITORS AND METHODS OF USE THEREOF - The present invention provides a novel gene, designated herein as “NPC1L1”, that is associated with lipid or glucose metabolism. The invention further provides the use of the NPC1L1 gene and its corresponding protein to diagnose a lipid condition in a cell or tissue and to screen for novel therapeutic compounds useful for treating lipid disorders and other NPC1L1-associated or mediated diseases or disorders. The invention further provides specific inhibitors of NPC1L1. | 02-05-2009 |
20090035785 | IMMUNOASSAY METHOD AND REAGENT THEREFOR - The present invention provides a novel immunoassay method with high reaction specificity and high sensitivity. The present invention also provides a method for immunoassaying a target antigen utilizing reactivation of an apoenzyme, which includes simultaneously or sequentially adding a test sample to an antibody specific to the target antigen, the target antigen labeled with a coenzyme, an apo-D-amino acid oxidase, a D-amino acid, and a reagent for detecting a hydrogen peroxide produced by the oxidase. | 02-05-2009 |
20090035786 | MULTI-ANALYTE AFFINITY COLUMN - A multi-analyte column is disclosed. The column may contain at least one unit of resin having ochratoxin specific affinity and, for each unit of resin having ochratoxin specific affinity, the column further contains about 0.95 to 1.05 units of resin containing antibody having specificity for zearalenone, about 1.9 to 2.1 units of resin containing antibody having specificity for aflatoxin, about 2.35 to 2.65 units of resin containing antibody having specificity for fumonisin, about 2.8 to 3.2 units of resin containing antibody having specificity for T-2 (and/or HT-2) and about 4.7 to 5.3 units of resin containing antibody having specificity for deoxynivalenol. One unit of resin is the quantity of resin containing antibody that will bind 50 ng of aflatoxin, 500 ng of deoxynivalenol, 3300 ng of fumonisin, 50 ng of ochratoxin, 830 ng T-2 (and/or HT-2) or 1140 ng of zearalenone, respectively. | 02-05-2009 |
20090035787 | ENZYMATIC SYNTHESIS OF SULFATED POLYSACCHARIDES WITHOUT IDURONIC ACID RESIDUES - Iduronic acid (IdoUA)-free heparan sulfate (HS)-like compounds are provided. Also provided are methods of synthesizing IdoUA-free HS-like compounds. The methods can include providing at least one O-sulfotransferase (OST) enzyme and a reaction mixture comprising 3′-phosphoadenosine 5′-phosphosulfate (PAPS); and incubating a polysaccharide substrate with the at least one OST and the reaction mixture, whereby the HS-like compounds are synthesized. Also disclosed are methods of synthesizing a library of HS-like compounds and methods of determining the mechanism of activity of HS-like compounds. | 02-05-2009 |
20090042209 | Neoplasia-Specific tNOX Isoforms and Methods - All neoplastic cells express one or more members of a unique family of cell surface ubiquinone (NADH) oxidase proteins with protein disulfide-thiol interchange activity (ECTO-NOX proteins) that are characteristically inhibited by quinone site inhibitors with anti-cancer activity. Cancers of different cellular or tissue origins express different tNOX cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative tNOX amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. | 02-12-2009 |
20090042210 | Sensors and methods for detecting diseases caused by a single point mutation - A method for generating antibodies preferable to either a normal protein and a mutated form of the normal protein, respectively, where a mutation associated with the mutated form includes either a single point mutation or a small number of point mutations where the method includes creating first and second antigenic peptides of a predetermined length corresponding respectively to common regions of the normal target protein and the mutated form, where the common regions are identical to one another except for the point mutation of the mutated form, obtaining first and second antibodies by multiplying the first and second antigenic peptides via hybridoma methods, and identifying the respective affinities of the first and second antibodies for the normal target protein and the mutated form. Also included are methods of using the first and second antibodies to detect and quantify respective amounts of a normal target protein and a mutated form of the target protein. Also included are immunological sensors the include the first and second antibodies for determining the presence and quantity of normal target proteins and mutant forms of the normal target proteins. | 02-12-2009 |
20090042211 | Method for the Selective Detection of Pathological Protein Depositions - The invention relates to a method for the selective detection of the presence and/or quantity of pathological protein depositions. | 02-12-2009 |
20090042212 | DETECTION OF PRIMARY INFECTIONS WITH PATHOGENS - The present invention relates to fusion proteins: suitable as test antigens in the detection of infections with pathogens, particularly of primary infections with pathogens. Further, the invention relates to methods for detecting and differentially determining antibodies, particularly IgM antibodies resulting from an infection with a pathogenic organism. Furthermore, test reagents for carrying out these methods are provided. | 02-12-2009 |
20090042213 | METHODS AND COMPOSITIONS FOR DETECTING THYROGLOBULIN IN A BIOLOGICAL SAMPLE - The invention provides a method and reagents for determining the presence and/or amount of human thyroglobulin in a biological sample. In one embodiment, the method comprises (a) digesting a biological sample containing proteins to provide peptide fragments; (b) contacting the digested sample with a binding reagent comprising a plurality of antibodies that are capable of binding to at least one thyroglobulin peptide fragment; and (c) determining the presence and/or amount of the thyroglobulin peptide fragments that are bound to the binding reagent. In some embodiments, the binding reagent comprises a plurality of antibodies capable of binding to at least one thyroglobulin peptide fragment set forth in TABLE 1. In some embodiments, the binding regent comprises a plurality of antibodies capable of binding to at least one thyroglobulin peptide selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:5. | 02-12-2009 |
20090042214 | BETA2-MICROGLOBULIN AND C REACTIVE PROTEIN (CRP) AS BIOMARKERS FOR PERIPHERAL ARTERY DISEASE - The present invention relates to use of β-2-microglobulin (B2M or β2M) and C-reactive protein (CRP) levels as biomarkers of peripheral artery disease and/or atherosclerosis. | 02-12-2009 |
20090047685 | ULTRAHIGHLY SENSITIVE DETERMINATION REAGENT FOR C-REACTIVE PROTEIN AND DETERMINATION METHOD - The present invention is related to an ultrahighly sensitive determination reagent for C-reactive protein (CRP) for use in determination of CRP in a test sample with high sensitivity; and a CRP determination method using the reagent. A reagent for determining C-reactive protein containing an insoluble carrier particle loading an antibody directed to the C-reactive protein via an amino acid; and a method for determining a C-reactive protein including the steps of reacting the reagent with an antigenic substance in a test sample, and determining a resulting aggregate. | 02-19-2009 |
20090047686 | METHODS FOR IDENTIFYING AND PRODUCING SPECIFIC AMINO ACID DEPENDENT ANTIBODIES AND USES THEREOF - The present invention relates to methods for producing antibodies that are selective for one or two of the N-terminal amino acid residues of PTH, the antibodies made by such methods, and methods of using them to determine PTH levels while avoiding interference from N-terminally truncated PTH peptides. | 02-19-2009 |
20090053730 | CHIMERIC HUMAN T1R1 TASTE RECEPTOR POLYPEPTIDES AND COMPOSITIONS CONTAINING SAME - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed. | 02-26-2009 |
20090053731 | Method for Detection of L523S Expression in Biological Samples - The present invention discloses methods for differentiating between normal or reactive cells and malignant cells in biological samples comprising: exposing the biological sample to an antibody to L523S protein and detecting the presence of the antibody bound to L523S protein within the malignant cells, in embodiments, such methods may further comprise: exposing the biological sample to an antibody to a second protein that is a marker of cell lineage and detecting the presence of the antibody to the second protein within cells corresponding to a particular cell lineage and/or may comprise: exposing the biological sample to an antibody to a third protein which is a marker of cells that are normal or reactive and detecting the presence of the antibody to the third protein within cells that are normal or reactive. | 02-26-2009 |
20090053732 | MICROFLUIDIC DEVICES, METHODS AND SYSTEMS FOR DETECTING TARGET MOLECULES - Microfluidic devices methods and systems for detecting a target in a fluidic component of a sample are shown. In such devices, methods and systems, the flow resistance of various channels where the sample is introduced is adjusted to control separation of the fluidic component from the sample and/or performance of assays for the detection of the target in the fluidic component in a controlled fashion. Such performance is controlled by binding affinity of the target with capture agents or diffusion of the target in the fluidic component. | 02-26-2009 |
20090053733 | SIMULTANEOUS ASSAY FOR DETERMINING DRUGS - A method and kits for assaying a sample of a human or mammalian bodily fluid to simultaneously determine whether one or more of a plurality of drugs and/or metabolites thereof are present in said sample and optionally to perform a semi-quantitative assay for said drug or drugs, comprising:
| 02-26-2009 |
20090053734 | DETERMINATION OF AM-BINDING PROTEINS AND THE ASSOCIATION OF ADRENOMEDULLIN (AM) THEREWITH - The present invention provides methods for the isolation, identification, and purification of adrenomedullin (AM)-binding proteins. Also, provided are methods for utilizing the purified AM-binding proteins, or functional portions thereof, to diagnose, treat, and monitor AM-related diseases, for example, diseases or disorders associated with abnormally elevated AM levels. In addition, the present invention provides a newly identified complex between AM and a specific AM-binding protein 1 (AMBP-1); which has been isolated and identified herein as factor H (fH). The invention also provides AM/AMBP complexes, particularly AM/FH complexes, and antibodies specifically reactive with this complexes. Further provided are methods for identifying and purifying complexes of AM and an AM binding protein using anti-AM/fH antibodies, and methods for treating conditions such as cancer or diabetes utilizing compositions comprising these antibodies. The present invention additionally provides methods for identifying antagonists agents that inhibit the function of AM, factor H, or the AM/factor H complex. The invention also provides methods for treating conditions such as cancer or diabetes using these antagonist agents. | 02-26-2009 |
20090061455 | Use of Glycosaminoglycans to Reduce Non-Specific Binding in Immunoassays - An immunoassay reagent is provided which comprises an analyte binding agent in a diluent, and a glycosaminoglycan in an amount sufficient to reduce non-specific binding in an assay of a sample for the analyte. Provided is such an immunoassay reagent in which the analyte is troponin I, the analyte binding agent is a biotinylated anti-troponin I antibody, and the glycosaminoglycan is chondroitin sulfate. A sample composition is also provided which comprises a sample to be assayed for the presence of an analyte, an analyte binding agent, and a glycosaminoglycan other than heparin. Further provided is a method of detecting an analyte in a sample, in which non-specific binding is reduced in the method using a glycosaminoglycan. | 03-05-2009 |
20090061456 | Method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells - A cancer test having prognostic utility in predicting time to disease progression, overall survival, and response to therapy in patients with MBC based upon the presence and number of CTC's. The Cell Spotter® System is used to enumerate CTC's in blood. The system immunomagnetically concentrates epithelial cells, fluorescently labels the cells and identifies and quantifies CTC's. The absolute number of CTC's detected in the peripheral blood tumor load is, in part, a factor in prediction of survival, time to progression, and response to therapy. The mean time to survival of patients depended upon a threshold number of 5 CTC's per 7.5 ml of blood. Detection of CTC's in metastatic cancer represents a novel prognostic factor in patients with metastatic cancers, suggests a biological role for the presence of tumor cells in the blood, and indicates that the detection of CTC's could be considered an appropriate surrogate marker for prospective therapeutic clinical trials. | 03-05-2009 |
20090061457 | Apolipoprotein E3 protein as a biomarker of Parkinson's disease - The present invention relates to an Apolipoprotein E3 protein as a biomarker for neurodegenerative disease, including Parkinson's disease, and the related diseases. More specifically, the present invention relates to the identification of an Apolipoprotein E3 protein, useful for the screening, diagnosis, and differentiation of Parkinson's disease from Alzheimer's disease, other neurodegenerative diseases, and normal controls. | 03-05-2009 |
20090061458 | Heterooligomeric Taste Receptor - Newly identified mammalian taste-cell-specific G protein-coupled receptors which function as hetero-oligomeric complexes in the sweet taste transduction pathway, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in sweet taste signaling as hetero-oligomeric complexes, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for identifying putative taste modulating compounds using such hetero-oligomeric complexes also described, as is a novel surface expression facilitating peptide useful for targeting integral plasma membrane proteins to the surface of a cell. | 03-05-2009 |
20090068676 | Diagnostic methods for congestive heart failure - The invention provides an assay for the quantification of circulating glycophorin in biological fluid samples. The circulating glycophorin measured by this assay is a truncated glycophorin diagnostic for congestive heart failure (CHF). | 03-12-2009 |
20090068677 | BIOMARKER FOR DIAGNOSING HEART DISEASE AND THE USE THEREOF - The invention relates to the following methods [1] to [3] and to a kit for carrying out the methods: | 03-12-2009 |
20090068678 | Method for identifying modulators of NOAH10 useful for treating Alzheimer's disease - Methods for identifying modulators of NOAH10 are described. The methods are particularly useful for identifying analytes that antagonize NOAH10's effect on processing of amyloid precursor protein (APP) to amyloid beta (Aβ) peptide and are useful for identifying analytes that can be used for treating Alzheimer disease. | 03-12-2009 |
20090068679 | Binding partners of the placental growth factor, especially antibodies directed against the placental growth factor, and production and use thereof - The invention relates to binding partners of the placental growth factor (or placenta growth factor, PIGF), especially antibodies directed against the placental growth factor, and production and use thereof. | 03-12-2009 |
20090068680 | Method for Characterizing Immune Disorders - Methods for characterizing immune diseases are provided which include exposing a sample of biological fluid from a patient to a pooled population of particles, wherein a first subset of particles is bound to a reactant that binds an antibody and a second subset of particles is bound to a reactant that binds an antigen. The methods further include determining a ratio of measured amounts of the antibody and the antigen in the sample. In some cases, the ratio is compared to one or more standard ratios representing differing states of the disease to determine a state of the disease within the patient. In other embodiments, the steps of exposing and determining a ratio of antibody to antigen are repeated for one or more additional samples of biological fluid taken from the patient. In such cases, at least two ratios are compared to analyze a progression of the disease. | 03-12-2009 |
20090075290 | IMMUNOCHEMICAL DETERMINATION METHOD AND DETERMINATION REAGENT FOR CYTOCHROME - An immunochemical method for the accurate measurement of the quantity of cytochrome c in a body fluid, in particular, blood, and a kit for the measurement. The quantity of cytochrome c can be measured accurately without being affected by any interfering substrate by reacting an antibody with cytochrome c in a buffer solution in an acidic range. | 03-19-2009 |
20090075291 | PEPTIDE-BASED REGULATION OF GAP JUNCTIONS - The present invention relates to proteins and polypeptides that (i) have the formula A-[W | 03-19-2009 |
20090075292 | METHODS FOR IDENTIFYING MODULATORS OF APOPTOSIS - The invention provides a method of identifying an effective compound that modulates the binding of Humanin to Bax or Bid. The invention also provides a method of identifying an effective compound that modulates an activity of Bax or Bid. In addition, the invention provides a method of identifying a Humanin-like compound that binds to Bax or Bid or modulates an activity of Bax or Bid, or inhibits the apoptotic activity of Bax or Bid. The invention further provides an isolated polypeptide containing a mitochondrial-derived form of Humanin (SEQ ID NO:3) or a functional fragment thereof where the fragment contains the methionine at position 16 of SEQ ID NO:3. | 03-19-2009 |
20090075293 | Methods for predicting embryo viability - The present invention provides methods for predicting the viability of an embryo or for predicting the likelihood of a negative outcome during pregnancy by identifying the presence or absence of or determining the amount of one or more pregnancy associated markers such as molecular isoforms of hCG in a sample. In many instances, the invention is applicable to embryos generated by in vitro fertilization techniques, for instance, to embryos developing in a growth media. The present invention further provides methods for determining the amount of a pregnancy associated markers such as molecular isoforms of hCG (hCG) in a sample. The present invention also provides a diagnostic kit for predicting the viability of an embryo or for predicting the likelihood of a negative outcome during pregnancy by identifying the presence of or determining the amount of one or more pregnancy associated markers such as molecular isoforms of hCG in a sample. | 03-19-2009 |
20090081691 | METHOD OF IDENTIFYING TRANSMEMBRANE PROTEIN-INTERACTING COMPOUNDS - A method for screening compounds for their ability to interact with transmembrane proteins is provided. Also provided is a method for determining whether proteins such as transmembrane proteins are able to oligomerise. | 03-26-2009 |
20090081692 | Ceramide Kinase Loop - An isolated polynucleotide of SEQ ID NO:1, an isolated polypeptide of SEQ ID NO:2, e.g. encoded by a polynucleotide of SEQ ID NO:1, a vector comprising such polynucleotide, an expression system, comprising such polynucleotide, a host cell comprising such expression system, the use of a such polypeptide or polynucleotide as a diagnostic reagent, screening assays and methods for identifying an agonist or an antagonist of a ceramide kinase by use of such polypeptide or polynucleotide and an agonist or an antagonist of a ceramide kinase obtained by such screening and their use. | 03-26-2009 |
20090081693 | MOLECULE ASSOCIATING WITH INTRACELLULAR C-TERMINAL DOMAIN OF RECEPTOR - Concerning intracellular signal transduction mechanism, there has been drawn a novel hypothesis that, even in the case where phosphorylation does not occur in the intracellular C-terminal domain of a receptor, an unknown molecule associates with the Pro-C terminal domain of a G protein-coupled receptor for each chemokine and thus leukocyte chemotaxis depending on the receptor is controlled. To examine this hypothesis and clarify therapeutic targets in inflammatory diseases as well as other various diseases, attempts are made to search for a CCR2-binding protein. | 03-26-2009 |
20090081694 | Modified well plates for molecular binding studies - Microtiter plates modified to permit their use for molecular binding studies. | 03-26-2009 |
20090081695 | Methods and Compositions for Detection of Ehrlichia chaffeensis (p120) - The invention provides methods and compositions for the detection of | 03-26-2009 |
20090081696 | LUMINESCENCE ENHANCER AND USE THEREOF - An object of the present invention is to provide a luminescence enhancer by which a luminescence such as chemiluminescence can be enhanced with higher sensitivity and the luminescence can be continued over a prolonged period of time. That is, the present invention provides a luminescence enhancer containing a heteropolymer as an active ingredient, a method for measuring the luminescence using a luminescent substrate and said luminescence enhancer, and a method for analyzing a substance to be measured in a specimen wherein the specimen, an antigen and/or antibody corresponding to a substance to be measured, an antigen and/or antibody labeled-form with an activator and a luminescent substrate are reacted in the presence of said luminescence enhancer to measure the luminescence. | 03-26-2009 |
20090081697 | Methods of growing crystals of free and antibiotic complexed large ribosomal subunits, and methods of rationally designing or identifying antibiotics using structure coordinate data derived from such crystals - Methods of growing crystals of free and antibiotic complexed large ribosomal subunits, coordinates defining the 3D atomic structure thereof and methods of utilizing such coordinates for rational design or identification of antibiotics or large ribosomal subunits having desired characteristics are disclosed. | 03-26-2009 |
20090087859 | Microfluidic device for detecting soluble molecules - The present disclosure provides a microfluidic device that is compatible with standard centrifuges and may be used for point-of-care disease detection. The detection methodology may be based on microELISA. | 04-02-2009 |
20090087860 | HIGHLY SENSITIVE SYSTEM AND METHODS FOR ANALYSIS OF PROSTATE SPECIFIC ANTIGEN (PSA) - The invention described herein provides methods, compositions, kits, and systems for the sensitive detection of prostate specific antigen. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of prostate specific antigen. | 04-02-2009 |
20090087861 | Chimeric Tymovirus-like Particles and Process Thereof - The present disclosure relates to chimeric tymovirus-like particles (TVLPs) comprising a fusion protein that further comprises of a first protein that is a truncated tymovirus coat protein and a second protein. These chimeric TVLPs are useful as antigens. The present disclosure provides a highly efficient means for differentiating Foot and Mouth Disease Virus (FMDV) infected animals from vaccinated animals. The present disclosure further provides a process for the production of chimeric TVLPs and a diagnostic kit for the determination of specific antibodies of FMDV to differentiate FMDV infected from vaccinated animals. The present disclosure also provides the use of the chimeric TVLPs for diagnostic purposes. | 04-02-2009 |
20090087862 | Chemical Sensing Device - The present invention relates to chemical sensing and in particular to a method for detecting an analyte in a sample of whole blood. The method comprise, in summary, the steps of: exposing the sample to a transducer having a tethered reagent; introducing a labelled reagent; irradiating the sample with a series of pulses of electromagnetic radiation at a wavelength of 600 run or above; and transducing and detecting the electrical signal and the time delay between each pulse. The label on the labelled reagent absorbs the electromagnetic radiation at a level which is at least equal to the absorption of the sample of whole blood at the wavelength of the electromagnetic radiation used. | 04-02-2009 |
20090092996 | MUCOPOLYSACCHARIDOSIS (MPS) DIAGNOSTIC METHODS, SYSTEMS, KITS AND ASSAYS ASSOCIATED THEREWITH - Methods, systems, kits and assays for diagnosing, monitoring or screening for mucopolysaccharidosis (MPS) and methods and systems for assaying test compounds for therapeutic activity are described, whereby MPS marker protein levels are assayed as an indication of MPS. | 04-09-2009 |
20090092997 | MODULATORS THAT PROMOTE CELL SURFACE EXPRESSION OF ODORANT RECEPTORS - The present invention relates to polypeptides capable of promoting odorant receptor cell surface localization and odorant receptor functional expression. The present invention further provides assays for the detection of ligands specific for various odorant receptors. Additionally, the present invention provides methods of screening for odorant receptor accessory protein polymorphisms and mutations associated with disease states, as well as methods of screening for therapeutic agents, ligands, and modulators of such proteins. | 04-09-2009 |
20090092998 | MARKER FOR ARRHYTHMIA RISK - The present invention relates to markers and methods for determining risk of ventricular arrhythmia in an individual. By using the markers of the present invention, individual with high risk of ventricular arrhythmia can properly be detected and treated. The present inventors have discovered that IL-6 and/or DROMs have strongly positive correlation with the risk of ventricular arrhythmia. | 04-09-2009 |
20090092999 | METHODS OF PREDICTING THERAPEUTIC RESPONSE IN ATOPIC DERMATITIS TO IL-31 ANTAGONISTS - The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population. | 04-09-2009 |
20090098568 | Method for immobilizing proteins - This invention provides a method for immobilizing proteins comprising: step 1 of purifying target proteins to be immobilized, which have a first tag portion and a second tag portion, with the use of the first tag portion; step 2 of activating reactive groups capable of covalently binding to the proteins on a carrier for immobilization; and step 3 of allowing a solution containing the proteins purified in step 1 to react with the carrier after step 2, wherein, in step 3, the proteins are immobilized on the carrier via interactions between the second tag portion and the site of the carrier to which the second tag portion binds and via covalent binding between the reactive groups and the proteins. This method enables the stable immobilization of various types of target proteins on a carrier regardless of the amounts of target proteins and without nonspecific immobilization of contaminating proteins. | 04-16-2009 |
20090098569 | Novel PGC-1 Isoforms and Uses Therefor - The invention provides isolated nucleic acid molecules, designated PGC-1b and PGC-1c nucleic acid molecules, which encode novel isoforms of PGC-1 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. | 04-16-2009 |
20090098570 | Lxr ligand testing method - A method of easily measuring whether or not an LXR ligand has the function of effecting, e.g., increasing, plasma triglyceride concentration and/or LDL cholesterol concentration in a mammal by using the binding activity between LXR and a coactivator, and a method of identifying LXR ligands that do not have the function of effecting, e.g., increasing, plasma triglyceride concentration and/or LDL cholesterol concentration by using the binding activity between LXR and a coactivator. | 04-16-2009 |
20090098571 | METHODS AND SUBSTANCES FOR THE DIAGNOSIS AND THERAPY OF SEPSIS AND SEPSIS-LIKE SYSTEMIC INFECTIONS - Uses of recombinant procalcitonin 3-116 in the diagnosis and therapy of septic diseases and the measurement of prohormones other than procalcitonin, and of dipeptidyl peptidase IV, as biormarkers in the diagnosis of sepsis. | 04-16-2009 |
20090098572 | BREAST CANCER RESISTANCE PROTEIN (BCRP) AND ANTIBODIES THERETO - The present invention provides a breast cancer resistance polynucleotide and protein of | 04-16-2009 |
20090104622 | Extracellular/Epidermal Growth Factor Like Protein - The present invention discloses an extracellular/epidermal growth factor polypeptides and polynucleotides encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and therapeutic uses of the polypeptides which include induction of DNA synthesis, stimulating wound healing, treating neurological disorders, treating ocular disorders, treating kidney and liver disorders and stimulating embryogenesis and angiogenesis. Also disclosed are antagonists against such polypeptide and their use as a therapeutic to treat neoplasia. Also disclosed are diagnostic assays for detecting altered levels of the polypeptide of the present invention and mutations in the nucleic acid sequences which encode the polypeptides of the present invention. | 04-23-2009 |
20090104623 | COMPOSITIONS FOR CONTROLLING HAIR GROWTH - FP-1 is a protein that is specifically expressed in the follicular papilla of the hair follicle. The nucleic acid and amino acid sequences of FP-1, as well as antibodies that specifically bind FP-1 are provided. In addition, methods of isolating follicular papilla cells and methods of modulating hair growth are also disclosed. | 04-23-2009 |
20090104624 | METHODS AND KITS FOR DETECTING ITA IN A BIOLOGICAL SAMPLE - Methods for detecting invasive trophoblast antigen (ITA) in biological samples comprise screening the samples for ITA using antibodies that bind to the ITA. The methods are useful to detect pregnancy, trophoblastic diseases, and Down's syndrome in fetuses of pregnant women. Some methods include screening the samples with a plurality of capture antibodies that specifically bind ITA. Chemiluminescent immunoassays are disclosed. The methods may be practiced with the diagnostic kits of the invention. | 04-23-2009 |
20090104625 | Homogeneous immunoassays for multiple allergens - A homogeneous immunoassay method and system for quantitative determination of total immunoglobulin E and specific antibody levels to a plurality of allergens, in which a relatively small sampling of blood is required. The method utilizes relatively small microparticles in aqueous suspension. The immunoassay procedure is an immunometric sandwich procedure preferably utilizing biotin-streptavidin signal amplification techniques and R-phycoerytherin fluorescent labels. | 04-23-2009 |
20090104626 | METHODS OF ISOLATING BIPOTENT HEPATIC PROGENITOR CELLS - A method of obtaining a mixture of cells enriched in hepatic progenitors is developed which comprises methods yielding suspensions of a mixture of cell types, and selecting those cells that are classical MHC class I antigen(s) negative and ICAM-1 antigen positive. The weak or dull expression of nonclassical MHC class I antigen(s) can be used for further enrichment of hepatic progenitors. Furthermore, the progenitors can be selected to have a level of side scatter, a measure of granularity or cytoplasmic droplets, that is higher than that in non-parenchymal cells, such as hemopoietic cells, and lower than that in mature parenchymal cells, such as hepatocytes. Furthermore, the progeny of the isolated progenitors can express alpha-fetoprotein and/or albumin and/or CK19. The hepatic progenitors, so isolated, can grow clonally, that is an entire population of progeny can be derived from one cell. The clones of progenitors have a growth pattern in culture of piled-up aggregates or clusters. These methods of isolating the hepatic progenitors are applicable to any vertebrates including human. The hepatic progenitor cell population is expected to be useful for cell therapies, for bioartificial livers, for gene therapies, for vaccine development, and for myriad toxicological, pharmacological, and pharmaceutical programs and investigations. | 04-23-2009 |
20090111121 | METHOD FOR DETECTING A BIOMARKER OF OXIDATIVE STRESS IN A BIOLOGICAL SAMPLE - A method for characterizing oxidative stress. The method includes dosing a ratio of HNE-to-DHN-protein in blood; comparing the ratio of HNE-to-DHN-protein in blood to a predetermined interval of ratio values associated with a predetermined level of oxidative stress; and classifying the oxidative stress as having reached the predetermined level if the ratio of HNE-to-DHN-protein in blood is within the predetermined interval of ratio values. | 04-30-2009 |
20090111122 | METHOD FOR NON-INVASIVE EXAMINATION OF NON-ALCOHOLIC STEATOHEPATITIS BY QUANTIFICATION OF CYTOCHROME-c, AND TEST KIT - It is found that blood cytochrome c levels quantified for non-alcoholic steatohepatitis patients are higher than those for healthy persons, and that the quantified blood cytochrome c values correlated with fat deposition rates in hepatocytes. It is possible to test non-alcoholic steatohepatitis by quantifying cytochrome c in serum. A test method and a test kit for the test are provided. | 04-30-2009 |
20090117580 | Structure of prl-1 protein crystal and the method of crystallization thereof - The present invention relates to a crystal structure of PRL-1 (Phospatase of Regenerating Liver) protein and a method of crystallization thereof. It has been found that the PRL-1 protein has a tertiary structure having 5 strands of beta-sheet surrounded by 6 alpha-helices and well-arranged active site with closed P-loop, and monomers form a trimer through farnesylation site in the C-terminus of said protein. Thus intra-cellular migration and membrane localization can be achieved. The said crystal structure of PRL-1 protein of the present invention is very useful for the development the agent which inhibits carcinogenesis and metastasis of the cancer. | 05-07-2009 |
20090117581 | Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS) - The present invention relates to methods for preparing an artificial immune system. The artificial immune system comprises a cell culture comprising T cells, B cells and antigen-primed dendritic cells. The artificial immune system of the present invention can be used for in vitro testing of vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics and other chemicals. | 05-07-2009 |
20090117582 | Diagnosis of Allergic Complaints, Atopic Diseases and/or Auto-Immune Diseases by the Identification of Antibodies Against CD28 in Human Serum - The invention relates to a method for diagnosing allergic complaints, atopic diseases and/or auto-immune diseases, according to which a sample from a patient is analysed for the presence of anti-CD28 auto-antibodies by bringing said sample into contact with CD28. If auto-antibodies bond to the CD28, this indicates the presence of an allergic complaint, atopic disease and/or auto-immune disease. The invention also relates to the use of CD28 for diagnosing said diseases and to a kit that is designed for this purpose, comprising CD28 and marked anti-immunoglobulin antibodies. | 05-07-2009 |
20090117583 | EGF-like nucleic acids and polypeptides and uses thereof - The invention provides isolated nucleic acid molecules, designated ELVIS-1, ELVIS-2, and ELVIS-3 (for Epidermal Growth Factor-Like Variant In Skin-1,2, and 3). ELVIS nucleic acid molecules encode wholly secreted and transmembrane proteins with homology to EGF and TGF-α. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. | 05-07-2009 |
20090117584 | Non-Human mammalian Arthritis Model Featuring Human Antibodies Against Citrul-Linated Proteins - Use of a non-human mammalian disease model, wherein the non-human mammal has been implanted with human synovial tissue or other human inflamed tissue containing anti-CCP (cyclic citrullinated peptide) antibody producing cells for (i) analyzing cellular processes in a disease associated with anti-CCP antibodies in such human synovial tissue or other human inflamed tissue, (ii) studying the role of anti-CCP antibodies in the induction and progression of a disease associated with anti-CCP antibodies, (iii) testing the efficacy of a therapeutic agent for the prevention or treatment of a disease associated with anti-CCP antibodies, and (iv) identifying a therapeutic agent useful for the prevention or treatment of a disease associated with anti-CCP antibodies. In one embodiment the non-human mammalian disease model is a mouse, such as a SCID mouse, and the disease associated with anti-CCP antibodies is arthritis, such as RA (rheumatoid arthritis). | 05-07-2009 |
20090117585 | ANTI-FUNGAL SCREENING METHOD - The present invention relates to a method for identification of anti-fungal agents and their mode of actions. In particular, it relates to cell wall disturbing anti-fungal agents and to an assay to identify them. More particularly, it relates to a screening method for the identification of an anti-fungal compound, which method comprises (i) contacting a potential anti-fungal compound with a polypeptide which is involved in cell wall synthesis; and then (ii) identifying the effect which the potential anti-fungal compound has on the activity of the polypeptide, whereby reduced polypeptide activity is indicative for anti-fungal activity of the potential anti-fungal compound. It also relates to an overexpressing host cell and to a kit for performing the assay. | 05-07-2009 |
20090117586 | FUNGAL CELL WALL SYNTHESIS GENE - A reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered. Further, genes conferring resistance to the above compounds were identified and methods of screening for compounds that inhibit the activity of the proteins encoded by these genes were developed. Therefore, through the novel compounds, the present invention showed that antifungal agents having a novel mechanism, i.e. inhibiting the process that transports GPI-anchored proteins to the cell wall, could be achieved. | 05-07-2009 |
20090117587 | High-Affinity Monoclonal Antibodies for Botulinum Toxin Type A - High affinity antibodies for binding epitopes of BoNT/A and hybridomas that produce such antibodies are described. The antibodies may be used in a kit for detecting BoNT/A in a sample. | 05-07-2009 |
20090117588 | Methods of diagnosing pre-eclampsia or eclampsia - Disclosed herein are kits for diagnosing pre-eclampsia and eclampsia or a propensity to develop pre-eclampsia or eclampsia that include agents for the detection of levels of free placental growth factor in a subject. | 05-07-2009 |
20090117589 | SYSTEMS AND METHODS FOR ANALYZING PERSISTENT HOMEOSTATIC PERTURBATIONS - This invention is in the field of homeostasis analysis. More particularly, it relates to systems and methods for analyzing persistent homeostatic perturbations, i.e. chronic stress, by measuring levels of biomarkers that are related to chronic stress. This invention is also directed to systems and methods for analyzing the molecular mechanisms of chronic stress. | 05-07-2009 |
20090123936 | CONFORMATIONALLY ABNORMAL FORMS OF TAU PROTEINS AND SPECIFIC ANTIBODIES THERETO - The invention relates to antibodies with a specificity to an abnormally truncated form of tau protein, which is conformationally different from normal tau, and does not bind to normal tau protein, conformationally different tau proteins (“tauons”) and diagnostic and therapeutical aspects in relation to Alzheimer's disease and related tauopathies. | 05-14-2009 |
20090123937 | Methods of selecting epidermal growth factor receptor (EGFR) binding agents - The present application relates to methods of selecting EGFr binding agents. In certain embodiments, such EGFr binding agents bind to at least a portion of a panitumumab epitope on an EGFr. In certain embodiments, such EGFr binding agents do not bind to a panitumumab epitope on an EGFr. | 05-14-2009 |
20090130689 | Method useful for detecting encephalopathies - The invention concerns a method of detecting a TSSE Disease or prion disease. The invention further concerns a method for amplifying oligomerization of isoforms of the cellular prion PrP | 05-21-2009 |
20090130690 | METHOD FOR THE DIAGNOSIS OF RHEUMATOID ARTHRITIS - The present invention relates to a novel diagnostic marker useful for the diagnosis of rheumatoid arthritis comprising the autoantibodies of mannose binding lectin protein and a process thereof. | 05-21-2009 |
20090136964 | NOVEL ANTI-HEPARAN SULFATE ANTIBODY, METHOD FOR DETECTION OF HEPARAN SULFATE, AND KIT FOR DETECTION OF HEPARAN SULFATE - An antibody which reacts with N-acetylheparosan and heparan sulfate that is derived from bovine kidney but does not substantially react with heparan sulfate derived from a murine Engelbreath-Holm-Swam tumor tissue, the antibody being produced with a hybridoma which is prepared using a substance composed of a protein and N-acetylheparosan bound to the protein. | 05-28-2009 |
20090136965 | Use of antibody-ligand binding to characterise diseases - We have found that when an antibody binds to (captures) its specific ligand, the antibody-ligand complex is redirected to a route of elimination which is different from that which occurs naturally for the specific ligand that is not bound to an antibody. As a consequence, the amount of antibody-bound ligand in the blood increases over time. The increase in total ligand concentration is a property that is specific to the patient to whom the antibody is administered. Accordingly, the invention provides a method for diagnosing disease in a subject and a method for identifying the most appropriate treatment for a particular patient. Patients who produce more ligand, and thus more antibody-ligand complex, may be more likely to have a disease which is predominantly driven by that ligand. These patients should respond better to a therapy targeted against that ligand. The better understanding of the underlying malfunctions in disease biology provided by the methods of the invention, in respect of the rates of production of natural ligands in health and disease, provides a logical and targeted selection of the appropriate treatments to address specific biological abnormalities. | 05-28-2009 |
20090136966 | Normalization of Complex Analyte Mixtures - The present invention relates to methods and compositions for the normalization of complex analyte mixtures. The invention allows the preparation of profiled samples from highly complex analyte mixtures, allowing the identification of relevant targets or biomarkers. The invention also relates to methods for producing devices, such as a support, suitable for normalization of complex analyte samples. The invention can be used for the normalization of any complex mixture, such as immunogenic libraries, particularly of human source, and to identify or produce biomarkers highly relevant to human traits or conditions. | 05-28-2009 |
20090136967 | Peptides for Discrimination of Prions - The aim of the present invention is to provide a non-intrusive way to isolate, concentrate and monitor the TSE disease-related pathogenic prion protein. The invention described several peptides and their ability to capture PrP | 05-28-2009 |
20090142772 | Devices and Methods for the Detection of Analytes - System and methods for detecting analytes such as pathogenic cells are described. The methods allow for the direct measurement of analytes such as pathogenic organisms without the need for sample preparation and/or PCR. The devices can be used individually as point-of-use sensors for airborne pathogens and other pathogenic organisms in foods and agriculture products. | 06-04-2009 |
20090142773 | METHODS AND CONTROLS FOR MONITORING ASSAY QUALITY AND ACCURACY IN PARATHYROID HORMONE MEASUREMENT - The present invention relates to the use of control compositions and kits comprising such to evaluate and monitor the consistency of assays utilized to determine parathyroid hormone levels. | 06-04-2009 |
20090142774 | METHOD FOR THE EARLY DETECTION OF RENAL INJURY - A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents. | 06-04-2009 |
20090148856 | Methods and apparatus for therapeutic drug monitoring using an acoustic device - Methods for therapeutic drug monitoring are provided. A plurality of particles, each of which is coated with a capture agent capable of binding a therapeutic drug of choice is combined with the sample to form a plurality of therapeutic drug-particle complexes. The system also includes a transport arrangement for transporting the sample and/or particles to the sensor surface, and optionally a magnetic field inducing structure constructed and arranged to establish a magnetic field at and adjacent to the sensor surface. The resonant sensor produces a signal corresponding to an amount of therapeutic drug-particle complexes that are bound to the sensor surface. | 06-11-2009 |
20090148857 | Method and apparatus for detection of analyte using an acoustic device - Methods for detecting analytes in a sample are provided. A plurality of particles, each of which is coated with a capture agent having an affinity for the analyte, is combined with the sample to form a plurality of analyte-particle complexes. The system also includes a transport arrangement for transporting the sample to the sensor surface, and a magnetic field inducing structure constructed and arranged to establish a magnetic field at and adjacent to the sensor surface. The resonant sensor produces a signal corresponding to an amount of analyte-particle complexes that are bound to the sensor surface. | 06-11-2009 |
20090148858 | METHODS FOR CHARACTERIZING BIOLOGICAL MOLECULE MODULATORS - Methods for characterizing a biochemical reaction and analysis of reaction products by establishing continuously variable concentration gradients of one or more reagents of the biochemical reaction are provided. Methods for determining mechanism of inhibition or activation, potency of inhibition or activation, or both of an enzyme inhibitor or activator, respectively, are also provided. The continuously variable concentration gradients can be established in a microfluidic chip. | 06-11-2009 |
20090148859 | Mtor Pathway Theranostic - This invention relates, e.g., to a method for predicting a subject's response to a chemotherapeutic agent and/or the subject's prognosis, comprising measuring the phosphorylation state of at least one member of the mTOR pathway, and/or of at least one member of an interconnected polypeptide pathway (e.g. a member of the Akt pathway or a member of the IRS pathway), compared to a baseline value, in a cancer tissue or cancer cell sample from the subject, wherein an elevated level of the phosphorylation state compared to the baseline value indicates that the subject is a non-responder to the chemotherapeutic agent and/or has a poor prognosis. Also described is a method for treating a cancer in a subject in need thereof, wherein the subject exhibits an elevated level of the phosphorylation state, comprising administering one or more inhibitors of the mTOR and/or an interconnected pathway. | 06-11-2009 |
20090148860 | METHODS OF DIAGNOSING MUSCLE DAMAGE - A method for assessing muscle damage in a biological sample obtained from a subject is disclosed. The method involves obtaining a biological sample from a subject being assessed for muscle damage, and evaluating the sample for the presence or absence of a myofilament protein modification product. The method can also be used to assess the extent and/or type of muscle damage in a subject by studying the profile of myofilament protein modification products detected in the sample taken from the subject. The invention further provides a method for screening for an agent which modulates the level of a myofilament protein modification product present in a biological sample or for a calcium sensitizing agent. The invention is applicable to cardiac muscle and skeletal muscle. | 06-11-2009 |
20090148861 | KIR CHANNEL MODULATORS - Provided is a three-dimensional structure of an alcohol bound to an alcohol-binding site of an inwardly rectifying potassium (Kir) channel, Kir channel alcohol modulators and methods for identifying Kir channel modulators. | 06-11-2009 |
20090148862 | Evaluation method of organic or bio-conjugation on nanoparticles using imaging of time-of-flight secondary ion mass spectrometry - A method of evaluating conjugation between materials using imaging of time-of-flight secondary ion mass spectrometry (TOF-SIMS) according to the present invention is carried out by following the steps which comprise, a) forming a spontaneous pattern on a substrate with a mixture comprising nanoparticles and a conjugation material selected from organic, bio or inorganic material, b) obtaining an ion detection pattern from said conjugation material and said nanoparticles, respectively, depending on their position on the substrate by using time-of-flight secondary ion mass spectrometry, and c) determining whether the conjugation is formed between said conjugation material and said nanoparticles by comparing the ion detection pattern of said conjugation material with the ion detection pattern of said nanoparticles. | 06-11-2009 |
20090148863 | Nanoparticle biosensors - Compositions which are useful in ultralow level of detection based on functionalized nanoparticles having exceptional combinations of properties including stability, brightness, binding specificity, and ability to be imaged at single nanoparticle resolution over desired period of time. The biological moieties on the nanoparticles preserve biological function. The nanoparticle surface can comprise a first monolayer component which is adapted to bind to a biological moiety. The biological moiety can be adapted to bind to an analyte. The nanoparticle surface can further comprise a second monolayer component, which is adapted to help expose the first monolayer component on the surface. Other components on the surface can help stabilize the nanoparticle. The nanoparticles are stable against aggregation, have photostability (non-photodecomposition and non-blinking), and can achieve single molecule detection in real time. Analytes can be detected at low levels both in solution and on surfaces such as cell surfaces. | 06-11-2009 |
20090148864 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CERVICAL DISEASE - Methods and compositions for identifying high-grade cervical disease in a patient sample are provided. The methods of the invention comprise detecting overexpression of at least one biomarker in a body sample, wherein the biomarker is selectively overexpressed in high-grade cervical disease. In particular claims, the body sample is a cervical smear or monolayer of cervical cells. The biomarkers of the invention include genes and proteins that are involved in cell cycle regulation, signal transduction, and DNA replication and transcription. In particular claims, the biomarker is an S-phase gene. In some aspects of the invention, overexpression of a biomarker of interest is detected at the protein level using biomarker-specific antibodies or at the nucleic acid level using nucleic acid hybridization techniques. Kits for practicing the methods of the invention are further provided. | 06-11-2009 |
20090148865 | POLYSACCHARIDE STRUCTURE AND SEQUENCE DETERMINATION - The invention provides a method for the structural analysis of a saccharide, comprising: a) providing on a surface a plurality of essentially sequence- and/or site-specific binding agents; b) contacting said surface with a saccharide to be analyzed, or with a mixture comprising a plurality of fragments of said saccharide; c) washing or otherwise removing unbound saccharide or saccharide fragments; d) adding to the surface obtained in step c) an essentially sequence- and/or site-specific marker, or a mixture of essentially sequence- and/or site-specific markers; e) acquiring one or more images of the markers that are bound to said surface; and f) deriving information related to the identity of the saccharide being analyzed from said image. | 06-11-2009 |
20090155810 | METHODS FOR PRODUCING MEMBERS OF SPECIFIC BINDING PAIRS - A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA. Using this method libraries of DNA encoding respective chains of such multimeric sbp members may be combined, thereby obtaining a much greater genetic diversity in the sbp members than could easily be obtained by conventional methods. | 06-18-2009 |
20090155811 | Lateral Flow Immunoassay With Encapsulated Detection Modality - A lateral flow immunoassay featuring encapsulated metal particles. The encapsulated particles may use SERS nanotags as the detection modality. The use of encapsulated particles as a detection modality, in particular encapsulated SERS tags increases the sensitivity of an LFI prepared for visual reading and introduces the ability to obtain substantially more sensitive qualitative results or quantitative results through the analysis of a SERS spectrum read from an LFI prepared in accordance with the present invention. The use of SERS as detection modality also enhances the ability of an LFI device to be used for a multiplexed test. Other aspects of the present invention include LFI devices specifically configured to test whole blood, a reader for the detection and interpretation of a multiplexed assay and the hardware and software components used to implement the reader. | 06-18-2009 |
20090155812 | APOLIPOPROTEIN FINGERPRINTING TECHNIQUE AND METHODS RELATED THERETO - A method for determining the concentration and modifications of apolipoprotein in biological samples including plasma, serum, and lipoprotein fractions, by obtaining a sample from a patient, adding a specific volume of an internal standard to the sample, applying the sample to a surface-enhanced, Protein G-coated, antibody-bound chip and removing unbound sample components, analyzing the sample by mass spectrometry, determining the concentration of the apolipoprotein using values of internal standards, and evaluating the concentration of the apolipoprotein, its isoforms, amino acid substitutions and modifications for use as a tool for diagnosing cancer, diabetes, stroke, stress, Alzheimer's disease, inflammation, neurological disease and cardiovascular diseases. | 06-18-2009 |
20090155813 | Methods and Devices for Diagnosis of Appendicitis - A method is provided for diagnosing appendicitis in a patient that includes identifying at least one symptom of appendicitis in the patient and identifying the presence of at least one molecule differentially associated with appendicitis in a fluid or tissue sample of said patient. MRP-8/14 and haptoglobin are examples of molecules differentially associated with appendicitis. Devices and kits for performing the appendicitis assays of this invention are also provided. In one embodiment, the device is in a flow-through immunoassay format for testing blood samples. Further, methods for screening for molecules differentially associated with appendicitis are provided that include the use of samples from patients being operated on for suspected appendicitis. | 06-18-2009 |
20090162868 | Gene Markers and Utilization of the Same - [Problems]To provide a gene marker which enables diagnosis of rejection, evaluation of the efficacy of an immunosuppressive agent, and determination of the presence or absence of immunological tolerance; methods that can be performed in a quick, simple, and convenient manner by using the gene marker as an indicator for diagnosing rejection, evaluating the efficacy of an immunosuppressive agent, identifying an immunosuppressive agent, selecting an immunosuppressive agent, determining the dose of an immunosuppressive agent, and judging the presence or absence of immunological tolerance; a kit; and a method for screening for an immunosuppressive agent or an immunological tolerance-inducing agent. | 06-25-2009 |
20090162869 | MEMBRANE MOLECULE EXPRESSED SPECIFICALLY IN ACTIVATED PLASMACYTOID DENDRITIC CELL - It is an object of the present invention to identify a membrane molecule that is specifically expressed on activated plasmacytoid dendritic cells, for the purpose of preventing or improving affection or disease such as cancer, autoimmune disease, allergy, or infectious disease by regulating the functions of dendritic cells capable of integrating an immune system. The present invention provides a protein having any one of the following amino acid sequences: | 06-25-2009 |
20090170115 | Crohn's disease anitbody epitope peptide and reagent for testing crohn's disease - An epitope peptide is provided, which is capable of binding specifically to an antibody characteristic of Crohn's disease that is specifically observed in patients with Crohn's disease, together with a test method for conveniently and rapidly determining whether a subject is affected by Crohn's disease by use of the above peptide. The epitope peptide to the Crohn's disease antibody comprises a peptide having an amino acid sequences represented by any one of SEQ ID NOS: 1 to 3 or a salt thereof. A test reagent and a test method for Crohn's disease are provided, which comprise the peptide as an active ingredient. | 07-02-2009 |
20090170116 | IL-13 Production Inhibitor - The present invention provides a screening method/screening kit for an IL-13 production inhibitor, which comprises using (a) a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or its partial peptide, or a salt thereof; and (b) a ligand capable of specifically binding to the protein; an IL-13 production inhibitor which is obtainable by said screening, and the like. The IL-13 production inhibitor which can be obtained by the screening of the present invention is useful as a prophylactic/therapeutic agent for, e.g., respiratory disease, etc. | 07-02-2009 |
20090170117 | THREE-DIMENSIONAL STRUCTURE OF FabK PROTEIN AND METHOD OF DEVELOPING A FabK PROTEIN INHIBITOR USING THE SAME - The present invention relates to a FabK (enoyl-acyl carrier protein reductase) protein derived from a | 07-02-2009 |
20090170118 | Formation and Encapsulation of Molecular Bilayer and Monolayer Membranes - Disclosed herein are compositions, methods, and devices related to bilayer and monolayer membranes, their encapsulation in a hydrogel, and their formation. Methods of using the disclose compositions and devices are also disclosed. | 07-02-2009 |
20090170119 | METHOD FOR AMPLIFYING VARIATION OF FREQUENCY OF SIGNAL IN PIEZOELECTRICAL BIOSENSOR - Provided is a method for amplifying a frequency variation of a detected signal in a biosensor that is used for detecting a biomolecule by measuring a change in frequency of an oscillating signal the change being caused by pressure a biomolecule applies to a piezoelectric substance. The method for amplifying a frequency variation of a detected signal comprises the steps of: (a) applying a sample to a probe being fixed to an upper portion of a substrate of the biosensor to allow a biomolecule in the sample to be bound to the probe; (b) applying, protein tagged with a metal particle to the biosensor to allow the protein, and the biomolecule to be bound with each other; and (c) applying a metal enhancer to the biosensor to allow the metal enhancer to be bound to the metal, particle having been bound to the protein | 07-02-2009 |
20090170120 | Clinical Correlates - A method of assessing an intracellular pathogen infection and/or monitoring an intracellular pathogen infection in an individual comprises determining whether the individual has (a) T-cells that secrete IFN-γ only, (b) T-cells that secrete IL-2 only or (c) T-cells that secrete both IFN-γ and IL-2 in response to an intracellular pathogen antigen and optionally determining any change in this cytokine profile. | 07-02-2009 |
20090170121 | ASSAY BUFFER, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME - Compositions, reagents, kits, systems, system components, and methods for performing assays. More particularly, the invention relates to the use of novel combinations of reagents to provide improved assay performance. | 07-02-2009 |
20090176243 | Novel monkey GPR103 and monkey QRFP and method of evaluating compound by using GPR103 - There are provided non-human primate and rat GPR103 genes and proteins and a compound evaluation method employing the genes or proteins. There are also provided highly useful novel ligands for functional analysis of the GPR103 genes and proteins and for the compound evaluation. The nucleic acids or proteins having the sequences listed as SEQ ID NOS: 1 to 4 provide non-human primate or rat GPR103 genes and proteins and information based on the genes and proteins. The genes and proteins can be used for evaluation of compounds. The nucleic acids or proteins having the sequence listed as SEQ ID NO: 5 or 6 provide a GPR103 ligand. | 07-09-2009 |
20090176244 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF CROHN'S DISEASE - The present invention provides methods and materials, including kits, to evaluate Crohn's disease, including to diagnose, monitor, or determine the efficacy of treatment for Crohn's Disease. The methods involve determining the presence, absence, or level of zonulin in a subject sample. In certain embodiments, the need for more laborious and/or invasive tests to monitor disease state is minimized or obviated. | 07-09-2009 |
20090176245 | Rheumatoid Arthritis Test Method and Treating Method - It is intended to evaluate the prognosis of rheumatoid arthritis based on the evaluation of the disease severity of the patient to select a treatment method suitable for each rheumatoid arthritis patients, and to measure HSC71 protein levels of the patients before and after the administrations of therapeutic agents to determine the efficacy of various therapeutic agents for each of rheumatoid arthritis patients, and to use thereof as a remedy for preventing onset and progression of rheumatoid arthritis. It has been revealed that whether HSC71 (heat shock cognate protein 71), which is a member of the heat shock protein 70 family, shows any difference in expression between rheumatoid arthritis patients and healthy subjects. In the case where the HSC71 protein is accelerated in a rheumatoid arthritis patient the HSC71 concentrations in the serum, synovial fluid, serebrospinal fluid, urine, saliva and sputum of the patient are measured to thereby examine the disease severity of rheumatoid arthritis. Based thereon, the prognosis of the rheumatoid arthritis is evaluated and a method suitable for the patient is selected. HSC71 protein levels are measured before and after the administration of therapeutic agents to a rheumatoid arthritis patient and the efficacy of the therapeutic agents are determined. Further, Use as a remedy or preventing the onset and progression of rheumatoid arthritis is intended. | 07-09-2009 |
20090176246 | ASSAY FOR MEASURING FACTOR VIIa-ANTITHROMBIN COMPLEXES - A method for determining the concentration of factor VIIa-antithrombin complexes is disclosed which has application to estimating the level of intravascular exposure of tissue factor, assessing patient risk for hypercoagulation or other coagulopathies, and monitoring patients for factor VIIa-antithrombin complexes over time which can reveal changes in risk for hypercoagulation or other coagulopathies and/or effectiveness of anticoagulant therapy. Antibodies suitable for use in an in vitro assay for determining the concentration of factor VIIa-antithrombin complexes and methods for making the same are also disclosed. | 07-09-2009 |
20090176247 | Determination of sFlt-1:Angiogenic Factor Complex - Methods for determining the presence or amount of a complex comprising a first and second molecular entity are provided, preferably an sFlt-1:PlGF complex. A determination of the presence or amount of the complex can be used in methods for predicting, detecting, monitoring a disease, or guiding therapy in respect to a disease such as vascular, vascular-related disease, cardiac, cardiac-related disease, cancer, cancer-related disease, preeclampsia, and preeclampsia-related disease. Determining sFlt- | 07-09-2009 |
20090176248 | Method For Evaluating Kidney Function In A Feline - Methods for (1) evaluating feline kidney function by determining ghrelin level in feline tissue or biofluid and correlating the ghrelin level directly to kidney function and (2) diagnosing kidney disease in a feline comprises determining an observed ghrelin level in a tissue or biofluid of the feline and comparing the observed ghrelin level to a reference ghrelin level indicative of normal kidney function, wherein an observed level lower than the reference level is indicative of kidney disease or susceptibility thereto. | 07-09-2009 |
20090176249 | Method for detecting cardiac collateral formation - The present invention relates to a method of detecting collateral artery formation by measuring the level of NT-pro-BNP or BNP in an individual. | 07-09-2009 |
20090181402 | COMPOSITIONS AND METHODS FOR COUPLING A PLURALITY OF COMPOUNDS TO A SCAFFOLD - Compositions and methods are provided for coupling a plurality of compounds to a scaffold. Compositions and methods are further provided for catalyzing a reaction between at least one terminal alkyne moiety and at least one azide moiety, wherein one moiety is attached to the compound and the other moiety is attached to the scaffold, forming at least one triazole thereby. | 07-16-2009 |
20090186364 | Method of Constructing Recombinant Proteoliposome for Diagnostic Use - [PROBLEMS] To provide a method for preparation of recombinant proteoliposomes suitable for diagnostic applications, a detection plate coated with the recombinant proteoliposomes, a detection kit and so on. | 07-23-2009 |
20090186365 | Use of 14-3-3- Proteins in Treatment and Prevention of Neurodegeneration - The present disclosure is directed to methods for treatment and prevention of disease states characterized by a decreased 14-3-3 polypeptide expression or activity. In one embodiment, the present disclosure provides methods for the treatment and/or prevention of Parkinson's disease, neurodegeneration and/or diseases characterized, at least in part, by neurodegeneration, by increasing a 14-3-3 polypeptide activity. | 07-23-2009 |
20090186366 | METHOD OF DETECTING INTERACTIONS BETWEEN PROTEIN COMPONENTS - A method of detecting protein interactions in a biological sample. Protein components in a first aliquot of a sample are labelled with a first bifunctional dye which cross-links any-interacting components. A second aliquot of said sample functions as a control sample, in which protein components are labelled with a different, mono functional dye. Thereafter, the two aliquots are mixed and all components are separated by electrophoresis. Finally, differences in luminescence of the separated dye-labelled components are detected. The two dyes should match one another with regard to charge and/or molecular weight but should emit different kinds of fluorescent light. | 07-23-2009 |
20090191570 | Inhibition of Interaction of PSD93 and PSD95 with nNOS and NMDA Receptors - PSD-95/SAP90 antisense-treated animals not only experience a significant decrease in MAC for isoflurane, but also experience an attenuation in the NMDA-induced increase in isoflurane MAC. PSD-95/SAP90 appears to mediate the role of the NMDA receptor in determining the MAC of inhalational anesthetics. Suppression of the expression of PSD-95/SAP90 in the spinal cord significantly attenuates responses to painful stimuli mediated through the N-methyl-D-aspartate receptor activation. In spinal cord neurons PSD-95/SAP90 interacts with the N-methyl-D-aspartate receptor subunits 2A/2B. Activation of the N-methyl-D-aspartate receptor in spinal hyperalgesia results in association of the N-methyl-D-aspartate receptor with PSD-95/SAP90. PSD-95/SAP90 is required for hyperalgesia triggered via the N-methyl-D-aspartate receptor at the spinal cord level. | 07-30-2009 |
20090191571 | Isolation and Detection of Pathogenic Prions - Peptide reagents that interact preferentially with the PrP | 07-30-2009 |
20090197278 | Antibodies to hADA2 - Human polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for therapeutic purposes. Antagonists against such polypeptides and their use as a therapeutic are also disclosed. Also disclosed are diagnostic methods for detecting disease which utilize the sequences and polypeptides. | 08-06-2009 |
20090197279 | MICROTUBULE SYNTHESIS AS A BIOMARKER - Stable isotope labeling was used to measure dynamics of tubulin incorporation into microtubule subpopulations representing different neuronal compartments in the murine hippocampus. Neuronal microtubules were largely static. Basal turnover was highest in tau-associated (axona) and growth cone), lower in MAP2-associated (somatodendritic), and lowest in cold stable (axonal shaft) subpopulations. Intracerebroventricular glutamate injection stimulated label incorporation into axonal shaft and somatodendritic microtubules, the latter dependent on cAMP-PKA. Hippocampus-dependent memory formation after contextual fear conditioning was accompanied by increased assembly of MAP2- and cold stable-microtubules. Both microtubule assembly and memory formation were inhibited by the microtubule depolymerizing drug, nocodazole. This approach allows for correlation with behavioral measures of learning and memory and for the screening of candidate agents for stimulatory activities on learning memory. | 08-06-2009 |
20090197280 | Methods and Devices for Rapid Assessment of Severity of Injury - Methods and devices for rapid assessment of the severity of injury not due to a natural disease based upon measurement of neutrophil gelatinase-associated lipocalin (NGAL) are provided. | 08-06-2009 |
20090197281 | METHODS FOR DIAGNOSIS AND TREATMENT OF CHRONIC IMMUNE DISEASES - Methods are provided for diagnosing and/or characterizing chronic immune disease activity in a subject. In the subject methods, a sample is obtained from a subject suspected of having or known to have a chronic immune disease. The sample is then assayed for the presence of native Stat-1 protein and/or any lower molecular weight fragments of Stat-1 protein present. The assay results are used to diagnose the presence of chronic immune disease activity and/or characterize chronic immune disease activity in the subject, e.g., to confirm an initial chronic immune disease diagnosis, to determine the stage of the disease, to monitor disease progression, to predict disease attacks, and the like. In certain embodiments, the assay results are also used to predict the effectiveness of a particularly treatment protocol, e.g., to determine whether an interferon based treatment protocol will be effective. In addition, methods of Stat-1 based methods of treating chronic immune disease conditions are provided. Also provided by the subject invention are kits for practicing the methods. | 08-06-2009 |
20090203034 | Reagents for the detection of tyrosine phosphorylation in brain ischemia signaling pathways - The invention discloses 99 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Brain Ischemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: protein kinases, adaptor/scaffold proteins, adhesion proteins, G proteins/GTPase/Guanine nucleotide exchange factors, Calcium binding proteins, cytoskeletal proteins, Channel proteins, Chaperone proteins, Helicases, Motor proteins, Translation proteins, RNA binding proteins, Ubiquitin conjugating system proteins, vesicle proteins and Receptor proteins. | 08-13-2009 |
20090203035 | FLUORESCENT PROTEINS WITH INCREASED PHOTOSTABILITY - The present invention relates to novel fluorescent protein variants of DsRed and eqFP578. Fluorescent protein variants having increased photostability and/or having reversible photoswitching behavior, as well as polynucleotides encoding such variants are provided herein. Methods of using these novel fluorescent protein variants and methods for constructing other fluorescent protein variants having increased photostability are also provided by the present invention. | 08-13-2009 |
20090203036 | EPITOPE REGIONS OF A THYROTROPHIN (TSH) RECEPTOR, USES THEREOF AND ANTIBODIES THERETO - The present invention is concerned with epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto. | 08-13-2009 |
20090203037 | Anti-T. Cruzi Antibodies and Methods of Use - The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of | 08-13-2009 |
20090203038 | Negative Mimic Antibody For Use as a Blocking Reagent In BNP Immunoassays - The present disclosure relates to isolated antibodies that do not bind to brain natriuretic peptide that can be used as a reagent to reduce heterophilic interference in an immunoassay. | 08-13-2009 |
20090203039 | MONOCLONAL ANTIBODY TO SOLUBLE LOX-1 - It is intended to provide a monoclonal antibody that specifically recognizes human soluble LOX-1, particularly a monoclonal antibody with a dissociation constant (Kd) for human soluble LOX-1 of 1×10 | 08-13-2009 |
20090208970 | Probe for detection and quantification of inositol-1,4,5-trisphosphate and a method for detecting and quantifying inositol-1,4,5-trisphosphate using the same - A probe for detection and quantification with high accuracy in a noninvasive manner as to where and when inositol-1,4,5-trisphosphate is generated in living cells, and a method for detecting and quantifying inositol-1,4,5-trisphosphate using the probe. | 08-20-2009 |
20090208971 | Insulin promoter factor 1 as target/marker of beta cell failure - The present invention relates to the monitoring of disease progression and diagnosis of beta-cell failure in diabetes by measuring levels of IPF-1 in a liquid sample, and to screening for novel compounds for the prevention and/or treatment of diabetes. | 08-20-2009 |
20090208972 | CYTOTOXIC PROTEIN AND UTLIZATION THEREOF - This invention relates to a new cytotoxic protein (M toxin, mucous layer devastating toxin) produced by | 08-20-2009 |
20090208973 | Methods to identify compounds useful for the treatment of proliferative and differentiative disorders - The present invention relates to the discovery, identification and characterization of nucleotides that encode novel substrate-targeting subunits of ubiquitin ligases. The invention encompasses nucleotides encoding novel substrate-targeting subunits of ubiquitin ligases: FBP1, FBP2, FBP3, FBP4, FBP5, FBP6, FBP7, FBP8, FBP9, FBP10, FBP11, FBP12, FBP13, FBP14, FBP15, FBP16, FBP17, FBP18, FBP19, FBP20, FBP21, FBP22, FBP23, FBP24, and FBP25, transgenic mice, knock-out mice, host cell expression systems and proteins encoded by the nucleotides of the present invention. The present invention relates to screening assays that use the novel substrate-targeting subunits to identify potential therapeutic agents such as small molecules, compounds or derivatives and analogues of the novel ubiquitin ligases which modulate activity of the novel ubiquitin ligases for the treatment of proliferative and differentiative disorders, such as cancer, major opportunistic infections, immune disorders, certain cardiovascular diseases, and inflammatory disorders. The invention further encompasses therapeutic protocols and pharmaceutical compositions designed to target ubiquitin ligases and their substrates for the treatment of proliferative disorders. | 08-20-2009 |
20090208974 | Human Neuronal Attachment Factor-1 - A human F-spondin-like protein and DNA (RNA) encoding such protein and a procedure for producing such protein by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for treating spinal cord injuries and damage to peripheral nerves by promoting neural-cell adhesion and neurite extension, inhibiting tumor metastases and tumor angiogenesis, and stimulating wound repair. Antagonists are also disclosed which may be utilized to prevent malaria. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, are also disclosed. | 08-20-2009 |
20090215069 | Pancreatic polypeptide as target/marker of beta cell failure - The present invention relates to the monitoring of disease progression and diagnosis of beta-cell failure in diabetes by measuring levels of pancreatic hormone in a liquid sample, and to screening for novel compounds for the prevention and/or treatment of diabetes. | 08-27-2009 |
20090215070 | Highly Sensitive Immunoassays and Antibodies for Detection of Blood Factor VIII - Disclosed are antibodies that selectively bind to blood coagulation factor FVIII, and highly sensitive immunological assays comprising these antibodies. Preferred assays can detect FVIII at about 3500-fold below the normal physiological levels, and have a wide array of applications including accurate monitoring of FVIII concentration in pharmaceutical products for treatment of blood coagulation disorders, and determination of FVIII levels in plasma of human patients, including those with blood coagulation disorders such as hemophilia. | 08-27-2009 |
20090215071 | METHODS OF TARGETING BAFF - The present disclosure provides compositions and methods relating to the structure of BAFF in solution. The disclosure includes BAFF 60-mers, BAFF trimers, methods of making BAFF 60-mers and BAFF trimers, antibodies that preferentially bind one form or the other, and methods of identifying or evaluating a compound on the basis of its relative binding to or activity towards a BAFF 60-mer and a BAFF trimer. The disclosure also provides computer-based systems and methods relating to BAFF structures. | 08-27-2009 |
20090215072 | METHODS AND COMPOSITIONS RELATED TO DETERMINATION AND USE OF WHITE BLOOD CELL COUNTS - Described herein is an analyte detection device and method related to a portable instrument suitable for point-of-care analyses. In some embodiments, a portable instrument may include a disposable cartridge, an optical detector, a sample collection device and/or sample reservoir, reagent delivery systems, fluid delivery systems, one or more channels, and/or waste reservoirs. Use of a portable instrument may reduce the hazard to an operator by reducing an operator's contact with a sample for analysis. The device is capable of obtaining diagnostic information using cellular- and/or particle-based analyses and may be used in conjunction with membrane- and/or particle-based analysis cartridges. Analytes, including proteins and cells and/or microbes may be detected using the membrane and/or particle based analysis system. | 08-27-2009 |
20090215073 | Layered peptide/antigen arrays - for high-throughput antibody screening of clinical samples - A method and composition for the identification of biomolecule in a sample are disclosed. The method comprises obtaining a coated capture membrane stack comprising a plurality of capture membranes with each capture membrane coated with a different peptide. The membrane stack is exposed to a sample, and, after a given amount of time for the sample to permeate the membrane stack, the membrane stack is removed from the sample carrier and the capture membrane to which the biomolecule adheres is identified. | 08-27-2009 |
20090215074 | Detection of the nucleolar channel system of human endometrium and uses thereof - Methods are disclosed for assaying at the light microscopic level for the presence or absence of nucleolar channel systems (NCSs) in an endometrial tissue sample, as are methods for determining whether or not a postovulatory human endometrium is in a state that is receptive for implantation of a human embryo, where the presence of NCSs indicates that the endometrium is in a state that is receptive for implantation of an embryo and the absence of NCSs indicates that the endometrium is not in a state that is receptive for implantation of the embryo, and methods for determining the effectiveness of a contraceptive in a woman, comprising assaying an endometrial tissue sample for the presence or absence of NCSs. | 08-27-2009 |
20090215075 | THREE-DIMENSIONAL STRUCTURE OF A DNAB-FAMILY REPLICATIVE HELICASE (G40P), USES THEREOF, AND METHODS FOR DEVELOPING ANTI-BACTERIAL PATHOGENS BY INHIBITING DNAB HELICASES AND THE INTERACTIONS OF DNAB HELICASE WITH PRIMASE - Structure and methods associated with the three-dimensional structure of G40P helicase and other structure models of any DnaB-like helicase obtained by computer modeling that bears similarity with a root-mean-square deviation (RMSD) of 2.0 with at least one of the three domain structures (N-globe, alpha-hairpin and the C-terminal ATPase domains). In one embodiment, a method for identifying a compound that binds to any fragment of a G40P protein is provided. The method including obtaining the three dimensional structure of the G40P hexamer whose sequence consists of SEQ ID NO:1 and identifying or designing one or more compounds that bind, mimic, enhance, disrupt, or compete with the G40P protein whose sequence consists of SEQ ID NO:1 or interactions of the G40P protein with its ligands based on the three dimensional structure of the G40P hexamer whose sequence consists of SEQ ID NO:1. | 08-27-2009 |
20090215076 | Methods and substances for the diagnosis and therapy of sepsis and sepsis-like systemic infections - Uses of recombinant procalcitonin 3-116 in the diagnosis and therapy of septic diseases and the measurement of prohormones other than procalcitonin, and of dipeptidyl peptidase IV, as biomarkers in the diagnosis of sepsis. | 08-27-2009 |
20090215077 | METHODS FOR DIAGNOSIS OF ACUTE CORONARY SYNDROME - Provided are methods for the detection and diagnosis of acute coronary syndrome or ACS. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of ACS. At least two new biomarkers for ACS are thus disclosed, MMP-3 and SGOT. Altogether the concentrations of twelve analytes provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering a heart attack. Other important biomarkers for ACS are described, including but not limited to IL-18, Factor VII, ICAM-1, Creatine Kinase-MB, MCP-1, Myoglobin, C Reactive Protein, von Willebrand Factor, TIMP-1, Ferritin, Glutathione S-Transferase, Prostate Specific Antigen (free), IL-3, Tissue Factor, alpha-Fetoprotein, Prostatic Acid Phosphatase, Stem Cell Factor, MIP-1-beta, Carcinoembryonic Antigen, IL-13, TNF-alpha, IgE, Fatty Acid Binding Protein, ENA-78, IL- | 08-27-2009 |
20090215078 | Doxorubicin Immunoassay - Novel conjugates of doxorubicin and novel doxorubicin immunogens derived from the 13 and 14 positions of doxorubicin and antibodies generated by these doxorubicin linked immunogens all of which are useful in immunoassays for the quantification and monitoring of doxorubicin in biological fluids. | 08-27-2009 |
20090220986 | ASSESSING NON-ALCOHOLIC FATTY LIVER DISEASE - The document provides methods and materials related to assessing NAFLD in a mammal. For example, methods and materials for determining whether or not a mammal has an NAFLD are provided. In addition, methods and materials for determining whether a mammal with an NAFLD has a severe or mild form of the NAFLD as well as methods and materials for determining whether a mammal with an NAFLD is likely to experience a severe or mild form of the NAFLD are provided. | 09-03-2009 |
20090220987 | Use of Intramolecularly, Covalently Cross-Linked Proteins As Binding Partners In Immunoassays - The invention concerns the use of intramolecularly, covalently cross-linked proteins and covalently cross-linked reverse transcriptase from HIV as immunological binding partners in immunoassays. It also concerns immunological test procedures for detecting an analyte in a sample in which intramolecularly, covalently cross-linked proteins are used as binding partners, and it further concerns intramolecularly, covalently cross-linked reverse transcriptase from HIV and a method for producing this reverse transcriptase. | 09-03-2009 |
20090233310 | PARTICLE AGGLUTINATION IN A TIP - An apparatus and a related method for performing particle agglutination reactions in a single, disposable probe tip are disclosed. The probe tip includes a sample cavity for sample acquisition, at least one flanking cavity for the capture of particles by centrifugation or other means, a transition zone for the mixing of the sample with reagents for agglutination and a detection zone for the optical detection of particle agglutination. A mechanism may be attached to the probe tip for the controlled movement of fluids through the internal volume of the probe tip. The probe tip is particularly useful for the automation of high-throughput agglutination-type assays. | 09-17-2009 |
20090233311 | METHODS AND SUBSTANCES FOR THE DIAGNOSIS AND THERAPY OF SEPSIS AND SEPSIS-LIKE SYSTEMIC INFECTIONS - Uses of recombinant procalcitonin 3-116 in the diagnosis and therapy of septic diseases and the measurement of prohormones other than procalcitonin, and of dipeptidyl peptidase IV, as biomarkers in the diagnosis of sepsis. | 09-17-2009 |
20090233312 | METHODS AND ASSAYS TO ASSESS CARDIAC RISK AND ISCHEMIA - The invention provides methods and apparatus to assess cardiac risk and ischemia by detecting or analyzing cardiac troponin levels. Also provided are methods to detect low levels of cardiac troponin in physiological fluid samples. | 09-17-2009 |
20090233313 | QUANTIFICATION AND AFFINITY CHARACTERIZATION OF ANTIBODIES FOR THE DIAGNOSIS OF DISEASE USING OPTICAL DIFFRACTION - The invention features methods and devices for the detection of antibodies. The invention also features methods for diagnosing disease and evaluating the efficacy of treatment of a subject with a disease. | 09-17-2009 |
20090233314 | Functional domain and associated molecule of dock2 essentially required in lymphocyte migration - The present invention is related to provide a method for screening a substance interfering in the association of DOCK2 and ELMO1, a method for screening a substance interfering in the association of ELMO1 and Tiam1, and a method for searching a therapeutic agent for immune related diseases such as allergy, autoimmune diseases, GvH, graft rejection with the use of these searching methods, and so on. It was found that in DOCK2-mutant lacking 504 amino acid residues at the N terminus of DOCK2, Rac-activating ability was significantly decreased, and that actin polymerization could not be induced, and ELMO1 was identified as a molecule binding to this domain. It was found that DOCK2 was associated to ELMO1 via SH3 domain. Moreover, it was found that ELMO1 is bound with Tiam1 functioning as Rac-specific GDP/GTP exchange factor (GEF). It was found that DOCK2 activates Rac by recruiting Tiam1 via ELMO1. | 09-17-2009 |
20090239238 | METHODS FOR MEASURING PRO-INFLAMMATORY SUBSTANCE LEVELS IN DIALYSIS SOLUTIONS AND DIALYSIS COMPONENTS - Methods of measuring levels of pro-inflammatory substances in dialysis solutions or specific dialysis components used to manufacture dialysis solutions are provided. In a general embodiment, the method comprises determining an IL-6 response versus a pro-inflammatory substance concentration of a reference standard containing a pro-inflammatory substance and establishing a dose-response curve of the IL-6 responses as a function of different pro-inflammatory substance concentrations of the reference standard. An IL-6 response of a test sample of a dialysis solution is determined. The corresponding pro-inflammatory substance concentration of the dialysis solution is then calculated using the dose-response curve. The IL-6 response of the reference standards and the dialysis solution can be determined using a high sensitivity PBMC IL-6 assay. | 09-24-2009 |
20090239239 | EUKARYOTIC AMADORIASE HAVING EXCELLENT THERMAL STABILITY, GENE AND RECOMBINANT DNA FOR THE EUKARYOTIC AMADORIASE, AND PROCESS FOR PRODUCTION OF EUKARYOTIC AMADORIASE HAVING EXCELLENT THERMAL STABILITY - Disclosed are: a eukaryotic amadoriase which is prepared by introducing a mutation into DNA encoding a eukaryotic amadoriase derived from a microorganism belonging to the genus | 09-24-2009 |
20090246794 | Methods and Kit for Detecting Breast Cancer - The present inventions relates to kits and methods for diagnosing and monitoring breast cancer. An increase in the level or activity of proteins of the ubiquitin/proteasome pathway, and ancillary proteins thereof, as compared to normal control or benign tissue is indicative of breast cancer. | 10-01-2009 |
20090246795 | IMMUNOASSAY DEVICE AND METHOD - An immunoassay device capable of assaying amount of an antigen by allowing a labeled antibody to specifically bind to a antigen analyte in a sample and assaying a label of a bound product, an interior of a single device has four regions comprises: (1) a first region where the antigen in the sample reacts with a first antibody that is the labeled antibody capable of specifically binding to the antigen, (2) a second region where first antibody that has not bound to the antigen reacts with a second biotin- or avidin-bound antibody, (3) a third region where, depending on whether the second antibody is biotin-bound antibody or avidin-bound antibody, either avidin or biotin is immobilized by immobilization means so as to be unable to move to the fourth region, and the second antibody is captured by the immobilized avidin or biotin, and (4) a fourth region where the label of the first antibody that has bound to the antigen is detected, being constructed in such a way that a solution can move sequentially through each region, the first antibody, which is the labeled antibody such that an antibody component is an F(ab′) fragment or reduced IgG, the F(ab′) fragment or reduced IgG being bound with the label in a predetermined proportion, is included in the first region or an adjacent region, and the second antibody is a biotin- or avidin-bound antibody, being of anti-idiotype antibody against the first antibody and a type that cannot bind to the bound product of the antigen and first antibody, and is included in the second region or an adjacent region. | 10-01-2009 |
20090246796 | ISOLATION AND ENUMERATION OF CELLS FROM A COMPLEX SAMPLE MATRIX - The present invention relates to methods and systems for labeling, isolating, detecting and enumerating biological cells, or other biological analytes of interest present in a sample, where the capturing complex may also serve as a labeling agent. In one embodiment, the capture complex is an encoded magnetic bead coupled to antibodies having a specific affinity for a cell surface protein on a cell of interest. The methods and systems of the present invention can be used for quantitative or qualitative detection. | 10-01-2009 |
20090246797 | MEDICAL DEVICE FOR THE ASSESSMENT OF INTERNAL ORGAN TISSUE AND TECHNIQUE FOR USING THE SAME - A system for tissue ischemia detection is provided that may be used to assess markers of tissue ischemia. Such a system may include a sensor that may be used directly on internal tissue to assess ischemic condition. Sensors to be used in conjunction with the provided system may include optical, chemical or electrochemical sensors that may be directly applied or affixed to the tissue, held proximate to the tissue, or spread over the tissue in the form of a gel. | 10-01-2009 |
20090246798 | METHOD OF DETECTING CANCER AND EVALUATING CANCER PROGNOSIS - A method of detecting cancer in a subject is provided. One step of the method includes obtaining a bodily sample from the subject. Next, the level of pro-prion protein (pro-PrP) in the bodily sample is detected. The level of pro-PrP in the bodily sample is then compared to a control level. An increased level of pro-PrP in the bodily sample as compared to the control level indicates that the subject has cancer or an elevated risk of having cancer. | 10-01-2009 |
20090246799 | Detection of Chronic Kidney Disease Patients or Coronary Artery Disease Using Bone Morphogenic Protein-4 - The invention is a method of detecting CAD in a CKD diagnosed human patient or CKD in a diagnosed CAD patient, or detection the presence of both CDK and CAD by assaying a plasma or serum sample of a human patient for elevated levels of BMP-4. | 10-01-2009 |
20090246800 | IMMUNOASSAY OF ANALYTES IN SAMPLES CONTAINING ENDOGENOUS ANTI-ANALYTE ANTIBODIES - The disclosure provides among other things an assay method that compensates for the presence of endogenous antibodies, e.g., autoantibodies, which might otherwise compromise the measurement of an analyte in a biological sample. In one embodiment, this method entails the use of a two labeled entities: a labeled detection agent and a labeled species-specific antibody, wherein the labeled species-specific antibody is specific for the species from which the biological sample was obtained. Sample analyte is bound by the detection agent and any anti-analyte autoantibodies present in the sample. Analyte bound by autoantibodies is detected via the species-specific antibody, optionally labeled. | 10-01-2009 |
20090246801 | RAPID TEST FOR GLYCATED ALBUMIN IN BLOOD - This invention describes a rapid assay for measuring the ratio of glycated albumin to total albumin in blood. Patients with diabetes have elevated levels of glucose in their blood that can react with plasma albumin to form glycated albumin. The amount of glycated albumin formed is directly correlated with the level of plasma glucose that the albumin has been exposed to over a period of time. The ratio of glycated albumin to total albumin in blood will provide an indication of the average amount of protein glycation that occurred over the preceding 2-3 week period. | 10-01-2009 |
20090253146 | Methods of expressing integrin beta6 subunits - The present invention provides substantially pure integrins containing a novel β subunit designated as β | 10-08-2009 |
20090253147 | Marker for stem cells - Methods and compositions are provided for the identification of stem cells, including neural, muscle and hair follicle stem cells. | 10-08-2009 |
20090258371 | METHOD OF DETECTING VERY LOW LEVELS OF ANALYTE WITHIN A THIN FILM FLUID SAMPLE CONTAINED IN A THIN THICKNESS CHAMBER - A method and apparatus for the detection and quantification of very low levels of a target analyte using an imaging system is provided. In the case of some analytes such as certain hormones, for example TSH, their levels may be as low as several tens of thousands of molecules per micro liter. These extremely low levels can be measured by using the present invention to count the individual molecules of analyte. The invention also has the advantage of being a primary quantitative method, which is one which needs no standardization. | 10-15-2009 |
20090258372 | Detection Systems Utilizing Supported Lipid Bilayers - The invention relates to lipid bilayer coated beads and methods of using those beads in immunoassays, in analytical assay and the like. | 10-15-2009 |
20090258373 | METHODS OF CONTROLLING THE SENSITIVITY AND DYNAMIC RANGE OF A HOMOGENEOUS ASSAY - A method is disclosed for accurately determining the concentration of a target analyte utilizes reagent pairs having different affinity for the target. The different affinity provides distinct binding profiles that can be analyzed to absolutely determine the analyte concentration. The method provides an assay system having expanded dynamic range to cover a wider range of analyte concentration and can overcome the hook-effect that commonly exists in homogenous assay systems. The method utilizes distinguishable signals that allows for the analysis of multiple binding profiles and multiplex analysis. | 10-15-2009 |
20090263821 | Ubiquitin Ligase Assays And Related Reagents - The disclosure provides, inter alia, methods and reagents for use in measuring the attachment of ubiquitin and ubiquitin-like proteins to a target protein, particularly an E3 protein. | 10-22-2009 |
20090263822 | In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases - An in vitro process for the detection and early detection of neurodegenerative diseases, for determination of the severity, and to evaluate the progression of and render a prognoses of neurogenerative diseases, in a patient suffering from a subjectively or objectively detectable cognitive impairment, by determining the concentration of an analyte selected from natriuretic peptides, in particular ANP, and, if necessary, BNP and/or CNP in a biological fluid of the patient, whereby the determination of the analyte is performed directly and/or indirectly as the determination of a relevant co-peptide generated from a mutual propeptide, and is based upon the measured concentration of the determined analyte thus making it possible to form conclusions about a neurodegenerative disease or an early form typical of such a disease or the course of the disease and/or the success of the efforts to relieve or prevent the disease. | 10-22-2009 |
20090263823 | GLYCEROGLYCOLIPID ANTIGEN OF MYCOPLASMA PNEUMONIAE - The present invention provides a novel glyceroglycolipid produced by | 10-22-2009 |
20090263824 | Detection of Neurodegenerative Disease - Provided are methods of assessing the absence or presence of a neurodegenerative disease in a subject comprising characterizing TDP-43 in a tissue sample of the subject. Also disclosed are methods for diagnosing a neurodegenerative disease in a subject, and methods for determining the efficacy of a drug against a neurodegenerative disease. Novel antibodies that bind to TDP-43 are also provided. | 10-22-2009 |
20090263825 | METHODS, IMMUNOASSAYS AND DEVICES FOR DETECTION OF ANTI-LIPOIDAL ANTIBODIES - Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, a method for immobilizing a lipoidal antigen, comprising cardiolipin, lecithin, and cholesterol, on a solid support (such as a nitrocellulose membrane) is described. The ability to immobilize a lipoidal antigen on a membrane satisfies a long-felt need for a membrane-based assay for the detection of anti-lipoidal antibodies. Also described are immunoassay devices for concurrently performing treponemal and non-treponemal tests for syphilis. | 10-22-2009 |
20090263826 | MEANS AND METHOD FOR DIAGNOSING HEMOLYTIC ANEMIA - The present invention relates to a method for diagnosing hemolytic anemia or a predis-position thereof. It also relates to a method of determining whether a compound is capable of inducing hemolytic anemia in a subject and to a method of identifying a drug for treating hemolytic anemia. Furthermore, the present invention relates to a data collection comprising characteristic values of metabolites, a data storage medium comprising said data collection, and a system and a device for diagnosing hemolytic anemia. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing hemolytic anemia in a subject. | 10-22-2009 |
20090263827 | Method for determining health status by analyzing analytes - A method to extract information from samples taken at different times from a mammalian. These samples are analyzed with respect to one or more analytes giving one or more responses, creating one or more response curves. From this/these response curves is/are changes in the responses calculated as slope, curvatures or mathematical functions. This is especially useful for early detection of acute myocardial infarction. | 10-22-2009 |
20090269776 | Magnetic Immunodiagnostic Method for the Demonstration of Antibody/Antigen Complexes especially of blood groups - The invention relates to a magnetic immunodiagnostic method for the demonstration of antibody-antigen complexes. One such method involves the research and/or identification of antibodies or antigens, preferably anti-antigen antibodies or antigens of a blood group, and comprises a suspension of magnetic particles coated with antigens that can be carried by cells such as erythrocytes. The invention also relates to a device and a kit for carrying out one such method. | 10-29-2009 |
20090269777 | IMMUNOASSAYS AND KITS FOR THE DETECTION OF NGAL - The present invention relates to NGAL immunoassays and kits, and to methods of using glycosylated mammalian NGAL and antibodies that bind to mammalian NGAL in immunoassays and kits. Among other things, the methods and kits can be employed to determine the amount of human NGAL monomer in a test sample, as well as to determine the proportion of human NGAL monomer to human NGAL dimer contained in a test sample. | 10-29-2009 |
20090269778 | BIOCOMPATIBLE THREE DIMENSIONAL MATRIX FOR THE IMMOBILIZATION OF BIOLOGICAL SUBSTANCES - The present invention relates to a method of producing a solid coated carrier carrying biological material. Furthermore, the invention relates to a solid coated carrier to which biological material is attached and uses of the solid coated carrier for the preparation of a medical product. Moreover, the invention provides a method for the contacting, filtration or cleaning of blood, lymph or liquor cerebrospinalis of a patient, a method for the diagnosis of a disease and a diagnostic composition. | 10-29-2009 |
20090269779 | Galectin-3 cleavage as a marker for matrix metalloproteinase activity in cancer - Provided are differential antibodies recognizing the cleaved and non-cleaved forms of matrix metalloproteinases (MMPs), and methods of using the antibodies as surrogate diagnostic markers for the presence of active MMPs in cancer, such as growing breast cancers. | 10-29-2009 |
20090269780 | Method for Creating a Standard for Multiple Analytes Found in a Starting Material of Biological Origin - The invention provides a method for creating a standard for multiple analytes comprising treating a portion of a sample to substantially remove analytes of interest to produce a series of specifically deficient samples; and determining and mixing an appropriate amount of the series of specifically deficient samples to create a standard. The analyte may be any substance to be measured. | 10-29-2009 |
20090269781 | Single-Molecule-Format Probe And Utilization Thereof - A single-chain probe of the present invention for detecting a ligand, comprises: a ligand binding protein for binding the ligand; a recognition protein for recognizing that the ligand is bound by the ligand binding protein; and C— and N-terminal fragments, generated by dissecting an enzyme, between the ligand binding protein and the recognition protein, wherein a carboxy terminal end of the C-terminal fragment is located upstream of an amino terminal end of the N-terminal fragment, and the C— and N-terminal fragments vary the enzyme activity via complementation in case where the recognition protein recognizes that the ligand is bound by the ligand binding protein. This makes it possible to achieve detection of a target protein-specific ligand using the single chain with a high efficiency. | 10-29-2009 |
20090269782 | DIAGNOSTIC METHOD FOR DETERMINING THE SUSCEPTIBILITY TO DELIVERY AND REAGENT KIT FOR USE THEREFOR - The invention relates to a diagnostic method for detecting susceptibility to delivery, and to a test kit for this purpose. A low, but higher than baseline level concentration of Insulin-like Growth Factor Binding Protein 1 (IGFBP-1), which is due to leakage from decidual cells, is detected by an immunological assay in a vaginal secretion sample. | 10-29-2009 |
20090275046 | Complement factor H protein as a biomarker of Parkinson's disease - The present invention relates to a Complement Factor H protein as a biomarker for neurodegenerative disease, including Parkinson's disease, and the related diseases. More specifically, the present invention relates to the identification of a Complement Factor H protein, useful for the screening, diagnosis, and differentiation between neurodegenerative diseases. | 11-05-2009 |
20090275047 | CRYSTAL STRUCTURE OF HUMAN SOLUBLE ADENYLATE CYCLASE - The invention provides the crystal structure of the solAC catalytic domain. The structure is set out in Tables 1 to 5. The structure may be used in to model the interaction of ligands such as pharmaceutical compounds with this protein, and to determine the structure of related adenylate cyclase molecules. | 11-05-2009 |
20090275048 | ANTI-ACHARAN SULFATE ANTIBODY AND ITS APPLICATION - An anti-acharan sulfate antibody, a hybridoma that produces the antibody, a detection method and a detection kit to which the antibody is applied are disclosed. The anti-acharan sulfate antibody can be produced by immunizing a mammal using as an antigen a substance obtained by chemically bonding a protein to acharan sulfate. | 11-05-2009 |
20090280500 | Assay for generation of a lipid profile using fluorescence measurement - The present invention relates to a method of generating a lipid profile for a sample solution. The method comprising: a first step of determining the concentration of total lipoprotein in a first aliquot of the sample using fluorescence analysis; a second step of determining the concentration of total cholesterol in a second aliquot of the sample using fluorescence analysis; and optionally a third step of determining the concentration of HDL in a third aliquot of the sample using fluorescence analysis. The concentrations of the total lipoprotein, and of total cholesterol may be used to calculate other lipid components and thereby generate a lipid profile. The invention also concerns apparatus that may be used to perform the method of the invention. | 11-12-2009 |
20090280501 | A Method And A Kit For Diagnosing Type 2 Diabetes, Metabolic Syndrome, Sub Clinical Atherosclerosis, Myocardial Infarct, Stroke Or Clinical Manifestations Of Diabetes - A method and a kit for diagnosing or prognosing susceptibility to develop type 2 diabetes, the metabolic syndrome, sub clinical atherosclerosis, myocardial infarct, stroke or clinical manifestations of diabetes in a subject. The method comprises detecting and quantifying the amount of bound protein (s), (apoCIII, apoCI, apoA1 or apoE) on small dense low density lipoproteins (sdLDL) particles in a blood sample from said subject. | 11-12-2009 |
20090280502 | ANTI-2-O-DESULFATED ACHARAN SULFATE ANTIBODY AND ITS APPLICATION - An antibody that reacts with 2-O-desulfated acharan sulfate, a hybridoma that produces the antibody, a detection method and a detection kit to which the antibody is applied are disclosed. The antibody that reacts with 2-O-desulfated acharan sulfate can be produced by immunizing a mammal using as an antigen a substance obtained by chemically bonding a protein to 2-O-desulfated acharan sulfate. | 11-12-2009 |
20090280503 | Method for detecting and treating skin disorders - The invention provides for methods of detecting and treating diseased tissue, particularly in skin diseases or disorders, such as psoriasis, scleroderma, eczema or atopic dermatitis tissue. The method involves administrating a composition comprising an antibody specific to the diseased tissue to a patient. After administration, the antibody in the composition binds to the exposed cell surface antigen (epitope) and allows the detection and/or disrupts the growth of the diseased tissue. In addition, this invention provides methods of treating psoriasis, scleroderma, eczema or atopic dermatitis by eliciting an immune response in an individual against an antigen which is only exposed to antibody detection in tissues affected by these disorders | 11-12-2009 |
20090280504 | NS1-NP Diagnostics of Influenza Virus Infection - The present application describes methods for assessing influenza infection, including prognosis. An assay that determines the amount of the NS1 and NP proteins of influenza virus shows enhanced sensitivity and reliability compared to either antigen alone. Many formats employ pan-specific antibodies (i.e., that react with all or at least with multiple strains within an influenza type). | 11-12-2009 |
20090280505 | METHOD FOR DETECTING LYSOSOMAL STORAGE DISEASES - A method for detecting lysosomal storage diseases including the steps of performing an assay for a single species of glycosaminoglycan contained in a specimen and correlating results of the assay with lysosomal storage diseases. A body fluid such as urine or blood can be employed as a specimen. The assay can be performed by use of a polypeptide that is capable of specifically binding to a glycosaminoglycan-containing molecule. The polypeptide may be an antibody, or a polypeptide having an antigen-binding site of an antibody. | 11-12-2009 |
20090286256 | ISOLATED HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES AND METHODS AND KITS FOR DETECTING HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES - The present disclosure relates to isolated human autoantibodies and assays and kits for detecting human autoantibodies reactive with at least one natriuretic peptide or natriuretic peptide fragment in a test sample. | 11-19-2009 |
20090286257 | WATER SOLUBLE NANOCRYSTALLINE QUANTUM DOTS CAPABLE OF NEAR INFRARED EMISSIONS - A novel quantum dot capable of near infrared emissions at wavelengths of 750-1100 is made by forming solid solutions of metal sulfide, metal selenide or metal sulfide selenide by incorporating a suitable amount of an additional metallic element or elements to provide an emission wavelength in the range of 750 nm to 1100 nm. The quantum dots may be enabled for bioconjugation and may be used in a method for tissue imaging and analyte detection. | 11-19-2009 |
20090286258 | ANALYSIS OF ANTIBODY DRUG CONJUGATES BY BEAD-BASED AFFINITY CAPTURE AND MASS SPECTROMETRY - Methods to detect, characterize, and quantitate biological samples after administration of antibody conjugates, antibody-drug conjugates of Formula I, antibodies, and fragments and metabolites thereof, by immunoaffinity bead separation, chromatography, and mass spectrometry are disclosed. | 11-19-2009 |
20090291453 | Method for Testing Alzheimer's Disease by Measuring Degradation Rate of B-Amyloid in Blood and Diagnostic Reagent - Provided is a method of testing Alzheimer's disease using serum or plasma as a sample. It is found that a β-amyloid peptide added to a blood sample is degraded. The degradation activity thereof was compared between the blood samples of normal subjects and Alzheimer's disease patients, and it is also found that the degradation activity is significantly higher in the blood of the normal subjects. | 11-26-2009 |
20090291454 | Detection method of bio material, fabrication method of chip for detection of bio mateiral, and chip for detecting of bio material - Provided are a method for detecting biomaterials, a method for fabricating a chip for biomaterial detection and a chip for biomaterial detection. The method for detecting biomaterials is characterized by comprising the steps of: (S | 11-26-2009 |
20090291455 | Cynomolgus gp80 Receptor and Uses - Isolated polynucleotides encoding cynomolgus monkey gp80, polypeptides obtainable from expression of these polynucleotides, compositions, recombinant cells, methods of making and using these polynucleotides, polypeptides, and compositions are useful in development of human therapeutics. | 11-26-2009 |
20090291456 | Method for Diagnosing Multiple Sclerosis - Disclosed is a method for diagnosing multiple sclerosis and more particularly to a method for diagnosing multiple sclerosis by measuring levels of antibodies to glycans in a biological sample. | 11-26-2009 |
20090298088 | CLEAVABLE CATALYTIC BINDING AND DETECTION SYSTEM - The present invention provides a detection reagent for detection of the presence of a substance of interest in a sample. The detection reagent comprises a binding portion, a linking portion, and a catalytic portion. The linking portion comprises a cleavage site for cleavage of the binding portion from the catalytic portion. According to the method, the detection reagent is caused to bind to the substance of interest. The bound reagent is then cleaved by breaking of a bond in the linking portion. Upon cleavage, the catalytic portion is removed from the binding reaction mixture and caused to catalyze a reaction that produces a detectable product. | 12-03-2009 |
20090298089 | Novel method for detecting and analyzing protein interactions in vivo - The invention relates to various methods of detecting and analyzing protein interactions in a cell, which methods involve the appearance of a specific protein interaction being converted to a permanent detection signal by means of providing, in a manner dependent on said protein interaction, a recombinase activity or protease activity. | 12-03-2009 |
20090298090 | METHODS TO MEASURE IMMUNOSUPPRESSIVE TACROLIMUS, SIROLIMUS, AND CYCLOSPORIN A COMPLEXES IN A BLOOD SAMPLE - The present invention provides methods, diagnostic assays, and diagnostic kits based on said methods, to determine levels of immunosuppressive complexes containing immunosuppressive drugs tacrolimus, sirolimus and cyclosporine A separately and in combination, formed in the blood of a drug-treated patient or in a patient candidate to immunosuppressive drug therapy. These methods, assays and kits are especially useful when using automated systems. | 12-03-2009 |
20090305296 | TEST KIT FOR DETECTING PERIODONTAL DISEASE - A test kit is disclosed for diagnosing periodontal disease in a patient by analysing a sample from the oral cavity of the patient. The test kit includes at least a first detection assay for detection of a first substance originating from bacteria and at least a second detection assay for detection of a second substance originating from the immune or inflammatory system of the patient. | 12-10-2009 |
20090305297 | Tyrosine phosphorylation sites - The invention discloses 397 novel phosphorylation sites identified in carcinoma and/or leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 12-10-2009 |
20090305298 | Binder for C-Reactive Protein - A polypeptide dimer is provided wherein both protomers have a sequence according to SEQ ID NO: 1 and at least one phosphocholine derivative is attached to the polypeptide. The polypeptide shows a specific binding for C-reactive protein (CRP). The utilization of the polypeptide in assays for determining the concentration of CRP is described. The purification of CRP, and compositions comprising the CRP also are provided. | 12-10-2009 |
20090305299 | Method for Determination of Prognosis of Prostate Cancer, and Diagnostic Agent for Use in the Method - A method for determining probability that prostate cancer will metastasize, as well as a diagnostic reagent used therefor is disclosed. It was discovered that the percentage that NF-κB-p65/RelA has the 254th amino acid threonine which is phosphorylated is significantly higher in the prostate cancer cells in the cases where the bone metastasis was observed than in the cases where bone metastasis was not observed. Thus, the method for determining probability that prostate cancer will metastasize comprises measuring human NF-κB-p65/RelA in which 254th amino acid threonine is phosphorylated, which human NF-κB-p65/RelA is contained in a prostate tissue separated from human. | 12-10-2009 |
20090305300 | METHODS AND KITS TO DIAGNOSE GROWTH HORMONE DEFICIENCY - A method of assessing growth hormone deficiency in a human or animal subject, the method comprising administering orally to the subject EP 1572 (Formula I) or EP 1573 (Formula II), obtaining a post-administration sample from the subject, determining the level of growth hormone in the sample and assessing whether the level of growth hormone in the sample is indicative of growth hormone deficiency in the subject. Preferably, the GH level in the sample is measured by immunoassay. Also disclosed is a kit of parts constituting a diagnostic kit comprising: (a) EP 1572 or EP 1573 formulated for oral administration; and (b) means for determining the level of growth hormone in a sample. | 12-10-2009 |
20090305301 | DETECTION OF VENOUS THROMBOEMBOLIC DISEASES BY MEASUREMENT OF D-DIMERS AND SOLUBLE FIBRIN LEVELS - A method and a test for detecting coagulation activation, in particular when it is responsible for thromboembolic venous diseases; employs assaying D-dimers and assaying the soluble fibrin produced during a fibrinolysis process activated in a blood sample. The method of the invention pertains to comparing the level of D-dimers corresponding to degradation of soluble fibrin and the level of D-dimers of the sample with normal threshold values. The test of the invention may also be used to determine whether anti-coagulation is sufficient in a patient. | 12-10-2009 |
20090305302 | MYCOBACTERIAL CULTURE SCREENING TEST FOR MYCOBACTERIUM AVIUM COMPLEX BACTERIA - A method of antigen-capture assays that uses the detection of antigens secreted into liquid culture is provided. Also provided are antibodies to | 12-10-2009 |
20090311714 | Methods for the Screening of Antibacterial Substances - The present invention concerns a method for the screening of antibacterial substances comprising a step of determining the ability of a candidate substance to inhibit the activity of a purified enzyme selected from the group consisting of: (i) a D-aspartate ligase comprising a polypeptide having an amino acid sequence possessing at least 50% amino acid identity with an amino acid sequence selected from the group consisting of SEQ ID No 1 to SEQ ID No 10, or a biologically active fragment thereof; and (ii) a L,D-transpeptidase comprising a polypeptide having an amino acid sequence possessing at least 50% amino acid identity with the amino acid sequence of SEQ ID No 11, or a biologically active fragment thereof. | 12-17-2009 |
20090311715 | IDENTIFYING CORONARY OR SOFT TISSUE CALCIFICATION - This document relates to methods and materials involved in identifying calcification (e.g., coronary calcification or soft tissue calcification) in mammals and assessing thrombotic risk in mammals. For example, methods and materials involved in using microvesicles as a marker to determine whether or not a mammal (e.g., a human) has calcification or an elevated risk of thrombosis are provided. In addition, methods and materials for determining the amount and source of microvesicles are provided. | 12-17-2009 |
20090311716 | METHODS TO TREAT OR PREVENT HORMONE-RESISTANT PROSTATE CANCER USING siRNA SPECIFIC FOR PROTOCADHERIN-PC, OR OTHER INHIBITORS OF PROTOCADHERIN-PC EXPRESSION OR ACTIVITY - The invention is directed to compounds and methods for treating or preventing hormone-resistant prostate cancer using siRNA specific for protocadherin-PC, or other inhibitors of protocadherin-PC expression or activity, including antisense oligonucleotides and antibodies. The invention also provides for the use of protocadherin-PC as an in vivo prostate cancer biomarker, and includes a kit for detecting prostate cancer in biological samples. Also covered by the invention is a transgenic non-human mammal engineered to overexpress protocadherin-PC specifically in the prostate. | 12-17-2009 |
20090317825 | ASSAY FOR PARKINSON'S DISEASE THERAPEUTICS AND ENZYMATICALLY ACTIVE PARKIN PREPARATIONS USEFUL THEREIN - The invention provides to assays for agent useful for treatment of Parkinson's Disease. Included are cell-based assays for agents that modulate the effect of Parkin proteins on proteasome function. The invention also provides recombinant, enzymatically active, Parkin protein produced in prokaryotic expression systems, such as | 12-24-2009 |
20090317826 | MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE IN THE DETECTION OF CERVICAL DISEASE - Compositions and methods for diagnosing high-grade cervical disease in a patient sample are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MCM2. Monoclonal antibodies having the binding characteristics of an MCM2 antibody of the invention are further provided. Hybridoma cell lines that produce an MCM2 monoclonal antibody of the invention are also disclosed herein. The compositions find use in practicing methods for diagnosing high-grade cervical disease comprising detecting overexpression of MCM2 in a cervical sample from a patient. Kits for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MCM2 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention. | 12-24-2009 |
20090325186 | Method for detecting analytes in a sample - The present invention relates to a method for detecting analytes in a sample comprising the steps of
| 12-31-2009 |
20090325187 | Immunomodulation - Medical use of ILT6 for modulating the immune response, as well as to pharmaceutical compositions containing ILT6. | 12-31-2009 |
20090325188 | Method for Detecting IL-16 Activity and Modulation of IL-16 Activity Based on Rantes Proxy Levels - Methods for detecting IL-16 biological activity, detecting modulation of IL-16 biological activity, and diagnosing the presence of or susceptibility of a subject to an IL-16-related disorder involve measuring and comparing the levels of RANTES proxy produced by eukaryotic cells, such as CD4+ and CD9+ cell lines, peripheral blood mononuclear cells, HuT-78 cells, and/or THP-1 cells. | 12-31-2009 |
20090325189 | Tyrosine phosphorylation sites - The invention discloses 443 novel phosphorylation sites identified in leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 12-31-2009 |
20090325190 | METHOD FOR QUANTITATIVE DETECTION OF DIABETES RELATED IMMUNOLOGICAL MARKERS - This invention discloses using SPR technology to simultaneously and quantitatively measure the concentrations of diabetes related immunological makers in a serum sample, which can be used to diagnose and/or early diagnose diabetes as well as to predict the onset risk of diabetes in first-degree relatives. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of relevant antigens and antibodies used for the detection of respective diabetes related immunological makers in a serum sample. | 12-31-2009 |
20090325191 | Method for the diagnosis of pathological conditions in animals - A method for diagnosing a disease or pathological condition in a non-human animal. An ion mobility spectrometry measurement (IMS) or a differential mobility spectrometry (DMS) is carried out on a body sample from the animal to determine an amount of ions formed by at least two biogenic amines contained in the sample. A ratio is calculated of the amounts of ions formed by the different biogenic amines in the sample, wherein the ratio is indicative of the presence or absence of the disease or pathological condition. | 12-31-2009 |
20100003694 | Biomarkers and Uses Thereof - The present invention provides biomarkers for schizophrenic and bipolar disorders and methods of diagnosis, monitoring and screening associated with the biomarkers and kits for performing such methods. | 01-07-2010 |
20100003695 | MICROWAVE TRIGGER METAL-ENHANCED CHEMILUMINESCENCE (MT MEC) AND SPATIAL AND TEMPORAL CONTROL OF SAME - The present invention relates to a method of imaging structures and features using plasmonic emissions from metallic surfaces caused by chemiluminescence based chemical and biological reactions wherein imaging of the reactions is enhanced by the use of microwave energy and further enhanced by using metallic geometric structures for spatially and temporally controlling the biological and chemical reactions. | 01-07-2010 |
20100003696 | METHOD OF DIAGNOSING AND MONITORING THE PROGRESS OF MULTIPLE SCLEROSIS, AND THE USE OF A TEST KIT THEREFOR - There is a described method and a test kit for diagnosing and monitoring the progress of multiple sclerosis by determining autoantibodies in bodily fluids by determining those antibodies which bind to a spectrin. A typical spectrin is alpha-fodrin. | 01-07-2010 |
20100003697 | Method and Apparatus for Measuring Analyte Transport Across Barriers - The present invention includes a method and apparatus for measuring the transport of analytes through a cell barrier. | 01-07-2010 |
20100003698 | Kit of Materials for Decreasing Interference in Results of Immunochemical Methods - A kit of materials is provided for decreasing or eliminating interference from molecules resulting from upstream immunochemical assays, such as Immunoprecipitation, that employ an Immunoglobulin Binding Molecule (an IBM, e.g., Protein A) in subsequent downstream methods, such as Western Blot. The kit may include packing material, a ligand of an immunoglobulin binding molecule, the IBM itself, a solid support for the IBM, dry solids, primary antibodies, secondary antibodies having a reporter molecule, IBMs having a reporter molecule and combinations of the above materials. | 01-07-2010 |
20100009378 | Mass Spectrometric Methods and Products - The invention involves assays, diagnostics, kits, and assay components for mass spectrometry and other methods to determine levels of glycated CD59 in subjects. | 01-14-2010 |
20100009379 | Nanoparticle-Textured Surfaces and Related Methods for Selective Adhesion, Sensing and Separation - Textured heterogeneous surfaces and related articles as can be used in conjunction with methods for selective sensing and/or separation. | 01-14-2010 |
20100009380 | COMPOSITIONS AND METHODS FOR CHARACTERIZATION OF CYSTEINE OXIDATIVE STATES - The present invention relates to compositions and methods for characterization of cysteine oxidative states. In particular, the present invention provides cysteine-oxidative-state-specific labeling agents and uses thereof. | 01-14-2010 |
20100009381 | Compositions and methods for detection and isolation of phosphorylated molecules - The present invention relates to phosphate-binding compounds that find use in binding, detecting and isolating phosphorylated target molecules including the subsequent identification of target molecules that interact with phosphorylated target molecules or molecules capable of being phosphorylated. A binding solution is provide that comprises a phosphate-binding compound, an acid and a metal ion wherein the metal ion simultaneously interacts with an exposed phosphate group on a target molecule and the metal chelating moiety of the phosphate-binding compound forming a bridge between the phosphate-binding compound and a phosphorylated target molecule resulting in a ternary complex. The binding solution of the present invention finds use in binding and detecting immobilized and solubilized phosphorylated target molecules, isolation of phosphorylated target molecules from a complex mixture and aiding in proteomic analysis wherein kinase and phosphatase substrates and enzymes can be identified. | 01-14-2010 |
20100009382 | METHODS AND COMPOSITIONS FOR DIAGNOSING LUNG CANCER - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ubiquilin 1 markers for cancer. | 01-14-2010 |
20100015633 | METHODS AND KIT FOR ANALYTE DETECTION - A method includes binding a probe to an analyte present in a sample, wherein the probe comprises a binder bonded to a metal particle that is capable of releasing metal ions when contacted with a reagent solution. The method includes contacting the metal particle with the reagent solution to release the metal ions, and observing an optical signal from the released metal ions to determine a presence or amount of the analyte in the sample. An associated kit is also provided. | 01-21-2010 |
20100015634 | IN SITU LYSIS OF CELLS IN LATERAL FLOW IMMUNOASSAYS - Devices and methods incorporate lysis agents into a point-of-care testing device. The sample is loaded, and then the sample travels until it encounters a lysis agent. The lysis agent is preferably pre-loaded onto the collection device. In a preferred embodiment, the initially lysis agent is localized between the sample application zone and the conjugate zone. The lysis agent is preferably soluble or miscible in the sample transport liquid, and the lysis agent is solubilized and activated upon contact with the sample transport liquid. The sample transport liquid then contains both lysis agent in solution or suspension and sample components in suspension. Any lysis-susceptible components in a sample, then being exposed in suspension to the lysis agent, are themselves lysed in situ. The running buffer then carries the analyte, including any lysis-freed components, to the detection zone. | 01-21-2010 |
20100021926 | METHOD FOR RAPID DETECTION OF LYMPHATIC FILARIASIS - There is provided by this invention a specific and sensitive diagnostic method for rapid detection of lymphatic filariasis. The method employs a combination of SXP/SXP-recombinant antigen, mouse monoclonal anti-human IgG4 antibody conjugated to a detection reagent and the technique of immunochromatography. | 01-28-2010 |
20100021927 | CHOLESTEROL LOADED INSECT CELL MEMBRANES AS TEST SYSTEMS FOR ABC TRANSPORTER PROTEINS - The invention provides for a novel cholesterol loaded insect cell membrane preparation having an increased cholesterol level as compared to physiological cholesterol levels of insect cell membranes or to control insect cell membrane preparations without cholesterol loading, wherein said cholesterol loaded membrane preparation comprises an ABC transporter protein having an increased substrate transport activity due to increased cholesterol level of the membrane. The invention also relates to reagent kits comprising the preparations of the invention. The invention also relates to methods for manufacturing said preparations and methods for measuring any type of activity of the ABC transporters present in the cholesterol loaded membranes as well as studying or testing compounds and interaction of compounds and ABC transporters, in this assay systems. The invention also provides for a test system useful for testing whether ABC transporter proteins can be activated by cholesterol in an insect cell membrane. | 01-28-2010 |
20100021928 | METHODS AND KITS FOR DIAGNOSING CANCER - Methods and kits for diagnosing cancer in a subject is disclosed. The method comprises determining a level and/or activity of at least one saliva secreted marker in a saliva sample of the subject wherein an alteration in said marker with respect to an unaffected saliva sample is indicative of the cancer, with the proviso that the saliva secreted marker is not circulatory carcinoembryonic antigen (CEA). | 01-28-2010 |
20100021929 | DETECTION OF A BIOMARKER OF ABERRANT CELLS OF NEUROECTODERMAL ORIGIN IN A BODY FLUID - Assays and kits for detecting aberrant cells of neuroectodermal origin in a body fluid of an individual, comprising testing for expression of GLAST1b as a biomarker of the cells are disclosed. Intact GLAST1b and/or fragments thereof may be detected in the fluid. Alternatively, another analyte indicative of the expression of GLAST1b by the cells may be detected. The assay is particularly suitable for detecting expression of aberrant neuronal populations such as resulting from brain hypoxia. The fluid can be cerebrospinal fluid (CSF). | 01-28-2010 |
20100021930 | APPLICATION OF SURFACE PLASMON RESONANCE TECHNOLOGY TO MATERNAL SERUM SCREENING FOR CONGENITAL BIRTH DEFECTS - This invention discloses using SPR technology to simultaneously and quantitatively detect the presence of serum markers in pregnant women for the purpose of screening for congenital birth defects. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of representative antibodies used to detect the respective serum markers in pregnant women for the purpose of maternal serum screening for congenital birth defects. | 01-28-2010 |
20100021931 | Fluorescence based reporter construct for the direct detection of TGF-beta receptor activation and modulators thereof - The invention comprises a fusion protein as sensor for TGF-beta receptor activity, a method for detecting receptor activity and to screening compounds for modulators of receptor activity. The fusion protein comprises a type I TGF-beta receptor, a circularly permutated fluorescent protein moiety (cpFP) and an activation state specific receptor binding domain, binding specifically to either the activated or inactive form of the TGF-beta receptor. An activation specific interaction between the receptor and the activation state specific receptor binding domain modulates the fluorescence of the cpFP inserted in between. Thus, activation of the receptor can be detected directly by a change in fluorescence of the cpFP. | 01-28-2010 |
20100021932 | Method for use of microdialysis - Very accurate measurements of mass transfer can be made rapidly by permitting diffusion of an agent desired to be measured into or out of a small, very precisely known volume of a microdialysis probe, then rapidly pumping or flushing (“pulsing”) the probe with a known volume of fluid as a single pulse. The diffusion and pulsing may be repeated. The method, hereinafter called pulsatile microdialysis (PMD) to distinguish it from prior art continuous flow microdialysis, is useful for measurements in a number of processes, including protein binding, adsorption to binding agents such as activated charcoal, release from microemulsion drug delivery systems, determination of drug diffusion coefficients and concentrations, and for various other purposes. | 01-28-2010 |
20100021933 | CELLOMICS SYSTEMS - In labeling a cell, and separating and collecting the cell according to a degree of the labeling using a cell separator, effects on the cell is minimized and the use of the collected cell is facilitated, thereby, when labeling a cell, the cell is labeled in the state where interaction of each cell is retained. In the labeling, a specific labeling material present on a surface of a target cell is taken in the cell via a transporter, and the cell is dispersed one by one to separate the same with a cell separator. Immediately after the separation, the cell is put in a solution not containing the specific labeling substance to remove the specific labeling substance taken in the cell. This series of steps is continuously conducted with a cell separation chip. | 01-28-2010 |
20100021934 | Perlecan Fragments as Biomarkers of Bone Stromal Lysis - A method for the detection in a body fluid of perlecan polypeptide fragments that are biomarkers of tumor metastasis, and antibodies for detecting these fragments are described. An immunoassay kit for detecting the presence of these biomarkers in a body fluid, such as serum or urine, is also described. | 01-28-2010 |
20100021935 | Goodpasture Antigen Binding Protein and Its Detection - The present invention provides native Goodpasture antigen binding protein isoforms, monoclonal antibodies directed against such proteins, and methods for their use. | 01-28-2010 |
20100021936 | Sensor for Spores - A sensor for spores, comprises spore-binding ligands and, on or within the body of the sensor, a material that is responsive to Ca-DPA (calcium-dipicolinic acid) but not to a (or another) germinant. | 01-28-2010 |
20100028901 | METHOD FOR DIAGNOSING IN VITRO OR EX VIVO PSYCHIATRIC DISORDERS AND/OR INTESTINAL DYSBIOSES - The invention relates to the use of at least one of the following Formula (I) compounds: | 02-04-2010 |
20100028902 | LIVING CELL FORCE SENSORS AND METHODS OF USING SAME - Disclosed herein are materials and methods for the efficient and universal fabrication of microcantilevers terminated with living cells. Methods disclosed describe the passive attachment of cells to microcantilevers that represent cells in suspension comprising living cells attached thereto via association with a hydrophobic layer. Also, disclosed are efficient methods for seeding single and multiple cells to cantilevers that represent isolated adherent cells and tissue constructs of tunable confluency. | 02-04-2010 |
20100028903 | METHOD AND DEVICE FOR EXAMINING THE ATTACHMENT OR DETACHMENT OF LIVING OR DEAD CELLS OR CELL-LIKE PARTICLES OR OTHER SURFACE ACCUMULATIONS ON SURFACES BY MEANS OF PLASMON RESONANCE AND USE OF SAID METHOD AND SAID DEVICE - The invention relates to the examination of the attachment or detachment of living or dead cells, or cell-like particles, or other surface accumulations on surfaces, by means of plasmon resonance. The reflected light is evaluated such that two or more intensity minima of the reflected light occurring within a time frame are registered in a time dependant manner for different incident angles. The registered measurement signals reflect the respective amount of the surface accumulation. In case two intensity minima have occurred at the same time, valuable information about particular processes regarding the surface accumulation, for example regarding the adhesion of cells, can be obtained. Said information is of particular importance in the field of medicine/biology. | 02-04-2010 |
20100028904 | WAY TO OBTAIN HIGH EXPRESSION CLONES OF MAMMALIAN CELLS USING A METHYLCELLULOSE WITH FLUORESCENT PROTEIN A OR G AND FLUORESCENT SCREENING METHOD - The invention provides a genetic screening method for identifying a transfected cell expressing the polypeptide of interest. The methods allows for high throughput screening of recombinant cells for elevated levels of expression of the polypeptide of interest using methylcellulose comprising fluorescent protein A or G to improve detection and cloning. The invention also provides capture media, formulations and methods of making and using thereof. | 02-04-2010 |
20100028905 | CHARACTERIZATION OF GRP94-LIGAND INTERACTIONS AND PURIFICATION, SCREENING, AND THERAPEUTIC METHODS RELATING THERETO - The presently disclosed subject matter discloses characterization of interactions between ligands and Hsp90 proteins, including GRP94, wherein ligand binding to the N-terminal nucleotide binding domain of GRP94 elicits a conformational change that converts the GRP94 from an inactive to an active conformation, and wherein the chaperone and peptide-binding activities of the GRP94 are markedly stimulated. Also disclosed are purification, screening, and therapeutic methods pertaining to the biological activity of GRP94, and in some instances HSP90, based upon the characterization of ligand interactions of Hsp90 peptide-binding proteins, including GRP94. | 02-04-2010 |
20100028906 | REDUCING THE RISK OF HUMAN ANTI-HUMAN ANTIBODIES THROUGH V GENE MANIPULATION - The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included. | 02-04-2010 |
20100035273 | METHOD AND DEVICE FOR SMALL SCALE REACTIONS - The present invention relates to a method and a device for small scale reactions, such as sample preparation of a desired substance in a sample. In the method using the device samples mixed with functionalized magnetic particles are magnetically transferred between different working stations on the device. The method uses a hydrophobic surface, such as a Petri dish, provided with hydrophilic spots of, for example, agarose beads located on said hydrophobic surface and provided with buffers, reactants or ligands. | 02-11-2010 |
20100035274 | Methods for Detecting Symmetrical Dimethylarginine - Method of detecting Symmetrical dimethyl arginine (SDMA) in biological samples. SDMA analogs for generating anti-SDMA antibodies having little or no cross-reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine. The analogs have a protected or free thiol (—SH) group or hydroxyl (—OH) group that allow them to be linked to a suitable conjugation target which can be, for example, a protein containing molecule of a label. The anti-SDMA antibodies can be used in diagnostic immunoassay for the diagnosis of SDMA associated disorders and/or diseases. | 02-11-2010 |
20100035275 | DIAGNOSIS AND RISK ASSESSMENT OF PANCREATIC DIABETES USING MR-PROADM - The invention relates to a method for diagnosis and/or risk assessment of pancreatic diabetes, in particular of diabetic sequelae, wherein a determination of the marker mid-regional proAdrenomedullin (MR-proADM: SEQ ID No. 2) or a partial peptide or fragment thereof or if contained in a marker combination (Panel, Cluster) is carried out on a patient under investigation. The invention further relates to a diagnostic device and a kit for carrying out said method. | 02-11-2010 |
20100035276 | IDENTIFYING VIRALLY INFECTED AND VACCINATED ORGANISMS - This document provides methods and materials related to assessing organisms for the presence or absence of anti-virus antibodies. For example, this document provides methods and materials that can be used to determine whether or not an organism (e.g., a member of a swine species such as a pig) contains anti-PRRS virus antibodies. In other embodiments, this document provides methods and materials that can be used to determine if a particular organism received a vaccine version of a virus, was infected with a naturally-occurring version of the virus, or is naive with respect to the virus. | 02-11-2010 |
20100041061 | Enhancing Endotoxin Detection - Provided herein are methods for detecting gram negative bacteria or lipopolysaccharide in a sample. Kits for detecting gram negative bacteria or lipopolysaccharide in a sample are provided. | 02-18-2010 |
20100041062 | DEVICES, SYSTEMS, AND METHODS FOR AIDING IN THE DETECTION OF A PHYSIOLOGICAL ABNORMALITY - The present invention comprises a method for identifying the presence or absence of a pulmonary embolism using a combination of tests and brightline thresholds. The first test is a blood based test measuring D-Dimer concentration and the second test is a respiratory analysis that determines a carboximetry ratio. If the measured D-Dimer value is at or above a threshold indicative of concern and the carboximetry value is equal to or less than a carboximetry ratio threshold, pulmonary embolism is present. If the measured D-Dimer value is at or above a threshold indicative of concern and the respiratory analysis yields a carboximetry ratio greater than the carboximetry ratio threshold, test results are inconclusive and additional testing is required to determine whether a pulmonary embolism is present. | 02-18-2010 |
20100041063 | ANTI-DRUG ANTIBODY ASSAY - The invention provides an antibody binding specifically to Cynomolgus IgG characterized by not binding to Human IgG, and a method for the immunological determination of an immune complex (DA/ADA complex) of a drug antibody (DA) and an antibody against said drug antibody (anti-drug antibody, ADA) in a sample of a monkey species using a double antigen bridging immunoassay. | 02-18-2010 |
20100041064 | DIAGNOSIS AND RISK STRATIFICATION OF INFECTIONS AND CHRONIC DISEASES OF THE RESPIRATORY TRACT AND LUNGS BY MEANS OF PROVASOPRESSIN, PARTICULARLY COPEPTIN OR NEUROPHYSIN II - The invention relates to a method for diagnosing and/or stratifying the risk of infections or chronic diseases of the respiratory tract and lungs, particularly lower respiratory tract infections and chronic obstructive pulmonary disease. In said method, provasopressin (proAVP) or fragments or partial peptides thereof, especially copeptin or neurophysin II, is/are determined. The invention further relates to suitable biomarker combinations for in-vitro diagnosis. | 02-18-2010 |
20100041065 | DETECTION METHOD, SAMPLE CELL AND KIT FOR DETECTION AND DETECTION APPARATUS - A labeling binding substance in an amount corresponding to the amount of a detection target substance contained in a liquid sample binds to a sensor portion, and the amount of the detection target substance is detected based on the amount of signal light output by excitation of a label of the labeling binding substance in an enhanced optical field on the sensor portion. In this detection method, a labeling substance that includes a light-responsive substance enclosed by a dielectric that transmits light output from the light-responsive substance is used as the label, and the labeling binding substance binds to the sensor portion through a plurality of fragmented antibodies. | 02-18-2010 |
20100041066 | NON-PRECIPITATING BODILY FLUID ANALYSIS SYSTEM - A bodily fluid analyzer including a dry test strip impregnated with a reagent providing a non-precipitating reaction to exclude non-desired analytes. The reagent complexes the non-desired analytes so they remain in solution but cannot participate in the test reaction. Red blood cells are removed from the detection area by slowing their vertical movement and stopping flow when the detection membrane is saturated. | 02-18-2010 |
20100047811 | METHOD FOR OPTIMIZING THE AUTOMATIC FLUORESCENCE PATTERN RECOGNITION IN IMMUNODAGNOSIS - The invention relates to a method for optimizing the automatic fluorescence pattern recognition in immunodiagnosis. In this method, in addition to or together with the fluorescence dye, one or more other indicator dyes for the identification of relevant structures are incubated before an image is taken with a camera. | 02-25-2010 |
20100047812 | PEPTIDE ANTIBODY DEPLETION AND ITS APPLICATION TO MASS SPECTROMETRY SAMPLE PREPARATION - The present invention relates, e.g., to a method for pre-processing a sample for mass spectral analysis, comprising cleaving proteins in the sample to peptides and immunodepleting highly abundant and/or well-ionizing and/or proteotypic peptides from the sample. Also described are methods for identifying well-ionizing peptides for use in this and other methods: analytic (diagnostic) methods using antibodies against highly ionizable peptides from a protein target of interest; and compositions kits and devices comprising antibodies of the invention. | 02-25-2010 |
20100047813 | BIOLUMINESCENCE RESONANCE ENERGY TRANSFER (BRET) SYSTEMS AND METHODS OF USE THEREOF - Briefly described, embodiments of this disclosure include bioluminescence resonance energy transfer (BRET) systems, methods of detecting a protein-protein interaction, noninvasive methods for detecting the interaction of a first protein with a second protein within a living animal, methods to determine the efficacy of a test compound administered to modulate the interaction of a first protein with a second protein in a living animal, BRET vectors, kits relating to each of the above, transgenic cell or progeny thereof and/or animals relating to each of the above, and the like. | 02-25-2010 |
20100047814 | PROTEIN INTERACTION REPORTER AGENTS AND METHODS FOR USING SAME - Particular aspects provide novel protein interaction reporter (PIR) compounds (e.g., formulas I and II), comprising at least two protein reactive moieties (e.g., N-hydroxysuccinamide), each linked to a reporter moiety (e.g., mass reporter) by a covalent labile bond that is differentially cleavable with respect to peptide bonds (e.g., by a method such as collisional activation in a mass spectrometer, activation by electron capture dissociation (ECD), photoactivation, etc.), wherein the reporter moiety is operatively releasable from the PIR agent upon cleavage of the labile bonds, the released reporter moiety having a characteristic identifying property or label (e.g., m/z value). Particular PIRs comprise a mass reporter moiety, and further comprise an affinity group, (e.g., biotin), linked to the PIR (e.g., to the mass reporter moiety) by a selectively cleavable bone (e.g. photo-labile bond)). Additional aspects provide methods for characterizing intermolecular or intramolecular protein interactions using one or more inventive PIR compounds. | 02-25-2010 |
20100047815 | METHOD TO DETECT TUMOR MARKERS AND DIAGNOSIS OF UNDIFFERENTIATED TUMORS - This invention discloses using SPR technology to simultaneously and quantitatively measure the concentrations of different tumor markers in a protein sample extracted from tumor tissue, which can be used for the diagnosis of undifferentiated tumors. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of monoclonal antibodies used for detecting tumor markers in a tumor tissue sample and for the diagnosis of undifferentiated tumors. | 02-25-2010 |
20100047816 | RAPID IMMUNOCHROMATOGRAPHIC DETECTION BY AMPLIFICATION OF THE COLLOIDAL GOLD SIGNAL - The present invention relates to a rapid immunochromatographic test device suitable to detect an antibody and/or antigen in at least one sample, uses of said device for detecting diseases in a sample, a method for the production of said device as well as a kit comprising the device. | 02-25-2010 |
20100047817 | Synaptotagmin and Collapsin Response Mediator Protein as Biomarkers for Traumatic Brain Injury - Collapsin response mediator proteins (CRMPs) decreased in tissue and increased in biological fluids after neural injury from traumatic brain injury (TBI). Significant decreases of CRMP1, CRMP2, CRMP4 and CRMP5 were accompanied by the appearance of distinct 58 kDa (CRMP-2) or 55 kDa (CRMP-4) breakdown products from proteolytic cleavage by calpain. Synaptotagmin breakdown products were also associated with TBI and could be detected along with intact protein in human cerebral spinal fluid (CSF). Both biomarkers were detected in human biofluid and related to recovery from traumatic brain injury. | 02-25-2010 |
20100047818 | DIAGNOSIS OF CARCINOMAS - The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages. | 02-25-2010 |
20100047819 | MULTIPLEX ASSAY FOR RHEUMATOID ARTHRITIS - Multiplex assays that allow for the detection and quantification of Rheumatoid Factor (RF) and anti-cyclic citrullinated peptide (CCP) antibodies in a single reaction mixture are provided. | 02-25-2010 |
20100047820 | DETECTING METHOD, DETECTING APPARATUS, DETECTION SAMPLE CELL, AND DETECTING KIT - A sample is supplied onto the sensor portion of a sensor chip. An excitation light beam is irradiated to generate an enhanced optical field to be generated on the sensor portion. Fluorescent labels are excited, and the amount of a detection target substance is detected, based on the amount of light which is generated due to excitation of the fluorescent labels. A first electric charge is present on the surface of the sensor portion. A fluorescent substance having fluorescent pigment molecules which are enveloped in a light transmitting material that transmits fluorescence generated by the fluorescent pigment molecules, the surfaces of which are charged with second electric charges opposite the first electric charge on the surface are employed as the fluorescent labels. The fluorescent substance is attracted to the sensor portion by static electric interactions between the two charges. | 02-25-2010 |
20100047821 | CROWN ETHER DERIVATIVES - The invention describes crown ether chelators, including crown ethers having the formula: | 02-25-2010 |
20100047822 | TIMP-4 AS A BIOMARKER FOR THE DIAGNOSIS OF CARDIAC INSUFFICIENCY - The invention relates to the use of the plasma concentration of the polypeptide “tissue inhibitor of metalloproteinase-4” (TIMP-4) as a biomarker for the diagnosis of heart failure. | 02-25-2010 |
20100055710 | Novel Carbohydrate Profile Compositions From Human Cells and Methods for Analysis and Modification Thereof - The invention describes methods for production of novel composition of glycans, glycomes, from human multipotent stem cells. The invention is further directed to methods for modifying the glycomes and analysis of the glycomes and the modified glycomes. Furthermore the invention is directed to stem cells carrying the modified glycomes on their surfaces. | 03-04-2010 |
20100055711 | METHODS FOR THE IDENTIFICATION OF PI3K INTERACTING MOLECULES AND FOR THE PURIFICATION OF PI3K - The present invention relates to a method for the identification of a PI3K interacting compound, comprising the steps of a) providing a protein preparation containing PI3K, b) contacting the protein preparation with phenylthiazole ligand 1 immobilized on a solid support under conditions allowing the formation of a phenylthiazole ligand 1-PI3K complex, c) incubating the phenylthiazole ligand 1-PI3K complex with a given compound, and d) determining whether the compound is able to separate PI3K from the immobilized phenylthiazole ligand 1. Furthermore, the present invention relates to a method for the identification of a PI3K interacting compound, comprising the steps of a) providing a protein preparation containing PI3K, b) contacting the protein preparation with phenylthiazole ligand 1 immobilized on a solid support and with a given compound under conditions allowing the formation of a phenylthiazole ligand 1-PI3K complex, and c) detecting the phenylthiazole ligand 1-PI3K complex formed in step b). Furthermore, the present invention relates to a method for the identification of a PI3K interacting compound, comprising the steps of a) providing two aliquots of a protein preparation containing PI3K, b) contacting one aliquot with the phenylthiazole ligand 1 immobilized on a solid support under conditions allowing the formation of a phenylthiazole ligand 1-PI3K complex, c) contacting the other aliquot with the phenylthiazole ligand 1 immobilized on a solid support and with a given compound under conditions allowing the formation of a phenylthiazole ligand 1-PI3K complex, and d) determining the amount of the phenylthiazole ligand 1-PI3K complex formed in steps b) and c). Furthermore, the present invention relates to a method for the identification of a PI3K interacting compound, comprising the steps of a) providing two aliquots comprising each at least one cell containing PI3K, b) incubating one aliquot with a given compound, c) harvesting the cells of each aliquot, d) lysing the cells in order to obtain protein preparations, e) contacting the protein preparations with the phenylthiazole ligand 1 immobilized on a solid support under conditions allowing the formation of a phenylthiazole ligand 1-PI3K complex, and f) determining the amount of the phenylthiazole ligand 1-PI3K complex formed in each aliquot in step e). | 03-04-2010 |
20100055712 | Oligopeptides for treatment of osteoporosis and other bone diseases and methods therefor - Methods of identifying compounds for treating Alzheimer's disease are disclosed. These methods comprise a) forming an in vitro mixture comprising i) cells expressing LDL receptor related protein 1 (LRP1), ii) an LRP1 ligand comprising a label, and iii) a candidate compound; and b) determining quantity of the label incorporated by the cells, whereby a candidate compound is deemed effective for treating Alzheimer's disease if the quantity of label incorporated by the cells exceeds that of a control in vitro mixture comprising cells expressing LRP1 and the LRP1 ligand, but not comprising the compound. | 03-04-2010 |
20100055713 | CHEMILUMINESCENCE SENSOR ARRAY - Embodiments of the invention relate to integrated chemiluminescence devices and methods for monitoring molecular binding utilizing these devices and methods. These devices and methods can be used, for example, to identify antigen binding to antibodies. The devices include both a chemiluminescence material and a detector integrated together. | 03-04-2010 |
20100062449 | Method Of Measuring PTX3 With High Sensitivity - To provide a method of determining vasculopathy, which is a risk factor of myocardial infarction, angiopathic dementia, etc., at an early stage thereof (i.e., mild vasculopathy). The present invention provides a method of determining the severity of mild vasculopathy, including determining PTX3 level in an assay sample by use of an anti-PTX3 monoclonal antibody. | 03-11-2010 |
20100062450 | Methods and Kits for Early Detection of Cancer or Predisposition Thereto - Methods and kits for diagnosing cancer or a pre-malignant lesion by determining the presence and/or level of circulating CD24 of a subject are provided. Also provided are methods and kits for determining if a subject is predisposed to gastrointestinal cancer by the determining the presence or absence, in a homozygous or heterozygous form of cancer associated genotype(s) in the CD24 and/or APC nucleic acid sequences. Also provided are methods and kits for monitoring efficacy of cancer therapy by determining the presence and/or level of circulating CD24 of a subject. | 03-11-2010 |
20100062451 | Bead-ligand-nascent protein complexes - Bead-ligand-nascent protein complexes, and method of creating and detecting a bead-ligand-nascent protein complexes, are described. PCR-amplified product which is attached to a surface, e.g. of a bead, is used to generate nascent protein, which in turn is captured on the bead and detected, e.g. by fluorescence. | 03-11-2010 |
20100062452 | METHODS FOR DETERMINING SIGNAL TRANSDUCTION ACTIVITY IN TUMORS - The method of the invention pertains to determining the signal transduction activity in a tissue section by immunohistochemistry techniques. The expression level of the receptor of interest is determined as well as the expression levels of one or more effector molecules of the receptor signal transduction pathway. Furthermore a combined ratio of expression levels of effector molecules in subcellular compartments with the receptor expression was found to have prognostic significance. | 03-11-2010 |
20100062453 | Method of diagnosing endometriosis in human subjects - A method for diagnosing endometriosis in a human subject comprising the steps of detecting a test amount of an antibody that specifically binds to ME-5 (SEQ ID NO:3) polypeptide or a peptide comprising an epitope of ME-5 in a sample from the subject; and comparing the test amount with a normal range of the antibody in a control sample from a subject who does not suffer from endometriosis, whereby a test amount above the normal range provides a positive indication in the diagnosis of endometriosis. | 03-11-2010 |
20100062454 | Method for predicting risk of acquiring influenza - An object of the present invention is to provide a method for predicting the risk of acquiring influenza, which is characterized by low price, low invasiveness, and applicability to total automation. The present invention provides a method for predicting the risk of acquiring influenza, which comprises measuring the ratio of anti-influenza IgA to the total IgA in a specimen collected from a subject. | 03-11-2010 |
20100062455 | Rapid Detection of Cholinesterase Inhibitors - The present invention relates to a rapid, high-throughput detection method for screening of potential casualties exposed to a cholinesterase inhibitor. A kit is provided for conducting the method that requires only a small volume of sample such as blood for detection and has a rapid screening throughput for multiple casualties. The kit is able to detect both free and protein-bound-cholinesterase inhibitors. The method should be able to differentiate asymptomatic exposure from the mass psychogenic illness cases. | 03-11-2010 |
20100062456 | T2R, A NOVEL FAMILY OF TASTE RECEPTORS - The invention provides nucleic acid and amino acid sequences for a novel family of taste transduction G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste transduction G-protein coupled receptors. | 03-11-2010 |
20100062457 | BIOMARKERS, KITS, AND METHOD FOR DIAGNOSING, MONITORING, AND/OR STAGING ALZHEIMER'S DISEASE - The present invention is directed to a biomarker and kit for diagnosing, monitoring and/or staging Alzheimer's disease comprising redox-reactive autoantibodies. The present invention is also directed to a method for diagnosing, monitoring and/or staging Alzheimer's disease which comprises conducting a blood test using the same. | 03-11-2010 |
20100062458 | MONOCLONAL AND POLYCLONAL ANTIBODIES TO EQUINE ALBUMIN AND HEMOGLOBIN AND APPARATUS AND METHODS USING THE ANTIBODIES IN THE IDENTIFICATION AND LOCALIZATION OF ULCERS AND OTHER DIGESTIVE TRACT BLEEDING IN EQUINES - A diagnostic and testing apparatus and related methods for the use of the same are disclosed which derive and use antibodies to equine albumin and equine hemoglobin in testing apparatus, kits, and methods for detecting and localizing gastric and colonic ulcers or bleeding in horses. Fecal droppings from a horse to be tested are placed in a container together with a buffered liquid solution and mixed thoroughly, following which several drops of liquid from the container are placed into a test kit. Visual markers in the test kits signify the detection of the indicators equine hemoglobin and equine albumin, which are respectively indicative of the presence of gastric and/or colonic ulcers or bleeding. | 03-11-2010 |
20100062459 | Tacrolimus Standard and Methods of Using Same - A composition and kit useful as a tacrolimus standard solution for immunoassays, and methods for making and using same. The composition and kits include a known amount of tacrolimus or a derivative thereof, and a non-specific protein capable of forming a complex with the tacrolimus or derivative thereof. The standard solution may be used to generate calibration curves for an immunoassay or to check the precision of an analytical instrument. | 03-11-2010 |
20100068724 | Biomaker for ovarian and endometrial cancer: hepcidin - The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry. | 03-18-2010 |
20100068725 | DIRECT DETERMINATION OF VITAMIN D IN SERUM OR PLASMA - A method for quantitating vitamin D metabolites directly in blood plasma or serum, without the need for prior purification of the vitamin D metabolites, comprising a digestion of the serum proteins with a serine protease such as proteinase K and sequence of steps for inhibiting the proteinase K activity in the competitive binding analysis. The advantages of this method are its high accuracy over the whole range of physiologically relevant values and that it can be easily adapted for a fully automated analysis of serum and plasma samples. | 03-18-2010 |
20100068726 | ANTIGEN DETECTION METHOD INVOLVING AN OLIGONUCLEOTIDE ENHANCED COLLOIDAL GOLD SIGNAL - The present invention refers to a rapid immunochromatographic test device for antigen detection, comprising a first and a second conjugate releasing pad, wherein the first conjugate pad comprises a gold conjugated protein linked first oligonucleotide and a gold conjugated antigen specific antibody, and the second conjugate pad comprises a gold conjugated protein linked second oligonucleotide, which second oligonucleotide is complementary to the first oligonucleotide. The present invention further refers to a use of such test device for antigen detection in urine or saliva, e.g. human choriogonadotropin (hCG) in urine. Embodiments of the test device are a test strip and a detection cup. The present invention also refers to a method for manufacturing such test device. | 03-18-2010 |
20100068727 | RAPID IMMUNOCHROMATOGRAPHIC DETECTION BY AMPLIFICATION OF THE COLLOIDAL GOLD SIGNAL - The present invention relates to a method for rapid immunochromatographic detection of a target in a sample by double sandwich immunoassay detection, wherein the target is an antibody and/or an antigen, using different colloidal gold conjugates conjugated with a first and a second specific antibody or antigen and with at least one oligonucleotide and its at least one complementary oligonucleotide and/or at least one non-specific antibody and its related non-specific antigen, to a rapid immunochromatographic detection device, to uses of the method for detecting diseases or specific conditions, and to a method for the manufacture of the device as well as to a kit which comprises the device. | 03-18-2010 |
20100068728 | POLYSACCHARIDE DERIVATIVES AND USES IN INDUCTION OF AN IMMUNE RESPONSE - The present invention generally provides compositions comprising a polysaccharide derivative, and methods of their preparation and use for the prevention or treatment of diseases caused by | 03-18-2010 |
20100068729 | METHOD AND KITS FOR THE DIAGNOSIS OF DIABETES - Provided are methods for the detection and diagnosis of a predisposition for developing diabetes. The methods are based on the discovery that abnormal levels of the selected analyte in biological samples, typically blood samples, of patients who are at risk are supportive of a diagnosis of a predisposition for developing diabetes. At least one new biomarker for a predisposition for diabetes is thus disclosed, IGF-1. Other important biomarkers for diabetes are described, including but not limited to ZAG, clusterin, corticosteroid-binding globulin, lumican, and serotransferrin. Kits containing reagents to assist in the analysis of biological samples are also described. | 03-18-2010 |
20100075337 | METHOD OF IDENTIFICATION OF CELLS THAT SHOW SENSITIVITY TO MODULATION OF SIGNALINGH MEDIATED BY FIBROBLAST GROWTH FACTOR RECEPTOR OR A VARIANT THEREOF - The invention is based on the finding that cells that show (especially tyrosine) phosphorylation of FGF-R substrate 2 (FRS-2), in contrast to cells that lack such phosphorylation, allow a prediction that treatment with a modulator, especially an inhibitor, of Fibroblast Growth Factor-Receptor signaling will be successful in cells e.g. from biological samples from patients that show such phosphorylation. Therefore, the phosphorylation of FRS-2 can serve as a biomarker for the possibility of successful treatment. The invention relates to various methods, uses, kits and reagents useful in applying this biomarker. | 03-25-2010 |
20100075338 | Whole Blood Assay - A method and apparatus to estimate the concentration of a target substance (e.g. Cholesterol or CRP) in the plasma component of awhole blood sample without the need to separate the red blood cells from the plasma prior to testing, thereby simplfying the design and construction of the test device. The invention achieves this by measuring the analyte under investigation in a time dependent (bio-/immuno-) chemical reaction and measuring separately, a marker substance (e.g haemoglobin) for the estimation of red blood cell volume, using a non-time-dependent alteration in physical property of the reaction mixture (in this instance, transmission) attributed to inherent filter effects on sample addition. These non-time- dependent changes are not part of the reaction chemistry, and are resolved from the time dependent alteration in physical property caused by the assay chemistry by continuous measurement and mathematical modelling. Algorithms that combine these two parameters are used to estimate the target substance and compensate for variations in the percentage haematocrit of the sample. The method equalises the assay response for subtle variations in patient sample (e.g. haematocrit). | 03-25-2010 |
20100075339 | SURFACE-ENHANCED RAMAN SCATTERING (SERS) BASED NANOPARTICLE COMPOSITES - Nanoparticle composites and method of use thereof for simultaneously sensing and probing a biological system, comprising providing a nanoparticle composite comprising a nanoparticle comprising a core and a shell; a first ligand bound to the nanoparticle, said first ligand capable of sensing pH; a second ligand bound to the nanoparticle, said second ligand distinct from said first ligand and capable of binding to a target; and bringing the nanoparticle composite into contact with the biological system to produce a first and a second pH-dependent signal; and analyzing the first or the second signal by means of surface-enhanced Raman spectroscopy. | 03-25-2010 |
20100075340 | Electrical Detection Of Biomarkers Using Bioactivated Microfluidic Channels - The present disclosure encompasses the manufacture and use of rapid and inexpensive electrical biosensors comprising microelectrodes in a micro-channel. The devices of the disclosure can be used to detect and quantify target cells, protein biomarkers, and nucleic acid biomarkers, and the like, by measuring instantaneous changes in ionic impedance. The micro-channel devices of the disclosure are also suitable for the detection of target protein and oligonucleotide, and small molecule target biomarkers using protein-functionalized micro-channels for the rapid electrical detection and quantification of any type of target protein biomarker in a sample. The biochip microfluidic devices may be combined with an integrated circuitry into a portable handheld device for multiplex high throughput analysis using an array of micro-channels for probing clinically relevant samples, such as the human serum, for multiple protein and nucleic acid biomarkers for disease diagnosis, and the detection of potentially pathogenic organisms. | 03-25-2010 |
20100081146 | METHOD OF REDUCING THE SENSITIVITY OF ASSAY DEVICES - A flow-through assay device for detecting the presence or quantity of an analyte residing in a test sample is provided. The device utilizes a scavenging zone that contains a capture reagent for the analyte of interest. The capture reagent may capture a quantity of the analyte that is less than or equal to a predefined base quantity of the analyte, such as a quantity considered “normal” for a particular test sample. Thus, the capture reagent is able to prevent some of the analyte from being detected. In this manner, the sensitivity of the assay device may be reduced in a simple, inexpensive, yet effective manner. | 04-01-2010 |
20100086937 | METHOD TO DETECT TREPONEMA PALLIDUM IMMUNOLOGICAL MARKERS FOR THE DIAGNOSIS OF SYPHILIS - This invention discloses using SPR technology to qualitatively detect the presence of | 04-08-2010 |
20100086938 | MASS SPECTROMETRY OF BIOLOGICAL SAMPLE USING IMMUNOPRECIPITATION - It is intended to provide an analysis method for a biological sample with clinical significance, which is a system being simple to such an extent that it can be applied to a clinical field, and capable of capping a molecule ionization suppression in mass spectrometry. Mass spectrometry of a biological sample using immunoprecipitation, comprising the steps of: preparing a sample containing an objective biological molecule; concentrating the biological molecule in the sample by immunoprecipitation using an antibody-bound carrier or a carrier to which a molecule capable of specifically binding to an antibody is bound; washing an immunoprecipitate of the biological molecule by using an aqueous solution containing a charge neutralizing agent as a washing liquid; and detecting the biological molecule by subjecting the washed immunoprecipitate to mass spectrometry. | 04-08-2010 |
20100086939 | DETERMINATION METHOD FOR ALLERGIC DISEASE - It is to provide a method for determining allergic diseases with a high sensitivity and accuracy which enables multilateral and global analysis with a minute amount of sample, even using body fluid other than blood such as saliva, nasal discharge and tears as a sample, particularly by suppressing nonspecific reaction as much as possible. A chemically modified diamond/DLC (Diamond-like Carbon) chip is activated with a reacting reagent, a coupling reaction with a peptide comprising allergen or allergen epitope is conducted, and a sample such as saliva, tears, and nasal discharge which has undergone pressure filtration with a low protein-adsorbing filter, is contacted with an allergen determination chip to which washing and blocking operations have been performed on unreacted active groups, and an allergen recognizing antibody in the sample captured by the allergen determination chip is detected by immunoassay using a labeled secondary antibody, wherein a glycine-containing solution is used for a washing solution and/or blocking solution used in the washing and blocking operations, is used. | 04-08-2010 |
20100086940 | Polynucleotide encoding an autoantigen associated with endometriosis - This invention provides a polynucleotide encoding Repro-EN-1.0 and IB1, polypeptides associated with endometriosis. Auto-antibodies against Repro-EN-1.0 and IB1 have been found in subjects diagnosed with endometriosis. This invention also provides methods of using this polynucleotide and polypeptide. | 04-08-2010 |
20100086941 | Methods for determining aged based accumulation of senescent cells using senescence specific DNA damage markers - One disclosure provides a method for determining a senescence based disorder by detection of cells with senescence specific DNA damage markers which includes the step of providing a sample with one or more cells. It also includes the steps of identifying with immunodetection the presence of activated DNA damage response proteins that are shown to be activated with senescence and identifying with immunodetection the inactivation of DNA damage response proteins that are shown to be inactive in senescence. | 04-08-2010 |
20100086942 | COMPOUNDS - The present invention relates to binding members, especially antibody molecules, for CXCL13. The binding members are useful for the treatment of disorders associated with CXCL13, including arthritic disorders such as rheumatoid arthritis. | 04-08-2010 |
20100092992 | LYSINE ACETYLATION SITES - The invention discloses 322 novel acetylation sites identified in various cancers, peptides (including AQUA peptides) comprising a acetylation site of the invention, antibodies specifically bind to a novel acetylation site of the invention, and diagnostic and therapeutic uses of the above. | 04-15-2010 |
20100092993 | QUANTITATIVE ANALYZING METHOD - This invention discloses an analyzing method for detecting a specific analyte in a fluid sample. The method comprises the following steps. First, a substrate is provided. The substrate has a channel provided concavely on an upper surface thereof. The channel comprises a first area, a second area and a third area, and these three areas are connected sequentially. Each of the second and the third areas comprises a nitrocellulose layers containing a reaction material and formed at the bottom thereof. The nitrocellulose layer of the third area can absorb a fixed volume of the fluid sample. Second, the fluid sample is applied to the first area and delivered by the second area and then to the third area. Finally, the reaction material reacts with the specific analyte in the fluid sample to produce a signal for detection. | 04-15-2010 |
20100092994 | High specificity monoclonal antibody against a protein or a polypeptide having oxidative modification - The present invention provides an antibody, which reacts with a FGA or FGA partial peptide in which a part of prolines in the molecule thereof are hydroxylated, and which does not react with an unmodified FGA or FGA partial peptide. | 04-15-2010 |
20100092995 | FLUORESCENT RUTHENIUM COMPOUNDS FOR DETECTING CALCIUM BINDING PROTEINS - A fluorescent compound exhibiting a high affinity to calcium-binding proteins (CaBP) is provided. The compound, containing ruthenium, enables to detect, identify, and isolate CaBPs involved in cellular signaling and regulation. The compound is employed for diagnosing a disorder associated with CaBPs defects. | 04-15-2010 |
20100092996 | MICROELECTRONIC SENSOR DEVICE FOR DETECTING LABEL PARTICLES - The invention relates to a microelectronic sensor device for the detection of target components that comprise label particles, for example magnetic particles ( | 04-15-2010 |
20100092997 | Method of Enhancing of Binding Activity of Antibody Composition to FcGamma Receptor IIIa - A method for enhancing a binding activity of an antibody composition to Fcγ receptor IIIa, which comprises modifying a complex N-glycoside-linked sugar chain which is bound to the Fc region of an antibody molecule; a method for enhancing an antibody-dependent cell-mediated cytotoxic activity of an antibody composition; a process for producing an antibody composition having an enhanced binding activity to Fcγ receptor IIIa; a method for detecting the ratio of a sugar chain in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain among total complex N-glycoside-linked sugar chains bound to the Fc region in an antibody composition; an Fc fusion protein composition produced by using a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked sugar chain; and a process for producing the same. | 04-15-2010 |
20100092998 | METHODS AND COMPOSITIONS RELATING TO E3 RING-E2 FUSION PROTEINS - Compositions are provided according to embodiments of the present invention which include an isolated fusion protein including an E3 protein RING motif bonded to an UCE E2 protein. In preferred embodiments, the C-terminus of the E3 protein RING motif is bonded to the N-terminus of the UCE E2 protein by an intervening peptide linker. Optionally, the peptide linker is 5-50 amino acids. Preferred is a peptide linker of 15-20 amino acids. Methods of identifying ubiquitylation modulators are provided according to embodiments of the present invention which include contacting an isolated fusion protein including an E3 protein RING motif bonded to an UCE E2 protein with a ubiquitylation substrate in the presence of a test substance. Ubiquitylation of the ubiquitylation substrate is then detected to determine the effect of the test substance on ubiquitylation of the ubiquitylation substrate. | 04-15-2010 |
20100092999 | XANTHURENIC ACID DERIVATIVE PHARMACEUTICAL COMPOSITIONS AND METHODS RELATED THERETO - The present invention relates to diuretic pharmaceutical compositions and methods and in particular to certain derivatives of the formula I: | 04-15-2010 |
20100099112 | QUANTITATIVE LATERAL FLOW SYSTEM AND ASSAY - The present invention relates to a lateral flow assay and system, including a test strip, for detection and quantification of analytes in samples, such as samples containing cells and fluid, where the assay is volume independent, and the sample size is less than about 100 μl, where the test strip includes a first membrane such as a sample filter, that is in capillary contact with an optional second membrane, such as a fluid collector, the second membrane, if present is in capillary contact with an optional third membrane, such as a conjugate pad containing a mobilizable detectable agent, or with a fourth membrane, which is a chromatographic strip, which optionally contains a mobilizable detectable agent, all such membranes being in fluid contact with a fifth membrane, such as a buffer pad, a sixth membrane, such as an absorbent pad, optionally a seventh membrane, which is also an absorbent pad, a capture band for capturing the analyte and at least one control band, or alternatively, the chromatographic strip contains the mobilizable detectable agent in place of a conjugate pad, where the test strip is configured to support removal of red blood cells from the sample and to allow uni-directional or bi-directional fluid flow of fluid from the sample filter to the capture band to be retained therein and detected thereon. | 04-22-2010 |
20100099113 | MINIMIZED SMALL PEPTIDES WITH HIGH AFFINITY FOR FACTOR VIII AND FACTOR VIII-LIKE PROTEINS - The present invention relates to the composition of small molecules and their use in the field of protein isolation, purification, stabilizing and/or enhancing its activity. In particular, the present invention relates to the synthesis and optimization of compounds comprising small peptides and peptide derivatives with affinity to coagulation Factor VIII and/or Factor VIII-like polypeptides and/or domains thereof. These compounds are useful for labeling, detecting, identifying, isolating and preferably for purifying, stabilizing and enhancing the activity of Factor VIII, Factor VIII-like polypeptides or domains thereof from physiological and non-physiological solutions comprising same. Further, these compounds may be used as ligands, which bind Factor VIII, Factor VIII-like polypeptides or domains thereof in methods of the present invention. | 04-22-2010 |
20100099114 | ANALYTICAL STRIP AND DETECTING METHOD USING THE SAME - An analytical strip and a detecting method using the analytical strip are provided. The analytical strip includes a substrate having a channel thereon. The channel has a first region, a second region and a third region, which are arranged successively. A first antibody is localized in the first region. A saccharide and a peroxidase are localized in the first or second region. A second antibody for recognizing a different epitope of an identical antigen with the first antibody is immobilized in the second region. A substrate reagent including a saccharide oxidase is localized in the third region. | 04-22-2010 |
20100099115 | SYSTEMS AND METHODS FOR PREPARING AND ANALYZING SAMPLES - The invention relates to systems and methods for preparing and analyzing samples (e.g., mucosal samples) for a microorganism of interest. In particular, the systems and methods are useful for detecting one or more analytes characteristic of a microorganism (i.e., microbe) of interest, such as components of cell walls that are characteristic of a microbe, particularly | 04-22-2010 |
20100099116 | Methods for Analysis of Hedgehog Pathway Inhibitors - One aspect of the present invention relates to a method of ascertaining the inhibitory activity in a mammal of a candidate inhibitor of the hedgehog pathway. In certain embodiments, the candidate inhibitor is administered systemically. In certain embodiments, the mammal is a rodent or primate. In certain embodiments, the mammal is a mouse. In certain embodiments, the candidate inhibitor is a small molecule or natural product. | 04-22-2010 |
20100099117 | DIAGNOSTIC METHOD FOR DETERMINING THE SUSCEPTIBILITY TO DELIVERY AND REAGENT KIT FOR USE THEREFOR - The invention relates to a diagnostic method for detecting susceptibility to delivery, and to a test kit for this purpose. A low, but higher than baseline level concentration of Insulin-like Growth Factor Binding Protein 1 (IGFBP-1), which is due to leakage from decidual cells, is detected by an immunological assay in a vaginal secretion sample. | 04-22-2010 |
20100105067 | BIOMARKERS FOR OVARIAN CANCER - The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as ovarian cancer, ovarian cancer of low malignant potential, benign ovarian disease or other malignant condition. The biomarkers can be detected by SELDI mass spectrometry. | 04-29-2010 |
20100105068 | HYBRIDOMAS PRODUCING ANTIBODIES AGAINST NON FUNCTIONAL P2X7 RECEPTOR - The present invention relates to the production of anti non functional P2X7 receptor monoclonal antibodies from hybridoma cell lines. | 04-29-2010 |
20100105069 | METHOD FOR DETECTING HUMAN PARVOVIRUS ANTIGEN - A method for detecting human parvovirus/erythrovirus antigen in a sample comprises contacting a buffer having a pH in the range 3.0 to 4.0, suitably a citrate/trisodium citrate buffer, with the sample followed by the measurement of the antigen. The measurement of the antigen can be by virus capture enzyme immunoassay. The method is a good indicator of recent infection and can be used in the screening of individual plasma units or pools from which blood products are extracted. | 04-29-2010 |
20100105070 | DIAGNOSIS AND TREATMENT OF PREECLAMPSIA - The present invention relates to biomarkers for preeclampsia as well as treatment of this disease. In particular, the invention relates to methods for diagnosis or aiding in the diagnosis of preeclampsia of a pregnant female mammal to detect elevated levels of free haemoglobin, particularly free fetal haemoglobin. This facilitates and makes possible early diagnosis and clinical intervention when a preeclamptic condition is found. In addition, the invention relates to a method to treat female mammals with preeclampsia with the purpose to reverse the pathological conditions associated with this disease. | 04-29-2010 |
20100105071 | METHODS FOR PREDICTING THE ONSET OF MENARCHE - Embodiments of the invention provide methods for predicting the onset of menarche, i.e. a females first menstrual period, through the measurement of salivary hormone levels (e.g. 17-β estradiol, testosterone, progesterone, and/or 17 hydroxy-progesterone (17-OHP)). In particular, the methods described herein enable a reliable determination that menarche will, or will not occur, within varied time intervals, e.g. 1 to 30 days, 1 to 45 days, 1 to 60 days and 1 to 90 days. Diagnostic kits and products of manufacture comprising the kits are also provided. | 04-29-2010 |
20100105072 | Methods of identifying respondents to hypoxia inducible factor 1-alpha inhibitors - This invention relates to methods of measuring HIF expression and activity, as well as measuring inhibition of HIF following administration of an HIF inhibitor useful in treating HIF related diseases. The present invention further relates to methods of identifying individuals who will respond to HIF inhibitors. The invention also relates to methods of monitoring a patient response to a given dosage of an HIF inhibitor. The invention also includes assays and kits for performing the methods described herein. | 04-29-2010 |
20100105073 | METHOD FOR THE PRODUCTION OF ANTIBODIES - The current invention is related to a method for the production of a human monoclonal antibody from a immunodeficient non-human animal, said method comprising contacting a new borne immunodeficient non-human animal with a human fetal liver stem cell (FL cell) to generate an immune transplanted non-human animal (reconstituted animal), subsequently contacting said reconstituted animal with a antigen, collecting from said reconstituted animal a human cell producing human antibody against said antigen, and isolating said antibody from said antibody producing cell. | 04-29-2010 |
20100105074 | HIGH THROUGHPUT FLOW CYTOMETRY SYSTEM AND METHOD - The invention provides systems, compositions, kits and methods for automated processing of biological samples and analysis using a flow cytometer. | 04-29-2010 |
20100112596 | KIT FOR DECIDING DEGREE OF MALIGNANCY IN PROSTATE CANCER AND METHOD OF USING THE SAME - The present invention relates to kits and methods for determining (diagnosing) prostate cancer malignancy and to predict patient prognoses. In addition to the Gleason's classification and the TMN classification, the invention kit and methods provide improved procedures with molecular markers. These new diagnostic methods provide methods capable of determining prostate cancer malignancy more accurately and easily through combination with the Gleason's classification via biopsies at an early stage before surgical operation; even when specimens taken through a fine needle examination are used instead of specimens extracted during a surgical operation. | 05-06-2010 |
20100112597 | Methods for Quantifying Protein Leakage From Protein Based Affinity Chromatography Resins - The present invention provides methods of quantifying protein leakage from a protein based affinity chromatography media (e.g., protein A, protein G and protein L based affinity chromatography media), where such a protein is used for isolating and/or removing a molecule which binds the protein (e.g., an immunoglobulin). | 05-06-2010 |
20100120054 | MONOMERIC AND POLYMERIC LINKERS USEFUL FOR CONJUGATING BIOLOGICAL MOLECULES AND OTHER SUBSTANCES - The present invention concerns monomeric or polymeric linker molecules useful in biological and chemical applications, their synthesis, and the synthesis and use of derivatives of the linkers conjugated to a variety of detectable labels and other substances. The linkers may be used, for example, in conjunction with fluorescent labels, nucleic acid or nucleic acid analog probes, and solid phase systems, and to enhance the solubility of the conjugated molecules. | 05-13-2010 |
20100120055 | TYROSINE PHOSPHORYLATION SITES - The invention discloses 318 novel phosphorylation sites identified in carcinoma, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 05-13-2010 |
20100120056 | DIAGNOSIS AND MONITORING OF DISEASES - The present invention relates to the diagnosis and monitoring of diseases and conditions by quantifying markers, including degradation products of disease-associated proteins, such as diketopiperazines composed of the two N-terminal amino acids or the two C-terminal amino acids of such proteins. The methods are useful for diagnosing or monitoring various diseases, including multiple sclerosis, Alzheimer's disease and ischemia. The invention further provides binding partners specific for the markers and compositions and kits for conducting the methods of the invention. | 05-13-2010 |
20100120057 | METHODS OF REDUCING NON-SPECIFIC INTERACTION IN METAL NANOPARTICLE ASSAYS - The present invention discloses methods of reducing non-specific interactions of interfering species present in a sample in metallic nanoparticle-based assays, thereby increasing the sensitivity of these assays. In particular, the methods entail neutralizing the chemical reactivity of functional groups present in interfering species by addition of a neutralizing agent, such as an alkylating agent or heavy metal ion. The methods are especially useful in assays for the detection of analytes in biological samples. Reagent kits and assay mixtures for the practice of the described methods are also disclosed. | 05-13-2010 |
20100120058 | IgE Antibodies to Chimeric or Humanized IgG Therapeutic Monoclonal Antibodies as a Screening Test for Anaphylaxis - The present invention provides an assay for detecting serum IgE antibody levels to cetuximab and to other proteins. The present invention further provides a method for predicting whether a subject will respond adversely to cetuximab treatment. The present further provides a method for detecting sensitivity to compounds comprising galactose-alpha-1,3-galactose. | 05-13-2010 |
20100120059 | INSTRUMENT SETUP SYSTEM FOR A FLUORESCENCE ANALYZER - The present invention reagents and methods for setting up an instruments having a multiplicity of detector channels for analyzing a multiplicity of fluorescent dyes. The present invention is particularly applicable in the field of flow cytometry. | 05-13-2010 |
20100124754 | Cloning, Expression And Purification Of Recombinant Porcine Intrinsic Factor For Use In Diagnostic Assay - The present invention relates to a new method of producing functionally active recombinant porcine Intrinsic Factor as well as the protein (i.e., porcine Intrinsic Factor) produced thereby. In particular, the vector comprising the DNA encoding the protein is introduced into a Chinese Hamster Ovary (CHO) host cell under conditions sufficient for optimal expression of functional protein. The expressed protein may then be subjected to three methods ultimately resulting in a protein having at least 97% purity. | 05-20-2010 |
20100124755 | PROSTATE CANCER AND MELANOMA ANTIGENS - Methods for identifying a human subject as a candidate for further prostate cancer or melanoma examination are disclosed. Also disclosed are methods for determining whether an immune therapy has elicited a tumor-specific immune response in a prostate cancer or melanoma patient. Further disclosed are kits that can be used to practice the above methods. Methods for identifying candidate compounds for further testing as preventive or therapeutic agents for melanoma are also disclosed. | 05-20-2010 |
20100129828 | METHOD OF ASSAYING LEUKOCYTE ELASTASE INHIBITOR FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER - The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Leukocyte Elastase Inhibitor tumor marker in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer. | 05-27-2010 |
20100129829 | USE OF PLASMA HSP90 RELATED TO MALIGNANCY - The present invention concerns diagnosing and/or prognosticating cancer in an individual and/or determining response to a Hsp90-interacting therapy in an individual. In particular, the methods and compositions of the therapy relate to levels of Hsp90-α in plasma. Additional methods concern determining levels of Hsp90-associated molecules. | 05-27-2010 |
20100129830 | Label Independent Detection Biosensor Composition and Methods Thereof - A biosensor article including a substrate; a tie-layer attached to the substrate surface; and a nanometer scale cross-linked acryloyl copolymer layer attached, for example, by copolymerization, to the tie-layer, as defined herein. Methods for making the biosensor article or cell culture article and methods for performing an assay of a ligand with the target derivatized biosensor article are also disclosed. | 05-27-2010 |
20100129831 | METHODS FOR DIAGNOSING HYPERSENSITIVITY REACTIONS - The invention is directed to the diagnosis of allergic reactions. Particularly, the invention is directed to in vitro assays for diagnosing systemic hypersensitivity reactions, and identifying agents causing these reactions. | 05-27-2010 |
20100136571 | I-PLASTIN ASSAY METHOD FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER - A method for the in vitro diagnosis of colorectal cancer by determining the presence of the I-Plastin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer. | 06-03-2010 |
20100136572 | METHOD OF ASSAYING APOLIPOPROTEIN AI FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER - The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Apolipoprotein AI tumor marker in a biological sample taken from a patient suspected of having colorectal cancer, it being understood that the assay is not turbidimetric. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer. | 06-03-2010 |
20100136573 | DIAGNOSING NEURODEGENERATIVE DISEASES - This document provides methods and materials related to determining whether or not a mammal (e.g., a human) has a neurodegenerative disease (e.g., frontotemporal dementia, AD, or amyotrophic lateral sclerosis (ALS)). For example, methods and materials for using the levels of TDP-43 polypeptides and/or TDP-43 polypeptide cleavage products (e.g., 25 kD and 35 kD TDP-43 polypeptide cleavage products) in a biological fluid (e.g., cerebrospinal fluid) to determine whether or not a mammal has a neurodegenerative disease (e.g., frontotemporal dementia, AD, or ALS) are provided. | 06-03-2010 |
20100136574 | METHOD FOR DETECTING A CHRONIC INFLAMMATORY-ASSOCIATED DISEASE - The present invention in one embodiment is an early detection marker for chronic or acute inflammatory-associated diseases. Chronic diseases may include atherosclerosis, Alzheimer's disease, asthma, rheumatoid arthritis, osteoarthritis, and inflammatory diseases of the bowel such as Crohn's disease, Ulcerative colitis, Irritable bowel syndrome and Inflammatory bowel disease. Acute diseases may include sepsis, acute systemic infections, acute lung injury, and acute respiratory distress syndrome. | 06-03-2010 |
20100136575 | B7-RELATED NUCLEIC ACIDS AND POLYPEPTIDES USEFUL FOR IMMUNOMODULATION - The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject. | 06-03-2010 |
20100143933 | Measurement value lowering inhibitor for immunoassay method and immunoassay method using the same - A measurement value lowering inhibitor for immunoassay method that is capable of enhancing the accuracy of immunoassay method through suppressing of any influences of interfering substances existing in an analyte sample; and using the inhibitor, an immunoassay method in which any measurement value lowering by interfering substances is suppressed and a reagent for immunoassay method. The measurement value lowering inhibitor for immunoassay method used to suppress any measurement value lowering by interfering substances is comprised of an ionic surfactant consisting of a polymer obtained by polymerization of a hydrophobic cyclic monomer having an ionic functional group, which has a molecular weight of 1000 to 10×10 | 06-10-2010 |
20100143934 | Modified animal lacking functional PYY gene, monoclonal antibodies that bind PYY isoforms and uses therefor - The present invention provides transgenic animals having a reduced level of expression of peptide YY (PYY) and drug screening platforms using the transgenic animals for identifying agonists and antagonists of PYY. The present invention further provides monoclonal antibodies that bind specifically to full-length PYY[1-36] or the processed form thereof i.e., PYY[3-36] and to diagnostic and drug screening platforms using the monoclonal antibodies. The invention has particular utility for the diagnosis of a predisposition or risk of a subject becoming obese, developing one or more pathologies associated with obesity, or developing a disease/disorder of bone tissue. | 06-10-2010 |
20100143935 | c-KIT Phosphorylation in Cancer - An antibody is disclosed for the detection of phosphorylated c-KIT. A method of diagnosing and monitoring cancers responsive to treatment using an anti-phospho-c-KIT antibody are also disclosed. A diagnostic kit is also provided for the detection and monitoring of cancers responsive to tyrosine phosphorylation inhibitor treatment. | 06-10-2010 |
20100143936 | Novel Specific Arabinose Transporter from the Yeast Pichia Stipitis, and Uses Thereof - The present invention relates to a polypeptide which has a novel specific arabinose transporter function as well as to nucleic acids coding therefore. The invention further relates to host cells, in particular modified yeast strains which contain the coding nucleic acids and express the polypeptide and functionally integrate it into the plasma membrane and are thus able to absorb L-arabinose. When using modified host cells which express additional proteins of the arabinose metabolic pathway, arabinose can be fermented by these cells, in particular into ethanol. The present invention is therefore relevant, inter alia, in connection with the production of biochemicals from biomass, such as bioethanol for example. | 06-10-2010 |
20100143937 | ASSAY METHODS FOR IDENTIFYING AGENTS THAT MODIFY THE ACTIVITY OF NAPE-PLD OR Abh4 - The present invention provides methods for the detection of agents that modify the activity of the N-acylphosphatidylethanolamine-hydrolysing phospholipase D (NAPE-PLD) enzyme or the Alpha/beta-hydrolase-4 (Abh4) enzyme. The disclosed methods are configured in an assay format amenable to high throughput screening applications. | 06-10-2010 |
20100143938 | HIGH SENSITIVITY QUANTITATION OF PEPTIDES BY MASS SPECTROMETRY - The instant invention provides an economical flow-through method for determining amount of target proteins in a sample. An antibody preparation (whether polyclonal or monoclonal, or any equivalent specific binding agent) is used to capture and thus enrich a specific monitor peptide (a specific peptide fragment of a protein to be quantitated in a proteolytic digest of a complex protein sample) and an internal standard peptide (the same chemical structure but including stable isotope labels). Upon elution into a suitable mass spectrometer, the natural (sample derived) and internal standard (isotope labeled) peptides are quantitated, and their measured abundance ratio used to calculate the abundance of the monitor peptide, and its parent protein, in the initial sample | 06-10-2010 |
20100151482 | DIAGNOSIS OF FASCIOLOSIS BY SKIN TEST (INTRADERMOREACTION) USING THE ANTIGEN FH8 (FASCIOLIN) - Fasciolosis is an anthropozoonotic disease caused by the Trematoda | 06-17-2010 |
20100151483 | REAGENTS FOR THE DETECTION OF PROTEIN PHOSPHORYLATION IN SIGNALING PATHWAYS - The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, adhesion/extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding/repair/replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G/regulator proteins, inhibitor proteins, motor/contractile proteins, phosphatase, protease, Ser/Thr protein kinases, protein kinase (Tyr)s, receptor/channel/cell surface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function. | 06-17-2010 |
20100151484 | KINASE AND UBIQUINATION ASSAYS - Compositions, including antibodies, polypeptides, and organic molecules, kits, and methods for probing molecular interactions (e.g., deubiquination, ubiquination and kinase activity), e.g., using resonance energy transfer (RET) are provided. | 06-17-2010 |
20100151485 | REAGENT FOR DETECTION OF ANALYTE AND PROCESS THEREOF - The present disclosure provides a reagent for detection of analyte in a sample and process of preparation of the reagent. The reagent comprises heparin and substrate coated with the analyte-counterpart. The analyte-counterpart of the reagent is capable of binding to said analyte. The present disclosure further provides a process for detection of an analyte in a sample by contacting said sample with said reagent and detecting formation of analyte-analyte counterpart complex. The present disclosure provides a kit for detection of an analyte in a sample. | 06-17-2010 |
20100151486 | OSTEOPONTIN FUNCTIONAL EPITOPES, MONOCLONAL ANTIBODIES AGAINST THE EPITOPES AND USES THEREOF - Provided are functional epitopes of osteopontin (OPN), monoclonal antibodies that specifically bind to the epitopes, immunoconjugates comprising the monoclonal antibodies and use of the monoclonal antibodies or immunoconjugates for manufacturing a medicament for the treatment of tumor. Also provided are nucleotide sequences encoding the monoclonal antibodies and vectors and host cells comprising the sequences. The monoclonal antibodies or immunoconjugates can be used for detecting the OPN, blocking the promoting metastasis-signaling pathway mediated by OPN and preventing the development and metastasis of tumor, thereby inhibiting the tumor. | 06-17-2010 |
20100151487 | Hepcidins as Biomarkers for Impending Lupus Nephritis Flare - Biomarkers for determining a kidney flare episode in systemic lupus erythematosus are described. | 06-17-2010 |
20100151488 | Rapid Test for Glycated Albumin - A rapid immunochromatographic assay system is provided for measuring the amount of glycated albumin in a blood sample relative to the total level of albumin in the sample. The assay system is comprised of a disposable cassette that contains the test strips and testing reagents, and a measurement device that automatically reads, calculates and displays the test results over a period of time. The test cassette contains two test strips that are used to measure glycated albumin and total albumin respectively. The strips are contiguous beneath the single sample application well so that the same sample is tested simultaneously by both test strips. Part of the sample will migrate thru the glycated albumin test strip where it will react with the glycated albumin test reagents to yield a glycated albumin result, while part of the sample will migrate thru the total albumin test strip where it will react with the total albumin test reagents to yield a total albumin result. The test cassette is placed within a measuring device such as a reflectance spectrometer or fluorometer, that reads, calculates and expresses the result as the percentage of glycated albumin relative to total albumin in the sample. The results of successive testing that are performed over a period of time are stored in the instrument's memory and displayed in a numerical or graphical format so that the individual's glycated albumin levels can be monitored over time. | 06-17-2010 |
20100151489 | Method for quantifying biomolecules conjugated to a nanoparticle - Disclosed embodiments concern quantifying a biomolecule conjugated to a nanoparticle. Quantifying typically comprises determining the number of biomolecules per nanoparticle. Any suitable biomolecule can be used, including but not limited to, amino acids, peptides, proteins, haptens, nucleic acids, oligonucleotides, DNA, RNA, and combinations thereof. A single type of biomolecule may be conjugated to the nanoparticle, more than one biomolecule of a particular class may be conjugated to the nanoparticle, or two or more classes of biomolecules may be conjugated to the nanoparticle. Certain disclosed embodiments comprise enzymatically or chemically digesting a biomolecule conjugated to the nanoparticle, or displacing a biomolecule using ligand-exchange chemistry. Where biomolecule concentrations are determined, any technique suitable for determining biomolecule concentration can be used, such as spectrophotometric techniques, including measuring tryptophan fluorescence and using a standard fluorescence intensity versus biomolecule concentration curve. | 06-17-2010 |
20100151490 | Antigenic Protein Conjugates and Process for Preparing Same - An improved process for the preparation of antigenic protein conjugates is provided. The conjugates preferably are formed through reaction with one or more free sulfhydryl groups in the antigenic protein. The process of the present invention preferably employs a trialkylphosphine as the reducing agent and allows for reduction of disulfide bonds in the antigenic protein and conjugation with a conjugate moiety, preferably in a single reaction vessel (i.e. “in situ”) because the process optimally does not require the removal of the reducing agent before subsequent addition of the sulfhydryl reactive agent. Antigenic protein conjugates prepared by the in situ process and their use in diagnostic immunoassays are also provided. | 06-17-2010 |
20100159471 | PROCESS FOR PRODUCTION OF COLLOIDAL GOLD AND COLLOIDAL GOLD - It is an object of the present invention to provide a method for producing gold colloid having a targeted particle size, a sharp particle size distribution and a uniform and perfect spherical shape. The present invention relates to a method for producing gold colloid including a nucleation step of forming nuclear colloidal particles by adding a first reducing agent to a first gold salt solution; and a growth step of growing nuclear colloid by adding a second gold salt and a second reducing agent to the solution of the nuclear colloidal particles, characterized in that the growth step is performed at least once; a citrate is used as the first reducing agent and an ascorbate is used as the second reducing agent; and the addition of the ascorbate in the growth step is performed simultaneously with addition of the second gold salt. According to the method for producing gold colloid of the present invention, gold colloid having a sharp particle size distribution and a uniform and perfect spherical shape can be obtained. | 06-24-2010 |
20100159472 | Method for Diagnosing Multiple Sclerosis - Disclosed is a method for diagnosing and prognosing multiple sclerosis and more particularly to a method for diagnosing and prognosing multiple sclerosis by measuring levels of antibodies. The levels of IgM-type anti-Glc(α1,2)Glc(α) or Glc(α1,3)Glc(α) or Glc(α1,6)Glc(α) antibodies in serum act as diagnostic markers for MS disease and as prognostic biomarkers for the conversion of CIS patients suggestive of MS to clinically definite MS (CDMS) within 24 months. | 06-24-2010 |
20100159473 | Peptide Standards - The invention relates to methods for making a peptide standard for mass spectrometry said method comprising (a) identifying endopeptidase cleavage sites in a parent polypeptide sequence of interest; (b) selecting peptide sequences from said parent polypeptide which are defined by endopeptidase cleavage sites of step (a); (c) adding a C-terminal extension to each selected sequence; wherein if the endopeptidase cleavage site is C-terminal to its recognition sequence then the C-terminal extension comprises 1 to 6 amino acids, wherein if the endopeptidase cleavage site is N-terminal to its recognition sequence then the C-terminal extension comprises said recognition sequence, wherein if the endopeptidase cleavage site is within its recognition sequence then the C-terminal extension comprises the remainder of said recognition sequence C-terminal to the cleavage site; and (d) synthesising a peptide having the extended amino acid sequence of step (c). The invention also relates to peptide standards and methods of analysing samples. | 06-24-2010 |
20100159474 | PROGNOSIS AND RISK ASSESSMENT IN PATIENTS SUFFERING FROM HEART FAILURE BY DETERMINING THE LEVEL OF ADM AND BNP - The present invention relates to a method for prognosis of an outcome or assessing the risk of a patient suffering from heart failure and/or shortness of breath, comprising the determination of the levels of ADM or fragments thereof or its precursor or fragments thereof and BNP or fragments thereof or its precursor or fragments thereof in said sample of said patient. | 06-24-2010 |
20100159475 | Methods For Determination of Calcineurin Activity and Uses in Predicting Therapeutic Outcomes - The methods of the disclosure provide fluorescence-based assays for calcineurin activity, especially in isolated T cells. The methods include the stimulation of the T cells with agents that specifically target the TCR with or without influencing co-stimulatory pathways. One TCR agonist is monoclonal antibodies specific for CD3, which more precisely distinguish the inducible activity of calcineurin than does an alternative method targeting the T cell receptor (CD3) combined with CD28 costimulation. This method more accurately distinguishes between the measured level of calcineurin activity of T cells from immunosuppressed transplant recipients and normal individuals, and thus has improved diagnostic accuracy with respect to the response of an individual to immunosuppressant therapy following an organ transplant. | 06-24-2010 |
20100159476 | DEVICE AND METHOD FOR DETECTING THE PRESENCE OF HEMOGLOBIN IN A BIOLOGICAL SAMPLE - A device and method for detecting the presence of hemoglobin in a biological sample, more particularly, the presence of blood in a fecal sample as an indicator of upper or lower gastrointestinal tract bleeding. | 06-24-2010 |
20100167306 | RAPID TEST FOR GLYCATED ALBUMIN IN SALIVA - This invention describes a rapid immunochromatographic assay for measuring the ratio of glycated albumin to total albumin in saliva. Patients with diabetes have elevated levels of glucose in their blood that can react with plasma albumin to form glycated albumin. The amount of glycated albumin formed is directly correlated with the level of plasma glucose that the albumin has been exposed to over a period of time. Saliva albumin is derived from plasma albumin and therefore contains glycated and non-glycated albumin fractions that can be measured. The ratio of glycated albumin to total albumin in saliva will provide an indication of the average amount of protein glycation that occurred over the preceding 2-3 week period. | 07-01-2010 |
20100167307 | NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS - Assay systems and specialized antibodies for the detection and quantitation of troponin I and troponin T in body fluids as an indicator of myocardial infarction. Since troponin I and T exist in various conformations in the blood, the ratios of the monomeric troponin I an T and the binary and ternary complexes, as well as which form of troponin present in the blood, may be related to the metabolic state of the heart. Disclosed is a system to determine the presence of a troponin form or a group of troponin forms in a sample of whole blood, serum or plasma. | 07-01-2010 |
20100167308 | METHOD FOR MEASURING AN ANALYTE IN BLOOD - An electrochemical immunosensor system with reduced interference, comprising: a first immunosensor that generates an electrochemical signal based on the formation of a sandwich between an immobilized antibody, a target analyte and a labeled antibody, wherein a portion of the signal arises from non-specific binding of the labeled antibody in the region of the first immunosensor, and
| 07-01-2010 |
20100167309 | APPARATUS AND METHOD FOR ANALYTE DETECTION - Disclosed is a testing device and methods for the identification of an analyte of interest in a sample. In a preferred embodiment, the testing device includes a front panel having at least one sample application aperture; a rear panel having at least one solvent application aperture; a sample collection matrix disposed between the rear panel and the front panel, the sample collection matrix being in communication with the sample and solvent application apertures of the front and rear panels; and at least one insertable test strip containing a reagent enabling detection of the analyte of interest. | 07-01-2010 |
20100173321 | Making a diagnosis in cases of cardiac disease using a combination of markers - The present invention concerns methods for diagnosing myocardial infarction, for performing risk stratification of myocardial infarction, for making a prognosis of a disease course in a myocardial infarction patient, for identifying a patient with elevated risk of myocardial infarction, or combinations thereof, wherein a determination of at least three markers is performed on a patient sample. Furthermore, kits for performing the methods are provided. | 07-08-2010 |
20100173322 | Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways - The invention discloses nearly 219 novel phosphorylation sites identified in signal transduction proteins and pathways underlying Anaplastic Large Cell Lymphoma (ALCL) involving the NPM-ALK translocation/fusion, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. | 07-08-2010 |
20100173323 | GLYCOSYLATION ENGINEERED ANTIBODY THERAPY - The instant invention is drawn to methods of generating a glycosylation-engineered antibody, and using the glycosylation-engineered antibody for treating a patient, particularly a cancer patient or a patient with an immune disease or disorder. The instant invention is also drawn to methods of generating a glycosylation-engineered antibody for use in the treatment of patients having a polymorphism that does not respond to conventional antibody therapy. The instant invention is also drawn to methods of improving the biological activity of an antibody by glycosylation engineering. The instant invention is also drawn to methods of modulating antibody-dependent cell-mediated cytoxicity (ADCC) using a glycosylation-engineered antibody. | 07-08-2010 |
20100173324 | ANTI-CD27 ANTIBODY - The present invention provides a monoclonal antibody which specifically recognizes CD27 containing an O-linked sugar chain to which galactose is not bound and binds to its extracellular region, or a method for using the same. | 07-08-2010 |
20100173325 | Composition and Method for Analysis of Target Analytes - A method of detecting analytes includes providing a mixture containing analytes to be analyzed and microparticles coated with competitive inhibitors of the analytes. First antibodies are reacted with the analytes and the competitive inhibitors under competitive binding conditions. The first antibodies bound to the competitive inhibitors are measured using flow cytometry. | 07-08-2010 |
20100173326 | SUBSTRATE AND METHOD FOR PRODUCING THE SUBSTRATE - A self assembling monolayer formed by the self assembling molecules is caused to bond onto the surface of a base material, and chelators are caused to bond onto the self assembling monolayer, to produce a substrate, in which the chelators are bound to the self assembling monolayer at a density within a range from 0.4/nm | 07-08-2010 |
20100173327 | NONHUMAN MODEL ANIMAL LACKING THE ABILITY TO CONTROL LYMPHOCYTE MIGRATION - The present invention provides a animal model useful in identifying a molecule controlling in a lymphocyte-specific manner migration and thus elucidating immune-related diseases and pathogenic conditions such as allergy, autoimmune diseases, GvH and graft rejections at a molecular level, or in developing a novel therapy. A nonhuman animal model such as a DOCK2 knockout mouse, in which the function to control lymphocyte migration has been deleted or suppressed, is generated by deleting DOCK2 gene on the chromosome. In this DOCK2 knockout mouse, the function of activating Rac to mediate actin cyteskeleton, the lymphocyte migration function in response to stimuli with chemokines such as SLC, SDF-1, BLC, the homing function to secondary lymphoid organs such as spleen, lymph nodes and Peyer's patches, and the function of emigrating mature thymic T cells into peripheral blood in response to stimulus with chemokine ELC are impaired, and as a result of this, immune responses are suppressed. | 07-08-2010 |
20100178656 | Multiple Analysis of Blood Samples - The invention relates to a method for detecting a plurality of antigenic molecules carried by erythrocytes and/or a plurality of anti-erythrocyte antibodies of an individual, comprising bringing a sample into contact with distinguishable beads, on which are attached a) antibodies specific for said antigens, or b) erythrocytes, erythrocyte membrane fragments or blood group antigens. | 07-15-2010 |
20100184082 | ANTIBODY AND IMMUNOASSAYS FOR DETERMINING THE PRESENCE OF DELTA9-TETRAHYDROCANNABINOL - Antibodies having specific binding for the parent THC (Δ | 07-22-2010 |
20100184083 | RELEASED CYTOKERATINS AS MARKERS FOR EPITHELIAL CELLS - The present invention is directed to methods of detecting viable epithelial cells in a sample. The method includes isolating the sample comprising cells from a patient and culturing the cells for a time sufficient for an epithelial cell-specific marker to be released from the cells. The marker includes a substantially full-length cytokeratin. The method further includes detecting the released marker. Detection of the marker indicates the presence of disseminated epithelial cells. Methods are also directed to identifying disseminated epithelial tumor cells. | 07-22-2010 |
20100184084 | METHODS FOR MEASURING PLATELET REACTIVITY OF INDIVIDUALS TREATED WITH DRUG ELUTING STENTS - A method is provided for measuring inhibition of platelet reactivity in an individual treated with a drug-eluting stent (DES). First, a blood sample is obtained from an individual treated with a DES and a P2Y12 antagonist. The blood sample is then mixed with particles comprising an attached GPIIb/IIIa receptor ligand, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1). The mixture is incubated under conditions suitable for agglutinating particles, and platelet-mediated agglutination is assessed in the mixture. The absence or reduction of agglutination indicates that the individual treated with a DES has reduced platelet reactivity. Also provided is a kit for measuring inhibition of platelet aggregation by a P2Y12 receptor antagonist that includes a GPIIb/IIIa receptor ligand immobilized on a particle, adenosine diphosphate (ADP), prostaglandin E1 (PGE1), an anticoagulant, and a buffer to maintain the anticoagulated blood in a condition suitable for platelet aggregation. | 07-22-2010 |
20100184085 | Prokaryotic collage-like proteins and uses thereof - The present invention provides recombinant triple helical proteins or collagen-like proteins comprising a prokaryotic protein or one or more domains of a prokaryotic protein comprising a collagen-like peptide sequence of repeated Gly-Xaa-Yaa triplets and, optionally, one or more domains from a mammalian collagen. Also provided are expression vectors and host cells containing the expression vectors to produce these recombinant proteins and methods of producing the same. Additionally, antibodies are provided that are directed against a recombinant collagen-like protein that, preferably, binds an integrin. Furthermore, a method of screening for potential therapeutic compounds that inhibit the integrin-binding or integrin-interacting activities of recombinant collagen-like proteins. | 07-22-2010 |
20100184086 | EARLY DETECTION OF CANINE LYME DISEASE BY SPECIFIC PEPTIDES AND ANTIBODIES - The present invention relates, in one aspect, to the detection of Lyme disease in canines by detecting the peptide or antibodies to an infection specific peptide after challenge with | 07-22-2010 |
20100190180 | Materials and Methods for Screening, Diagnosis and Prognosis of Conditions Associated With Stat Protein Expression - The subject invention concerns methods and materials for cancer screening using platinum complexes to detect a STAT protein biomarker. Platinum (IV) complexes interacting with STATs directly correlate with the STAT expression. In one embodiment, fluorescently-labeled and/or antibody-linked platinum (IV) complexes can be used to assess the STAT expression and define malignant potential. Other methods such as imaging (MRI, e.g.) can also be used to assess platinum-STAT interactions. The STAT protein can be, for example, STAT3. | 07-29-2010 |
20100190181 | BIOMARKERS FOR PREECLAMPSIA - The present invention relates to novel biomarkers such as histidine and ketone bodies and methods of use thereof for detecting preeclampsia in pregnant individuals and for identifying individuals at risk at an early stage of pregnancy. | 07-29-2010 |
20100190182 | DIAGNOSTIC COMPOSITION AND METHOD FOR THE DETECTION OF A TRICHINELLA INFECTION - A diagnostic composition to detect antibodies in a sample obtained from an animal or human being infected by | 07-29-2010 |
20100190183 | PROTEIN LABELLING WITH TAGS COMPRISING ISOTOPE-CODED SUB-TAGS AND ISOBARIC SUB-TAGS - Subject of the present invention are new isotopic and isobaric tagged molecules, kits comprising them and methods of using them in mass spectrometry. | 07-29-2010 |
20100190184 | SCREENING METHOD UTILIZING NOVEL SUBSTRATE C-RET FOR GAMMA-SECRETASE - The present invention provides a method of screening for compounds which affect the processing of c-Ret by γ-secretase. The method involves contacting a first biological composition containing γ-secretase or a biologically active fragment thereof with a second biological composition containing c-Ret in the presence and absence of a candidate compound; measuring the cleavage of the c-Ret in the presence and absence of the candidate compound; selecting those candidate compounds which affect the cleavage of the c-Ret by γ-secretase; and identifying the candidate compounds selected in the previous step as compounds which affect the processing of c-Ret by γ-secretase. | 07-29-2010 |
20100190185 | NOVEL NON-INVASIVE MARKER FOR LIVER FUNCTION AND DISEASE - A monoclonal antibody or fragment thereof, capable of specifically binding to at least one epitope of sH2a and/or being elicited by at least one epitope, and assays, kits, and methods of use thereof diagnosing liver disease or condition, detecting liver function and assessing the efficacy of therapy to a liver disease. | 07-29-2010 |
20100196918 | ANALYTE SENSORS, METHODS FOR PREPARING AND USING SUCH SENSORS, AND METHODS OF DETECTING ANALYTE ACTIVITY - Embodiments of the present disclosure provide for analyte sensors, methods for producing and using the analyte sensors, methods of detecting and/or measuring analyte activity, methods for characterizing analyte cellular activity, methods of detecting pH change in a system, method of controlling the concentration of an analyte in a system, fusion proteins, polynucleotides, and vectors corresponding to the analyte sensors, kits, and the like. | 08-05-2010 |
20100196919 | PEPTIDES, ANTIBODIES AND FRAGMENTS THEREOF FOR THE TREATMENT AND DIAGNOSTIC OF CELIAC DISEASE - The present invention discloses a peptide having an amino acid sequence comprising an epitope recognized by Igs of patients with active celiac disease and not recognized by Igs of patients on gluten-free diet, antibodies directed against this peptide and methods for diagnosing the celiac disease in a subject, or to check the effect of a therapy or of a diet treatment in a celiac disease affected subject, or to assess the risk of developing celiac disease in a subject vaccinated with a Rotavirus VP7 protein. | 08-05-2010 |
20100196920 | NANOSCOPIC BIOMOLECULAR ABSORPTION SPECTROSCOPY ENABLED BY SINGLE NANOPARTICLE PLASMON RESONANCE ENERGY TRANSFER - The disclosure provides methods and compositions useful for measuring a target analyte in a sample with nanoparticle plasmon resonance. In particular the disclosure provides methods and compositions for measuring a target analyte comprising plasmon resonance energy transfer. | 08-05-2010 |
20100196921 | Method for Predicting the Outcome of a Critically Ill Patient - The present invention relates to a method for predicting the outcome of a critically ill patient, said method comprising measuring the concentration of Chromogranin A or a fragment thereof in a biological sample obtained from said patient. | 08-05-2010 |
20100196922 | FLUORESCENT METAL ION INDICATORS WITH LARGE STOKES SHIFTS - The present invention provides fluorogenic compounds for the detection of target metal ions wherein the compounds exhibit a Stokes shift greater than 50 nm and the detectable signal is modulated by photoinduced electron transfer (PET). The present compounds consist of three functional elements, the ion sensing moiety (chelating moiety), the reporter moiety (fluorophore or fluorescent protein) and spacer or linker between the sensing and reporter moieties of the present compound that allows for PET upon binding of a metal ion and excitation by an appropriate wavelength. | 08-05-2010 |
20100196923 | PLURIPOTENT ADULT STEM CELLS - Disclosed herein are pluripotent adult stem cells and methods of use thereof. The cells are found in, or collected from, an adult tissue or fluid. In some embodiments, the cells are c-kit positive and SSEA-4 positive, and can he differentiated into multiple tissue types, e.g., adipogenic, osteogenic, myogenic, endothelial, neurogenic and hepatic tissues. | 08-05-2010 |
20100196924 | Method for Diagnosing Tumors - The present invention describes a method for diagnosing tumors of the reproductive organs which is characterised by determination of the afamin content in a sample of a body fluid or in a tissue sample, wherein a tumour is diagnosed if the afamin content in the sample is decreased compared to the afamin content in a sample from a person without a tumour of the reproductive organs. | 08-05-2010 |
20100203549 | CALIBRATED RPMA ASSAY - This invention relates, e.g., to a set of calibrants for determining the amount in a sample of an analyte (e.g., a protein, such as a protein that has been post-translationally modified), comprising a plurality of calibrants, which contain a range of amounts (e.g., defined amounts and/or serial dilutions) of the analyte, spanning the expected amount of the analyte in the sample. In each of the calibrants, a defined amount of the analyte is present in the same suitable, biological diluent (e.g., a cell or tissue lysate, or a bodily fluid). In one embodiment of the invention, the diluent reflects the same or a similar biological milieu (proteins, lipids, serum proteins, serum matrix proteins, etc.) as that in the sample in which the analyte to be measured is present. In embodiments of the invention, a single calibrant (e.g., a cell lysate) may comprise as many as hundreds of analytes, and can be used for the quantification of those hundreds of analytes in a sample. Methods are described for performing an assay (e.g. RPMA analysis), in which the calibrants of a set of calibrants of the invention are immobilized on each of the surfaces to which samples to be analyzed are immobilized, thereby providing an internal calibration curve for quantifying an RPMA assay. | 08-12-2010 |
20100203550 | METHOD OF PERFORMING AN IMMUNOASSAY IN BLOOD - An electrochemical immunosensor system with reduced interference, comprising: a first immunosensor that generates an electrochemical signal based on the formation of a sandwich between an immobilized antibody, a target analyte and a labeled antibody, wherein a portion of the signal arises from non-specific binding of the labeled antibody in the region of the first immunosensor, and
| 08-12-2010 |
20100203551 | MONOCYTE ACTIVATION TEST BETTER ABLE TO DETECT NON-ENDOTOXIN PYROGENIC CONTAMINANTS IN MEDIAL PRODUCTS - An improved monocyte activation test is described that is better able to detect non-endotoxin pyrogens in medical products, in which a sample is incubated with a monocyte-containing reagent in an assay system comprising at least one surface comprising polypropylene. The invention also concerns assay systems for use in these tests that include at least one microtiter well having at least one interior surface comprising polypropylene and having a shape such that monocyte-containing reagent is concentrated in the well to provide greater cell to cell contact. The invention also relates to a diagnostic kit that can be used to test for the presence of non-endotoxin pyrogens in a sample. | 08-12-2010 |
20100209936 | Novel recombinant 15-kDa polypeptide and use of same in detecting human infection with Bartonella henselae - Disclosed are the cloning and expression of a novel antigen of | 08-19-2010 |
20100209937 | FLUORESCENCE MICROSCOPE IN A MICROWAVE CAVITY - The present invention relates to an optical imaging system communicatively connected to a microwave energy producing source wherein the combination provides for increases in chemical reaction times and the ability to monitor the reactions in real time with sufficient resolution to view the location of intracellular components labeled with luminescent molecules as well as interaction with other biomolecules and responses to localized environmental variables in living cells and tissues during the application of a microwave field. | 08-19-2010 |
20100209938 | METHODS AND SYSTEMS FOR DETECTION OF STOICHIOMETRY BY FORSTER RESONANCE ENERGY TRANSFER - Methods to detect stoichiometries of protein complexes and/or interactions between proteins based on detection and quantification of FRET and related systems and compositions. | 08-19-2010 |
20100209939 | BNP(1-32) EPITOPE AND ANTIBODIES DIRECTED AGAINST SAID EPITOPE - The present invention relates to a polypeptide carrying a human BNP(I-32) epitope according to Formula (I): a | 08-19-2010 |
20100209940 | FIBROSIS BIOMARKER ASSAY - Methods of diagnosis or of quantitation of fibrosis comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of said measure in said patient above a normal level with the presence or extent of fibrosis. The immunoassay is conducted by a method comprising: | 08-19-2010 |
20100216156 | CANCER MARKERS - Provided are previously uncharacterized markers of cancers, for example colorectal cancers, and uses of these as diagnostic and prognostic markers of cancers, and in particular colorectal cancers. The markers are SEQ ID NO:1—hnRNP-K; SEQ ID NO:2—HMG-1; SEQ ID NO:3—proteasome subunit alpha type 1; SEQ ID NO:4—bifunctional purine biosynthesis protein; SEQ ID NO:5—STI1; SEQ ID NO:6—annex in IV; SEQ ID NO:7—60 kDa heat shock protein; SEQ ID NO:8—T complex protein 1 beta subunit; SEQ ID NO:9—T complex protein 1 epsilon subunit; SEQ ID NO:10—mortalin; and SEQ ID NO:11—TER-ATPase. The invention further provides related methods and materials for the use of the markers in therapeutic intervention in colorectal and other cancers e.g. to specifically target neoplastic cells without causing significant toxicity in healthy tissues, and to provide methods for the evaluation of the ability of candidate therapeutic compounds to modulate the biological activity of cancerous cells from the colon, rectum and other tissues. | 08-26-2010 |
20100216157 | IMMUNOGLOBULIN PEPTIDES AGAINST HEATED BOVINE BLOOD - The present invention is related to immunoglobulin peptides that recognize a thermostable antigen from bovine blood. The invention also provides methods for determining the presence of bovine blood in a food sample or an animal feed sample. | 08-26-2010 |
20100216158 | DIAGNOSTIC TEST FOR HEAD AND FACIAL PAIN - A diagnostic test for a head and facial pain disorder in a human patient includes providing test strip containing one or more antibodies corresponding one or more biological markers associated with the disorder or with multiple disorders. A saliva sample is collected from the human patient and applied to the test strip. The test strip is subsequently evaluated for evidence of binding of one or more of the antibodies with any biological markers present in the saliva sample. The progression of the head and facial pain disorder in the patient may be measured by collecting and evaluating additional saliva samples over time and comparing any changes in the amount of binding activity between or among samples. | 08-26-2010 |
20100221740 | METHODS, IMMUNOASSAYS AND DEVICES FOR DETECTION OF ANTI-LIPOIDAL ANTIBODIES - Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, a method for immobilizing a lipoidal antigen, comprising cardiolipin, lecithin, and cholesterol, on a solid support (such as a nitrocellulose membrane) is described. The ability to immobilize a lipoidal antigen on a membrane satisfies a long-felt need for membrane-based assay for the detection of anti-lipoidal antibodies. Also described are immunoassay devices for concurrently performing treponemal and non-treponemal tests for syphilis. | 09-02-2010 |
20100221741 | ANALYSIS DEVICE, AND ANALYSIS APPARATUS AND METHOD USING THE SAME - An analysis device includes: a separation cavity | 09-02-2010 |
20100221742 | NOVEL CANCER ASSOCIATED ANTIBODIES AND THEIR USE IN CANCER DIAGNOSIS - The present invention relates to an antibody having specificity for a polypeptide comprising an amino acid sequence of SEQ ID No:2 or an isoform thereof or a polypeptide comprising SEQ ID NO:2. | 09-02-2010 |
20100221743 | Methods for Diagnosing and Treating Endoplasmic Reticulum (ER) Stress Diseases - The present invention provides methods and reagents to quantify endoplasmic reticulum stress (ER stress) levels, and methods and compounds for treating ER stress disorders such as diabetes. Methods for quantifying ER stress in mammalian cells are exemplified. | 09-02-2010 |
20100221744 | METHOD FOR PREDICTION OF POSTOPERATIVE PROGNOSIS AND DIAGNOSIS KIT - The present invention relates to a method for predicting the postoperative prognosis of a lung adenocarcinoma patient with high sensitivity and/or specificity by identifying a protein with an expression level that specifically varies in a lung adenocarcinoma patient, comprising: step (a) of determining expression levels of myosin IIA and/or vimentin in a biological sample collected from a lung adenocarcinoma patient; and step (b) of predicting or determining a prognosis based on the expression levels of myosin IIA and/or vimentin obtained as a result of determination. | 09-02-2010 |
20100221745 | ABNORMAL PRION PROTEIN BINDER, AND METHOD FOR DETECTION OF ABNORMAL PRION PROTEIN - Disclosed are: a method for detecting pathogenic isoform of prion protein as distinguished from normal prion protein in a simple manner, rapidly, with a high degree of sensitivity and quantitatively without the need of the enzymatic treatment with protease K; and a reagent for use in the method. Specifically disclosed are: a pathogenic isoform of prion protein binder which comprises lactoferrin; and a method for detecting pathogenic isoform of prion protein by using the pathogenic isoform of prion protein binder. | 09-02-2010 |
20100221746 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE - The present invention relates to pharmaceutical compositions for the treatment and/or prophylaxis of disease associated with fibrosis in a vertebrate, said composition comprising at least one activin antagonist, and optionally a pharmaceutically acceptable carrier, adjuvant and/or diluent. The invention also relates to methods of treatment of disease associated with fibrosis in a vertebrate, as well as methods for diagnosing such conditions, and kits therefor. | 09-02-2010 |
20100227333 | METHOD OF DETECTING INFECTION WITH UROGENITAL MYCOPLASMAS IN HUMANS AND A KIT FOR DIAGNOSING SAME - A method and a kit are provided for detecting an infection by mycoplasma, particularly an urogenital infection in humans. The presence of specific anti-mycoplasma antibodies in a biological sample of a diagnosed subject is detected by reaction with an immobilized mixture of various antigenic determinants associated with a variety of pathological states. | 09-09-2010 |
20100233723 | DRY STICK DEVICE AND METHOD FOR DETERMINING AN ANALYTE IN A SAMPLE - The present invention relates to a dry stick test device for the determination of an analyte in a sample by means of a chemical assay. The device comprises: (i) optionally a solid support, (ii) at least one reagent pad comprising a reagent capable of reacting with the analyte, a derivative of said analyte or an indicator compound for said analyte to provide a detectable signal when in moistened state, and (iii) a development pad which is located in contact with the at least one reagent pad, optionally between the solid support and the at least one reagent pad, said development pad comprises at least one controlling compound capable of providing a condition required for the reagent to react with the analyte to provide a detectable signal, wherein the at least one reagent pad and the development pad are arranged to avoid precipitation of sample component(s) on the top-face of the device. | 09-16-2010 |
20100233724 | MARKERS OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND METHODS OF USE THEREOF - Novel methods for assessing the level of triglycerides in the liver of a subject are described, comprising determining the amount of a lipid metabolite in a sample from a body fluid of the subject. The methods may be used, for example, in diagnosing and monitoring liver disorders such as steatosis, NAFLD and NASH. | 09-16-2010 |
20100233725 | IMMUNOASSAYS EMPLOYING NON-PARTICULATE CHEMILUMINESCENT REAGENT - Methods and reagents are disclosed for conducting assays. Embodiments of the present methods and reagents are concerned with chemiluminescent reagents for determining the presence and/or amount of an analyte in a sample suspected of containing the analyte. The reagent is non-particulate and comprises a binding partner for the analyte and a chemiluminescent composition comprising an olefinic compound and a metal chelate. In embodiments of an assay, a combination is provided that comprises a sample suspected of containing the analyte, a chemiluminescent reagent as described above and a sensitizer reagent capable of generating singlet oxygen. The combination is subjected to conditions for binding of the analyte to the binding partner for the analyte. The sensitizer is activated and the amount of luminescence generated by the chemiluminescent composition is detected wherein the amount of luminescence is related to the amount of the analyte in the sample. | 09-16-2010 |
20100233726 | TANDEM FLUORESCENT PROTEIN CONSTRUCTS - This invention provides tandem fluorescent protein construct including a donor fluorescent protein moiety, an acceptor fluorescent protein moiety and a linker moiety that couples the donor and acceptor moieties. The donor and acceptor moieties exhibit fluorescence resonance energy transfer which is eliminated upon cleavage. The constructs are useful in enzymatic assays. | 09-16-2010 |
20100233727 | MARKER FOR ARRHYTHMIA RISK - The present invention relates to markers and methods for determining risk of ventricular arrhythmia in an African American or woman patient. By using the markers of the present invention, individual with high risk of ventricular arrhythmia can properly be detected and treated. The present inventors have discovered that, in African American and women, IL-6 and/or DROMs and/or CRP have strongly positive correlation with the risk of ventricular arrhythmia. | 09-16-2010 |
20100233728 | METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY - A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents. | 09-16-2010 |
20100240065 | Prolyl Hydroxylase Compositions and Methods of Use Thereof - The invention provides methods and compositions for making and using novel HIF-specific prolyl hydroxylase (HPH) enzymes from rhesus monkeys. | 09-23-2010 |
20100248255 | NOVEL PEPTIDES - The present invention provides novel peptides with circulation-modulating activity. These peptides are useful as circulation-modulating agents and vasopressors because of their circulation-modulating activity, and can be used for treating diseases of the circulatory system such as myocardial infarction, ischemic heart disease, cerebral infarction, or the like. | 09-30-2010 |
20100248256 | HEPATOCELLULAR CARCINOMA PROTEIN MARKER, AND METHOD FOR DETECTION OF HEPATOCELLULAR CARCINOMA USING THE SAME - Provided are: a method of assessing hepatocellular carcinoma by using a protein with a different phosphorylated state in hepatocellular carcinoma cells compared with non-hepatocellular carcinoma cells; and a hepatocellular carcinoma protein marker for detecting hepatocellular carcinoma formed of the protein. The hepatocellular carcinoma protein marker for detecting hepatocellular carcinoma includes tumor rejection antigen gp96 formed of the amino acid represented by SEQ ID NO: 1, and is measured for its phosphorylated state to detect the presence or absence of hepatocellular carcinoma. | 09-30-2010 |
20100248257 | Compiled Methods for Analysing and Sorting Samples - The present invention relates to the fields of analysis, diagnostics, prognostics, standardization, characterization and enumeration of entities such as biological cells, as well as therapeutical applications. Accordingly, the present invention in preferred aspects is directed to methods for the detection and/or analysis and/or isolation and optionally further manipulation of entities, such as cells, particles, and supra-molecular structures. | 09-30-2010 |
20100248258 | Immunoassay biochip - The present invention is about a microfluidic chip for rapid detection of different target proteins and a method for using the same. The microfluidic chip utilizes antibody-conjugated magnetic beads to bind to the target proteins to form a magnetic complex, and then use the signal labeled-antibodies that can recognize said magnetic complex. Purifying said magnetic complex by the micro-magnetic field on biochip, and introducing said purified magnetic complex into the fluorescent detection area on the chip to detect the amount of the target protein in said purified complex immediately. | 09-30-2010 |
20100248259 | NATRIURETIC PEPTIDE/GDF-15 RATIO FOR DIAGNOSIS OF CARDIAC DISORDERS - The present invention is concerned with methods and devices for medical diagnosis. Specifically, it relates to a method of diagnosing a cardiac disorder, the method including (a) determining the amount of a natriuretic peptide in a sample of the subject, (b) determining the amount of GDF-15 in a sample of the subject, (c) calculating the ratio (natriuretic peptide/GDF-15), and (d) diagnosing if the subject is suffering from a cardiac disorder, based of the ratio calculated in step (c). The method allows determining whether an elevated amount of GDF-15 in a sample of a subject is related to cardiac disorders, in particular myocardial dysfunction and/or heart failure, or if the elevation is related to a different pathological state Moreover, the present invention relates to a diagnostic device and a kit for carrying out the aforementioned method. | 09-30-2010 |
20100248260 | GLYCOSAMINOGLYCAN-COATED PARTICLES AND USES THEREOF - The present invention is directed to metallic particles coated with glycosaminoglycans and methods for preparing them. Methods of using such glycosaminoglycan-coated metallic particles in biomedical and other applications are also disclosed. In certain embodiments, methods for assaying glycosaminoglycan-degrading activity in biological fluids, test samples, and/or therapeutic formulations using the glycosaminoglycan-coated particles are provided. Such methods may be used, for example, in diagnostic tests for diseases such as cancer, inflammatory diseases, or autoimmune diseases and to test activity of enzymes being developed as therapeutics. | 09-30-2010 |
20100248261 | METHOD TO DETERMINE PROTEIN INTERACTION SITES - The invention provides improved crosslinkers which permit more efficient determination of protein interactions in biological samples. | 09-30-2010 |
20100248262 | Anti-Fibronectin Fragment Monoclonal Antibody - A method for measuring a fibronectin fragment which is easy to handle and has excellent measuring accuracy, specificity and reproducibility is provided. An anti-fibronectin fragment monoclonal antibody which reacts with a human fibronectin fragment but does not react with human fibronectin, a measuring reagent containing the monoclonal antibody, a method for measuring a fibronectin fragment which uses the monoclonal antibody and a hybridoma which produces the monoclonal antibody are provided. | 09-30-2010 |
20100255496 | METHODS OF ISOLATING CELLS AND GENERATING MONOCLONAL ANTIBODIES - The invention provides methods for isolating cells, particularly antibody-secreting cells that have a high likelihood of secreting antibodies specific for a desired antigen for the purpose of making monoclonal antibodies. | 10-07-2010 |
20100255497 | ANALYTE DETECTION - The present invention relates to analyte detection test systems, including test systems for the oral detection of analytes in saliva. The present invention also provides compositions and methods for storing multiple assay tests and compositions and methods for measuring the concentration of analytes in a sample. | 10-07-2010 |
20100255498 | METHODS FOR IDENTIFYING COMPOUNDS THAT REGULATE BETA-ARRESTIN SIGNALING COMPLEXES - A method of screening a candidate compound for βArrestin mediated anti-G protein coupled receptor signaling activity is comprises: (a) contacting said candidate compound to a βArrestin signaling complex or a constituent thereof, under conditions in which a signaling complex is formed; and then (b) detecting the presence or absence of disruption of said signaling complex, disruption of said complex indicating said compound has βArrestin mediated anti-G protein coupled receptor signaling activity. Compositions and kits for carrying out the method are also described. | 10-07-2010 |
20100261194 | NEUTROKINE-ALPHA ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to a Neutrokine-alpha antibody and a process for producing a Neutrokine-alpha antibody. The invention further relates to screening methods for identifying compounds that inhibit or enhance the action of Neutrokine-alpha. Also provided are diagnostic methods for detecting autoimmune disorders and therapeutic methods for treating autoimmune disorders using a Neutrokine-alpha antibody. | 10-14-2010 |
20100261195 | RAPID ANTEMORTEM DETECTION OF INFECTIOUS AGENTS - Methods for detection of the presence or absence of PrP | 10-14-2010 |
20100261196 | METHODS OF IDENTIFYING SMALL MOLECULES FOR RENEWALS, SURVIVAL AND MIGRATION OF CARDIAC PROGENITORS - The present invention relates to a small molecule high-throughput screening assay consisting of detectably labeled cardiac progenitor cells. The invention also describes a method of identifying small molecules from the high-throughput assay affecting cardiogenesis and/or modulating cardiac progenitor cell development. Also described are methods of stimulating maturation of cardiac progenitor cells using a GSK-3β inhibitor. | 10-14-2010 |
20100267046 | ISOFORM-SELECTIVE INHIBITOR AND ACTIVATORS OF PDE3 CYCLIC NUCLEOTIDE PHOSPHODIESTERASES - The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments. | 10-21-2010 |
20100267047 | Test Method on Feline Vaccinated with Feline Immunodeficiency Virus Vaccine, and Antigen for Use in the Test - Since FIV-vaccinated cats produce antibodies against FIV, distinguishing them from FIV-infected cats is difficult by serological diagnostic methods using FIV and FIV-derived substances. The present invention enables tests for determining the presence or absence of a FIV vaccination history in a cat by detecting antibodies that are produced as a result of vaccination of a cat with an FIV vaccine, but not as a result of FIV infection. Using the methods of the present invention, whether an anti-FIV antibody-positive cat is infected with FIV or has been vaccinated can be conveniently distinguished. | 10-21-2010 |
20100267048 | METHOD FOR MEASUREMENT OF HEMOGLOBIN AND HEMOGLOBIN DERIVATIVE, AND MEASUREMENT KIT - Hemoglobin in a sample solution is quickly and reliably denatured; at the same time, quick and accurate measurement of hemoglobin and a hemoglobin derivative is realized. In a method for measuring hemoglobin and a hemoglobin derivative, and a reagent composition, a measurement kit, an analysis device, and an analysis system used in the method, a sample solution containing a blood component is treated with a nonionic surfactant, an oxidizing agent, and a metal salt to denature hemoglobin in the sample solution to measure the hemoglobin, and thereafter the amount of a hemoglobin derivative in the sample is measured by an immunological method using an antibody specifically binding to a denatured site of the denatured hemoglobin derivative. | 10-21-2010 |
20100267049 | DIAGNOSTIC DEVICES AND RELATED METHODS - Devices, systems, and methods for detecting the presence of one or more analytes in a sample are described. In some variations, a test strip may be used to detect and/or analyze one or more analytes in a sample. In certain variations, a test strip configured to receive a sample for detection of an analyte therein may comprise a substrate and a coating on a portion of the substrate, the coating comprising a combination of a first analyte capture agent configured to bind to a first analyte and a second analyte capture agent configured to bind to a second analyte that is different from the first analyte. | 10-21-2010 |
20100267050 | METHODS AND COMPOSITIONS FOR TARGETING POLYUBIQUITIN - Anti-polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided. | 10-21-2010 |
20100267051 | ANNEXIN FOR CANCER RISK ASSESSMENT - A method treats urogenital and/or intestinal tract cancer and includes administering a therapeutically effective amount of at least one annexion protein, annexin of A3, to a mammal. | 10-21-2010 |
20100267052 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TYPE 2 DIABETES - The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes. | 10-21-2010 |
20100267053 | AKT3 POLYPEPTIDES - The present invention provides, in part, AKT3 polypeptides and methods of use thereof along with nucleic acids encoding the polypeptides. For example, methods for screening for AKT3 inhibitors are provided herein. | 10-21-2010 |
20100273177 | Methods and Devices for Testing Saliva - Provided are methods and devices for performing sensitive, rapid antigen testing of saliva, which yield sensitivity comparable to both rapid antigen tests and saliva culture. | 10-28-2010 |
20100273178 | Affinity selected signature peptides for protein identification and quantification - A method for protein identification in complex mixtures that utilizes affinity selection of constituent proteolytic peptide fragments unique to a protein analyte. These “signature peptides” function as analytical surrogates. Mass spectrometric analysis of the proteolyzed mixture permits identification of a protein in a complex sample without purifying the protein or obtaining its composite peptide signature. | 10-28-2010 |
20100273179 | METHOD FOR TESTING OR SCREENING PROTEIN SYNTHESIS INHIBITORS - This invention provides methods for screening an inhibitor of protein synthesis by measuring the level of relocalization of an SMN complex component from the cytoplasm to the nucleus. Additionally, the invention provides a kit and a system for screening protein synthesis inhibitors in a cell. | 10-28-2010 |
20100273180 | DECORIN POLYPEPTIDE AND METHODS AND COMPOSITIONS OF USE THEREOF - The present invention provides methods for decreasing expression of a decorin polypeptide in a cell, methods for identifying an agent that alters, preferably decreases, the distribution of decorin polypeptide in a cell, and methods for determining a prognosis for oral cancer in a subject through the use of a compound that binds decorin polypeptide. Also provided are antibodies that specifically bind decorin polypeptides and double stranded polynucleotides, for instance, dsRNAs, that inhibit expression of a polynucleotide encoding a decorin polypeptide. | 10-28-2010 |
20100273181 | METHODS FOR THE DETECTION OF GLYCATED HEMOGLOBIN - Particular aspects of the present invention relate to methods for detecting glycated hemoglobin in, for example, human whole blood, that are not affected by the presence of variation in amino acid sequence that can exist in hemoglobin β chains. The methods detect all glycated hemoglobin in a sample, regardless of the form of the hemoglobin that has been glycated, and thus detect glycated human Hemoglobin A, Hemoglobin S, and Hemoglobin C. | 10-28-2010 |
20100273182 | Truncated Proteins As Cancer Markers - Methods/reagents for detecting and/or treating cancers or potential cancers are disclosed. In one embodiment, methods and reagents for detecting truncated forms of P2X | 10-28-2010 |
20100273183 | DIAGNOSTIC ASSAY FOR ANTI-VON WILLEBRAND FACTOR CLEAVING PROTEASE (ADAMTS13) ANTIBODIES - This invention relates to a kit to be used in an assay system for determination of an anti-von Willebrand Factor-cleaving protease (“anti-vWF-cp”) antibody in a sample. The kit comprises vWF-cp and/or vWF-fragment(s) immobilized on a solid phase. The kit can be used in a method for determination of anti-vWF-cp antibodies from a patient, for the diagnosis of disorders associated with the occurrence of anti-vWF-cp-antibodies, and the differentiation of various forms of thrombotic microangiopathy. | 10-28-2010 |
20100279306 | ANALYSIS OF PHOSPHORYLATED GLYCANS, GLYCOPEPTIDES OR GLYCOPROTEINS BY IMAC - The present disclosure provides technologies for enriching, detecting, and/or quantifying phosphorylated glycans and/or glycoconjugates (e.g., glycopeptides, glycolipids, proteoglycans, etc.). Specifically, the present disclosure provides methods that utilize immobilized metal affinity chromatography (IMAC) to isolate and/or to characterize phosphorylated glycans. The present disclosure particularly provides methods for distinguishing sulfated and phosphorylated glycans. | 11-04-2010 |
20100279307 | Angiogenesis Inhibiting Molecules, Their Selection, Production and Their Use in the Treatment of Cancer - The present invention relates to a method for providing molecules that are capable of inhibiting angiogenesis, comprising the steps of providing a range of molecules; testing whether these molecules can prevent interaction between JAM-B and JAM-C; testing the positive molecules for their ability to block angiogenesis in vivo; and selecting molecules that are positive in the angiogenesis test as angiogenesis inhibiting molecules. The method may further comprise the step of isolating or producing the angiogenesis inhibiting molecules. The invention further relates to the angiogenesis inhibiting molecules thus provided and produced, to their use in the treatment of cancer, to therapeutical compositions comprising them. In a particular embodiment the invention relates to monoclonal antibodies, in particular Mab H33, to soluble JAM-C and JAM-B and to small molecules. | 11-04-2010 |
20100279308 | RAPID LATERAL FLOW GLYCAN-DETECTING DEVICE - A glycan-detecting device containing a sample pad, a membrane in communication with the sample pad, a labeled lectin, an immobilized lectin of the same type, and an immobilized antibody specific to the lectin. | 11-04-2010 |
20100279309 | MICROFLUIDIC CHIPS AND SYSTEMS FOR ANALYZING PROTEIN EXPRESSION, AND METHODS OF USE THEREOF - Microfluidic chips, systems including at least one integrated microfluidic chip operably connected to hardware (e.g., docking device, high voltage electrodes, portable fluorescence microscope, computer, etc.), and methods for analyzing peptides (e.g., toxins), proteins (e.g., cancer biomarkers, recombinant human growth hormone, recombinant human erythropoietin), and protein expression in biological samples (e.g., human serum, urine, or tissue, marine organism, seafood, etc.) have been developed. On a single microfluidic chip as described herein, several sequential processes for analyzing a protein (e.g., cell culturing, cell lysis, protein enrichment, protein labeling, and protein detection) can be performed in an automated fashion. The microfluidic chips, systems, and methods described herein provide real-time, high-throughput, highly-specific detection of proteins such as recombinant erythropoietin, recombinant human growth hormone and marine biotoxins, as well as important biomarkers in the cancer signaling pathway network for early and precise cancer diagnosis. | 11-04-2010 |
20100279310 | ASSAY DEVICE AND METHOD - An assay method is described, which comprises the steps of immobilizing a binding partner (e.g., an antigen or antibody) for an analyte to be detected (e.g., an antibody or antigen) on a portion of a surface of a microfluidic chamber; passing a fluid sample over the surface and allowing the analyte to bind to the binding partner; allowing a metal colloid, e.g., a gold-conjugated antibody, to associate with the bound analyte; flowing a metal solution, e.g., a silver solution, over the surface such as to form an opaque metallic layer; and detecting the presence of said metallic layer, e.g., by visual inspection or by measuring light transmission through the layer, conductivity or resistance of the layer, or metal concentration in the metal solution after flowing the metal solution over the surface. | 11-04-2010 |
20100279311 | METHOD FOR SCREENING OF CELL-PROTECTING AGENT - The invention provides a screening method and screening kit for a cell protecting agent. Specifically, the invention provides a method for screening a cell protecting agent showing an Hsp90-binding activity and a heat shock protein expression-inducing activity but having no Hsp90 client protein degradation-promoting activity. The method comprises the following steps (1) to (3): (1) measuring the binding property of a test compound to Hsp90; (2) measuring the activity of a test compound to induce the expression of a heat shock protein, or measuring the activity of a test compound to disrupt an Hsp90/HSF-1 complex, by using a cell capable of expressing the heat shock protein; and (3) measuring the activity of a test compound to induce the degradation of an Hsp90 client protein by using a cell capable of expressing the Hsp90 client protein. The invention further provides specifically a kit for screening a cell protecting agent, comprising (1) Hsp90; (2) a reagent for measuring the heat shock protein expression-inducing activity; (3) an imidazothiazine derivative; and (4) a reagent for quantifying an Hsp90 client protein. | 11-04-2010 |
20100285490 | DETECTION APPARATUS - The present invention relates to, in part, methods, reagents and apparatuses for the detection of agents. The present invention also relates, in part, to compositions including, but not limited to, flow cells, assay chambers, reagent reservoir delivery units and devices for holding an assay chamber. The present invention also provides various components and combinations of components for various detection apparatuses. The present invention also relates to a portable agent detection apparatus that can be used in the field or at a point of care and is not limited to specialized laboratories or limited to use by highly skilled users. | 11-11-2010 |
20100285491 | USE OF IGFBP-7 IN THE ASSESSMENT OF HEART FAILURE - The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7. | 11-11-2010 |
20100285492 | USE OF SLIM-1 IN THE ASSESSMENT OF HEART FAILURE - The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker SLIM-1, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SLIM-1 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SLIM-1 as a marker protein in the assessment of heart failure, a marker combination comprising SLIM-1 and a kit for measuring SLIM-1. | 11-11-2010 |
20100285493 | METHOD FOR DETERMINING AMINO-TERMINAL PROANP IN PATIENTS HAVING A CARDIAC DISEASE OR BEING SUSPECTED OF DEVELOPING OR HAVING A CARDIAC DISEASE - The present invention relates to an in vitro method for medical diagnosis, prognosis and therapy follow-up for patients having a cardiac disease or being suspected of developing or having a cardiac disease comprising the steps of: providing a sample of a patient having a cardiac disease or being suspected of developing or having a cardiac disease, determining amino-terminal proANP or partial peptides thereof having from 12 to 98 amino acids in said sample using at least one antibody that binds specifically to a partial sequence of amino-terminal proANP, attributing the determined amino-terminal proANP level or the level of partial peptides thereof to a clinical picture wherein the attribution is carried out independent of the BMI of the patient. The present invention further concerns a rapid test assay and a kit for conducting the method of the present invention and the use of antibodies suitable for the method and assays according to the present invention. | 11-11-2010 |
20100285494 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL - The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues. | 11-11-2010 |
20100285495 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL - The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues. | 11-11-2010 |
20100285496 | Methods and Devices for the Detection of Biofilm - The present invention provides methods and kits for biofilm detection. | 11-11-2010 |
20100285497 | MARKERS OF ENDOTHELIAL CELLS AND USES THEREOF - Use of a beta tubulin isotype that is differentially expressed between activated endothelial cells and quiescent endothelial cells for identifying an agent which inhibits or promotes angiogenesis and/or vascular function. | 11-11-2010 |
20100285498 | METHODS FOR DETECTING PRE-DIABETES AND DIABETES USING DIFFERENTIAL PROTEIN GLYCOSYLATION - Methods for identifying individuals who are not yet diabetic (pre-diabetic), but who are at significant risk of developing diabetes, such as type 2 diabetes, are disclosed herein. Methods are also provided for the identification of diabetic subjects. Also disclosed are methods for identifying individuals with diabetic complications. The methods include the identification of an overall glycosylation profile of proteins in a biological fluid, such as saliva, urine, or serum. In some examples, the methods include determining the amount of one or more protein in a biological fluid or determining the glycosylation pattern of one or more proteins in a biological fluid. | 11-11-2010 |
20100285499 | HUMAN p51 GENES AND GENE PRODUCTS THEREOF - Novel human genes falling within the category of family genes relating to p53 gene which is known as a cell proliferation regulatory gene, and gene products thereof. A human p51 gene characterized by containing a base sequence encoding an amino acid sequence represented by SEQ ID NO:1; a human p51 gene having a base sequence consisting of the 145- to 1488-bases in the sequence represented by SEQ ID NO:2; vectors containing these genes; host cells transformed with these vectors; a process for producing a p51 protein having the amino sequence represented by SEQ ID NO:1; which comprises culturing the above host cells and harvesting the protein from the thus obtained culture; and the p51 protein having the amino acid sequence represented by SEQ ID NO:1. | 11-11-2010 |
20100285500 | NEUROFURANS-INDICES OF OXIDANT STRESS - The invention is drawn to a new class of isoeicosanoids that have been identified as products of the oxidation of docosahexaenoic acid (DHA). The invention provides compositions and methods related to the new class of molecules. | 11-11-2010 |
20100285501 | METHODS FOR DIAGNOSING ENDOMETRIOSIS - Provided herein is a method for diagnosing and monitoring endometriosis in a subject by measuring levels of the β-subunit of fibrinogen. | 11-11-2010 |
20100291586 | METHOD FOR THE DIAGNOSIS OR THE SCREENING OF AN ARBOVIRUS INFECTION, REAGENTS USEFUL IN SAID METHOD AND THEIR APPLICATIONS - Method for the diagnosis or the screening of an arbovirus infection and preferably a flaviviridae infection and more preferably a flavivirus infection, reagents useful in said method and their applications. Said method comprises: (i) contacting a sample from the subject or animal with a solid support sensitized with an Ig binding protein which is directed against a specific class of Ig molecules of the subject or animal species under consideration and (ii) incubating the immunocomplex formed in (i) with a detector molecule consisting of a hybrid protein comprising at least an arboviral ED3 domain and an alkaline phosphatase (PhoA), the detection of said immunocomplex being the sign of the presence of an arbovirus in said sample. | 11-18-2010 |
20100291587 | BIOMARKER FOR DIAGNOSING HEART DISEASE AND THE USE THEREOF - The invention relates to the following methods [1] to [3] and to a kit for carrying out the methods: | 11-18-2010 |
20100297661 | Diagnostic Composition and Kit for Renal Cell Carcinoma - Disclosed herein are a composition and a kit for diagnosing renal cell carcinoma. The composition and kit employ, as a renal cell carcinoma marker, nicotinamide N-methyltransferase, L-plastin, secretagogin, NM23A, CapG, which is an actin regulatory protein, and/or C4a anaphylatoxin. | 11-25-2010 |
20100297662 | ANTIBODY AND USE THEREOF - An antibody provided by the present invention has a low reactivity with amyloid precursor proteins, and has a higher reactivity with amylospheroids than with amyloid β fibrils or monomeric amyloid β-proteins. According to the present invention, an antibody is provided that has a higher reactivity with amylospheroids than with amyloid precursor proteins, and has any one or more of the following properties: (i) a higher activity with amylospheroids than with amyloid β fibrils; (ii) a higher reactivity with amylospheroids than with monomeric amyloid β-proteins; and (iii) an activity of inhibiting neuronal cell death induced by amylospheroids. | 11-25-2010 |
20100297663 | METHODS AND SYSTEMS FOR ASSAYING, MAINTAINING, AND ENHANCING THE ACTIVITY OF THE IMMUNE SYSTEM OF A SUBJECT - A method for non-invasively assessing a subject's health includes evaluating a state of a subject's immune response. Such a method may include obtaining a salivary sample from the subject and assaying the salivary sample for IgA. The state of a component of the subject's immunity may be evaluated in conjunction with the administration of one or more substances known to elicit a cell-mediated immune response to the subject to determine the effect of the one or more substances on the subject's humoral, or antibody-mediated, immune response. Assay methods may also be used to optimize the dosage of an immune support component to be administered to a particular subject. Systems that include assays for evaluating the state of a subject's immune response and nutraceuticals are also disclosed. | 11-25-2010 |
20100304397 | Chromogenic test kit for detecting health conditions in saliva - A device and method for detecting diseases, disorders and health conditions in saliva or other body fluid. The method employs solid phase immunoassay and similar detecting processes along with one of several bioluminescent reactions such that the presence of specific biomarkers is reported visually on a chromogenic panel incorporated directly into the test kit. The device does not require electricity or refrigeration, and results in a small, sealed diagnostic packet that can be safely discarded or stored as necessary. | 12-02-2010 |
20100304398 | NOVEL DIAGNOSTIC SENSOR FOR RAPID AND REPRODUCIBLE RO52 PROTEIN DOMAIN DETECTION - The present invention relates to the use of specific synthetic sensor molecules for the discrimination of proteins and protein domains involved in autoimmunity. More specifically, in one embodiment, the invention relates to the detection of antibodies which bind to specific domains of the Ro52 protein. In another embodiment, the invention relates to the use of specific synthetic sensor molecules to identify domains of the Ro52 protein with different antibody specificities. The invention also includes a method for assessing the risk that a fetus will develop congenital heart block. The invention enables the evaluation and differential diagnosis of a range of autoimmune disorders, allowing appropriate treatment or more generally medical intervention decisions to be made. | 12-02-2010 |
20100304399 | METHOD FOR CONTINUOUSLY DETECTING GLUCOSE CONCENTRATION IN SAMPLE, KIT THEREOF AND METHOD FOR USING BIOSENSOR - The invention provides a method for continuously detecting glucose concentration in a sample, including: (a) providing a biosensor comprising a transducer and a polysaccharide covered on the surface of the transducer; (b) providing a carbohydrate binding protein solution, wherein the carbohydrate binding protein has at least one receptor, and the receptor is capable of binding to the polysaccharide and glucose; (c) mixing a sample and the carbohydrate binding protein solution to form a mixture; (d) contacting the mixture with the biosensor; (e) detecting the amount of carbohydrate binding proteins bound to the polysaccharide by the biosensor, wherein glucose concentration of the sample is inversely proportional to the amount of carbohydrate binding proteins bound to the polysaccharide; and (f) refreshing the surface of the biosensor with a high concentration glucose solution. | 12-02-2010 |
20100304400 | DISTINGUISHING ASSAY - The current invention comprises a method for determining of an antibody against a drug antibody in a sample using an immunoassay comprising a capture drug antibody and a tracer drug antibody, wherein the method comprises providing i) a capture drug antibody, which is the drug antibody conjugated to a solid phase, ii) a tracer drug antibody, which is the drug antibody conjugated to a detectable label, contacting the capture drug antibody separately with i) the sample, ii) the sample, to which the drug antibody in monomeric form has been added, iii) the sample, to which the drug antibody in oligomeric form has been added, and determining an antibody against the drug antibody in the sample by a positive immunoassay in i) and a negative immunoassay in ii) and iii). | 12-02-2010 |
20100304401 | YS68 GENE INVOLVED IN PRIMITIVE HEMATOPOIESIS - A novel gene, dubbed “YS68”, involved in primitive hematopoiesis was successfully isolated from cDNA derived from mouse yolk sacs. In addition, a human gene corresponding to this gene was successfully isolated. Expression characteristics of these genes suggested their involvement in primitive hematopoiesis. The proteins of this invention and genes encoding the proteins may be utilized as tools for drug development against diseases, such as hematological disorders. | 12-02-2010 |
20100311074 | SWITCH-REGION: TARGET AND METHOD FOR INHIBITION OF BACTERIAL RNA POLYMERASE - The invention provides a target and methods for specific binding and inhibition of RNA polymerase from bacterial species. The invention provides methods for identifying agents that bind to a bacterial RNA polymerase, and that inhibit an activity of a bacterial RNA polymerase, through interactions with a bacterial RNA polymerase homologous switch-region amino-acid sequence. Said methods comprise preparing a reaction solution comprising the compound to be tested and an entity containing a bacterial RNAP homologous switch-region amino-acid sequence, and detecting binding or inhibition. The invention has applications in control of bacterial gene expression, control of bacterial viability, control of bacterial growth, antibacterial chemistry, and antibacterial therapy. | 12-09-2010 |
20100311075 | HUMAN SODIUM-DEPENDENT BILE ACID TRANSPORTER PROTEINS - A novel sodium-dependent bile acid transporter protein, an Na | 12-09-2010 |
20100311076 | METHOD OF BINDING PROTEINS TO CARRIERS BY MAKING USE OF TAMAVIDINS - The present invention provides a method of binding a protein to a carrier in such a way that the protein is not impaired in its function but can be allowed to act more efficiently than when it is bound directly. | 12-09-2010 |
20100311077 | Use of GPR100 Receptor in Diabetes and Obesity Regulation - We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a Gpr100 associated disease, in particular diabetes and obesity, the method comprising determining whether a candidate molecule is an agonist or antagonist of Gpr100 polypeptide, in which the Gpr100 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 5, or a sequence which is at least 90% identical thereto. | 12-09-2010 |
20100311078 | IMMUNOREGULATION IN CANCER, CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES - The present invention primarily relates to a method for analyzing the amount of immunoregulatory integrin binding factors and/or patient endogenous antibodies which are directed against such factors, the factors having the capacity to modulate the immune functions in a subject suffering from cancer or inflammatory or autoimmune diseases, by utilizing binding reagents to determine these factors and/or the patient endogenous antibodies which are directed against such factors, whereby the prognosis and/or the therapeutic efficacy of any treatment of a subject suffering from cancer or inflammatory or autoimmune diseases can be determined and/or monitored. The invention further relates to the use of therapeutically active compounds for eliminating, inhibiting or enhancing such binding factors for the manufacture of pharmaceuticals to be used in the treatment of cancer, inflammatory conditions or autoimmune diseases. | 12-09-2010 |
20100311079 | ASSAY FOR CARDIAC TROPONIN AUTOANTIBODIES - The invention provides among other things methods and kits based on assaying for cardiac troponin autoantibodies, either in conjunction with an assay for cardiac troponin and/or as an independent indicator of cardiac pathology, such as myocarditis, cardiomyopathy, and/or ischemic heart disease. Assay methods of the invention can be employed among other things to identify cardiac pathology, or risk thereof, in subjects who have an autoimmune disease or who are related to an individual with an autoimmune disease. In particular embodiments, the invention also provides a method of determining whether a subject having, or at risk for, a cardiac pathology is a candidate for immunosuppressive therapy or immunoabsorption therapy. The invention also provides kits and kit components that are useful for performing the methods of the invention. | 12-09-2010 |
20100311080 | WATER-SOLUBLE NANOCRYSTALS THROUGH DUAL-INTERACTION LIGANDS - A dual-interaction ligand for rendering otherwise hydrophobic nanoparticles water soluble or suspendable has a hydrophilic base with a plurality of hydrophilic segments extending from a core of the base, where at least one segment or the core contains a hydrophobic groups capable of forming van der Waal interaction between hydrophobic groups of the dual-interaction ligand and other hydrophobic ligands, and at least one complexing functionality to complex a metal atom or ion of a nanoparticle. The dual-interaction ligands can be combined with hydrophobic nanoparticles, where the dual-interaction ligands can displace some or all of the hydrophobic ligands of the hydrophobic nanoparticles, to form a nanoparticle-dual interaction ligand complex that can be dissolved or dispersed readily in an aqueous solution. The dual interaction ligand can be functionalized to attach an antibody or other biomolecules such that the nanoparticle dual-interaction ligands complexes can contain biomolecules. Such biomolecules modified nanoparticle dual-interaction ligands can be used for sensing, labeling, optical imaging, magnetic resonance imaging, cell separation, and treatment of diseases. | 12-09-2010 |
20100317021 | FLUIDIC ANTIBODY-CONTAINING DEVICES AND METHODS - The invention relates to devices and methods for analyzing a sample (and preferably preparing a sample), which is particularly used in analysis, such as analysis of a sample for a bacterium of interest. | 12-16-2010 |
20100317022 | METHODS OF DIAGNOSING TISSUE FIBROSIS - The present invention provides a method of diagnosing the presence or severity of tissue fibrosis in an individual by detecting α2-macroglobulin (α2-MG) in a sample from the individual; detecting hyaluronic acid (HA) in a sample from the individual; detecting tissue inhibitor of metalloproteinases-1 (TIMP-1) in a sample from the individual; and diagnosing the presence or severity of tissue fibrosis in the individual based on the presence or level of α2-MG, HA and TIMP-1. | 12-16-2010 |
20100317023 | BIOCHEMICAL MARKERS FOR CVD RISK ASSESSMENT - A method of diagnosis of cardiovascular disease (CVD) an immunoassay to measure aggrecan fragments in said sample, and association of an elevation above a normal level with the presence of CVD, is conducted by contacting aggrecan fragments in said sample with an first antibody reactive with an N-terminal first epitope formed by cleavage of aggrecan by a proteinase and with a second antibody reactive with a second aggrecan epitope which is present in aggrecan at a location in the C-terminal direction from the location of said N-terminal epitope, and measuring the extent of simultaneous binding of both antibodies. | 12-16-2010 |
20100317024 | DERIVATIVES, REAGENTS, AND IMMUNOASSAY FOR DETECTING LEVETIRACETAM - Levetiracetam (LEV) derivatives, methods for synthesizing LEV derivatives, and immunodiagnostic assays for LEV. The synthesis methods described herein include chirally-selective, liquid-phase synthesis steps to produce selected LEV derivatives in high-yield. LEV derivatives can include operative groups, such as: immunogenic moieties that can be used to prepare anti-LEV antibodies; antigenic moieties that can be used in immunodiagnostic assays for LEV; or tracer moieties that can be used in immunodiagnostic assays. Additionally, the LEV derivatives can be used in immunodiagnostic assays to compete with LEV for anti-LEV antibodies. | 12-16-2010 |
20100317025 | Diagnostic Method for Celiac Sprue - Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue. | 12-16-2010 |
20100317026 | VMP-Like Sequences Of Pathogenic Borrelia - The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic | 12-16-2010 |
20100317027 | SULFENIC ACID-REACTIVE COMPOUNDS AND THEIR METHODS OF SYNTHESIS AND USE IN DETECTION OR ISOLATION OF SULFENIC ACID-CONTAINING COMPOUNDS - The present invention provides compounds of Formula I: | 12-16-2010 |
20100323368 | Cytokine production-inducing antibody - The invention relates to a method of measuring the activation of an effector cell belonging to the immune system, which may or may not be transformed, using a monoclonal (AcMo) or polyclonal antibody. The invention is characterised in that it consists in: bringing into contact (i) CD16 receptor-expressing cells in a reaction medium in the presence of the antibody and (ii) the antigen of said antibody, and measuring the quantity of at least one cytokine produced by the CD16 receptor-expressing cell. The invention also relates to the selection of an antibody capable of inducing the expression of cytokines and interleukins, such as IFN? or IL2 which are intended for the treatment of autoimmune and inflammatory diseases, cancers and infections by pathogens. | 12-23-2010 |
20100323369 | Diagnostic Testing Process - A method and apparatus for use in a flow through assay process is disclosed. The method is characterised by a “pre-incubation step” in which the sample which is to be analysed (typically for the presence of a particular protein), and a detection analyte (typically one or more antibodies bound to colloidal gold or a fluorescent tag) which is known to bind to the particular protein may bind together for a desired period of time. This pre-incubation step occurs before the mixture of sample and detection analyte come into contact with a capture analyte bound to a membrane. The provision of the pre-incubation step has the effect of both improving the sensitivity of the assay and reducing the volume of sample required for an assay. An apparatus for carrying out the method is disclosed defining a pre-incubation chamber for receiving the sample and detection analyte having a base defined by a membrane and a second membrane to which a capture analyte is bound. In one version the pre-incubation chamber is supported above the second membrane in one position but can be pushed into contact with the membrane carrying the capture analyte thus o permitting fluid transfer from the incubation chamber through the capture membrane. In another version the membrane at the base of the incubation chamber is hydrophobic and its underside contacts the capture membrane and when a wetting agent is applied to the contents of the pre-incubation chamber fluid transfer occurs. | 12-23-2010 |
20100330582 | METHOD FOR PRODUCTION OF NOVEL NANO SILICA PARTICLE AND USE OF THE NANO SILICA PARTICLE - The present invention presents a silica particle containing at least one silica compound selected from a group consisting of mercapto-propyl-trimethoxysilane (MPS), mercapto-propyl-triethoxysilane (MPES), mercapto-propyl-methyldimethoxysilane (MPDMS), trimethoxy[2-(7-oxabicyclo[4.1.0]-hepto-3-yl)ethyl]silane(EpoPS), thiocyanatopropyltriethoxysilane (TCPS), and acryloxypropyltrimethoxysilane (AcPS), which can be provided and utilized as a label, a marker, or the like for qualitative test and quantitative test for such as prophylactic agent, therapeutic agent, diagnostic agent, diagnostic and therapeutic agent or the like in dental, medical and veterinary fields regardless of fields. | 12-30-2010 |
20100330583 | Compositions and methods for identification of PARP function, inhibitors, and activators - The invention provides nucleic acids encoding PARP fusion proteins, PARP fusion proteins, antibodies that bind to one or more of these PARP fusion proteins, and transgenic cells expressing one or more PARP fusion proteins. The invention also provides methods for identifying an agent as a specific PARP inhibitor or activator requiring contacting one or more PARP fusion proteins with a labeled nicotinamide adenine dinucleotide substrate and the agent and measuring the amount of labeled of ADP-ribose covalently attached to the one or more PARP fusion proteins. The invention also provides methods for identifying an agent that specifically binds to one or more PARP fusion proteins and methods for quantitating the level of one or more PARP proteins in a sample. | 12-30-2010 |
20100330584 | LONG WAVELENGTH FLUOROGENIC INTRACELLULAR ION INDICATORS THAT ARE WELL RETAINED IN THE CYTOSOL - Cell permeable metal ion indicator compounds and methods of their use and synthesis are described. The compound comprises a metal chelating moiety (M | 12-30-2010 |
20100330585 | LATERAL FLOW ASSAY SYSTEM AND METHODS FOR ITS USE - A lateral flow test system together with methods for its use in the detection of one or more analytes, or components, of interest within a sample, such as a biological sample, is provided. The system comprises a liquid formulation of a gold conjugate and a lateral flow assay device that does not include a conjugate pad having conjugate dried thereon. | 12-30-2010 |
20100330586 | METHOD FOR IDENTIFYING COMPOUNDS FOR TREATMENT OF PAIN - Methods and products for the attenuation or treatment of pain and the reduction of nociception are described. The methods and products are based on the modulation of CNS intracellular chloride levels. The methods and products may also relate to modulation of the activity and/or expression of a chloride transporter, such as the KCC2 potassium-chloride cotransporter. Also described herein are commercial packages and uses based on such modulation. Related methods for identifying or characterizing a compound for the treatment of pain, the reduction of nociception and the diagnosis and prognostication of pain are also described. | 12-30-2010 |
20100330587 | Annexin Proteins and Autoantibodies As Serum Markers For Cancer - The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of expression of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods. Such kits can be used to screen subjects for increased levels of annexin proteins, or for the detection of autoantibodies to annexin proteins, as a diagnostic, predictive or prognostic indicator of cancer. | 12-30-2010 |
20110003310 | ORAL FLUID RAPID IMMUNOCHROMATOGRAPHY TEST - The present invention relates to an oral fluid rapid immunochromatography test. More particularly, the present invention relates to an oral fluid collection swab separate from a lateral flow immunochromatography strip for detecting an analyte in oral fluid, consisting essentially of a sample pad, a conjugate pad, a test zone and control zone pad made of at least one matrix material, wherein the conjugate pad lies downstream of the sample pad, and is striped with a conjugate; the test and control zone pad lies downstream of the conjugate pad, wherein the test zone is immobilized with an specific binding reagent that specifically binding to the target analyte; and the control zone, downstream of the test zone, is immobilized with a second capture reagent. The invention also relates to a method for manufacturing the strip, a lateral flow immunochromatography method for detecting an analyte in oral fluid by using the strip, and kits containing the strip. | 01-06-2011 |
20110003311 | DIAGNOSIS SYSTEM FOR DETERMINING THE BIOLOGICALLY EFFECTIVE PARATHYROID HORMONE ACTIVITY IN A SAMPLE - Diagnosis system or immunoassay for the determination of the effective parathyroid hormone activity in a sample, and for a diagnosis and treatment of calcium metabolism disturbances, osteopathies and hyper- or hypoparathyroidisms. The parathyroid hormone activity is measured with the aid of an antibody which binds to an epitope in the region of the receptor binding structure | 01-06-2011 |
20110008798 | Lipid insertion for antigen capture and presentation and use as a sensor platform - It has been found that moieties containing a lipophilic domain, e.g., lipophilic pathogen activated molecular patterns (PAMPs), insert into the lipid bilayer on a cell membrane to facilitate antigen recognition by the innate immune response receptors. This changes the basic understanding of antigen recognition by the innate immune system. A sensor platform for the ultra-sensitive and specific detection of moieties containing such a lipophilic domain, e.g., PAMPs, that are associated with a disease, has now been developed. To date, this approach has been validated with Lipoarabinomannan (LAM) from | 01-13-2011 |
20110008799 | PHENOTYPIC RATIO OF SERUM AMYLOID IN PRE- AND TYPE 2 DIABETES - The present invention is directed to diagnosing, determining, and/or monitoring type 2 diabetes, pre-diabetes, insulin resistance, and their related conditions by detecting levels and modulations of Serum amyloid A protein (SAA), SAA variants and/or the phenotypic ratio of SAA. The present invention is also directed to methods for identifying and evaluating therapeutic treatments for type 2 diabetes, pre-diabetes, insulin resistance, and their related conditions by monitoring SAA, SAA variants, and/or the phenotypic ration of SAA. | 01-13-2011 |
20110014626 | METHODS FOR MEASURING THE INSULIN RECEPTOR ALPHA SUBUNIT - Presence of free insulin receptor α-subunit in blood was discovered. Furthermore, methods for measuring the insulin receptor α-subunit was provided, the method comprising the steps of contacting the insulin receptor α-subunit in a blood sample with an antibody recognizing the insulin receptor α-subunit, and detecting the binding between the two. Measurement of the free insulin receptor α-subunit in the blood is useful for evaluating risk factors for diabetes. | 01-20-2011 |
20110014627 | METHOD FOR DETERMINING ANTAGONIST ACTIVITY TO A CYTOKININ RECEPTOR - The present invention provides a method for analyzing agonist-activity to a cytokinin receptor, which comprises (1) bringing an examinee substance into contact with a transformed cell into which DNA coding the cytokinin receptor is introduced and (2) measuring the existence or the quantity of intracellular signal transduction from the cytokinin receptor expressed in the transformed cell, and, a method for analyzing antagonist activity to a cytokinin receptor, which comprises (1) bringing an examinee substance and a substance having agonist-activity to the cytokinin receptor into contact with a transformed cell into which DNA coding the cytokinin receptor is introduced and (2) measuring the existence or the quantity of intracellular signal transduction from the cytokinin receptor expressed in the transformed cell, and the like. | 01-20-2011 |
20110014628 | Identification of Surface-Associated Antigens for Tumor Diagnosis and Therapy - An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene. | 01-20-2011 |
20110020833 | Method for Detecting Analytes - The subject of this invention is a process for detection of analytes from biological samples comprising the following process steps:
| 01-27-2011 |
20110020834 | HIGH SENSITIVITY MECHANICAL RESONANT SENSOR - A system and method for detecting mass based on a frequency differential of a resonating micromachined structure, such as a cantilever beam. A high aspect ratio cantilever beam is coated with an immobilized binding partner that couples to a predetermined cell or molecule. A first resonant frequency is determined for the cantilever having the immobilized binding partner. Upon exposure of the cantilever to a solution that binds with the binding partner, the mass of the cantilever beam increases. A second resonant frequency is determined and the differential resonant frequency provides the basis for detecting the target cell or molecule. The cantilever may be driven externally or by ambient noise. The frequency response of the beam can be determined optically using reflected light and two photodetectors or by interference using a single photodetector. | 01-27-2011 |
20110020835 | Device and Method for Detecting Small Quantities of Light, Comprising an Electronic Image Converter Embodied in Semiconductor Technology - The invention relates to a device for detecting small quantities of light, comprising an electronic image converter embodied in semiconductor technology for detecting the photons representing the small quantities of light and an electronic circuit connected to the electronic image converter for reading the electronic image converter and for generating a signal representing the number of photons received by the electronic image converter, wherein the electronic image converter comprises at least 100,000 light-sensitive cells and the electronic circuit is adapted to add together the signals coming from light-sensitive cells placed on the electronic image converter. | 01-27-2011 |
20110020836 | PROCESS FOR DIFFERENTIAL POLYPEPTIDES DETECTION AND USES THEREOF - Provided herein is an affinity media and the construction and use thereof. The affinity media may be used, for example, for the detection of differential proteins/peptides by depletion of proteins/peptides similar to those in a control sample from a test sample in the search for biologically and pathologically important proteins/peptides. The detected differential proteins/peptides provide vital information for biomarker discovery, drug target discovery, and personalized medicine and treatment. | 01-27-2011 |
20110020837 | Method for isolating or identifying a target protein interacting with a lipid in a cell - The invention is in the field of molecular biology and cell biology. It provides tools and methods for studying the interaction of proteins and lipids in vivo as well as in vitro. The invention relates to a method for isolating or identifying a target protein interacting with a lipid in a cell. This method employs novel dual-labeled lipid precursors such as fatty acids or their derivatives. These lipid precurors comprise two functional groups: a photoactivatable group, such as a diazirine ring, as well as a terminal alkyne or azide moiety. | 01-27-2011 |
20110020838 | MOLECULES FOR THE TREATMENT OF LUNG DISEASE INVOLVING AN IMMUNE REACTION TO CONNECTIVE TISSUE FOUND IN THE LUNG - Various embodiments include methods for diagnosing and treating medical conditions that involve an autoimmune response to connective tissue such as collagen found in organs such as the lung. In one method pulmonary disease and disorders such as Idiopathic Pulmonary Fibrosis (IPF) are diagnosed by analyzing fluid or tissue samples obtained from a patient for evidence of an autoimmune response to various types of collagen including, for example, Type V. One type of assay for evidence of an autoimmune response to Type V collagen comprises the steps of obtaining a fluid or tissue sample from a patient, contacting at least a portion of the sample with antigen to anti-Type V collagen antibody and monitoring the mixture of sample and antigen for changes indicative of the presence of anti-Type V collagen in the sample. Another embodiment includes treating pulmonary diseases such as IPF by administering a therapeutically effective dose of epitopes of various collagens including Type V collagen. | 01-27-2011 |
20110033866 | Resonance Energy Transfer Assay with Cleavage Sequence and Spacer - A molecular construct comprises a donor label, an acceptor label, a linker peptide disposed between the donor and the acceptor, the linker having a cleavage site sequence, and a spacer between at least one of (a) the donor and the cleavage site sequence and (b) the acceptor and the cleavage site sequence. Preferably, the construct is selected from the group consisting of CFP-(SGLRSRA)-SNAP-25-(SNS)-YFP, and CFP-(SGLRSRA)-synaptobrevin-(SNS)-YFP. In preferred embodiments, the linker peptide is a substrate of a botulinum neurotoxin selected from the group consisting of synaptobrevin (VAMP), syntaxin and SNAP-25, or a fragment thereof that can be recognized and cleaved by the botulinum neurotoxin. Advantageously, the spacer increases the electronic coupling between the donor label and the acceptor label relative to a corresponding construct without the spacer. | 02-10-2011 |
20110033867 | Use of biomarkers for detecting ovarian cancer - The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject. | 02-10-2011 |
20110033868 | USE OF A NITRATED PROTEIN OR PEPTIDE SEQUENCE FOR THE IMPLEMENTATION OF A METHOD OF DIAGNOSIS - The present invention relates to the use of quantitative assay, in particular in vitro, in a biological sample, of the degree of nitration of tyrosine residues of a particular nitrated protein or physiological peptide sequence, for the implementation of a method of in vitro diagnosis of the state of severity and progressiveness of a chronic or acute pathology associated with nitrating stress. | 02-10-2011 |
20110033869 | Enzyme Triggered Redox Altering Chemical Elimination (E-Trace) Immunoassay - The present invention is directed to electronic methods of detecting target analytes such that upon binding of the target analyte a shift in electrochemical potential is seen. This assay relies on the use of an electroactive moiety (“EAM”) that is attached to an electrode and comprises a self-immolative moiety, whose presence gives the EAM a first E0, and whose absence, upon irreversible cleavage gives the EAM a second E0. This difference is detected, and if such change occurs, it is an indication of the presence of a target analyte. | 02-10-2011 |
20110033870 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 02-10-2011 |
20110033871 | METHOD FOR THE DETERMINATION OF TRICHINELLA INFECTIONS AND DIAGNOSTIC COMPOSITION FOR SUCH METHODS - Method for the determination of | 02-10-2011 |
20110033872 | METHOD AND APPARATUS FOR DETECTING UNDESIRED MEASUREMENT CONDITIONS - The invention relates to a method and apparatus for detecting undesired measurement conditions in a sample container. The method comprises measuring a fluorescent property of the sample container comprising a sample substrate with impregnated blood sample and incubation buffer to which the blood sample is to be eluted, and determining, based on temporal and/or spectral characteristics of the fluorescent property, whether the fluorescent property is characteristic to a sample container comprising a sample substrate and incubation buffer under said undesired measurement conditions or to a sample container suitable for optical measurement of analyte contained in the sample. Thus undesired measurement condition can be a floating sample substrate or a foreign body in the sample container. By means of the invention, reliability of neonatal screening, for example, can be increased. | 02-10-2011 |
20110039276 | IDENTIFYING ORGAN DAMAGE - The present invention provides methods for identifying whether or not a patient has, or is at risk of developing drug induced organ damage and methods of treating patients having drug induced organ damage. In particular, the invention relates to a method for identifying whether or not a patent has, or is at risk of developing paracetamol induced liver damage. | 02-17-2011 |
20110039277 | Methods of Labeling Proteins - Methods are provided for labeling specific oxidized proteins. Methods also are provided for determining the oxidation state of a cell. Such methods are useful as diagnostic, therapeutic and screening agents. | 02-17-2011 |
20110045490 | BIOMARKER FOR THE PREDICTION OF RESPONSIVENESS TO AN ANTI-TUMOUR NECROSIS FACTOR ALPHA (TNF) TREATMENT - The invention refers to a method for diagnosing an individual who is to be subjected to or is being subjected to an anti-tumour necrosis factor alpha (TNFα or TNF) treatment to assess the responsiveness to an anti-TNF treatment which comprises the detection of immunoglobulin(s) against one or more biomarker proteins in a bodily fluid or an excrement of said patient, and sorting the individual into one of two categories based on detection of said immunoglobulin(s), wherein individuals are classified as NON-responder or responder. The invention refers to diagnostic kits comprising said one or more biomarker proteins and the use of these kits for assessing the responsiveness to an anti-TNF treatment of an individual who is to be subjected to or is being subjected to an anti-TNFα treatment. | 02-24-2011 |
20110045491 | CYCLIC NUCLEOTIDE-SPECIFIC PHOSPHODIESTERASES FROM LEISHMANIA AND USES THEREOF - The present invention, relates to novel amino acid and nucleic acid sequences of cyclic nucleotide-specific phosphodiesterases from the parasite | 02-24-2011 |
20110045492 | MICROFLUIDIC SYSTEM AND A METHOD OF PERFORMING A TEST - The invention relates to a microfluidic system comprising a microfluidic device having a first and a second opposite surfaces and an optical detector, the microfluidic device comprises a flow channel with a detection channel section having a length of at least about 1 mm, the microfluidic device comprises at least one aperture section comprising at least a part of said detection channel section and a transparent window into said detection channel section, the optical detector is arranged to be in optical communication with said aperture section to determining at least one optical property of said aperture section as a function of time. The flow channel may have capillary dimensions and/or it may wholly or fully be arranged to drive a fluid flow by applying external forces. | 02-24-2011 |
20110045493 | Hydrophilic, High Protein Binding, Low Fluorescence, Western Blotting Membrane - Hydrophilic membrane particularly suited for blotting applications, preferably Western blotting. A pre-wet hydrophobic membrane substrate, preferably made of PVDF, is contacted with a monomer solution and subjected to a UV-initiated free radical polymerization step to render the substrate permanently hydrophilic. The resulting membrane exhibits low background fluorescence, high protein binding, excellent retention of protein sample spot morphology, and extended dynamic range (high signal-to-noise ratio, enhanced sample detectability). The membrane demonstrates comparable or higher performance in Western blotting applications than conventional nitrocellulose Western blotting membranes, particularly for protein detection at low sample concentrations, and is directly water-wettable, eliminating the need for an alcohol pre-wet step prior to use. | 02-24-2011 |
20110053171 | METHOD AND APPARATUS FOR ANTIGEN RETRIEVAL PROCESS - The invention provides a method for antigen retrieval of a formaldehyde-fixed tissue sample comprising incubating a formaldehyde-fixed tissue sample in a first antigen retrieval solution at a temperature of greater than 90° C., transferring the tissue sample to a second antigen retrieval solution, and incubating the tissue sample in the second antigen retrieval solution at a temperature of greater than 90° C. The invention also provides a kit and sample delivery device for carrying out the method. | 03-03-2011 |
20110053172 | ONE STEP NANOSENSOR FOR SINGLE AND MULTIDRUG RESISTANCE IN ACUTE CORONARY SYNDROME (ACS) - An embodiment relates to a method of detecting a drug resistance in a patient comprising adding nanoparticles to sample platelets to form activated platelets containing the nanoparticles and comparing a difference in activation of the activated platelets and the sample platelets. Another embodiment relates to a method of monitoring a thrombotic risk factor in a subject in a general population comprising adding nanoparticles to sample platelets to form activated platelets containing the nanoparticles and comparing a difference in activation of the activated platelets and the sample platelets. Yet another embodiment relates to a kit comprising nanoparticles, a fluorescence dye tagged antibody and optionally a buffer, wherein the kit is configured to detect a drug resistance in a patient or a likelihood of the thrombotic risk factor in a subject in general population. | 03-03-2011 |
20110053173 | Game with detection capability - Methods and systems are described herein relating to game systems. In one aspect, a game system includes: at least one game component configured for use in a game system by an individual player; at least one sensor system operably connected to the at least one game component and configured to detect one or more analyte, the at least one sensor system including a signal transmitter; at least one signal detector configured to detect a signal transmitted from the at least one sensor system; and at least one principal game unit operably connected to the at least one signal detector, the at least one principal game unit including at least one signal transmitter configured to transmit a signal responsive to the at least one signal detector. | 03-03-2011 |
20110053174 | Magnetic-nanoparticle conjugates and methods of use - The present invention provides novel compositions of binding moiety-nanoparticle conjugates, aggregates of these conjugates, and novel methods of using these conjugates, and aggregates. The nanoparticles in these conjugates can be magnetic metal oxides, either monodisperse or polydisperse. Binding moieties can be, e.g., oligonucleotides, polypeptides, or polysaccharides. Oligonucleotide sequences are linked to either non-polymer surface functionalized metal oxides or with functionalized polymers associated with the metal oxides. The novel compositions can be used in assays for detecting target molecules, such as nucleic acids and proteins, in vitro or as magnetic resonance (MR) contrast agents to detect target molecules in living organisms. | 03-03-2011 |
20110053175 | Asymmetrically branched polymer conjugates and microarray assays - A composition comprising a conjugate of a randomly and asymmetrically branched dendritic polymer. | 03-03-2011 |
20110053176 | PARTICLE SUSPENSION AND REAGENT KIT FOR USE IN IMMUNOASSAY - A particle suspension for use in immunoassay, comprising: particles for use in immunoassay; and a silicone antifoam agent, is disclosed. And a reagent kit for use in immunoassay, comprising: a reagent containing particles and a silicone antifoam agent; another reagent containing an antigen or antibody capable of binding to a target substance and particles; and a further reagent containing a labeled antigen or antibody capable of binding to the target substance, is disclosed. | 03-03-2011 |
20110053177 | MASS SPECTROMETRIC METHODS AND PRODUCTS - The invention involves assays, diagnostics, kits, and assay components for mass spectrometry and other methods to determine levels of glycated CD59 in subjects. | 03-03-2011 |
20110059463 | Serine and Threonine Phosphorylation Sites - The invention discloses 726 novel phosphorylation sites identified in carcinoma and leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies that specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 03-10-2011 |
20110059464 | Biomarker Panel For Prediction Of Recurrent Colorectal Cancer - The present invention provides a biomarker panel predictive of whether colorectal cancer is likely to recur or metastasize in an afflicted patient. By identifying the likelihood of recurrence, a treatment provider may determine in advance those patients who would benefit from certain types of treatment. The present invention further provide methods of identifying gene and protein expression profiles associated with the likelihood of recurrence/metastasis of colorectal cancer in a patient sample. | 03-10-2011 |
20110065121 | METHOD FOR THE DETECTION OF APOPTOSIS - Methods for the detection of apoptosis by measuring apoptotic bodies shed by apoptotic cells are provided, as are kits to carry out such methods. | 03-17-2011 |
20110065122 | METHOD FOR ACCESSING MICROBIAL DIVERSITY - A method of interfering with quorum sensing regulation of genes to promote cell growth is disclosed. The method of is aimed at accessing microbial biodiversity. The method involves obtaining an environmental sample comprising at least one novel (uncultivated in the laboratory) microorganism, contacting the environmental sample with an effective amount of an agent or combination of agents which interferes with the quorum sensing regulation of genes, growing the treated sample in a culture medium containing the quorum sensing signal disrupting agent or agents, and analyzing the colonies of microorganisms grown to demonstrate genetic novelty. | 03-17-2011 |
20110065123 | Methods for diagnosis of Clostridium difficile and methods and vectors for recombinant toxin expression - Cell-based methods for rapid real time assay of a presence of | 03-17-2011 |
20110070592 | DETECTION OF ANTIBODY THAT BINDS TO WATER SOLUBLE POLYMER-MODIFIED POLYPEPTIDES - The present invention provides analytical methods for detecting anti-polymer antibody in an individual. The methods involve contacting a sample from the individual with a water soluble polymer-modified carrier and detecting binding of antibody to the water soluble polymer on the water soluble polymer-modified carrier wherein binding is indicative of the presence of antibody to the water polymer-modified polypeptide. Antibody may be detected to water soluble polymers such as polyethylene glycol, polysialic acid, dextran, hydroxyalkyl starch, or hydroxyethyl starch. When antibody to the water soluble polymer polyethylene glycol is to be detected, the carrier is modified with a non-linear polyethylene glycol derivative. | 03-24-2011 |
20110070593 | Conjugates of biological substances - Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and 3′-position, their bioconjugates and their uses are described. 1,3′-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1′-crosslinked or non-crosslinked dyes. The invention includes derivative compounds having one or more benzo nitrogens. | 03-24-2011 |
20110076691 | TWO STEP LATERAL FLOW ASSAY METHODS AND DEVICES - A two step lateral flow assay method for identifying IgE antibodies in a sample comprises applying a sample to a sample port of a device, wherein the device is adapted to deliver the sample to a lateral flow matrix having a plurality of IgE antigen species immobilized at respective positions at a first location; allowing the sample to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species to a second location downstream of the first location; and, after a predetermined period of time, applying liquid buffer to the lateral flow matrix to mobilize labeled reagent which is adapted to bind anti-IgE antibody and which is dried on the lateral flow matrix at a location upstream of the sample port delivery of the sample to the lateral flow matrix, and allowing labeled reagent mobilized by the liquid buffer to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species and bind with any IgE antibody bound to the immobilized IgE antigen species, and to travel to a second location downstream of the first location where the mobilized labeled reagent causes a visible change to occur at the second location. | 03-31-2011 |
20110081656 | Secreted proteins and uses thereof - The invention provides isolated nucleic acid molecules, designated TANGO 228 nucleic acid molecules, which encode secreted proteins with homology to the rat MCA-32 protein, isolated nucleic acid molecules, designated TANGO 240 nucleic acid molecules, which encode secreted proteins with homology to the | 04-07-2011 |
20110081657 | CONTROLLED PLATELET ACTIVATION TO MONITOR THERAPY OF ADP ANTAGONISTS - A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIIb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi. | 04-07-2011 |
20110086362 | High-Throughput Method for Quantifying Sialylation of Glycoproteins - Provided herein methods and kits for detecting and/or quantifying sialic acid content of glycosylated molecules that does not require purification of the glycosylated molecule of interest or purification of the labeled product. The methods and kits provided herein are fast and suitable for high-throughput use. | 04-14-2011 |
20110086363 | Method and apparatus to conduct kinetic analysis of platelet function in whole blood samples - Adhesion of platelets to blood vessel walls is the first step that promotes arrest of bleeding by interaction of the platelet receptors with various extracellular matrix proteins that become exposed on vascular injury. A flow chamber is provided for use in analyzing or studying platelet function, in whole blood, either as part of a batch process or in real time. In the flow chambers, an inert polydimethylsiloxane (PDMS) surface is plasma-activated and a homobifunctional cross-linker is used to immobilize platelet-binding proteins onto a chamber wall surface. Immobilized collagen and fibrinogen may thus be assayed by continuously monitoring the adhesion of ADP and Ca | 04-14-2011 |
20110086364 | DETECTION OF CANNABIS USE - A binding partner, especially an antibody fragment that specifically recognizes an antigen-antibody immune complex between anti-THC and THC (tetrahydrocannabinol), is disclosed. The binding partner facilitates a non-competitive homogenous immunoassay for detection of | 04-14-2011 |
20110091901 | Vectors and Methods for Screening Cells for High Expression of Protein of Interest (POI) - This invention refers to industrial production of proteins. More particularly, the invention refers to a fusion protein as a novel chimeric selection marker comprising a peptide conferring resistance to an antibiotic, or a fragment, allelic variant, splice variant or mutein thereof, and at least one sequence comprising SEQ ID NO: 1, 2 or 3, preferably for producing a protein of interest (POI). The inventive chimeric selection marker exhibits: (i) a resistance to an antibiotic; and (ii) a fluorescence activity upon binding of a ligand to the sequence comprising SEQ ID NO: 1, 2 or 3. The invention further refers to nucleic acids encoding the inventive fusion protein and to expression vectors, comprising the inventive fusion protein and additionally the protein of interest (POI). Finally, uses of the inventive chimeric selection marker for screening cells for high expression of a protein of interest (POI) are disclosed. | 04-21-2011 |
20110091902 | METHOD OF ASSAYING PHYSIOLOGICALLY ACTIVE SUBSTANCE OF BIOLOGICAL ORIGIN, KIT FOR ASSAYING PHYSIOLOGICALLY ACTIVE SUBSTANCE OF BIOLOGICAL ORIGIN AND APPARATUS FOR ASSAYING PHYSIOLOGICALLY ACTIVE SUBSTANCE OF BIOLOGICAL ORIGIN - Provided is a technique whereby a physiologically active substance of biological origin such as an endotoxin or β-D-glucan can be more conveniently and accurately detected and the concentration thereof can be determined even in the case of using a sample which contains a substance affecting LAL activity. For example, a sample is brought into contact with a substance ( | 04-21-2011 |
20110097732 | NOVEL BIOMARKER FOR THE PROGNOSIS OF BREAST CANCER - The present invention relates to methods of determining the predilection for survival for an individual having breast cancer comprising: obtaining a breast tissue sample from said individual, measuring the amount of Wrap53 in the nucleus of cells in said breast tissue sample, and/or measuring the amount of Wrap53 in the cytoplasm of cells in said breast tissue sample, and wherein both the nuclear levels, the cytoplasmic levels and/or the ratio between the nuclear and cytoplasmic levels of Wrap53 may be used alone or in combination in breast cancer prognosis. The invention furthermore relates to antibodies and kits relating to Wrap53. | 04-28-2011 |
20110097733 | PROCESS FOR THE PRODUCTION OF A HYBRIDOMA AND ANTIBODY OBTAINED THEREFROM, ABLE TO RECOGNIZE MORE THAN ONE VITAMIN D METABOLITE - The invention concerns a process for the production of a hybridoma, and of a monoclonal antibody or fragments thereof able to recognize 25-hydroxyvitamin D | 04-28-2011 |
20110097734 | Flow Control Technique for Assay Devices - A method for controlling fluid flow in an assay device that employs a membrane is provided. Specifically, one or more recessed regions are formed in the membrane by applying a solvent treatment thereto. The solvent treatment is selected based on its particular dissolving capacity for the material used to form the membrane. For example, an alcohol-based solvent, such as methanol, may be used as a solvent for nitrocellulose membranes. Upon contact with the solvent treatment, a recessed region is formed that may serve a variety of different functions relating to flow control. In one particular embodiment, the recessed region may function as a metering channel that is capable of delivering a controlled volume of the test sample to a detection zone upon initiation of the assay. | 04-28-2011 |
20110104705 | Musclin receptor and use thereof - The present invention provides a receptor of musclin and a screening system for an agonist and/or antagonist of the receptor by means of the interaction of musclin and the receptor. Hence, provided is a screening method for a substance that alters the bindability (i) a protein containing the same or substantially the same amino acid sequence as the amino acid sequence shown by SEQ ID NO:2 or a partial peptide thereof or a salt thereof and (ii) musclin or a partial peptide thereof or a salt thereof, containing using both. | 05-05-2011 |
20110104706 | NOVEL KINASES AND USES THEREOF - Novel kinase polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase proteins, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided. | 05-05-2011 |
20110104707 | Methods and products for diagnosing autoimmune disease and gastric cancer linked with atrophic gastritis - The present invention relates to a method for examining a person having symptoms and/or biomarker indicating an autoimmune disease for the presence of atrophic gastritis. The biomarker combination, which diagnoses atrophic gastritis, acts also as a part of a biomarker panel that helps diagnosis and assessment of autoimmune disease as well. The invention relates also to products used in these methods. | 05-05-2011 |
20110104708 | Method for Sensing a Chemical - The present invention relates to a method for detecting an analyte ( | 05-05-2011 |
20110104709 | POROUS SOLID PHASE FOR BINDING ASSAY, AND BINDING ASSAY METHOD USING THE SAME - A porous solid phase for binding assay that enables a test sample such as whole blood to be analyzed promptly, conveniently, accurately, and inexpensively without requiring a pretreatment, and a binding assay method using said porous solid phase are disclosed. At least one surfactant is incorporated into the porous solid phase for binding assay prior to addition of a test sample, the at least one surfactant being selected from the group consisting of (A) a sugar-containing surfactant that comprises a compound shown by a general formula (I), (B) a sugar-containing surfactant that comprises a sucrose fatty acid ester wherein the constituent fatty acid has 5 to 14 carbon atoms, and (C) a steroid surfactant. | 05-05-2011 |
20110104710 | CONSTRUCTION OF EXPRESSION SYSTEM FOR RNA POLYMERASE DERIVED FROM INFLUENZA VIRUS, CRYSTALLIZATION OF THE RNA POLYMERASE, AND SCREENING METHOD FOR ANTI-INFLUENZA AGENT - The present invention aims to express influenza virus RNA polymerase on a large scale, to crystallize the influenza virus RNA polymerase, and to provide a method for screening a substance capable of serving as an active ingredient in anti-influenza drugs which target a protein highly conserved among influenza virus species. | 05-05-2011 |
20110111422 | SENSOR PROTEINS AND ASSAY METHODS - The present invention relates to biosensors. In some embodiments, the biosensors are modified ligand binding molecules. In some embodiments, the modified ligand binding molecule is a phosphate binding protein (PBP). In some embodiments, the modified ligand binding molecules are labeled to be capable of RET, e.g., comprising a donor and acceptor moiety. In some embodiments of the invention, there is a detectable change in RET (e.g., FRET) when the modified ligand binding molecule binds and/or releases the ligand (e.g., phosphate). The invention also provides related methods, reactions and assays. | 05-12-2011 |
20110111423 | Demethylated and / or oxidized membrane DNA - A process for the preparation of oxidized and/or demethylated antigens comprising the steps of
| 05-12-2011 |
20110111424 | ANALYSIS OF UBIQUITINATED POLYPEPTIDES - The invention relates to antibody reagents that specifically bind to peptides carrying a ubiquitin remnant from a digested or chemically treated biological sample. The reagents allow the technician to identify ubiquitinated polypeptides as well as the sites of ubiquitination on them. The reagents are preferably employed in proteomic analysis using mass spectrometry. The antibody reagents specifically bind to the remnant of ubiquitin (i.e., a diglycine modified epsilon amine of lysine) left on a peptide which as been generated by digesting or chemically treating ubiquitinated proteins. The inventive antibody reagents' affinity to the ubiquitin remnant does not depend on the remaining amino acid sequences flanking the modified (i.e., ubiquitinated) lysine, i.e., they are context independent. | 05-12-2011 |
20110111425 | ENHANCED IMMUNOASSAY SENSOR - Disclosed herein are devices for detecting the presence of a target analyte in a fluid sample. The biosensor device can comprise at least a reaction chamber and a detection chamber. The device can comprise a amplifying mechanism such that one target analyte molecule present in the fluid sample can lead to generation/activation of multiple detection agent molecules, and therefore, an amplified signal. Also disclosed are the methods of manufacturing and using such a biosensor device. | 05-12-2011 |
20110117571 | Transporter assay - This invention concerns a non-radioactive homogenous proximity assay for cellular transport system. The assay format disclosed here takes advantageous of the fact that ABC transporters have two similar ATP binding sites, and thus allowing two ATP molecules to bind simultaneously to these adjacent sites. | 05-19-2011 |
20110117572 | Antibody Specific to the AIMP2-DX2 - The present invention relates to a variant of AIMP2 lacking exon 2 gene, named as AIMP2-DX2 gene, which is specifically expressed in cancer cells. The AIMP2-DX2 gene and siRNA targeting AIMP2-DX2 can be successfully used in the development of diagnosis and treatment of cancer | 05-19-2011 |
20110124006 | METHOD FOR SCREENING OF THERAPEUTIC AGENT FOR CANCER - A screening method for a therapeutic agent for cancer, the method including: a step of measuring an interaction between NLRR1 and EGFR under each condition of being in the presence of a test substance and in the absence of a test substance; and a step of determining that the test substance is a therapeutic agent for cancer when the interaction between NLRR1 and EGFR in the presence of the test substance is weaker than the interaction between NLRR1 and EGFR in the absence of the test substance. | 05-26-2011 |
20110124007 | UTILITY OF HIGH MOLECULAR WEIGHT MELANOMA ASSOCIATED ANTIGEN IN DIAGNOSIS AND TREATMENT OF CANCER - HMW-MAA antibody cocktails and their uses in detecting cancer and isolating cancer cells are disclosed. Also disclosed are methods of detecting cancer based on the presence of an HMW-MAA genomic sequence in circulating DNA, as well as the increased expression of the HMW-MAA gene and the reduced methylation of the HMW-MAA gene promoter in tissues and circulating cells. | 05-26-2011 |
20110124008 | NOVEL Au/Ag CORE-SHELL COMPOSITE USEFUL FOR BIOSENSOR - In accordance with an aspect of the present invention, there is provided an Au/Ag core-shell composite including an Au nanoparticle; an Ag nanoparticle layer surrounding the Au nanoparticle; and a receptor having a target material recognition site bondable or reactable with a target material, wherein one end of the receptor is bonded on the surface of the Au nanoparticle, so that a portion of the receptor is embedded into the Ag nanoparticle layer, and the target material recognition site is exposed to the outside of the Ag nanoparticle layer. The Au/Ag core-shell composite can provide a stable bond between Au nanoparticle and organic molecule, and superior optical characteristics of Ag nanoparticle. Thus, a biosensor using the composite in accordance with an aspect of the present invention can effectively and efficiently detect target bio material and be variously used in medical and pharmaceutics. | 05-26-2011 |
20110129846 | PHOTONIC BIOSENSOR, PHOTONIC BIOSENSOR ARRAY, AND METHOD OF DETECTING BIOMATERIALS USING THE SAME - A photonic biosensor, a photonic biosensor array, and a method of detecting a bio-material using the same are provided. The photonic biosensor includes a light emitting diode configured to emit light, a photodiode (PD), an optical fiber configured to connect the light emitting diode with the PD, and a micro-fluidic channel disposed on the optical fiber. Bio-antibodies or aptamers are fixed to the surface of the optical fiber, and the micro-fluidic channel includes gold (Au) nanoparticles to which bio-antibodies or aptamers are fixed. The photonic biosensor may be configured using absorption of surface plasmons in Au nanoparticles with respect to light traveling through the surface of the optical fiber configured to connect the light emitting diode with the PD, thus simplifying the manufacture of the biosensor and reducing the manufacturing cost. | 06-02-2011 |
20110129847 | MICROFLUIDIC CONTROL CHIP AND METHOD OF DETECTING PROTEIN USING THE SAME - Provided is a microfluidic control chip, which includes a filter section having a filter to which anti-immunoglobulin antibodies, which are bound to endogenous antibodies in blood to thereby remove the endogenous antibodies, are immobilized, a first reaction section to which detection antibodies immobilized to fluorescent nano-particles are adsorbed, the detection antibodies being bound to proteins to be detected in blood which is introduced from the filter section with the endogenous antibodies removed therefrom, and a second reaction and detection section including capture antibodies immobilized thereto, binding the capture antibodies to the proteins, which are bound to the detection antibodies introduced from the first reaction section, and detecting a concentration of the proteins based on an intensity of fluorescent light. Thus, the microfluidic control chip can minimize interference of an immune response to maximize the immune response. | 06-02-2011 |
20110129848 | Antibody Recognizing G Protein, and Agent and Kit Using the Same - A novel protein (Gm1) includes an amino acid sequence part having a high homology with a domain having a high homology with a GTP binding site and a GTPase site conserved among G protein α subunits and a trimer forming domain conserved among G protein α subunits. The Gm1 protein is involved in signal transduction via a G protein-coupled receptor (GPCR) stimulation. The Gm1 protein is expressed intensively in human brain, thymus, testes, spleen, small intestine, uterus and heart. A method for screening for a substance capable of regulating a cellular signal transduction employs a polynucleotide encoding the Gm1 protein | 06-02-2011 |
20110129849 | DETECTION OF PROSTATE CANCER USING PSA GLYCOSYLATION PATTERNS - The present invention features novel methods for determining if a subject has prostate cancer. The present invention is based on the development of lectin immunosorbant assays which analyze α2,6-linked sialylation of total serum PSA by | 06-02-2011 |
20110136131 | Method for measuring enzyme activity and column for use in measuring enzyme activity - A method of measuring an enzyme activity, which comprises the steps of:
| 06-09-2011 |
20110136132 | IMMUNODETECTION PROBE AND METHOD OF IMMUNODETECTION USING THE SAME - An immunodetection probe comprises a needle structure having a compartment and configured to be inserted into an organic tissue, a dialysis membrane configured to isolate the compartment from the organic tissue, a detection device having a detection portion and a plurality of receptors, a first optical fiber coupled to the needle structure, and a pair of tubes connected to the compartment. The plurality of receptors are disposed on an end surface of the detection portion for conjugating a target antibody, wherein the detection portion is disposed in the compartment. The first optical fiber is configured to introduce light incident on photo-induced molecules adjacent to the end surface of the detection portion so as to cause a change in the pH level of the solution adjacent to the end surface of the detection portion. The pair of tubes is configured to transport the solution containing the photo-induced molecules into the compartment. | 06-09-2011 |
20110136133 | METHOD FOR DIFFERENTIATING BETWEEN MULTIPLE SCLEROSIS SUBTYPES - Disclosed herein is a method for differentiating between multiple sclerosis subtypes in a patient. The method comprises a) determining an amount of an IAP gene expression level in a blood sample obtained from the patient; and b) correlating the amount of the IAP gene expression level in the blood sample with the presence of a multiple sclerosis subtype in the patient. | 06-09-2011 |
20110136134 | Method for Assessing the Damage of Keratin Fibers - Method for assessing damages of keratin fibers using a cationic fluorescent compound comprising a cationic ammonium group and being free of carboxyl and/or sulfonyl groups and method for comparing the damages of different keratin fibers using said cationic fluorescent compound. Said methods are useful for quantitatively and/or qualitatively assessing the degree of damages of keratin fibers and also to compare the damages of fibers of different origin, different portions of fibers and/or fibers treated with different cosmetic, chemical and/or mechanical treatments. Said methods are also useful for supporting advertising claims about the superiority of a composition and/or a treatment versus others. | 06-09-2011 |
20110136135 | APPARATUS AND METHOD FOR PROCESSING BIOLOGICAL SAMPLES - A method and an automated apparatus for processing at least one biological sample arranged on a slide. At least one capillary staining module has a slide rack holder configured to detachably hold a slide rack configured to hold slides, and a capillary lid rack holder configured to detachably hold a capillary lid rack configured to hold capillary lids, wherein the slide rack can be removed independently of removing the capillary lid rack. A first fluid container has a first fluid. The apparatus being configured to automatically rotate the one or more slides, and to move the lids towards the slides to automatically form a capillary gap between each slide and each capillary lid, said capillary gap functioning as a capillary chamber; and to supply an amount of the first fluid to the slide. | 06-09-2011 |
20110136136 | Methods For Detection Of Hydrophobic Drugs - Methods and reagents are disclosed for pretreating a sample suspected of containing a hydrophobic drug for conducting an assay method for detecting the hydrophobic drug. A combination is provided in a medium. The combination comprises (i) the sample, (ii) a releasing agent for releasing the hydrophobic drug and the metabolites from endogenous binding moieties, and (iii) a selective solubility agent that provides for substantially equal solubility of the hydrophobic drug and the metabolites in the medium. The selective solubility agent comprises a water miscible, non-volatile organic solvent and is present in the medium in a concentration sufficient to provide for substantially equal solubility of the hydrophobic drug and the metabolites in the medium. The medium, which may further comprise a hemolytic agent, is incubated under conditions for releasing the hydrophobic drug and the metabolites from endogenous binding moieties. For conducting an assay for the hydrophobic drug, the above pretreatment is performed and to the medium is added reagents for determining the presence and/or amount of the hydrophobic drug in the sample wherein the reagents comprise at least one antibody for the hydrophobic drug. The medium is examined for the presence of a complex comprising the hydrophobic drug and the antibody for the hydrophobic drug, the presence and/or amount of the complex indicating the presence and/or amount of the hydrophobic drug in the sample. | 06-09-2011 |
20110143363 | DETERMINATION OF FREE FRACTIONS - The invention relates to methods for the determination of pharmacological properties of substances, such as, e.g., chemical substances. The invention also relates to methods and kits for use in the determination of the free fraction, fu, of pharmacologically active compounds in aqueous solutions and serum. The invention also relates to the above methods in which solid particles, coated with a lipophilic medium, are used. | 06-16-2011 |
20110143364 | CENTRIFUGAL MICRO-FLUIDIC STRUCTURE FOR MEASURING GLYCATED HEMOGLOBIN, CENTRIFUGAL MICRO-FLUIDIC DEVICE FOR MEASURING GLYCATED HEMOGLOBIN, AND METHOD FOR MEASURING GLYCATED HEMOGLOBIN - Disclosed are a centrifugal micro-fluidic structure for measuring glycated hemoglobin, a centrifugal micro-fluidic device for measuring glycated hemoglobin, and a method for measuring glycated hemoglobin. According to the disclosure, immunosorbent assay and affinity measurements are simultaneously conducted using only a single device in order to detect hemoglobin variants or interfering substances and, therefore, the detected results are applied to analysis of measurement results so as to eliminate and/or compensate for, or calibrate errors in measurement of, glycated hemoglobin, thereby more accurately measuring the glycated hemoglobin. | 06-16-2011 |
20110143365 | METHODS AND DEVICES TO ENHANCE SENSITIVITY AND EVALUATE SAMPLE ADEQUACY AND REAGENT REACTIVITY IN RAPID LATERAL FLOW IMMUNOASSAYS - Methods and devices for rapid lateral flow immunoassays to detect specific antibodies within a liquid sample while also validating the adequacy of the liquid sample for the presence of immunoglobulin and the integrity and immunoreactivity of the test reagents that detect the antibodies of interest, without requiring instrumentation. The methods and devices provide for delivery of a diluted liquid sample to a single location that simultaneously directs the liquid flow along two or more separate flow paths, one that serves as a positive control to confirm that all critical reagents of the test are immunoreactive, and that the sample being tested is adequate, and the other to detect specific antibodies if present. | 06-16-2011 |
20110143366 | PROTEIN BIOMARKERS FOR IN VITRO TESTING OF DEVELOPMENTAL TOXICITY AND ENBRYOTOXICITY OF CHEMICAL SUBSTANCES - Presently, the toxicological assessment of chemicals is mainly performed in vivo using a variety of animal species and in addition taking into account human clinical, biochemical, pathological and morphological data. Over the past years it became increasingly clear that some substances are particularly harmful for children and thus there is a focus on the special vulnerability of the developing human brain. Meanwhile there is a recommendation to test substances with a known neurotoxic or teratogenic (in particular a neuroteratogenic) risk additionally for embryotoxicity. Moreover the US Environmental Protection Agency (EPA) requires embryotoxicity tests for pesticides. Further tests are required if substances shall be used as medicaments (S7A Safety Pharmacology Studies for Human Pharmaceuticals, Guidelines of the International Conference on Harmonization, ICH, 2001). | 06-16-2011 |
20110151475 | LAB-ON-A-CHIP AND METHOD OF DRIVING THE SAME - Provided are a lab-on-a-chip and a method of driving the same. The lab-on-a-chip includes a first region where a lower substrate and an upper substrate are bonded to each other, a second region where the lower and upper substrates are not bonded to each other, a gap control member disposed at a terminal of the second region facing an interface between the first and second regions, and configured to control a gap between the lower and upper substrates at the terminal of the second region, and a pressure application member disposed at the terminal of the second region facing the interface between the first and second regions, and configured to apply pressure to the upper substrate at the terminal of the second region to reduce a gap between the lower and upper substrates in the center of the second region. Thus, binding events between a fluid sample to be analyzed and a reagent can be maximized so that a high signal can be obtained using only an infinitesimal quantity of sample. | 06-23-2011 |
20110151476 | METHOD OF DETECTION AND/OR TITRATION IN VITRO OF AN UNCONVENTIONAL TRANSMISSIBLE AGENT - The invention relates to an in vitro method for the in vitro detection and/or titration of a non-conventional transmissible agent (NCTA) or of a protein of pathological conformation, which is a marker for infectiousness related to the NCTA, in a sample, comprising: replication or propagation, in cells in culture, of the NCTA present in the sample, and then repeated incubation with a substrate which allows amplification of the NCTA or of the protein of pathological conformation, nonpathological conformer of the NCTA, before determination of the presence and/or of the amount of the NCTA or of the protein of pathological conformation in the sample. | 06-23-2011 |
20110151477 | METHODS FOR DETECTING ANTIBODIES IN MUCOSAL SAMPLES AND DEVICE FOR SAMPLING MUCOSAL MATERIAL - A method to detect local antibodies such as antigen-specific IgE via a brush biopsy specimen of a mucosal surface of a subject is disclosed. The method is easily performed in an office setting on both adult and pediatric patients. Also disclosed is a brush device specially designed for harvesting materials from a mucosal surface such as the medial surface of the inferior turbinate. | 06-23-2011 |
20110151478 | TRANSCRIPTIONAL BIOMARKERS AND METHODS FOR DETECTING AND ISOLATING CANCER CELLS IN BODY FLUIDS AND TISSUE SPECIMENS - The invention provides molecules that target cancer-specific transcription complexes (CSTC), compositions and kits comprising CSTC-targeting molecules, and methods of using CSTC-targeting molecules for the treatment, detection and monitoring of cancer. | 06-23-2011 |
20110151479 | MICROFLUIDIC SYSTEMS INCORPORATING FLOW-THROUGH MEMBRANES - Disclosed is a flow-through membrane assay that takes advantage of a high surface area and rapid transport while allowing individual control over flow rates and times for each step of a multi-step assay. A microfluidic card features channels in communication with a porous membrane, channels on either side of membrane to allow transverse flow across the membrane, capturing a labeled target from the sample by flowing the sample across the membrane, or capturing a target from the sample followed by flowing a reagent containing a label that binds to the target. Fluid can be pushed or pulled through the assay membrane by external control. Air near the membrane is managed by diverting air between fluids to a channel upstream of the assay membrane, venting air between fluids through a hydrophobic membrane upstream of the assay membrane, and/or by venting trapped air through a hydrophobic membrane downstream of the assay membrane. | 06-23-2011 |
20110159514 | BIOMARKER FOR OSTEOARTHRITIS AND/OR OTHER AGEING-RELATED DISEASES, AND USE THEREOF - The invention relates to the identification of a biomarker whose abundance in biological sample is changed in subjects with osteoarthritis and/or other ageing-related diseases. The biomarker has applications in the diagnosis of osteoarthritis and/or other ageing-related diseases, in determining the prognosis for an individual diagnosed with osteoarthritis and/or other ageing-related diseases, and in monitoring the efficacy of treatment for osteoarthritis and/or other ageing-related diseases. | 06-30-2011 |
20110159515 | COMPOSITIONS AND METHODS FOR THE RAPID GROWTH AND DETECTION OF MICROORGANISMS - The invention relates to assay methods for use in detecting specific materials such as core oligosaccharides derived from microorganisms, particularly pathogenic microorganisms, in a test sample. The invention further relates to compositions and methods for the rapid growth of such microorganisms enabling detection of same significantly earlier than is currently possible. In particular embodiments the invention is directed towards the rapid growth and/or detection of | 06-30-2011 |
20110159516 | PCan065 Antibody Compositions and Methods of Use - The invention provides isolated anti-PCan065 antibodies that bind to PCan065. The invention also encompasses compositions comprising an anti-PCan065 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-PCan065 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-PCan065 antibodies. The invention encompasses a method of producing the anti-PCan065 antibodies. Other aspects of the invention are a method of killing an PCan065-expressing cancer cell, comprising contacting the cancer cell with an anti-PCan065 antibody and a method of alleviating or treating an PCan065-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-PCan065 antibody to the mammal. | 06-30-2011 |
20110159517 | Zinc binding compounds and their method of use - The present invention provides a metal chelator and methods that facilitate binding, detecting, monitoring and quantitating of zinc ions in a sample. The metal chelating moiety of the zinc-binding compound is an analog of the well-known calcium chelator, BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid), wherein the chelating moiety has been modified from a tetraacetic acid moiety to a tri- di- or monoacetic moiety. This change in acetic acid groups on the metal chelating moiety results in the selective bindings of zinc ions in the presence of calcium ions, both of which are present in biological fluids and intracellular cytosolic fluid and organelles. | 06-30-2011 |
20110159518 | METHOD FOR THE DIAGNOSIS OF THE PRESENCE OF AN OVARIAN CANCER - The invention provides an isolated antigen polypeptide that can be expressed in a subject with ovarian cancer. Also provided is the diagnosis of ovarian cancer by using the antigen polypeptide of the invention and the prevention and/or treatment of ovarian cancer by suppressing the gene of the antigen polypeptide of the invention. | 06-30-2011 |
20110165586 | Detection Method of Bio-Chemical Material Using Surface-Enhanced Raman Scattering - Provided is a detection method of a biochemical material using surface-enhanced Raman scattering in order to detect the existence of a biochemical material in a target subject or its content therein, more particularly a detection method of a biochemical material facilitating multiplex detection with high-sensitivity, high-reproducibility, high-reliability, and high-precision owing to multiple hot spots formed on the nanowire surface of a single crystal body by the bond of multiple nanoparticles which are physically separated from each other. | 07-07-2011 |
20110165587 | Method for live-cell activity assay - Provided are technologies capable of direct measurement of activity of a bioactive substance in cell using nanowires, more particularly, a method for measuring intracellular activity of a bioactive substance using a nanowire support to which cells are immobilized and a nanowire support to which target substances for the subject bioactive substance are immobilized, and a chip for measuring intracellular activity of a bioactive substance including nanowires to which cells are immobilized and nanowires to which a target substance for the subject bioactive substance is immobilized. | 07-07-2011 |
20110165588 | METHOD FOR QUANTIFYING PHOSPHOKINASE ACTIVITY ON PROTEINS - The invention involves a method for measuring phosphorylation of proteins at specific sites and, as such, is an indicator of the protein kinase activity of enzymes capable of phosphorylating those sites. The method involves the in vitro or in vivo phosphorylation of a target protein at a specific serine, threonine or tyrosine residue, subjecting that protein (non-phosphorylated) to reaction mixture containing all reagents, including phosphokinase which allow the creation of a phosphorylated form of protein. The phosphorylated protein is measured by contacting it with an antibody specific for the phosphorylation site(s). The invention includes antibodies useful in practicing the methods of the invention. The invention particularly relates to all proteins modified by phosphorylation and dephosphorylation as illustrated by Tau, Rb and EGFR proteins and antibodies specific for the site of phosphorylation of the Tau, Rb or EGFR proteins. | 07-07-2011 |
20110165589 | DEVICE AND METHOD FOR SEPARATING AND ANALYZING BLOOD - The invention provides a device for detecting FABP in a blood sample from a patient, methods for analyzing blood on the presence of FABP, as well as methods and kits for the detection of FABP in a blood sample from a patient. | 07-07-2011 |
20110165590 | Vaccine Protection Assay - The present invention relates to the field of Serum Bactericidal Activity (SBA) assays for Gram negative bacteria, in particular | 07-07-2011 |
20110165591 | USE OF BIGLYCAN IN THE ASSESSMENT OF HEART FAILURE - The invention relates to a method for assessing heart failure in vitro and involves the steps of measuring in a sample the concentration of the marker biglycan, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for biglycan and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of biglycan as a marker protein in the assessment of heart failure, a marker combination comprising biglycan and a kit for measuring biglycan. | 07-07-2011 |
20110165592 | ANTIBODIES AGAINST HUMAN EPO RECEPTOR - An antibody binding to human EPO receptor, characterized in specifically binding EPO receptor fragment LDKWLLPRNPPSEDLPGPGGSVDIV (SEQ ID NO:1), CSSALASKPSPEGASAASFEY (SEQ ID NO:2), or GGLSDGPYSNPYENSLIPAAEP (SEQ ID NO:3) is useful for the analysis of EPO receptor in human tissue. | 07-07-2011 |
20110171661 | METHOD FOR DIAGNOSIS OF POST-OPERATIVE RECURRENCE IN PATIENTS WITH HEPATOCELLULAR CARCINOMA - Provided are a method of diagnosing the recurrence or possibility of recurrence of hepa | 07-14-2011 |
20110171662 | NON-DENATURING LYSIS REAGENT - The invention provides a lysis reagent and method for preparing a test sample for use in an assay, wherein the method yields a homogeneous lysis mixture suitable for use in automated pipetting systems without the need for a centrifugation step. The lysis reagent includes a glycol and an alcohol. Other aspects of the invention include related immunoassays and test kits. | 07-14-2011 |
20110177522 | Methods for Producing Olfactory GPCRs - The subject invention provides a method for producing an olfactory GPCR in a cell. In general, the methods involve introducing an expression cassette containing a promoter operably linked to a nucleic acid encoding an olfactory PCR into a macroglial cell, e.g., a Schwann or oligodendritic cell, and maintaining the cell under conditions suitable for production of the olfactory GPCR. Also provided is a macroglial cell containing a recombinant nucleic acid encoding an olfactory GPCR, methods of screening for modulators of olfactory GPCR activity, and a kit for producing an olfactory GPCR in a macroglial cell. The invention finds most use in research on flavors and fragrances, and, consequently, has a variety of research and industrial applications. | 07-21-2011 |
20110177523 | METHODS OF ANALYZING SAMPLES FOR BACTERIA USING WHOLE CELL CAPTURE AND ATP ANALYSIS - The invention relates to methods of capturing bacterial whole cells that includes the use of one or more antibodies having antigenic specificities for one or more distinct analytes characteristic of the specific bacterium, followed by analyzing the target whole cells using a direct or indirect ATP assay. | 07-21-2011 |
20110177524 | Recombinant Fibrinogen - The present invention relates to nucleotide sequences encoding a fibrinogen alpha, beta or gamma chain. The sequences are optimized for expression in a eukaryotic cell culture system. Such optimized nucleotide sequences allow for the efficient expression of recombinant fibrinogen and variants thereof in intact form in a eukaryotic cell culture system. | 07-21-2011 |
20110183351 | Compositions and methods for therapeutic delivery with microorganisms - Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, devices, and systems that include modified microorganisms including at least one genetic element encoding at least one therapeutic agent or environmental treatment agent. | 07-28-2011 |
20110183352 | Configurable Diagnostic Systems and Methods for Performing Assays - A method and system for configuring an analyzer is disclosed. The analyzer receives a strip identifier from a strip or a vial identifier from a vial. The parameter module in the analyzer determines the parameters corresponding to the received strip identifier or the vial identifier. The parameter module then configures the analyzer to perform a test with the strip using the determined parameters. In one embodiment, the diagnostic test module determines the test corresponding to the received strip identifier or the vial identifier and the diagnostic test module configures the analyzer to perform the determined test with the strip. In another embodiment, the association determination module determines if the received strip identifier and vial identifier are associated with each other. If not, the analyzer renders an error requesting a correct strip. | 07-28-2011 |
20110183353 | COMPOSITION AND METHOD FOR DIAGNOSING FUNGAL DISEASE - Methods of diagnosing a fungal infection using anti-glycan antibodies alone or in combination with other anti-fungal diagnostic tests are described. Laminaribioside and chitobioside are used as antigens to detect human antibodies. | 07-28-2011 |
20110183354 | HUMAN Fc GAMMA RECEPTOR III - The present invention relates to the field of human immunoglobulin receptors, specifically the glycostructure of a human Fc gamma receptor IIIa recombinantly expressed in human embryonic kidney cells and Chinese hamster ovary cells. | 07-28-2011 |
20110183355 | POLYMER PARTICLE CONTAINING FLUORESCENT MOLECULE AND METHOD FOR PRODUCING THE SAME - Polymer particles are provided which contain fluorescent molecules with high presence ratio in a polymer layer thereof and a method for preparing thereof. Polymer particles are swelled in a non-aqueous solution excluding exclusively water preferably promotes selling of the polymer layer and transfer of the fluorescent molecules to the polymer layer could not protected by water molecules such that much more fluorescent molecule may be introduced into inside of the polymer layer. Furthermore, since the water is added to the reaction system prior to evaporation removal of the non-aqueous solvent, dry-up of the polymer particles is prevented by the water remained in the reaction system and the polymer particles including fluorescent molecules with high presence ratio of the fluorescent molecules preferably keep high dispersibility using the above described procedures. | 07-28-2011 |
20110183356 | METHOD TO IDENTIFY PATIENTS AT RISK FOR LUNG TRANSPLANT REJECTION - Various embodiments include methods for diagnosing and treating medical conditions that involve an autoimmune response to connective tissue such as collagen found in organs such as the lung. In one method pulmonary disease and disorders such as Idiopathic Pulmonary Fibrosis (IPF) are diagnosed by analyzing fluid or tissue samples obtained from a patient for evidence of an autoimmune response to various types of collagen including, for example, Type V. One type of assay for evidence of an autoimmune response to Type V collagen comprises the steps of obtaining a fluid or tissue sample from a patient, contacting at least a portion of the sample with antigen to anti-Type V collagen antibody and monitoring the mixture of sample and antigen for changes indicative of the presence of anti-Type V collagen in the sample. Another embodiment includes treating pulmonary diseases such as IPF by administering a therapeutically effective dose of epitopes of various collagens including Type V collagen. | 07-28-2011 |
20110189691 | Gene and protein expression profiles associated with the therapeutic efficacy of EGFR-TK inhibitors - The present invention provides protein and gene expression profiles indicative of whether a patient afflicted with non-small cell lung cancer is likely to be responsive to treatment with a therapeutic compound that is a EGFR-TK inhibitor. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and protein expression profiles, and assays for identifying the presence of a gene or protein expression profile in a patient sample. | 08-04-2011 |
20110189692 | ASSAY FOR PATHOGENIC CONFORMERS - The invention provides methods for detecting the presence of a non-prion pathogenic conformer in a sample by contacting the sample suspected of containing a non-prion pathogenic conformer with a pathogenic conformer-specific binding reagent under conditions that allow the binding of the reagent to the pathogenic conformer, if present; and detecting the presence the pathogenic conformer, if any, in the sample by its binding to the reagent; where the pathogenic conformer-specific binding reagent is typically derived from a prion protein fragment and interacts preferentially with a pathogenic prion protein. Methods for diagnosis of conformational diseases are also provided. | 08-04-2011 |
20110189693 | Methods for Cancer Diagnosis, Anti-Cancer Drug Screening, and Test of Drug Effectiveness on the Basis of Phoshorylation of Ras at Thr-144 and Thr-148 - Methods of diagnosing cancer and screening for an anti-cancer drug using Ras are provided. Ras has a very significant role as a prevalent proto-oncogene which has abnormalities in most forms of cancer, and thus the methods of diagnosing cancer and screening for an anti-cancer drug using Ras may be applied to various forms of cancer. The generation of various forms of cancer in the early stages may be determined by examining whether or not phosphorylation of Ras occurs at Thr-144 and Thr-148 sites, By such a mechanism, an anti-cancer drug having excellent anti-cancer effectiveness may be screened, or the effectiveness of the anti-cancer drug may be tested. | 08-04-2011 |
20110189694 | METHODS FOR DETECTION AND DIAGNOSIS OF A BONE OR CARTILAGE DISORDER - The present invention is directed to methods for the detection and diagnosis of bone and/or cartilage disorders, wherein the level of expression of a polypeptide in a test sample is measured by contacting the test sample with an antibody that specifically binds to said polypeptide and measuring the binding of said antibody to said test sample. | 08-04-2011 |
20110195428 | COMPOSITION, KIT, AND METHOD FOR ASSAYING AGEING AND DISEASE ACCOMPANIED WITH VASCULAR DISORDER - The present invention relates to a method for detecting an ageing or a disease accompanied with a vascular disorder such as age-related macular degeneration, comprising measuring one or more of polypeptides comprising any of amino acid sequences shown in SEQ ID NOS: 1 to 21, mutants thereof, or fragments thereof in a biological sample from a subject, and also to a composition or kit for diagnosing an ageing or a disease accompanied with a vascular disorder such as age-related macular degeneration. | 08-11-2011 |
20110195429 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of soluble p-selectin, protein NOV homolog, soluble epidermal growth factor receptor, netrin-4, haptoglobin, heat shock protein beta-1, alpha-1-antitrypsin, leukocyte elastase, soluble tumor necrosis factor receptor superfamily member 6, soluble tumor necrosis factor ligand superfamily member 6, soluble intercellular adhesion molecule 2, active caspase-3, and soluble platelet endothelial cell adhesion molecule as diagnostic and prognostic biomarkers in renal injuries. | 08-11-2011 |
20110195430 | HIGH PRESSURE ENZYMATIC DIGESTION SYSTEM FOR PROTEIN CHARACTERIZATION - An on-line method and system for obtaining samples for proteomic analysis that utilizes pressure and a preselected agent to obtain a processing sample in a significantly shorter period of time than prior art methods and which maintains the integrity of the processing sample through the preparatory process, and provides enhanced protein capture. In one embodiment of the invention, a sample and an enzyme are combined and subjected to a pressure, preferably a pressure cycle range that varies between 0 to 35 kpsi, for a period of time of preferably less than 60 seconds. This process results in producing a sample suitable for analysis, which is preferably introduced to another analytical instrument such as a mass spectrometry instrument, or other device. | 08-11-2011 |
20110201015 | METHOD FOR MEASURING ENDOTOXIN AND REAGENT KIT FOR MEASURING ENDOTOXIN - A technique which is less likely to be affected by turbid or color of samples and with which prompt and simple detection or concentration measurement of endotoxin can be achieved is provided. A reagent in which proteins contained in LAL are adsorbed or bound onto fine particles dispersed in a previously prepared drug liquid is prepared, and this reagent and a sample containing endotoxin are mixed. By doing this, endotoxin acts on the proteins on the fine particles and the fine particles are associated with one another to form a large aggregate at an early stage. By optically measuring the formation of this aggregate, detection or concentration measurement of endotoxin is performed. | 08-18-2011 |
20110201016 | METHOD FOR DETECTING MODULATOR FOR REGULATING ACTIVITY OF CELLULAR COMPONENT IN CELL - A method for detecting a modulator that can regulate biological and/or physiological activity of a cellular component is provided. The method can detect a modulator, after determining whether there is a competitive reaction between a reference substance and a modulator toward the cellular component in a cell by imaging a magnetic pattern magnetized in a direction of a magnetic line of force and a pattern of a label bound to the cellular component. The method has a benefit that since the reaction of a cellular component with a reference substance and a modulator such as a drug occurs in a cell, the competition reaction between the reference substance and the modulator toward the cellular component can reflect the real metabolism occurred in a live cell. It can also allow the result of interaction between the cellular component and the modulator such as a drug to be visualized and to be identified directly in a live cell. Additionally, the method has advantages to screen many modulators using a few reference substances and to detect the functions of the modulator in a cell, e.g., its efficacy without modifying the modulator by introducing the reference substance. | 08-18-2011 |
20110201017 | LUPUS ANTICOAGULENT TESTING - The present invention relates generally to the field of diagnostic screening and diagnostic assays. In particular, the present invention provides an improved, rapid, and efficient method of screening for antiphospholipid antibodies, such as lupus anticoagulants (LA). The invention also relates to a kit for screening plasma levels for antiphospholipid antibodies in subjects in need thereof, such as those at risk for or suffering from, inter alia, antiphospholipid syndrome (APS) and systemic lupus erythromatosus (SLE). | 08-18-2011 |
20110201018 | METHODS AND COMPOSITIONS FOR RISK STRATIFICATION - The present invention provides an approach for the simultaneous determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of potentiators of cellular activation allows for characterization of such pathways and cell populations. | 08-18-2011 |
20110201019 | Methods and Compositions for Detecting Receptor-Ligand Interactions in Single Cells - The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state. | 08-18-2011 |
20110207145 | METHODS AND COMPOSITIONS FOR DETECTING RECEPTOR-LIGAND INTERACTIONS IN SINGLE CELLS - The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state. | 08-25-2011 |
20110212461 | PREDICTION OF CARDIOTOXICITY - The likelihood that a compound will exhibit cardiotoxicity in an in vitro or in vivo assay predicted by the ability of the compound to inhibit at least one kinase from a selected group. | 09-01-2011 |
20110212462 | ULTRA-SENSITIVE DETECTION OF MOLECULES USING DUAL DETECTION METHODS - Described herein are systems and methods for the detection of and/or determination of a measure of the concentration of analyte molecules or particles in a fluid sample. In some cases, the systems and methods employ techniques to reduce or limit the negative effects associated with non-specific binding events. Certain methods of the present invention involve associating the analyte molecules at least a first type of binding ligand and at least a second type of binding ligand, and spatially segregating the analyte molecules into a plurality of locations on a surface. The presence of an analyte molecule at or in a location may be determined by determining the presence of both the first type of binding ligand and the second type of binding ligand. | 09-01-2011 |
20110212463 | HYBRID TARGET ANALYTE RESPONSIVE POLYMER SENSOR WITH OPTICAL AMPLIFICATION - Disclosed is a product that includes an optical sensor; a target-responsive hydrogel matrix on a surface of the optical sensor (where the hydrogel matrix comprises one or more target-specific receptors and one or more target analogs), and one or more high refractive index nanoparticles within the hydrogel matrix, where a detectable change occurs in a refractive index of the hydrogel matrix when contacted with one or more target molecules. Sterile packages and detection devices containing the product, and methods of detecting a target molecule using the product, are also disclosed. | 09-01-2011 |
20110212464 | PACAP AS A MARKER FOR CANCER - The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the proapoptotic caspase adaptor protein (=PACAP) as a universal marker of different types of cancer. PACAP aids in the assessment of pulmonary or lung cancer (LC), particularly of non-small cell lung carcinoma (NSCLC), but also of other specific types of cancer. Such specific types of cancer are e.g. colon, bladder, cervix, ovary, endometrial, head and neck, breast, melanoma, pancreas, kidney, prostate, esophagus, stomach or bile duct cancer. Furthermore, the present invention especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring PACAP in said sample. Measurement of PACAP can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery. | 09-01-2011 |
20110217718 | Methods and Kits for Distinguishing Between Specific and Non-Specific Protein Associations - The present invention is method of determining whether or not associations between a given protein and other proteins in a cell are specific. The method comprises (a) providing a first sample of the cells in which the given protein contains a tag, (b) providing a second sample of the same cells, wherein the given protein and the other proteins are metabolically labeled, and wherein neither the given protein nor the other proteins are tagged, (c) mixing and lysing the first cell sample and the second cell sample to provide a mixture of proteins, (d) binding the tag of the given protein to a substrate, (e) isolating proteins associated with the tagged given protein bound to the substrate, whereby the associated proteins comprise: (i) proteins specifically associated with the tagged given protein, (ii) proteins non-specifically associated with the tagged given protein, or (iii) a combination thereof, (f) determining whether each associated protein is unlabeled or a mixture of labeled and unlabeled proteins, wherein if the associated protein is not labeled, then that protein was specifically associated in the cell with the tagged given protein. | 09-08-2011 |
20110223611 | LENALIDOMIDE AND THALIDOMIDE IMMUNOASSAYS - Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids. | 09-15-2011 |
20110223612 | Magnetic Sensor Based Quantitative Binding Kinetics Analysis - Methods for quantitatively determining a binding kinetic parameter of a molecular binding interaction are provided. Aspects of embodiments of the methods include: producing a magnetic sensor device including a magnetic sensor in contact with an assay mixture including a magnetically labeled molecule to produce a detectable molecular binding interaction; obtaining a real-time signal from the magnetic sensor; and quantitatively determining a binding kinetics parameter of the molecular binding interaction from the real-time signal. Also provided are systems and kits configured for use in the methods. | 09-15-2011 |
20110223613 | METHOD OF IMAGING BY MASS SPECTROMETRY AND NEW MASS TAG ASSOCIATED TRITYL DERIVATIVES - The present invention concerns a method of analyzing at least one specific molecule in a sample using a compound of formula (I″) wherein Z binds specifically to said at least one specific molecule, Y is independently a cleavable single bond, linker atom or group, and R is independently a substituent such as H, C | 09-15-2011 |
20110223614 | TOXIN DETECTION METHOD - According to the present invention, an antibody against a Panton-Valentine leukocidin toxin contained in | 09-15-2011 |
20110223615 | Rapid Expression Cloning of Human Monoclonal Antibodies from Memory B Cells - The present application provides methods for producing human monoclonal antibodies without using hybridoma technology, antibodies produced used the described methods, and methods for using the antibodies to treat or prevent disease conditions (e.g., infection by pathogens such as the Human Immunodeficiency Virus). | 09-15-2011 |
20110229907 | USE OF CARDIAC HORMONES TO ASSESS RISK OF CARDIOVASCULAR COMPLICATION FROM VOLUME OVERLOAD - The disclosure relates to the use of cardiac hormones, particularly natriuretic peptides, for assessment of risk of suffering from a cardiovascular complication, particularly heart disease or acute coronary syndrome, as a consequence of intravasal volume overload. In particular, the disclosure relates to a method for diagnosing the risk of a patient whose intravasal volume is increased or will be increased of suffering from a cardiovascular complication as a consequence of the increase of intravasal volume, comprising the steps of (a) taking a body fluid or tissue sample, and (b) measuring, preferably in vitro, the level of a cardiac hormone such as NT-proBNP. | 09-22-2011 |
20110229908 | METHODS AND PRODUCTS FOR MEASURING FREE IMMUNOGLOBULIN LIGHT CHAIN MOLECULES - The present invention provides improved methods for measuring the ratio of free K immunoglobulin light chain molecules to free λ immunoglobulin light chain molecules in a test sample, using a monoclonal antibody that specifically binds to free K and a monoclonal antibody that specifically binds to free λ. The application also provides specific monoclonal antibodies that can be used in the method of the invention, as well as kits containing said monoclonal antibodies. | 09-22-2011 |
20110229909 | RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies - This invention provides antibodies immunologically specific for ρ1-GABA | 09-22-2011 |
20110236904 | DETECTION OF TUMOR STEM CELLS AND TUMOR CELLS IN EPITHELIAL-MESENCHYMAL TRANSITION IN BODY FLUIDS OF CANCER PATIENTS - The present invention relates to the detection of tumor stem cells and tumor cells in epithelial-mesenchymal transition and uses of such methods. | 09-29-2011 |
20110236905 | METHOD FOR SCREENING CATTLE, CATTLE SCREENED, AND CATTLE SCREENING KIT - There are provided a method for screening individual cattle having useful economic traits in which proteins related to the economic traits of beef cattle are identified by proteomics and are used as biomarkers, and a cattle screening kit for use in the method. | 09-29-2011 |
20110236906 | SECRETORY PROTEIN BIOMARKERS FOR HIGH EFFICIENCY PROTEIN EXPRESSION - The instant invention relates to the field of protein production, and in particular is relates to compositions and processes for improving the production levels of recombinant proteins expressed in host cells. | 09-29-2011 |
20110244475 | MN Gene and Protein - Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular contacts. The MN protein binding site is a therapeutic target that can be blocked by organic or inorganic molecules, preferably organic molecules, more preferably proteins/polypeptides that specifically bind to that site. Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Vectors are provided that encode the variable domains of MN-specific antibodies and a flexible linker polypeptide separating those domains. Further vectors are disclosed that encode a cytotoxic protein/polypeptide operatively linked to the MN gene promoter, and which vectors preferably further encode a cytokine. The MN gene promoter is characterized, and the binding site for a repressor of MN transcription is disclosed. | 10-06-2011 |
20110244476 | METHOD FOR EVALUATION OF QUALITY OF BLOOD SAMPLE - A method for evaluating the quality of a blood sample, comprising the steps of: mixing labeled anti-cortisol antibodies with a blood sample to be subjected, to conduct the antigen-antibody reaction of the labeled anti-cortisol antibody with cortisol contained in the blood sample, developing a mixture obtained in the above step on an immunochromatographic test strip having a substrate on which cortisol is immobilized to cause the antigen-antibody reaction of the labeled anti-cortisol antibodies which are free in the mixture with the cortisol immobilized on the substrate, thereby bonding the antibody to the cortisol, determining the amount of the labeled anti-cortisol antibodies bonded to the cortisol in the above step, and evaluating whether or not the blood sample has a quality suitable for suprarenal vein sampling test on the basis of the amount of the labeled anti-cortisol antibodies determined in the above step. | 10-06-2011 |
20110244477 | ANTIBODY-SECRETING CELL ASSAY - An improved assay is described where a surface is provided with immobilized anti-Ig antibodies rather than antigen and where specific antibody-secreting cells (ASC) are detected using soluble antigen probes containing one of several possible labels. The method gives improved sensitivity with less background and is also more representative because antigen binding does not employ immobilized antigen. The assay is particularly effective for measuring antibody secreting cells against HIV, for determining whether an infection is acute as opposed to old or latent, for mapping epitopes and for measuring for ASCs against different antigens in the same reaction. | 10-06-2011 |
20110244478 | Methods and Compositions for Treating Bleeding Disorders - Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described. | 10-06-2011 |
20110244479 | Plasmon Resonant Particles, Methods and Apparatus - A method and apparatus for interrogating a target having a plurality of plasmon resonant particles (PREs) distributed in the target are disclosed. In the method, a field containing the target is illuminated, and one or more spectral emission characteristics of the light-scattering particles in the field are detected. From this data, an image of positions and spectral characteristic values in the field is constructed, allowing PREs with a selected spectral signature to be discriminated from other light-scattering entities, to provide information about the field. Also disclosed are a novel PRE composition for use in practicing the method, and a variety of diagnostic applications of the method. | 10-06-2011 |
20110250613 | Arrayed Multiple Ubiquitin Binding Domains as Linkage-specific Polyubiquitin Affinity Reagents - Linkage-specific polyubiquitin recognition is thought to make possible the diverse set of functional outcomes associated with ubiquitination. Thus far, mechanistic insight into this selectivity has been largely limited to single domains that preferentially bind to lysine 48-linked polyubiquitin (K48-polyUb) in isolation. A mechanism is proposed herein, linkage-specific avidity, in which multiple ubiquitin-binding domains are arranged in space so that simultaneous, high-affinity interactions are optimum with one polyUb linkage but unfavorable or impossible with other polyUb topologies and monoUb. The model used herein is human Rap80, which contains tandem ubiquitin interacting motifs (UIMs) that bind to K63-polyUb at DNA doublestrand breaks. The sequence between the Rap80 UIMs positions the domains for efficient avid binding across a single K63 linkage, thus defining selectivity. K48-specific avidity is also demonstrated in a different protein, ataxin-3. Using tandem UIMs, the general principles governing polyUb linkage selectivity and affinity in multivalent ubiquitin receptors are established. | 10-13-2011 |
20110250614 | METHODS AND COMPOSITIONS FOR DETECTING THE ACTIVATION STATE OF MULTIPLE PROTEINS IN SINGLE CELLS - The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state. | 10-13-2011 |
20110250615 | Methods and Compositions for Detection of Ehrlichia chaffeensis (VLPT) - The invention provides methods and compositions for the detection of | 10-13-2011 |
20110256549 | Novel reagents for directed biomarker signal amplification - Described herein are methods, compositions and articles of manufacture involving neutral conjugated polymers including methods for synthesis of neutral conjugated water-soluble polymers with linkers along the polymer main chain structure and terminal end capping units. Such polymers may serve in the fabrication of novel optoelectronic devices and in the development of highly efficient biosensors. The invention further relates to the application of these polymers in assay methods. | 10-20-2011 |
20110256550 | Novel reagents for directed biomarker signal amplification - Described herein are methods, compositions and articles of manufacture involving neutral conjugated polymers including methods for synthesis of neutral conjugated water-soluble polymers with linkers along the polymer main chain structure and terminal end capping units. Such polymers may serve in the fabrication of novel optoelectronic devices and in the development of highly efficient biosensors. The invention further relates to the application of these polymers in assay methods. | 10-20-2011 |
20110256551 | SYSTEMS AND DEVICES FOR ANALYSIS FOR SAMPLES - Systems and methods for analysis of samples, and in certain embodiments, microfluidic sample analyzers configured to receive a cassette containing a sample therein to perform an analysis of the sample are described. The microfluidic sample analyzers may be used to control fluid flow, mixing, and sample analysis in a variety of microfluidic systems such as microfluidic point-of-care diagnostic platforms. Advantageously, the microfluidic sample analyzers may be, in some embodiments, inexpensive, reduced in size compared to conventional bench top systems, and simple to use. Cassettes that can operate with the sample analyzers are also described. | 10-20-2011 |
20110262931 | MAST CELL CARBOXYPEPTIDASE AS A MARKER FOR ANAPHYLAXIS AND MASTOCYTOSIS - The present invention relates to use of mast cell carboxypeptidase as a marker for anaphylaxis or mastocytosis in serum, plasma or saliva samples. Detection of elevated mast cell caroboxypeptidase in for example serum samples is proposed for reducing false negatives in relation to diagnosis of anaphylaxis and various categories of mastocytosis by picking up serum tryptase-negative cases. | 10-27-2011 |
20110262932 | COMPOSITIONS - The invention generally relates to compositions that include magnetic particles bound to pathogens in a body fluid. | 10-27-2011 |
20110262933 | COMPOSITIONS AND METHOD FOR ISOLATING MID-LOG PHASE BACTERIA - The invention generally relates to compositions and methods for isolating mid-log phase bacteria. In certain embodiments, the invention provides a magnetic particle conjugated to an antibody that includes an epitope specific for mid-log phase bacteria. | 10-27-2011 |
20110262934 | METHOD FOR EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE USING PHOTOTRANSISTOR - Disclosed is a method for the early diagnosis of Alzheimer's disease. In the method, cells in which a biomarker characteristic of Alzheimer's disease, preferably beta-amyloid, is labeled with magnetic beads are selectively located in the channel region of a phototransistor, and a difference in photocurrent between normal cells and the cells comprising the protein biomarker labeled with magnetic beads is sensed to diagnose Alzheimer's disease at an early stage. | 10-27-2011 |
20110262935 | METHOD FOR DETECTING A PRION INFECTION - The invention relates to an in vitro method for detecting and/or titrating an unconventional transmissible agent (UTA) or a protein of pathological conformation which is a marker for the infectivity of the UTA, in a sample, comprising a step of concentrating the sample before and after digestion with a protease. | 10-27-2011 |
20110269146 | Expression Vectors and Cell Lines Expressing Vascular Endothelial Growth Factor D, and Method of Treating Melanomas - This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases. | 11-03-2011 |
20110269147 | Methods, Devices, and Systems for Glycated Hemoglobin Analysis - Methods, devices, and systems for measuring the concentration of glycated hemoglobin (HbA | 11-03-2011 |
20110269148 | Nanoaggregate Embedded Beads Conjugated To Single Domain Antibodies - A nanoaggregate embedded bead is formed from an inner core formed of comprising metallic nanoparticles and Raman active reporter molecules, an outer shell, and single-domain antibodies to target the bead to a specific target. The nanoaggregate embedded bead may be used in methods to detect analytes or pathogens in biological or environmental samples using Raman spectroscopy. | 11-03-2011 |
20110269149 | METHOD FOR QUANTIFICATION OF BODY INTERNAL CONCENTRATION OF PROTEIN-BASED DRUG - It is an object of the invention to provide a method for rapid and accurate quantification of a sample in the human body of a patient. | 11-03-2011 |
20110275091 | USE OF PRECURSORS OF TACHYKININS AND/OR THEIR FRAGMENTS IN MEDICAL DIAGNOSTIC - The present invention relates to the use of protachykinin and/or fragments thereof that can be isolated from body fluids, tissues or other bioiological samples and therefore, serves as a marker peptide for medical diagnosis of diseases/disorders of the central nervous system, including Alzheimer's disease, Parkinson's disease, depression and/or conditions of pain, neurological, endocrinological, cerebral, muscular, local, systemic, chronic, inflammatory diseases, infectious diseases comprising bacterial and viral infections, meningitis, sepsis, Crohn's disease, colitis ulcerosa, sickle cell anemia, ischemia, amyotrophic lateral sclerosis, arthritis comprising rheumatoid arthritis, bronchitis, hyperalgesia, asthma, intoxication comprising bacterial intoxication, immunological disorders, poly/-trauma comprising cranio-cerebral trauma, tumors/cancer, stroke, stress, atopis dermatitis, HIV, Huntington's disease, burns, schizophrenia, Hirschsprung's disease, allergies, familial dysautononmia (Riley Day syndrome), hematopoietic disorders, gliomas comprising glioblastomas and astrocytomas, disorders of the blood brain barrier. The invention further provides antibodies for binding to certain proteins and their fragments, more specifically protachykinin and protachykinin peptides. In accordance with the invention, a kit useful for the above-mentioned diagnosis is also provided. | 11-10-2011 |
20110275092 | METHOD FOR DETECTING BIOLOGICAL MARKERS BY AN ATOMIC FORCE MICROSCOPE - A method for detecting biological markers involves preparing sample slices using a hard granular labeling material such as hard nano-gold granular material. The sample slices are fixed to sample patches. The sample is scanned using the atomic force microscope (AFM) in tapping mode to collect the height, amplitude and phase data of the hard granular material. The hard labeling material is mainly determined through changes in discrepancies in phase diagram color, while height and amplitude diagrams are used to provide auxiliary evidence of sample morphological features. Integrating these data with the state of the biological target object can thus determine the existence of a marked object. | 11-10-2011 |
20110275093 | NOVEL USE OF ADENOVIRUSES AND NUCLEIC ACIDS THAT CODE FOR SAID VIRUSES - The present invention is related to the use of a virus, preferably an adenovirus, for the manufacture of a medicament, whereby the virus is replication deficient in cells which do not have YB-1 in the nucleus, and the virus codes for an oncogene or oncogene product, in particular an oncogene protein, which transactivates at least one viral gene, preferably an adenoviral gene, whereby the gene is selected from the group comprising E1B55kDa, E4orf6, E4orf3 and E3ADP. | 11-10-2011 |
20110281278 | High Throughput Assay for Discovering New Inhibitors of the GIRK1/4 Channel - In certain embodiments of the present disclosure, a method for determining an inhibitor of acetylcholine-activated potassium channel is described. The method includes incubating a cardiac cell in a solution comprising a test compound. The method further includes adding a muscarine (M2) receptor agonist to the cardiac cell in the solution and monitoring the cardiac cell for a change in membrane potential. A statistically insignificant change in the membrane potential following addition of the muscarine (M2) receptor to the solution signifies that the test compound is a K | 11-17-2011 |
20110287442 | Tumor Antigen Protein, Gene, or Peptides from Topoisimerase 2 Alpha - Provided is a tumor antigen protein, gene, or peptides derived from topoisomerase 2 alpha. As it is discovered that topoisomerase 2 alpha binds to an MHC class I or II antigen, thereby forming a complex, and the complex is recognized by cytotoxic T lymphocytes, the tumor antigen can be used in tumor immunotherapy. | 11-24-2011 |
20110287443 | HIGH LEVEL EXPRESSION OF RECOMBINANT TOXIN PROTEINS - The present invention relates to the field of recombinant toxin protein production in bacterial hosts. In particular, the present invention relates to production processes for obtaining high levels of a recombinant CRM197, Diphtheria Toxin, Pertussis Toxin, Tetanus Toxoid Fragment C, Cholera Toxin B, Cholera holotoxin, and | 11-24-2011 |
20110287444 | IMMUNOASSAY METHOD FOR HUMAN CXCL1 PROTEIN - An object of the present invention is to detect a human CXCL1 protein with high sensitivity. An immunoassay method is provided for a human CXCL1 protein, by which human CXCL1 or a fragment thereof in a sample is measured using two or more types of anti-human CXCL1 monoclonal antibodies or fragments thereof, wherein:
| 11-24-2011 |
20110287445 | Mutant ROS Expression In Human Cancer - The invention provides the identification of the presence of mutant ROS protein in human cancer. In some embodiments, the mutant ROS are FIG-ROS fusion proteins comprising part of the FIG protein fused to the kinase domain of the ROS kinase. In some embodiments, the mutant ROS is the overexpression of wild-type ROS in cancerous tissues (or tissues suspected of being cancerous) where, in normal tissue of that same tissue type, ROS is not expressed or is expressed at lower levels. The mutant ROS proteins of the invention are anticipated to drive the proliferation and survival of a subgroup of human cancers, particularly in cancers of the liver (including bile duct), pancreas, kidney, and testes. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS polypeptides (e.g., a FIG-ROS(S) fusion polypeptide), probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The identification of the mutant ROS polypeptides enables new methods for determining the presence of these mutant ROS polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention. | 11-24-2011 |
20110287446 | IMMUNOANALYTICAL METHOD AND SYSTEM USING MASS SPECTROMETRY TECHNOLOGY - An immunoanalytical system in which, after a sample such as a patient's serum is subjected to a pretreatment by an immunological pretreatment device, the sample is subjected to light detection by an immunological photometric detection system. Subsequently, the mass spectrometric pretreatment device performs a pretreatment, and the mass spectrometric detection system performs mass spectrometry. The mass spectrometric detection system performs mass spectrometry on components contained in a supernatant. A signal intensity and peak area for each of components are calculated from an obtained chromatograph. A quantitative value measured based on the immunoanalytical method is calculated for each of the components on the basis of the relative ratios of the components. | 11-24-2011 |
20110287447 | APPARATUS FOR AND METHOD OF AUTOMATED PROCESSING OF BIOLOGICAL SAMPLES - Provided herein is a bioprocessing device, bioprocessing card, and fluidics cartridge for performing automated bioprocessing of a sample. The bioprocessing card may include a plurality of pipette tips; and at least one pump in fluid communication with the plurality of pipette tips. In some embodiments, the pumps and the pipette tips are in fluid communication through a processing channel which may be a microscale channel. Also provided herein is an automated bioprocessing device comprising: at least one bioprocessing card; at least one fluidic cartridge; and an automated control system configured to control automated bioprocessing of a sample. Further provided herein are methods of use of the device, card, and cartridge. | 11-24-2011 |
20110287448 | DIAGNOSTIC METHOD FOR DISEASES BY SCREENING FOR HEPCIDIN IN HUMAN OR ANIMAL TISSUES, BLOOD OR BODY FLUIDS AND THERAPEUTIC USES THEREFOR - The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin. | 11-24-2011 |
20110294136 | BIOMARKER FOR DIAGNOSING PANCREATIC CANCER - The invention relates to a method for diagnosing pancreatic cancer (PaCa) or the precursor diseases and/or concomitant diseases thereof, in particular pancreatic ductal adenocarcinoma (PDAC), pancreatic intraepithelial neoplasia (PanIN), pancreatic lesions, chronic pancreatitis (CP), including endocrine pancreatic tumors. In said method, the diagnosis is performed using selected biomarkers. The invention further relates to biomarker combinations suitable for carrying out said method, particularly for in vitro diagnosis. | 12-01-2011 |
20110294137 | Sensor - The invention relates to an ADP binding molecule comprising a polypeptide, said polypeptide comprising amino acid sequence corresponding to at least amino acids 11 to 310 of SEQ ID NO:1, wherein said polypeptide comprises a substitution relative to SEQ ID NO:1 at amino acid C287, and wherein said polypeptide comprises a further cysteine residue for attachment of at least one reporter moiety, and wherein said polypeptide has at least 68% sequence identity to SEQ ID NO:1 at the amino acid residues corresponding to those shown in column III of table A. | 12-01-2011 |
20110294138 | METHODS FOR SIMULTANEOUSLY MEASURING THE IN VIVO METABOLISM OF TWO OR MORE ISOFORMS OF A BIOMOLECULE - The present invention encompasses methods for the simultaneous measurement of the in vivo metabolism of two or more isoforms of a biomolecule. The biomolecule is typically produced in the central nervous system. | 12-01-2011 |
20110294139 | DISPOSABLE CHIP-TYPE FLOW CELL AND FLOW CYTOMETER USING SAME - The present invention provides an apparatus for analyzing particles in a solution including a unit configured to place a flow cell having a flow path for flowing a sample solution containing the particles; a unit configured to illuminate the sample solution flowing through the flow path of the flow cell; a photodetector that detects a scattered light and/or fluorescence generated from the particles in the sample solution; and a unit configured to analyze the particles based on their signal intensities detected by the photodetector, wherein the flow cell has the flow path formed in a substrate, a reflection plane is formed on the side surface of the flow path, the reflection plane leads the lights generated in the flow path of the flow cell and advancing in the substrate in-plane direction to a specified region of the surface of the flow cell, and the photodetector detects the light exiting from the specified region to the outside. | 12-01-2011 |
20110294140 | Lysis Reagent For Use With Capture-In-Solution Immunoassay - The invention provides a lysis reagent and method for preparing a test sample for use in an assay, wherein the method yields a homogeneous lysis mixture suitable for use in automated pipetting systems without the need for a centrifugation step. The lysis reagent includes a glycol and non-specific animal immunoglobulins. Other aspects of the invention include related immunoassays and test kits. | 12-01-2011 |
20110300555 | ASSAY DEVICE COMPRISING BUBBLE-FORMING MEANS - Disclosed is a method for determining the presence and/or amount Oran analyte of interest in a liquid sample comprising the steps of: contacting the liquid sample suspected of containing analyte with a gas generating means (eg. catalase and peracid or peroxygen compound), which gas generating means forms a gas dependent upon the presence, absence or amount of analyte, which gas creates one or more bubbles in the liquid sample which act to alter the flow of liquid along a flow path; and determining an alteration of flow in the liquid wherein the alteration of flow of liquid along the flow path is indicative of the presence and/or amount of analyte in the liquid sample. | 12-08-2011 |
20110306057 | Phosphorylated RalA - Antibodies that are specific for human RalA that is phosphorylated at one or both of Ser183 and Ser194 are described as various methods such antibodies, including diagnostic methods and screening methods. | 12-15-2011 |
20110311987 | OXYGEN DETECTION USING METALLOPORPHYRINS - An oxygen sensor includes a metalloporphyrin for detecting oxygen levels. The oxygen sensors may also include a light source and a detector. The sensors are configured to measure changes in spectra in response to the redox reaction. They can detect a variety of samples for presence and changes in oxygen concentration in both solution and gaseous form. | 12-22-2011 |
20110311988 | POLYMER END GROUP DETECTION - Provided herein are processes of detecting and quantifying the number of polymer end groups in a sample. In particular instances provided herein are processes of detecting. | 12-22-2011 |
20110318753 | NEW COMPOUND, PHOSPHORYLATION INHIBITOR, INSULIN RESISTANCE IMPROVING AGENT, PREVENTIVE OR THERAPEUTIC AGENT FOR DIABETES, AND SCREENING METHOD - A new compound inhibiting phosphorylation of Ser727 of STAT3, a phosphorylation inhibitor containing the new compound, an insulin resistance improving agent and a preventive or therapeutic agent for diabetes; and a screening method for at least one of the insulin resistance improving agent and the preventive or therapeutic agent for diabetes. | 12-29-2011 |
20120003664 | METHOD FOR EVALUATING PRE-TREATMENT - The present invention relates to methods for evaluating tissue pre-treatment such as ischemic time, fixation time and alcohol time in an immunohistochemical assay by using one or more internal controls. Said internal controls may be biomarker specific or tissue specific. Also included are uses and kits comprising said internal controls. | 01-05-2012 |
20120009590 | DEVICE AND NON-TOXIC COMPOSITIONS AND METHODS FOR PERMEABILIZATION OF DROSOPHILA EMBRYOS - The invention provides compositions and methods for permeabilizing insect embryos by removing the waxy layer of the shell using a solution containing a non-toxic cyclic terpene and a non-toxic surfactant, preferably a non-ionic surfactant. The invention further provides kits to practice the method of the invention. The invention also provides methods for toxicology and other high throughput screening method including the compositions and methods of embryo permeabilization provided herein. | 01-12-2012 |
20120009591 | METHOD FOR DETECTION OF AN ENZYME-SUBSTRATE REACTION - The present invention relates to a method for detection of an enzyme-substrate reaction by capturing the product of the reaction on a solid support. More closely, the invention relates to a solid phase system for enzyme characterisation and screening of enzyme-targeted drugs. The method comprises the following steps a) rapidly mixing an enzyme solution with a substrate solution to start a reaction between enzyme and substrate wherein said reaction may result in product formation; and b) monitoring any binding of the product to a capturing agent immobilised on a solid surface, wherein said capturing agent is directed against the product of the enzymatic reaction. In a preferred embodiment the method comprises a further step c) measuring the initial rate of the product binding to the capturing agent and thereby characterize the enzymatic reaction. The method may also be used for drug screening. | 01-12-2012 |
20120015371 | Methods for Measuring Concentrations of Biomolecules - The present invention provides methods for measuring the absolute concentration of a biomolecule of interest in a subject. Such biomolecules may be implicated in one or more neurological and neurodegenerative diseases or disorders. Also provided is a method for determining whether a therapeutic agent affects the in vivo metabolism of a central nervous system derived biomolecule. Also provided are kits for performing the methods of the invention. | 01-19-2012 |
20120015372 | METHODS AND COMPOSITIONS FOR PATHOGEN DETECTION USING FLUORESCENT POLYMER SENSORS - Compositions, methods and related apparatus, as can be used for selective pathogen detection and identification. | 01-19-2012 |
20120015373 | ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS - Disclosed are methods for assay of an analyte employing acridone dyes having the structure: | 01-19-2012 |
20120015374 | ENIGMA-MDM2 INTERACTION AND USES THEREOF - The present invention relates to Enigma (PDLIM7)-Mdm2 interaction and use thereof. More particularly, it may induce an effective apoptosis of cancer cells by inhibition of an Enigma expression or an Enigma activity which induces Mdm2 destabilization and p53 activity; it may assess the prognosis of anti-cancer therapy by determining that Enigma, which is induced by SRF, is overexpressed in cancer tissues with Mdm2; it may screen anti-cancer activity substances by selecting a factor to inhibit specific binding between Enigma and Mdm2. Enigma-Mdm2 interaction and Enigma expression regulation may be utilized usefully for preventing cancers and developing therapeutic methods and anti-cancer agents. | 01-19-2012 |
20120015375 | MCM6 AND MCM7 MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE IN THE DETECTION OF CERVICAL DISEASE - Compositions and methods for diagnosing high-grade cervical disease in a patient sample are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MCM6 or MCM7. Monoclonal antibodies having the binding characteristics of an MCM6 or MCM7 antibody of the invention are further provided. Hybridoma cell lines that produce an MCM6 or MCM7 monoclonal antibody of the invention are also disclosed herein. The compositions find use in practicing methods for diagnosing high-grade cervical disease comprising detecting overexpression of MCM6, MCM7, or both MCM6 and MCM7 in a cervical sample from a patient. Kits for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MCM6 or an MCM7 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention. | 01-19-2012 |
20120021430 | FUNCTIONAL LIPID CONSTRUCTS - The invention relates to methods for effecting qualitative and quantitative changes in the functional moieties expressed at the surface of cells and multi-cellular structures, and functional lipid constructs for use in such methods. In particular, the invention relates to functional lipid constructs and their use in diagnostic and therapeutic applications, including serodiagnosis, where the functional moiety is a carbohydrate, peptide, chemically reactive group, conjugator or fluorophore. | 01-26-2012 |
20120021431 | DIAGNOSTIC METHODS USING BNP - The present invention provides a new method and kit for determining the overload of atrium or ventricle in a subject comprising at least a step of measuring levels of proBNP-108 in a sample from the subject. The disclosed methods and kits are useful, for example, in the diagnosis, prevention and/or treatment of cardiac diseases, particularly heat failure, aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, and atrial fibrillation. | 01-26-2012 |
20120021432 | Phosphorylated NF45 Biomarkers, Antibodies And Methods Of Using Same - The present invention relates to isolated phosphorylated NF45 peptides and isolated phosphorylation site-specific antibody or antigen-binding portion thereof that specifically binds a phosphorylated NF45 protein. The present invention also relates to methods of utilizing these antibodies to determine the therapeutic efficacy of a candidate compound and methods for screening for candidate compounds that increase the phosphorylation of NF45 protein in a cell. | 01-26-2012 |
20120021433 | REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE - This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications. In particular, the medical device reduces interference with an optical signal which is indicative of the presence of an analyte in a bodily sample. | 01-26-2012 |
20120021434 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS - The invention relates to a method for treating B-cell regulated autoimmune disorders using compounds that modulate the activity of c-Rel. | 01-26-2012 |
20120028265 | METHODS OF USING RET NANOSENSORS - The present invention provides methods for detecting and monitoring metabolite concentrations, which comprise detection and measurement of Fluorescence Resonance Energy Transfer upon ligand binding. The methods of the present invention are useful for real time monitoring of changes in metabolite levels in living cell cultures. | 02-02-2012 |
20120028266 | DISCOVERY OF CANDIDATE BIOMARKERS OF IN VIVO APOPTOSIS BY GLOBAL PROFILING OF CASPASE CLEAVAGE SITES - The present invention relates to the discovery of novel biomarkers of in vivo apoptosis based on a large number of caspase-like cleavage sites. These biomarkers are useful for detection and quantification of apoptosis in a biological sample. The invention also provides synthetic peptides and proteins corresponding to neo-epitopes created by proteolytic processing of these cleavage sites. The synthetic peptides can be used as standards to enable identification and quantitation of these biomarkers using mass spectrometry. The synthetic proteins can be used to generate antibodies and other binding reagents specific for these biomarkers. Methods for detecting apoptosis as well as for diagnosing or for providing a prognosis for a disease or disease state characterized by apoptosis are also provided herein. Finally, the invention provides compositions and kits for performing the methods of the invention. | 02-02-2012 |
20120028267 | METHOD FOR INCREASING SENSITIVITY USING LINKER AND SPACER IN CARBON NANOTUBE-BASED BIOSENSOR - Disclosed is a method of detecting even a very small amount of a target substance by mixing a linker and a spacer at a suitable ratio and immobilizing the mixture on the surface of carbon nanotubes in a carbon nanotube-based biosensor. This method detects a specific substance at the level of femtomoles and lowers the detection limit of conventional carbon nanotube transistor sensors. Accordingly, the method detects even a very small amount of a target substance, and thus the carbon nanotube-based biosensor is a highly useful sensor which can be used either as a medical sensor for diagnosing diseases or as an environmental sensor. | 02-02-2012 |
20120028268 | METHOD OF PREDICTING ACUTE APPENDICITIS - Embodiments of the invention provide method and devices for predicting the likelihood of acute appendicitis without invasive exploratory medical procedures. Several protein biomarkers: leucine-rich α-2-glycoprotein (LRG); S100-A8 (calgranulin); α-1-acid glycoprotein 1 (ORM); plasminogen (PLG); mannan-binding lectin serine protease 2 (MASP2); zinc-α-2-glycoprotein (AZGP1); Apolipoprotein D (ApoD); and α-1-antichymotrypsin (SERPINA3); are increased in the urine of patients with appendicitis. The method and devices comprise detecting the levels of these biomarkers and comparing with reference levels found in healthy individuals. | 02-02-2012 |
20120028269 | Methods For Detection Of Gastric Cancer - The invention is directed to non-invasive methods of detecting gastric cancer in an individual in need thereof comprising determining an expression level of inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) in the individual and comparing the expression level to a control, wherein an increase in the expression level of ITIH3 in the individual compared to the control is indicative of gastric cancer in the individual. | 02-02-2012 |
20120028270 | METAL-ENHANCED BIOLUMINESCENCE: AN APPROACH FOR MONITORING BIOLOGICAL BIOLUMINESCENT PROCESSES - The present invention relates to surface plasmon-coupled bioluminescence, wherein bioluminescent emission from a bioluminescent chemical reaction couples to surface plasmons in metallized particles thereby enhancing the signal. Importantly, these plasmonic emissions emitted from metallic particles generated without an external excitation source but instead from induced electronically excited states caused by the bioluminescent chemical reaction. | 02-02-2012 |
20120028271 | Methods and Kit for Detecting Breast Cancer - The present inventions relates to kits and methods for diagnosing and monitoring breast cancer. An increase in the level or activity of proteins of the ubiquitin/proteasome pathway, and ancillary proteins thereof, as compared to normal control or benign tissue is indicative of breast cancer. | 02-02-2012 |
20120028272 | DEVICE AND METHODS FOR ISOLATING CELLS - The invention provides a device and methods for separating and isolating cells. | 02-02-2012 |
20120028273 | Particle Analysis Assay for Biomolecular Quantification - A method is provided for carrying out multi-step separations of objects bearing at least two binding sites. In the first step, a first binder/bead composition is bound to objects that bear the first binding site, and then unbound objects, i.e. objects not bearing the first binding site, are separated from bound objects. In the second step, a second binder/bead composition is bound to the remaining objects that bear the second binding site, and then the objects that are bound to both beads are removed from those objects that are bound to only one bead. The beads can differ in magnetic responsiveness, charge, size, color, and the like, and these differences can be used to carry out the separation steps. | 02-02-2012 |
20120034618 | METHODS FOR CULTURE AND PRODUCTION OF SINGLE CELL POPULATIONS OF HUMAN EMBRYONIC STEM CELLS - We used ACCUTASE®, a commercially available cell detachment solution, for single cell propagation of pluripotent hESCs. Unlike trypsin dissociation, ACCUTASE® treatment does not significantly affect the plating efficiency of hESC dissociation into single cells. Cultures dissociated with ACCUTASE® to single cells at each passage maintain a higher proportion of pluripotent cells as compared to collagenase-passaged hESCs. ACCUTASE®-treated hESCs can be grown to a high density as monolayers, and yet retain their pluripotency. | 02-09-2012 |
20120034619 | METHOD OF DETERMINING THE OLIGOMERIC STATE OF A PROTEIN COMPLEX - A method of counting protein subunits to determine the oligomeric state of an oligomeric protein complex includes tagging and expressing the protein subunits with a mass/charge tag and selectively removing each mass/charge tag. The number of protein subunits of the oligomeric complex corresponds to the number of mass/charge tags removed. | 02-09-2012 |
20120034620 | COMPOSITIONS AND METHODS FOR ADHESION OF INTACT CELLS TO AN APPARATUS - Bio-adhesive compositions that include an extra-cellular matrix protein, bovine serum albumin conjugated with a fluorophore, and an aggregate are provided. The bio-adhesive composition may also include at least one component selected from the group consisting of collagen type IV, laminin, and chitosan. Also provided are methods of making the present compositions, that include taking a desired amount of extracellular matrix gel to liquid form of extracellular matrix; adding a desired amount of bovine serum albumin conjugated with a fluorophore; adding a desired amount of aggregate; and mixing. Further provided are methods for attaching cells to an apparatus using the present bio-adhesive compositions, and methods of attaching the present bio-adhesive compositions to an apparatus. Also provided are kits that include the present composition, components thereof or apparatuses, having the present composition attached thereto. | 02-09-2012 |
20120034621 | MICROORGANISM CONCENTRATION PROCESS AND DEVICE - A process for capturing or concentrating microorganisms for detection or assay comprises (a) providing a concentration device comprising a sintered porous polymer matrix comprising at least one concentration agent that comprises an amorphous metal silicate and that has a surface composition having a metal atom to silicon atom ratio of less than or equal to 0.5, as determined by X-ray photoelectron spectroscopy (XPS); (b) providing a sample comprising at least one microorganism strain; and (c) contacting the concentration device with the sample such that at least a portion of the at least one microorganism strain is bound to or captured by the concentration device. | 02-09-2012 |
20120040368 | MUTATED VOLTAGE-GATED SODIUM CHANNEL NAV ALPHA SUBUNIT FOR IDENTIFICATION OF MODULATORS - Reagents, methods and kits for screening for compounds that modulate the activity of voltage-gated sodium channels (NaV), such as human NaV1.5/SC-N5A/hH1 are described. The reagents, methods and kits are based on mutated NaV alpha subunit polyptides of SEQ ID NO:5 with mutations at positions 372, 898, 1419 and 1711 (the DEKA motif) and at positions 11485, 1486 and 1487 (the IFM motif) resulting in increased permeability for a group IIA divalent cation (Ca | 02-16-2012 |
20120040369 | ON-BOARD CONTROL DETECTION - Embodiments disclosed herein relate to a sensor comprising an on-board control system and a testing system. The on-board system can determine viability of the control system or the testing system. Also disclosed are methods of using such a sensor. | 02-16-2012 |
20120045772 | Affinity Hydrogel and Label Independent Detection Methods Thereof - A biosensor article including a substrate having polymer modified surface, the polymer comprising the formula (I) | 02-23-2012 |
20120045773 | CELL ADHESION INHIBITOR AND APPLICATIONS THEREOF | 02-23-2012 |
20120058488 | WIRELESS BASED MARINE PATHOGENS DETECTION SYSTEM - Embodiments of the present Invention provide antibody functionalized high electron mobility transistor (HEMT) devices for marine or freshwater pathogen sensing. In one embodiment, the marine pathogen can be | 03-08-2012 |
20120064538 | IMMUNOCHROMATOGRAPHY DETECTION OF MULTIDRUG-RESISTANT STAPHYLOCOCCUS AND DIAGNOSTIC KIT - This invention provides a immunochromatography detection device that can detect PBP2′ produced specifically by a bacterium of multidrug-resistant | 03-15-2012 |
20120064539 | RESISTANCE TO AUXINIC HERBICIDES - The invention provides methods of identifying herbicidal auxins. The invention further provides auxin-herbicide-resistant plants and genes conferring auxin-herbicide resistance. This invention also provides a method of identifying other proteins that bind picolinate auxins from additional plant species. The invention further provides a method to identify the molecular binding site for picolinate auxins. The invention also includes the use of the picolinate herbicidal auxin target site proteins, and methods of discovering new compounds with herbicidal or plant growth regulatory activity. The invention also includes methods for producing plants that are resistant to picolinate herbicidal auxins. Specific examples of novel proteins associated with herbicide binding include AFB5, AFB4, and SGT1b. | 03-15-2012 |
20120064540 | RESISTANCE TO AUXINIC HERBICIDES - The invention provides methods of identifying herbicidal auxins. The invention further provides auxin-herbicide-resistant plants and genes conferring auxin-herbicide resistance. This invention also provides a method of identifying other proteins that bind picolinate auxins from additional plant species. The invention further provides a method to identify the molecular binding site for picolinate auxins. The invention also includes the use of the picolinate herbicidal auxin target site proteins, and methods of discovering new compounds with herbicidal or plant growth regulatory activity. The invention also includes methods for producing plants that are resistant to picolinate herbicidal auxins. Specific examples of novel proteins associated with herbicide binding include AFB5, AFB4, and SGT1b. | 03-15-2012 |
20120064541 | N-GLYCAN CORE BETA-GALACTOSYLTRANSFERASE AND USES THEREOF - The present invention relates to new galactosyltransferases, nucleic acids encoding them, as well as recombinant vectors, host cells, antibodies, uses and methods relating thereto. | 03-15-2012 |
20120070844 | Method For Quantifying Modified Peptides - The present invention provides a method for quantifying modified peptides in a sample, the method comprising: (a) obtaining peptides from the sample; (b) adding reference modified peptides to the peptides obtained in step (a) to produce a mixture of peptides and reference modified peptides; (c) carrying out mass spectrometry (MS) on said mixture of peptides and reference modified peptides to obtain data relating to the peptides in the sample; and (d) comparing the data relating to the peptides in the sample with data in a database of modified peptides using a computer programme; wherein the database of modified peptides is compiled by a method comprising: (i) obtaining peptides from a sample; (ii) enriching modified peptides from the peptides obtained in step (i); (iii) carrying out liquid chromatography-tandem mass spectrometry (LC-MS/MS) on the enriched modified peptides obtained in step (ii); (iv) comparing the modified peptides detected in step (iii) to a known reference database in order to identify the modified peptides; and (v) compiling data relating to the modified peptides identified in step (iv) into a database. | 03-22-2012 |
20120070845 | METHODS, SYSTEMS AND REAGENTS FOR IMPROVED IMMUNODETECTION - The instant invention provides methods, systems and reagents for immunodetection involving novel epitope tags and antibodies which recognize these new epitope tags as well as the antibodies which detect the FLAG epitope tag. Fusion proteins comprising the epitope tags, as well as methods of purifying these proteins and kits detecting these proteins are also provided. | 03-22-2012 |
20120077206 | Rapid Microbial Detection and Antimicrobial Susceptibility Testing - A method for the detection of microorganisms in a sample comprising contacting said sample with a biosensor concentration module, allowing microorganisms to grow for a first period of time and detecting growth of discrete microorganisms as an indication of the presence of said microorganisms. | 03-29-2012 |
20120082998 | DETECTION OF BACTERIAL INFECTIONS IN SUBJECTS SUFFERING FROM DYSPNEA - The field of the present invention is the diagnosis and/or prediction and/or therapy follow-up of bacterial infections in subjects suffering from dyspnea. It is a subject of the present invention to provide a method for the diagnosis and/or prediction and/or therapy follow-up of bacterial infections in subjects suffering from dyspnea. | 04-05-2012 |
20120088250 | DEVICES, SYSTEMS, AND METHODS FOR THE COLLECTION OF BODY FLUIDS - Devices, systems, and methods for the collection of biological samples. In at least one exemplary embodiment, a device comprises a collection medium having top and bottom surfaces and a predetermined size and shape, the top surface comprising a position marker and at least one binding site operable to bind a biological sample, a protective facing substantially impermeable to the biological sample, the protective facing coupled to the top surface of the collection medium and having a size and shape substantially similar to the predetermined size and shape of the collection medium. The protective facing being sized and shaped to define a first void positioned to allow for the transfer of the biological sample through the protective facing and onto the at least one binding site of the collection medium, and a second void positioned to expose the position marker for alignment of the collection medium. | 04-12-2012 |
20120088251 | MASS SPECTROMETRIC METHODS AND PRODUCTS - The invention involves assays, diagnostics, kits, and assay components for mass spectrometry and other methods to determine levels of glycated CD59 in subjects. | 04-12-2012 |
20120094303 | DEVICE FOR ASSAYING ANALYTES IN BODILY FLUIDS - A device for determining the presence and/or quantity of one or more analytes in a sample of human body fluid has a container for receiving a sample of body fluid, with an interior that is delimited by a base and by a circumferential surface. It further comprises at least one test strip and a holding element for receiving and holding the one or more test strips. The holding element is designed such that it has a shape corresponding and adapted to the peripheral circumferential surface of the container. The device further comprises an elongate sampling element having an absorbent sampler that takes up the sample of body fluid and by means of which the sample of body fluid is transferred into the container. Further, the base of the container has a central elevation via which the sample of body fluid can be conveyed from the sampler, by compression thereof on the elevation, to the at least one test strip. | 04-19-2012 |
20120094304 | METHOD OF PREPARING HUMAN LUNG TISSUE STEM CELLS AND METHOD OF INDUCING DIFFERENTIATION INTO HUMAN ALVEOLAR EPITHELIAL CELLS - Provided are: a method of preparing cells that simultaneously express a type II alveolar epithelial cell marker and a stem cell marker, including a process of isolating and extracting constituent cells from human lung tissue, and a process of separating and culturing lung tissue stem cells from the obtained isolated cells; human lung tissue stem cells that are obtained from the method of preparation and are able to differentiate into alveolar epithelial cells; a method of inducing differentiation into human lung epithelial cells, consisting of culturing the human lung tissue stem cells; human alveolar epithelial cells prepared through the method of inducing differentiation; and a method of screening that uses the human lung tissue stem cells or human alveolar epithelial cells. | 04-19-2012 |
20120094305 | Methods For Treating And Diagnosing Fibrotic And Fibroproliferative Diseases - The present invention provides compositions and methods for diagnosing and treating fibrotic lung disease. In one embodiment the diagnostic method comprises determining the amount of circulating CXCL-12 in a patient relative to a control. | 04-19-2012 |
20120094306 | PREDICTIVE EVALUATION OF THE RESPONSE TO TAXANE-INCLUDING CHEMOTHERAPY - The present invention relates to methods and kits for a predictive evaluation of the effectiveness of a taxane-including treatment of a tumour or of cancer cells. | 04-19-2012 |
20120100557 | SAMPLE PREPARATION DEVICE AND ASSOCIATED METHOD - A sample preparation device and associated method is provided for preparing samples according to an assay protocol. A cell deposition module deposits a sample on each a plurality of assay devices supported by a support device. An epitope retrieval module deposits a reagent on each of the samples. Each of the samples is brought to a selected temperature. A heating device, corresponding to each of the assay devices, directly interacts with the corresponding assay device may be used to heat each assay device to the selected temperature, in conjunction with the epitope retrieval module depositing the reagent on each of the samples. A staining module deposits a staining reagent on each of the samples, and removes excess staining reagent. The staining, epitope retrieval, and cell deposition modules cooperate with the support device and heating devices to form a unitary sample preparation device. | 04-26-2012 |
20120107829 | STABILIZING COMPOSITIONS FOR IMMOBILIZED BIOMOLECULES - The present invention relates to the use of a composition comprising (a) at least three different amino acids, (b) at least two different amino acids and a saponin or (c) at least one dipeptide or tripeptide for stabilizing biomolecules immobilized on a solid carrier. The invention furthermore relates to a method for producing stabilized biomolecules, comprising embedding the biomolecules in the composition according to the invention and a method of producing a solid carrier having biomolecules attached thereto. The invention furthermore relates to a solid carrier producible or produced by the method of the invention and a method of diagnosing a disease using the carrier of the invention. | 05-03-2012 |
20120107830 | REAGENTS FOR BIOMOLECULAR LABELING, DETECTION AND QUANTIFICATION EMPLOYING RAMAN SPECTROSCOPY - The present disclosure provides isotopically substituted compounds of the formula (II): | 05-03-2012 |
20120107831 | METHOD FOR DETECTING AFFERENT LYMPH VESSEL INFLOW REGIONS AND METHOD FOR IDENTIFYING SPECIFIC CELLS - Regions where metastatic cancer cells can exist are detected with high accuracy in a sentinel lymph node. Quantum dots are injected into the vicinity of a cancer in a living body, thereby identifying the location of the sentinel lymph node by means of fluorescence. Subsequently, the sentinel lymph node is extracted. With respect to the sentinel lymph node extracted with quantum dots injected, structural analysis is conducted by means of precision fluorescence measurement which uses a confocal fluorescence microscope for monomolecular observation. Specifically, the fluorescence intensity is measured with respect to each of multiple areas in the sentinel lymph nodes, and out of the multiple areas measured, one or more areas are detected as afferent lymph vessel inflow regions in descending order of fluorescence intensity. | 05-03-2012 |
20120107832 | METHOD FOR THE DETECTION OF ORGAN OR TISSUE INJURY - This invention relates to methodology for detecting, assessing and/or diagnosing the presence of organ or tissue injury. More specifically, the present invention relates to methodology for detecting particular serum biomarkers that can be used in the detection, assessment and/or diagnosis of organ (e.g. liver) or tissue (e.g. skin) injury. | 05-03-2012 |
20120115160 | METHOD FOR DETECTING INVASIVE MICROVESCLES DERIVED FROM TUMOR CELLS - The present application relates to the isolation and analysis of populations of microvesicles, such as populations of microvesicles that are shed by tumor cells and contain the protein ARF6. Invasive microvesicles from tumor cells contain a variety of specific proteins, including ARF6. | 05-10-2012 |
20120115161 | COMPOSITIONS AND METHODS FOR DEMONSTRATING SECRETORY IMMUNE SYSTEM REGULATION OF STEROID HORMONE RESPONSIVE CANCER CELL GROWTH - Serum-containing and serum-free immunoglobulin inhibitors of steroid hormone responsive cancer cell growth are disclosed, along with their methods of production. Also disclosed are defined cell culture media, assay protocols, and model systems using the inhibitors for demonstrating steroid hormone growth effects of natural and synthetic substances, and other cell culture applications. The disclosed compositions and methods employing the immunoglobulin inhibitors are also useful as reagents in research, and for the diagnosis, treatment and prevention of mucus epithelial cancers. | 05-10-2012 |
20120115162 | ANTI-FATTY ACID AMIDE HYDROLASE-2 ANTIBODIES AND USES THEREOF - Antibodies that specifically bind to fatty acid amide hydrolases and methods of using the antibodies are provided herein. | 05-10-2012 |
20120115163 | MARKED PEPTIDES AND USE THEREOF FOR ASSAYING CIRCULATING IRAP - A method for the assay of the circulating extracellular portion of the IRAP protein (“insulin responsive aminopeptidase”) includes at least one stage of quantitative assay of the purified, secreted, extracellular portion of IRAP, via at least one labelled peptide, the labelled peptide interacting specifically with the extracellular portion of IRAP. | 05-10-2012 |
20120115164 | MAMMALIAN CYTOKINES; RELATED REAGENTS - Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided. | 05-10-2012 |
20120122114 | IMMUNOASSAY FOR THE DETECTION OF PROCALCITONIN - The present invention relates to an in vitro method for the detection of Procalcitonin or a fragment thereof of at least 20 amino acid residues in length in a biological sample derived from a bodily fluid obtained from a subject, comprising the steps of: (i) contacting said sample with at least two antibodies or functional fragments thereof directed against different epitopes within Procalcitonin, and (ii) qualitatively or quantitatively detecting binding of said at least two antibodies to Procalcitonin or said fragment thereof, wherein binding indicates the presence or concentration of Procalcitonin or said fragment in said sample, wherein at least one antibody or functional fragment thereof is directed against an epitope comprised in the sequence spanning amino acid residues 2 to 52 of Procalcitonin. The invention also pertains to antibodies directed against an N-terminal epitope of Procalcitonin and kits comprising antibodies directed against PCT. | 05-17-2012 |
20120135420 | Method for detecting the presence of target bacteria or a target component carbohydrate antigen thereof - A process is disclosed for separating a carbohydrate antigen from a Gram-positive or Gram-negative bacteria in a purified form that contains no more than 10% protein. The separated antigen is coupled to an affinity column, over which polyclonal antibodies to the same bacteria are chromatographed and recovered in a purified form that exhibits high specificity and sensitivity in immunoassays for the raw carbohydrate antigen corresponding to the purified antigen on the column. A particularly preferred form of rapid immunochromatographic assay employing the purified antibodies, which assay is very useful as an aid to rapid diagnosis of diseases caused by bacteria, is disclosed. | 05-31-2012 |
20120142016 | Array-based bioactivated nanopore devices - A nanopore device capable of single molecule detection is described. The nanopores are formed in thin, rigid membranes and modified by a sputtered metal that forms an overhang during application. The overhang causes the pore to be narrower in a certain region, allowing passage of only a single molecule through the pore at a time, or binding to a biomolecule on the pore to be detected by a change in ionic current flow through the nanopore. Embodiments include a silicon nitride membrane formed on a silicon substrate and having a nanopore drilled with a focused ion beam system, followed by gold sputtering onto the membrane. Devices are formed with one or more nanopores and chambers having electrodes on either side of the nanopore. | 06-07-2012 |
20120142017 | BIOSENSOR DEVICE AND MANUFACTURING METHOD THEREOF - Disclosed is a biosensor device, comprising: a capillary tube with probe molecules immobilized on the inner wall surface thereof, and a liquid sample containing target molecules, said biosensor device being characterized in that a contact angle between the inner wall surface of the capillary tube and the liquid sample changes because of the specific interaction between the probe molecules and the target molecules, which leads, in turn, to a change in the height of the liquid sample in the capillary tube. | 06-07-2012 |
20120142018 | Rapid Single Cell Based Parallel Biological Cell Sorter - A disposable rapid cell sorter comprises of microfluidic chip with electrodes and sorts biological cells of interest through magnetic field and electric field based on biological cell functional antibody bonded magnetic beads and luminescent labeling. | 06-07-2012 |
20120142019 | Sample Metering Device and Assay Device with Integrated Sample Dilution - In one embodiment, the invention is to a sample metering device, comprising a sample holding chamber oriented between a sample entry port and a sample isolation unit and having a diluent introduction port disposed therebetween for introduction of a diluent into the sample holding chamber. The volume within the sample holding chamber between the diluent introduction port and the sample isolation unit defines a metered volume of a sample for analysis. In another embodiment, the invention is to an apparatus and method for rapid determination of analytes in liquid samples by various assays including immunoassays incorporating a sample dilution feature, preferably suitable for low range sample dilution, and preferably capable of being used in the point-of-care diagnostic field. | 06-07-2012 |
20120142020 | Sample Metering Device and Assay Device with Integrated Sample Dilution - In one embodiment, the invention is to a sample metering device, comprising a sample holding chamber oriented between a sample entry port and a sample extraction unit, wherein a portion of said extraction unit defines a metered volume of a sample. A diluent may be transported over and/or through the extraction unit to form a diluted sample for sample analysis. In another embodiment, the invention is to an apparatus and method for rapid determination of analytes in liquid samples by various assays including immunoassays incorporating a sample dilution feature, capable of being used in the point-of-care diagnostic field is provided. The devices and methods of the invention preferably are well-suited for high range sample dilution. | 06-07-2012 |
20120142021 | pH MODULATION METHODS AND SYSTEMS FOR DETECTING BINDING EVENTS - Methods and systems for detecting binding between first and second molecules using a pH-sensitive fluorophore. A change in fluorescence emission intensity of the fluorophore is indicative of binding. | 06-07-2012 |
20120142022 | GLYCOSYLATED MAMMALIAN NGAL AND USE THEREOF - The present invention relates to glycosylated mammalian NGAL, and methods of using said glycosylated mammalian NGAL. | 06-07-2012 |
20120149028 | DETECTION AND VISUALIZATION OF THE CELL CYCLE IN LIVING CELLS - The present invention relates to a nucleic acid molecule encoding a polypeptide specifically binding to proliferating cell nuclear antigen (PCNA), said nucleic acid molecule comprising a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence deviating from SEQ ID NO: 2 by conservative substitution of one or more amino acids in position 1 to 28, 38 to 52, 63 to 98 and 115 to 123 of SEQ ID NO: 2. The present invention also relates to a vector comprising the nucleic acid molecule of the invention, a host cell comprising the nucleic acid molecule of or the vector of the invention and a method of detecting the amount and/or location of PCNA in living cells, a method of screening for compounds having an effect on the cell cycle. | 06-14-2012 |
20120149029 | Magnetic Needle Biopsy - An apparatus and method for performing biopsies in-vivo using magnetically labeled nanoparticles is disclosed. One embodiment of the apparatus is called a magnetic needle. When used in a biopsy, one embodiment of the present invention collects diseased cells in-vivo which have been tagged with magnetic nanoparticles coated with receptors for specific diseased cells. | 06-14-2012 |
20120156686 | Multifunctional particles providing cellular uptake and magnetic motor effect - Preparation of novel multifunctional particles and nanomaterials having a useful combination of magnetic and optical properties and biocompatibility. The internalization efficiencies in various in vitro cell studies have been investigated, and the external magnetic motor effect on the floating cells internalized with magnetic nanoparticles were clearly observed, for the first time. The particle surfaces can be derivatized with, for example, DNA or antibodies. The system is stable, versatile, and well-controlled. Novel gene delivery can be achieved using nanoparticles as a carrier. | 06-21-2012 |
20120156687 | NANOPARTICLES WITH MOLECULAR RECOGNITION ELEMENTS - A method of multiple protein biomarker detection, comprising providing at quantum dot-antibody conjugates that have an affinity for at least two different protein biomarkers; contacting the conjugates with a sample from a subject; allowing the proteins to bridge the antibodies, forming protein biomarker/quantum dot-antibody conjugate agglomerates; detecting the presence of the biomarkers by excitation of the agglomerates. | 06-21-2012 |
20120156688 | USE AND MAKING OF BIOSENSORS UTILIZING ANTIMICROBIAL PEPTIDES FOR HIGHLY SENSITIVE BIOLOGICAL MONITORING - A biosensor and method of making are disclosed. The biosensor is configured to detect a target and may include a peptide immobilized on a sensing component, the sensing component having an anode and a cathode. The immobilized peptide may comprise an antimicrobial peptide binding motif for the target. The sensing component has an electrical conductivity that changes in response to binding of the immobilized peptide to the target. The immobilized peptide may bind one or more targets selected from the list consisting of: bacteria, Gram-negative bacteria, Gram-positive bacteria, pathogens, protozoa, fungi, viruses, and cancerous cells. The biosensor may have a display with a readout that is responsive to changes in electrical conductivity of the sensing component. The display unit may be wirelessly coupled to the sensing component. A resonant circuit with an inductive coil may be electrically coupled to the sensing component. A planar coil antenna may be disposed in proximity to the resonant circuit, the planar coil antenna being configured to provide power to the sensing component. | 06-21-2012 |
20120164657 | Method of detecting botulinum neurotoxin and antibodies that neutralize botulinum neurotoxin action - A highly sensitive method of analyzing a sample for the presence or activity of botulinum neurotoxin (BoNT) or antibodies specific for botulinum neurotoxin is disclosed. In one embodiment, the method comprises the steps of preparing primary non-human mammalian or avian spinal cord cells, and exposing the cells to a test sample, in parallel with a control sample, and examining the extent of cleavage of the intracellular neuronal target protein in both the test and control sample. | 06-28-2012 |
20120164658 | Transcription Factor Modulator - The present invention relates to novel agents that are useful for modulating transcription factor activity. In particular, the present invention relates to a transcription factor modulator comprising (i) a pharmaceutically-effective amount of a HLS-5 polypeptide, isoform thereof, functional fragment thereof or pharmaceutical composition thereof or (ii) a compound or composition capable of regulating the endogenous levels of HLS-5 or its activity; or (iii) combinations thereof. | 06-28-2012 |
20120164659 | HUMAN HCV-INTERACTING PROTEINS AND METHODS OF USE - The present invention generally relates to a method for identifying and cloning nucleic acid molecules encoding a new class of proteins or fragments thereof, capable of interacting with proteins associated with the Human Hepatitis C virus (HCV) and thus being suitable either alone or in complex with the HCV protein for serving as a target for the development of antiviral drugs. In this context, the present invention provides novel HCV-interacting proteins and complexes as well as antibodies which specifically recognize and bind to the complex or to specific domains of HCV proteins. | 06-28-2012 |
20120171695 | SPONTANEOUSLY CONTRACTING FISH CELL AGGREGATES, USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF - The invention relates to an in vitro method for producing spontaneously contracting fish cell aggregates, to the fish cell aggregates obtained thereby, and to the use thereof, in particular for testing biological active substances and pharmaceuticals. The in vitro method according to the invention for producing contracting fish cell aggregates comprises the following steps: a) mechanical comminution and/or partial enzymatic digestion of fish embryos or fish larvae; b) transfer of the comminuted and/or partially digested fish tissue into an enzyme-free medium and removing the supernatant by centrifuging to obtain a cell pellet; c) re-suspension of the cell pellet in a cell culture medium; d) culturing the cells, with the medium being changed at least once, until spontaneously contracting cell aggregates form. | 07-05-2012 |
20120178097 | METHODS AND DESIGN OF MEMBRANE FILTERS - The present invention provides methods for designing a filtration systems for capturing viable tumor cells, such as circulating tumor cells at high efficiency and high viability. The methods involve development of a set of “key engineering design parameters” that are crucial to achieve high tumor cell viability. These important design parameters include the filter geometry design, fluid delivery method, transfilter pressure and total filtration time. | 07-12-2012 |
20120178098 | WHOLE BLOOD ASSAY FOR MEASURING AMPK ACTIVATION - A method of sample analysis is provided. In certain embodiments, the method comprises: a) labeling cells of a blood sample using an antibody that specifically binds to phospho-AMPK or a phosphorylated target thereof, to produce a labeled sample; and b) measuring antibody binding by a population of blood cells of the labeled sample using flow cytometry. In particular embodiments, the method may further comprise, prior to the labeling step: contacting blood with a test agent ex vivo or in vivo; and comparing the evaluation to results obtained from a reference sample of blood cells. | 07-12-2012 |
20120178099 | HIGHLY FLUORESCENT CARBON NANOPARTICLES AND METHODS OF PREPARING THE SAME - Highly fluorescent carbon nanoparticles (FCNs), with tunable emission colours of particle size between 1-10 nm also stable in solid form with high quantum yield (>5%) and its method of synthesis thereof yielding said carbon nanoparticles in milligram to gram scale in high synthesis yield (>80%). The present invention also provides for highly fluorescent carbon nanoparticle solution doped with heteroatom (such as oxygen, nitrogen) and its method of synthesis favoring yield of the said doped carbon nanoparticles of even smaller size ranging from 1-5 nm with narrow size distribution, and also provides for functionalized FCNs that are non-toxic, functional, soluble and stable fluorescent carbon nanoparticles with retained fluorescence for variety of end uses in biomedics, imaging applications, and detection techniques. | 07-12-2012 |
20120190039 | RAF DIMERS AND USES THEREOF - Disclosed herein are mutated RAF and KSR nucleic acids and polypeptides. Also disclosed are methods of using the mutated RAF and KSR to inhibit the dimerization of RAF/RAF and RAF/KSR. Also disclosed are methods of using the mutated RAF and KSR to screen for inhibitors of dimerization. | 07-26-2012 |
20120190040 | CELL CONCENTRATION, CAPTURE AND LYSIS DEVICES AND METHODS OF USE THEREOF - The present invention provides a microfluidic devices and methods of use thereof for the concentration and capture of cells. A pulsed non-Faradic electric field is applied relative to a sample under laminar flow, which results to the concentration and capture of charged analyte. Advantageously, pulse timing is selected to avoid problems associated with ionic screening within the channel. At least one of the electrodes within the channel is coated with an insulating layer to prevent a Faradic current from flowing in the channel. Under pulsed application of a unipolar voltage to the electrodes, charged analyte within the sample is moved towards one of the electrodes via a transient electrophoretic force. | 07-26-2012 |
20120190041 | METHODS, IMMUNOASSAYS AND DEVICES FOR DETECTION OF ANTI-LIPOIDAL ANTIBODIES - Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, a method for immobilizing a lipoidal antigen, comprising cardiolipin, lecithin, and cholesterol, on a solid support (such as a nitrocellulose membrane) is described. The ability to immobilize a lipoidal antigen on a membrane satisfies a long-felt need for membrane-based assay for the detection of anti-lipoidal antibodies. Also described are immunoassay devices for concurrently performing treponemal and non-treponemal tests for syphilis. | 07-26-2012 |
20120196297 | MASS TAGS FOR MASS SPECTROMETRIC ANALYSIS OF IMMUNOGLOBULINS - The present invention is a method for the characterization or detection of one or more antibodies in a sample. The method comprises obtaining a tagged antigen comprising an antigen and a mass tag attached to the antigen. The tagged antigen has specificity for the antibody. In addition, the method comprises combining the tagged antigen with the antibody to form a tagged antigen-antibody complex. Further, the method comprises cleaving the mass tag from the tagged antigen-antibody complex. Thereafter, the method comprises analyzing the mass tag via a mass spectrometer to determine the presence of the mass tag in the sample and correlating the presence of the mass tag with a presence of the antibody in the sample. | 08-02-2012 |
20120196298 | MITOCHONDRIAL FUNCTION OF PROHIBITIN 2 (PHB2) - The present invention relates to a PHB2 gene regulator and a therapeutic drug for mitochondrial-function-related disease containing the same, for example. | 08-02-2012 |
20120202216 | NOVEL PHOTOACTIVABLE FLUORESCENT DYES FOR OPTICAL MICROSCOPY AND IMAGING TECHNIQUES - The present invention relates to novel photoactivable rhodamine or carbopyronine derivatives of the following general formulae G1-G4 (I), G1: A1=O, A2=N, A3=C; G2: A1=S, A2=N, A3=C; G3: A1=O, A2=O, A3=N; G4: A1=S, A2=O, A3=N; comprising UV light absorbing chromophores which after photolysis by irradiation at 254-490 nm (preferably at 375-420 nm) generate fluorescent rhodamine or carbopyronine derivatives and small non-toxic fragments such as N | 08-09-2012 |
20120202217 | AUTOANTIBODY ENHANCED IMMUNOASSAYS AND KITS - The present disclosure provides immunoassays and kits for detection or quantification of an analyte of interest in a test sample that potentially contains endogenously produced autoantibodies reactive with the analyte | 08-09-2012 |
20120208202 | Method for the Reduction of Biological Sampling Errors by Means of Image Processing - The present invention relates to methods and devices for reducing biological sampling errors by means of image processing. Image processing techniques are used to determine the volume of sample added to a device, such as a diagnostic test, and to correct for user error in sampling techniques. | 08-16-2012 |
20120208203 | COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION - The present invention is directed to compositions and methods for modulating c-Rel-dependent cytokine production without materially altering the level of expression of NFκB and/or the amount of IκB. The present invention is also directed to screening for modulators of c-Rel activity as determined by assaying for altered subcellular localization of c-Rel but where the level of expression of NFκB and/or the amount of IκB is materially unaltered. | 08-16-2012 |
20120208204 | Compositions and Methods for Inhibiting Tumor Growth - The invention provides methods and compositions for inhibiting p53-inactivated cancers. Cancer cells are preferentially inhibited compared to normal cells by inhibiting tumor survival kinases that are required for growth of tumor cells but not normal cells. | 08-16-2012 |
20120208205 | POINT-OF-CARE TEST SYSTEM AND METHOD FOR APPLYING A SAMPLE - The present invention relates to a test system or assay system (detection system) and to a test method, preferably in use in the point-of-care (PoC) field. | 08-16-2012 |
20120208206 | METHOD FOR PRODUCING MAST CELLS FROM PLURIPOTENT STEM CELLS - The present invention relates to a method for producing human mast cells from human pluripotent stem cells. More particularly, the present invention provides a method for producing human mast cells from human pluripotent stem cells, comprising the steps of: (a) culturing human pluripotent stem cells under a condition suitable for promoting differentiation of the human pluripotent stem cells into hematopoietic progenitor cells expressing CD34; and (b) culturing the cells obtained in step (a) in the presence of hematopoietic factors comprising thrombopoietin (TPO) and Flt3 ligand. | 08-16-2012 |
20120208207 | Sample Processing Device - A floating chamber set may include a plurality of containers coupled to a frame such that each container translates vertically within a limited vertical range independent of the other containers. Each container may be perforated to allow liquid penetration. | 08-16-2012 |
20120219961 | Methods of running assays using intrachain fluorophore-quencher FRET-aptamers - The present invention describes methods for the production and use of single chain (single-stranded) fluorescence resonance energy transfer (“FRET”) DNA or RNA aptamers containing fluorophores (F) and quenchers (Q) at various loci within their structures, such that when its specific matching analyte is bound and the FRET-aptamers are excited by specific wavelengths of light, the fluorescence intensity of the system is modulated (increased or decreased) in proportion to the amount of analyte added. F and Q are covalently linked to nucleotide triphosphates (NTPs), which are incorporated by various nucleic acid polymerases such as Taq polymerase during the polymerase chain reaction (PCR) and then selected by affinity chromatographic, size-exclusion or molecular sieving, and fluorescence techniques. Further separation of related FRET-aptamers can be achieved by ion-pair reverse phase high performance liquid chromatography (HPLC) or other types of chromatography. Finally, FRET-aptamer structures and the specific locations of F and Q within FRET-aptamer structures are determined by digestion with exonucleases and mass spectral nucleotide sequencing analysis. | 08-30-2012 |
20120219962 | HUMAN EMBRYONIC STEM CELL METHODS AND PODXL EXPRESSION - A method of identifying an undifferentiated human embryonic stem cell in a sample which may contain such cells, the method comprising identifying the cell or cells within the sample that express podocalyxin-like protein (PODXL) on their surface. A method of isolating an undifferentiated human embryonic stem cell from a sample containing such cells, the method comprising isolating the cell or cells within the sample that express PODXL on their surface. Typically, the methods use an antibody which binds to PODXL. Undifferentiated human embryonic stem cells isolated by the method may be useful in cell therapy. Also, in particular, compositions of cells differentiated from a human embryonic stem cell but which composition has been depleted of undifferentiated human embryonic stem cells are provided which are useful in cell therapy. | 08-30-2012 |
20120225435 | NANOPIPETTE APPARATUS FOR MANIPULATING CELLS - Disclosed herein are methods and systems for controlled ejection of desired material onto surfaces including in single cells using nanopipettes, as well as ejection onto and into cells. Some embodiments are directed to a method and system comprising nanopipettes combined with an xyz controller for depositing a user defined pattern on an arbitrary substrate for the purpose of controlled cell adhesion and growth. Alternate embodiments are directed to a method and system comprising nanopipettes combined with an xyz controller and electronic control of a voltage differential in a bore of the nanopipette electroosmotically injecting material into a cell in a high-throughput manner and with minimal damage to the cell. Yet other embodiments are directed to method and system comprising functionalized nanopipettes combined with scanning ion conductance microscopy for studying molecular interactions and detection of biomolecules inside a single living cell. | 09-06-2012 |
20120225436 | Immuno-Based Botulinum Toxin Serotype A Activity Assays - The present specification discloses SNAP-25 compositions, methods of making α-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P | 09-06-2012 |
20120231469 | FORMALIN-FIXED ISOTOPE-LABELED REFERENCE STANDARDS AND METHODS FOR FABRICATION AND USE THEREOF - One or more cells are labeled with minor stable isotopes, characterized, and preserved for subsequent use as a bio-specimen reference standard. The one or more cells are grown in culture media supplied with minor stable isotopes in concentrations substantially different from normally occurring concentrations, thereby supplanting major stable isotopes that would normally be incorporated into the proteins of the cells. The proteins of the cells are thus labeled by the minor stable isotopes and can be used in proteomic characterization of the cells. The cells are preserved by fixation as a reference standard. Cells of the reference standard are mixed with the sample and subject to mass spectrometry evaluation, whereby the labeled proteins of the reference standard can be used in determining the proteome of the sample. | 09-13-2012 |
20120231470 | METHODS AND SYSTEMS ASSOCIATED WITH DETECTION OF FATTY ACID ELONGATION IN A CELL - Methods and systems to identify compounds capable of altering a fatty acid elongation pathway and for identifying conditions under which fatty acids elongation can occur in a cell are described. The methods and systems comprise labeled fatty acid precursors and cells capable of elongating fatty acids. Methods for providing suitable components of an assay for identifying compounds capable of altering a fatty acid elongation pathway are described. | 09-13-2012 |
20120231471 | MARKER ASSOCIATED WITH NON-ALCOHOLIC STEATOHEPATITIS - Disclosed is a novel NASH marker for use in a method for detecting NASH or evaluating the severity of NASH, which utilizes at least one factor selected from the group consisting of an IL-1 receptor antagonist, sCD40, HMGB1, sPLA2 group IIA and an sPLA2 activity as the marker. Also disclosed is a method for detecting NASH or evaluating the severity of NASH in a subject, which utilizes the marker. | 09-13-2012 |
20120231472 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of C—C motif chemokine 23, Transmembrane glycoprotein NMB, Brain-derived neurotrophic factor, Cathepsin S, Transforming growth factor beta-2, Urokinase-type plasminogen activator, Angiopoietin-2, Matrilysin, Carcinoembryonic antigen-related cell adhesion molecule 1, Creatine kinase MB, Insulin, Immunoglobulin M, Immunoglobulin E, Macrophage migration inhibitory factor, Galectin-3, Transforming growth factor beta-3, Heparan sulfate, soluble Cadherin-3, Complement C5, Platelet factor 4, Platelet basic protein, and Stromelysin-2 as diagnostic and prognostic biomarkers in renal injuries. | 09-13-2012 |
20120231473 | FLOW CYTOMETRY METHOD THROUGH THE CONTROL OF FLUORESCENCE INTENSITIES - Provided is a flow cytometry method including adjusting cell populations targeted by antibodies conjugated with a same-color fluorochrome to show different fluorescence intensities according to types of the antibodies. Unlike a conventional flow cytometry method capable of classifying a positive and negative of one target using one antibody per color, the flow cytometry method adjusts several types of antibodies conjugated with a single-color fluorochrome to respectively show different fluorescence intensities, or adjusts the amounts of antibodies conjugated with a fluorochrome differently according to types of the antibodies, thereby classifying a positive and negative of multiple targets using one color. Accordingly, even when a current flow cytometer capable of classifying a limited number of colors is used, it is possible to classify a variety of cell populations to be clinically examined. | 09-13-2012 |
20120237944 | DETECTION DEVICE FOR THE IN VIVO AND/OR IN VITRO ENRICHMENT OF SAMPLE MATERIAL - The present invention refers to a detection device for the in vivo and/or in vitro enrichment of sample material, the detection device comprising a functional surface equipped with detection receptors. To further improve the enrichment of sample material by using a detection device of the aforementioned type, it is provided according to the invention that the functional surface has a three-dimensional structure with mutually facing functional sections which form spaces that can be filled with a sample liquid. Furthermore, the present invention provides for a use and for a method for the use of the detection device. | 09-20-2012 |
20120237945 | CHIMERIC PCSK9 PROTEINS, CELLS COMPRISING SAME, AND ASSAYS USING SAME - A chimera protein comprising in the following order: a signal peptide, a proprotein convertase subtilisin/kexin type 9 preproprotein (PCSK9) sequence consisting of amino acid residues at positions 35 to 696 of SEQ ID NO: 38, a transmembrane domain and a cytosolic domain, wherein said cytosolic (CT) domain comprises a sequence able to recycle the protein from the cellular membrane to endosomes. | 09-20-2012 |
20120237946 | MESENCHYMAL STEM CELL AND THE METHOD OF USE THEREOF - Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells. | 09-20-2012 |
20120244546 | ANTIBODIES SPECIFIC TO CARBAMAZEPINE - The present disclosure is directed to antibodies specific to carbamazepine, immunogens used to produce the antibodies, and immunoassay kits and methods for using the antibodies. | 09-27-2012 |
20120244547 | BIOSENSOR - Disclosed herein are biosensors for the detection of airborne biomolecules. The biosensors include a housing, a sensing component, and optionally a sample capture component. The biosensors may utilize a gel-based detection platform. | 09-27-2012 |
20120244548 | Methods Of Determining Skeletal Maturity - The present invention provides methods to determine skeletal maturity. | 09-27-2012 |
20120244549 | Detection Method for Methyltransferase Enzymatic Activity - This invention provides methods to determine the activity of methyltransferase enzymes which employ S-adenosylmethionine (SAM) as a substrate and transfer a methyl group to convert this substrate to S-adenosylhomocysteine (SAH), by measuring SAH conversion to AMP. | 09-27-2012 |
20120244550 | IMAGE-BASED QUANTITATION OF MOLECULAR TRANSLOCATION - The use of an imaging system, cell compartment markers, and molecular markers in methods for correlating the movement of molecules within a cell to a particular compartment are provided, including measuring and correlating molecule movement in adherent and non-adherent cells. | 09-27-2012 |
20120244551 | PORPHYRINIC COMPOUNDS FOR USE IN FLOW CYTOMETRY - The present invention provides a method of detecting (e.g., by flow cytometry) a target compound, cell or particle, wherein the target is labelled with a detectable luminescent compound. The method comprises utilizing as the detectable luminescent compound a compound comprising a porphyrinic macrocycle such as a porphyrin, chlorin, bacteriochlorin, or isobacteriochlorin. In particular embodiments, the detectable luminescent compound comprises a compound of the formula A-A′-Z-B′-B, wherein: A is a targeting group or member of a specific binding pair that specifically binds the detectable luminescent compound to the target compound, cell or particle; A′ is a linker group or covalent bond; B′ is a linker group or covalent bond; B is a water-soluble group; and Z is the porphyrinic macrocycle. | 09-27-2012 |
20120244552 | Modified Method of Agglutination to Detect Infections Caused by Microorganisms - Provided herein is a modified method of agglutination to detect infections caused by microorganisms including the steps of staining the test serum, plasma or blood or purified antibodies with a protein stain; mixing serum, plasma or blood with stained antibodies with an equal quantity of colored antigen particles on a glass slide; adding diluted Antiglobulin conjugated with Biotin to the mixture; subjecting the mixture to the step of mixing, adding diluted Avidin (preferably tagged with a visible indicator) to the mixture and thoroughly mixing all the ingredients. | 09-27-2012 |
20120252031 | COMPOSITIONS AND METHODS FOR REGULATING SAS1R - The present invention provides compositions and methods useful for regulating fertilization and for use as a contraceptive based on the discovery herein of an oocyte specific protein, SAS1R (Sperm Acrosomal SLLP1 Receptor), which is a sperm protein receptor. Six SAS1R variants, including the full length SAS1R, were identified. mSLLP1 and SAS1R co-localized to oocytes and to acrosomes of acrosome-reacted sperm. Interactions between mSLLP1 and SAS1R were demonstrated by far-western analysis, in a yeast two-hybrid system under stringent selection conditions, and by immunoprecipitation of SAS1R by anti-mSLLP1 as well as the converse. Purified recombinant SAS1R was found to have protease activity, to inhibit fertilization in-vitro, and to induce an immune response in females. Together, the results suggest SAS1R is a proteolytically active, oocyte and early embryo specific oolemmal metalloprotease receptor for the sperm intra-acrosomal ligand SLLP1 and is a target for regulating fertilization and as a contraceptive. | 10-04-2012 |
20120252032 | Immunoassay Device with Improved Sample Closure - An apparatus and method for sealing a fluid sample collection device, comprising loading a fluid sample collection device with a fluid sample, said device comprising a housing having at least one substantially planar surface that includes an orifice in fluid communication with an internal fluid sample holding chamber which terminates at an internal capillary stop; and slidably moving a sealing element over at least a portion of said substantially planar surface in a way that displaces any excess fluid sample away from the orifice, seals the fluid sample within said holding chamber, and inhibits the fluid sample from prematurely breaking through the internal capillary stop. | 10-04-2012 |
20120252033 | SUBSTANCE DETERMINING APPARATUS - The invention relates to a substance determining apparatus and method for determining a substance within a fluid. Particles attach to the substance and bind to a binding surface ( | 10-04-2012 |
20120252034 | QUALITY ASSAYS FOR ANTIGEN PRESENTING CELLS - The present invention provides methods for evaluating the quality of a preparation of antigen presenting cells, such as dendritic cells. Assays for antigen-independent co-stimulation of T cells and for presentation of predetermined antigen by APCs are provided | 10-04-2012 |
20120252035 | GDF-15 and/or Troponin T for Predicting Kidney Failure in Heart Surgery Patients - The present disclosure relates to the field of laboratory diagnostics. Specifically, means and methods are disclosed for determining a patient's risk of suffering from acute kidney injury after a surgical procedure based on the detection of GDF-15, troponin T and/or a natriuretic peptide. | 10-04-2012 |
20120258466 | FILTRATION DEVICE FOR ASSAYS - A device and method for filtering blood is disclosed herein. The device can filter blood and attach analytes within the blood to magnetic particles. The analytes can then be strongly bound to an analyzing device by a magnetic force. The analytes can then be counted by the analyzing device and the result can be displayed. | 10-11-2012 |
20120258467 | TRANSDERMAL SYSTEMS, DEVICES, AND METHODS TO OPTICALLY ANALYZE AN ANALYTE - The invention provides transdermal optical analysis systems, test sensors, methods, and kits for determining the presence and/or concentration of at least one analyte in a fluid sample. The system includes a transdermal test sensor including an aqueous material including at least one analyte selective reagent and at least one optically active moiety. The optical system preferably uses fluorescent spectroscopy to correlate fluorescent emission or adsorption from a dye with the analyte concentration of the sample. An optical light source and/or detector may be housed with the aqueous material in a housing or external to the housing of the aqueous material. | 10-11-2012 |
20120264137 | TECHNIQUES FOR BUFFERLESS LYSING OF CELLS AND SEPARATION OF CELLULAR COMPONENTS USING MODIFIED MEMBRANES - A porous membrane for lysis of a cell population enriched from a biological sample, and isolation of cellular components is provided. The porous membrane contains embedded lysing agents to perform lysing. The biological sample is brought into contact with the membrane. Lysis occurs through the action of the embedded lysing agents on the biological sample. The pores of the porous membrane are designed to have dimensions to allow only a desired type of cellular component(s) resulting from lysis to pass through the membrane, thereby achieving isolation of the desired cellular component(s). The action of lysing agents is combined with the filtration properties of porous membranes resulting in an easy-to-use and cost-effective technique. | 10-18-2012 |
20120270229 | DEVICE FOR DETECTION OF ANALYTES AND USES THEREOF - Devices and methods for the detection of antigens are disclosed. Devices and methods for detecting food-borne pathogens are disclosed. | 10-25-2012 |
20120276549 | Photonic biosensors incorporated into tubing, methods of manufacture and instruments for analyziing the biosensors - Tubing such as clear plastic disposable tubing or glass tubing includes a photonic sensor formed in or placed within the tubing. The photonic sensors can take the form of photonic crystal sensors, distributed feedback laser sensors, and surface enhanced Raman spectroscopy (SERS) sensors, including photonic crystal enhanced SERS sensors. Detection arrangements for the sensors are described. The invention has many applications including tubing used in hospital care (e.g., urinary catheters, intravenous fluid delivery tubing, tubing used in dialysis, e.g. heparin lines or blood tubing sets), food manufacturing, pharmaceutical manufacturing, water quality monitoring, and environmental monitoring. | 11-01-2012 |
20120276550 | MICROFLUIDICS APPARATUS AND METHODS - This invention relates to microfluidics apparatus and methods for particle concentration in sensors for sensing biological entities such as cells, spores and the like. We describe a microfluidic sensor for sensing biological particles including a particle concentration device for performing concentration of particles in three dimensions. The sensor device comprises a substrate bearing a microfluidic channel or chamber for carrying a conductive fluid bearing the particles. The channel has: first and second electrodes spaced apart on the channel or chamber for defining an electric field therebetween, and a sensing surface on an inner surface of the channel or chamber. The particle concentration device comprises means for applying an ac voltage across the electrodes to perform simultaneously: i) electrohydrodynamic generation of a convection current flow in the fluid; and ii) 3D concentration of the particles in said fluid by dielectrophoretic attraction or repulsion of the particles towards or away from a region of increased electric field, to increase a concentration of the particles at sensing surface of said sensor. | 11-01-2012 |
20120282625 | MICROFLUIDIC DEVICE COMPRISING MICROCHANNEL WHERE PROTRUSIONS ARE FORMED ON BOTTOM SURFACE - Disclosed is a microfluidic device comprising a microchannel through which fluid can flow. Protrusions are formed on the bottom surface of the microchannel. The microfluidic device increases detection sensitivity by improving optical characteristics and enhances the reactivity of biochemical reaction by slowing down the velocity of fluid flowing inside the microchannel. | 11-08-2012 |
20120282626 | Selective Incorporation of 5-hydroxytryptophan into Proteins in Mammalian Cells - This invention provides methods and compositions for incorporation of an unnatural amino acid into a peptide using an orthogonal aminoacyl tRNA synthetase/tRNA pair. In particular, an orthogonal pair is provided to incorporate 5-hydroxy-L-tryptophan in a position encoded by an opal mutation. | 11-08-2012 |
20120288870 | Means for the inhibition of anti-beta1-adrenergic receptor antibodies - Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-β1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition. | 11-15-2012 |
20120288871 | Modified Carbocyanine Dyes and Their Conjugates - Chemically reactive carbocyanine dyes incorporating an indolium ring moiety that is substituted at the 3-position by a reactive group or by a conjugated substance, and their uses, are described. Conjugation through this position results in spectral properties that are uniformly superior to those of conjugates of spectrally similar dyes wherein attachment is at a different position. The invention includes derivative compounds having one or more benzo nitrogens. | 11-15-2012 |
20120295273 | N-ACETYLHEXOSAMINE-CONTAINING N-GLYCANS IN GLYCOPROTEIN PRODUCTS - The present invention provides methods of evaluating a glycoprotein preparation for the absence, presence or amount of an N-acetylhexosamine glycan, e.g., an N-acetylglucosamine glycan. | 11-22-2012 |
20120295274 | REPORTER VECTOR PRESENTING EXTRACELLULAR BINDING CAPACITY TO METALLIC COMPOUNDS - According to one embodiment, a reporter vector presenting an extracellular binding capacity to metallic compounds contains a nucleotide sequence exhibiting a promoter activity depending on a specific condition, a nucleotide sequence encoding a metallic compound-binding peptide presented extracellularly, and a nucleotide sequence encoding transcription termination signals. | 11-22-2012 |
20120295275 | Monoclonal Antibodies and Uses Thereof - The technology relates to monoclonal antibodies useful in the identification of cancer cells. In one embodiment, mAbs with specificity for tumor antigens are provided. In one embodiment, methods for treating cancer using mAbs are provided. In another embodiment, methods for detecting cancerous cells are provided. In another embodiment, kits for detecting cancerous cells are provided. | 11-22-2012 |
20120295276 | MASS SPECTRAL ANALYSIS - The invention generally relates to mass spectral analysis. In certain embodiments, methods of the invention involve analyzing a lipid containing sample using a mass spectrometry technique, in which the technique utilizes a liquid phase that does not destroy native tissue morphology during analysis. | 11-22-2012 |
20120295277 | DEVICE AND METHOD FOR DETECTING THE PRESENCE OF HEMOGLOBIN IN A BIOLOGICAL SAMPLE - A device and method for detecting the presence of hemoglobin in a biological sample, more particularly, the presence of blood in a fecal sample as an indicator of upper or lower gastrointestinal tract bleeding. | 11-22-2012 |
20120295278 | FLUORESCENCE DETECTING METHOD, METHOD FOR PRODUCING FLUORESCENT BEADS, AND FLUORESCENT BEADS - Two or more kinds of fluorescent beads containing at least two kinds of basic fluorochromes different in fluorescence intensity, fluorescence wavelength, and fluorescence relaxation time from each other, wherein a content ratio between the at least two kinds of basic fluorochromes and absolute amounts of contents of the basic fluorochromes are set so as to be different between different kinds of fluorescent beads. The fluorescent beads are used in a flow cytometer for fluorescence detection. This makes it possible to identify a greater variety of beads than before with high accuracy in a single measurement. | 11-22-2012 |
20120295279 | PRETREATMENT SOLUTION FOR IMMUNOHISTOCHEMICAL STAINING AND CONDENSED SOLUTION THEREOF - Disclosed are a pretreatment solution for immunohistochemical staining, which elutes a paraffin-containing embedding medium from a glass slide with a tissue specimen embedded in the medium, and retrieves antigenicity of the tissue specimen, and which is usable three or more times, and a pretreatment solution concentrate for immunohistochemical staining which allows ready preparation of the pretreatment solution. The pretreatment solution for immunohistochemical staining contains an antigen retrieving agent, particular nonionic surfactants, and cyclodextrin or a derivative thereof, with the balance being not less than 80 mass % of water. The content of the antigen retrieval agent is such that the pH of the pretreatment solution is in a predetermined range, and the content of cyclodextrin or a derivative thereof is a particular amount. | 11-22-2012 |
20120301893 | Analyte Detection Devices, Multiplex and Tabletop Devices for Detection of Analyte, and Uses Thereof - Devices and methods for the detection of analytes are disclosed. Devices and methods for detecting food-borne pathogens are disclosed. | 11-29-2012 |
20120301894 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS - Provided in certain embodiments are new methods for forming azido modified biomolecule conjugates of reporter molecules, carrier molecules or solid support. In other embodiments are provided methods for enzymatically labeling a biomolecules with an azide group. | 11-29-2012 |
20120309016 | 3D ADCC NK FACS ASSAY - Herein is reported a cell analytical technology based on a three-dimensional spheroid/aggregate co-culture assay, wherein the spheroid or aggregate is formed of tumor and natural killer cells. This method is useful for the in vitro functional analysis of antibodies in single and high-throughput format. | 12-06-2012 |
20120309017 | PERINUCLEOLAR COMPARTMENT AS A CANCER MARKER - The present invention relates to compositions and methods for cancer diagnostics, prognostics and predictions, including but not limited to, cancer markers. In particular, the present invention provides perinucleolar compartments and their resident molecules as cancer markers. | 12-06-2012 |
20120315644 | ANTI-NPC2 MONOCLONAL ANTIBODIES AND A METHOD OF DETECTING FATTY LIVER TISSUE, CANCER CELLS OR CANCER TISSUE BY USING THEM - The present invention is related to anti-NPC2 monoclonal antibodies, which against NPC2 or glycosylated-NPC2; and is related to a method of detecting fatty liver tissues, cancer cells or cancer tissues by evaluating the expression level of NPC2 or glycosylated-NPC2 in the cells or tissues. | 12-13-2012 |
20120315645 | MULTIPLE REACTION MONITORING LC-MS/MS METHOD TO DETECT THERAPEUTIC ANTIBODIES IN ANIMAL SAMPLES USING FRAMEWORK SIGNATURE PEPTIDES - Methods are disclosed to detect, characterize, measure, and quantitate human and humanized antibodies, and their conjugates, present in pre-clinical animal biological samples, including plasma/serum and tissue samples. | 12-13-2012 |
20120315646 | OLIGOTHIOPHENE DERIVATE AS MOLECULAR PROBES - The present invention relates to oligothiophene derivatives binding specifically to neural stem cells and neural cancer stem cells. More specifically, the invention relates to methods for detecting neural stem cells or neural cancer stem cells using said oligothiophene derivatives in a biological sample, as well as uses and kits relating thereto. | 12-13-2012 |
20120315647 | Immunoassay Reagent Composition - An apparatus and method for sealing a fluid sample collection device, comprising loading a fluid sample collection device with a fluid sample, said device comprising a housing having at least one substantially planar surface that includes an orifice in fluid communication with an internal fluid sample holding chamber which terminates at an internal capillary stop; and slidably moving a sealing element over at least a portion of said substantially planar surface in a way that displaces any excess fluid sample away from the orifice, seals the fluid sample within said holding chamber, and inhibits the fluid sample from prematurely breaking through the internal capillary stop. | 12-13-2012 |
20120315648 | METHOD OF IDENTIFICATION OF CELLS THAT SHOW SENSITIVITY TO MODULATION OF SIGNALING MEDIATED BY A FIBROBLAST GROWTH FACTOR RECEPTOR OR A VARIANT THEREOF - The invention is based on the finding that cells that show (especially tyrosine) phosphorylation of FGF-R substrate 2 (FRS-2), in contrast to cells that lack such phosphorylation, allow a prediction that treatment with a modulator, especially an inhibitor, of Fibroblast Growth Factor-Receptor signaling will be successful in cells e.g. from biological samples from patients that show such phosphorylation. Therefore, the phosphorylation of FRS-2 can serve as a biomarker for the possibility of successful treatment. The invention relates to various methods, uses, kits and reagents useful in applying this biomarker. | 12-13-2012 |
20120322079 | METHOD FOR TESTING OR SCREENING PROTEIN SYNTHESIS INHIBITORS - This invention provides methods for screening an inhibitor of protein synthesis by measuring the level of relocalization of an SMN complex component from the cytoplasm to the nucleus. Additionally, the invention provides a kit and a system for screening protein synthesis inhibitors in a cell. | 12-20-2012 |
20120329068 | FLUORESCENT DYES, FLUORESCENT DYE KITS, AND METHODS OF PREPARING LABELED MOLECULES - The present invention provides methods, compositions, and kits useful in preparing labeled molecules, which are useful in the detection of binding partners. | 12-27-2012 |
20130004962 | METHOD FOR EVALUATING CELL AGING BY EXPRESSION LEVEL OF COFILIN - The present invention discloses a concept that the expression level of cofilin may reflect the senescent condition of a cell or tissue. According to the findings in present invention, a method for determining the cellular senescent condition in a cell or tissue sample by evaluating the expression level of cofilin is provided. The detection of the expression level of cofilin is also used to screen an effective compound or composition for regulating the senescent condition in target cells. | 01-03-2013 |
20130011851 | Lateral Flow Immunoassay With Encapsulated Detection Modality - A lateral flow immunoassay featuring encapsulated metal particles. The encapsulated particles may use SERS nanotags as the detection modality. The use of encapsulated particles as a detection modality, in particular encapsulated SERS tags increases the sensitivity of an LFI prepared for visual reading and introduces the ability to obtain substantially more sensitive qualitative results or quantitative results through the analysis of a SERS spectrum read from an LFI prepared in accordance with the present invention. The use of SERS as detection modality also enhances the ability of an LFI device to be used for a multiplexed test. Other aspects of the present invention include LFI devices specifically configured to test whole blood, a reader for the detection and interpretation of a multiplexed assay and the hardware and software components used to implement the reader. | 01-10-2013 |
20130011852 | COMPOUNDS THAT INTERACT WITH KINASES - A method of inhibiting or effecting the activity of protein kinase activity which comprises contacting a protein kinase with a compound of formula (I) being a derivative of a furanose or pyranose form of a monosaccharide, or a pharmaceutically acceptable salt thereof. | 01-10-2013 |
20130011853 | ANTI-HEDGEHOG ANTIBODIES - The invention relates to anti-hedgehog antibodies, their use in the detection of hedgehog expression in tissue, and to the use of such detection in the treatment of cancer. | 01-10-2013 |
20130011854 | PRESSURE-ASSISTED MOLECULAR RECOVERY (PAMR) OF BIOMOLECULES, PRESSURE-ASSISTED ANTIGEN RETRIEVAL (PAAR), AND PRESSURE-ASSISTED TISSUE HISTOLOGY (PATH) - A method is disclosed for reversing fixation-induced cross-linking in tissue specimens that have been preserved for histological examination. The method involves placing the fixed tissue in a liquid under elevated temperature and pressure conditions that are sufficient to reverse the fixation-induced cross-linking, restore antigenicity to proteins, and permit improved molecular and proteomic analysis of the preserved tissue specimen. Methods are also disclosed for processing tissues for histological examination under elevated pressure conditions that enhance the perfusion of liquid reagents into the tissue and reduce overall processing times. | 01-10-2013 |
20130011855 | Methods for Determining Aged Based Accumulation of Senescent Cells Using Senescense Specific DNA Damage Markers - One disclosure provides a method for determining a senescence based disorder by detection of cells with senescence specific DNA damage markers which includes the step of providing a sample with one or more cells. It also includes the steps of identifying with immunodetection the presence of activated DNA damage response proteins that are shown to be activated with senescence and identifying with immunodetection the inactivation of DNA damage response proteins that are shown to be inactive in senescence. | 01-10-2013 |
20130011856 | CARTRIDGE FOR AUTOMATIC MEASUREMENT AND MEASURING DEVICE USING THE SAME - An object of the present invention is to provide a cartridge for automatic measurement used in an automatic measuring device, capable of automatically performing measurement including heat treatment of a sample, and a measuring device using the cartridge. | 01-10-2013 |
20130017553 | PIPETTES, METHODS OF USE, AND METHODS OF STIMULATING AN OBJECT OF INTEREST - The present invention features a freestanding microfluidic pipette with both solution exchange capability and fluid re-circulation, enabling highly localized and contamination- free fluid delivery within a confined volume in the vicinity of the pipette exit. Preferably, the device features direct positioning, so the pipette can be directed at a point or object of interest, such as a biological or artificial cell, a defined surface area or a sensor element within an open volume, using micro- or nanopositioning techniques. One aspect of the invention provides a free-standing pipette. The free-standing pipette includes a microfluidic device comprising one or more channels with exits leading into an open-volume and a positioning device programmed to hold the microfluidic device at an angle from a horizontal axis. | 01-17-2013 |
20130017554 | SUMO-SPECIFIC AFFINITY TAG - A new SUMO-specific affinity tag is described herein, based on the amino acid sequence from 403-621 of the SUMO protease Ulp1, and containing a crucial substitution of serine for cysteine. This affinity tag is particularly useful for a range of applications, including detection and affinity purification of sumoylated proteins from cell extracts. | 01-17-2013 |
20130017555 | FACS-BASED METHOD FOR OBTAINING AN ANTIBODY SEQUENCE - In certain embodiments, the method may comprises: a) contacting a population of permeabilized, cross-linked antibody-producing cells with a labeled antigen to produce a labeled sample in which cells that produce an antibody that specifically binds to said antigen are intracellularly labeled; b) using FACS to isolate cells that are intracellularly labeled, thereby producing labeled cells; c) uncrosslinking said labeled cells to produce uncrosslinked cells; and d) amplifying heavy and light chain-encoding nucleic acid from individual uncrosslinked cells, thereby obtaining nucleic acid that encodes the variable domain of antibody that specifically binds to said antigen. | 01-17-2013 |
20130022989 | DENTAL STEM CELL REPROGRAMMING - Provided is dental stem cell comprising an Oct3/4 transgene. Also provided is a method of making a pluripotent stem cell. Additionally, a method of preparing an insulin-secreting cell is provided. Further provided is an insulin-secreting cell prepared by that method. A method of preparing a chondrocyte-like cell is also provided, as is a chondrocyte-like cell prepared by that method. Additionally provided is a method of preparing a myocyte-like cell. Also, a myocyte-like cell prepared by that method is provided. A method of preparing a hair follicle-like cell is additionally provided, as is a hair follicle-like cell prepared by that method. A method of preparing a neuron-like cell is additionally provided, as is a neuron-like cell prepared by that method. | 01-24-2013 |
20130022990 | CELLULAR LABELING FOR NUCLEAR MAGNETIC RESONANCE TECHNIQUES - This disclosure provides, in part, fluorocarbon imaging reagents and formulations for the ex vivo labeling of cells. Labeled cells may be detected in vivo or ex vivo by a nuclear magnetic resonance technique, such as magnetic resonance imaging (MRI) or magnetic resonance spectroscopy (MRS). The disclosure additionally provides methods for using the imaging reagents in a variety of clinical procedures. | 01-24-2013 |
20130022991 | CELL FREE CD4 QUANTITATION AND METHODS OF USE - The present invention provides a low-cost cell-free assay, the α-test, that provides point-of-care CD4 enumeration using a single platform assay thereby eliminating the need for high-end instrumentation, calibrated pipetting, and specialized technical training. The number of CD4 T cells in blood is driven by the concentration of the protein α1proteinase inhibitor (α1PI, α1antitrypsin, serpin A1). The invention features, in part, methods for determining the number of CD4+ T cells in a sample comprising determining the concentration of alpha 1 proteinase inhibitor (α1PI) in a sample; wherein the number of CD4+ T-cells is related to the concentration of α1PI. | 01-24-2013 |
20130029349 | ASSAYS FOR THE DETECTION OF MICROBES - Methods, devices, and kits are provided herein for the accurate and rapid detection of disease causing microbes in a sample by the detection of microbial components of which correlate to the presence of the microbe. Kits include a first binding agent operatively coupled to an immobilized support; and a second binding agent operatively coupled to one or more pH indicating moieties wherein the first and second binding agents bind with sufficient specificity to the microbial component to permit detection of that component which correlates to the presence of the microbe in the sample. | 01-31-2013 |
20130029350 | BI-STABLE OSCILLATOR - In accordance with the present invention there is provided a bi-stable oscillator circuit for detecting a load imparted to a surface. The bi-stable oscillator comprises an electrical amplifier, at least one resonator comprising an electrical transducer having a resonant frequency, a surface of the resonator forming the surface on which the load is to be detected and an impedance network having a resonant frequency. The resonator is arranged to be exposed to an environment under test, and the resonator and the impedance network are connected in parallel with the electrical amplifier such that when a load imparted to the surface exceeds a pre-determined threshold value the oscillator circuit oscillates at the resonant frequency of the impedance network and when a load imparted to the surface is less than the threshold value the oscillator circuit oscillates at the resonant frequency of the resonator, switching of the circuit oscillation frequency being indicative of the load crossing the predetermined threshold value. | 01-31-2013 |
20130034861 | EARLY MARKER OF PROTEINURIA IN PATIENTS TREATED WITH AN ANTI-VEGF TREATMENT - This document provides methods and materials related to determining whether or not a human receiving a therapy (e.g., an anti-VEGF therapy such as a bevacizumab therapy) has developed or is at risk for developing proteinuria. For example, methods and materials for detecting urinary podocytes to determine whether or not a human receiving anti-VEGF therapy has or is at risk for developing proteinuria or kidney injury are provided. | 02-07-2013 |
20130034862 | Methods for Diagnosis, Prognosis and Methods of Treatment - The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN. | 02-07-2013 |
20130040306 | BACKSCATTERING INTERFEROMETRIC ANALYSIS OF MEMBRANE MATERIALS - Disclosed are improved optical detection methods comprising multiplexed interferometric detection systems and methods for determining a characteristic property of a sample, together with various applications of the disclosed techniques. | 02-14-2013 |
20130040307 | METHOD AND APPARATUS FOR AUTOMATED ANALYSIS - A method and apparatus for pretreatment of a sample of whole blood in a discrete fluid analyzing instrument comprises automated means for handling and analyzing the sample and means for performing a pretreatment step on the sample or a sub-sample of the sample. The means for pretreatment are used for immobilizing at least one substance or analyte from the sample or sub-sample wherein the substance or analyte is reversibly immobilized. Usually, the apparatus further comprises means for eluting the substance or analyte from the capture means prior to analysis. | 02-14-2013 |
20130040308 | COMPOSITIONS AND METHODS FOR CHARACTERIZING A MYOPATHY - The invention provides compositions, methods, and kits diagnosing, monitoring, and otherwise characterizing a myopathy and for detecting the presence of autoantibodies in a biological sample. | 02-14-2013 |
20130045486 | Composition for Cancer Prognosis Prediction Comprising Anti-TMAP/CKAP2 Antibodies - The present invention relates to an antibody which specifically binds to TMAP (tumor associated microtubule associated protein)/CKAP2 (cytoskeleton associated protein 2) or a fragment thereof, and a method for identifying the presence or absence of mitosis and a method for diagnosing cancer prognosis using the same. More specifically, the present invention relates to a composition for diagnosing cancer prognosis comprising an anti-TMAP/CKAP2 antibody or an antigen-binding site thereof, a method for detecting TMAP/CKAP2 using the composition, an anti-TMAP/CKAP2 antibody for diagnosing cancer prognosis, a method for providing information for diagnosing cancer prognosis using the composition, a method for screening a cancer therapeutic agent comprising the step of determining changes in the level of TMAP/CKAP2 antigen-antibody reaction by the treatment of a candidate substance, and a composition for determining cell-division cycles using the composition. | 02-21-2013 |
20130045487 | METHOD FOR DISCOVERING NEUROGENIC AGENTS - A cell line and an assay for discovering neurogenic drugs are described. The assay allows for systematic screening of test agents such as libraries of compounds. | 02-21-2013 |
20130052655 | ASSAY UTILIZING IMMUNOCHROMATOGRAPHY, IMMUNOCHROMATOGRAPHIC TEST STRIP, AND ASSAY REAGENT KIT FOR IMMUNOCHROMATOGRAPHY - The present invention provides a measurement method utilizing immunochromatography, an immunochromatographic test strip, and a reagent kit of immunochromatography capable of accurate short-time measurement of an analyte in blood with simple operations as compared to the conventional methods. The present invention provides a method of measurement by immunochromatography in which concentrations of an analyte and hemoglobin in the same sample are measured by immunochromatography to perform hematocrit correction of a measurement value of the analyte by using a measurement value of hemoglobin, as well as a test strip and a reagent kit for immunochromatography. | 02-28-2013 |
20130052656 | FRET MEASUREMENT METHOD AND FRET MEASUREMENT DEVICE - Disclosed herein is a method for measuring FRET by irradiating with laser light a measurement sample. FRET is transfer of energy from a first molecule to a second molecule. The first molecule and the second molecule are included in the measurement sample in which ligands are bound to receptors. The method includes the steps of: irradiating the measurement sample with laser light; measuring fluorescence emitted by the measurement sample; calculating a fluorescence lifetime of the first molecule; calculating a binding ratio; setting a binding condition for the measurement sample; and calculating a dissociation constant. In the dissociation constant calculating step, the dissociation constant is determined by using a least-squares method to fit a function having, as variables, a total concentration of the receptor in the measurement sample and the dissociation constant to the binding ratio calculated in the binding ratio calculating step. | 02-28-2013 |
20130065245 | Device - Provided is an assay device and kit for detecting the presence or amount of an analyte of interest. | 03-14-2013 |
20130078643 | DEVICE AND METHOD OF DETECTING TSH - A device for detecting the concentration of biological materials, is formed in a body having a plurality of fluidic paths connectable to a multi-microbalance structure carrying a plurality of microbalances, each microbalance having a sensitive portion facing a reaction chamber. The body and the multi-microbalance structure are configured to be mechanically coupled together and each microbalance is configured to be coupled to a respective fluidic path. Each fluidic path includes an inlet, a duct and a liquid waste, each duct being configured to be coupled with a respective reaction chamber. The plurality of fluidic paths and microbalances form at least one first and one second reference cells and one first sample cell. | 03-28-2013 |
20130084579 | DRUG SUSCEPTIBILITY USING RARE CELL DETECTION SYSTEM - Methods for determining the efficacy of a given drug for a specific patient with cancer in vitro prior to, or after, the initiation of treatment of the patient are disclosed. Blood from the cancer patient is separated into an assay test tube and a control test tube. The blood in the assay test tube is exposed to a cancer drug. The two test tubes are then visually examined and compared to determine the effect of the cancer drug on cancer cells, other rare cells in the blood, or on normal constituents of the blood of a cancer patient. | 04-04-2013 |
20130084580 | CHROMATOGRAPHIC KIT AND CHROMATOGRAPHY METHOD - A chromatographic kit is provided including a labeling substance holding area having a labeling substance modified with a first binding substance of a test substance, and a labeling substance capturing area having a second binding substance of the test substance or a binding substance of the first binding substance in this order from upstream to downstream of a development direction of a test sample including the test substance, and further including an area having a color developing reagent in order to detect a first amplification reagent of two types of amplification reagents used to amplify the signal of the labeling substance when detecting the labeling substance. | 04-04-2013 |
20130089869 | Methods For and Uses of Mechanical Stiffness Profiling of Cancer Cells - Methods of predicting the invasiveness or metastatic potential of cancer cells are provided herein. Methods of screening for cancer cells or diagnosing cancer in a subject are also provided. Methods of screening for agents capable of reducing invasiveness or metastasis of cancer cells are also provided. All of the methods rely on analyzing the creep compliance or spring constant of cells. | 04-11-2013 |
20130089870 | METHOD FOR SELECTING HUMAN INDUCED PLURIPOTENT STEM CELLS - The present invention provides a method for selecting human induced pluripotent stem (iPS) cells which can be safely used for transplantation. That is, the present invention provides a method for selecting human iPS cells having reduced differentiation resistance, comprising the steps of: (1) inducing differentiation of human iPS cells; (2) detecting remaining undifferentiated cells after the step (1); and (3) selecting human iPS cells whose rate of remaining undifferentiated cells detected in step (2) is equivalent to or not more than that of control cells. | 04-11-2013 |
20130095498 | NOVEL GROUP B STREPTOCOCCUS ANTIGENS | 04-18-2013 |
20130095499 | Methods, compositions and kits for imaging cells and tissues using nanoparticles and spatial frequency heterodyne imaging - Methods, compositions, systems, devices and kits are provided herein for preparing and using a nanoparticle composition and spatial frequency heterodyne imaging for visualizing cells or tissues. In various embodiments, the nanoparticle composition includes at least one of: a nanoparticle, a polymer layer, and a binding agent, such that the polymer layer coats the nanoparticle and is for example a polyethylene glycol, a polyelectrolyte, an anionic polymer, or a cationic polymer, and such that the binding agent that specifically binds the cells or the tissue. Methods, compositions, systems, devices and kits are provided for identifying potential therapeutic agents in a model using the nanoparticle composition and spatial frequency heterodyne imaging. | 04-18-2013 |
20130095500 | AUTOMATED DEVELOPER FOR IMMUNO-STAINED BIOLOGICAL SAMPLES - Disclosed herein are systems and methods for the developing of immuno-stained biological samples. The systems disclosed herein are automated and are configured to control one or more steps of the developing procedure. Reagents may be added using automatic syringe dispensing. Reagent temperature, reagent stirring, and wash procedures are programmable and can be separately controlled for separate immuno-staining procedures that are performed at the same time. | 04-18-2013 |
20130095501 | LEGIONELLA TEST - A device and method for qualitatively and/or quantitatively detecting | 04-18-2013 |
20130102008 | Method for Screening for S1P Lyase Inhibitors Using Cultured Cells - To provide a method for screening using cultured cells, intended to find a compound which increases the amount of sphingosine-1-phosphate or dihydrosphingosine-1-phosphate by SPL inhibitory activity rapidly, simply and highly sensitively. Provided are: a rapid and simple measurement method employing a scintillation proximity assay (SPA); a method with greatly improved detection sensitivity to the activity of a compound by controlling the concentration of the vitamin B | 04-25-2013 |
20130109029 | Methods And Compositions For Cellular Imaging And Cancer Cell Detection Using Light Harvesting Conjugated Polymer-Biomolecular Conjugates | 05-02-2013 |
20130109030 | EXAMINATION SYSTEM WITH SAMPLE INCUBATION | 05-02-2013 |
20130115617 | METHODS OF CELL CULTURE FOR ADOPTIVE CELL THERAPY - Production and use of novel therapeutic cells, called T-Vehicles, in the allogeneic Adoptive Cell Therapy setting allows a wide range of therapeutic benefits to accrue with minimal or no risk of GVHD. T-Vehicles are created from donor T cells that are altered to contain therapeutic attributes that do not include their native antigen receptors and can deliver therapeutic benefits irrelevant of their native antigen specificity. T-Vehicles can possess highly restricted native antigen specificity that renders them unable to recognize antigens present on normal cells and incapable of initiating GVHD, making them ideal transport vehicles to deliver various therapeutic attributes in vivo. In essence, production and use of T-Vehicles is a paradigm shift that opens the door to therapeutic application of T cells in ways not previously contemplated, independent of whether or not there is an HLA match between the donor and the recipient. | 05-09-2013 |
20130115618 | PHOSPHOLIPID PROFILING AND CANCER - In general, the present invention provides prognostic and predictive methods and kits for determining the lipogenicity of a tumor in a subject, by making use of phospholipid profiling, whereby a relative increase in mono-unsaturated phospholipid species in combination with a relative decrease in poly-unsaturated phospholipid species is indicative for a more resistant and aggressive lipogenic cancer phenotype. | 05-09-2013 |
20130115619 | UBIQUITINATION ASSAY - The present invention related to a method of assaying ubiquitination in a sample by combining ubiquitin and two or more of E1, E2, E3 and a substrate protein in a sample under conditions suitable for ubiquitination to take place, exposing the sample with a labelled binding partner which is specific for the ubiquitin and measuring the amount of labelled ubiquitin bound to any one of the components in the sample, wherein one or more of the components in the sample comprises an immobilisation tag which facilitates its immobilisation onto a solid surface. | 05-09-2013 |
20130115620 | Novel Hemopoietin Receptor Protein, NR10 - The inventors succeeded in isolating a novel hemopoietin receptor gene (NR10) using a sequence predicted from the extracted motif conserved in the amino acid sequences of known hemopoietin receptors. It was expected that two forms of NR10 exists, a transmembrane type and soluble form. Expression of the former type was detected in tissues containing hematopoietic cells. Thus, NR10 is a novel hemopoietin receptor molecule implicated in the regulation of the immune system and hematopoiesis in vivo. These novel receptors are useful in screening for novel hematopoietic factors capable of functionally binding to the receptor, or developing medicines to treat diseases related with the immune system or hematopoietic system. | 05-09-2013 |
20130122513 | DETECTION OF MAGNETICALLY LABELED BIOLOGICAL COMPONENTS - A sample acquiring device for detection of biological components in a liquid sample is disclosed, comprising a measurement cavity for receiving a liquid sample and a reagent comprising an antibody linked with a magnetic particle and arranged in a dry form inside the measurement cavity. A method is further disclosed, comprising mixing the reagent with the liquid sample, introducing the liquid sample into the measurement cavity, applying a magnetic field to the liquid, wherein the magnetic particles move in the magnetic field, thereby moving the biological components to which the magnetically labeled antibodies are bound to, acquiring at least one digital image of the sample after the magnetic field has been removed, digitally analysing the at least one digital image for identifying biological components and detecting the magnetically labeled biological components in the measurement cavity. A system comprising the sample acquiring device and a measurement apparatus is also disclosed. | 05-16-2013 |
20130122514 | METHODS FOR DETERMINATION OF PROTEIN PHOSPHATASE ACTIVITY, AND USES IN PREDICTING THERAPEUTIC OUTCOMES - One aspect of the present disclosure encompasses methods for determining a protein kinase or phosphatase activity in a biological sample, comprising: contacting in a reaction mix a first test sample and a fluorescently-labeled peptide substrate capable of being modified by a protein phosphatase or a protein kinase, contacting the reaction mix with a TiO | 05-16-2013 |
20130122515 | METHOD FOR THE SELECTIVE DETERMINATION OF PROCALCITONIN 1-116 - The present invention provides an immunodiagnostic method for determining procalcitonin and procalcitonin derivatives in a biological sample of a patient, in particular in the monitoring and control of treatment and the monitoring of the progression of a local or systemic bacterial infection, inflammation, sepsis or neurodegenerative disease. In particular, the method detects molecular forms of intact procalcitonin 1-116, or procalcitonin partial peptides derived therefrom that retain amino acids alanine and proline (Ala-Pro, AP) in positions 1 and 2 of the amino terminus of the complete procalcitonin 1-116. The method uses antibodies that selectively bind an epitope comprising amino acids 1 and 2 of procalcitonin 1-116 (SEQ ID NO: 1) and can distinguish between intact procalcitonin 1-116 and for example, procalcitonin 3-116. | 05-16-2013 |
20130122516 | DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY - Particular disclosed embodiments disclosed herein concern using a one or more various mass tags, which can be specifically deposited at targets through direct or indirect enzymatic-catalyzed transformation, to provide a method for identifying targets in tissue samples. The mass tags may be labeled with stable isotopes to produce mass tags having the same chemical structure but different masses. Mass codes produced by ionizing the mass tags are detected and/or quantified using mass spectrometry. The method can be used for multiplexed detection of multiple targets in a particular sample. In some embodiments, a map divided into sections representing sections of the tissue sample may be prepared, with the map sections including data corresponding to quantification data wherein the size of a mass peak is determined and correlated with the amount of a target for the corresponding tissue sample section. | 05-16-2013 |
20130122517 | METHOD OF PERFORMING AN ASSAY - The present invention relates to a method and kit for performing assays like immunoassays. The assays are performed by using two different types of magnetic beads. | 05-16-2013 |
20130130272 | METHOD, REAGENT, AND APPARATUS FOR DETECTING A CHEMICAL CHELATOR - A method for detecting a first chelator (shown in the figure as dipicolinic acid DPA ( | 05-23-2013 |
20130130273 | METHOD FOR DETECTING INTERACTIONS BETWEEN TWO AND MORE BIOLOGICAL MACROMOLECULES - Disclosed is a novel method for detecting interactions of biomolecules. More particularly, the disclosed method includes (a) preparing a cell comprising (i) a first construct comprising a bait, a first labeling material and a translocation module; and (ii) a second construct comprising a prey and a second labeling material; (b) detecting the distribution of the first construct and the second construct in the cell. the present invention provides a method capable of detecting bindings and interactions occurring in a living cell in real time, and a method for screening a material that alters the binding and the interaction. The method of the present invention overcomes the disadvantages including inaccuracy and complexity of existing biomaterial interaction detection techniques. By labeling both constructs to promote accuracy, the present invention provides a novel real-time, antibody-free analysis. | 05-23-2013 |
20130130274 | DETECTION METHOD - A method of analysis of a hydrocarbon fuel for the presence of a micro-organism comprises contacting a fuel sample with an aqueous diluent and with an antibody reactive with the micro-organism, or reactive with a metabolite of breakdown product produced by the micro-organism, to detect the presence or absence of the micro-organism. | 05-23-2013 |
20130137112 | DYES FOR ANALYSIS OF PROTEIN AGGREGATION - Provided are dyes and compositions which are useful in a number of applications, such as the detection and monitoring protein aggregation, kinetic studies of protein aggregation, neurofibrillary plaques analysis, evaluation of protein formulation stability, and analysis of molecular chaperone activity. | 05-30-2013 |
20130137113 | Photoreactive Regulator of Protein Function and Methods of Use Thereof - The present invention provides a synthetic regulator of protein function, which regulator is a light-sensitive regulator. The present invention further provides a light-regulated polypeptide that includes a subject synthetic regulator. Also provided are cells and membranes comprising a subject light-regulated polypeptide. The present invention further provides methods of modulating protein function, involving use of light. The present invention further provides methods of identifying agents that modulate protein function. | 05-30-2013 |
20130137114 | Bioprobe, Method of Preparing the Bioprobe, and Analysis Apparatus and Method Using the Bioprobe - The present invention relates to a bioprobe including a substrate and inorganic nanoparticles attached to the surface of the substrate, a method of preparing the bioprobe, and an analysis apparatus and method using the bioprobe. In the bioprobe according to the present invention, inorganic nanoparticles introduced to the substrate serve as a linker to which a target-specific substance such as an antibody can be bound, and they also increase the surface area of the substrate, thus increasing a surface area where a target substance to be detected can contact the substrate. In this regard, the bioprobe can be effectively used for detection, dosing, or analysis of various biomolecules or other chemical substances. | 05-30-2013 |
20130137115 | HOMOGENEOUS DETECTION METHOD - The invention relates to methods for the quantitative or qualitative detection of an analyte in an assay and adequate reagents therefor, particularly a homogeneous binding test. According to the invention, an analyte-specific binding partner R1 comprises more than one specific binding point for a specific binding partner X that is associated with a component of a signal-forming system while a second analyte-specific binding partner R2 comprises more than one specific binding point for a specific binding partner Y which is also associated with a component of a signal-forming system. | 05-30-2013 |
20130143228 | ACTIVITY BASED PROBES (ABPs) INTERACTING WITH GLYCOSIDASES - An activity based probe (ABP) comprising a glycosidase inhibitor, and a detection-group. The ABPs of the inventions are used for diagnosing storage disorder for screening of compounds suitable for preventing and/or treating a storage disorder, for monitoring of therapeutic enzymes for lysosomal storage disorders, and for ultra-sensitive visualization of glycosidase-fusion proteins in molecular imaging. | 06-06-2013 |
20130143229 | REAGENT FOR ASSAYING ANTI-TREPONEMA PALLIDUM ANTIBODY - To provide a reagent for assaying anti- | 06-06-2013 |
20130143230 | MICROFLUIDIC-BASED CELL-CULTURING PLATFORM AND METHOD - A microfluidic-based platform with cultured three-dimensional tissues simulates major human physiological systems for rapid evaluation of individual drugs prior to clinical testing or for personalized medical applications. The platform integrates the circulatory and lymphatic systems in a physiologically correct manner. The physiological systems may be simulated in the platform by microfluidic tissue culture devices which accommodate various tissues and provide integrated microvascular and lymphatic systems. Biomimetic nanofiber meshes or microfiber structures may be used to provide the cells with a physiologically relevant substrate. Each device may have an on-board detection system utilizing optical fiber bundles for microarray multiplexing of biomarkers, label-free SERS measurement of drugs, and microendoscopic confocal imaging of cells and tissues. | 06-06-2013 |
20130143231 | MST1/STK4 PHOSPHO-THREONINE 120 (pMST-T120) ANTIBODY - The present invention relates to prostate cancer (PCa). More specifically, the invention provides a MST1 phosphothreonine (pMST1-T120) antibody that can be used in various assays to study correlations between Mst1 function and T120 site phosphorylation. The present invention can also be used to determine disease development and/or progression of prostate cancer in a subject using the antibodies disclosed herein. | 06-06-2013 |
20130149712 | FOLLISTATIN-LIKE PROTEIN-1 AS A BIOMARKER FOR INFLAMMATORY DISORDERS - The present invention relates to methods and compositions for diagnosis of inflammatory disorders, and in non-limiting embodiments, of inflammatory disorders associated with elevated interleukin-1β (“IL-1β”), based on increased levels of follistatin-like protein 1 (“FSTL-1”). In particular non-limiting embodiments, the invention further provides for methods of identifying subjects with systemic onset juvenile idiopathic arthritis (“SOJIA”) who are at increased risk for developing macrophage activation syndrome (“MAS”) comprising detecting, in said subjects, hyper-increased levels of FSTL-1. In additional non-limiting embodiments, the invention provides for methods of identifying subjects with Kawasaki disease who are at increased risk of developing aortic aneurysms comprising detecting, in said subjects, hyper-increased levels of FSTL-1. | 06-13-2013 |
20130157281 | Factor IXa Crystals, Related Complexes and Methods - The present invention relates to factor IXa complexes and crystals thereof as well as methods for identifying inhibitors of factor IXa. | 06-20-2013 |
20130157282 | CHEMILUMINESCENCE COMPACT IMAGING SCANNER - Systems, devices, and methods for accurately imaging chemiluminescence and other luminescence are disclosed. A compact, flat-bed scanner having a light-tight enclosure, one or more detector bars of linear charge-coupled device (CCD) or complementary metal oxide semiconductor (CMOS) imaging chips, and high working numerical aperture (NA) optics scans closely over a sample in one direction and then the opposite direction. Averages or other combinations of intensity readings for each pixel location (x, y) between the two or more passes are averaged together in order to compensate for luminescence that varies over time. On-chip pixel binning and multiple clock frequencies can be used to maximize the signal to noise ratio in a CCD-based scanner. | 06-20-2013 |
20130157283 | RAPID PATHOGEN DIAGNOSTIC DEVICE AND METHOD - A microfluidic device of a diagnostic and detection system includes an inlet port connected by one or more microchannels to an outlet port and includes a capture and visualization chamber (CVC) connected to at least one microchannel. A fluid to be analyzed can be mixed with magnetic microbeads that have an affinity to become bound to target components, such as pathogens in the fluid. The fluid including the magnetically bound target components can be injected through the microfluidic device. Magnetic field gradient, such as provided by permanent or electro-magnets, can be applied to the fluid and the magnetically bound target components flowing through the microfluidic device to cause the magnetically bound target components to migrate into the (CVC) and become separated from the fluid. The magnetically bound target components can be analyzed and tested using various techniques to detect the presence of specific organic and inorganic materials, such as pathogens in bio-fluids and contamination in liquid food sources (e.g. water). The device and method provide a system for rapidly detecting pathogens and contamination in relatively small fluid samples. | 06-20-2013 |
20130157284 | COLORIMETRIC AND FLUORESCENT PROTEINS - The invention relates to intracellular lipid binding proteins that bind retinoids and/or dye ligands and that are modified to transmit or emit light at a variety of different wavelengths. | 06-20-2013 |
20130157285 | IDENTIFICATION OF INVASIVE AND SLOW-GROWING TUMORIGENIC CELL SUBSETS IN TUMORS - HA-based functional probes and a multiplexed targeting strategy for detection and isolation of invasive subpopulations in breast cancer cell lines. Methods for using HA metabolism for profiling and sorting breast cancer heterogeneity. As such, HA-based functional probes have appropriate targeting capacity and safety profiles for development as imaging and therapeutic agents for following repair and neoplastic disease processes such as breast cancer. | 06-20-2013 |
20130157286 | FLUIDIC CONNECTORS AND MICROFLUIDIC SYSTEMS - Fluidic connectors, methods, and devices for performing analyses (e.g., immunoassays) in microfluidic systems are provided. In some embodiments, a fluidic connector having a fluid path is used to connect two independent channels formed in a substrate so as to allow fluid communication between the two independent channels. One or both of the independent channels may be pre-filled with reagents (e.g., antibody solutions, washing buffers and amplification reagents), which can be used to perform the analysis. These reagents may be stored in the channels of the substrate for long periods amounts of time (e.g., 1 year) prior to use. | 06-20-2013 |
20130157287 | BIOLOGICAL SUBSTANCE DETECTION METHOD - A biological substance detection method for detecting a biological substance specifically in a pathological specimen, comprising a step of immunologically staining the pathological specimen using a fluorescent label, a step of staining the pathological specimen with a staining reagent for morphology observation purposes (eosin) to observe the morphology of the pathological specimen, a step of irradiating the stained pathological specimen, with excited light to cause the emission of a fluorescent and detecting the biological substance in the pathological specimen. In the step of immunologically staining the pathological specimen, a special fluorescent particle for which the excitation wavelength appears in a region that is different from the excitation wavelength region of eosin is used as the fluorescent label. | 06-20-2013 |
20130164759 | COMPOSITIONS AND METHODS FOR SCREENING FOR LYME DISEASE - The invention provides compositions, methods, and kits for the diagnosis or detection of infection by a pathogen that causes Lyme disease in a subject. | 06-27-2013 |
20130164760 | METHODS AND COMPOSITIONS FOR PREPARING SAMPLES FOR IMMUNOSTAINING - Compositions and methods for preparing a sample for immunological staining are provided. Compositions include kits comprising a first solution comprising a surfactant and a second solution comprising a chaotropic agent. Methods comprise contacting a sample, such as cells or tissues, with a first solution comprising a surfactant and then contacting the sample with a second solution comprising a chaotropic agent. The method does not require extreme heat for antigen retrieval and therefore, maintains the cellular morphology of the sample. | 06-27-2013 |
20130164761 | CARRIER POLYMER PARTICLE, PROCESS FOR PRODUCING THE SAME, MAGNETIC PARTICLE FOR SPECIFIC TRAPPING, AND PROCESS FOR PRODUCING THE SAME - Carrier polymer particles comprising organic polymer particles having a particle diameter of 0.1 to 20 micrometers and a saccharide with which the surface of the organic polymer particles is covered, the organic polymer particles and the saccharide being chemically bonded. | 06-27-2013 |
20130171658 | ISOLATION AND DEGLYCOSYLATION OF GLYCOPROTEINS - The invention provides more rapid and cost-effective methods of deglycosylating target glycoproteins. In methods of the invention, the target glycoprotein is isolated from initial samples, which may contain multiple other glycoproteins, by subjecting the initial sample to a solid phase containing an affinity ligand, such as a deglycosylated antibody, that interacts specifically with the target glycoprotein. Once separated from the sample, the target glycoprotein can be deglycosylated in situ, or eluted from the solid phase, quantitated, and then deglycosylated. | 07-04-2013 |
20130177922 | METHODS AND APPARATUS FOR TREATING SAMPLES WITH ACOUSTIC ENERGY - This invention relates to systems and methods for applying acoustic energy to a sample. According to one aspect of the invention, a system comprises a housing, a chamber for receiving the sample, an acoustic energy source for providing a focused acoustic field to the sample according to a treatment protocol, a processor for determining the treatment protocol, a sensor for detecting information about the sample, and a user interface for communicating with a user. | 07-11-2013 |
20130183680 | ASSAYS AND METHODS FOR THE DIAGNOSIS OF POST-STREPTOCOCCAL DISORDERS - Provided are methods for diagnosing a disease in a subject with a previous streptococcal infection by determining the presence or absence of one or more autoantibodies in a biological sample from the subject, wherein the one or more autoantibodies recognize an antigen from a protein selected from the group consisting of ELAVL2, ELAVL3, ELAVL4, Nova-1, Nova-2, Cdr1, Cdr2; and Cdr3. The presence of such autoantibodies is indicative of a positive diagnosis for a post-streptococcal disease such as PANDAS, post-GABHS glomerulonephritis, rheumatic fever, autism and Syndenham's chorea. | 07-18-2013 |
20130183681 | DEVICE AND METHOD OF MONITORING A PATIENT - A device for remote management of patients suffering or likely to suffer from heart failure that can measure the amplitude and frequency changes of one or more biomarkers. The device aids in predicting the need for medical intervention in such patients. The device may further aid in monitoring the efficacy and safety of treatment in such patients. | 07-18-2013 |
20130183682 | Detection and Measurement of Blood-Feeding Activity - This invention provides compositions and methods for detection of hematophagous ectoparasitic activity in an enclosure or area. The compositions comprise a reagent or reagents which are reactive against antigens or markers as they appear in the excrement or other ectoparasitic materials. Such markers or antigens may be produced by the ectoparasite itself or may have been introduced into the ectoparasite because of its blood feeding activity. The method of the present invention comprises collecting from the enclosure or area, a sample comprising environmental dust or materials and subjecting the sample to tests for detecting the presence of hematophagous ectoparasitic markers, host markers or both. | 07-18-2013 |
20130189705 | MONOCLONAL ANTIBODIES AGAINST PCBP-1 ANTIGENS, AND USES THEREFOR - The present invention provides and includes monoclonal antibodies (MoAbs or mAbs) specific or preferentially selective for PCBP-1 antigens, hybridoma lines that secrete these PCBP-1 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect PCBP-1 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble form of PCBP-1. The present invention further includes chimeric and humanized antibodies, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment or diagnosis of cancer progression. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express PCBP-1 antigens. | 07-25-2013 |
20130196336 | TRANSGLUTAMINASE 6 AS A DIAGNOSTIC INDICATOR OF AUTOIMMUNE DISEASES - The embodiments relate to the diagnosis of disorders or dysfunctions characterised by autoimmune responses to a novel antigen, transglutaminase 6, by the detection of autoantibodies to the novel antigen. | 08-01-2013 |
20130196337 | N-ACETYL-D-GLUCOSAMINE FOR ENHANCED SPECIFICITY OF STREP A IMMUNOASSAY - Methods, compositions and kits for detecting Group A | 08-01-2013 |
20130196338 | DETECTION OF BIOMARKERS AND BIOMARKER COMPLEXES - The invention features methods and devices for the detection of biomarker complexes and their components and for the sequential detection of multiple epitopes of a biomarker. The invention also features methods for diagnosing disease and evaluating the efficacy of treatment of a subject with a disease. | 08-01-2013 |
20130196339 | SLIDE POCKET - A slide pocket includes a first shell portion having a slide well with a depth suitable for accepting a sample-containing portion of a slide thereby positioning a sample affixed to the sample-containing portion of the slide within the slide well. The slide well has a plurality of beveled interior walls, the beveled portions functioning to prevent the sample affixed to the sample-containing portion of the slide from contacting any surface of the slide well during insertion. The slide pocket has a second shell portion, mateable in fluid tight engagement with the first shell portion. The second shell portion has a slide well. The first and second shell portions engage to define a single continuous slide chamber, a fluid input channel and fluid input port in communication with the single continuous slide chamber, and a fluid output channel and fluid output port in communication with the single continuous slide chamber. | 08-01-2013 |
20130196340 | EX VIVO PLASMA ENZYME ACTIVITY ASSAY USING INHIBITORS AS A NEGATIVE CONTROL - An improved assay for enzyme activity in bodily fluids which permits the influence of other components of the fluid to be accounted for is improved by using a negative control where the enzyme is inactivated or bound. | 08-01-2013 |
20130196341 | METHODS AND COMPOSITIONS FOR DETECTION OF ANALYTES - Disclosed are methods and compositions for detecting analytes, including proteins, polysaccharides, viruses, nucleic acids and cells. The methods and compositions utilize a reporter probe, suitably a multivalent reporter probe, to detect the presence of the analytes. The methods and compositions can be used for non-enzymatic detection of nucleic acids. | 08-01-2013 |
20130203065 | METHOD FOR ELECTROCHEMICAL DETECTION OF BINDING REACTIONS - A method for performing homogeneous immunoassay formats with electrochemical detection in solution includes combining two different conjugates as reagents with a sample or a sample/buffer mixture, one conjugate including a redox marker and an analyte molecule and the second conjugate including an anti-redox marker antibody or a specifically binding fragment thereof and a molecule specifically binding the analyte. | 08-08-2013 |
20130203066 | METHOD FOR DETECTING INVASIVE MICROVESCLES DERIVED FROM TUMOR CELLS - The present application relates to the isolation and analysis of populations of microvesicles and the identification of invasive microvesicles in the populations such as populations of microvesicles that are shed by tumor cells. Invasive microvesicles from tumor cells contain a variety of specific proteins, such as ARF6. | 08-08-2013 |
20130203067 | DETECTION OF INTRACELLULAR BINDING EVENTS BY MEASURING PROTEIN ABUNDANCE - Methods and compositions are provided to measure the binding of a test compound to a target peptide by measuring the effect of the compound on the abundance of the target peptide inside a cell. The target peptide may bind the test compound at an active site or an allosteric site, and it has been found that such binding may stabilize the target peptide against cellular degradation. The target peptide will preferably comprise a destabilizing mutation which shortens the half life of the target peptide within the cell, typically a mammalian cell. Test compounds, including small molecules, have been found to stabilize target peptides. Also provided are systems and kits for use in practicing the methods. | 08-08-2013 |
20130203068 | DUAL-ACCEPTOR TIME-RESOLVED-FRET - Methods for determining the presence or absence of a plurality of analytes in a sample with dual-acceptor time-resolved fluorescence resonance energy transfer are provided. | 08-08-2013 |
20130203069 | Dynamic Assay for Maintenance and Disruption of Tissue Level Organization and Architecture - A micropatterning approach, systems and methods that confine cells to a specified geometry combined with an algorithm to quantify changes of cellular distribution over time to measure the ability of different cell types to self-organize relative to each other and detect loss of cellular self-organization. | 08-08-2013 |
20130203070 | METHODS OF USING IL-31 ANTAGONISTS IN DISEASES MEDIATED BY CUTANEOUS LYMPHOCYTE ANTIGEN POSITIVE T CELLS - The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population. | 08-08-2013 |
20130203071 | PEPTIDE APTAMERS FOR MANIPULATING PROTEIN FUNCTION - Peptide aptamers and the methods to produce cassettes including the aptamers and manipulating them, are described. The peptide aptamer cassettes are useful to, e.g., inhibit protein function such as proteins necessary for the transformation of plants, or to replicate cells. | 08-08-2013 |
20130203072 | APPARATUS FOR PROCESSING BIOLOGICAL SAMPLES AND METHOD THEREOF - The present invention provides devices, apparatuses and methods for automated processing of biological samples. This invention provides automated devices and automated methods of sequentially treating a biological sample with processing fluids in more than one washing basin. In some embodiments, the invention provides automated devices and automated methods of western blot processing. In some embodiments, the invention provides automated devices and automated methods of Southern blot processing. In some embodiments, the invention provides automated devices and automated methods of northern blot processing. In some embodiments, the invention provides automated devices and automated methods of staining biomolecules on solid supports. In some embodiments, the invention provides automated devices and automated methods of nucleic acid separation and isolation. | 08-08-2013 |
20130210026 | BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO KINASE INHIBITORS - The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with inhibitors of EGFR kinase, PDGFR kinase, or FGFR kinase. Based on the surprising discovery that tumors cells after having undergone an EMT, while being mesenchymal-like, still express characteristics of both epithelial and mesenchymal cells, and that such cells have altered sensitivity to inhibition by receptor protein-tyrosine kinase inhibitors, in that they have become relatively insensitive to EGFR kinase inhibitors, but have frequently acquired sensitivity to inhibitors of other receptor protein-tyrosine kinases such as PDGFR or FGFR, methods have been devised for determining levels of specific epithelial and mesenchymal biomarkers that identify such “hybrid” tumor cells (e.g. determination of co-expression of vimentin and epithelial keratins), and thus predict the tumor's likely sensitivity to inhibitors of EGFR kinase, PDGFR kinase, or FGFR kinase. Improved methods for treating cancer patients with EGFR, PDGFR or FGFR kinase inhibitors that incorporate such methodology are also provided. | 08-15-2013 |
20130210027 | TEST SYSTEM AND METHOD - The present invention relates to an apparatus for detecting compounds, the apparatus having a device defining a disk-shaped geometry, the device having a centre, a plurality of fluid channels each comprising a fluid inlet positioned at a first distance from the centre and a fluid channel end at a second distance from the centre, the second distance being larger than the first distance, one or more sensors arranged at each fluid channel, wherein the sensors each comprise at least one optical detectable member, the test apparatus further comprising one or more optical sensing devices arranged for sensing the at least one optical detectable member of the one or more sensors, and a rotation device adapted for rotating the device so that the sensors pass over the one or more optical sensing devices. Further the present invention relates to a method for determining compounds comprising providing an apparatus for detecting compounds having a device defining a disk-shaped geometry, the device having a centre, a plurality of fluid channels each comprising a fluid inlet positioned at a first distance from the centre and a fluid channel end at a second distance from the centre, the second distance being larger than the first distance, one or more sensors arranged at each fluid channel, wherein the sensors each comprise at least one optical detectable member, the test apparatus further comprising one or more optical sensing devices arranged for sensing the at least one optical detectable member of the one or more sensors, and a rotation device adapted for rotating the device so that the sensors pass over the one or more optical sensing devices, the method comprising: providing a fluid at an inlet near the centre of the device, rotating the device, and obtaining properties of the sensors using the optical sensing devices. | 08-15-2013 |
20130217030 | INFECTION PROGNOSTIC ASSAY - The invention provides a method of prognosis of a subject with an infection, identifying a subject at greater risk of death from an infection and/or identifying a subject at greater risk of developing an infection, the method comprising detecting an amount of free light chains (FLC) in a sample from the subject, wherein a higher amount of FLC is associated with decreased survival due to the infection and/or increased risk from an infection and/or having an increased risk of developing an infection. A method of monitoring an infection, comprising detecting an amount of free light chains (FLC) in a sample from a patient having an infection and comparing the amount of FLC in the sample with an amount of FLC detected in a sample previously obtained from the patient, wherein an increase in the amount FLC detected, compared to the previous sample, indicates an increase in the infection in the patient, and a decrease in the amount of FLC indicates a decrease in the infection in the patient. Assay kits for use in the method are also provided. Assay kits comprising one or more anti-FLC antibodies and one or more anti-bacterial antigen antibodies are also provided. | 08-22-2013 |
20130217031 | GLYCEROGLYCOLIPID ANTIGEN OF MYCOPLASMA PNEUMONIAE - The present invention provides a novel glyceroglycolipid produced by | 08-22-2013 |
20130217032 | LIGAND FUNCTIONALIZED POLYMERS - Ligand functionalized substrates, methods of making ligand functionalized substrates, and methods of using functionalized substrates are disclosed. | 08-22-2013 |
20130224759 | METHODS, DEVICES, KITS AND COMPOSITIONS FOR DETECTING ROUNDWORM - Methods, devices, kits and compositions for detecting the presence or absence of roundworm in a mammalian sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of roundworm in a fecal sample from a mammal that may also be infected with one or more of hookworm, whipworm, and heartworm. Confirmation of the presence or absence of roundworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated. | 08-29-2013 |
20130224760 | Zinc-Responsive Peptides, and Methods of Use Thereof - Described herein are compounds and methods useful in the detection of, e.g., Zn | 08-29-2013 |
20130224761 | NON COVALENT MOLECULAR STRUCTURE, COMPRISING A PORPHYRIN BASED GLYCOCONJUGATE, DEVICE COMPRISING THE SAME AND ITS USE FOR DETECTION OF LECTIN - The present invention relates to a non covalent molecular structure comprising a carbon nanostructure and a porphyrin based glycoconjugate (I) which is linked to the said carbon nanostructure by a non covalent link, the said glycoconjugate (I) having the formula (I): wherein M is a metal selected in the group comprising Fe, Ni, Zn, Cu, Mn, Cr or Co, B is a group which is present on at least one of the four phenyl group (C | 08-29-2013 |
20130224762 | MAGNETIC CELL DETECTION - Specific labeling of cells enables magnetic cell detection. The cell type to be detected is labeled, magnetic labels being bound to epitopes of a first cell-specific epitope type via antibodies of a first antibody type. Additionally, second/further magnetic labels are bound to epitopes of a second cell-specific epitope type on the cells via antibodies of a second antibody type, or the magnetic labels are bound to the antibodies of the first antibody type via antibodies of another antibody type and the antibodies of the first antibody type are bound to the epitopes of the first cell-specific epitope type on the cells. | 08-29-2013 |
20130236906 | DIAGNOSTIC METHOD FOR THE DETECTION OF CELLS EX VIVO - The present invention provides an ex vivo method for detecting a subset of cells with a specific binding domain, the binding domain, diagnostic compositions comprising the binding domain, and kits comprising the binding domain. | 09-12-2013 |
20130236907 | COMPOSITION, APPARATUS, AND METHOD FOR SEPARATING AN ANALYTE FROM A SAMPLE - An analyte is separated from a fluid sample by introducing the sample into a cartridge having a sample port and a first flow path extending from the sample port. The first flow path includes an extraction chamber containing a solid support for capturing the analyte from the sample. The cartridge has a second flow path for eluting the captured analyte from the extraction chamber, the second flow diverging from the first flow path after passing through the extraction chamber. The sample is forced to flow through the extraction chamber and into a waste chamber, thereby capturing the analyte with the solid support as the sample flows through the extraction chamber. The captured analyte is then eluted from the extraction chamber by forcing an elution fluid to flow through the extraction chamber and along the second flow path. | 09-12-2013 |
20130244248 | METHOD FOR ISOLATING A CHEMOTHERAPEUTIC AGENT RESISTANT CANCER CELL WITH STEM CELL PROPERTIES - The invention relates to the use of encapsulates of cancer cells, in agarose coated, agarose containing beads, for isolating chemotherapeutic resistant cells which have at least one stem cell property, such as expression of OCT4. The cells thus isolated are also a feature of the invention, as is a method for screening for potential therapeutic | 09-19-2013 |
20130244249 | HIERARCHICAL FILMS HAVING ULTRA LOW FOULING AND HIGH RECOGNITION ELEMENT LOADING PROPERTIES - Hierarchical films with structurally regulated functionalities through the integration of two-dimensional and three-dimensional structures to achieve ultra low nonspecific binding and high loading of molecular recognition elements, and methods for making and using the films. | 09-19-2013 |
20130244250 | ANALYTE SENSORS, METHODS FOR PREPARING AND USING SUCH SENSORS, AND METHODS OF DETECTING ANALYTE ACTIVITY - Analyte sensors, methods for producing and using analyte sensors, methods of detecting and/or measuring analyte activity, detecting pH change, and/or, controlling the concentration of an analyte in a system, are disclosed. Embodiments of the analyte sensors according to the disclosure can provide an accurate and convenient method for characterizing analyte activity, detecting pH change, controlling the concentration of an analyte in a system, and the like, in both in vivo and in vitro environments, in particular in living cell imaging. | 09-19-2013 |
20130244251 | BODIPY Structure Fluorescence Dye for Neural Stem Cell Probe - The present invention is directed to a fluorescence compound represented by structural Formula (I), with specificity to neural stem cells: I or a pharmaceutically acceptable salt thereof. The variables for structural Formula (I) are defined herein. Also described are methods for detection of neural stem cells, comprising using a compound of structural Formula (I) or pharmaceutically acceptable salts thereof. Compounds of structural Formula (I) can detect and separate neural stem cells without immunostaining, providing a much shorter and more convenient method for detection of neural stem cells. | 09-19-2013 |
20130260387 | DETERMINATION OF GLYCATED PROTEIN - The present invention provides methods for quantitation of glycated protein in a biological sample using a solid support matrix by making a first bound protein measurement total bound protein under conditions where both glycated and non-glycated protein bind to the support in making a second bound protein measurement under conditions where glycated protein is bound to the support and non-glycated protein is not substantially bound. Diagnostic devices and kits comprising the methods of the present invention are also provided | 10-03-2013 |
20130260388 | BLOOD MARKERS FOR DIAGNOSING EPITHELIUM DERIVED CANCERS AND MONOCLONAL ANTIBODIES THEREOF - The present invention provides uses of cytokeratins as markers for diagnosing epithelium derived cancers. The present invention provides caner-related epitopes of cytokeratins and monoclonal antibodies which specifically recognize the epitopes. The present invention also provides methods for the early screen, diagnosis or prognosis of epithelium derived cancers in subjects, methods for the evaluation of therapeutic effect of related medicaments or therapies, and kits for accomplishing the methods. | 10-03-2013 |
20130266956 | MICROFLUIDIC DEVICES AND METHODS FOR ASSAYING A FLUID SAMPLE USING THE SAME - Multi-directional microfluidic devices and methods for using the same are provided. Aspects of the present disclosure include microfluidic devices that include a chamber having a separation medium, a first binding medium, and a second binding medium. In addition, the devices include a flow field element configured to subject the chamber to two or more directionally distinct flow fields. Methods of using the devices, as well as systems and kits that include the devices are also provided. The devices, systems and methods find use in a variety of different applications, including diagnostic, research and validation assays. | 10-10-2013 |
20130266957 | HIGHLY FLUORESCENT POLYMER NANOPARTICLE - Fluorescent nanoparticles are provided. The nanoparticles are formed from poly[2-methoxy-5-(2-ethylhexyloxy)-1,4-(1-cyanovinylene-1,4-phenylene)]. Also provided are methods for imaging a target to which the nanoparticles are bound. | 10-10-2013 |
20130266958 | METHOD FOR ACTIVATING HELPER T CELL - The present invention relates to a method for activating helper T cells, which includes the step of activating helper T cells by adding a WT1 peptide to antigen presenting cells, wherein the WT1 peptide has the ability to bind to any MHC class II molecule of an HLA-DRB1* 0101 molecule, an HLA-DRB1* 0401 molecule, an HLA-DRB1* 0403 molecule, an HLA-DRB1* 0406 molecule, an HLA-DRB1* 0803 molecule, an HLA-DRB1* 0901 molecule, an HLA-DRB1* 1101 molecule, an HLA-DRB3* 0202 molecule, an HLA-DRB4* 0101 molecule, an HLA-DPB1* 0201 molecule or an HLA-DPB1* 0301 molecule, and the like. | 10-10-2013 |
20130266959 | PRINCIPLE COMPONENT ANALYSIS (PCA) - BASED ANALYSIS OF DISCONTINUOUS EMISSION SPECTRA IN MULTICHROMATIC FLOW CYTOMETRY - The invention relates to a system for acquiring discontinuous emission spectra data, whereby the data is analyzed by a multivariate statistic model or equivalent model, such as principal component analysis and the use of the system for flow cytometry. | 10-10-2013 |
20130273557 | COMPOUNDS AND METHODS OF MODULATING MITOCHONDRIAL BIOENERGETIC EFFICIENCY THROUGH AN INTERACTION WITH ATP SYNTHASE (COMPLEX V) AND ITS SUBUNITS - The present invention provides, in part, methods of identifying compounds that can bind to an ATP synthase complex, increase bioenergetic efficiency, decrease oxygen consumption or the rate thereof, increase oxygen utilization efficiency, increase cell survival or any combination thereof, and methods of using compounds and/or identified compounds to increase bioenergetic efficiency, increase oxygen utilization efficiency, decrease oxygen consumption, increase cell survival, or any combination thereof. | 10-17-2013 |
20130273558 | Treatment of Conditions Involving Demyelination - The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of an Sp35 antagonist. | 10-17-2013 |
20130273559 | PROCESS FOR PREPARING A CHEMICAL STRUCTURE HAVING A PHASE PARTITION, CAPABLE OF GENERATING A SPECIFIC FLUORESCENCE SPECTRUM AND USES THEREOF - The subject matter of the invention is a process for preparing an assembled chemical structure or a mixture of such structures, this structure having a phase partition, wherein the phases are in particular of hydrophobic and hydrophilic nature, such as a composite/synthetic particle or a liposome, and being capable of generating an original fluorescence spectrum. The subject matter of the invention is also said assembled structures and mixture thereof and also the compositions or kit comprising same. The invention also relates to the use of these assembled structures and mixture thereof, in particular for medical imaging in vivo or for in vitro diagnosis of a pathological condition, but also for labelling a sample, an object or a composition that is liquid, or for authentification thereof. The invention also comprises the objects or liquids labelled with the assembled structures, a mixture thereof or with the compositions according to the invention. | 10-17-2013 |
20130273560 | ANALYZING A METABOLITE LEVEL IN A SAMPLE - The invention generally relates to methods for analyzing a metabolite level in a sample. In certain embodiments, methods of the invention may involve obtaining a sample, analyzing the sample using a mass spectrometry technique to determine a level of at least one metabolite in the sample, and correlating the metabolite level with an originating source of the sample, thereby analyzing the sample. | 10-17-2013 |
20130280732 | DIAGNOSTIC DRUG AND DIAGNOSTIC METHOD FOR ALZHEIMER'S DISEASE - The present invention provides an agent for determining Alzheimer's disease, comprising an anti-S38AA antibody, a method of determining Alzheimer's disease in a test animal, comprising detecting an S38AA fragment in a sample collected from said animal, and a method of screening for a substance that treats or prevents Alzheimer's disease, comprising contacting a test substance with a cell permitting measurement of production of a S38AA fragment, measuring the production amount of the S38AA fragment in the cell, and comparing the production amount with that of the S38AA fragment in a control cell free of contact with the test substance, and selecting a test substance that down-regulates the production amount of the S38AA fragment as a substance capable of treating or preventing Alzheimer's disease, based on the comparison results. | 10-24-2013 |
20130288265 | UBIQUITIN LIGASE ASSAYS AND RELATED REAGENTS - The disclosure provides, inter alia, methods and reagents for use in measuring the attachment of ubiquitin and ubiquitin-like proteins to a target protein, particularly an E3 protein. | 10-31-2013 |
20130288266 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BI-VALENT BINDING AGENT - A bi-valent binding agent having a first monovalent binder that binds to a polypeptide epitope of a target polypeptide, a second monovalent binder that binds to a posttranslational polypeptide modification on the target polypeptide and a linker. Further disclosed are methods for the detection of a posttranslationally modified target polypeptide, for making the disclosed bi-valent binding agent, and for use of the disclosed bi-valent binding agent in histological staining procedures. | 10-31-2013 |
20130288267 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT - A bivalent binding agent, capable of binding a polypeptide dimer, consisting of two monovalent binders linked to each other via a linker, the first monovalent binder binds an epitope of a first target polypeptide comprised in said dimer and the second monovalent binder binds to an epitope of a second target polypeptide comprised in said dimer. Each monovalent binder has a Kdiss in the range of 5×10 | 10-31-2013 |
20130295582 | PAN-KINASE ACTIVATION AND EVALUATION OF SIGNALING PATHWAYS - Methods and reagents are provided for determining the activation state of a signal transduction pathway signaling protein. There exists a need in the art for methods that can monitor the efficacy of a signal transduction inhibitor in a patient. Other needs exist for detecting and monitoring certain disease or disorders that are associated with aberrant activation of a signal transduction pathway signaling protein. The present assay provides a highly sensitive assay that is also useful in patient populations in which obtaining a large cellular sample is difficult, for example, neonates. | 11-07-2013 |
20130295583 | Method to Increase Specificity and/or Accuracy of Lateral Flow Immunoassays - The present invention includes methods and devices for preventing interfering substances from affecting the accuracy of a lateral flow immunoassay. In preferred embodiments, a test strip includes a capturing zone that includes at least one mobile capturing reagent that separates at least one interfering substance from the analyte. The capturing zone is preferably located upstream of the sample application zone. In some embodiments, the reagent/conjugate zone is also located upstream of the sample application zone. The capturing zone may be located upstream, downstream, or overlapping with the reagent/conjugate zone in these embodiments. In other preferred embodiments, one or more mobile capturing reagents are included in the elution medium/running buffer. In yet other embodiments, the capturing reagent is incorporated into a sample collection device of a sample collection system, preferably separate from the chromatographic test strip. A lysis zone is also included in some preferred embodiments. | 11-07-2013 |
20130295584 | HISTONE PROTEIN UBIQUITINATION AS A CANCER BIOMARKER - The present disclosure relates generally to the field of cancer diagnosis. More specifically, the present disclosure relates to the identification and use of monoubiquitination of histone 2B as a biomarker for the diagnosis and prognosis of cancer including, but not limited to, parathyroid cancer. The present disclosure also relates to the identification of binding between CDC73 and RNF20, and the use of CDC73 and RNF20 in an assay for screening for an agent that modulates monoubiquitination of a histone protein. | 11-07-2013 |
20130295585 | STIMULI-RESPONSIVE POLYMER DIAGNOSTIC ASSAY COMPRISING MAGNETIC NANOPARTICLES AND CAPTURE CONJUGATES - The present disclosure utilizes the aggregation of stimuli-responsive polymers to isolate a diagnostic target (e.g., an antigen) from a solution using magnetophoresis. Isolating the diagnostic target provides a route to identify the presence of the diagnostic target in the solution. | 11-07-2013 |
20130295586 | PREPARATION OF NANOCRYSTALS WITH MIXTURES OF ORGANIC LIGANDS - Semiconductor nanocrystals prepared using a mixture of organic ligands (e.g., oxoacids), as well as compositions, kits, and methods of using such semiconductor nanocrystals are disclosed. | 11-07-2013 |
20130295587 | METHOD OF COUPLING BINDING AGENTS TO A SUBSTRATE SURFACE - A chemical modification method of a defined area on a substrate surface, comprising the steps of:
| 11-07-2013 |
20130302817 | Functionalized Microfluidic Device And Method - A microfluidic device and method is provided for handheld diagnostics and assays. The device includes a base having outer surface and a channel therethough for receiving fluid therein. The channel has input and output ports communicating with the outer surface. A lid is also provided. The lid has an outer surface, a first well having a port communicating with the outer surface of the lid, and a second well having a port communicating with the outer surface. The lid moveable between a first disengaged position and a second engaged position wherein the first port of the lid is adjacent the input port of the channel and the second port is adjacent the output port of the channel. | 11-14-2013 |
20130302818 | IN SITU HEAT INDUCED ANTIGEN RECOVERY AND STAINING APPARATUS AND METHOD - An automated microscope slide staining system and staining apparatus and method that features a plurality of individually operable miniaturized pressurizable reaction compartments or a pressurizable common chamber for individually and independently processing a plurality of microscope slides. The apparatus preferably features independently movable slide support elements each having an individually operable heating element. | 11-14-2013 |
20130309688 | Efficient Processing Systems and Methods for Biological Samples - Systems and methods of sample and staining processing including compression and dynamic movement of liquids in a fluidically moving substantially contained liquid bridge perhaps between a hydrophobic wand and a hydrophilic sample support element. Embodiments may include low volume reagent and perhaps even low volume buffer wash in sample processing. In addition, antibodies can be conjugated with nanoparticles and can be used in sample processing. Exposing a sample with or without movement to AC, DC, or even a permanent magnet field may improve staining. Staining with nanoparticle reagents could be quantified using a microscope with a magnetometer below the slide viewing area. The detection of nanoparticles attached to the chemistry may facilitate the quantification of cancerous cells stained in the tissue. | 11-21-2013 |
20130316365 | Method of Preparing a Biological Sample for Inspection with Electron Microscopy and Fluorescent Light Microscopy - The invention relates to a method of forming sections for inspection in an electron microscope and a fluorescent light microscope. Conventionally these sections are made by for example the Tokuyama method, which involves freeze substitution and fixing at cryogenic temperatures. A problem is the time that it takes to come from a sample to sections, as the diffusion speed of the chemicals (organic solvents and fixatives) is extremely low. The invention comprises the sectioning of the sample at cryogenic temperature and fixing afterwards. As the sections are much thinner (e.g. 100 nm or less) than the sample (often >1 μm), the total time it takes to come from a sample to a section ready for inspection is less than 8 hours. This makes it possible to achieve results relevant for health care within one workday. | 11-28-2013 |
20130330738 | Sumoylation Control Agent and Uses Thereof - The present invention relates to novel agents that are useful for controlling sumoylation. In particular, the present invention relates to a sumoylation control agent comprising: (i) a pharmaceutically-effective amount of a HLS-5 polypeptide, isoform thereof, functional fragment thereof, or a pharmaceutical composition thereof; or (ii) a compound or composition capable of modulating the endogenous levels of HLS-5 or its activity; or (iii) combinations thereof. | 12-12-2013 |
20130330739 | Devices and Methods for Separating Magnetically Labeled Moieties in a Sample - Devices for separating magnetically labeled moieties in a sample are provided. Aspects of the devices include a magnetic field source, a first magnetic field guide having a wedge-shaped portion with an apex edge, and a second magnetic field guide having a wedge-shaped portion with an apex edge. The apex edge of the first magnetic field guide is aligned substantially across from and parallel to the apex edge of the second magnetic field guide, and the device is configured to separate magnetically labeled moieties from non-magnetically labeled moieties in the sample. Also provided are methods of using the devices, as well as systems and kits configured for use with the devices and methods. | 12-12-2013 |
20130337466 | METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE USING BIOMATERIAL - Provided is a method for diagnosing Alzheimer/s disease using a decomposed biomaterial. The method includes: preparing magnetic particles on which primary capture antibodies specifically bound to beta-amyloid are adsorbed; decomposing a biomaterial including beta-amyloid; binding the beta-amyloid to the primary capture antibodies; binding secondary capture antibodies labeled with a fluorescent material to the magnetic particles bound to the beta-amyloid to form a complex; disposing the complex in a channel region of a photo field effect transistor in which a photocurrent is changed according to the amount of incident light; and measuring the photocurrent changed by light excited from the complex to quantify the concentration of the beta-amyloid existing in the biomaterial. | 12-19-2013 |
20130337467 | P28GANK MONOCLONAL ANTIBODY AND PEPTIDES FOR PREPARATION THEREOF AND USE THEREOF - The invention provides the sequences of two polypeptides comprising the amino acid sequences as shown in SEQ ID NO:1 and SEQ ID NO:2, which can be used for the preparation of monoclonal antibodies against human p28 | 12-19-2013 |
20130337468 | COMPETITIVE BIOSENSOR HAVING ELEVATED SENSITIVITY - The present invention relates to measures for determining glucose and for diagnosing diseases based on impaired glucose metabolism. In particular the present invention relates to a device comprising a hydrogel having a glucose-binding protein and a ligand of the glucose-binding protein incorporated therein, wherein the hydrogel comprises a first hydrogel matrix made of alginate and a second hydrogel matrix which forms an interpenetrating network within the first hydrogel matrix. The invention further relates to the use of such a device for determining the glucose content in a sample and to the use of the device for diagnosing impaired glucose metabolism in a test subject. | 12-19-2013 |
20130344499 | DYES AND METHODS OF MARKING BIOLOGICAL MATERIAL - Disclosed is a dye having the chemical formula: | 12-26-2013 |
20130344500 | TISSUE ADHESIVE SUBSTRATES - Described herein are tissue adhesive substrates and methods of making such substrates. Tissue adhesive substrates comprise a glass substrate and a silane covalently bound to the glass substrate. In some variations, the silane may be an amino silane, and may comprise an aryl or an alkyl moiety. In other variations, the silane may be coated with carbon. Silanes may be deposited onto the glass substrate by vapor deposition. Tissue adhesive substrates comprising carbon-coated silanized glass substrates may be capable of retaining a tissue section through multiple cycles of antibody staining and stripping without discernible or substantial damage to the tissue section. In addition, carbon-coated tissue adhesive substrates may also provide a fiduciary marker for closed-loop autofocussing mechanisms. | 12-26-2013 |
20130344501 | METHODS FOR PRODUCING THREE-DIMENSIONAL PHYSIOLOGICALLY RELEVANT IMMUNE TISSUE SYSTEMS UNDER LOW FLUID SHEAR CONDITIONS - Methods of producing a three-dimensional, physiologically relevant immune tissue system, including culturing an immune cell and at least one other cell type separately; placing immune cell and the at least one other cell type in a low fluid shear environment for a time period; and co-culturing the cells under conditions selected to produce a three-dimensional immune tissue system with physiologically relevant characteristics. | 12-26-2013 |
20140004528 | Spectroscopic Troponin I Detection and Quantification Using Plasmonic Nano-Materials | 01-02-2014 |
20140004529 | SENSING METHOD | 01-02-2014 |
20140011210 | ACTINOBACILLUS SUIS ANTIGENS - The invention provides immunogenic compositions useful for inhibiting, treating, protecting, or preventing infection by | 01-09-2014 |
20140017698 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT - An assay for Alzheimer's disease (AD) pathology in a living patient is disclosed wherein an amount of α7nAChR or TLR4 in a FLNA-captured protein complex or α7nAChR in an Aβ-captured protein complex or α7nAChR-FLNA, or TLR4-FLNA and/or α7nAChR-Aβ | 01-16-2014 |
20140017699 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT - An assay for Alzheimer's disease (AD) pathology in a living patient is disclosed wherein an amount of α7nAChR or TLR4 in a FLNA-captured protein complex or α7nAChR in an Aβ-captured protein complex or α7nAChR-FLNA, or TLR4-FLNA and/or α7nAChR-Aβ | 01-16-2014 |
20140024041 | SOFT SUBSTRATE FOR CELL CULTURE AND PROCESS FOR PREPARING THE SAME - The present invention relates to a method for producing a soft substrate and to the soft substrate produced thereby, said substrate being particularly useful for cell culture. | 01-23-2014 |
20140030731 | REGENTS FOR PROBING ROCKS ACTIVATION - A set of agents is provided for probing/detecting the activation of Rho-associated protein kinase I and II individually encoding their amino acid sequence (SEQ ID NO:1 for ROCKI and SEQ ID NO:2 for ROCKII) in biological samples. The agents include one antibody to specifically recognize ROCKI Ser | 01-30-2014 |
20140038201 | SUB-DIFFRACTION LIMIT IMAGE RESOLUTION IN THREE DIMENSIONS - The present invention generally relates to sub-diffraction limit image resolution and other imaging techniques, including imaging in three dimensions. In one aspect, the invention is directed to determining and/or imaging light from two or more entities separated by a distance less than the diffraction limit of the incident light. In some cases, the position of the entities can be determined in all three spatial dimensions (i.e., in the x, y, and z directions), and in certain cases, the positions in all three dimensions can be determined to an accuracy of less than about 1000 nm. In some cases, the z positions may be determined using one of a variety of techniques that uses intensity information or focal information (e.g., a lack of focus) to determine the z position. Non-limiting examples of such techniques include astigmatism imaging, off-focus imaging, or multi-focal-plane imaging. | 02-06-2014 |
20140038202 | ASSAY DETECTION SYSTEMS AND METHODS - Described herein are methods and devices for detecting one or more targets in a sample using an assay device, optical illumination, and optical detection. | 02-06-2014 |
20140051091 | MODULATORS OF ALPHA-SYNUCLEIN TOXICITY - Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity. | 02-20-2014 |
20140051092 | Method And Apparatus For The Analysis Of Biological Samples - A method for the detection and quantitation of analytes of interest and variants of the analyte of interest comprising the steps of:
| 02-20-2014 |
20140057280 | METHODS AND COMPOSITIONS FOR HIGHLY SPECIFIC CAPTURE AND RELEASE OF BIOLOGICAL MATERIALS - Disclosed herein are hydrogel compositions and methods of making hydrogel compositions. Furthermore, methods of specifically capturing and releasing biological materials from a sample using the disclosed hydrogel compositions are disclosed, including methods of utilizing the compositions in microfluidic devices. | 02-27-2014 |
20140057281 | METHOD OF PRODUCING RETINAL PIGMENT EPITHELIAL CELL SHEET - The present invention provides a method of producing a cell sheet including the following steps
| 02-27-2014 |
20140057282 | SWITCHABLE AFFINITY BINDERS - Methods and kits for binding and releasing biological targets, comprising, a binder having an environmentally reactive molecular switch that can switch between a high affinity state, to bind the target, to a low affinity state, to release the target. In one embodiment, the binder is a pre-existing chemical sequence, composition, or structural configuration but unknown or unspecified and still viable as a binder for attaching a molecular switch. | 02-27-2014 |
20140065635 | PROGNOSTIC TESTS FOR DEVELOPMENT OF DERMAL STRETCH MARKS AND IMPLICATIONS FOR THE PREVENTATIVE TREATMENT THEREOF - Various methods of assessing the regenerative potential of dermal tissue in a patient may be determined and methods to determine the potential development of stretch marks in a patient are provided. Through the analysis of a series of dermal tissue samples, a method of monitoring the aging process of the dermal tissue of a patient is possible. Damaged or stretched marked skin may also be used in the development of various diagnostic therapies relating to the inducement of the extracellular matrix components of the skin due to the loss of elastic fibers generally found in stretch marked skin. | 03-06-2014 |
20140065636 | METHODS FOR MEASURING CONCENTRATIONS OF BIOMOLECULES - The present invention provides methods for measuring the absolute concentration of a biomolecule of interest in a subject. Such biomolecules may be implicated in one or more neurological and neurodegenerative diseases or disorders. Also provided is a method for determining whether a therapeutic agent affects the in vivo metabolism of a central nervous system derived biomolecule. Also provided are kits for performing the methods of the invention. | 03-06-2014 |
20140065637 | Determining Information for Cells - Systems, methods, and devices for determining information for cells are provided. The systems, methods, and devices are configured such that information for more than 100,000 cells can be determined in a single run. The devices are configured to immobilize the cells. The devices also include features that can be used by the systems and methods for determining and tracking the positions of each of the cells in the device on a cell-by-cell basis. The systems and methods are configured for substantially high resolution of the cells while the cells are immobilized in the device. In addition, environmental control subsystems are provided that can control an environment of the cells while the device is positioned in the system or the method is being performed without altering positions of the cells within the device. | 03-06-2014 |
20140065638 | Methods and Compositions for Measuring Cell Permeability - Embodiments of the present invention provide an in vitro assay that measures cell monolayer permeability. The assay utilizes detection of a binding pair initially separated by the cell monolayer as a qualitative and quantitative measure of the permeability of the monolayer. In certain embodiments, the assay is performed in the presence of a test substance that may or may not affect cell permeability. In particular aspects, the assay is performed on a substrate that is elastic. One can also assay spatial resolution of local changes by visualizing regional variations of the cell monolayers. | 03-06-2014 |
20140065639 | METHOD OF ANALYZING IMAGE OF CELL IN LAMINATED STRUCTURE AND METHOD OF EVALUATING LAMINATED STRUCTURE FOR CORNEAL TRANSPLANTATION - A method of analyzing an image of a cell in a laminated structure may include the steps of: (a) fluorescently labeling a cell nucleus in the laminated structure having at least one cell layer and one or more other types of biomolecules; (b) acquiring a plurality of planar tomographic fluorescent labeled images in different height directions from the laminated structure for each type of fluorescently labeled biomolecules after the step (a); (c) superimposing a planar tomographic fluorescent labeled image group acquired in the step (b) to construct a three-dimensional tomographic image; (d) dividing the three-dimensional tomographic image constructed in the step (c) into one or two or more cell regions; (e) producing one planar stacked image for each divided cell region after the step (d); and (f) performing image analysis on each planar stacked image produced in the step (e) to analyze cells in the laminated structure. | 03-06-2014 |
20140072981 | CYSTEINE HYDRAZIDE NICOTINAMIDE FOR GLYCOMICS AND GLYCOPROTEOMICS USES - A cysteine hydrazide nicotinamide (Cyhn) reagent designed for the enrichment of bacterial glycoproteins is provided. Methods for purification of free oligosaccharides and their analysis are also provided. | 03-13-2014 |
20140080136 | COMPOSITIONS, KITS, AND METHODS FOR DETECTING AND ANALYZING VESICLES - Provided are compositions, kits, and methods for detecting a vesicle comprising a membrane permeable marker that is converted into a detectable marker inside the vesicle. | 03-20-2014 |
20140080137 | MODIFIABLE CHEMICAL INDUCERS OF PROXIMITY AND METHODS OF USING THE SAME - Methods of reversibly inducing proximity of first and second target molecules in a sample are provided. Aspects of the methods include contacting the sample with a modifiable chemical inducer of proximity (MCIP) that reversibly induces proximity of the first and second target molecules, upon application of a stimulus that modifies the MCIP. Aspects of the invention further include methods for regulating a biological process in a cell. Aspects of the invention further include compositions, e.g., compounds and kits, etc., that find use in methods of the invention. | 03-20-2014 |
20140080138 | Biomarkers for Head-and-Neck Cancers and Precancers - The invention provides markers and methods for detecting head-and-neck precancers, (including OPLs), cancers and related disease conditions in a subject. The invention also provides localization and imaging methods for head-and-neck precancers (including OPLs) and cancers, along with kits for carrying out methods of the invention. The invention further provides therapeutic applications for head-and-neck precancers (including OPLs) and cancers which employ head-and-neck precancer and cancer markers, and binding agents for the markers. Methods of identifying a subject having oral dysplasia that is at high risk of malignant transformation are provided. | 03-20-2014 |
20140080139 | HIGH-SENSITIVITY NANOSCALE WIRE SENSORS - One aspect of the invention provides a nanoscale wire that has improved sensitivity, for example, as the carrier concentration in the wire is controlled by an external gate voltage. In one set of embodiments, the nanoscale wire has a Debye screening length that is greater than the average cross-sectional dimension of the nanoscale wire when the nanoscale wire is exposed to a solution suspected of containing an analyte. In certain instances, the Debye screening length associated with the carriers inside nanoscale wire may be adjusted by adjusting the voltage, for example, a gate voltage applied to an FET structure. In some cases, the nanoscale wire can be operated under conditions where the carriers in the nanoscale wire are depleted and the nanoscale wire has a conductance that is not linearly proportional to the voltage applied to the nanoscale wire sensor device, for example, via a gate electrode. | 03-20-2014 |
20140080140 | SCREENING FOR NEUROTOXIC AMINO ACID ASSOCIATED WITH NEUROLOGICAL DISORDERS - Methods for screening for neurological disorders are disclosed. Specifically, methods are disclosed for screening for neurological disorders in a subject by analyzing a tissue sample obtained from the subject for the presence of elevated levels of neurotoxic amino acids or neurotoxic derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neurological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a subject, by determining the levels of β-N-methylamino-L-alanine (BMAA) in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neurological disorders are disclosed. Methods for inhibiting, treating or preventing neurological disorders are disclosed. | 03-20-2014 |
20140080141 | CLEAR MARGIN DETERMINATION DURING CANCER SURGERY - One or more aqueous, near infrared emitting, high yield, highly photoluminescent, stable quantum dots conjugated to one or more biomarkers specific moieties. The conjugated quantum dots have an enhanced detection sensitivity and selectivity and may be formed using a novel and efficient method for conjugating one or more biomarker specific moieties to the quantum dots. The invention is further directed to a method for using the conjugated quantum dots for cancer detection in the margin of excised tissue. | 03-20-2014 |
20140087391 | Detection of Tumor Stem Cells and Tumor Cells in Epithelial-Mesenchymal Transition in Body Fluids of Cancer Patients - The present invention relates to the detection of tumor stem cells and tumor cells in epithelial-mesenchymal transition and uses of such methods. According to the present invention said method comprises a selecting step for selection or enrichment of said predetermined cells from the sample wherein the sample is contacted with the solid surface for preferential binding of said predetermined cells to the solid surface and then the sample is removed d from the solid surface in a washing step. The inventive method is characterized in that the sample contains a polyol at least during one of contacting the sample with the solid surface and the washing step and in a detection step detecting in said cells, preferentially selected or enriched by said selecting step, the presence or absence of expression of at least one marker associate with at least one the group comprising tumor stem cells and tumor cells in epithelial-mesenchymal transition. | 03-27-2014 |
20140093887 | PORPHYRINIC COMPOUNDS FOR USE IN FLOW CYTOMETRY - The present invention provides a method of detecting (e.g., by flow cytometry) a target compound, cell or particle, wherein the target is labelled with a detectable luminescent compound. The method comprises utilizing as the detectable luminescent compound a compound comprising a porphyrinic macrocycle such as a porphyrin, chlorin, bacteriochlorin, or isobacteriochlorin. In particular embodiments, the detectable luminescent compound comprises a compound of the formula A-A′-Z-B′-B, wherein: A is a targeting group or member of a specific binding pair that specifically binds the detectable luminescent compound to the target compound, cell or particle; A′ is a linker group or covalent bond; B′ is a linker group or covalent bond; B is a water-soluble group; and Z is the porphyrinic macrocycle. | 04-03-2014 |
20140106367 | SWALLOWTAIL MOTIFS FOR IMPARTING WATER SOLUBILITY TO PORPHYRINIC COMPOUNDS - Porphyrinic compounds that contain solubilizing groups are described, along with methods of making and using the same and compositions comprising such compounds. Examples of such compounds include compounds of Formula I: | 04-17-2014 |
20140106368 | FLUIDIZED BED DETECTOR FOR CONTINUOUS, ULTRA-SENSITIVE DETECTION OF BIOLOGICAL AND CHEMICAL MATERIALS - The present invention is generally directed to a fluidized bed detector for continuous detection of biological and chemical materials comprising a fluidized bed of detecting elements suspended in a continuous flow system wherein the detecting elements remain in the system when a first force trying to move the detecting elements to the bottom of the system is balanced with a second opposing force of a flowing gas or liquid trying to move detecting elements to the top of the system and wherein the presence of a target molecule in the flowing gas or liquid disrupts the balance of the first and second forces causing the detecting element to exit the system. The release of the detecting element indicates the presence of the target molecule and may be captured, concentrated, or both for further evaluation by other assays or other means. Also disclosed is the related method of detecting biological and chemical materials using a fluidized bed detector. | 04-17-2014 |
20140113305 | EXOSOMES AND DIAGNOSTIC BIOMARKERS - The invention provides methods for the detection of | 04-24-2014 |
20140113306 | DIAGNOSTIC AND SCREENING METHODS FOR INFLAMMATION - This invention is directed to methods, kits and compositions for the diagnosis and treatment of conditions associated with sub-clinical inflammatory conditions such as diabetes mellitus. | 04-24-2014 |
20140113307 | METHOD FOR ANALYZING PROTEIN-PROTEIN INTERACTION ON SINGLE-MOLECULE LEVEL IN CELL ENVIRONMENT, AND METHOD FOR MEASURING DENSITY OF PROTEIN ACTIVATED IN CYTOSOL - A method of analyzing protein-protein interactions includes: preparing two substrates, in which first protein-binding molecules that are biomolecules to be bound to the first proteins are attached to each of the substrates; inducing binding between the first proteins and the first protein-binding molecules on the first substrate and the second substrate, respectively, by supplying the first proteins included in the control group-cell to the first substrate among the two substrates and supplying the first proteins included in the experimental group-cell to the second substrate among the two substrates; supplying cell lysates of cells including the marker-tagged second proteins to the first substrate and the second substrate, respectively; and comparing the interactions between the first proteins and the second proteins on the first substrate and the second substrate in the supply of the cell lysates to the first substrate and the second substrate, respectively. | 04-24-2014 |
20140113308 | MCAM AS A BIOMARKER FOR FLUID HOMEOSTASIS - The application discloses MCAM as a new biomarker for fluid homeostatic imbalance; methods for predicting, diagnosing, prognosticating and/or monitoring fluid homeostatic imbalance based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 04-24-2014 |
20140120549 | HIGH SENSITIVITY QUANTITATION OF PEPTIDES BY MASS SPECTROMETRY - The instant invention provides an economical flow-through method for determining amount of target proteins in a sample. An antibody preparation (whether polyclonal or monoclonal, or any equivalent specific binding agent) is used to capture and thus enrich a specific monitor peptide (a specific peptide fragment of a protein to be quantitated in a proteolytic digest of a complex protein sample) and an internal standard peptide (the same chemical structure but including stable isotope labels). Upon elution into a suitable mass spectrometer, the natural (sample derived) and internal standard (isotope labeled) peptides are quantitated, and their measured abundance ratio used to calculate the abundance of the monitor peptide, and its parent protein, in the initial sample. | 05-01-2014 |
20140120550 | CELL ANALYSIS BY MASS CYTOMETRY - A combination of mutually exclusive cell-based analytical techniques can be applied to the same group of cells for analysis. The same group of cells can be prepared for analysis by each technique resulting with candidate cells targeted for mass cytometry analysis. This configuration allows for the correlation of the information between each technique to produce a matrix of multi dimension of cellular information with the same group of cells. | 05-01-2014 |
20140127707 | SUBJECT INFORMATION ACQUIRING APPARATUS AND METHOD - A subject information acquiring apparatus including: a generation section that generates terahertz waves to be irradiated at a test object in a plurality of kinds of states including a state in which a target material that takes a specific portion of the test object as a target has been introduced into the test object; a detection section that detects terahertz waves that are propagated from the test object and outputs a signal; a processing section that acquires information of the test object using the signals detected by the detecting section and information relating to a characteristic portion of a wavelength spectrum of the target material. | 05-08-2014 |
20140127708 | PREDICTIVE BIOMARKERS FOR PROSTATE CANCER - The invention relates to compositions and methods for detecting, screening, diagnosing or determining the progression of, regression of and/or survival from a proliferative disease or condition, specifically prostate cancer. The invention also provides new assays and kits for the staging or stratifying prostate cancer patients or patients suspected of having prostate cancer. | 05-08-2014 |
20140127709 | METHOD FOR DETERMINING THE PRESENCE OR ABSENCE OF A BIOMARKER - A method of determining the presence or absence in a sample of a biomarker, the method comprising: (a) linking an antigen to colloidal gold to provide a gold-antigen species; (b) contacting the gold-antigen species with the sample; (c) adding a diagnosis agent to the sample; and (d) observing the colour of the sample. | 05-08-2014 |
20140134637 | METHODS OF MODULATING SMYD3 FOR TREATMENT OF CANCER - The present invention features a method for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of retinoblastoma by SMYD3. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified. | 05-15-2014 |
20140134638 | ENRICHMENT OF ANTIGEN-SPECIFIC PLASMABLASTS - The present invention relates to methods for enrichment of antigen-specific plasmablasts. The methods are useful for the identification of antibodies, including rare antibodies which recognize more than one antigen. | 05-15-2014 |
20140134639 | METHOD FOR TREATMENT OF BLOOD TUMOR USING ANTI-TIM-3 ANTIBODY - Disclosed is a therapeutic method including administering a TIM-3 antibody or its TIM-3 binding fragment to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(−)CD34(+)CD38(−) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Conceived diseases include those diseases which can be treated through the binding or targeting of the TIM-3 antibody or its TIM-3 binding fragment to blood tumor cells (AML cells, CML cells, MDS cells, ALL cells, CLL cells, multiple myeloma cells, etc.), helper T cell (e.g., Th1 cells, Th17 cells), and antigen-presenting cells (e.g., dendritic cells, monocytes, macrophages, and cells resembling to the aforementioned cells (hepatic stellate cells, osteoclasts, microglial cells, intraepidermal macrophages, dust cells (alveolar macrophages), etc)). | 05-15-2014 |
20140141449 | Autoantibody Biomarkers for IGA Nephropathy - Aspects of the present invention include methods for diagnosing and monitoring IgAN in a subject. In practicing one aspect of the subject methods, a sample from a subject is analyzed for the presence of one or more specific autoantibodies to determine the IgAN phenotype of the subject. Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods. The methods and compositions find use in a variety of applications. | 05-22-2014 |
20140147857 | METHODS FOR DIAGNOSIS PROGNOSIS AND METHODS OF TREATMENT - The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN. | 05-29-2014 |
20140147858 | MONOCLONAL ANTIBODIES AGAINST PCBP-1 ANTIGENS, AND USES THEREFOR - The present invention provides and includes monoclonal antibodies specific or preferentially selective for PCBP-1 antigens, as well as methods utilizing these antibodies to determine the severity of breast cancer in a patient. | 05-29-2014 |
20140154697 | APPARATUS AND METHOD FOR MEASURING BINDING KINETICS WITH A RESONATING SENSOR - Apparatus and method for detecting a presence of a subject material in a fluid sample using at least one resonating sensor immersible in the fluid sample. Binding kinetics of an interaction of an analyte material present in the fluid sample are measured with the resonating sensor, which has binding sites for the analyte material. Prior to exposing the resonating sensor to the fluid sample, operation of the resonating sensor is initiated, which produces a sensor output signal representing a resonance characteristic of the resonating sensor. Optionally, a reference resonator is used that produces a reference output signal. The reference resonator lacks binding sites for the analyte. Introduction of a fluid sample to the resonating sensor is automatically detected based on detection of a characteristic change in the sensor output signal or a reference output signal, or both. In response to the detecting of the introduction of the fluid sample, automated measurement of the binding kinetics of the analyte material to the resonating sensor are measured. | 06-05-2014 |
20140162281 | COMPOSITIONS AND KITS FOR SEPARATING CELLS AND METHOD OF SEPARATING CELLS USING THE SAME - Provided are compositions, kits, and methods for separating cells including complexes of at least one type of linker capable of binding to an antibody or antigen binding fragment and a solid phase. | 06-12-2014 |
20140162282 | METHODS FOR DETERMINING DRUG EFFICACY USING CEREBLON-ASSOCIATED PROTEINS - Use of cereblon-associated proteins as biomarkers for clinical sensitivity to cancer, inflammatory diseases, and patient response to drug treatment. | 06-12-2014 |
20140162283 | Compositions and Methods for Detecting Mycobacterium - The present disclosure provides methods of detecting | 06-12-2014 |
20140162284 | In Vitro Assay Method Using Immunological Technique - The present invention relates to a novel method of in vitro assay of the molecules of the extracellular matrix synthesized by cells in culture and uses thereof in the form of a kit for in vitro measurement and/or for a method of screening of cosmetic and/or pharmaceutical ingredients. | 06-12-2014 |
20140170670 | Methods and Compositions for Antibody Therapy - Methods and materials are provided for determining the responsiveness of a subject to a therapy, such as an antibody therapy and for selecting and/or for treating a subject based on an FcγRIIA polymorphism, or an FcγRIIIA polymorphism, or both an FcγRIIA polymorphism and an FcγRIIIA polymorphism, including where the treatment is an therapy, such as rituximab. Methods and materials are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's FcγRIIA polymorphism, or FcγRIIIA polymorphism, or both the FcγRIIA polymorphism and the FcγRIIIA polymorphism. | 06-19-2014 |
20140170671 | APPARATUS AND METHODS FOR THREE-DIMENSIONAL TISSUE MEASUREMENTS BASED ON CONTROLLED MEDIA FLOW - An apparatus including a plurality of wells for conducting analysis of three-dimensional cell samples (e.g., tissue samples) and methods for experimenting with a three-dimensional sample. A removable insert for use with the apparatus enables plunger-driven perfusion of the three-dimensional sample. | 06-19-2014 |
20140170672 | Portable Clinical Analysis System for Immunometric Measurement - The present invention covers the integration and utility of accelerometer features into a clinical analysis system. For example, measurement of dynamic acceleration and orientation of a blood-testing instrument with respect to Earth's gravitational field may be used to determine reliability of a test procedure and optionally to provide corrective elements thereof. | 06-19-2014 |
20140186851 | METHOD OF ANALYZING BINDING EFFICIENCY OF ADHESIVE NANOPARTICLES - Provided is a method of analyzing binding efficiency of adhesive nanoparticles. The method includes (a) injecting a solution containing nanoparticles into a first chamber slide, (b) evaporating only the solution from the first chamber slide into which the solution containing the nanoparticles is injected, and measuring a saturation temperature using a thermal imager while radiating light from a light source, (c) injecting cells into a second chamber slide, (d) injecting a solution containing nanoparticles into the second chamber slide in which the cells are cultured, (e) removing nanoparticles which are not bound to the cells from the second chamber slide into which the cells and the nanoparticles are injected, and (f) evaporating only the solution from the second chamber slide from which the nanoparticles are removed, and measuring a saturation temperature using a thermal image while radiating light from the light source. | 07-03-2014 |
20140193829 | MONOCLONAL ANTIBODIES AGAINST SCRAPIE PRION PROTEIN - The present invention relates to monoclonal antibodies against PrP | 07-10-2014 |
20140193830 | OPTICAL BIOSENSORS - Provided are biosensors, compositions comprising biosensors, and methods of using biosensors in living cells and organisms. The biosensors are able to be selectively targeted to certain regions or structures within a cell. The biosensors may provide a signal when the biosensor is targeted and/or in response to a property of the cell or organism such as membrane potential, ion concentration or enzyme activity. | 07-10-2014 |
20140199704 | MULTIPLEX CELL SIGNALLING ASSAYS - Disclosed are methods useful in multiplex cell-based assays for compound screening employing imaging instrumentation. The methods described herein offer high content information relating to the biological potency of test agents, off-target effects and cellular toxicity of potential drug candidates. | 07-17-2014 |
20140206016 | Rapid Method for Detection of Pathogen - The present specification discloses methods of detecting a pathogen of interest and components useful in carrying out these methods, including a pre-enrichment media, and enrichment media and a detection solution. | 07-24-2014 |
20140212888 | T CELL RECEPTOR AND USES THEREOF - A method has been developed to efficiently proliferate and culture a CTL specific to WT1 peptides under limiting dilution conditions. Utilizing this method, CTLs capable of recognizing both a state where a wildtype WT1 specific peptide is presented by HLA-A*24:02 and a state where a mutant WT1 specific peptide is presented by HLA-A*24:02 have been successfully obtained. | 07-31-2014 |
20140212889 | METHOD FOR STAINING TISSUE - It is an object of the present invention to provide a tissue staining method that makes it possible to observe both information on the morphology of a tissue and information on a biological substance such as an antigen molecule to be detected on a single section and in a single view field. The present invention provides a tissue staining method, including carrying out (A) a HE (hematoxylin-eosin) staining, and (B) a histochemical staining, serially on a single tissue section, wherein the histochemical staining is defined as a histochemical technique for detecting a biological substance to be detected in a tissue in a visible manner by use of a binding reaction between the biological substance to be detected and a probe biological substance capable of binding specifically to the biological substance to be detected. | 07-31-2014 |
20140220588 | FLUORESCENT DYES WITH PHOSPHORYLATED HYDROXYMETHYL GROUPS AND THEIR USE IN LIGHT MICROSCOPY AND IMAGING TECHNIQUES - The invention relates to novel fluorescent dyes with phosphorylated hydroxymethyl groups, a method for preparing the same as well as to their use in imaging techniques. The fluorescent dyes are coumarin, rhodamine or BODIPY dyes having of one of the following general formulae I-III: | 08-07-2014 |
20140220589 | ULTRASENSITIVE DETECTION OF BETA HEMOLYTIC STREPTOCOCCUS - The present invention is directed to a method for the ultrasensitive detection of beta hemolytic | 08-07-2014 |
20140220590 | METHODS OF USING BENZOTHIAZOLE DERIVATIVE COMPOUNDS AND COMPOSITIONS - This invention provides benzothiazole derivative compounds, compositions comprising such compounds, methods of preparing such compounds, and methods of using such compounds for detecting amyloid deposit(s) and for diagnosing a disease, disorder or condition characterized by amyloid deposit(s). | 08-07-2014 |
20140220591 | UBIQUITIN CHAIN ANALYSIS - There is described a method for analyzing ubiquitin polymers using linkage-specific deubiquitinase enzymes. Novel specificities of deubiquitinase enzymes are also provided. | 08-07-2014 |
20140234854 | METHOD FOR EVALUATION OF PRESENCE OF OR RISK OF COLON TUMORS - The disclosed methods are used to predict or assess colon tumor status in a patient. They can be used to determine nature of tumor, recurrence, or patient response to treatments. Some embodiments of the methods include generating a report for clinical management. The methodology provided herein is intended to detect technical variations and to allow for data normalization and enhance signal detection and build predictive proteins profiles of disease status and response. | 08-21-2014 |
20140234855 | CHROMOPHORE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Chromophore compositions and methods of making and using the same are provided. Aspects of the chromophore compositions include a chromophore component having a chromophore, such as a fluorescent dye moiety, stably associated with a prosthetic group binding cavity of a metalloprotein. Also provided are methods of making, methods of use, systems and kits related to the subject fluorescent compositions. | 08-21-2014 |
20140234856 | SENSOR FOR DETECTING ANALYTES - A sensor for detecting an analyte can include a photoluminescent nanostructure embedded in a sensor hydrogel. The sensor hydrogel can be supported by a substrate hydrogel. | 08-21-2014 |
20140234857 | COMPOSITIONS AND METHODS FOR TOXIGENICITY TESTING - The present invention relates to compositions and methods for testing agents (e.g., | 08-21-2014 |
20140234858 | HSF1 AS A MARKER IN TUMOR PROGNOSIS AND TREATMENT - In some aspects, the invention relates to Heat Shock Protein-1 (HSF1) gene and HSF1 gene products. In some aspects, the invention provides methods of tumor diagnosis, prognosis, treatment-specific prediction, or treatment selection, the methods comprising assessing the level of HSF1 expression or HSF1 activation in a sample obtained from the tumor. In some aspects, the invention relates to the discovery that increased HSF1 expression and increased HSF1 activation correlate with poor outcome in cancer, e.g., breast cancer. | 08-21-2014 |
20140242601 | MOLECULARLY IMPRINTED POLYMER-BASED PASSIVE SENSOR - Systems and methods for the detection of one or more target molecules emitted from microbial sources are described. The systems and methods may include a molecularly imprinted polymer film; a strain sensitive surface, wherein the molecularly imprinted polymer film comprises a polymer host with one or more binding sites for one or more target molecules. The molecularly imprinted polymer film may be coated upon the strain sensitive surface. | 08-28-2014 |
20140242602 | USES OF LABELED HSP90 INHIBITORS - The disclosure provides evidence that the abundance of this particular “oncogenic HSP90” species, which is not dictated by HSP90 expression alone, predicts for sensitivity to HSP90 inhibition therapy, and thus is a biomarker for HSP90 therapy. The disclosure also provides evidence that identifying and measuring the abundance of this oncogenic HSP90 species in tumors predicts of response to HSP90 therapy. “Oncogenic HSP90” is defined herein as the HSP90 fraction that represents a cell stress specific form of chaperone complex, that is expanded and constitutively maintained in the tumor cell context, and that may execute functions necessary to maintain the malignant phenotype. Such roles are not only to regulate the folding of overexpressed (i.e. HER2), mutated (i.e. mB-Raf) or chimeric proteins (i.e. Bcr-Abl), but also to facilitate scaffolding and complex formation of molecules involved in aberrantly activated signaling complexes (i.e. STATS, BCL6). | 08-28-2014 |
20140242603 | METHODS AND APPARATUS FOR TARGET CELL MAGNETIC ENRICHMENT, ISOLATION AND BIOLOGICAL ANALYSIS - Disclosed here are methods and apparatus for target cell magnetic enrichment, isolation, and biological analysis. The target cells are labeled with magnetic nano-particles in a separate tube, container or in a device with soft magnetic collectors but not activated during the labeling period. Labeled biological samples will be used for targets enrichment and isolation using a magnetic device (permanent magnet or electromagnet). The labeled sample passes through a tube/channel within a magnetic field so the magnetic nano-particle labeled targets can be captured. Once the magnetic field is turned off, the captured targets can be released in a container. The labeling of the targets also can be performed in a device with soft magnetic collectors inside. Without magnetic activation, the device is just like a regular biological sample incubator. Thus the targets are labeled during the mixing and incubation. Once the device is placed in the magnetic field, the soft magnetic collectors are activated and the labeled target cells are isolated. After the washing process, the pure targets are released into the target collector by turning off the magnetic field with or without centrifugation. The magnet can be a permanent magnet or an electromagnet producing the magnetic field for targets to bind to the soft magnetic collectors in the device. The soft magnetic collectors can function as a magnet for capturing and releasing targets without the need of separation covers between magnet and target biological structures. The methods and apparatus improve the targets capturing sensitivity which improves the operation of the device. The methods and apparatus can be used for enrichment, isolation and material transferring. | 08-28-2014 |
20140242604 | ULTRA-FAST PATHOGEN TOXIN DETECTION ASSAY BASED ON MICROWAVE-ACCELERATED METAL-ENHANCED FLUORESCENCE - The present invention provides for a system and method to detect low levels of the anthrax protective antigen (PA) exotoxin in biological fluids, wherein the system uses a metal-enhanced fluorescence (MEF)-PA assay in combination with microwave-accelerated PA protein surface absorption. Microwave irradiation rapidly accelerates PA deposition onto the surface adjacent to deposited metallic particles and significantly speeding up the MEF-PA assay and resulting in a total assay run time of less than 40 min with an analytical sensitivity of less than 1 pg/ml PA. | 08-28-2014 |
20140242605 | Heat-Transfer Resistance Based Analysis of Bioparticles - A bio-sensing device suitable for the detection and/or characterization of target bioparticles and corresponding method is described. The bio-sensing technique is based on the impact on the heat transfer resistivity value of bioparticles binding in binding cavities of a structured substrate. By sensing temperatures and determining a heat transfer resistivity value based thereon, a characteristic of the target bioparticles can be derived. | 08-28-2014 |
20140248631 | DIAGNOSIS OF SEPSIS AND SYSTEMIC INFLAMMATORY RESPONSE SYNDROME - The present invention relates a method for the diagnosis, prediction or risk stratification for mortality and/or disease outcome of a subject that has or is suspected to have sepsis, comprising determining the presence and/or level of antitrypsin (ATT) or fragments thereof in a sample taken from said subject and/or determining the presence and/or level of transthyretin (TTR) or fragments thereof, wherein the presence and/or level of ATT and/or TTR or fragments thereof is correlated with an increased risk of mortality and, wherein said increased risk of mortality and/or poor disease outcome is given if the level of ATT is below a certain cut-off value and/or the level of fragments thereof is above a certain cut-off value and/or said increased risk of mortality and/or poor disease outcome is given if the level of TTR is below a certain cut-off value and/or the level of fragments thereof is below a certain cut-off value. The invention relates in general to the use of ATT and/or TTR or its fragments for the diagnosis of sepsis, and to nucleotides of SEQ ID NO. 2 to 14. | 09-04-2014 |
20140248632 | Magnetically Induced Microspinning for Super-Detection and Super-Characterization of Biomarkers and Live Cells - Identification, quantification and characterization of biological micro- and nano-systems is enabled by magnetically spinning these natural, non-magnetic systems with the aid of induced magnetization. Biofriendly magnetic micro- and nano-labels enable magnetorotation in extremely weak electromagnetic fields. The spinning of these micromotors can be observed by a simple, CD-like, optical tracking system. The spinning frequency response enables real-time monitoring of single (cancer) cell morphology, with sub-microscopic resolution, yielding previously undeterminable information. Likewise, it enables super-low detection limits for any (cancer) biomarker. | 09-04-2014 |
20140248633 | LEUKEMIA STEM CELL TARGETING LIGANDS AND METHODS OF USE - The present invention is directed to C-type lectin-like molecule-1 (CLL1) specific ligand peptides, comprising the amino acid motif LR(S/T), and methods of their use, e.g., for imaging detection for diagnosis of leukemia and the presence of leukemic stem cells (LSCs) and targeted therapy against leukemia mediated at least in part by CLL1-expressing LSCs. | 09-04-2014 |
20140248634 | VIMENTIN AS A BIOMARKER FOR THE PROGRESSION OF MYELOPROLIFERATIVE NEOPLASMS - The disclosure relates to novel compounds that are capable of modulating Jak2 kinase activities, compounds that have therapeutic use in treating or preventing a subject suffering from or susceptible to a Jak2 mediated disease or disorder, and methods of use and compositions thereof. | 09-04-2014 |
20140255950 | HERG1 AND GLUT-1 IN COLORECTAL CANCER - The present invention describes the determination of the prognostic impact of hERG1 potassium channels along with other hypoxia-related biomolecular parameters, in patients who underwent radical surgery with curative intent for non metastatic CRC. | 09-11-2014 |
20140273000 | METHODS FOR ANALYZING BLOOD TO DETECT DISEASES ASSOCIATED WITH ABNORMAL PROTEIN AGGREGATION - A method of detecting a disease associated with abnormal protein aggregation in a subject is provided, the method comprising (a) contacting leukocytes from the subject with a probe that binds to pathogenic protein aggregates, and (b) detecting the probe bound to the pathogenic protein aggregates, wherein the presence of pathogenic protein aggregates in the leukocytes is indicative that the subject has a disease associated with abnormal protein aggregation. In one embodiment, the disease is Alzheimer's disease or mild cognitive impairment. | 09-18-2014 |
20140273001 | FELINE BITTER TASTE RECEPTORS AND METHODS - A family of novel feline bitter taste receptors, referred to as feline TAS2R (fTAS2R), are disclosed herein. Isolated polynucleotides encoding the novel feline bitter taste receptors and chimeric polypeptides are also disclosed, as are expression vectors and host cells for expression of the novel feline bitter taste receptors. Methods of identifying compounds that bind to the novel feline bitter taste receptors and modulate their activity are disclosed. | 09-18-2014 |
20140273002 | NANOSPLASMONIC IMAGING TECHNIQUE FOR THE SPATIO-TEMPORAL MAPPING OF SINGLE CELL SECRETIONS IN REAL TIME - A label-free method for the spatio-temporal mapping of protein secretions from individual cells in real time by using a chip for localized surface plasmon resonance (LSPR) imaging. The chip is a glass coverslip compatible for use in a standard microscope having at least one array of functionalized plasmonic nanostructures patterned onto it. After placing a cell on the chip, the secretions from the cell are spatially and temporally mapped using LSPR imaging. Transmitted light imaging and/or fluorescence imaging may be done simultaneously with the LSPR imaging. | 09-18-2014 |
20140273003 | SUPER-RESOLUTION FLUORESCENCE LOCALIZATION MICROSCOPY - The present invention relates generally ultrasensitive assays for use in diagnostics and in methods of drug screening and personalizing therapy for an individual patient. Specifically, the present invention relates to improved imaging and computational methods for detecting molecular phenotypes. | 09-18-2014 |
20140273004 | MOLECULES AND METHODS FOR ITERATIVE POLYPEPTIDE ANALYSIS AND PROCESSING - Reagents and methods for the digital analysis of proteins or peptides are provided. Specifically provided herein are proteins for identifying the N-terminal amino acid or N-terminal phosphorylated amino acid of a polypeptide. Also, an enzyme for use in the cleavage step of the Edman degradation reaction and a method for using this enzyme are described. | 09-18-2014 |
20140273005 | Magnecytometer For The Detection Of One Or More Analytes - A system and method for analyzing a sample of liquid having an NMR signal in response to a magnetic field for the presence of an analyte. Included is an NMR device having a testing section that is adapted to contain a liquid and apply a magnetic field to the liquid. A complex comprised of a conjugate having a field gradient bound to the analyte that is of sufficient magnitude to quench the NMR signal of the liquid when in the test section whereby the presence of the complex is determined by the absence of the NMR signal. | 09-18-2014 |
20140273006 | METHOD OF THERAPY SELECTION FOR PATIENTS WITH CANCER - The present invention provides methods for detecting, measuring and quantitating the expression and activation states of signal transduction analytes in cells such as tumor cells. The invention also provides methods for selecting therapy, optimizing therapy, monitoring therapeutic efficacy, and/or detecting therapeutic resistance. Accordingly, the methods are useful for improving cancer therapy selection and disease monitoring. | 09-18-2014 |
20140287427 | COMPOSITIONS AND METHODS FOR CAPTURE OF CELLULAR TARGETS OF BIOACTIVE AGENTS - The present invention provides compositions and methods for capture and identification of the cellular targets of a bioactive agent. In particular, provided herein are bioactive agents tethered to capture ligand, cellular targets (optionally tagged with a reporter), capture proteins (optionally present as capture dimers), surfaces (e.g., displaying, capture ligands, capture proteins, or capture dimers), and methods of capturing and identifying the cellular targets of a bioactive agent therewith. | 09-25-2014 |
20140287428 | METHOD FOR DETECTION OF BACTERIA IN MILK - A method of detecting the presence of bacteria in milk is provided, wherein milk is contacted with a preparation which may comprise an effective amount of at least one type of antibodies, said antibodies being capable of specifically binding to bacteria to be detected; staining said antibodies, before or after said contacting, with a staining preparation, said staining preparation being selected so that the antibodies stained therewith exhibit a color change or a change in color concentration when in contact with said bacteria; and determining the concentration of stained antibodies bound to bacteria in said milk from the presence and/or the relative intensity of the color change caused by contacting said milk with said stained antibodies. | 09-25-2014 |
20140287429 | PRETREATMENT SOLUTION FOR IMMUNOHISTOCHEMICAL STAINING AND CONDENSED SOLUTION THEREOF - Disclosed are a pretreatment solution for immunohistochemical staining, which elutes a paraffin-containing embedding medium from a glass slide with a tissue specimen embedded in the medium, and retrieves antigenicity of the tissue specimen, and which is usable three or more times, and a pretreatment solution concentrate for immunohistochemical staining which allows ready preparation of the pretreatment solution and a method of immunohistochemical staining using the same. The pretreatment solution contains an antigen retrieving agent, particular nonionic surfactants, and cyclodextrin or a derivative thereof, with the balance being not less than 80 mass % of water. The content of the antigen retrieval agent is such that the pH of the pretreatment solution is in a predetermined range, and the content of cyclodextrin or a derivative thereof is a particular amount. | 09-25-2014 |
20140287430 | ABSORBENT PAPER AND USE THEREOF FOR BREAST CANCER DETECTION - Biological samples of mammary fluid or components thereof are obtained using a breast pump device coupled with an absorbent paper or membrane, optionally facilitated by administering oxytocin to the subject. The breast pump device stimulates expression of mammary fluid and provides for collection of diagnostic samples on the absorbent paper or membrane to evaluate breast disease, including cancer. The biological sample may include fluid containing one or more of cells or cellular components, proteins, glycoproteins, peptides, nucleotides or other desired constituents comprising a breast disease marker. Absorbent paper or membrane, and methods relating to the paper or membrane, and a breast pump device are also provided. | 09-25-2014 |
20140287431 | ANTIBODY SPECIFIC TO PROFILAGGRIN C-TERMINAL DOMAIN, AND USE THEREOF - The present invention provides an antibody specific to a C-terminal domain of a human profilaggrin gene, wherein the C-terminal domain is a peptide comprising the amino acid sequence set forth in SEQ ID NO:1 or a variant thereof, a method for detecting a filaggrin gene mutation using the antibody, and a kit for the detection. | 09-25-2014 |
20140295451 | METHOD, COMPOSITION AND KIT OF VISUALISATION AND CHARACTERIZATION OF THE NERVOUS SYSTEM BY COMBINING THE STAINING FOR METAL IMPREGNATION AND IMMUNOHISTOCHEMISTRY - A method of visualization and characterization of the nervous system, which combines two techniques for tissue staining, mercuric impregnation and immunohistochemistry, is described. The method disclosed makes compatible one with the other procedures of staining by carrying them out on tissues subjected to adequate fixing procedures. Thus, the method makes feasible to combine morphometric analysis, which can typically be carried out with mercuric impregnation, with antigenic and/or neurochemical cellular characterization, which can typically be obtained with immunohistochemistry. The method has proven simple, reliable, and suitable for both conventional microscopy and confocal laser scanning microscopy. | 10-02-2014 |
20140295452 | ANTI-CMET ANTIBODY AND ITS USE FOR THE DETECTION AND THE DIAGNOSIS OF CANCER - The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to a novel antibody capable of binding specifically to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for this antibody. The invention likewise comprises the use of said antibody, and corresponding processes, for detecting and diagnosing pathological hyperproliferative oncogenic disorders associated with expression of cMet. In certain embodiments, the disorders are oncogenic disorders associated with increased expression of cMet polypeptide relative to normal or any other pathology connected with the overexpression of cMet. The invention finally comprises products and/or compositions or kits comprising at least such antibody for the prognosis or diagnostic of certain cancers. | 10-02-2014 |
20140295453 | SAMPLE ANALYZER, SAMPLE ANALYSIS METHOD, AND NON-TRANSITORY STORAGE MEDIUM - To provide a sample analyzer capable of accurately obtaining the number of analyzable samples. When analyzing a sample collected from a subject, a CPU of the sample analyzer calculates the number of analyzable samples based on a remaining number of tests of a reagent set in a reagent holding section and the number of tests of the reagent to be consumed in measurement of a control, and causes a output section to display the number of analyzable samples. When creating a calibration curve, the CPU calculates the number of analyzable samples based on a remaining number of tests of the reagent set in the reagent holding section, the number of tests of the reagent to be consumed in measurement of the control, and the number of tests of the reagent to be consumed in measurement of a calibrator, and causes the output section to display the number of analyzable samples. | 10-02-2014 |
20140295454 | VARIANTS OF VEGFR AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF PREGNANCY ASSOCIATED MEDICAL CONDITIONS - An isolated polypeptide comprising an amino acid sequence at least 70% homologous to SEQ ID NO: 4 and an isolated polynucleotide encoding same are disclosed. A polynucleotide comprising a nucleic acid sequence capable of specifically hybridizing to the isolated polynucleotide and an isolated antibody comprising an antigen recognition domain which specifically binds the isolated polypeptide are also disclosed. Pharmaceutical compositions, methods of diagnosing and treating comprising same are also disclosed. | 10-02-2014 |
20140302515 | BIOMARKERS FOR BREAST CANCER PATIENTS - Kaiso, a transcriptional regulator with bimodal DNA-binding specificity, is over-expressed in breast cancer cells, and its nuclear localization is correlated with malignant and lymph node metastasis. Depleted expression of Kaiso in those cells results in a significant decrease in basal and EGF-induced cell migration, and this is associated with increased E-cadherin expression. The data reported and described herein provide significant evidence that Kaiso is involved in breast cancer invasion and metastasis. Kaiso nuclear localization is a biomarker that is associated with invasive and metastatic infiltrating ductal breast cancer that may be used to monitor, detect, and/or track the progress of disease in a patient. | 10-09-2014 |
20140302516 | POLYMER DOT COMPOSITIONS AND RELATED METHODS - Lyophilized polymer dot compositions are provided. Also disclosed are methods of making and using the lyophilized compositions and kits supplying the compositions. | 10-09-2014 |
20140302517 | ANTI-IDIOTYPE ANTIBODY AGAINST ANTI-C-MET ANTIBODY - Disclosed are an anti-idiotype antibody that specifically binds to an idiotope site of an anti-c-Met antibody, the use of the anti-idiotype antibody for detecting the anti-c-Met antibody, and methods, polypeptides, polynucleotides, compositions, and vaccines related thereto. | 10-09-2014 |
20140302518 | DETECTION OF INFECTIOUS PRION PROTEIN BY SEEDED CONVERSION OF RECOMBINANT PRION PROTEIN - The present disclosure relates to methods and compositions for the detection of infectious proteins or prions in samples, including the diagnosis of prion related diseases. One embodiment is an ultrasensitive method for detecting PrP-res (PrP | 10-09-2014 |
20140302519 | ENDOGLYCOSIDASE FROM STREPTOCOCCUS PYOGENES AND METHODS USING IT - The invention provides an endoglycosidase, referred to as EndoS49 and having the amino acid sequence of SEQ ID NO: 1. EndoS49 was isolated from | 10-09-2014 |
20140302520 | METABOLISM OF SOD1 IN CSF - The disclosure relates to methods for the diagnosis and treatment of neurological and neurodegenerative diseases, disorders, and associated processes. Specifically, the disclosure relates to a method for measuring the metabolism of central nervous system derived biomolecules in a subject in vivo. Further disclosed are methods for measuring the in vivo metabolism (e.g. the rate of synthesis, the rate of clearance) of neurally derived biomolecules, such as superoxide dismutase 1 (SOD1). | 10-09-2014 |
20140302521 | SAMPLE PRESERVATION METHOD AND SAMPLE PRESERVATION SUBSTRATE - The invention discloses a cellulose or glass fibre paper for preservation of biological samples, which comprises 4-30 wt % of a hydrophilic branched carbohydrate polymer. It also discloses a method for preservation of biological samples by applying and drying them on the paper. | 10-09-2014 |
20140302522 | METHOD FOR PREDICTING THE PRESENCE OF REPRODUCTIVE CELLS IN TESTIS - The present invention relates to testicular germline markers and their use for predicting the presence or not of reproductive cells in testis of an infertile or hypo fertile male subject. | 10-09-2014 |
20140308676 | CITRULLINATED PROTEINS: A POST-TRANSLATED MODIFICATION OF MYOCARDIAL PROTEINS AS MARKER OF PHYSIOLOGICAL AND PATHOLOGICAL DISEASE - Disclosed herein are methods for diagnosing cardiovascular disease. The methods comprise detection of citrullinated proteins. | 10-16-2014 |
20140308677 | PROTEINS AND METHOD FOR DETECTION OF LYME DISEASE - Recombinant | 10-16-2014 |
20140308678 | SMYD2 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS - The present invention arises from the discovery that the SMYD2 gene is both specifically over-expressed in cancer and involved in cancer cell survival. The present invention features methods for detecting or diagnosing the presence of or predisposition for developing cancer, using the SMYD2 gene as a diagnostic marker. The present invention further provides methods of screening for therapeutic substances useful in either or both of the treatment and prevention of cancer. | 10-16-2014 |
20140315212 | ALPHA TOXIN DETECTION OF GPI ANCHORED PROTEINS - The present invention relates to a method for the purification, concentration and identification of glycosylphosphatidylinositol anchored proteins (GPI-APs) from a biological sample (cells, tissues and/or blood/serum) in a patient or subject, including a human patient or subject. A new method to separate GPI-anchored glycoproteins, a class of glycoproteins found in all animal cells and fluids including serum, from other glycoproteins and proteins for the purpose of identifying potential biomarkers for various diseases, including cancer, especially breast cancer, vaginal cancer, endometrial cancer, uterine cancer, cervical cancer, pancreatic cancer and prostate cancer. The method uses the alpha-toxin from | 10-23-2014 |
20140315213 | SYSTEM FOR DETECTING RARE CELLS - This disclosure provides a system for detecting rare cells. The system includes a substrate, an extension coupled to the substrate and extending outwardly from the substrate, and a functionalized graphene oxide disposed on the extension. This disclosure also provides a method for detecting rare cells using the system of this disclosure. The method includes the steps of providing the system and introducing a sample of bodily fluid to the system such that the sample interacts with the functionalized graphene oxide. | 10-23-2014 |
20140322720 | COMPOSITION FOR DIAGNOSING, TREATING, AND PREVENTING AGE-RELATED MACULAR DEGENERATION AND METHOD FOR DIAGNOSING AGE-RELATED MACULAR DEGENERATION - There is provided a composition for diagnosing, treating, and preventing an age-related macular degeneration and a method for diagnosing an age-related macular degeneration. | 10-30-2014 |
20140322721 | MARKERS FOR PREECLAMPSIA - This document provides methods and materials related to determining whether or not a pregnant mammal (e.g., a pregnant human) has preeclampsia. For example, methods and materials related to the use of urinary podocytes to determine whether or not a pregnant human has preeclampsia are provided. | 10-30-2014 |
20140322722 | COMPOSITIONS AND METHODS FOR DETECTION OF DEFENSINS IN A PATIENT SAMPLE - Methods, devices and compositions for diagnosing, predicting and monitoring a urinary tract infection in a subject are described. The detection, prediction and monitoring of a urinary tract infection in a subject by detection of HD5 in the urine of a subject is described. | 10-30-2014 |
20140322723 | DIABETES DIAGNOSIS THROUGH THE DETECTION OF GLYCATED PROTEINS IN URINE - The invention involves methods, compositions, and kits for detecting glycated proteins in a sample (e.g., urine or other bodily fluid) from a subject. Also provided are methods, compositions, and kits for diagnosing or following a diabetic condition of the subject or screening for a diabetic condition in a population of subjects based upon the detection of the glycated protein(s) in the sample. | 10-30-2014 |
20140322724 | HOMOGENEOUS COMPETITIVE LATERAL FLOW ASSAY - A patient or animal side method and assay for eliminating the hook effect in the detection of a target analyte such as an acute phase protein in a bodily fluid in which the target analyte comprises a member of a specific binding pair comprising applying the sample to a solid phase carrier material, generating a signal in accordance with downstream movement of the labelled first or second members and the target analyte to bind with the complimentary immobilised first or second members, and detecting the presence of the target analyte in accordance with the signal generated at the complimentary immobilised first or second members. | 10-30-2014 |
20140329250 | CALCIUM-BINDING PHOTOPROTEIN - The invention provides calcium-binding photoproteins which can detect light emission with a higher sensitivity. The proteins of the invention comprising the amino acid sequence of SEQ ID NO: 2 can be used for the detection and measurement of calcium ions. The proteins of the invention are useful as reporter proteins, luminescent markers, etc. The polynucleotides of the invention are useful as reporter genes, etc. | 11-06-2014 |
20140329251 | LTBP2 AS A BIOMARKER FOR LUNG INJURY - The application discloses LTBP2 as a new biomarker for pulmonary injury; methods for the diagnosis, prediction, prognosis and/or monitoring of said pulmonary injury based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 11-06-2014 |
20140335535 | PEPTIDE MARKER FOR CANCER DIAGNOSIS AND CANCER DIAGNOSIS METHOD USING THE SAME - The present invention relates to a peptide marker for cancer diagnosis and a cancer diagnosis method using the same, more precisely to a peptide marker for cancer diagnosis screened by the following steps: separating and concentrating glycoproteins including a certain glycan chain related to the occurrence of cancer; hydrolyzing the glycoproteins to obtain polypeptides; and quantitatively analyzing the polypeptides to identify certain polypeptides that can track quantitative changes in glycoproteins glycosylated in a specific manner by the occurrence of cancer, and to a cancer diagnosis method using the said peptide marker. | 11-13-2014 |
20140335536 | VACCINE FOR THE TREATMENT OF MYCOBATERIUM RELATED DISORDERS - The invention relates to genes and proteins involved in the sporulation of | 11-13-2014 |
20140342372 | FLUORESCENT TWO-HYBRID (F2H) ASSAY FOR DIRECT VISUALIZATION OF PROTEIN INTERACTIONS IN LIVING CELLS - The present invention relates to an in vitro method for detecting protein-protein interactions comprising: (a) expressing in a eukaryotic cell a first fusion protein comprising (i) a (poly)peptide that, when expressed in a cell, accumulates at distinct sites in the nucleus of the cell or interacts with proteinaceous or non-proteinaceous structures accumulated at distinct sites in the nucleus of the cell; and (ii) a (poly)peptide specifically binding to GFP; (b) expressing in the same cell a second fusion protein comprising (i) GFP; and (ii) a bait (poly)peptide; (c) expressing in the same cell a third fusion protein comprising (i) a fluorescent (poly)peptide, the excitation and/or emission wavelength of which differs from that of GFP; and (ii) a prey (poly)peptide; and (d) detecting the fluorescence emission of the fluorescent parts of the second and the third fusion protein in the cell upon excitation, wherein a co-localization of the fluorescence emission of both fusion proteins in the cell nucleus is indicative of an interaction of the bait and the prey (poly)peptide. The invention also relates to an in vitro method for detecting protein-protein interactions comprising: (a) expressing in a eukaryotic cell a first fusion protein comprising (i) a fluorescent (poly)peptide; (ii) a (poly)peptide that, when expressed in a cell, accumulates at distinct sites in the nucleus of the cell; and (iii) a bait (poly)peptide (b) expressing in the same cell a second fusion protein comprising (i) a fluorescent (poly)peptide, the excitation and/or emission wavelength of which differs from that of the fluorescent (poly)peptide comprised in said first fusion protein; and (ii) a prey (poly)peptide and (c) detecting the fluorescence emission of the fluorescent parts of the first and the second fusion protein in the cell upon excitation, wherein a co-localization of the fluorescence emission of both fusion proteins in the cell nucleus is indicative of an interaction of the bait and the prey (poly)peptide. Furthermore, the present invention relates to methods for identifying a compound modulating the interaction of two (poly)peptides and methods of determining the relative strength of the interaction of two proteins with a third protein. | 11-20-2014 |
20140349305 | SYSTEMS AND METHODS FOR ONE OR MORE OF DETECTING, ISOLATING, IDENTIFYING, TRANSPORTING AND QUANTIFYING A TARGET ANALYTE IN A FLUID - A system for one or more of detecting, isolating, identifying, transporting, and quantifying a target analyte in a fluid suspected of containing the target analyte. The system includes a magnetic nanocomposite having one or more selectively magnetic nanoparticles in a first nanocontainer, and a first binding moiety linked to the first nanocontainer and adapted to specifically bind the target analyte, and a luminescent nanocomposite having one or more selectively luminescent nanoparticles in a second nanocontainer, and a second binding moiety linked to the second nanocontainer and adapted to specifically bind the target analyte. The magnetic nanocomposite and the luminescent nanocomposite do not specifically bind to each other in the absence of the target analyte. The first and second binding moieties may be adapted to simultaneously bind the target analyte to form a magnetic luminescent nanoassembly. | 11-27-2014 |
20140349306 | NOVEL HUMAN EXOSOMAL PROTEINS AND USE THEREOF - There are provided novel human exosomal proteins and use thereof. | 11-27-2014 |
20140349307 | Barrier Layer for Glucose Sensor - An optical glucose sensor for detecting and/or quantifying the amount of glucose in a sample comprising:
| 11-27-2014 |
20140349308 | Methods for the Diagnosis and Treatment of Neurological and Neurodegenerative Diseases, Disorders and Associated Processes - Methods for the diagnosis, prognosis, treatment and determining the efficacy of a therapeutic regimen for neurological and neurodegenerative diseases, disorders, and associated processes include using a detectable label to measure levels of alpha-synuclein. | 11-27-2014 |
20140356880 | APPARATUS FOR AUTOMATED DETERMINING OF AT LEAST TWO DIFFERENT PROCESS PARAMETERS - An apparatus for automated determining of at least two different process parameters of a process liquid of a process, especially a bioprocess, comprising: a first measuring cell, which is embodied to provide a first measurement signal dependent on a first process parameter of a first sample of the process liquid; a second measuring cell, which is embodied to provide a second measurement signal dependent on a second process parameter of a second sample of the process liquid; and a control and evaluation system, which serves for monitoring and/or controlling the process, and which is embodied to receive and to process the first and second measurement signals, especially based on the first measurement signal to determine a measured value of the first process parameter and based on the second measurement signal to determine a measured value of the second process parameter; wherein the first measurement signal and the second measurement signal serve different functions in the context of the monitoring and/or controlling of the process. The first process parameter can be a control parameter (critical process parameter, CPP), and the second process parameter can be a product quality parameter (critical quality attribute, CQA) of the process. | 12-04-2014 |
20140356881 | INSPECTION INSTRUMENT, INSPECTION SYSTEM, AND INSPECTION METHOD - With an inspection instrument in which an optical window is disposed so as to enable optical detection in a sample holder, an analysis involving use of a three-order nonlinear Raman scattering microscope, a treatment with an agent, such as staining, and an analysis involving use of a normal optical microscope are serially carried out without opening and closing of the inspection instrument. Thus, in addition to reference information based on result of analysis of a stained sample, more multiple pieces of auxiliary information related to the morphological or functional characteristics of the sample can be obtained from the sample while the reliability of comparison thereof with the reference information is well maintained. | 12-04-2014 |
20140363823 | SENSITIVE AND RAPID DETERMINATION OF ANTIMICROBIAL SUSCEPTIBILITY - The present invention relates to moving microorganisms to a surface, where they are grown in the presence and absence of antimicrobials, and by monitoring the growth of the microorganisms over time in the two conditions, their susceptibility to the antimicrobials can be determined. The microorganisms can be moved to the surface through electrophoresis, centrifugation or filtration. When the movement involves electrophoresis, the presence of oxidizing and reducing reagents lowers the voltage at which electrophoretic force can be generated and allows a broader range of means by which the target can be detected. Monitoring can comprise optical detection, and most conveniently includes the detection of individual microorganisms. The microorganisms can be stained in order to give information about their response to antimicrobials. | 12-11-2014 |
20140363824 | Fluorescent Metal Ion Indicators with Large Stokes Shifts - The present invention provides fluorogenic compounds for the detection of target metal ions wherein the compounds exhibit a Stokes shift greater than 50 nm and the detectable signal is modulated by photoinduced electron transfer (PET). The present compounds consist of three functional elements, the ion sensing moiety (chelating moiety), the reporter moiety (fluorophore or fluorescent protein) and spacer or linker between the sensing and reporter moieties of the present compound that allows for PET upon binding of a metal ion and excitation by an appropriate wavelength. | 12-11-2014 |
20140370518 | METHOD FOR DETECTING RISK OF ALZHEIMER'S DISEASE - The present invention provides a method for detecting the risk of Alzheimer's disease, comprising detecting immunomagnetic reduction signals of two biological markers in a biological sample from a subject, wherein the two biological markers is tau protein and Aβ-42 protein, respectively; and calculating concentrations of the above two biological markers and using the product of the concentrations of the above two biological markers to diagnosing the risk of Alzheimer's disease, wherein the concentration is calculated by the conversion of the magnetic reduction signals. | 12-18-2014 |
20140370519 | UNIVERSAL SAMPLE PREPARATION SYSTEM AND USE IN AN INTEGRATED ANALYSIS SYSTEM - The invention provides for devices and methods for interfacing microchips to cartridges and pneumatic manifolds. The cartridges, microchips, and pneumatic manifolds can be integrated with downstream preparation devices, such as thermal regulating devices and separation and analysis devices. | 12-18-2014 |
20140377769 | LAMIN A/C AND PRELAMINS AS INDICATORS OF FRAILTY AND VULNERABILITY OR RESILIENCY TO ADVERSE HEALTH OUTCOMES - The present invention provides LMNA gene products as biomarkers for the determination of the vulnerability of an individual to an adverse health outcome when the individual is submitted to a stressor. As herewith provided, a decreased expression of a lamin A/C polypeptide, an increased expression in a lamin precursor polypeptide or a decreased ratio between the lamin A/C polypeptide/lamin precursor polypeptide is observed in individuals who are more vulnerable to an adverse health outcome upon the introduction of a stressor. In some embodiments, these susceptible individuals are considered as frail. The present application provides methods for using this biomarker to assess the risk associated thereto, commercial packages for performing the methods, software products as well as associated systems. | 12-25-2014 |
20140377770 | THERMAL CONTRAST ASSAY AND READER - Assays used in conjunction with a thermal contrast reader are disclosed. In the assay, the test strip includes materials that can develop a thermal response if a target analyte is present in a sample. The thermal contrast reader includes housing having an opening to receive the test strip at a test location, an energy source directed at the test location and a heat sensor directed at the test location. The heat sensor is configured to sense heating of the test strip upon activation of the heat source at the test location, if the target analyte is present in the sample. The heat sensor can provide sensor output using diagnostic circuitry coupled to the sensor output and configured to provide a diagnostic output. The diagnostic output can indicate the diagnostic condition of the patient as a function of the sensor output. The present disclosure also includes methods of detecting target analytes and kits comprising lateral flow assays and thermal contrast reader. | 12-25-2014 |
20140377771 | Device and Method for Carrying out Haematological and Biochemical Measurements from a Biological Sample - The present invention concerns a device for analyzing biological parameters from a sample ( | 12-25-2014 |
20140377772 | Detection of Conductive Polymer-Labeled Analytes - The disclosure relates to the detection of analytes (e.g., biological pathogens such as bacteria or viruses) using a conductive polymer label. The disclosed detection system utilizing the conductive polymer label generally involves the formation of an analyte conjugate between the target analyte and a conductive polymer moiety conjugated to the target analyte. The conductive polymer portion of the analyte conjugate is electrically activated to form an electrically activated analyte conjugate having an increased electrical conductivity relative to the analyte conjugate as originally formed. The electrically activated analyte conjugate can then be detected by any suitable means, such as by conductimetric or electrochemical detection. | 12-25-2014 |
20150010916 | POROUS FILM MICROFLUIDIC DEVICE FOR AUTOMATIC SURFACE PLASMON RESONANCE QUANTITATIVE ANALYSIS - A porous film microfluidic device includes a sample well, a porous film support structure, including a first, second, and third port, wherein the first port is connected to the sample well, a porous film is formed over the bottom of the porous film support structure, and a glass fiber film is formed between the porous film support structure and the porous film, a waste tank connected to the second port of the porous film support structure, wherein a water absorption element is disposed in the waste tank, a buffer solution tank connected to the third port of the porous film support structure and sealed by a sealing film, and a COC plastic prism disposed over the bottom of the porous film support structure. The COC plastic prism includes a metal film in contact with the porous film and a metal oxide layer formed over the COC plastic prism. | 01-08-2015 |
20150010917 | METHOD TO IDENTIFY LIGANDS FOR SIGMA-1 RECEPTORS - An assay for identifying ligands of the σ | 01-08-2015 |
20150010918 | IMMUNOCHROMATOGRAPHIC ASSAY WITH MINIMAL REAGENT MANIPULATION - The present invention provides a method for determining the presence or absence of an analyte in a sample with minimal sample preparation. The invention further provides immuno-chromatographic devices for determining the presence or absence of an analyte in a sample from which the analyte should be extracted, this device comprising an analyte extraction zone wherein one or more mobile extraction solutions are impregnated, and wherein at least one of said extraction solutions comprises an animal serum or plasma component. | 01-08-2015 |
20150010919 | Polysiloxane Substrates with Highly-Tunable Elastic Modulus - A highly tunable bioscaffold is provided, as well as a method of manufacture of the bioscaffold and methods of use of the bioscaffold, for example for drug testing, cell propagation and for optimizing growth of a cell type, for example corneal endothelial cells. | 01-08-2015 |
20150024402 | METHOD AND KIT FOR MEASURING INTERACTION BETWEEN MOLECULES - The present invention relates to methods of measuring interaction between a first and a second molecule, for example a protein and an antibody, by conjugation of one of these molecules with nanoparticles, and measuring the interaction between the first and second molecule via changes in the optical properties of the nanoparticles. The present invention further relates to methods of coating nanoparticles. | 01-22-2015 |
20150031046 | Bioanalytical Reagent used in Heterogeneous Phase and Usage Method Thereof - A bioanalytical reagent used in a heterogeneous phase and a usage method thereof are provided to increase the signal intensity from the bioanalytical reagent. The bioanalytical reagent includes a target detector and a signal generator. The signal generator is represented by the following formula: (p1) | 01-29-2015 |
20150037810 | DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS - The increased efficacy and reduced unwanted side effects of drugs can be insured by treating only responsive patients. In an embodiment of the invention, signaling pathways that a particular drug interferes with, are derive together with predictive biomarkers and dynamic biomarker that can read the activity of these pathways before and after drug treatment in order to select a responder patient population. In an alternative embodiment of the invention, certain core pathways that the drug does not interfere with and that are known to be causally involved in a particular disease(s) can be identified, and derive the biomarkers for those to be able to exclude these patients that suffer from a disease in which those drug non effected pathways are involved from being treated with the specific drug in question. | 02-05-2015 |
20150037811 | pH-SENSITIVE FLUORESCENT SENSORS FOR BIOLOGICAL AMINES - The invention is directed to dual-analyte fluorescent chemosensors for the direct detection and visualization (imaging) of neurotransmitters released upon exocytosis. The inventive sensor exploits the high concentration of neurotransmitters (e.g., glutamate, norepinephrine, and dopamine) and capitalizes upon the pH gradient between the vesicle and synaptic cleft. | 02-05-2015 |
20150037812 | FLUORESCENT PROTEIN-BASED INDICATORS - The presently-disclosed subject matter includes fluorescent protein-based indicators for detecting ions, small molecule analytes, or combinations thereof. In some embodiments the indicators include a polypeptide, which itself includes a fluorescent polypeptide, a compound-binding polypeptide, and a polypeptide target of the compound-binding polypeptide. In some embodiments the polypeptide includes an EosFP polypeptide, a calmodulin polypeptide, and a M13 polypeptide, or fragments and/or variants thereof. The presently-disclosed subject matter also includes methods for detecting calcium in a sample with embodiments of the present polypeptides. In some embodiments the present indicators experience a permanent shift from green to red fluorescent when exposed to an detecting substance, such as calcium. | 02-05-2015 |
20150044689 | Diagnostic Test for Infectious Diseases in Cattle - The invention relates to an isolated or recombinant protein from the shark | 02-12-2015 |
20150044690 | FRET MEASUREMENT DEVICE AND FRET MEASUREMENT METHOD - FRET measurement uses a FRET probe that includes a probe element X containing a donor fluorescent substance and a probe element Y containing an acceptor fluorescent substance and enables FRET to occur when the probe element X and the probe element Y approach to each other or bind together. The modulation frequency of laser light with which the FRET probe is irradiated is adjusted to an optimum modulation frequency that maximizes a difference between the phase difference of donor fluorescence emitted from the donor fluorescent substance with respect to intensity modulation of the laser light at the time when FRET occurs and the phase difference of donor fluorescence emitted from the donor fluorescent substance with respect to intensity modulation of the laser light at the time when FRET does not occur. | 02-12-2015 |
20150050663 | Optimal Gonadotropin Dosage - The present invention provides a method for predicting the ovarian response of a subject to ovarian stimulation with a gonadotropin, said method comprising: (i) contacting monocyte or macrophage cells from said subject in vitro with a gonadotropin; and (ii) assessing uptake of said gonadotropin into said cells; wherein uptake, particularly increased uptake, of gonadotropin into said cells is indicative of reduced ovarian stimulation. | 02-19-2015 |
20150056631 | Methods and Compositions for Diagnosing Disease - The present invention relates to methods and compositions for diagnosing a disease or disorder in a subject by introducing into cells of the subject a diagnostic gene switch construct and monitoring expression of a reporter gene. The invention further relates to methods and compositions for monitoring the progression of a disease or disorder or the effectiveness of a treatment for a disease or disorder. | 02-26-2015 |
20150064711 | ASSAY LABEL - This invention relates to an assay label comprising an amorphous carbon particle, a functionalised dextran polymer attached to the surface of the carbon particle and a first member of a complementary binding pair covalently bonded to the functionalised dextran polymer. The invention also provides a device incorporating the assay label, which further comprises a radiation source adapted to generate a series of pulses of electromagnetic radiation at a wavelength such that the absorption of the radiation by the label generates energy by non-radiative decay; a sample chamber containing a transducer having a pyroelectric or piezoelectric element and electrodes which is capable of transducing energy generated by non-radiative decay into an electrical signal; and a detector which is capable of detecting the electrical signal generated by the transducer. | 03-05-2015 |
20150064712 | ANALYTIC PLATES WITH MARKABLE PORTIONS AND METHODS OF USE - An analytic plate or other substrate having a permanent etchable, laserable, and/or developable marking surface coating (referred to herein as an “etchable coating” or as a “developable coating”) that is present on at least a portion of any side or surface thereof and is used to deposit a permanent indicium thereon, and a method of using the analytic plate or substrate. | 03-05-2015 |
20150072353 | ANALYTE SENSORS, METHODS FOR PREPARING AND USING SUCH SENSORS, AND METHODS OF DETECTING ANALYTE ACTIVITY - Analyte sensors, methods for producing and using analyte sensors, methods of detecting and/or measuring analyte activity, detecting pH change, and/or, controlling the concentration of an analyte in a system, are disclosed. Embodiments of the analyte sensors according to the disclosure can provide an accurate and convenient method for characterizing analyte activity, detecting pH change, controlling the concentration of an analyte in a system, and the like, in both in vivo and in vitro environments, in particular in living cell imaging. | 03-12-2015 |
20150072354 | COMPOUNDS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LEISHMANIASIS - Compounds and methods are provided for diagnosing, preventing, treating and detecting leishmaniasis infection and stimulating immune responses in patients are disclosed. The compounds disclosed are include polypeptides and fusion proteins that contain at least one immunogenic portion of one or more | 03-12-2015 |
20150079604 | SOLUBLE IMMUNOREACTIVE TREPONEMA PALLIDUM TpN47 ANTIGENS - The invention concerns soluble variants of | 03-19-2015 |
20150079605 | Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including an Exogenously Incorporated Nucleic Acid Expressing an Exogenous Membrane Immunoglobulin Reactive to a First Antigen and Including an Endogenous Gene Expressing an Endogenous Secreted Immunoglobulin Reactive to a Second Antigen - Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin reactive to a first antigen and at least one endogenous secreted immunoglobulin reactive to a second antigen. | 03-19-2015 |
20150079606 | FLUIDIC CONNECTORS AND MICROFLUIDIC SYSTEMS - Fluidic connectors, methods, and devices for performing analyses (e.g., immunoassays) in microfluidic systems are provided. In some embodiments, a fluidic connector having a fluid path is used to connect two independent channels formed in a substrate so as to allow fluid communication between the two independent channels. One or both of the independent channels may be pre-filled with reagents (e.g., antibody solutions, washing buffers and amplification reagents), which can be used to perform the analysis. These reagents may be stored in the channels of the substrate for long periods amounts of time (e.g., 1 year) prior to use. | 03-19-2015 |
20150086997 | SYSTEMS AND DEVICES FOR ANALYSIS OF SAMPLES - Systems and methods for analysis of samples, and in certain embodiments, microfluidic sample analyzers configured to receive a cassette containing a sample therein to perform an analysis of the sample are described. The microfluidic sample analyzers may be used to control fluid flow, mixing, and sample analysis in a variety of microfluidic systems such as microfluidic point-of-care diagnostic platforms. Advantageously, the microfluidic sample analyzers may be, in some embodiments, inexpensive, reduced in size compared to conventional bench top systems, and simple to use. Cassettes that can operate with the sample analyzers are also described. | 03-26-2015 |
20150093757 | METHODS. APPARATUS AND SYSTEMS FOR DETECTION OF TOTAL PROTEIN USINGCAPILLARY ELECTROPHORESIS - Capillary electrophoresis methods for determining the relative amount of protein in a sample comprising a population of proteins are provided. The methods comprise charge and/or size separation of a target protein or a plurality of target proteins present in a sample, for example a biological sample, by capillary electrophoresis in a separation matrix comprising a haloalkane compound, and downstream detection and quantification of the total amount of protein in the sample. Optionally, the method further comprises detection and quantification of one or more specific target proteins in the sample. Systems for carrying out the methods are also provided. | 04-02-2015 |
20150111218 | CELL DIFFERENTIATION ASSAY METHOD, CELL ISOLATION METHOD, METHOD FOR PRODUCING INDUCED PLURIPOTENT STEM CELLS, AND METHOD FOR PRODUCING DIFFERENTIATED CELLS - Provided are a method for accurately evaluating the differentiation status of stem cells by selectively staining only stem cells in an undifferentiated state, and a method for positively isolating only stem cells in an undifferentiated state. Specifically provided is a method for determining differentiation of a cell comprising a step of contacting a test cell with a probe comprising protein (A) or (B) below and a step of detecting the presence of binding of the probe to the test cell. The method for determining differentiation of a cell is capable of detecting the presence or absence of an undifferentiated stem cell in test cells by using a probe that specifically reacts with undifferentiated stem cells and detecting the presence of bonding to the test cell. (A) A protein comprising an amino acid sequence shown in SEQ ID NO: 1 and recognizing a sugar chain structure of “Fucα1-2Galβ1-3GlcNAc” and/or “Fucα1-2Galβ1-3GalNAc;” and (B) a protein comprising an amino acid sequence showing 80% or more similarity to the amino acid sequence shown in SEQ ID NO: 1 and recognizing a sugar chain structure of “Fucα1-2Galβ1-3GlcNAc” and/or “Fucα1-2Galβ1-3GalNAc.” | 04-23-2015 |
20150111219 | LIPOSOMAL COMPOSITION COMPRISING A STEROL-MODIFIED LIPID AND A PURIFIED MYCOBACTERIAL LIPID CELL WALL COMPONENT AND ITS USE IN THE DIAGNOSIS OF TUBERCULOSIS - A liposomal composition comprising a sterol-modified lipid and a purified mycobacterial lipid cell wall component or analog or derivative thereof is described. The composition is useful as a lipid antigen-presenting vehicle for the detection of lipid antigen specific biomarker antibodies in antibody containing biological samples in the diagnosis of active tuberculosis. The purified lipid cell wall component is typically a purified mycolic acid or a mixture of mycolic acids from a | 04-23-2015 |
20150111220 | METHOD FOR EVALUATION OF PRESENCE OF OR RISK OF COLON TUMORS - The disclosed methods are used to predict or assess colon tumor status in a patient. They can be used to determine nature of tumor, recurrence, or patient response to treatments. Some embodiments of the methods include generating a report for clinical management. The methodology provided herein is intended to detect technical variations and to allow for data normalization and enhance signal detection and build predictive proteins profiles of disease status and response. | 04-23-2015 |
20150111221 | METHOD FOR EVALUATION OF PRESENCE OF OR RISK OF COLON TUMORS - The disclosed methods are used to predict or assess colon tumor status in a patient. They can be used to determine nature of tumor, recurrence, or patient response to treatments. Some embodiments of the methods include generating a report for clinical management. The methodology provided herein is intended to detect technical variations and to allow for data normalization and enhance signal detection and build predictive proteins profiles of disease status and response. | 04-23-2015 |
20150118688 | METHODS, SYSTEMS, AND DEVICES FOR DETECTING AND IDENTIFYING MICROORGANISMS IN MICROBIOLOGICAL CULTURE SAMPLES - Provided herein are methods, systems, and devices for detecting and/or identifying one or more specific microorganisms in a culture sample. Indicator particles, such as surface enhanced Raman spectroscopy (SERS)-active nanoparticles, each having associated therewith one or more specific binding members having an affinity for the one or more microorganisms of interest, can form a complex with specific microorganisms in the culture sample. Further, agitating magnetic capture particles also having associated therewith one or more specific binding members having an affinity for the one or more microorganisms of interest can be used to capture the microorganism-indicator particle complex and concentrate the complex in a localized area of an assay vessel for subsequent detection and identification. The complex can be dispersed, pelleted, and redispersed so that the culture sample can be retested a number of times during incubation so as to allow for real-time monitoring of the culture sample. | 04-30-2015 |
20150118689 | SYSTEMS AND METHODS FOR WHOLE BLOOD ASSAYS - A system comprised of a device for measuring hemoglobin content and/or determining a hematocrit value and/or measuring a hematocrit value, and a device for measuring or detecting an analyte, and a method for measuring or determining the presence of at least one analyte are described. | 04-30-2015 |
20150125872 | FET SENSING CELL AND METHOD OF IMPROVING SENSITIVITY OF THE SAME - The present disclosure provides a device, such as a FET sensing cell, which includes a first dielectric layer over a substrate, an active layer over the first dielectric layer, a source region in the active layer, a drain region in the active layer, a channel region in the active layer situated between the source region and the drain region, a sensing film over the channel region, a second dielectric layer over the active layer, wherein an opening is formed in the second dielectric layer and the sensing film is located within the opening, a first electrode located within the second dielectric layer and a fluidic gate region located over the second dielectric layer and extending into the opening. The present disclosure also provides a method for improving the sensitivity of a device by adjusting a sensing value. | 05-07-2015 |
20150125873 | METHOD AND DEVICE FOR DETECTING AN ANALYTE - According to the invention there is provided a method of detecting an analyte including the steps of: i) providing a sample which contains the analyte and magnetic nanoparticles, in which the magnetic nanoparticles include a magnetic body portion which acts as a signalling vector and at least one receptor moiety attached to the body portion for binding to the analyte; ii) applying a magnetic field across at least a portion of the sample to orient the magnetic nanoparticles with respect to the applied magnetic field; iii) introducing electromagnetic radiation into the sample; iv) detecting a physical property which varies in dependence on the orientation of the magnetic nanoparticles with respect to the applied magnetic field, wherein the physical property is associated with the interaction of the electromagnetic radiation with the magnetic body portion which thereby acts as a signalling vector; and v) correlating the detected physical property with the presence of the analyte. | 05-07-2015 |
20150125874 | TRANSIENT FLOW ASSAY - Described herein are assays for determining total suspended solids (TSS) in liquids. Here TSS can be determined by flowing turbid liquid samples in a porous medium. Using such an assay, TSS can be determined with small volumes of liquid and in short times without the need for dedicated optics and instruments. The assays can be used to determine total suspended solids in any liquid medium, for example, the assay can be used in an immunoprecipitin assay to determine the amount of antigen or antibody present in blood or other fluid. | 05-07-2015 |
20150125875 | METHODS FOR ISOTOPICALLY LABELING BIOMOLECULES USING MAMMALIAN CELL-FREE EXTRACTS - Methods for producing an isotope-labeled mammalian, including a human, biomolecule, such as polypeptides and proteins, in a cell-free protein synthesis system. A biomolecule standard is produced having at least one isotope different in abundance than that of the naturally occurring isotopes in the biomolecule. Methods for quantifying biomolecules standards expressed using mammalian cell-free extracts are disclosed. Methods for producing such standards, kits, systems and reagents, relating to the use of isotope-labeled biomolecule as quantification standards in mass spectrometric and nuclear magnetic resonance analysis. | 05-07-2015 |
20150132766 | IMAGING CELL SORTER - The present invention provides a cell enrichment/purification device having a function of continuously enriching cells, a function of locating the cells in a particular area of a flow path in a continuous array after the cell enrichment, a function of recognizing the shape of the cells and fluorescence emission from the cells at the same time in units of one cell based on an image, and a function of recognizing the cells based on the information on the shape and fluorescence emission to separate/purify the cells. | 05-14-2015 |
20150132767 | ERG/TFF3/HMWCK TRIPLE IMMUNOSTAIN FOR DETECTION OF PROSTATE CANCER - This invention relates to a triple immunostaining assay (ERG/TFF3/HMWCK) for sensitive and specific detection of prostate cancer. Positive staining for at least one of ERG or TFF3 combined with negative staining of HMWCK in a sample such as prostate tissue sample is indicative of cancer. | 05-14-2015 |
20150132768 | Anti-Pancreatic Cancer Antibodies - Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful therapeutic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection, diagnosis and/or treatment of cancer, such as pancreatic cancer. The antibodies, such as PAM4 antibodies, bind to a PAM4 antigen that shows unique cell and tissue distributions compared with other known antibodies such as CA19.9, DUPAN2, SPAN1, Nd2, B72.3, and Le | 05-14-2015 |
20150140569 | ELISpot diagnostic kit for neuromyelitis optica and its application - An ELISpot diagnosis kit for NMO and its application are characterized in that, the polypeptide fragment specific to NMO effector T-cell is obtained through topological conformation analysis of aquaporin-4 (AQP-4), followed by the structural analyses of the related polypeptides after combination and rearrangement so as to screen out the brand-new polypeptide fragment suitable for NMO disease diagnosis. In the ELISpot experiment, by utilizing the obtained polypeptide fragment, stimulate the effector T-cell in the NMO disease to secrete IL-4, proving the feasibility and scientific value of that polypeptide fragment in the NMO diagnosis. This method is with strong specificity, high sensitivity and easy operations, and it can be developed into the diagnosis kit for the diagnosis and differential diagnosis of NMO in the clinical examination, laying the foundation for the early discovery and treatment of NMO. | 05-21-2015 |
20150140570 | HIGH-SPEED TWO-STEP INCUBATION METHOD AND APPARATUS FOR IN-VITRO DIAGNOSTIC TESTING - An incubator including a container having an interior chamber capable of receiving a sample holder having samples, a lower heated surface disposed within the interior chamber of the container, and a movement mechanism coupled to the container and the lower heated surface. In one embodiment, the movement mechanism is configured to move the lower heated surface to a position in which the lower heated surface essentially contacts the sample holder. A method of rapidly heating and incubating a sample for biochemical or immunological testing is further disclosed. | 05-21-2015 |
20150140571 | ANTIGEN DETECTION METHOD WHICH USES LECTIN AND COMPRISES ENZYME TREATMENT STEP - An antigen detection method detects an antigen having a specific sugar chain in a sample with a lectin that binds to plural kinds of sugar chains including the specific sugar chain. The detection method includes: a first step of bringing the lectin into contact with the sample; a second step of bringing a glycohydrolase capable of cleaving at least one kind of sugar chain to which the lectin can bind into contact with the sample, the at least one kind of sugar chain excluding the specific sugar chain among the plural kinds of sugar chains; and a step of detecting the antigen bound with the lectin after the first and second steps. | 05-21-2015 |
20150140572 | COMPOSITION FOR USE IN MYCOBACTERIA DIAGNOSIS - The present invention relates to a composition having the activity of degrading the cell wall of a | 05-21-2015 |
20150147761 | SPECIFIC BIOMARKERS FOR HEPATOCELLULAR CARCINOMA (HCC) - The invention relates to specific marker proteins (biomarkers) for Hepatocellular carcinoma (HCC). The invention relates to a method for the diagnostic study of biological samples of a human for Hepatocellular carcinoma, the sample being studied for one or more proteins as a marker for Hepatocellular carcinoma, a concentration of the proteins which is elevated or decreased in relation to the healthy state indicating the presence of Hepatocellular carcinoma, a diagnostic test kit and a method of screening compounds effective in HCC. | 05-28-2015 |
20150291991 | METHODS AND COMPOSITIONS RELATING TO AMYLOIDOGENIC POLYPEPTIDES - The technology described herein relates to the expression of polypeptides, e.g. heterologous polypeptides using a bipartite curli signal sequence. | 10-15-2015 |
20150293083 | METHOD FOR DETECTING FOOD POISONING BACTERIA USING MAGNETIC NANOPARTICLES AND SOLUTION HAVING HIGH VISCOSITY - The present invention relates to a method for detecting food poisoning bacteria, and more particularly, to a method for rapidly and quantitatively isolating food poisoning bacteria contents which contaminate food and the like. The method according to the present invention is characterized by including the steps of: introducing magnetic nanoparticles which can bind to bacteria into a sample for measuring the bacteria so as to bind the magnetic nanoparticles to the bacteria; isolating the magnetic nanoparticles; passing the nanoparticles which are isolated by using magnetism through a solution having high viscosity so as to separate the magnetic nanoparticles to which bacteria are bound from magnetic nanoparticles to which no bacteria are bound; and quantifying the magnetic nanoparticles to which bacteria are bound. | 10-15-2015 |
20150306597 | REDUNDANT MICROFLUIDIC MEASUREMENT TECHNIQUES - Techniques for redundant microfluidic measurements include a substrate in which is formed a microchannel in fluid communication between an entry port and an exit port. The microchannel includes a redundant portion that has multiple sub-channels. A first sub-channel is configured to pass a first fraction of a total flow passing through the entry port. The apparatus also includes a sensor configured to detect separate signals emitted from within the first sub-channel and from within a different sub-channel in the redundant portion of the microchannel. | 10-29-2015 |
20150307593 | METHODS FOR DIAGNOSING AND/OR TREATING STERILITY - The present invention concerns a polypeptide comprising the N-terminal fragment of a cystatin, and/or a cystatin expression inducer for use for the treatment of sterility and/or infertility, and a method of diagnosing and/or predicting sterility and/or infertility of a subject and/or of a couple of subjects, which method comprises measuring the level of at least one cystatin in a biological sample of a male subject and/or measuring the level of at least one cystatin in a biological sample of a female subject, and optionally measuring further the level of at least one cathepsin in a biological sample of said male of female subject. | 10-29-2015 |
20150309025 | PROCESS AND MACHINE FOR AUTOMATED AGGLUTINATION ASSAYS - The machine is configured to perform an automated rapid plasma reagent (RPR) agglutination test or other agglutination test. The machine includes a sample rack with multiple sample locations thereon and a reagent rack for storing of reagent. A shaker assembly supports at least one microtiter plate or other well supporting structure thereon with a plurality of wells in the plate. An automated syringe or other aspirator and dispenser accesses samples and reagent and deposits them within wells of the microtiter plate. The shaker assembly shakes multiple samples within the wells of the microtiter plate according to the RPR or other agglutination test. Finally, a camera photographs the wells of the plate, preferably from above with a light source below and the plate at least partially transparent, to evaluate whether the specimen is reactive or non-reactive. Test results and photographic evidence of the test results are preferably archived within a database. | 10-29-2015 |
20150309046 | METHOD AND ANTIBODIES FOR THE IDENTIFICATION OF UBIQUITINATED PROTEINS AND SITES OF UBIQUITINATION - There is provided antibodies, epitopes and methods for detecting ubiquitinated polypeptides and ubiquitination sites in proteins. The antibodies recognize a fragment of ubiquitin that is created after samples are treated with the proteoloytical enzyme LysC (or LysN). | 10-29-2015 |
20150316541 | METHOD FOR IMMUNOLOGICALLY ASSAYING HEMOGLOBIN A1C IN SPECIMEN - Means that enables an immunoassay of hemoglobin A1c in a whole blood sample without pretreatment of the sample is disclosed. The immunoassay of hemoglobin A1c in a sample according to the present invention comprises bringing latex particles into contact with a non-pretreated whole blood sample in a hypotonic solution, and then bringing hemoglobin A1c adsorbed on the latex particles into contact with an anti-hemoglobin A1c antibody. The immunoassay is preferably carried out by an agglutination method. The hypotonic solution is, for example, a buffer containing a Good's buffer at a concentration of 0.02 to 0.2 mol/L, which Good's buffer has the maximum buffer capacity in the neutral to alkaline region. | 11-05-2015 |
20150323465 | SURFACE ENHANCED SPECTROSCOPY-ACTIVE COMPOSITE NANOPARTICLES - Submicron-sized particles or labels that can be covalently or non-covalently affixed to entities of interest for the purpose of quantification, location, identification, tracking, and diagnosis, are described. | 11-12-2015 |
20150323523 | PROCESSING OF FLUIDS CONTAINING INTERFERING PARTICLES - The invention relates to a method and a processing device for the processing of a fluid containing interfering particles, for example for the processing of blood comprising red blood cells (C). Magnetic particles (MP) are added to the fluid and distributed with the help of a magnetic field in a blocking zone (BZ) such that migration of the interfering particles (C) through the blocking zone (BZ) is impeded, preferably completely prevented. The blocking zone (BZ) hence acts as a filter element by which interfering particles (C) can for example be kept away from a detection region ( | 11-12-2015 |
20150323532 | MULTIPLE EPITOPE DETECTION IN AN FFPE TISSUE SECTION - A method for labelling a tissue section is provided. In certain embodiments, the method may comprise: (a) labeling a formalin-fixed paraffin embedded (FFPE) tissue section using a first set of labeling reagents that comprises a first primary antibody and a first labeled secondary antibody; (b) treating the labeled tissue with a protease, thereby digesting the first primary antibody and/or the first labeled secondary antibody and separating the label from the FFPE tissue section; (c) washing the tissue section to remove the separated label and the protease; and (c) labeling the FFPE tissue section using a second set of labeling reagents that comprises a second primary antibody and a second labeled secondary antibody. A kit for performing the method is also provided. | 11-12-2015 |
20150338403 | EMBODIMENTS OF A COMPOSITION COMPRISING DIATOM FRUSTULES AND A METHOD OF USING - A composition comprising a diatom frustule and a metal coating, and a method for making the same, are disclosed herein. The metal coating may comprise a metal film or metal nanoparticles, which may be attached to the surface via a linker. The composition has a surface coverage ratio of from about 1% to about 100%. The composition may also comprise an antibody. Also disclosed is a method for using the composition comprising contacting the composition with a target molecule, exposing the composition to light, and measuring the resulting Raman scattering. | 11-26-2015 |
20150346196 | ANTIBODY COMPOSITION, KIT FOR PREPARING ANTIBODY COMPOSITION, AND IMMUNOSTAINING METHOD - An antibody composition, which is an aspect of the present invention, contains at least one compound selected from the group consisting of urea and urea derivatives, the compound being contained in the antibody composition at a concentration of not less than 0.1 M and less than 1 M, the antibody composition being a solution. | 12-03-2015 |
20150346198 | Lipid Membrane Enveloped Particles with Membrane Proteins - The present invention relates to model lipid bilayers surrounding a nano- or microsized particle comprising, membrane proteins immobilized to the surface of the particle and a sheet of a lipid bilayer interspaced between the membrane proteins and enveloping said particle, wherein said membrane protein is immobilized to the surface of the particle by a linker molecule with a length of at most 5.5 nm, as well as method of using said particles in membrane protein ligand binding or activity assays. | 12-03-2015 |
20150346209 | METHOD OF LABELING SULFENIC ACID-CONTAINING PROTEINS AND PEPTIDES - A method of labeling a sulfenic acid (—SOH) group of a cysteine residue in a protein or peptide, comprises contacting said protein or peptide with a beta-ketoester to covalently couple said beta-ketoester to said cysteine residue and form a beta-ketoester-labeled cysteine residue in said protein or peptide. | 12-03-2015 |
20150355139 | GAAS-BASED DETECTOR HIGHLY STABLE IN AQUEOUS SOLUTIONS - The present invention provides semiconductor devices, particularly devices based on the Molecular Controlled Semiconductor Resistor (MOCSER), which are highly stable in aqueous solutions. The semiconductor devices of the invention may be used for the detection of various target molecules, e.g., proteins, peptides, carbohydrates and small molecules, in different solutions such as physiological solution, bodily fluids and bodily fluid-based solutions. | 12-10-2015 |
20150355201 | FOLATE DERIVATIVES, USEFUL IN PARTICULAR IN THE CONTEXT OF THE FOLATE ASSAY - Use of a folate derivative to assay in vitro the folate in a sample such as a biological sample. | 12-10-2015 |
20150362477 | DENSITY-BASED SEPARATION OF BIOLOGICAL ANALYTES USING MULTIPHASE SYSTEMS - The disclosed methods use a multi-phase system to separate samples according to the density of an analyte of interest. The method uses a multi-phase system that comprises two or more phase-separated solutions and a phase component such as a surfactant or polymer. The density of the analyte of interest differs from the densities of the rest of the sample. The density of the analyte of interest is substantially the same as one or more phases. Thus, when the sample is introduced to the multi-phase system, the analyte of interest migrates to the phase having the same density as the analyte of interest, passing through one or more phases sequentially. | 12-17-2015 |
20150368620 | METHOD OF DETACHING ADHERENT CELLS FOR FLOW CYTOMETRY - In one aspect, a method for detaching adherent cells can include adding a cell lifting solution to the media including a sample of adherent cells and incubating the sample of adherent cells with the cell lifting solution. No scraping or pipetting is needed to facilitate cell detachment. The method do not require inactivation of cell lifting solution and no washing of detaching cells is required to remove cell lifting solution. Detached cells can be stained with dye in the presence of cell lifting solution and are further analyzed using flow cytometer. The method has been tested using 6 different cell lines, 4 different assays, two different plate formats (96 and 384 well plates) and two different flow cytometry instruments. The method is simple to perform, less time consuming, with no cell loss and makes high throughput flow cytometry on adherent cells a reality. | 12-24-2015 |
20150377862 | METHOD TO EVALUATE THE TISSUE TARGETING OF A MOLECULE OF INTEREST - The invention relates to a method for evaluating if a molecule of interest binds or is incorporated in, at least one target tissue comprising visualizing and comparing the distribution of the molecule of interest and of at least one control compound within the target tissue or on the target tissue surface of at least one animal that has previously received the molecule of interest and/or the control compound. Advantageously, the distribution of the molecule of interest is visualized and compared with the distribution of positive and negative compounds using mass spectrometry imaging on the surface of the target tissue. | 12-31-2015 |
20150377865 | Method for using nanodiamonds to detect nearby magnetic nanoparticles - An imaging agent for detecting analytes in an environment includes functionalized nanodiamonds and functionalized magnetic particles that can selectively interact with an analyte. Each functionalized nanodiamond contains at least one color center configured emit light in response to illumination. At least one property of the light emitted by the color centers is related to the proximity of the functionalized magnetic particles to the color centers. This property can be detected to determine that the functionalized nanodiamonds are proximate to the functionalized magnetic particles, to determine that the functionalized nanodiamonds and the functionalized magnetic particles are interacting with the analyte, or other applications. Devices and methods for detecting properties of the analyte by interacting with the functionalized nanodiamonds and functionalized magnetic particles are also provided. | 12-31-2015 |
20150377892 | DOMINANT NEGATIVE HSP110 MUTANT AND ITS USE IN PROGNOSING AND TREATING CANCERS - The present invention relates to a mutated heat-shock protein 110 (HSP110) lacking its substrate binding domain, which does not exhibit its chaperon activity and/or is not capable of binding to best-shock protein 70 (HSP70) and/or to beat-shock protein 27 (HSP27), but which is capable of binding to a wild-type HSP110. Such a mutated heat-shock protein 110 can be used (i) in methods for proposing survival and/or the response to a treatment of a patient suffering from a cancer, more particularly from a cancer liable to have a microsatellite instability (MSI) phenotype, such as colorectal cancer (CRC), and (ii) for treating cancers. | 12-31-2015 |
20160002713 | METHODS OF MULTIPLEXING DNA SENSORS AND LOCALIZING DNA SENSOR - The present disclosure relates to a method of multiplexing DNA sensors and optionally measuring pH in cell, a method of localizing DNA sensor in Golgi Network of scFv-Furin expressing cell and a method of identifying optimal location of fluorophore pair on the DNA sensor for multiplexing DNA sensors. The DNA sensors of the present disclosure follow independent cellular pathways and do not interact with or compromise functionality of another DNA sensor. | 01-07-2016 |
20160003804 | COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION - The present invention is directed to compositions and methods for modulating c-Rel-dependent cytokine production without materially altering the level of expression of NFκB and/or the amount of IκB. The present invention is also directed to screening for modulators of c-Rel activity as determined by assaying for altered subcellular localization of c-Rel but where the level of expression of NFκB and/or the amount of IκB is materially unaltered. | 01-07-2016 |
20160003855 | USE OF LIPID PARTICLES IN MEDICAL DIAGNOSTICS - Disclosed herein are methods for identifying one or more diseased cells in a subject, methods for cancer diagnosis, methods for determining cancer progression in a subject and methods for assessing health status in a subject. | 01-07-2016 |
20160011200 | REPLICATION PROTEIN | 01-14-2016 |
20160011220 | Systems and Methods to Quantify Analytes in Keratinized Samples | 01-14-2016 |
20160024252 | Oxazoline Polymer Compositions and Use Thereof - Compositions comprising an oxazoline polymer and optional linkers to carry a variety of molecules. | 01-28-2016 |
20160025714 | APPARATUS AND METHOD FOR DETECTING AND COUNTING RARE CELLS IN BLOOD - The present invention relates to an apparatus and method for detecting and enumerating a rare cell in blood. The apparatus comprises a sample collector configured to collect a blood sample and receive a complex in which a target antibody and a marker are coupled; a measuring kit connected to the sample collector in such a way that a mixture of the blood sample and the complex is injected into the measuring kit, thereby individually trapping a blood cell; and a detector configured to detect and enumerate the rare cell having an antigen-antibody reaction with the target antibody among the blood cell trapped in the measuring kit. | 01-28-2016 |
20160025736 | HETEROGENEOUS LUMINESCENT OXYGEN CHANNELING IMMUNOASSAYS AND METHODS OF PRODUCTION AND USE THEREOF - Chemiluminescent detection systems, kits and microfluidics devices containing same, as well as methods of production and use thereof, are disclosed. Immunoassay technologies are widely used in the field of medical diagnostics. One example of a commercially used immunoassay is the induced luminescence Immunoassay (LOCI) technology. The currently available LOCI′″ technology involves a homogeneous assay {i.e., no wash steps involved) that has high sensitivity, and the assay uses several reagents and requires that two of these reagents (referred to as a ““sensibead” and a “chemibead”) held by other immunoassay reagents to be in dose proximity to achieve a signal. | 01-28-2016 |
20160032236 | NANOPORE SENSOR FOR ENZYME-MEDIATED PROTEIN TRANSLOCATION - Described herein is a device and method for translocating a protein through a nanopore and monitoring electronic changes caused by different amino acids in the protein. The device comprises a nanopore in a membrane, an amplifier for providing a voltage between the cis side and trans side of the membrane, and an NTP driven unfoldase which processed the protein to be translocated. The exemplified unfoldase is the ClpX unfoldase from | 02-04-2016 |
20160032349 | MITRECIN A POLYPEPTIDE WITH ANTIMICROBIAL ACTIVITY - The present invention provides a Mitrecin A polypeptide useful in prevention and treatment of one or more bacteria. Also provided is a method to kill or prevent growth of one or more bacteria comprising contacting the one or more bacteria with a Mitrecin A polypeptide. The target bacteria can be selected from the group consisting of a Gram-positive bacterium, a Gram-negative bacterium, or both. In one embodiment, the present invention is drawn to a polynucleotide encoding a Mitrecin A polypeptide, a vector comprising the polynucleotide, a host cell comprising the polynucleotide, or a composition comprising the Mitrecin A polypeptide, the polynucleotide, the vector, or the host cell. | 02-04-2016 |
20160033506 | METHODS OF MEASURING ADAMTS 13-MEDIATED IN VIVO CLEAVAGE OF VON WILLEBRAND FACTOR AND USES THEREOF - The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma. | 02-04-2016 |
20160041176 | ANTIBODIES AGAINST ACTIN-BINDING PROTEIN GIRDIN AND METHODS OF MAKING AND USING THE SAME - Antibodies are provided that specifically bind to Acting Binding Protein Girdin (Akt Phosphorylation Enhancer), a new substrate of serine/threonine kinase. Additionally, methods of making hybridomas for producing said antibodies and methods of detecting girdin using said antibodies are provided herein. The antibodies and methods are useful for detecting girdin in tissue samples, such as tissue samples from subjects having or suspected of having a disorder in which any of cell motility, cell movement, and angiogenesis is involved. | 02-11-2016 |
20160047733 | APPARATUS AND METHOD FOR ANALYZING AND SORTING CELL PARTICLES INSOLUTION - The present invention provides an apparatus for analyzing particles in a solution including a unit configured to place a flow cell having a flow path for flowing a sample solution containing the particles; a unit configured to illuminate the sample solution flowing through the flow path of the flow cell; a photodetector that detects a scattered light and/or fluorescence generated from the particles in the sample solution; and a unit configured to analyze the particles based on their signal intensities detected by the photodetector, wherein the flow cell has the flow path formed in a substrate, a reflection plane is formed on the side surface of the flow path, the reflection plane leads the lights generated in the flow path of the flow cell and advancing in the substrate in-plane direction to a specified region of the surface of the flow cell, and the photodetector detects the light exiting from the specified region to the outside. | 02-18-2016 |
20160047735 | ON-CHIP MICROFLUIDIC PROCESSING OF PARTICLES - A microfluidic device comprises: a channel extending from a plurality of inlets to a plurality of outlets, wherein the channel is bounded by a first wall and a second wall opposite from the first wall; and an array of obstacles disposed within the channel configured to deflect particles in a sample comprising the particles toward the second wall when the particles are flowed from the inlets to the outlets. The particles are inputted into at least one of the plurality of inlets and are deflected through a series of parallel flow streams flowing from the plurality of inlets to the plurality of outlets while being deflected toward the second wall, wherein streams in the parallel flows comprise a reagent. Microfluidic devices and methods greatly improve cell quality, streamline workflows, and lower costs. Applications include research and clinical diagnostics in cancer, infectious disease, and inflammatory disease, among other disease areas. | 02-18-2016 |
20160047767 | OPERATING IMPRINTED THIN-FILM ELECTRONIC SENSOR STRUCTURE - A method of operating an imprinted electronic sensor to sense an environmental factor includes providing spatially separated micro-channels in a cured layer on a substrate. A multi-layer micro-wire is formed in each micro-channel. Each multi-layer micro-wire includes at least a conductive layer and a reactive layer exposed to the environmental factor. The conductive layer is a cured electrical conductor located only within the micro-channel and at least a portion of the reactive layer responds to the environmental factor. A controller is provided for electrically controlling first and second groups of multi-layer micro-wires, each first and second group including one or more multi-layer micro-wires. The reactive layer is exposed to the environment. The controller measures the electrical response of the first and second groups of multi-layer micro-wires. The electrical response includes at least one of the amperometric response, the resistance, the capacitance, the impedance, the complex impedance, or the inductance. | 02-18-2016 |
20160047805 | IN SITU-DILUTION METHOD AND SYSTEM FOR MEASURING MOLECULAR AND CHEMICAL INTERACTIONS - The present invention relates to a method for testing multiple analyte concentrations within a biosensor system through a single injection of sample. The method involves flowing a fluid sample containing a neat analyte concentration along a flow path in a fluid system and diluting the sample by causing it to merge with a fluid that is free of analyte in a second flow path under laminar flow conditions. The merged fluid stream is directed through a turbulent third flow path of a very low dead volume. The third flow path carries the merged fluid stream to a sensing region where the analyte is exposed to an immobilized ligand. The concentration of analyte can be controlled in this method by adjusting the flow rates of the sample flow and analyte-free fluid flow. A fluidic system for carrying out this method is also disclosed. | 02-18-2016 |
20160047831 | MASS SPECTRAL ANALYSIS - The invention generally relates to mass spectral analysis. In certain embodiments, methods of the invention involve analyzing a lipid containing sample using a mass spectrometry technique, in which the technique utilizes a liquid phase that does not destroy native tissue morphology during analysis. | 02-18-2016 |
20160061843 | BIOMARKER ASSAY - Methods for measuring the phosphorylation of Signal Transducer and Activator of Transcription (STAT) proteins in sputum, and the application of such methods in evaluating therapeutic agents are provided. | 03-03-2016 |
20160068884 | METHODS FOR DETERMINING PRESENCE OR ABSENCE OF GLYCAN EPITOPES ON GLYCOPROTEINS - The disclosure relates to in vitro methods of detecting presence or absence of a target carbohydrate on a glycoprotein. The disclosure also relates to in vitro methods of detecting presence or absence of a glycan epitope on a glycoprotein. | 03-10-2016 |
20160069903 | METHOD FOR DETECTING CELLS - The present invention relates to methods for detecting the chromatin state of a cell based on recording a super resolution image of nucleosome organization and correlating said imaged with size of nucleosomal clutches, nucleosomal density and/or number of nucleosomes per nucleosomal clutches. Additionally, the invention relates to a kit comprising a first antibody capable of specifically binding to a histone protein and a photo switchable fluorophore linked-secondary antibody and the use of the kit of the invention for detecting the chromatin state of a cell and isolating a cell in an open chromatin state or in a close chromatin state. The invention also relates to a device adapted to detect the chromatin state of a cell. | 03-10-2016 |
20160069908 | METHODS FOR ANALYZING BLOOD TO DETECT DISEASES ASSOCIATED WITH ABNORMAL PROTEIN AGGREGATION - A method of detecting a disease associated with abnormal protein aggregation in a subject is provided, the method comprising (a) contacting non-plasma blood elements from the subject with a probe that binds to pathogenic protein aggregates, and (b) detecting the probe bound to the pathogenic protein aggregates, wherein the presence of pathogenic protein aggregates in the non-plasma blood elements is indicative that the subject has a disease associated with abnormal protein aggregation. In one embodiment, the disease is Alzheimer's disease, mild cognitive impairment or traumatic brain injury. | 03-10-2016 |
20160075797 | Anti-Vasa Antibodies, and Methods of Production and Use Thereof - Anti-VASA antibodies (mAbs), particularly humanized mAbs that specifically bind to VASA with high affinity, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-VASA mAbs are provided. The disclosure also provides nucleic acid molecules encoding the anti-VASA mAbs, expression vectors, host cells, methods for making the anti-VASA mAbs, and methods for expressing the anti-VASA mAbs. Finally, methods of using the anti-VASA mAbs to isolate and/or purify cells expressing VASA are disclosed. | 03-17-2016 |
20160076978 | DEPOSITION AND IMAGING OF PARTICLES ON PLANAR SUBSTRATES - Among other aspects, the present invention provides for the deposition of biological particles, such as cells, in a liquid, in a desired two-dimensional pattern on a planar surface of a substrate so as to permit rapid, simple, and sensitive detection of cells and/or sub-cellular components (e.g., proteins, biomarkers) disposed on the substrate. In various aspects, the systems and methods can enable reproducible high-throughput screening and/or allow for sensitive and specific detection of rare events in heterogeneous cell populations within a biological sample, with limited or no selective cell loss or sample enrichment. | 03-17-2016 |
20160077106 | DIAGNOSIS OF LIVER PATHOLOGY THROUGH ASSESSMENT OF ANTI-GAL IgG GLYCOSYLATION - Methods for diagnosing pathology of the liver in subject suspected of having such pathology by measuring the glycosylation of anti-gal IgG in various biological fluids of the subject. | 03-17-2016 |
20160084770 | SYSTEM AND METHOD OF NEPHELOMETRIC DETERMINATION OF AN ANALYTE - A nephelometry system for an automatic analysis device may include a light source, a stop, and a photodetector on the one hand and a receptacle position on the other hand that are movable relative to one another in order to improve the measurement quality of a nephelometry system. The nephelometry system may determine a location of an interval I of recorded light intensity signals which only contains light intensity signals that emerge from a scattered portion of a light beam after passing through a measurement cell placed into the nephelometry system. Methods of nephelometric determination of an analyte are also provided, as are other aspects. | 03-24-2016 |
20160084862 | INFORMATION NOTIFICATION SAMPLE PROCESSING SYSTEM AND METHODS OF BIOLOGICAL SLIDE PROCESSING - A sample processing system that may be automated and methods are disclosed where samples are arranged on a carrier element and a process operation control system automatically processes the samples perhaps robotically with an operationally-influential exteriorly-consequential information monitor or a data capture element. Significant process details as well as operationally-influential exteriorly-consequential information may be monitored and an automatic notice element may cause notification of a person at some display that may be remote. Various people may be notified, such as an administrator, a supplier, or a manufacturer of an opportunity for some action such as reagent reordering or the like. A simulated motion display may be included to “watch” simulated operation in real time or long after completion of the actual processing. | 03-24-2016 |
20160091494 | DIAGNOSTIC METHOD FOR HEPATIC CANCER - Methods and kits for analysing a sample from a test subject. The methods involve determining the level of at least one compound selected from the group consisting of N-acetylglutamate, methionine, acetylcarnitine, indole-3-acetate, 2-oxoglutarate, anserine, aspartate and butyrate in the sample from the test subject; and comparing the level of the at least one compound determined to at least one control level, wherein the levels of the at least one compound are indicative of whether the subject has hepatic cancer. | 03-31-2016 |
20160097080 | ASSAYS, METHODS AND MEANS - A novel class of hydroxylases is described having the amino acid sequence of SEQ ID NO: 2, 4, 6 and 8, and variants and fragments thereof having HIF hydroxylation activity. The polypeptides of the invention have in particular prolyl hydroxylase activity. An assay method monitors the interaction of the HIF hydroxylase with a substrate. Modulators of HIF hydroxylase are provided for use in the treatment of a condition associated with increased or decreased HIF levels or activity or for the treatment of a condition where it is desirable to modulate HIF levels or activity. | 04-07-2016 |
20160097763 | CARTRIDGE-BASED DETECTION SYSTEM - Disclosed is a cartridge-based detection system to prepare an injected sample to be investigated for determination of a microbial pathogen or another analyte of interest using a detector features a field-safe cartridge. The system features a plurality of reagent chambers located within the cartridge. The system features a rotating cylindrical dial that facilitates a sequential introduction of various fluids contained in each reagent chamber into the dial whereby the fluid washes internally for contact therein. A dial channel is located through the dial. A dual window region of interrogation is centrally located in the dial. The dial is pivoted into position to fluidly connect each mated anterior and posterior reagent chamber via the dial channel. Methods of used are also disclosed. | 04-07-2016 |
20160108089 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES - The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications. | 04-21-2016 |
20160115448 | CORTICAL INTERNEURONS AND OTHER NEURONAL CELLS PRODUCED BY THE DIRECTED DIFFERENTIATION OF PLURIPOTENT AND MULTIPOTENT CELLS - Provided are cortical interneurons and other neuronal cells and in vitro methods for producing such cortical interneurons and other neuronal cells by the directed differentiation of stem cells and neuronal progenitor cells. The present disclosure relates to novel methods of in vitro differentiation of stem cells and neural progenitor cells to produce several type neuronal cells and their precursor cells, including cortical interneurons, hypothalamic neurons and pre-optic cholinergic neurons. The present disclose describes the derivation of these cells via inhibiting SMAD and Wnt signaling pathways and activating SHH signaling pathway. The present disclosure relates to the novel discovery that the timing and duration of SHH activation can be harnessed to direct controlled differentiation of neural progenitor cells into either cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons. The present disclosure also relates to compositions of cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons, and their precursors, that are highly enriched and can be used in variety of application. These cells can be used therapeutically to treat neurodegenerative and neuropsychiatric disorders, and can be used for disease modeling and drug screening. | 04-28-2016 |
20160116384 | EXPANSION MICROSCOPY - The present invention relates to an enlarged sample of interest for microscopy and methods for enlarging a sample of interest and the optical imaging of a sample of interest with resolution better than the classical microscopy diffraction limit, by synthesizing a swellable polymer network within a sample, it can be physically expanded, resulting in physical magnification. | 04-28-2016 |
20160123851 | CELL STAINING METHOD AND SAMPLE COLLECTION TUBE USED FOR THE SAME - An object of the present invention is, in the case when a specific substance that has expressed on cells to be detected in a liquid sample is to be specifically stained, to provide a convenient cell staining method by which the damage and loss (flow out) of the cells in the collected sample are prevented, and the time has been shortened in a procedure for staining the cells in the liquid sample. Furthermore, another object of the present invention is to provide a sample collection tube that is suitable for use in the above-mentioned cell staining method. A method for specifically staining a specific substance possessed by cells in a sample, including performing the following steps in one step: (A) a step of performing an immobilization treatment of the cells; and (B) a step of performing a permeabilization treatment of the cells. | 05-05-2016 |
20160123854 | METHODS FOR PHENOTYPING OF INTACT WHOLE TISSUES - In various embodiments, the present application teaches methods and compositions for tissue clearing in which whole organs and bodies are rendered macromolecule-permeable and optically-transparent, thereby exposing their cellular structure with intact connectivity. In some embodiments, the present application teaches PACT, a protocol for passive tissue clearing and immunostaining of intact organs. In other embodiments, the present application teaches RIMS, a refractive index matching media for imaging thick tissue. In yet other embodiments, the application teaches PARS, a method for whole-body clearing and immunolabeling. | 05-05-2016 |
20160123989 | METHODS AND KITS OF DETERMINING WHETHER A SUBJECT IS SUSCEPTIBLE TO HAVE A HYPER-AGGRESSIVE BEHAVIOUR - The present invention relates to methods and kits of determining whether a subject is susceptible to have a hyper-aggressive behaviour. In particular, the present invention relates to a method for determining whether a subject is susceptible to have a hyper-aggressive behaviour comprising the steps consisting of i) isolating the auto antibodies that bind to adrenocorticotropic hormone (ACTH) from a blood sample obtained from the subject, ii) determining the affinity of the isolated autoantibodies iii) comparing the affinity determined at step ii) with a predetermined reference value and iv) concluding that the subject is susceptible to have a hyper-aggressive behaviour when the affinity determined at step ii) is higher than the predetermined reference value. | 05-05-2016 |
20160131648 | ALKYL QUINOLONES AS BIOMARKERS OF PSEUDOMONAS AERUGINOSA INFECTION AND USES THEREOF - A method of determining the | 05-12-2016 |
20160137990 | CRYSTAL STRUCTURE OF BLOOD COAGULATION FACTOR XIIIA - The present invention relates to crystal forms of blood coagulation factor XIIIa, crystal structure information obtained from them, methods of preparing such crystal forms, their use for the identification and/or design of inhibitors of blood coagulation factor XIIIa activity and methods for identifying, optimizing and designing compounds which should have the ability to interact with or inhibit blood coagulation factor XIIIa. | 05-19-2016 |
20160139143 | DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY - Particular disclosed embodiments disclosed herein concern using a one or more various mass tags, which can be specifically deposited at targets through direct or indirect enzymatic-catalyzed transformation, to provide a method for identifying targets in tissue samples. The mass tags may be labeled with stable isotopes to produce mass tags having the same chemical structure but different masses. Mass codes produced by ionizing the mass tags are detected and/or quantified using mass spectrometry. The method can be used for multiplexed detection of multiple targets in a particular sample. In some embodiments, a map divided into sections representing sections of the tissue sample may be prepared, with the map sections including data corresponding to quantification data wherein the size of a mass peak is determined and correlated with the amount of a target for the corresponding tissue sample section. | 05-19-2016 |
20160139144 | ASSAYS FOR DETECTION OF PHENYLALANINE AMMONIA-LYASE AND ANTIBODIES TO PHENYLALANINE AMMONIA-LYASE - Provided herein are methods of detecting the presence of a pegylated enzyme, an enzyme-specific antibody (e.g., a neutralizing antibody or of a particular isotype), or a polyethylene glycol (PEG)-specific antibody in a sample, such as a bodily fluid or tissue of a patient. In certain embodiments, the enzyme is phenylalanine ammonia-lyase (PAL), such as | 05-19-2016 |
20160153997 | OLIGOPEPTIDE SPECIFIC TO COLORECTAL CANCER CELL AND APPLICATION THEREOF | 06-02-2016 |
20160161478 | Systems and Methods for Bioprocess Analysis - Disclosed herein are systems, methods, and devices for monitoring and controlling bioprocess parameters. The systems and methods enable automated operation with real-time analysis of process conditions and analyte or biologic production. | 06-09-2016 |
20160161484 | PEPTIDES DERIVED FROM MYOSIN 19 AND METHODS OF USE THEREOF - Isolated peptides and compositions comprising same are provided. Further, methods for targeting mitochondria in a cell, methods for assessing mitochondrial function in a cell and methods for diagnosing mitochondria associated diseases are provided. | 06-09-2016 |
20160169894 | ASSAYS FOR BTK INHIBITORS | 06-16-2016 |
20160169905 | A METHOD OF DIAGNOSING TUBERCULOSIS | 06-16-2016 |
20160178618 | 3D TISSUE MODEL FOR SPATIALLY CORRELATED ANALYSIS OF BIOCHEMICAL, PHYSIOLOGICAL AND METABOLIC MICRO-ENVIRONMENTS | 06-23-2016 |
20160178636 | Conjugating Molecules to Particles | 06-23-2016 |
20160193606 | METHODS OF AND DEVICES FOR CAPTURING CIRCULATING TUMOR CELLS | 07-07-2016 |
20160195515 | CORNEODESOMOSOMES AND BARRIER FUNCTION MATURATION | 07-07-2016 |
20160195526 | IN-VITRO MAGNETIC RESONANCE DETECTION OF A TARGET SUBSTANCE | 07-07-2016 |
20160195535 | METHOD FOR DETECTING PROSTATIC BASAL CELLS | 07-07-2016 |
20160195537 | BIOMARKERS FOR CHOLANGIOCELLULAR CARCINOMA (CCC) | 07-07-2016 |
20160195550 | METABOLISM OF SOD1 IN CSF | 07-07-2016 |
20160195561 | Analysis Device and Analysis Method | 07-07-2016 |
20160202256 | Biosensors Engineered from Conditionally Stable Ligand-Binding Domains | 07-14-2016 |
20160252503 | A TESTING DEVICE FOR TESTING ANALYTES IN LIQUID SAMPLES | 09-01-2016 |
20160252506 | SILICON NANOWIRE-BASED SENSOR ARRAYS | 09-01-2016 |
20160377630 | METHODS TO DETERMINE THE PRESENCE OF AN ANTIBODY THAT BINDS MODIFIED HUMAN THYMIC STROMAL LYMPHOPOIETIN (TSLP) - Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described. | 12-29-2016 |
20170234802 | IMPROVEMENTS IN AND RELATING TO DEVICES | 08-17-2017 |
20170234817 | LATERAL FLOW ASSAYS WITH THERMAL CONTRAST READERS | 08-17-2017 |
20170234875 | Methods and kits for screening transplant recipients and candidates | 08-17-2017 |
20180024072 | METHODS AND APPARATUS FOR INFRARED AND MID-INFRARED SENSING | 01-25-2018 |
20180024124 | An Extraction Reagent of Immunosuppressant Drug for Immunoassays | 01-25-2018 |
20180024149 | PREDICTIVE MARKERS OF IBD | 01-25-2018 |
20190145961 | PPAR AGONIST OR LXR AGONIST FOR USE IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS BY MODULATION OF LAP ACTIVITY | 05-16-2019 |
20190145966 | MEMBRANE-BASED ANALYTICAL DEVICE FOR BODILY FLUIDS | 05-16-2019 |
20190145967 | INDEX OF LOCAL SEVERITY OF ATOPIC DERMATITIS IN SKIN AND THERAPEUTIC EFFECT THEREON | 05-16-2019 |
20190145987 | A NEW BIOMARKER EXPRESSED IN PANCREATIC BETA CELLS USEFUL IN IMAGING OR TARGETING BETA CELLS | 05-16-2019 |
20220137045 | METHOD FOR ESTIMATING THE EFFECTIVENESS OF TREATMENT WITH AN ANTI-CD20 AGENT IN A PATIENT WITH RHEUMATOID ARTHRITIS AND HAVING HAD AN INADEQUATE RESPONSE TO AT LEAST ONE BIOTHERAPY - The present invention relates to a method for estimating the effectiveness of treatment with an anti-CD20 agent in a patient with rheumatoid arthritis and who has had an inadequate response to at least one prior biotherapy, consisting in analysing a biological sample of said patient for the expression of a set of biomarkers, the results of which make it possible to determine whether said agent is a treatment that will engender a beneficial response for said patient. The present invention also relates to a system for estimating the effectiveness of said treatment in said patient comprising means for measuring or receiving data, the expression level of said biomarkers and means for processing these data configured to estimate said effectiveness of said treatment in said patient. | 05-05-2022 |
20220137046 | CHIMERIC PROTEIN, METHOD OF PRODUCTION AND USE THEREOF, AND ALSO A NUCLEIC ACID MOLECULE, EXPRESSION CASSETTE, EXPRESSION VECTOR, HOST CELL, COMPOSITION FOR THE DIAGNOSIS OF LEISHMANIASIS, KIT FOR THE DIAGNOSIS OF LEISHMANIASIS AND METHOD OF DIAGNOSIS OF LEISHMANIASIS IN VITRO - The present invention relates to chimeric proteins, their uses and production method comprising native protein fractions from | 05-05-2022 |
20220137060 | FULL LENGTH KINASE ACTIVITY-CONFORMATION REPORTER - The present invention provides a reporter for a protein fragment complementation assay characterized in that the reporter is a fused protein comprising a first fragment, a second fragment and a protein kinase sequence section, wherein the first fragment and the second fragment are derived from different sections of the same split protein, and wherein the protein kinase sequence section intervenes between the first fragment and the second fragment and wherein the kinase sequence section comprises a kinase domain sequence and one or more regulatory sequence(s). Further the invention provides polynucleotides and cells encoding for the reporter as well as methods of conducting a protein fragment complementation assay with the reporter according to the invention. | 05-05-2022 |
20220137062 | KIT FOR PREPARING SAMPLE FOR DETECTING MONOCLONAL ANTIBODY - A sample preparation kit related to the present invention provides a significantly versatile analytical technique that is not affected by the diversity of antibodies, difference in species, matrix and the like. For preparing a sample to be used for detection of a monoclonal antibody through high-performance liquid chromatography-mass spectrometry (LC-MS), the kit includes a porous body for immobilizing a monoclonal antibody to be detected; nanoparticles with an immobilized protease; a reaction vessel for selectively digesting the monoclonal antibody by bringing the porous body and nanoparticles into contact; a buffer to be introduced into the reaction vessel along with the nanoparticles and porous body so that a protease reaction is carried out; and a filtration membrane to remove the porous body and nanoparticles after the proteolysis so as to extract the reaction product and the buffer. | 05-05-2022 |
20220137063 | Proteoform Specific Process Validation - A system and method is provided for validating the manufacturing process for the production of complex biological compositions, and particularly for providing process validation information for evaluation by a federal regulatory agency. The system and method continuously and chronologically assess the concentration of proteoforms within the biological composition as it is being produced in a fermentor. Samples from the fermentor are analyzed in a pre-selected array of analysis columns, with data generated by the columns being accumulated and evaluated, and particularly compared with data from previous stages in the production process. A continuous process validation system includes top-down and bottom-up analysis sectors, each including a plurality of different analysis columns that can be selected by the controller for a particular biological composition and a particular production process. | 05-05-2022 |
20220137067 | ANTIBODY POTENCY ASSAY - The present invention provides a cell-based assay for measuring antibody potency. Antigen, bound to a surface, is contacted with the antibody which in turn is contacted with a reporter cell. Compositions and kits are also contemplated. | 05-05-2022 |
20080199910 | Production of recombinant insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) in transgenic monocots - Two important human proteins, insulin growth factor I (IGF-I) and insulin growth factor binding protein 3 (IGFBP-3) have been produced in monocots. The recombinantly produced proteins exhibit the known activities of the native forms. | 08-21-2008 |
20080199911 | VP1 OF FOOT-AND-MOUTH DISEASE VIRUS - A pure, water-soluble polypeptide containing one or more monomers of a VP1 protein of a foot-and-mouth disease virus; or a pure, water-insoluble polypeptide comprising two or more monomers of a VP1 protein of a foot-and-mouth disease virus. Also disclosed are a vaccine containing the polypeptide, a method of producing the polypeptide, and a method of inducing an immune response in a subject by administering to the subject an effective amount of the polypeptide. | 08-21-2008 |
20080199912 | Methods for Obtaining Optically Active Epoxides and Diols from 2,3-Disubstituted and 2,3-Trisubstituted Epoxides - The invention provides yeast strains, and polypeptides encoded by genes of such yeast strains, that have enantiospecific internal epoxide hydrolase activity. The invention also features nucleic acid molecules encoding such polypeptides, vectors containing such nucleic acid molecules, and cells containing such vectors. Also embraced by the invention are methods for obtaining optically active internal epoxides and corresponding optically active internal diols. | 08-21-2008 |
20080199913 | Production of Recombinant Il-18 Binding Protein - The invention relates to a process for the production of IL-18 binding protein (IL-18BP), and to a composition comprising IL-18BP characterized by a specific glycosylation pattern. | 08-21-2008 |
20080227158 | NOVEL POLYPEPTIDE, NOVEL DNA AND NOVEL ANTIBODY - The present invention relates to a polypeptide having an activity of suppressing aging; DNA encoding the polypeptide; a method for improving livestock, using the DNA; a recombinant DNA prepared by inserting the DNA into a vector; a transformant harboring the recombinant; a method for preparing the polypeptide of the present invention, using the transformant; an antibody which recognizes the polypeptide; a ligand for the polypeptide of the present invention; a compound inhibiting specific binding between the polypeptide and ligand of the present invention; a compound enhancing the expression of an aging-suppressing gene encoding the aging-suppressing polypeptide of the present invention; an oligonucleotide comprising a sequence of 10 to 50 nucleotides in the nucleotide sequence of the DNA; and a therapeutic agent for a syndrome resembling premature aging, a therapeutic agent for adult diseases or an aging-suppressing agent, using the same. | 09-18-2008 |
20080254513 | Cell Culture Medium - The invention relates to nutrient media, in particular cell culture media, which contain at least one substance selected from the group comprising citric acid, succinic acid, malic acid, α-keto-glutaric acid, fumaric acid, oxalacetic acid, isocitric acid, oxalosuccinic acid, tartaric acid, lactic acid, adipic acid and mixtures thereof and salts, derivatives or complexes of these acids. The invention further relates to the use and methods of production of said cell culture media, methods of cultivation of a cell culture in a cell culture medium according to the invention and cells that can be obtained by said methods. | 10-16-2008 |
20080311625 | Immortal Pluripotent Stem Cell Line, Cell Lines Derived Therefrom, Methods of Preparing Thereof and Their Uses - The present invention relates to immortal pluripotent stem cells derived from a human leukaemia cell line, preferably a human monocytoid cell line and more preferably the human monocytoid cell line, THP1. The present invention further relates to cell lines derived from the immortal pluripotent stem cell line having the phenotype of cell strains characteristic of human tissues, particularly having a human hepatocyte phenotype, as well as the methods for preparing thereof. The present invention further relates to the use of the derived cell line with a human hepatocytic phenotype for the production of albumin and blood coagulation factors. | 12-18-2008 |
20080318277 | Expression of human milk proteins in transgenic plants - The invention is directed to seed and seed extract compositions containing levels of a human milk protein between 3-40% or higher of the total protein weight of the soluble protein extractable from the seed. Also disclosed is a method of producing the seed with high levels of extractable human milk protein. The method includes transforming a monocotyledonous plant with a chimeric gene having a protein-coding sequence encoding a protein normally present in human milk under the control of a seed maturation-specific promoter. The method may further includes a leader DNA sequence encoding a monocot seed-specific transit sequence capable to target a linked milk protein to a storage body. | 12-25-2008 |
20090111147 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides - Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses. | 04-30-2009 |
20100093037 | GROWTH OF MICROORGANISMS IN MEDIA CONTAINING SOY COMPONENTS - The present invention provides novel methods of growing of microorganisms in cell culture media comprising soy components (e.g., soy molasses) as a carbon source. The present invention further provides novel cell culture media comprising soy components (e.g., soy molasses) as a carbon source. In certain embodiments, inventive cell culture media substantially lack a carbon source other than soy molasses (e.g., the media substantially lack glucose and glycerol). In certain embodiments, inventive cell culture media comprise soy components (e.g., soy molasses) as the sole carbon source. | 04-15-2010 |
20100184147 | METHOD FOR CONTROLLING pH, OSMOLALITY AND DISSOLVED CARBON DIOXIDE LEVELS IN A MAMMALIAN CELL CULTURE PROCESS TO ENHANCE CELL VIABILITY AND BIOLOGIC PRODUCT YIELD - Methods for controlling the level of dissolved carbon dioxide and limiting osmolality in a mammalian cell culture process to enhance cell growth, viability and density, and increase biologic product concentration and yield are provided. Such control of the level of dissolved carbon dioxide and pH as well as the resulting ability to limit osmolality in a mammalian cell culture process is achieved by adopting alternative pH control strategies and CO | 07-22-2010 |
20100203591 | Bioreactor, in particular for NMR spectroscopy - A description is given of a bioreactor ( | 08-12-2010 |
20100221783 | Expression Cloning Method Suitable for Selecting Library Clones Producing a Polypeptide of Interest - The present invention relates to methods for producing a recombinant polypeptide of interest, the method comprising the steps of: a) providing a polynucleotide library encoding one or more polypeptides of interest, wherein the library was prepared in an expression cloning vector comprising at least the following elements: i) a polynucleotide encoding a selectable marker; ii) a fungal replication initiation sequence, preferably an autonomously replicating sequence (ARS); and iii) a polynucleotide comprising in sequential order: a promoter derived from a fungal cell, a cloning-site into which the library is cloned, and a transcription terminator; b) transforming a mutant of a parent filamentous fungal host cell with the library, wherein the frequency of non-homologous recombination in the mutant has been decreased compared to the parent; c) culturing the transformed host cell obtained in (b) under conditions suitable for expression of the polynucleotide library; and d) selecting a transformed host cell which produces the polypeptide of interest. | 09-02-2010 |
20100273216 | METHODS FOR PROTEIN REFOLDING - Provided herein are methods for refolding proteins. The methods involve covalently modifying a denatured protein with a nonproteinaceous polymer and then renaturing the modified protein. | 10-28-2010 |
20100279353 | Process of producing fibrinolytic enzyme from mushroom - A fibrinolytic enzyme isolated from a culture broth of a mushroom has a characteristic of degrading a fibrin and a fibrinogen without activating an activity of a plasminogen. The plasminogen is activated to generate a plasmin to degrade the fibrin and/or fibrinogen, so that the fibrinolytic enzyme be used for the thrombosis-related diseases to degrade the fibrin and fibrinogen of blood clots without activate the plasminogen, so as to avoid a hemorrhage due to the over activation the plasminogen to over generate the plasmin. | 11-04-2010 |
20110020872 | MICROORGANISM PRODUCING CYCLIC COMPOUND - A microorganism which produces compounds useful as an antifungal agent, particularly a therapeutic agent for deep-seated mycoses, such as mycotic sinusitis, is provided. The present inventors have conducted intensive studies on naturally-occurring microorganisms as a research for antifungal compounds, and found a fungus | 01-27-2011 |
20110053224 | NOVEL COMPOSITION OF MATTER AND METHOD FOR STIMULATING THE GROWTH OF BENEFICIAL MICROORGANISMS - The invention describes a novel composition of matter obtained from the leaves of green plants, which is useful in promoting the growth of beneficial microorganisms. Specifically, that the invention describes a hydrolysate prepared from plant leaf biomass (leaf biomass hydrolysate or ‘LBH’) which dramatically stimulates the growth of beneficial microorganisms. Use of LBH as a fermentation substrate can also stimulate rapid production of organic acids and other organic compounds. LBH can be used as a substrate to promote the fermentation-based production of biobased industrial chemicals or biofuels, LBH can be utilized as a prebiotic to promote the growth of beneficial probiotic organisms, hi addition, LBH may also be useful in stimulating the fermentation-based production of other products, examples of which include preservatives, antibiotics, antigens, vaccines, amino acids, vitamins, recombinant proteins, bioremediation treatments, and immobilized enzymes. | 03-03-2011 |
20110212489 | CULTURE MEDIUM FOR EUKARYOTIC CELLS - A proteolysate of a seed material derived from a plant species of the Asteraceae family, such as sunflower, has improved properties as a constituent of a culture medium for culturing eukaryotic, in particular animal cells. The seed material is defatted and is hydrolysed to a degree of 10-50% and subsequently separated from insolubles. The cells are particularly cultured for producing desired protein products. | 09-01-2011 |
20110236930 | CHEMOSELECTIVE LIGATION - The present invention features a chemoselective ligation reaction that can be carried out under physiological conditions. In general, the invention involves condensation of a specifically engineered phosphine, which can provide for formation of an amide bond between the two reactive partners resulting in a final product comprising a phosphine moiety, or which can be engineered to comprise a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine byproduct and producing a native amide bond in the final product. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids). | 09-29-2011 |
20120100576 | PERFUSION BIOREACTOR - The present invention pertains to a system for culturing cells comprising a culturing bag and a continuous flow centrifuge wherein the cells are continuously separated from the supernatant and are recycled into the culturing bag. Further provided are methods for culturing cells and for producing a biological substance using the device for culturing cells, and the use of a bag for culturing cells in said device or said methods. In particular, a perfusion system for culturing cells is provided wherein the wave technology for culturing cells is combined with continuous flow centrifugation for separating the medium from the cells. | 04-26-2012 |
20120149062 | High Purity Lipopeptides - The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of | 06-14-2012 |
20120156726 | VELOCITY FACTOR - The current invention is directed to the velocity factor. Based on the velocity factor antibodies can be classified, i.e. antibodies can be characterized on their binding properties as e.g. entropic or enthalpic antigen binder. A velocity factor based classification does not require detailed thermodynamic determinations and/or calculations. The velocity factor is the ratio of the antigen-antibody complex association rate constants ka determined at 37° C. and 13° C. As only two experimental determinations are required to calculate the velocity factor this is a fast and high-throughput suited method. | 06-21-2012 |
20120258498 | HIGH YIELD ANTIBIOTICS PRODUCING FUNGUS STRAIN, PREPARATION METHOD AND USE THEREOF - High yield antibiotics producing fungus strain, preparation method and use thereof are provided. The fungus strain is a mutant derived from | 10-11-2012 |
20130059339 | Apparatus and Methods for Cell Culture - A bioreactor ( | 03-07-2013 |
20130280760 | HIGH PURITY LIPOPETIDES - The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of | 10-24-2013 |
20130309722 | USE OF BROWNED GLUCOSE AS A FEED SUBSTRATE - A method for fermenting a microorganism, producing a compound of interest, in a culture medium comprising: adding a browned glucose solution to the culture medium, wherein the browned glucose solution is a glucose solution that has been acid treated and heated to a temperature of at least 90 degrees Celsius, and wherein the glucose solution has a concentration of at least 500 g/l. | 11-21-2013 |
20150017687 | METHOD FOR OBTAINING A GLYCOPROTEIN COMPOSITION - Provided is a method for producing glycoprotein with a specific glycoform compostion. The desired glycoform profile is brought about Iby altering the culture conditions on the basis of IVCC rather than the age of the culture. Further, the method renders a high product yield. | 01-15-2015 |
20150329830 | MYELOMA CELL CULTURE IN TRANSFERRIN-FREE LOW IRON MEDIUM - The present invention relates to a method for culturing mammalian cells in a culture medium which is transferrin free and which contains no lipophilic or synthetic nitrogen-containing chelators. Also provided is the use of the medium and a process for providing a mammalian product by culturing cells capable of producing the product in the medium. | 11-19-2015 |
20150361143 | METHOD FOR PRODUCING HIGH-QUALITY RECOMBINANT ALLERGENS IN A PLANT - A method for producing a recombinant protein in a plant, in particular a tobacco plant, preferably | 12-17-2015 |
435700200 | Fused or hybrid cells | 17 |
20090221040 | ANTIBODIES ACTIVE AGAINST A FUSION POLYPEPTIDE COMPRISING A HISTIDINE PORTION - The present invention relates to an antibody active against a fusion polypeptide comprising a histidine portion, a process for the preparation thereof and its use. | 09-03-2009 |
20090317869 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION - The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation. | 12-24-2009 |
20130323790 | HUMAN LAMBDA LIGHT CHAIN MICE - Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ sequences from a transgene or an episome wherein the hVλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human λ variable sequences, including human antibodies, are provided. | 12-05-2013 |
20140087423 | Method for Controlling the Main Complex N-Glycan Structures and the Acidic Variants and Variability in Bioprocesses Producing Recombinant Proteins - The present invention relates to a method of controlling quality and quantity of posttranslational modification of a recombinantly produced polypeptide/protein (glycoprotein), wherein the posttranslational modification affects the glycosylation profile and/or the acidic variants profile, as manifested in CEX profiles, wherein the polypeptide/protein (glycoprotein) production is in eukaryotic host cells, the method comprising the following steps: a) cultivating the eukaryotic cells in a suitable medium under conditions which allow the expression of the polypeptide/protein, wherein the content of the dissolved CO | 03-27-2014 |
20140193855 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS - This application describes an antibody that specifically binds to a synthetic oligomer (e.g., an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies. | 07-10-2014 |
20080199883 | Schizophrenia Related Gene and Protein - The invention relates to polynucleotides of the PAPAP gene, polypeptides encoded by the PAPAP gene, and antibodies directed specifically against such polypeptides. The invention also concerns methods for the treatment or diagnosis of schizophrenia, bipolar disorder or related CNS disorder. The invention also concerns the interaction of PAPAP with schizophrenia candidate gene g34872. | 08-21-2008 |
20080199884 | Method For Measuring Protozoan Oocyst and Detecting Reagent - The present invention provides a method for measuring oocyst of protozoa, such as | 08-21-2008 |
20080206784 | Target Substance-Capturing Body, Device for Capturing Target Substance, and Instrument, Kit and Method for Detecting Target Substance by Use of Them - It is intended to provide a target substance-capturing body comprising: a base consisting of a soluble protein; and two or more functional domains capable of binding to different target substances. | 08-28-2008 |
20080206785 | ASSAYS FOR SENSORY MODULATORS USING A SENSORY CELL SPECIFIC G-PROTEIN ALPHA SUBUNIT - The invention identifies nucleic acid and amino acid sequences of a sensory cell specific G-protein alpha subunit that are specifically expressed in sensory cells, e.g., taste cells, antibodies to such G-protein alpha subunits, methods of detecting such nucleic acids and subunits, and methods of screening for modulators of a sensory cell specific G-protein alpha subunit. | 08-28-2008 |
20080206786 | Trace amine receptor 1 of the african green monkey - A trace amine receptor 1 has been isolated from the genome of | 08-28-2008 |
20080213798 | NOVEL C. ELEGANS P21-ACTIVATED KINASE (PAK) GENE AND ASSOCIATED LOSS-OF-FUNCTION PHENOTYPES THAT FACILITATE SCREENING FOR SMALL MOLECULE MODULATORS OF PAK ACTIVITY IN THE NEMATODE, CAENORHABDITIS ELEGANS - The invention refers to a novel | 09-04-2008 |
20080213799 | Method for Detection of Substance Bound to Nuclear Receptor - Provided is a detection method including exposing, to contact with a surface to which a cofactor has been bound, a nuclear receptor protein serving as a counterpart of the cofactor and a test sample; and detecting a substance which is contained in the test sample and which binds to the nuclear receptor, on the basis of a change in degree of binding between the nuclear receptor protein and the cofactor. The detection method is means for detecting a living-body-related substance, which means employs a nuclear receptor-cofactor system, exhibits detection high sensitivity, provides a convenient detection process, and realizes efficient establishment of a detection system. | 09-04-2008 |
20080220444 | Bone Marrow Proliferation Assay - Disclosed herein are assay methods for assessing the myelotoxicity of a pharmacologic agent or a putative pharmacologic agent. Also, disclosed are kits and mixtures of cytokines and growth factors useful in the assay methods disclosed herein. | 09-11-2008 |
20080220445 | Method of Screening Transmembrane Enzyme Inhibitory Substance - The present invention provides a screening method for a compound inhibiting a transmembrane enzyme activity by binding to a transmembrane region of the enzyme, characterized by using (a) a protein having a part or all of an amino acid sequence of the enzyme, comprising a region comprising an active center and a part or all of a transmembrane region of the transmembrane enzyme, and optionally (b) a protein having a part of an amino acid sequence of the transmembrane enzyme, comprising the region comprising the active center and lacking the above-mentioned part or all of the transmembrane region, and measuring the binding of a test substance to each protein and the enzyme activity of each protein, as well as a kit for screening comprising the above-mentioned protein of (a) and (b). Also, the present invention provides a β-secretase selective inhibitor comprising a β-secretase inhibiting substance binding to a transmembrane region of the enzyme, and particularly an inhibitor for prophylaxis and/or treatment of Alzheimer's disease, Down syndrome or Age-Associated Memory Impairment. | 09-11-2008 |
20080220446 | Method for Detecting and/or Removing Protein and/or Peptide Comprising a Cross-Beta Structure From an Aqueous Solution Comprising a Protein - The invention relates to the field of aqueous solutions comprising a protein. More specifically, the invention relates to the detection and/or removal of conformationally altered proteins and/or peptides comprising a cross-β structure from an aqueous solution comprising a protein. The invention provides methods for detecting and/or removing proteins and/or peptides comprising a cross-β structure from an aqueous solution comprising a protein, said method comprising contacting said aqueous solution comprising a protein with at least one cross-β structure-binding compound resulting in a bound protein or peptide with cross-β structure. The invention further provides a aqueous solution comprising a protein obtainable by a method of the invention, and a kit for carrying out the methods of the invention. | 09-11-2008 |
20080227114 | COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION - The present invention is directed to compositions and methods for modulating c-Rel-dependent cytokine production without materially altering the level of expression of NFκB and/or the amount of IκB. The present invention is also directed to screening for modulators of c-Rel activity as determined by assaying for altered subcellular localization of c-Rel but where the level of expression of NFκB and/or the amount of IκB is materially unaltered. | 09-18-2008 |
20080241858 | RAPID MICROBIAL DETECTION AND ANTIMICROBIAL SUSCEPTIBIILITY TESTING - A method for the detection of microorganisms in a sample comprising contacting said sample with a biosensor concentration module, allowing microorganisms to grow for a first period of time and detecting growth of discrete microorganisms as an indication of the presence of said microorganisms. | 10-02-2008 |
20080241859 | AGLYCO PRODUCTS AND METHODS OF USE - Glycoconjugates, therapeutic compositions containing the glycoconjugates and therapeutic methods of using the glycoconjugates are disclosed. In particular, peptide constituents of aglyco 10B, which are immunogenic epitopes responsible for recognition of antigens by the immune system are provided. These glycoconjugates are useful in prevention of influenza virus binding to cells, treatment of schizophrenia and diagnosing chronic viral disease associated with development of cancer. | 10-02-2008 |
20080241860 | METHODS AND APPARATUS TO RECOGNIZE NERVE INJURIES - Methods and apparatus are described to recognize nerve injuries, specifically brachial plexus injuries, and their severity, preferably of newborn children. To achieve an inexpensive and quick test, which can be executed without harming the patient, it is proposed to measure the motor neuron loss by measuring a biochemical marker, i.e. NSE or protein S100 in a body fluid. | 10-02-2008 |
20080248492 | Membrane Based Assays - Membrane-based assays using surface detector array devices suitable for use with a biosensor are disclosed. The device is formed of a substrate having a surface defining a plurality of distinct bilayer-compatible surface regions separated by one or more bilayer barrier regions. The bilayer-compatible surface regions carry on them, separated by an aqueous film, supported fluid bilayers. The bilayers may contain selected receptors or biomolecules. A bulk aqueous phase covers the bilayers on the substrate surface. Arrays may be engineered to display natural membrane materials in a native fluid bilayer configuration, permitting high-throughput discovery of drugs that target and affect membrane components. The membrane-based assays detect binding events by monitoring binding-induced changes in one or more physical properties of fluid bilayers. | 10-09-2008 |
20080261237 | Inositol-Phosphate Derivatives and Method of Detecting Inositol-1-Phosphate - The present invention relates to inositol phosphate derivatives, in which the inositol phosphate is substituted with one or two reactive groups G or one or two conjugated substances or molecules M, said reactive group(s) G or said substance(s) or molecule(s) M being linked to IP1 via a linkage group L, M being chosen from the following group: a tracer, an immunogen, a member of a binding partner pair, a solid support. | 10-23-2008 |
20080268465 | Process and Kit for Determining Binding Parameters of Bioaffinity Binding Reactions - A process for determining binding parameters, including dissociation constants and sorption rate constants, of the binding between a biomolecule and a binding partner thereof, both being present in a liquid phase, and comprising a marker-free binding step, characterized by the following steps: (a) attaching either (a | 10-30-2008 |
20080268466 | Method and Device for Trichomonas Detection - A method and kit for detecting | 10-30-2008 |
20080268467 | Methods and compositions for modulating telomerase reverse transcriptase (TERT) expression - Methods and compositions are provided for modulating, e.g., increasing or decreasing, the expression of telomerase reverse transcriptase (TERT). In the subject methods, the binding interaction of the TERT Site C repressor site with a Site C repressor protein complex made up of one or more proteins is modulated to achieve the desired change in TERT expression. A feature of the subject invention is that the target Site C repressor protein complex includes a MRG15 protein. The subject methods and compositions find use in a variety of different applications, including the immortalization of cells, the production of reagents for use in life science research, therapeutic applications; therapeutic agent screening applications; and the like. | 10-30-2008 |
20080268468 | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells - The present disclosure relates to a method for metabolic oligosaccharide engineering that incorporates derivatized alkyne-bearing sugar analogs as “tags” into cellular glycoconjugates. The disclosed method incorporates alkynyl derivatized Fuc and alkynyl derivatized ManNAc sugars into a cellular glycoconjugate. A chemical probe comprising an azide group and a visual probe or a fluorogenic probe is used to label the alkyne-derivatized sugar-tagged glycoconjugate. In one aspect, the chemical probe binds covalently to the alkynyl group by Cu(I)-catalyzed [3+2] azide-alkyne cycloaddition and is visualized at the cell surface, intracellularly, or in a cellular extract. The labeled glycoconjugate is capable of detection by flow cytometry, SDS-PAGE, Western blot, ELISA or confocal microscopy, and mass spectrometry. | 10-30-2008 |
20080268469 | Systems and Methods for Analyzing a Particulate - Systems and methods are provided for analyzing particulates. A liquid having a plurality of particulates substantially linearly ordered in a streamline can be externally controlled to provide flow in first and second directions, where, generally, the first direction is opposite to the second direction. A target particulate can be measured from the plurality of particulates at or near a measurement area while the liquid flows in the first flow direction. The flow direction can be reversed and measured at the measurement area while flowing in the second direction. The particulates substantially retain the same linear order during at least one cycle, a cycle being defined by movement in the first direction followed by movement in the second direction. | 10-30-2008 |
20080286805 | Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use - Accordingly, the invention provides constructs in which the nucleic acids encoding | 11-20-2008 |
20080286806 | Ligand for G-protein coupled receptor GPR43 and uses thereof - The present invention is related to the G-protein coupled orphan receptor GPR | 11-20-2008 |
20080286807 | Methods and Reagents for Elimination or Reduction of False Positives in the Analysis of a Sample - Methods, apparatuses, and systems for eliminating or reducing false positives in assays are provided. More specifically, there is provided a method to absorb a false positive signal with an absorber in favor of detecting a true positive signal. Embodiments of the present invention include but are not limited to systems and methods for detecting antibodies with greater specificity than available assays and also for detecting a greater variety of antibodies. | 11-20-2008 |
20080293076 | Method to improve barrier function of cell-cell junctions - Described are methods of increasing the barrier function of a cell-cell junction, comprising activating a PDZ-GEF2 protein, wherein the PDZ-GEF2 protein comprises an amino acid sequence encoded by a gene corresponding to the RapGEF6 gene. Further described are methods for selecting an activator of PDZ-GEF2, comprising contacting a plurality of candidate compounds to at least two cells of a first cell type and at least two cells of a second cell type, both cell types capable of forming cell-cell junctions, measuring the maturation of cell-cell junctions before and after contacting the two cell types with the plurality of candidate compounds, and selecting a compound from the plurality of candidate compounds that is more capable of increasing the integrity of a cell-cell junction between at least two cells of the first cell type, as compared to its capability of increasing the integrity of a cell-cell junction between cells of the second type, wherein in the second cell type, the amount and/or activity of PDZ-GEF2 is decreased, compared to the first cell type. | 11-27-2008 |
20080293077 | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic and other uses - The invention relates to the discovery and characterization of several genes and the polypeptides they encode: thymotaxin (Tango-45), Tango-63d, Tango-63e, Tango-67, and huchordin (Tango-66). Thymotaxin is a new member of the C-C family of chemokines. Tango-63d and Tango-63e are two novel polypeptides within the tumor necrosis factor (TNF) receptor superfamily. Tango-67 is related to a number of growth factors, particularly members of the connective tissue growth factor family. Huchordin is related to chordin, a known protein that is involved in the induction of twinned axes, can completely rescue axial development in ventralized embryos, is a potent dorsalizing factor, and plays a crucial role in regulating cell-cell interactions in the organizing centers of head, trunk, and tail development. The invention encompasses nucleic acid molecules encoding nucleic acids and polypeptides of the invention, or mutant forms thereof that encode dysfunctional receptor polypeptides, vectors containing these nucleic acid molecules, cells harboring recombinant DNA molecules encoding nucleic acids or polypeptides of the invention, or mutant forms thereof, host fusion proteins that include functional or dysfunctional polypeptides of the invention, transgenic animals that express nucleic acids or polypeptides of the invention, screening methods and therapeutic methods employing the nucleic acid molecules and polypeptides described above, substantially purified nucleic acids and polypeptides of the invention, and therapeutic compositions containing these nucleic acid molecules and polypeptides. | 11-27-2008 |
20080311590 | Portable Materials and Methods for Ultrasensitive Detection of Pathogen and Bioparticles - The present invention provides systems for ultrasensitive detection of pathogens and bioparticles. One embodiment of the system comprises an optical detection scheme that allows for the detection of the fluorescence signal of bacteria or other bioparticles in less than about 20 minutes. A microflow channel allows for an assay probing volume of as little as a few picoliters. In one embodiment, the system uses RuBpy dye-doped silica nanoparticles bioconjugated with specific monoclonal antibodies of the target bioparticles. The system allows for the rapid and highly sensitive and specific detection of bacteria or other bioparticles without the need for amplification or enrichment of the sample. | 12-18-2008 |
20090004674 | ACPL-related assays - The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. | 01-01-2009 |
20090011430 | ELECTRICAL DETECTION USING CONFINED FLUIDS - A device having: a laminar flow channel for liquids; two or more electrodes; a confining fluid inlet; a sample inlet; and a meter for measuring the impedance of any fluid between the electrodes. The device may have one or more specific binding sites, or it may have sheathing and unsheathing fluid transporting structures. A method of: providing the device; flowing a confining fluid and a conductive liquid that may contain cells or particles through the channel as described herein; and measuring the impedance between the electrodes. | 01-08-2009 |
20090035788 | Genetically encoded bioindicators of calcium-ions - The present invention relates to novel types of cellular calcium probes that are based on Troponin C and two chromophors suitable for FRET (fluorescence resonance energy transfer). The Troponin C-based calcium sensors of the invention function in diverse subcellular environments, for example even when tethered to a cellular membrane. The invention further provides nucleic acid constructs encoding the calcium probes of the invention, expression constructs, host cells and transgenic animals. Furthermore, methods for the detection of changes of local calcium concentrations and for detecting the binding of a small molecule to fragments of Troponin C are provided. | 02-05-2009 |
20090042215 | Cell Permeability Assay in a Living Array of Multiple Cell Types and Multiple Layers of a Porous Substrate - The present invention provides a device for determining drug efficacy on target cells comprising (1) a porous support (B) having first and second surfaces and at least one area with a plurality of through-going channels, wherein said area comprises on said first surface at least one region, which can be contacted with target cells, and said area comprises on said second surface at least one region comprising a layer of barrier cells presenting a significant barrier adhered to said second surface, wherein said region on the first surface is located opposite to said region on the second surface of the porous support (B), and wherein said layer of barrier cells provides a barrier for the passage of drugs, and (2) a support (A) comprising drugs, which can be contacted with the barrier cells of the porous support (B). | 02-12-2009 |
20090042216 | Method for purifying proteins and/or biomolecule or protein complexes - The present invention relates to a method for detecting and/or unifying proteins and/or biomolecule or protein complexes, as well as fusion proteins, nucleic acids, vectors and cells suitable for this method. | 02-12-2009 |
20090047687 | Indane Acetic Acid Derivatives and Their Use as Pharmaceutical Agents, Intermediates, and Method of Preparation - This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation. | 02-19-2009 |
20090068681 | METHODS AND COMPOSITIONS FOR RISK STRATIFICATION - The present invention provides an approach for the simultaneous determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of potentiators of cellular activation allows for characterization of such pathways and cell populations. | 03-12-2009 |
20090075294 | Eukaryotic mechanosensory transduction channel - The present invention provides, for the first time, nucleic acids encoding a eukaryotic mechanosensory transduction channel (MSC) protein. The proteins encoded by these nucleic acids form channels that can directly detect mechanical stimuli and convert them into electrical signals. These nucleic acids and the proteins they encode can be used as probes for sensory cells in animals, and can be used to diagnose and treat any of a number of human conditions involving inherited, casual, or environmentally-induced loss of mechanosensory transduction activity. | 03-19-2009 |
20090075295 | PORPHYRINIC COMPOUNDS FOR USE IN FLOW CYTOMETRY - The present invention provides a method of detecting (e.g., by flow cytometry) a target compound, cell or particle, wherein the target is labelled with a detectable luminescent compound. The method comprises utilizing as the detectable luminescent compound a compound comprising a porphyrinic macrocycle such as a porphyrin, chlorin, bacteriochlorin, or isobacteriochlorin. In particular embodiments, the detectable luminescent compound comprises a compound of the formula A-A′-Z-B′—B, wherein: A is a targeting group or member of a specific binding pair that specifically binds the detectable luminescent compound to the target compound, cell or particle; A′ is a linker group or covalent bond; B′ is a linker group or covalent bond; B is a water-soluble group; and Z is the porphyrinic macrocycle. | 03-19-2009 |
20090075296 | METHODS AND COMPOSITIONS FOR ASSAYING REGULATORY T CELLS - Methods and compositions for determining whether a T cell is a regulatory T cell and for determining whether a population of cells includes at least one regulatory T cell or a cell with the potential to become a regulatory T cell. The invention includes methods and compositions for detecting TGF-β on the surface of a cell. The invention also provides methods and compositions for evaluating the suppressive activity of a regulatory T cell based on the presence and/or the amount of membrane-bound TGF-β. | 03-19-2009 |
20090075297 | MAMMALIAN GALANIN RECEPTORS - The present invention provides isolated mammalian GalR3 receptors, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the receptors using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptors and are useful for treating medical conditions caused or mediated by galanin. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian GalR3 receptors. | 03-19-2009 |
20090081698 | High throughput cell-based assays, methods of use and kits - In the present invention cells are placed in a multiwell plate and grown. When the assay is to be performed, one uses gravity to wash away any unbound ligands rather than vacuum or centrifugation. The cells are then examined to detect the bound ligand. To perform the washing step(s) the plate is placed into a carrier pate having open wells in register with the wells of the filter plate or one may use a wicking device or an underdrain attached to the bottom of the filter plate. Sufficient wash liquid is added to allow for filtration by the effect of gravity to occur. Cells are retained within the wells at a rate of 4 times that of other rapid methods. | 03-26-2009 |
20090081699 | METHODS AND COMPOSITIONS FOR RISK STRATIFICATION - The present invention provides an approach for the simultaneous determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of potentiators of cellular activation allows for characterization of such pathways and cell populations. | 03-26-2009 |
20090081700 | Methods of use of the TACI/TACI-L interaction - The invention discloses a novel interaction between a TNF receptor (TACI) and its interacting ligand (TACI-L). Also disclosed are methods of screening candidate molecules to determine potential antagonists and agonists of the TACI/TACI-L interaction. The use of the antagonists and agonists as therapeutics to treat autoimmune diseases, inflammation, and to inhibit graft vs. host rejections is further disclosed. | 03-26-2009 |
20090081701 | METHOD OF SELECTIVE PROTEIN ENRICHMENT AND ASSOCIATED APPLICATIONS - The present invention provides methods of selective enrichment of ligands present in a biological sample. One or a plurality of receptor carriers are used to capture ligands capable of binding to receptors immobilized on the surface of the receptor carriers. Receptor carriers bound with the ligands are separated from the remaining sample and the ligands are then eluted with a ligand elution solution to result in an enriched ligand sample. The enriched ligand sample may be used for further isolation of one or more ligands of interest, or for ligand profiling using 2-D gel electrophoresis coupled with mass spectrometry, for example. Such ligand profiling may have a number of applications, such as disease diagnosis, pathogen detection and drug screening. | 03-26-2009 |
20090087863 | Method For Detecting Polypeptide Toxic to Diabrotica Insects - Disclosed is a novel Lepidopteran- and Coleopteran-active δ-endotoxin polypeptide, and compositions comprising the polypeptide, peptide fragments thereof, and antibodies specific therefor. Also disclosed are vectors, transformed host cells, and transgenic plants that comprise nucleic acid segments encoding the polypeptide. Also disclosed are methods of identifying related polypeptides and polynucleotides, methods of making and using transgenic cells comprising the novel sequences of the invention, as well as methods for controlling an insect population, such as the Western Corn Rootworm and Colorado potato beetle, and for conferring to a plant population resistance to the target insect species. | 04-02-2009 |
20090093000 | Glycoprotein and apolipoprotein biopolymer markers predictive of Alzheimers disease - The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease. | 04-09-2009 |
20090093001 | HIGH CONTENT SCREENING - A high content screening (HCS) assay for rapidly screening one or more compounds to determine functional response or pharmacological properties thereof, comprising: i) priming a cell or cell material with a sensor for a biological response; ii) contacting the compound(s) to be tested with the primed cell or cell material or contacting a cell or cell material which has been contacted with the compound(s) with the primed cell or cell material; iii) simultaneously or subsequently contacting with a fluorescent agonist or a fluorescent neutral antagonist wherein the binding of the fluorescent agonist or antagonist and its associated biological response are detected or monitored in the same cell and are distinct allowing separate readout. | 04-09-2009 |
20090098573 | Nucleic acids and proteins of insect Or83b odorant receptor genes and uses thereof - The present invention relates to insect odorant receptor genes and methods for identifying odorant receptor genes. The invention provides nucleotide sequences of insect odorant receptor genes Or83b, amino acid sequences of their encoded proteins (including peptides or polypeptides), and related products and methods. The nucleic acids of the invention may be operatively linked to promoter sequences and transformed into host cells. Methods of production of an Or83b odorant receptor protein (e.g., by recombinant means), and derivatives and analogs thereof, are provided. Antibodies to an Or83b odorant receptor protein, and derivatives and analogs thereof, are provided. Methods for identifying molecules that bind or modulate the activity of these Or83b odorant receptor genes are provided. Molecules found to bind or modulate the activity of Or83b genes may be formulated into pest control agents by providing a carrier. In a preferred embodiment, molecules that bind or modulate the activity of an Or83b gene from one species but not others is desired. Methods to modify the insect behavior by modifying an insect Or83b odorant are also provided. | 04-16-2009 |
20090098574 | FUNCTIONALIZATION OF GOLD NANOPARTICLES WITH ORIENTED PROTEINS, APPLICATION TO THE HIGH-DENSITY LABELLING OF CELL MEMBRANES - The present invention relates to nanoparticles the surface of which is modified by deposition of proteins. The invention further relates to a method for producing said nanoparticles and to their use in biological research and in the biomedical field (for example labelling and diagnosis). | 04-16-2009 |
20090111123 | COMPOSITIONS FOR DETECTING ANTIBODIES TO BABESIA MICROTI AND METHODS OF USES THEREOF - The present invention relates to one or more peptides which may be used to test for the presence of antibodies to | 04-30-2009 |
20090117590 | Human calcium sensitive potassium channel beta3 subunit proteins, encoding nucleic acid and uses thereof - The present invention is directed to novel human DNA sequences encoding calcium sensitive potassium channel subunits β2, β3a, β3b, β3c, and β3d, the proteins encoded by the DNA sequences, vectors comprising the DNA sequences, host cells containing the vectors, and methods of identifying inhibitors and agonists of calcium sensitive potassium channels containing human β2, β3a, β3b, β3c, or β3d subunits and inhibitors and agonists of β3 gene transcription. | 05-07-2009 |
20090123938 | Mammalian monocyte chemoattractant protein receptors - Novel human chemokine receptors, MCP-1RA and MCP-1RB, and processes for producing them are disclosed. The receptors, which are alternately spliced versions of MCP-1 receptor protein may be used in an assay to identify antagonists of MCP-1 which are therapeutically useful in the treatment of atherosclerosis and other diseases characterized by monocytic infiltrates. | 05-14-2009 |
20090123939 | Biologically enhanced electrically-active magnetic nanoparticles for concentration, separation, and detection applications - The disclosure generally relates to a particulate composition formed from a conductive polymer (e.g., conductive polyanilines, polypyrroles, polythiophenes) bound to magnetic nanoparticles (e.g., Fe(II)- and/or Fe(III)-based magnetic metal oxides). The particulate composition can be formed into a biologically enhanced, electrically active magnetic (BEAM) nanoparticle composition by further including a binding pair member (e.g., an antibody) bound to the conductive polymer of the particulate composition. Methods and kits employing the particulate composition and the BEAM nanoparticle composition also are disclosed. | 05-14-2009 |
20090123940 | MOLECULES INVOLVED IN SYNAPTOGENESIS AND USES THEREFOR - The present invention is based on the discovery that neuronal pentraxins play a role in the clustering and internalization of AMPA receptors, synaptogenesis, and metabotropic glutamate receptor-mediated long term depression (LTD) of a synapse. Accordingly, there are provided methods of identifying compounds that that modulate mGluR-mediated AMPA receptor internalization and LTD. Further provided are cleavage products of a member of the neuronal pentraxin family, neuronal pentraxin receptor (NPR). Also provided are isolated peptides comprising the Narp association regions 1 and 2 (NAR1 and NAR2, respectively) and the Narp binding motif (NBM) of AMPA receptors. Finally, there are provided antibodies that block binding of neuronal pentraxins to AMPA receptors, in particular, antibodies that bind NAR1, or NAR2, or NBM. | 05-14-2009 |
20090130691 | SCREENING PROTEINASE MODULATORS USING A CHIMERIC PROTEIN AND SKI-I PROPROTEIN CONVERTASE SUBSTRATES AND INHIBITORS - A chimeric protein comprising in sequence a signal peptide, a first amino acid tag, a proteinase bait, a second amino acid tag, a transmembrane domain and a cytosolic domain, wherein the cytosolic (CT) domain comprises a sequence able to recycle the protein from the cellular membrane to endosomes. A cell line expressing the chimeric protein and an assay using the cell line. | 05-21-2009 |
20090136968 | Novel in vitro methods for studying receptors recognizing volatile compounds - The present invention in particular relates to in vitro methods to identify and/or confirm the binding and/or function of a volatile compound onto a membrane-integrated receptor using volatile-compound-Binding Protein (BP) or compositions thereof. Additionally, the present invention relates to kits comprising receptor proteins recognizing volatile compounds or a candidate receptor for said compound; and; BP, a complex or composition thereof. Said kits may be used to identify and/or confirm the binding and/or function of volatile compounds onto a membrane-integrated receptor. | 05-28-2009 |
20090142775 | Methods For Separating Organelles - Methods and kits for separating organelles of a specific type from a mixture of organelles of different types are described. The methods comprise providing a mixture of organelles of different types, adding probes to the mixture to form an organelle-probe complex with a distinct diffusion coefficient, and separating the organelles of the specific type from the mixture of organelles based upon the diffusion coefficient of the complex. The probes used in these methods include an affinity portion which binds selectively to the organelle of the specific type and a tag portion which imparts the distinct diffusion coefficient to the complex. | 06-04-2009 |
20090170122 | Human intestinal NPT2B - A novel human sodium phosphate cotransporter expressed on the apical surface of intestinal epithelial cells (huNpt2B) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting Npt2B activity in a host and methods of treating disease conditions associated with Npt2B activity. | 07-02-2009 |
20090170123 | Identification of Novel Protein Targets on the Surface of Stressed Cells - The present invention in the field of biochemistry and medicine is directed to novel methods for identifying molecules, typically proteins, that move to the cell surface when cells are stimulated or stressed can act as receptors even thought they are not transmembrane molecules and normally originate in the cytosol. Such molecules are useful targets for development of agents that can image or treat tumors or other pathologies. Methods to detect or identify such proteins that have translocated to the cell surface when cells are stressed by an angiogenic environment, environmental stresses, the stimulation of cell proliferation and differentiation, or after exposure to certain drugs such as cancer chemotherapeutics, are disclosed. | 07-02-2009 |
20090170124 | HYDROGEL THIN FILM FOR USE AS A BIOSENSOR - The present disclosure provides a biosensor capable of producing an indicator response upon detection of the presence of certain metabolites in a biological sample. The biosensor includes a hydrogel that is functionalized with affinity molecules specific to markers for one or more pathogens. The biosensor also includes a detection system adapted to detect the binding the pathogen-specific markers with their corresponding affinity molecules. | 07-02-2009 |
20090176250 | Immunoliposome-Nucleic Acid Amplification (ILNAA) Assay - Immunoliposomes and use thereof in highly specific and sensitive nucleic acid amplification assays relying on amplification of specific nucleic acid sequences released from encapsulation within a liposome after a receptor on the liposome couples with a targeted analyte/antigen immobilized on a select surface. The immunoliposome nucleic acid amplification assay permits both quantitative and qualitative analyte detection. | 07-09-2009 |
20090191572 | Imaging, diagnosis and treatment of disease - The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascular endothelium. | 07-30-2009 |
20090191573 | METHOD AND KIT FOR DETERMINING ANTIGEN CONTENT IN A SAMPLE USING DOUBLE IMMUNOHISTOCHEMICAL DETECTION - A method for determining antigen content in a region of interest of a sample is disclosed. The method includes a sequential immunomarking resulting in two chromogenic signals, which are respectively provided by a labile and a stabile chromogenic product. The method further involves acquisition, analysis and evaluation of digital images from such signals. A kit for determining antigen content in a region of interest of a sample is also described. | 07-30-2009 |
20090197282 | METHOD AND SYSTEM FOR SCREENING THE RECEPTOR-LIGAND BINDING IN LIVE CELL - The invention relates to methods and system for detecting ligand binding to membrane receptors and endocytosis. A method for detecting ligand binding to a membrane receptor includes the steps of: incubating the cell with a dye and a ligand; and detecting dye-containing endocytic vesicles in the cell. A system for screening ligand binding to membrane receptors includes an automatic liquid handling device; an x-y stage for positioning a plate; a microscope configured to image endocytic vesicles of a cell; a software for automatic analysis of FM spots (endocytic vesicles); and a control unit configured to control the movement of the x-y stage and the microscope. | 08-06-2009 |
20090203040 | Detection of specific nitrated markers - Methods are described for improving the diagnostic possibilities of diseases where oxidative NO-modifications occur, for example inflammatory conditions, cancer, Parkinson's or Alzheimer's disease, and to provide means of monitoring the effects of therapeutical measures taken towards such diseases. The invention enables the detection of disease specific catabolic markers related to oxidative NO-modifications, utilizing an immunoassay comprising antibodies directed against nitrated and non-nitrated epitopes characteristic of a specific protein. | 08-13-2009 |
20090203041 | BMP4 INHIBITORS - A fragment of Gremlin having the sequence of amino acids shown in SEQ ID NO:2 or a functional subsequence of the fragment is described. The fragment is capable of altering BMP4 activity. Also provided is a polynucleotide encoding the fragment. Also disclosed is an assay for testing a molecule for Gremlin inhibitory activity. The invention also provides a method of inhibiting BMP4 activity. | 08-13-2009 |
20090203042 | NOVEL BT TOXIN RECEPTORS FROM LEPIDOPTERAN INSECTS AND METHODS OF USE - The invention relates to Bt toxin resistance management. The invention particularly relates to the isolation and characterization of nucleic acid and polypeptides for a novel Bt toxin receptor. The nucleic acid and polypeptides are useful in identifying and designing novel Bt toxin receptor ligands including novel insecticidal toxins. | 08-13-2009 |
20090208975 | Device and methods for detecting a target cell - The present invention relates to devices for detecting intact target cells in a sample comprising a detection zone comprising an immobilized specific binding reagent, capable of forming a complex with a target analyte on a target cell. Once labeled, detection of the label indicates the absence, presence and/or amount of the target cell in a sample. The embodiments further relate to kits comprising the devices, and methods of using the devices to screen for the presence, absence, and/or amount of a target cell in a sample. | 08-20-2009 |
20090215079 | Method and Devices for the Detection of Microorganisms and/or the Activity Thereof - In a method for detection of microorganisms and/or their activity with biosensors, on a surface of a substrate over portions thereof at least one ligand for binding a receptor or at least one receptor for a ligand or at least one ligand for binding a receptor and at least one receptor for either the one or a further ligand are immobilized chemically, physically, or biologically, wherein physical or physicochemical changes, caused at receptors by binding of ligands that are emitted by microorganisms in the process of quorum sensing are measured. | 08-27-2009 |
20090220988 | METHOD OF REVEALING A BIOLOGICAL PROCESS USING A FRET MEASUREMENT - The present invention relates to a method of revealing a biological process using a FRET measurement, which comprises the following steps:
| 09-03-2009 |
20090220989 | Particle-Based Analyte Characterization - Methods for assaying a sample for an analyte are provided. In various embodiments, the methods comprise contacting a sample suspected of containing the analyte with a non-uniform particle comprising a capture molecule, and further contacting the particle with a detection moiety comprising a label that permits detection of the analyte when associated with the particle. The methods may be performed to detect and/or quantitate analyte in the sample. In some embodiments, the methods may be performed in an automated manner, and may use an optical and/or cytometric apparatus for performing the method(s). The methods may further be performed with automated vessel-processing apparatus(es), such as plate loaders, plate washers, etc. Also provided are complexes containing the described materials formed by an assay of the invention, including excited state complexes. Kits useful for performing such methods are also provided. | 09-03-2009 |
20090233315 | MAGE-C2 antigenic peptides and uses therefor - This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ∃ | 09-17-2009 |
20090239240 | Mutant Forms of Fas Ligand and Uses Thereof - The invention provides for DNA encoding Fas ligand muteins and chimeras and the proteins encoded thereby. The invention further includes the use of DNA and vectors to produce transformed cells expressing the mutant or chimeric Fas ligand. When the Fas ligand of the invention is a non cleavable form, the cells expressing the Fas ligand are useful in vitro for identifying Fas expressing cells or in vivo for reducing populations of Fas expressing cells. Thus, in other embodiments, the present invention is also directed to a method for treating a patient, for example a mammal, for autoimmune disease or transplant rejection by administering a Fas ligand therapeutic agent. The therapeutic agent is a polypeptide, a polynucleotide encoding the polypeptide or a small molecule. The polypeptides include full-length Fas ligand polypeptide, or a biologically active variant, derivative, portion, fusion or peptide thereof. | 09-24-2009 |
20090239241 | METHODS AND COMPOSITIONS FOR DIAGNOSIS, STRATIFICATION, AND MONITORING OF ALZHEIMER'S DISEASE AND OTHER NEUROLOGICAL DISORDERS IN BODY FLUIDS - The inventors have discovered a collection of proteinaceous biomarkers (“AD biomarkers) which can be measured in peripheral biological fluid samples to aid in the diagnosis of neurodegenerative disorders, particularly Alzheimer's disease and mild cognitive impairment (MCI). The invention further provides methods of identifying candidate agents for the treatment of Alzheimer's disease by testing prospective agents for activity in modulating AD biomarker levels. | 09-24-2009 |
20090246802 | ANNEXIN-BASED APOPTOSIS MARKERS - The present invention describes an annexin derivative and a method of using the annexin derivative as a biosensor for real-time visualization of phosphatidylserine exposure, apoptosis, live-cell imaging and monitoring of cell health. | 10-01-2009 |
20090253148 | FLUORESCENCE POLARIZATION hERG ASSAY - Disclosed are assays, methods, and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. In particular, whether a test compound has the effect to prolong the Q-T interval as measured by an electrocardiogram in a human. The assays, methods, and kits disclosed herein make use of the binding interaction between novel fluorescent tracers and the hERG K | 10-08-2009 |
20090263828 | Novel assay for precursor T-cells having high proliferative capacity (PHPC-asay) - Diagnostic assay of antigen-specific T-cell precursors to determine the immunological status of patients suffering in chronic infectious diseases and to anticipate the disease progression and the response to therapy | 10-22-2009 |
20090269783 | B7-H2 molecules, novel members of the B7 family and uses thereof - Novel B7-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length B7-like proteins, the invention further provides isolated B7-like fusion proteins, antigenic peptides, and anti-B7-like antibodies. The invention also provides B7-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a B7-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided. | 10-29-2009 |
20090275049 | EphA4 POLYPEPTIDE HAVING A NOVEL ACTIVITY AND USE THEREOF - The present invention provides a polynucleotide which consists of a partial sequence of a polynucleotide encoding the amino acid sequence as shown in SEQ ID NO: 2, wherein the former polynucleotide encodes a polypeptide consisting of a partial amino acid sequence of SEQ ID NO: 2 whose N-terminus starts between positions 564 and 621 of SEQ ID NO: 2. | 11-05-2009 |
20090275050 | 14273 receptor, a novel G-protein coupled receptor - The present invention relates to a newly identified receptor belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders, specifically, cardiovascular diseases, including congestive heart failure. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides. | 11-05-2009 |
20090275051 | LUMINOGENIC AND NONLUMINOGENIC MULTIPLEX ASSAY - A method to detect the presence or amount of at least one molecule for an enzyme-mediated reaction in a multiplex luminogenic/nonluminogenic assay is provided. | 11-05-2009 |
20090280506 | SF, A NOVEL FAMILY OF TASTE RECEPTORS - The invention provides isolated nucleic acid and amino acid sequences of taste cell specific G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste cell specific G-protein coupled receptors. | 11-12-2009 |
20090286259 | SCREENING METHOD FOR GPCR LIGANDS - This invention relates to a method of identifying a compound capable of binding to a target domain of a G-protein coupled receptor comprising the steps of: (a) providing a receptor comprising said target domain and a first group linked to said target domain; (b) bringing into contact said receptor of (a) with a test molecule comprising a second group and said compound linked to each other, wherein said first group binds said second group; and (c) determining, subsequent to the binding of said first group to said second group, whether said compound binds to said target domain. | 11-19-2009 |
20090291457 | RE-TARGETED TOXIN CONJUGATES - The present invention provides a method for designing a re-targeted toxin conjugate for use in treating a medical condition or disease. Also provided, is the use of said conjugates in the manufacture of a medicament for treating medical conditions or diseases. The conjugates include a Targeting Moiety, which directs the conjugate to a desired target cell, and are characterised by a Targeting Moiety that increases exocytic fusion in the target cell. The present invention also provides methods for identifying agonists suitable for use as Targeting Moieties, and methods for preparing conjugates comprising said Targeting Moieties. | 11-26-2009 |
20090298091 | Modulation of T Cell Recruitment - The instant invention is based, at least in part, on the discovery that T-bet controls ThI cell recruitment to sites of inflammation. This invention pertains to, inter alia, methods of identifying agents that modulate the effects of T-bet on the recruitment of T cells to sites of inflammation by modulating P-selectin-mediated T cell rolling and/or stable adherence of a T cell to a vascular endothelial cell, as well as methods of use therefore. | 12-03-2009 |
20090298092 | ANALYTICAL SYSTEM, AND ANALYTICAL METHOD AND FLOW STRUCTURE THEREOF - An analytical system includes a working fluid, a uniform dividing unit and a separating unit. The working fluid includes a first component and a second component with different characteristics. The uniform dividing unit is utilized to uniformly divide the working fluid and relatively rotated with respect to a reference axis. Under a capillarity force as well as the result of Coriolis force and siphon force, the first component can be separated from the second component by the separating unit. | 12-03-2009 |
20090305303 | IMMUNOCHROMATOGRAPHY DEVICE FOR THE DIAGNOSIS OF DISEASES IN A SAMPLE - An immunochromatography device for determining the presence of a binding analyte in a biological sample of a subject, includes the steps of a sample application site for receiving the biological sample; at least one conjugate pad allowing the binding analyte present in the biological sample to bind to a labeled agent; and at least one test pad comprising assay areas, wherein the sample application site is adapted to direct at least part of said biological sample of a subject through the at least one conjugate pad into at least three assay areas of the at least one test pad and at least one of the at least one test pad comprises two assay areas. | 12-10-2009 |
20090305304 | High Resolution Label Free Analysis of Cellular Properties - The invention provides methods of detecting a change in cell growth patterns. | 12-10-2009 |
20090305305 | Method and probes for the detection of a tumor-specific fusion protein - The invention relates to the detection of fusion proteins. Described are a set of at least a first and a second molecular probe, each probe provided with a dye wherein the dyes together allow energy transfer, at least one probe provided with a reactive group allowing juxtaposing at least the first and second probes wherein the reactive group allows modulation of juxtaposing the probes such that there is an increased likelihood of energy transfer between the dyes. A method is provided which permits detecting the presence of a fusion protein in a cell at the single cell level. | 12-10-2009 |
20090311717 | MICROFLUIDIC CHIP DESIGN COMPRISING CAPILLARIES - The invention provides a microfluidic device wherein capillaries are connected to the microfluidic device by a deformable penetrable substance. | 12-17-2009 |
20090311718 | DEGRADED AGONIST ANTIBODY - The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking a cell surface molecule(s) to thereby serve as an agonist. The modified antibody can be used as a signal transduction agonist and, therefore, useful as a preventive and/or remedy for various diseases such as cancer, inflammation, hormone disorders and blood diseases. | 12-17-2009 |
20090317827 | Receptor In Dendritic Cells - The present invention provides the use of GPR91 as a target in dendritic cells. | 12-24-2009 |
20090317828 | Diagnostic Kits to Detect SP22 and SP22 Antibodies - Oral, topical and injectable contraceptives, which are based on sperm protein 22 kDa (SP22) polypeptides and antibodies and infertility diagnostics and kits are provided. | 12-24-2009 |
20090317829 | High-throughput assay for sugar-mediated drug transport - The invention provides a rapid, quantitative assay to directly assess the impact of a diverse range of sugars upon the sugar-mediated uptake of corresponding sugar-conjugates into various cell types. | 12-24-2009 |
20090325192 | Rapid particle detection assay - The present invention proves instruments and methods for detecting and/or quantitating an analyte in a fluid sample. The fluid sample is placed in a sample chamber having a small, shallow detection region. The analyte is magnetically labeled using magnetic particles coated with a binding reagent, and is detectably labeled using a fluorescent dye or other detection reagent. The magnetically labeled analyte is concentrated into the detection region using a focusing magnet positioned underneath the sample chamber detection region. Concentrated analyte is measured using excitation optics positioned on top of the sample chamber detection region, adapted to illuminate only the detection region, and detection optics positioned on top of the detection region, adapted to detect only light emitted from the detection region. In a preferred embodiment, the invention provides a simple, rapid assay for measuring the concentration of CD4 | 12-31-2009 |
20100003699 | TISSUE CARBOHYDRATE COMPOSITIONS AND ANALYSIS THEREOF - The present invention reveals novel methods for producing novel carbohydrate compositions, glycomes, from animal tissues. The tissue substrate materials can be total tissue samples and fractionated tissue parts, or artificial models of tissues such as cultivated cell lines. The invention is further directed to the compositions and compositions produced by the methods according to the invention. The invention further represent methods for analysis of the glycomes, especially mass spectrometric methods. | 01-07-2010 |
20100003700 | Optoelectronic sensor - A device for detecting the presence of an antigen including (1) a cell having antibodies which are expressed on the surface of the cell and are specific for the antigen to be detected, where binding of the antigen to the antibodies results in an increase in calcium concentration in the cytosol of the cell, the cell further having a emitter molecule which, in response to the increased calcium concentration in the cytosol, emits a photon; (2) a liquid medium for receiving the antigen and in which the cell is immersed; and (3) an optical detector arranged for receiving the photon emitted from the cell. | 01-07-2010 |
20100009383 | Method for the simple and rapid detection of cells and biomolecules by means of paramagnetic particles - The invention relates to a simple and rapid method for the detection of cells and biomolecules by means of paramagnetic particles (beads) without separating the detected biomolecules or target cells from the beads before evaluating the specific bond. | 01-14-2010 |
20100009384 | ACTR-1, a novel human acyltransferase and uses thereof - The invention provides isolated nucleic acid molecules, designated ACTR-1 nucleic acid molecules, which encode novel acyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing ACTR-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an ACTR-1 gene has been introduced or disrupted. The invention still further provides isolated ACTR-1 proteins, fusion proteins, antigenic peptides and anti-ACTR-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. | 01-14-2010 |
20100009385 | ASSAYS AND ENHANCERS OF THE HUMAN DELTA ENAC SODIUM CHANNEL - This invention relates to electrophysiological assays that measure sodium conductance activity of a delta human epithelial sodium channel (ENaC) in the presence and absence of delta hENaC enhancers. Also, the invention generally relates to assays for identifying compounds that enhance the activity of delta hENaC, especially in an oocyte expression system. These compounds have potential application in modulating (enhancing) salty taste perception. | 01-14-2010 |
20100009386 | METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF LUNG DISEASES AND KITS THEREOF - The invention provides biomarkers and combinations of biomarkers that are useful in diagnosing lung diseases such as non-small cell lung cancer or reactive airway disease. The invention also provides methods of differentiating lung disease, methods of monitoring therapy, and methods of predicting a subject's response to therapeutic intervention based on the extent of expression of the biomarkers and combinations of biomarkers. Kits comprising agents for detecting the biomarkers and combination of biomarkers are also provided. | 01-14-2010 |
20100009387 | Detection of early stages and late stages HPV infection - Embodiments of the invention provide methods, monoclonal antibodies, polyclonal antibodies, assays, and kits for detecting HPV infection and HPV related cancer diagnosis, including infection by various HPV genotypes, early and/or late stage HPV-associated or HPV-specific cancers. Various specific or pan monoclonal antibodies recognizing specific epitope for specific HPV protein or HPV type, or common epitope for various HPV proteins or HPV types are obtained. The invention also provides one or more solid surface to coat the testing cell lysate. Also, the anti-HPV antibody can be coated on the solid surface of the invention to capture HPV proteins and detect HPV infection. | 01-14-2010 |
20100021937 | METHOD FOR DETECTING PATHOGENS USING MICROBEADS CONJUGATED TO BIORECOGNITION MOLECULES - A method and system are provided for the simultaneous detection and identification of multiple pathogens in a patient sample. The sample is combined with microbeads, which have been injected with quantum dots or fluorescent dye and conjugated to pathogen-specific biorecognition molecules, such as antibodies and oligonucleotides. Treatment options may be determined based on the identities of the pathogens detected in the sample. | 01-28-2010 |
20100021938 | Diagnosis and Prediction of Alzheimer's Disease - Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β peptide (Aβ) in the brain. Aβ is derived from amyloid precursor protein (APP) by β- and γ-secretases, with the β form (sAPPβ) being associated with the disease state, and the α form (sAPPα) being associated with the non-disease state. The present inventor proposes that defined the ratio of sAPPα to sAPPβ or the ratio of CTFα to CTFβ provide and accurate diagnosis of the disease, as well as a predictor for asymptomatic patients at risk of developing AD. In addition, drug screening and monitoring of treatment effectiveness can exploit this same sAPPα/sAPPβ or CTFα/CTFβ ratio. | 01-28-2010 |
20100035277 | METHOD AND APPARATUS FOR DETERMINING THE CELL ACTIVATION OF A TARGET CELL BY AN ACTIVATOR - The invention relates to a method and a device for determining the cell activation of a target cell by an activator, said method having the following steps: provision of a probe measuring device with a probe sample arrangement having a measuring probe and a sample holder; loading of the probe sample arrangement with a target cell and with an activator assigned to the target cell, the measuring probe being loaded with the activator, and the sample holder being loaded with the target cell, or vice versa; relative mutual displacement of the measuring probe and the sample holder until contact is made between the target cell and the activator by means of a displacement apparatus of the probe measuring device; recording of measurement values, indicating binding between the target cell and the activator, for the measuring probe with the probe measuring device during the relative displacement of the measuring probe and the sample holder; and determination of a dimension for the cell activation of the target cell from the measurement values recorded. | 02-11-2010 |
20100035278 | BIOLOGICAL SUBSTANCE ANALYSIS CHIP, BIOLOGICAL SUBSTANCE ANALYSIS KIT AND METHOD OF BIOLOGICAL SUBSTANCE ANALYSIS USING THEM - The present invention provides a biological substance analysis chip capable of quantitative measurement in a minute region through immobilization of a biological substance trapping probe to a substrate surface in a more uniform density, a biological substance analysis kit that uses said chip, and a biological substance analysis method that uses the above. | 02-11-2010 |
20100041067 | Reaction Sensing in Living Cells - Chemical reactions occurring within a living cell are measured in a manner that does not affect the viability of the cell or the reaction under study. In one embodiment, one or more sensors are introduced into the cell and/or covalently associated with the exterior cell membrane. The sensor(s) emit an observable signal indicating a value of a parameter associated with the chemical reaction, e.g., the concentration of a reaction product. Because cell viability is not compromised, the cell may be stimulated (e.g., by subjection to an agonist or antagonist, a pathogen, a pharmaceutical compound, or a potential toxin) so as to affect the reaction under study. | 02-18-2010 |
20100047823 | Polypeptides - The use of polypeptides capable of binding to PtdIns(3,4)P | 02-25-2010 |
20100055714 | IKB kinase, subunits thereof, and methods of using same - The present invention provides an isolated nucleic acid molecules encoding IκB kinase (IKK) catalytic subunit polypeptides, which are associated with an IKK serine protein kinase that phosphorylates a protein (IκB) that inhibits the activity of the NF-κB transcription factor, vectors comprising such nucleic acid molecules and host cells containing such vectors. In addition, the invention provides nucleotide sequences that can bind to a nucleic acid molecule of the invention, such nucleotide sequences being useful as probes or as antisense molecules. The invention also provides isolated IKK catalytic subunits, which can phosphorylate an IκB protein, and peptide portions of such IKK subunit. In addition, the invention provides anti-IKK antibodies, which specifically bind to an IKK complex or an IKK catalytic subunit, and IKK-binding fragments of such antibodies. The invention further provides methods of substantially purifying an IKK complex, methods of identifying an agent that can alter the association of an IKK complex or an IKK catalytic subunit with a second protein, and methods of identifying proteins that can interact with an IKK complex or an IKK catalytic subunit. | 03-04-2010 |
20100062460 | Novel fluorochromes for organelle tracing and multi-color imaging - Provided are compounds, methods and kits for identifying in cells of interest organelles including nuclei and a wide variety of organelles other than nuclei (non-nuclear organelles), as well as cell regions or cell domains. These compounds and methods can be used with other conventional detection reagents for identifying the location or position or quantity of organelles and even for distinguishing between organelles in cells of interest. | 03-11-2010 |
20100062461 | MULTIPLEX DETECTION OF CELL SURFACE RECEPTORS OR IMMOBILIZED ANTIGENS - The present invention provides an antibody-based multiplex detection method for identifying one or more epitopes in one or more samples, the method comprising the steps of: (a) contacting each of the samples comprising the epitopes with one or more antibodies specific to the epitopes to be detected; (b) washing unbound antibodies away and eluting bound antibodies from the epitope carriers to provide separate antibody eluates; and (c) detecting and quantifying antibodies in the antibody eluates to generate separate profiles of antibodies for each of the samples. The epitopes to be detected can be located intracellularly, or present on the surface of cells or an artificial surface. In general, the epitopes are derived from protein, polypeptides with or without post-translational modification, carbohydrate, nucleic acid, or lipid. | 03-11-2010 |
20100075341 | STANDARDIZED EVALUATION OF THERAPEUTIC EFFICACY BASED ON CELLULAR BIOMARKERS - The present invention provides materials and methods for predicting the response of a disease state to a therapeutic agent. A targeting moiety specific for a biological marker is labeled with a reporter moiety and used to analyze cells characteristic of the disease state. The output of the reporter moiety, which may be fluorescence intensity, is compared to the output of reference standard analyzed under similar or identical conditions. The use of a reference standard allows biomarker reporting to be normalized. Biomarker values can then be correlated from sample to sample and from laboratory to laboratory based on quantitative calibration on a universal reference standard. | 03-25-2010 |
20100086943 | METHOD FOR THE DETECTION OF POST-TRANSLATIONAL MODIFICATIONS - Method for the detection in homogeneous medium of a post-translational modification of a protein substrate catalyzed by a cell enzyme, characterized in that the post-translational modification reaction takes place in intact living cells, in that these cells comprise a heterologous expression vector coding for a fusion protein comprising the protein substrate and a first coupling domain and in that it comprises the following stages: (v) Incubation of the cells in the presence or in the absence of a compound to be tested capable of modulating the activity of said enzyme, (vi) Addition to the reaction medium of a first fluorescent compound member of a first pair of FRET partners covalently bonded to a coupling agent capable of binding specifically to the first coupling domain present on the protein substrate, (vii) Addition to the reaction medium of a second fluorescent compound member of this first pair of FRET partners, and covalently bonded to a binding domain specific to the site of the protein substrate having undergone the post-translational modification and not binding to the non-modified protein substrate, (i) Measurement of the FRET signal emitted by the sample, this signal being representative of the quantity of protein substrate having undergone said post-translational modification; and cells for the implementation of said method. | 04-08-2010 |
20100093000 | Tyrosine phosphorylation sites - The invention discloses novel phosphorylation sites identified in carcinoma and/or leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 04-15-2010 |
20100105075 | SYSTEMS AND METHODS OF VOLTAGE-GATED ION CHANNEL ASSAYS - Systems and methods are provided for optically measuring ion concentrations in biological samples. The systems and methods employ polymer-based optical ion sensors that include ion-selective ionophores and a pH sensitive chromionophore. Electrodes are providing for electrically stimulating the biological samples. | 04-29-2010 |
20100120060 | METHOD FOR DETERMINING MOLECULES OR MOLECULE PARTS IN BIOLOGICAL SAMPLES - The invention relates to a method for determining molecules, molecule groups, and/or molecule parts in biological samples. The method includes spiking the sample at least once with at least one light emitting marker and measuring the light emission of the marker. Herein, it is intended that the light emission inherent to the sample is reduced or eliminated by means of bleaching prior to measuring the light emission of the marker. | 05-13-2010 |
20100120061 | RAPID IMMUNOCHROMATOGRAPHIC DETECTION BY AMPLIFICATION OF THE COLLOIDAL GOLD SIGNAL - The present invention relates to a rapid immunochromatographic test device suitable to detect an antibody and/or antigen in a sample, uses of said device for detecting diseases in a sample, a method for the production of said device as well as a kit comprising the device. | 05-13-2010 |
20100120062 | RHIZOME VIABILITY DETERMINATION METHOD - A method of determining the viability of a rhizome comprises the sequential steps of: (a) sampling material from the rhizome; (b) contacting material sampled in step (a) with an effective amount of a formulation comprising a first viability indicator; and (c) observing the action of the first viability indicator on the sampled rhizome material, to determine the viability of the rhizome. The method may further comprise one or more additional sequences involving the additional steps of: (d) contacting material sampled in step (a) with an effective amount of a formulation comprising a further viability indicator different to that used in step (b); and (e) observing the action of the further viability indicator on the sampled rhizome material, to determine the viability of the rhizome. In this way, an overall assessment of the viability of the rhizome can be made based on the action of a plurality of viability indicators, each relying on an interaction with different reagents in the plant cells. | 05-13-2010 |
20100120063 | GPCR Arrestin Assays - Sensitive assays for candidate compounds affecting GPCR activity are provided using a cell containing fusion proteins comprising a first fusion protein comprising (a) a target GPCR fused to a small fragment of β-galactosidase through a linker comprising a phosphorylation site or (b) a GPCR or a protein of interest, where the GPCR and protein of interest form a complex and one of them is fused to the small fragment of β-galactosidase; and a second fusion protein comprising arrestin fused to a large fragment of β-galactosidase. In (a), the affinity of the small and large fragments is optimized based on the background to signal ratio and the absolute signal observed. The assay is performed using a β-galactosidase substrate that provides a detectable optical signal. | 05-13-2010 |
20100143939 | Intracellular antibodies - The invention related to intracellular single domain immunoglobulins, and to a method for determining the ability of an immunoglobulin single domain to bind to a target in an intracellular environment, comprising the steps of: a) providing a first molecule and a second molecule, wherein stable interaction of the first and second molecules leads to the generation of a signal; b) providing a single intracellular immunoglobulin domain which is associated with the first molecule, said single immunoglobulin domain being free of complementary immunoglobulin domains; c) providing an intracellular target which is associated with the second molecule, such that association of the immunoglobulin domain and the target leads to stable interaction of the first and second molecules and generation of the signal; and d) assessing the intracellular interaction between the immunoglobulin domain and the target by monitoring the signal. | 06-10-2010 |
20100151491 | CHEMICAL SURFACE NANOPATTERNS TO INCREASE ACTIVITY OF SURFACE-IMMOBILIZED BIOMOLECULES - The present invention has been achieved in order to solve the problems which may occur in the nanopatterning of biomolecules with an aim to improve the activity and bio-recognition properties of the surface-immobilized biomolecules. A structure for bio-detection according to one aspect of the present invention comprises a large-scale chemical nanopattern of fouling and non-fouling areas fabricated on a homogeneous surface of the structure; and a biomolecule confined to the fouling area. | 06-17-2010 |
20100151492 | METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS - PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist. Methods are also disclosed for determining the efficacy of a PD-1 antagonist in a subject administered the PD-1 antagonist. In some embodiments, these methods include measuring proliferation of memory B cells in a sample from a subject administered the PD-1 antagonist. | 06-17-2010 |
20100151493 | MULTICOLOR FLOW CYTOMETRY COMPOSITIONS CONTAINING UNCONJUGATED PHYCOBILIPROTEINS - Novel compositions containing (i) ligand conjugated phycobiliprotein tandem dyes and (ii) unconjugated phycobiliproteins are provided wherein the phycobiliproteins are derived from the same bacterial or eukaryotic algae species. The phycobiliproteins must be the same or different, but must contain some non-crosslinked subunits which exchange. Also provided are methods for preparing these compositions, kits containing these compositions or components of the same, and methods of using these compositions for cellular and non-cellular analysis. | 06-17-2010 |
20100173328 | Apparatus for measuring a cell number and a quantity of a cellular protein expression and the method thereof - The apparatus and method thereof for harmlessly and continuously measuring and recording a target protein expression and a number of growing cells are provided. By causing an AC current to flow through an electrode where cells grows thereon, the target protein expression and the number of growing cells are obtained via converting the impedance values of the electrode. | 07-08-2010 |
20100173329 | Exposed proliferation-related peptides, ligands and methods employing the same - Novel thymidine kinase (TK1) derived peptide consisting of the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 is employed to obtain ligands having specificity to the peptide. The ligand may be an antibody or fragment thereof and may be used in various methods and kits for health screening and the like. | 07-08-2010 |
20100184087 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use - A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaryl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, a thiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels. | 07-22-2010 |
20100190186 | Method for Pathogen Capture from Mammalian Blood - Disclosed is a method for isolating, and thereby concentrating, microorganisms from mammalian blood. The method may be used in conjunction with PCR amplification of the DNA/RNA of the microorganism(s) to identify pathogenic microorganisms within the blood without requiring that those organisms be cultured as a first step in the identification process. | 07-29-2010 |
20100196925 | Methods for Screening Cells and Antibodies - The invention provides methods of detecting a change in cell growth patterns, methods of screening many different antibodies in one receptacle, and methods of detecting specific binding of an antibody to a protein or cell, wherein the antibody is in a mixture of many different antibodies. | 08-05-2010 |
20100203552 | INTERACTION OF BIM WITH TRIM2 - Methods, compositions, and cells for drug screening based on interaction between a Bim polypeptide and a TRIM2 polypeptide. Methods and compositions for treating cancer based on tested levels of Bim and TRIM2 proteins are also provided. | 08-12-2010 |
20100216159 | SWITCHABLE AFFINITY BINDERS - Methods and kits for binding and releasing biological targets, comprising, a binder comprising an environmentally reactive molecular switch that can switch between a high affinity state, to bind the target, to a low affinity state, to release the target. | 08-26-2010 |
20100227334 | Reaction sensing in living cells - Chemical reactions occurring within a living cell are measured in a manner that does not affect the viability of the cell or the reaction under study. In one embodiment, one or more sensors are introduced into the cell and/or covalently associated with the exterior cell membrane. The sensor(s) emit an observable signal indicating a value of a parameter associated with the chemical reaction, e.g., the concentration of a reaction product. Because cell viability is not compromised, the cell may be stimulated (e.g., by subjection to an agonist or antagonist, a pathogen, a pharmaceutical compound, or a potential toxin) so as to affect the reaction under study. | 09-09-2010 |
20100240066 | COMPOUNDS AND METHODS FOR MODULATING CADHERIN-MEDIATED PROCESSES - Peptides comprising a cadherin cell adhesion recognition (CAR) sequence, and compositions comprising such peptides, are provided. Methods of using such peptides for modulating cadherin-mediated processes in a variety of therapeutic contexts are also provided. Methods are also provided for identifying compounds that are capable of modulating cadherin-mediated processes. | 09-23-2010 |
20100255499 | COMPOSITIONS AND METHODS FOR TRANSPORT OF MOLECULES WITH ENHANCED RELEASE PROPERTIES ACROSS BIOLOGICAL BARRIERS - Conjugates of a cargo molecule with a transporter molecule are disclosed, where the cargo molecule and the transporter molecule are linked covalently by a releasable linker. The cargo of the conjugate can be a biologically active agent or a reporter molecule. The transporter modulates the transport of the cargo across a biological barrier (e.g., a cell membrane) compared to the transport of the unconjugated cargo. Releasable linkers suitable for rapid and facile conjugation to various types of cargo and transporters are also disclosed, along with methods for using the linkers in the synthesis of conjugates. | 10-07-2010 |
20100261197 | Method, System, and Compositions for Cell Counting and Analysis - The present invention provides a low cost imaged-based system for detecting, measuring and/or counting labeled features of biological samples, particularly blood specimens. In one aspect, the invention includes a system for imaging multiple features of a specimen that includes one or more light sources capable of successively generating illumination beams each having a distinct wavelength band and a plurality of differentially excitable labels capable of labeling a specimen comprising multiple features, such that each different feature is labeled with a different differentially excitable label. System of the invention may further include a controller operationally associated with the one or more light sources for successively directing illumination beams onto the specimen so that each of the different differentially excitable labels is successively caused to emit an optical signal within the same wavelength band, an optical system capable of collecting such emitted optical signals and forming successive images corresponding to the labeled features of the specimen on a light-responsive surface to form successive sets of image data thereof, and a disposable cuvette for collection and optical analysis of non-red blood cells. | 10-14-2010 |
20100273184 | DEVICE FOR MAGNETIC DETECTION OF INDIVIDUAL PARTICLES IN A MICROFLUID CHANNEL - A device dynamically detects particles of a fluid. The device can be miniaturized for detecting and selecting magnetized particles, particularly cells. | 10-28-2010 |
20100273185 | Detection of Biased Agonist Activation - The invention provides single assay methods to detect the activity of biased agonists or agonists that are less than full agonists on cells. | 10-28-2010 |
20100279312 | METHOD OF SCREENING APOPTOSIS ACCELERATING COMPOUND OR ANTI-APOPTOTIC COMPOUND AND METHOD OF DETERMINING MALIGNANCY OF NEURODEGENERATIVE DISEASE - Screening methods for determining pro-apoptotic compounds or anti-apoptotic compounds comprise measuring the interaction between p53 and NEDL1 in the presence and in the absence of a test compound, and comparing the strength of interaction between p53 and NEDL1 in the presence and in the absence of the test compound. | 11-04-2010 |
20100279313 | Novel secreted immunomodulatory proteins and uses thereof - The invention concerns cDNA molecules encoding TANGO 191 and TANGO 195, both of which are transmembrane proteins. | 11-04-2010 |
20100291588 | SYSTEMS AND METHODS INCLUDING SELF-CONTAINED CARTRIDGES WITH DETECTION SYSTEMS AND FLUID DELIVERY SYSTEMS - Methods, systems, and apparatus for detecting the presence of analytes are described. A fluid or gas sample may pass through a microsieve-based detection system and/or a particle-based detection system of a cartridge. Detection and analysis techniques may be applied to determine the identity and quantity of the captured analytes. | 11-18-2010 |
20100291589 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL - The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues. | 11-18-2010 |
20100297664 | PARATOPE AND EPITOPE OF ANTI-MORTALIN ANTIBODY - The amino acid sequences of paratope regions involved in internalizing function of an anti-mortalin antibody into tumor cells were determined for the L-chain and H-chain variable regions of cellular internalizing anti-mortalin antibodies and non-internalizing anti-mortalin antibodies. Cancer-cell-specific drug delivery is provided by using the mortalin-binding activity of a single-chain antibody (scFv) wherein L-chain and H-chain variable regions both having the paratope region are linked together via a peptide linker. Also, the sequence of 6 amino acids of an epitope to be recognized by an anti-mortalin antibody having the internalizing function was determined. With the use of an expression vector comprising a nucleic acid that encodes the epitope, an agent for accelerating internalization of a mortalin antibody, a drug bound thereto, and the like into cancer cells is provided. | 11-25-2010 |
20100304403 | MULTIPLEX ASSAY METHODS AND COMPOSITIONS - Luminescence assays and compositions for assay of biomolecular interaction and activity and detection of modulators of biomolecular interaction and activity are provided. Technology described herein has utility in a variety of assay formats and types, for example, simultaneous monitoring multiple parameters which affect interaction and activity of biological molecules. Compositions and methods are provided herein which include a first solid-phase support associated with a first specific binding agent and a photosensitizer; a second solid-phase support associated with a second specific binding agent and a first emission system; and a third solid-phase support associated with a third specific binding agent and a second emission system. | 12-02-2010 |
20100317028 | BIOASSAY METHOD FOR YOKUKANSAN - The invention intends to find out an in-vitro bioassay system capable of ensuring qualities of yokukansan to a higher degree, and provides a bioassay method for yokukansan, comprising competitively reacting labeled ligand and a test sample containing yokukansan with cells or cell membranes expressing serotonin 1A receptors, and measuring binding activity of yokukansan from the amount of the labeled ligand bound, and a bioassay method for yokukansan, comprising reacting labeled GTP and a test sample containing yokukansan with cells or cell membranes expressing serotonin 1A receptors, and measuring receptor-agonist activity of yokukansan from the amount of the labeled GTP bound. | 12-16-2010 |
20110014629 | METHODS FOR IMPROVING THE RECOVERY OF TROPONIN I AND T IN MEMBRANES, FILTERS AND VESSELS - A method to facilitate recovery troponin I and/or troponin T from a sample comprising addition of troponin C to the sample or to a surface from which the troponin I and/or troponin T are recovered. | 01-20-2011 |
20110014630 | Fluorescent Carbon Nanoparticles - Disclosed are photoluminescent particles. The particles include a core nano-sized particle of carbon and a passivation agent bound to the surface of the nanoparticle. The passivation agent can be, for instance, a polymeric material. The passivation agent can also be derivatized for particular applications. For example, the photoluminescent carbon nanoparticles can be derivatized to recognize and bind to a target material, for instance a biologically active material, a pollutant, or a surface receptor on a tissue or cell surface, such as in a tagging or staining protocol. | 01-20-2011 |
20110027800 | Derivatives of 1,2-dihydro-7-hydroxyquinolines Containing Fused Rings - The present invention describes novel dyes, including coumarins, rhodamines, and rhodols that incorporate additional fused aromatic rings. The dyes of the invention absorb at a longer wavelength than structurally similar dyes that do not possess the fused aromatic rings. Many of the dyes of the invention are useful fluorescent dyes. The invention includes chemically reactive dyes, dye-conjugates, and the use of such dyes in staining samples and detecting ligands or other analytes. | 02-03-2011 |
20110065124 | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses - The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. | 03-17-2011 |
20110065125 | CONTROLLED PLATELET ACTIVATION TO MONITOR THERAPY OF ADP ANTAGONISTS - A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIIb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi. | 03-17-2011 |
20110065126 | SUBSTANCE-IMMOBILIZING SUBSTRATE, SUBSTANCE-IMMOBILIZED SUBTRATE, AND ANALYSIS METHOD - The present invention relates to a substance-immobilizing substrate for immobilizing a substance to be detected by chemiluminescence. The substance-immobilizing substrate of the present invention comprises a metal portion composed of at least one metal selected from the group consisting of chromium and molybdenum, or an alloy of the metal on at least a portion of a surface of the substrate. The present invention further relates to a substance-immobilized substrate wherein a substance is immobilized on the substance-immobilizing substrate. The substance is immobilized on the metal portion and the substrate is used for detecting the immobilized substance by chemiluminescence. The present invention further relates to an analysis method comprising directly or indirectly detecting by chemiluminescence a substance that is immobilized on a substrate. The substrate comprises a metal portion composed of at least one metal selected from the group consisting of chromium and molybdenum, or an alloy of the metal on at least a portion of a surface of the substrate, and the substance is immobilized on the metal portion. | 03-17-2011 |
20110081658 | T1R3 BINDING ASSAYS - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed. | 04-07-2011 |
20110091903 | METHOD OF ANALYZING A SAMPLE FOR A BACTERIUM USING DIACETYLENE-CONTAINING POLYMER SENSOR - The invention relates to methods of analyzing a sample for a bacterium of interest. In particular, the methods involve an initial capture process that includes the use of one or more antibodies having antigenic specificities for one or more distinct analytes characteristic of the specific bacterium. After initial capture of a specific bacterium, techniques of analyzing involve colorimetric techniques, particularly using colorimetric sensors that include polydiacetylene (PDA) materials. | 04-21-2011 |
20110091904 | METHOD FOR DETERMINATION OF AFFINITY AND KINETIC CONSTANTS - The invention is related to a method for quantification of a first dissociation equilibrium constant K | 04-21-2011 |
20110097735 | FLUORESCENT PYRENE COMPOUNDS - The present invention relates to fluorescent pyrene dyes in general. The present invention provides a wide range of fluorescent dyes and kits containing the same, which are applicable for labeling a variety of biomolecules, cells and microorganisms. The present invention also provides various methods of using the fluorescent dyes for research and development, forensic identification, environmental studies, diagnosis, prognosis, and/or treatment of disease conditions. | 04-28-2011 |
20110104711 | GPR81-Ligand complexes and their preparation and use - Complexes of GPR81 receptor components and ligand components, such as L-lactate or GHB, may be used as an assay reagent for screening for modulators of GPR81 receptor activity. | 05-05-2011 |
20110111426 | METHOD OF BIOASSAYING YOKUKANSAN - The invention intends to find out a bioassay system with an in-vitro test capable of ensuring the higher quality of yokukansan, and provides a bioassay method for yokukansan, comprising competitively reacting a labeled ligand and yokukansan with cells or cell membranes expressing glutamate receptors, measuring the binding activity of yokukansan, and evaluating the pharmacological activity value of yokukansan from the measurement value. | 05-12-2011 |
20110129850 | MICROFLUIDIC PLATFORM FOR CELL CULTURE AND ASSAY - A microfluidic chip for at least one of cell culturing and cell assay has a cell culture chamber defined by the microfluidic chip, a first microchannel defined by the microfluidic chip and constructed to provide a fluid path to said cell culture chamber, the microchannel having a pneumatic valve formed therein to permit selective opening and closing of a fluid path to said cell culture chamber, and a second microchannel defined by the microfluidic chip and constructed to provide a fluid path from the cell culture chamber. | 06-02-2011 |
20110129851 | Methods for Obtaining Bioactive Compounds from Phytoplankton - Phytoplankton represent a potential source of bioactive compounds. The present disclosure provides, inter alia, methods for identifying glycerolipids and apoptosis-inducing sphingosine-like lipids from virally-infected phytoplankton. | 06-02-2011 |
20110143367 | ANTIBODIES AGAINST APRIL AS BIOMARKERS FOR EARLY PROGNOSIS OF LYMPHOMA PATIENTS - The invention relates to antibodies directed against APRIL (A Proliferation Inducing TNF Ligand, also known as TALL-2), in particular the monoclonal antibody Aprily-2, hybridoma cells producing monoclonal antibody Aprily-2, and the use of a combination of an antibody against membrane-anchored APRIL and Aprily-2 in the diagnosis of B cell lymphoma resistance to treatment and the prognosis of clinical development of Diffuse Large B-Cell (DLBCL) lymphoma from high risk patients (>60 years and International Prognostic Index >2). An amino acid sequence GTGGPSQNGEGYP called Stalk, useful in the preparation of antibodies, is described. | 06-16-2011 |
20110151480 | METHODS OF PURIFYING ZSIG33 - The present invention relates to a method of forming a peptide-receptor complex with zsig33 polypeptides and their receptors as well as antibodies. Methods of modulating gastric contractility, nutrient uptake, growth hormones, the secretion of digestive enzymes and hormones, and/or secretion of enzymes and/or hormones in the pancreas are also included. | 06-23-2011 |
20110159519 | OPTICAL BIOSENSORS - Provided are biosensors, compositions comprising biosensors, and methods of using biosensors in living cells and organisms. The biosensors are able to be selectively targeted to certain regions or structures within a cell. The biosensors may provide a signal when the biosensor is targeted and/or in response to a property of the cell or organism such as membrane potential, ion concentration or enzyme activity. | 06-30-2011 |
20110159520 | HYBRID PROTEINS COMPRISING MEMBRANE RECEPTOR AND ION CHANNEL, AND THEIR USE AS BIOSENSORS - The present invention relates to the use of a hybrid protein including the sequence of a first membrane receptor fused at its C-terminus to the N-terminus of an ion channel, and possibly containing a linker between the C-terminus of the first membrane receptor and the N-terminus part of the ion channel, the linker being absent in the natural configuration of the first membrane receptor and the ion channel, as a biosensor for: the screening of drugs modulating the activity of the first membrane receptor in its natural configuration, and/or for the in vitro diagnosis of pathologies associated with the presence or the variation of amount of a molecule modifying the activity of the first membrane receptor in its natural configuration. | 06-30-2011 |
20110177525 | ANTIBODIES AND METHODS OF DIAGNOSING DISEASES - The present invention generally relates to antibodies and use of these antibodies in diagnostic assays for various disease states, including cancer. In certain embodiments, the invention provides an isolated human or humanized antibody or functional fragment thereof including an antigen-binding region that is specific for an epitope on a protein, in which the epitope is specific to a tissue or body fluid and the epitope is indicative of a disease. | 07-21-2011 |
20110189695 | METHOD AND DEVICE FOR PRODUCING METAL-CONTAINING ORGANIC COMPOUNDS - The invention relates to a method and to a device for producing conjugates comprising or consisting of a metallic nanoparticulate component and an organic component. Said method enables activated or reactive nanoparticles containing metal to be produced by irradiating a metal body with a laser beam and prevents the modification and damage of organic components of said conjugates by laser irradiation. Said nanoparticulate metallic component comprises plasmon resonant metal. According to the invention, the claimed method of production enables particles having a metal centre and a metal-oxide covering to be produced, in particular when using a carrier fluid containing oxygen, e.g. alcohol or water. | 08-04-2011 |
20110189696 | MONOCLONAL ANTIBODY STRO-4 - The present invention relates to a monoclonal antibody designated STRO-4 which specifically binds human and ovine HSP-90beta and its use for enriching multipotential cells such a mesenchymal precursor cells (MPCs). | 08-04-2011 |
20110195431 | HUMAN ORPHAN G PROTEIN-COUPLED RECEPTORS - The invention disclosed in this patent document relates to transmembrane receptors, more particularly to endogenous, human orphan G protein-coupled receptors. | 08-11-2011 |
20110201020 | T1R HETERO-OLIGOMERIC TASTE RECEPTORS AND CELL LINES THAT EXPRESS SAID RECEPTORS AND USE THEREOF FOR IDENTIFICATION OF TASTE COMPOUNDS - The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners. | 08-18-2011 |
20110207146 | METHODS AND COMPOSITIONS FOR DETECTING RECEPTOR-LIGAND INTERACTIONS IN SINGLE CELLS - The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state. | 08-25-2011 |
20110229910 | Fluorescent Substrates for Neurotransmitter Transporters - The invention is based on the finding that IDT307 and analogs thereof are fluorescent substrates transported by several neurotransmitter transporters. Provided are methods for the analysis of neurotransmitter transport and binding using IDT307 and its analogs. The invention also provides rapid methods for screening for modulators of neurotransmitter transport. | 09-22-2011 |
20110236907 | RADIOLABLED CYCLOPAMINE ASSAY FOR THE SMOOTHENED RECEPTOR - The present invention discloses novel methods for screening compositions for both agonist and antagonist activity on the smoothened receptor. The assay tests ligands on the activity of the receptor using a cyclopamine binding and ultra high receptor expression. | 09-29-2011 |
20110250616 | ELECTROACTIVE SURFACE-CONFINABLE MOLECULES - The invention provides compositions, kits, methods, and species that include electroactive entities which can serve as signaling entities in chemical and/or biochemical assays. The electroactive species can be metallocenes, such as ferrocenes, including substituents that affect the oxidation/reduction potential (redox potential) of the species. By controlling the redox potential of the species, multiple species can be used in a single assay, each species having a different redox potential, for simultaneous signaling of different binding events. Additionally, species having redox potentials lower than 490 mV can be provided, allowing signaling within a potential range easily detectable in the presence of biological fluids. | 10-13-2011 |
20110250617 | DEVICE AND ANALYZING SYSTEM FOR CONDUCTING AGGLUTINATION ASSAYS - A device for conducting an agglutination assay comprising several reaction vessels, each reaction vessel comprising an upper chamber having an opening for accepting reactants and/or a sample; and a lower chamber comprising an end in communication with the upper chamber for receiving fluids from the upper chamber, a closed end opposite to the end, and a matrix for separating agglutinates from non-agglutinates; wherein the device further comprises a rotating support able to rotate around an axis and holding pivotally the reaction vessels in a way to allow the reaction vessels to pivot about an axis essentially perpendicular to the rotation axis of the support when the latter is rotated, such that the fluids remain in the upper chamber when the support is not rotated, and can flow from the upper chamber to the lower chamber and into the matrix when the support is rotated. | 10-13-2011 |
20110256552 | METHOD FOR PREPARING A SUBSTRATE FOR IMMOBILIZING A CELL, SAID SUBSTRATE AND USES THEREOF - The present invention relates to a method of preparation of a solid substrate capable of immobilizing at least one cell and/or at least one part of a cell, said method comprising a step consisting of fixing, to said solid substrate, a fusogenic compound capable of being inserted in cell membranes. The present invention also relates to a method for immobilizing at least one cell and/or at least one part of a cell using the solid substrate thus prepared, said solid substrate and its uses in the area of biomedical diagnostics or health monitoring of biological fluids or intended for human or animal use. | 10-20-2011 |
20120015376 | Free Solution Measurement Of Molecular Interactions By Backscattering Interferometry - Disclosed are methods, systems, and apparatuses for the free solution measurement of molecular interactions by backscattering interferometry (BSI). Molecular interaction can be detected between analytes in free-solution wherein at least one of the analytes is label-free and detection is performed by back-scattering interferometry. Further, molecular interaction can be detected between analytes in free-solution, wherein at least one of the analytes is label-free, wherein one of the analytes is present in a concentration of less than about 5.0×10 | 01-19-2012 |
20120034622 | ACTIVATION AND MONITORING OF CELLULAR TRANSMEMBRANE POTENTIALS - The use of nanostructures to monitor or modulate changes in cellular membrane potentials is disclosed. | 02-09-2012 |
20120034623 | UP-CONCENTRATION OF ORGANIZ MICROOBJECTS FOR MICROSCOPIC IMAGING - A method of analyzing a sample fluid containing organic microobjects is proposed. The method comprises the steps of: up-concentrating (S | 02-09-2012 |
20120040370 | SYSTEMS AND METHODS FOR RAPIDLY CHANGING THE SOLUTION ENVIRONMENT AROUND SENSORS - The invention provides microfluidic systems for altering the solution environment around a nanoscopic or microscopic object, such as a sensor, and methods for using the same. The invention also provides a system and methods for modulating, controlling, preparing, and studying receptors. | 02-16-2012 |
20120077207 | CD86 and CD80 receptor competition assays - The present invention discloses a method for assaying the binding of L104EA29YIg to a receptor. The receptor is preferably CD86 or CD80. The present invention also discloses antibodies to be used in the assay, as well as hybridomas expressing the antibodies. | 03-29-2012 |
20120122115 | Bacterial quorum sensing biosensor - The present invention generally relates to fluorescent resonance energy transfer protein compounds and methods for using such compounds as biosensors. The present invention also relates to one or more nucleic acids for encoding the protein compounds, vectors containing the nucleic acids, cells transformed by the vectors, and methods for making and using the foregoing compositions. | 05-17-2012 |
20120156689 | METHOD AND APPARATUS FOR DETERMINING AN ANALYTE PARAMETER - A method of determining an analyte parameter is described for an analyte in a detection region having at least one analyte binding zone. The method includes detecting presence of an analyte element bound at the binding zone, incrementing or decrementing a count and preventing recount of the element to obtain absolute quantification. | 06-21-2012 |
20120231474 | CONSTRUCTS THAT ALLOW FOR DETECTION AND QUANTITATION OF MEMBRANE PROTEINS - A construct is described that allows for detection and quantitation of membrane-bound polypeptides. | 09-13-2012 |
20120270230 | MUTANT G-PROTEIN COUPLED RECEPTORS AND METHODS FOR SELECTING THEM - The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same. | 10-25-2012 |
20120270231 | LATTICE-MISMATCHED CORE-SHELL QUANTUM DOTS - The disclosure relates to lattice-mismatched core-shell quantum dots (QDs). In certain embodiments, the lattice-mismatched core-shell QDs are used in methods for photovoltaic or photoconduction applications. They are also useful for multicolor molecular, cellular, and in vivo imaging. | 10-25-2012 |
20120270232 | CHARACTERIZATION OF GRANULOCYTIC EHRLICHIA AND METHODS OF USE - The present invention relates, in general, to methods of screening a sample obtained from a subject for antibodies relating to granulocytic ehrlichia (GE) infection. | 10-25-2012 |
20120329069 | METHODS FOR ANTIBODY ENGINEERING - The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications. | 12-27-2012 |
20130078644 | Post-Translational Modifications Identified by Elemental Analysis - Methods and kits for enzymes involved in post-translational modifications are provided. The methods employ elemental analysis, including ICP-MS. The methods allow for the convenient and accurate analysis of post-translation modifications of substrates by enzymes involved in post-translational modifications, including kinase and phosphatase enyzmes | 03-28-2013 |
20130084581 | Method of Identifying Transmembrane Protein-Interacting Compounds - A method for screening compounds for their ability to interact with transmembrane proteins is provided. Also provided is a method for determining whether proteins such as transmembrane proteins are able to oligomerise. | 04-04-2013 |
20130210028 | Biological Assays Using Microparticles - Encoded microparticles described are useful in the study of many different biological agents in multiplex assays. For instance, the encoded microparticles may be employed in various co-precipitation assays to purify and/or isolate various analytes of interest. Encoded microparticles may also be used as real-time detectors in many different situations whereby binding of a secreted analyte or contaminating analyte may be detected using various labeling techniques. Further, encoded microparticles may be attached in a specific manner to particular cell types, for instance in a heterogeneous mixture of cells, either fixed in tissue or circulating, to allow identification, localization and/or sorting of the cells in the context of various biological events under various environments or conditions. | 08-15-2013 |
20130230864 | METHOD FOR AND USE OF DIGITAL HOLOGRAPHIC MICROSCOPY AND IMAGING ON LABELLED CELL SAMPLES - The present invention relates to use of a digital holographic microscopy and imaging setup and a method of digital holographic microscopy and imaging for detecting molecules or structures stained or labelled to at least one cell or conjugated to antibodies which are bound either directly to said at least one cell or indirectly via another or several antibodies in a chain bound to said at least one cell. | 09-05-2013 |
20130273561 | LIPID ENCAPSULATION OF SURFACE ENHANCED RAMAN SCATTERING (SERS) NANOPARTICLES - Phospholipid-microvesicle-encapsulated surface enhanced Raman scattering (SERS) nanoparticles and methods for making the encapsulated particles are described. The encapsulated particles can be used in nanomedicine. Four Raman-active species were used. A bilayer was observed by TEM, and the SERS spectrum of each dye species (SERS reporter) was confirmed. | 10-17-2013 |
20130288268 | SULFENIC ACID-REACTIVE COMPOUNDS AND THEIR METHODS OF SYNTHESIS AND USE IN DETECTION OR ISOLATION OF SULFENIC ACID-CONTAINING COMPOUNDS - The present invention provides compounds of Formula I: | 10-31-2013 |
20130309689 | METHODS AND REAGENTS FOR BIOMOLECULE LABELING, ENRICHMENT AND GENTLE ELUTION - Methods and sets of non-biological reagents (elution reagents, tag isomers, tag reactive groups, crosslinkers) for single or multiplexed capture and gentle elution of biomolecules. Examples are provided using amine- and cysteine-reactive reagents for enrichment of proteins, peptides, and rare peptide modifications. | 11-21-2013 |
20130309690 | TETRAMERIC ALPHA-SYNUCLEIN AS BIOMARKERS - The present invention provides the surprising finding that alpha-synuclein exists in vivo as a folded tetramer. Provided are various methods and technologies that arise from this finding, including methods and kits for identifying individuals susceptible to or suffering from certain diseases, disorders or conditions associated with stability of alpha-synuclein tetramers, and/or individuals likely (or not) to respond to therapy with agents that alter level and/or stability of alpha-synuclein tetramers. | 11-21-2013 |
20130316366 | EXPRESSION OF SECRETED AND CELL-SURFACE POLYPEPTIDES - Some embodiments herein provide compositions and methods for expressing secreted and cell-surface-bound polypeptides in a single cell. In some embodiments, secreted and cell-surface polypeptide are produced from a single polynucleotide. The polynucleotide can comprise a sequence (or sequence encoding a polypeptide) that mediates separation of a membrane anchor from the polypeptide. In some embodiments, a desired ratio of secreted to surface-bound polypeptide is obtained by selecting a sequence that mediates a desired level of separation of the membrane anchor from the polypeptide. | 11-28-2013 |
20130316367 | Discrete Contact MR Bio-Sensor with Magnetic Label Field Alignment - The invention describes a family of sensors for assaying macro-molecules and/or biological cells in solution. The invention also describes methods of making and using the sensors. Each sensor has the form of a well (a hollow cylinder having a floor but no lid) or a trench whose walls comprise a plurality of GMR or TMR devices. Suitably shaped magnets located below each well's floor pull labeled particles into the well/trench and up against the inner wall where a field gradient orients them for optimum detection. Any unattached labels that happen to also be in the well/trench are removed through suitably sized holes in the floor. | 11-28-2013 |
20130316368 | MULTI-TARGET PHOTONIC BIOSENSOR, AND METHOD FOR MANUFACTURING AND PREPARING SAME - A component or device is provided for the detection or the measurement in parallel of one or more specific types of biological or chemical target products. This component includes a group of nanotubes selected and/or functionalized to interact with the target product, around an optical waveguide. Thus, an optical coupling is produced between the optical waveguide and one or more optical characteristics of these nanotubes, the modifications of which are evaluated in the presence of the target product. In addition, a method is provided for manufacturing and preparing such a component or device, and a detection method using them, as well as a post-manufacture preparation method comprising a specific functionalization for different target products starting from the same type of pluripotent generic component. Also provided is a family of PFO-based functionalization polymers. | 11-28-2013 |
20130344502 | VIBRATING MICROPLATE BIOSENSING FOR CHARACTERISING PROPERTIES OF BEHAVIOUR BIOLOGICAL CELLS - There is described a system for testing a sample. The system comprises a microplate, at least one actuator, a plurality of mutually spaced sensors, and a processor. The microplate has a test portion including an interactive substance. The interactive substance is inherently interactive with a specified test substance. The microplate is arranged such that at least the test portion of the microplate may be brought into contact with the sample. The at least one actuator is operable to vibrate the microplate. The plurality of mutually spaced sensors are coupled to the microplate. Each sensor is operable to provide a respective sensory data time series during vibration of the microplate. The microplate and the sensors are arranged such that the provided sensory data time series are not independent from one another. The processor is operable to receive the sensory data time series from the sensors and to process the received sensory data time series so as to provide information about the test substance in the sample based on the sensed interaction between the test substance and the interactive substance on the test portion of the microplate. A corresponding method of testing a sample is also described. | 12-26-2013 |
20140057283 | IMPEDANCE BASED DEVICES AND METHODS FOR USE IN ASSAYS - A method for assaying target molecules in a sample liquid, the method comprising: providing an impedance monitoring device operably connected to an impedance analyzer; adding a sample liquid suspected of having target molecules to the well thereby permitting binding of target molecules to the capture molecules; monitoring impedance of the well; and determining the presence, amount or concentration of target molecules in the liquid sample from the monitored impedance. The device includes a nonconducting substrate having a well, at least two electrodes fabricated on a bottom of the well and on a same plane, wherein the surfaces of the at least two electrodes are modified with capture molecules configured to bind target molecules in a liquid sample, and at least two connection pads electrically connected to the at least two electrodes. | 02-27-2014 |
20140057284 | PHOTOLUMINESCENT MOLECULAR COMPLEX AND METHOD FOR DETERMINING OF THE CONCENTRATION OF SAID MOLECULAR COMPLEX - The invention concerns novel molecular complexes with photoluminescent probes whose specific association with purine-binding proteins leads to increased emission of long lifetime luminescence, and the application of the probes for monitoring activity of protein kinases (PKs) and other purine-binding proteins, screening of compounds as inhibitors of PKs and characterization of inhibitors targeted to the kinase, and methods of manufacturing of such probes. The invention concerns also the use of the improved method for monitoring activity of protein kinases in living cells, characterization of inhibitors of protein kinases, analysis of protein kinase-based disease biomarkers and other tasks of biological and medical importance. | 02-27-2014 |
20140065640 | Interferometric Detection Using Nanoparticles - This invention provides methods and systems for detecting interaction between members of a binding pair. The method involves associating one member of the binding pair with a nanoparticle and detecting the interaction between the two molecules by back-scattering interferometry. | 03-06-2014 |
20140113309 | METHOD AND APPARATUS FOR ANALYZING PROTEIN-PROTEIN INTERACTION ON SINGLE-MOLECULE LEVEL WITHIN THE CELLULAR ENVIRONMENT - A method of analyzing protein-protein interactions includes binding the first proteins to the substrate where the first proteins are tagged with the first markers which bind specifically to the biomolecules immobilized on the substrate or the first proteins bind specifically to the biomolecules immobilized on the substrate; incubating the substrate bound first proteins with cell lysate containing the second proteins which are tagged with second markers; analyzing the interactions between the first proteins and the second proteins in the cell lysate, and obtaining the first analytic value representing the kinetic picture of the interactions; incubating the substrate bound first proteins with cell lysate mixture of a cell lysate consisting of the second markers-tagged second proteins and another cell lysate comprising other proteins including unlabelled second proteins and obtaining the second analytic value; comparing and analyzing the first and the second analytic values. | 04-24-2014 |
20140127710 | BACKGROUND-FREE MAGNETIC FLOW CYTOMETRY - The invention relates to an apparatus and a method for magnetic flow cytometry, wherein magnetic units ( | 05-08-2014 |
20140170673 | UNITARY CARTRIDGE FOR PARTICLE PROCESSING - A single disposable cartridge for performing a process on a particle, such as particle sorting, encapsulates all fluid contact surfaces in the cartridge for use with microfluidic particle processing technology. The cartridge interfaces with an operating system for effecting particle processing. The encapsulation of the fluid contact surfaces insures, improves or promotes operator isolation and/or product isolation. The cartridge may employ any suitable technique for processing particles. | 06-19-2014 |
20140220592 | METHOD OF CALIBRATION - The following processes are performed to improve the accuracy of the process of estimating the volume of a cell clump from an image including the cell clump. First, the image including the cell clump is acquired, and the optical density of the cell clump in the image is measured. Cross-section information about the cell clump is acquired by observation using a confocal microscope or by physical cutting. Based on the cross-section information, the vertical height of the cell clump is determined. Thereafter, data representing a relationship between the aforementioned optical density and the height is acquired. This improves the accuracy of the process of converting the optical density into the height to thereby achieve the accurate estimation of the volume of the cell clump. | 08-07-2014 |
20140234859 | CONTROLLED PLATELET ACTIVATION TO MONITOR THERAPY OF ADP ANTAGONISTS - A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIIb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi. | 08-21-2014 |
20140302523 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same - The present invention includes compounds that are useful in perturbing or disrupting the function of a transmembrane or intracellular protein, whereby binding of a compound to the transmembrane or intracellular protein induces proteasomal degradation of the transmembrane or intracellular protein. The present invention further includes a method of inducing proteasomal degradation of a transmembrane or intracellular protein. The present invention further includes a method of identifying or validating a protein of interest as a therapeutic target for treatment of a disease state or condition. | 10-09-2014 |
20150037813 | ANTIBODY AGAINST AFFINITY COMPLEX - The present invention provides a means and a method for specifically measuring a substance such as a small substance with high sensitivity by a sandwich method. Specifically, the present invention provides an antibody capable of specifically binding to an affinity complex and a method of measuring of the affinity complex comprising measuring the affinity complex using the antibody capable of specifically binding to the affinity complex. The antibody of the present invention may be a full-length antibody. The antibody of the present invention may also have a region derived from an immunoglobulin from an animal having an ability of gene conversion (e.g., a complementarity-determining region, a framework region, or a variable region). Examples of at least one factor that constitutes the affinity complex include a small substance or a protein (e.g., antibody). | 02-05-2015 |
20150056632 | FLUORESCENT DYES, FLUORESCENT DYE KITS, AND METHODS OF PREPARING LABELED MOLECULES - The present invention provides methods, compositions, and kits useful in preparing labeled molecules, which are useful in the detection of binding partners. | 02-26-2015 |
20150064713 | METHODS, KITS AND MEANS FOR DETERMINING INTRACELLULAR INTERACTIONS - Methods, kits and systems for determining whether a reaction occurs between a chimeric transmembrane receptor and an intracellular interaction partner thereof within a cell. | 03-05-2015 |
20150111222 | GENETICALLY ENCODED BIOSENSORS - The present disclosure provides, inter alia, genetically encoded recombinant peptide biosensors comprising analyte-binding framework portions and signaling portions, wherein the signaling portions are present within the framework portions at sites or amino acid positions that undergo a conformational change upon interaction of the framework portion with an analyte. | 04-23-2015 |
20150301048 | METHODS FOR DETECTING ALLOSTERIC MODULATORS OF PROTEIN - The present invention discloses, inter alia, methods for labeling a target protein with an SHG-active probe for detection by second harmonic or sum-frequency generation in order to identify agents which bind to an allosteric site on the target protein thereby altering its structural conformation | 10-22-2015 |
20150316481 | ENCAPSULATED DYE COATED NOBLE METAL NANOPARTICLES WITH INCREASED SURFACE ENHANCED RAMAN SCATTERING PROPERTIES AS CONTRAST AGENTS - The present disclosure provides semiconductor-metal composite nanoparticles with optical properties that are superior to those of pure materials for use as contrast agents. The composites include noble metal nanoparticles having a layer of linker molecules being bound to the surface of the noble metal nanoparticle and a layer of dye molecules bound to the layer of linker molecules. The dye molecules are selected such that they form an ordered structure that exhibits a collective absorption band shift, compared to the individual dye molecule, when bound to the noble metal nanoparticle. This structure is encapsulated in a stabilizing coating layer forming a multi-shell structure with properties suitable for biosensing and other detection applications which exhibit enhanced Raman scattering compared to nanoparticles having dye molecules bound thereto not in the ordered structure. | 11-05-2015 |
20150316557 | COUMARIN-BASED FLUOROGENIC AGENTS AND USES THEREOF FOR SPECIFIC PROTEIN LABELLING - There are provided fluorescent labelling agents comprising a dimaleimide core connected to a fluorophore, processes for preparation thereof, and uses thereof for labelling and/or detection of specific protein targets. Fluorescent labelling agents comprising a compound having the structure of Formula I, and salts thereof, are described. | 11-05-2015 |
20150355072 | Method for Enriching and Isolating Cells Having Concentrations Over Several Logarithmic Steps - For flow cytometric measurement, a channel includes a magnetic sensor and is disposed downstream of a chamber. The chamber and the channel form a closed system, wherein an axis of the channel extends along a flow direction of the channel. A closed system is present if the chamber merges directly into the channel. A magnet, more particularly a permanent magnet, and a deflection device, are both arranged at a predefined side of the channel. Here, the deflection device has at least one segment. Each segment is arranged in a concentration region of the channel. Each segment has a guide for guiding cells toward the axis. The deflection device thus enables an enrichment of magnetically marked cells, which are pulled to the channel side by the magnet in the respective concentration region, on the axis and guidance of these cells along the axis to the magnetic sensor. | 12-10-2015 |
20150377896 | Method of Identifying Transmembrane Protein-interacting Compounds - A method for screening compounds for their ability to interact with transmembrane proteins is provided. Also provided is a method for determining whether proteins such as transmembrane proteins are able to oligomerise. | 12-31-2015 |
20160033519 | BROMODOMAIN BINDING REAGENTS AND USES THEREOF - The present invention provides compounds of the Formula (I) and (II), and salts thereof, wherein L | 02-04-2016 |
20160041188 | PEPTIDE WITH GOLD BINDING AND EGFR RECEPTOR AFFINITY AND SAME ATTACHED TO GOLD NANOSTRUCTURE - An embodiment of the invention is a peptide comprising four domains, wherein domain I consists of thioctyl or monocytl, domain II consists of 2 to 3 positively charged amino acids selected from the group consisting of lysine and arginine, domain III consists of a dimeric ethylene unit; and domain IV comprises the peptide with SEQ ID No. 1 or a sequence having at least 90% identity to SEQ ID No. I. The peptide is preferably attached to a gold nanostructure, preferably a gold nanorod to provide an EFGR kit. An EFGR detection kit of the invention employs a gold nanostructure attached to a peptide sequence, the peptide sequence includes a binding sequence with an affinity toward EGFR, a ligand bound to gold atoms of the nanorod, a positively charged amino acid that maintains activity of the binding sequence, and a unit that increases hydrophilicity of the peptide sequence. | 02-11-2016 |
20160061847 | T2R Taste Receptors and Genes Encoding Same - Newly identified mammalian taste-cell-specific G Protein-Coupled Receptors and the genes encoding said receptors are described. Specifically, T2R taste G Protein-Coupled Receptors that are believed to be involved in bitter taste sensation, and the genes encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating a novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. | 03-03-2016 |
20160108015 | Carbofluorescein Lactone Ion Indicators and Their Applications - Fluorescent dyes useful for preparing fluorescent metal ion indicators, the fluorescent indicators themselves, and the use of the fluorescent indicators for the detection, discrimination and quantification of metal cations are provided. | 04-21-2016 |
20160123970 | MOLECULAR CYTOMETRY - The invention relates to methods and devices for molecular cytometry. The molecular cytometer is for use in the analysis of molecular tag labeled particles. In the molecular cytometer, volatile molecular tags attached to the particles, such as cells, are released as groups of molecular tags and ionized by the method of soft ionization to produce corresponding groups of molecular ions. The molecular cytometer has two detectors, one to detect the presence of the groups of molecular ions and the other to detect mobility separated molecular ions. The mobility separated molecular ions are synchronized to correspond with the groups of molecular ions. | 05-05-2016 |
20160146782 | Diagnostic Method and System - The present invention relates to a method of diagnosis which identifies one or more individual cells and comprises determining at least one of a cell dimension and a cell area, and determining at least one of dark/light cell contrast characteristics, cell area characteristics, cell colour characteristics, cell roughness characteristics, distances between cell nuclei and cell convexity. A computer readable medium, a computer apparatus and a diagnostic system is also provided. | 05-26-2016 |
20160153952 | DETECTION AND RECOVERY OF CHEMICAL ELEMENTS FROM FLUIDS WITH TECTRABRACHION | 06-02-2016 |
20160161415 | METAL-ANTIBODY TAGGING AND PLASMA-BASED DETECTION - A target within a sample can be characterized using an energy source configured to transform a metal in the sample into a plasma and an optical spectroscopic detector configured to detect electromagnetic radiation emitted by the plasma to provide an optical-spectrum signal. A processor can determine presence of the metal in the sample using the optical-spectrum signal. The target can include a microbe or biological toxin. A recognition construct comprising a metal and a scaffold can be applied to the sample. The scaffold can bind to the target. Energy can be applied to transform at least some of the sample into a plasma. Electromagnetic radiation emitted by the plasma can be detected to provide an optical-spectrum signal of the sample. A preparation subsystem can add the recognition construct to the sample and a washing subsystem can wash unbound recognition construct out of the sample. | 06-09-2016 |
20160169876 | EXOSOME ANALYSIS METHOD, EXOSOME ANALYSIS CHIP, AND EXOSOME ANALYSIS DEVICE | 06-16-2016 |
20160169921 | MODULATING BACTERIAL MAM POLYPEPTIDES IN PATHOGENIC DISEASE | 06-16-2016 |
20160200785 | ENGINEERED OPSONIN FOR PATHOGEN DETECTION AND TREATMENT | 07-14-2016 |
20160376338 | HEAT-SENSING PROTEIN SWITCHES AND USES THEREOF - A region of the TRPV1 protein that functions as a temperature switch (FIG. | 12-29-2016 |
435700210 | Producing monoclonal antibody | 12 |
20080199888 | Non-endogenous, constitutively activated versions of human G protein coupled receptor: FSHR - The invention disclosed in this patent document relates to transmembrane receptors, particularly to a human G protein-coupled receptor, more particularly to a follicle stimulating hormone receptor (FSHR), and most particularly to mutated (non-endogenous) versions of the human FSHR for evidence of constitutive activity. | 08-21-2008 |
20080199889 | Human orphan G protein-coupled receptors - The invention disclosed in this patent document relates to transmembrane receptors, more particularly to endogenous, human orphan G protein-coupled receptors. | 08-21-2008 |
20080213803 | ASSESSMENT OF NEURONS IN THE ARCUATE NUCLEUS TO SCREEN FOR AGENTS THAT MODIFY FEEDING BEHAVIOR - Screening methods of use in identifying agents that affect caloric intake, food intake, appetite, and energy expenditure are disclosed herein. These methods are used to identify agents of use in treating obesity, or that can be used to decrease the weight of a subject. These methods can also be used to identify agents of use in treating anorexia or cachexia and can be used to increase appetite and to increase the weight and lean body mass of a subject. | 09-04-2008 |
20080220450 | Population Based Prediction Methods for Immune Response Determinations and Methods for Verifying Immunological Response Data - The present invention provides means to assess immune response profiles of populations. In particular, the present invention provides means to qualitatively assess the immune response of human populations, wherein the immune response directed against any protein of interest is analyzed. The present invention further provides means to rank proteins based on their relative immunogenicity. In further embodiments, the present invention provides means for verifying immunological response data, as well as means for predicting immune responses directed against any antigen/immunogen. In addition, the present invention provides means to create proteins with reduced immunogenicity for use in various applications. | 09-11-2008 |
20080220451 | T1R2 BINDING ASSAYS - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular taste stimulus in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed. | 09-11-2008 |
20080220452 | KIT FOR DETERMINING POLYSACCHARIDE-BINDING ABILITY OF MONONUCLEAR CELLS PRESENT IN PERIPHERAL BLOOD - A kit for the determination of the ability of a peripheral blood mononuclear cell to bind to a polysaccharide herein provided comprises a detection reagent comprising a fluorescence-labeled immunostimulant polysaccharide; and a reference reagent comprising a fluorescence-labeled material of a polysaccharide different from that used in the fluorescence-labeled immunostimulant polysaccharide, and/or an immunostimulant polysaccharide which is not labeled with any fluorescent material and whose polysaccharide moiety is identical to that included in the fluorescence-labeled immunostimulant polysaccharide. The use of this kit would permit the estimation of the polysaccharide-binding ability of a peripheral blood mononuclear cell in a higher precision of estimation. | 09-11-2008 |
20080227118 | Protein Immobilization Method and Quantification Method - The present invention relates to a method for immobilizing a protein in a sample, which could not easily be immobilized by the conventional immobilization method, to a solid-phase; a method for quantitative determination of protein wherein an effect of inhibitory substance coexisting in a sample prepared using the immobilization method can be reduced; and a rapid and highly precise method for detecting an abnormal PrP and a method for determining BSE using the immobilization method as compared with the conventional method. The present invention provides: “a method for immobilizing a protein to a solid-phase comprising contacting the protein with the solid-phase having hydrophobic surface in the presence of a lower alcohol, and a halogenocarboxylic acid and/or a long chain alkyl sulfate, and an immobilizing reagent solution to be used therefor; a method for quantitative determination of protein comprising contacting a protein-staining solution with the solid-phase immobilized with a protein by the immobilization method, and determining a degree of color development generated thereby; an immunoblotting method wherein the solid-phase immobilized with a protein by the immobilization method is used; and a method for detecting an abnormal PrP a method for determining BSE by using the immobilization method.” | 09-18-2008 |
20080227119 | ELISA for VEGF - The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA methods and kits for VEGF as an antigen are provided to detect types of VEGF levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index. | 09-18-2008 |
20080227120 | FRET-BASED ASSAY FOR SCREENING MODULATORS OF RECEPTOR CYCLING - Automated FRET imaging of membrane-bound receptor/ligand complexes can discriminate between a clustered organization of ligand/receptor complexes that occurs during the early endocytic stages following internalization and a random distribution characteristic of late stage disassociation of ligand from the receptor. In the case of the low density lipoprotein receptor (LDL-R) and its ligand, LDL, this feature of FRET imaging forms the basis of an assay to monitor the endosomal release of cholesterol into the cell and identify compounds which alter pH in the endosome thereby inhibiting the disassociation of ligand and cholesterol from the receptor, a mechanism that is involved in regulation of plasma/serum cholesterol. | 09-18-2008 |
20080227121 | Inducible ligand for alpha1beta1 integrin and uses - The present invention is directed to the identification and use of agents, particularly peptides and monoclonal antibodies that disrupt the interaction between Collagen XIII and α1β1 integrin. | 09-18-2008 |
20080233598 | Nucleic acid and corresponding protein entitled 121P2A3 useful in treatment and detection of cancer - A novel gene (designated 121P2A3) and its encoded protein, and variants thereof, are described wherein 121P2A3 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 121P2A3 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 121P2A3 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 121P2A3 can be used in active or passive immunization. | 09-25-2008 |
20080248495 | Guinea pig proteinase-activated receptor 4 and its activating peptide - This invention relates to nucleic acid encoding guinea pig PAR 4 and to the protein encoded thereby. The guinea pig DNA and protein are useful for the development of models of human platelet aggregation. The invention further relates to an animal model to assess the role of PAR antagonists in thrombosis. | 10-09-2008 |
20080248496 | NUCLEAR MATRIX PROTEIN ALTERATIONS ASSOCIATED WITH COLON CANCER AND COLON METASTASIS TO THE LIVER, AND USES THEREOF - Proteins useful in the diagnosis of proliferative disorders of the colon are present in nuclear matrix protein preparations and can be characterized by molecular weight, isoelectric point, and amino acid sequence. The proteins may be identified, for example, by 2D-gel electrophoresis or by specific binding partners, such as antibodies. | 10-09-2008 |
20080254487 | Connective Tissue Growth Factor Signaling - The present invention provides compounds and agents that modulate CTGF-mediated cell adhesion and/or binding of CTGF to cells. The invention further provides assays that may be used to identify additional modulators of CTGF-mediated cell adhesion and CTGF binding to cells, and assays that may be used to identify compounds or agents that modulate interaction of CTGF with HSPGs. | 10-16-2008 |
20080261242 | Highly Sensitive System and Methods for Analysis of Troponin - The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin. | 10-23-2008 |
20080268470 | METHODS OF SELECTING CELL CLONES - The invention describes novel methods for selecting cell clones which produce high amounts of protein of interest. In one method the amount of protein is measured before the cells are passaged for the first time. In another method a high throughput automated platform is used under sterile environment conditions with class A particle load of less than 100 particles per m3. | 10-30-2008 |
20080268471 | USE OF SPECIFIC T2R RECEPTORS TO IDENTIFY COMPOUNDS THAT BLOCK BITTER TASTE - Assays for identifying compounds that modulate, preferably inhibit bitter taste associated with the activation of hT2R4, hT2R44 and/or hT2R61 are provided. The compounds identified according to these assays should modulate, e.g., inhibit bitter taste associated with bitter tasting compounds including quinine, 6-nitrosaccharin, saccharin and/or denatonium. These compounds are useful additives for foods, beverages or medicinal preparationshaving a bitter taste. | 10-30-2008 |
20080268472 | High throughput assay systems and methods for identifying agents that alter expression of cellular proteins - Disclosed are high throughput assay systems and methods for identifying agents that alter the level of expression of proteins in mammalian cells, particularly integral membrane proteins. | 10-30-2008 |
20080274480 | Botulinum Toxin Type a Immunoresistant Assay - The present specification discloses methods for determining Botulinum Toxin Type A immunoresistance in a mammal by detecting the amount of BoNT/A toxin-BoNT/A receptor complexes or the amount of free BoNT/A present or absent in a sample. | 11-06-2008 |
20080286813 | Antibody specific for mutant presenilin 1 and method of use thereof - The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes. | 11-20-2008 |
20080299586 | OLFACTORY RECEPTORS FOR ISOLVALERIC ACID AND RELATED MALODORANTS AND USE THEREOF IN ASSAYS FOR IDENTIFICATION OF BLOCKERS - A subgenus of olfactory receptors (ORs) that are activated by isovaleric acid (IVA) are identified as well as assays that utilize one or more of these ORs. These assays are useful for identifying potential anti-odorants which may be used in deodorants, air and carpet fresheners, fabric deodorizers, and other compositions for camouflaging odor attributable to IVA and related carboxylic acids. | 12-04-2008 |
20080299587 | METHODS OF MEASURING INHIBITION OF PLATELET AGGREGATION BY THROMBIN RECEPTOR ANTAGONISTS - A method is provided for measuring inhibition of platelet aggregation by a thrombin receptor antagonist. First, a blood sample is obtained from a patient treated with a thrombin receptor antagonist. The blood sample is mixed in combination with particles including an immobilized GPIIb/IIIa receptor ligand and a thrombin receptor activator. The combination is then incubated under conditions suitable for agglutinating the particles, and platelet-mediated agglutination is assessed in the mixture. The absence of agglutination indicates that the patient has reduced ability to form platelet thrombi in response to the thrombin receptor antagonist treatment. Also provided is a kit for measuring inhibition of platelet aggregation by a thrombin receptor antagonist that includes a GPIIb/IIIa receptor ligand immobilized on a particle, a thrombin receptor activator, an anticoagulant, and a buffer to maintain the anticoagulated blood in a condition suitable for platelet aggregation. | 12-04-2008 |
20080299588 | Methods For Measuring Bone Formation - The present invention relates to methods for detecting and monitoring bone mineralization. The invention provides antibodies, kits, and methods of use for detecting or monitoring the rate of bone mineralization associated with bone disorders such as osteoporosis. | 12-04-2008 |
20080305498 | Biomarkers for Use in Vessel Disorders - The present invention relate to a method of diagnosing a subject having a vessel disorder. More particularly, a biological sample is obtained from a subject suspected of having a vessel disorder. A protein profile is determined or measured in the sample using procedures described herein, for example, mass spectrometry or immunodetection. The protein profile from the subject is compared to a protein profile in a healthy control, wherein an alteration in the levels of a protein of the profile in the subject compared to the healthy control is indicative of a vessel disorder. | 12-11-2008 |
20080305499 | Anti-Synoviolin Antibody - The present invention relates to an antibody against synoviolin or a fragment thereof for providing a monoclonal antibody capable of recognizing a part of synoviolin, which monoclonal antibody is capable of inhibiting the auto-ubiquitination of synoviolin. | 12-11-2008 |
20080305500 | NOVEL CELL-BASED ASSAYS FOR IDENTIFYING ENHANCERS OR INHIBITORS OF T1R TASTE RECEPTORS (T1R2/T1R3 SWEET) AND UMAMI (T1R1/T1R3 UMAMI) TASTE RECEPTORS - This invention relates to improved assays for identifying modulators (enhancers or inhibitors) of sweet (T1R2/T1R3) and umami (T1R1/T1R3) taste receptors. These receptors may comprise the endogenous T1Rs e.g., from humans or rodents, or may comprise functional variants such as chimeric taste receptors comprising the extracellular portion of one T1R or a variant or fragment thereof, either T1R1 or T1R2, and the transmembrane portion of another T1R or a variant or fragment thereof, either T1R1 or T1R2, preferably associated with a T1R3 polypeptide and a suitable G protein. The subject assays preferably use endogenous taste or gastrointestinal cells which express T1R taste receptors or recombinant cell which express such T1Rs, for example mammalian cells or | 12-11-2008 |
20080305501 | Compositions and Methods for Modulating Rank Activities - The present invention provides methods for identifying agents capable of modulating RANK-mediated invention also provides pharmaceutical compositions and methods of using the same for treating osteoporosis or other diseases. The present invention is based on the functional and structural analysis of a novel RANK signaling motif that was found to play a distinct role in activating RANK-mediated intracellular signaling. This motif can be used to screen for RANK modulators. This motif for treating a variety of diseases that are caused by or associated with abnormal RANK expression or activities. | 12-11-2008 |
20080311593 | METHODS OF DIAGNOSING NON-ALCOHOLIC STEATOHEPATITIS (NASH) - Non-invasive methods for detecting non-alcoholic fatty liver disease (NAFLD) and identifying the presence or absence of non-alcoholic steatohepatitis (NASH) in a subject utilize one or more biomarkers. The methods can differentiate between subjects with NASH and those with simple steatosis. Kits containing one or more agents for measuring the level of the biomarkers can be utilized to perform the described methods. | 12-18-2008 |
20080318251 | Mammalian Sweet And Amino Acid Heterodimeric Taste Receptors - The present invention provides isolated nucleic acid and amino acid sequences of sweet or amino acid taste receptors comprising two heterologous G-protein coupled receptor polypeptides from the T1R family of sensory G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet and amino acid taste receptors. | 12-25-2008 |
20080318252 | Rapid assay to test anti-cancer drugs under physiological conditions - This invention relates to an assay that allows for the rapid determination of the activity of a given drug against leukemic cells either taken from a patient or derived from a cell line. The assay is performed in the presence of whole blood or serum. | 12-25-2008 |
20090004676 | T1R3 receptor binding assays for identification of taste modulatory compounds - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically. T | 01-01-2009 |
20090011437 | Methods of Detecting Antibodies Specific for Denatured HLA Antigens - The invention is directed to methods of screening for HLA antibodies comprising detecting antibodies specific for native HLA antigens and denatured HLA antigens. The invention also provides for method of predicting whether a transplant recipient has an increased risk for rejecting the transplanted organ. | 01-08-2009 |
20090017471 | SOLUBLE ErbB3 METHOD OF DETECTION - The present invention discloses a method using human soluble ErbB3, for example p85-sErbB3, as a negative regulator of heregulin-stimulated ErbB2, ErbB3, and ErbB4 activation. The present invention also discloses p85-sErbB3 binding to heregulin with an affinity comparable to that of full-length ErbB3, and competitively inhibiting high affinity heregulin binding to ErbB2/ErbB3 heterodimers on the cell surface of breast carcinoma cells. The present invention also uses p85-sErbB3 to inhibit heregulin-induced phosphorylation of ErbB2, ErbB3, and ErbB4 in cells, as a negative regulator of heregulin-stimulated signal transduction, and as a block for cell growth. The present invention is also directed to nucleic acids and expression vectors encoding p85-sErbB3, host cells harboring such expression vectors, and methods of producing the protein. The present invention discloses a method of therapeutically treating human malignancies associated with heregulin-mediated cell growth such as breast and prostate cancer. | 01-15-2009 |
20090023159 | Method for the in vitro diagnosis of alzheimer's disease using a monoclonal antibody - The invention relates to a method for the in vitro diagnosis of Alzheimer's disease using a monoclonal antibody. Said antibody can bind at least to amino acids 12-16 of the β-amyloid peptide, specifically detecting the neuritic plaques which are characteristic of Alzheimer's disease, without detecting diffuse plaques which are not defining characteristics of the disease. Within the neuritic plaques, the monoclonal antibody can detect a different sub-group in the composition of the different deposited isoforms of the β-amyloid peptide, which is associated with the disease progression stage. In addition, the antibody can bind to isoforms of the β-amyloid peptide in biological fluids such as urine. As a result, the inventive monoclonal antibody, the cell lines that produce said antibody and compositions containing same can be used in the in vitro diagnosis of Alzheimer's disease and in determining the disease progression stage. | 01-22-2009 |
20090035791 | Neural Colony Forming Assay - A neural colony forming cell (NCFC) assay is described. The assay allows one to distinguish neural stem cells from neural progenitor cells. In one embodiment, the present invention provides a method for identifying neural stem cells or neural progenitor cells comprising: (a) suspending neural cells in a semi-solid medium which supports the growth of neural cells; (b) plating the cells in the semi-solid medium at a density that allows for the production of colonies; (c) culturing the plated cells until size differences can be discerned between the colonies; and (d) estimating colony size wherein the larger colonies are likely produced by neural stem cells and wherein the small colonies are likely produced by neural progenitor cells In alternate embodiments, NSC can be distinguished from neural progenitor cells by determining the morphology or antigen expression of the colonies. | 02-05-2009 |
20090042219 | Novel Transporter Protein in Mammal and Utilization of the Same - The present invention provides a lipid membrane that contains a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, or 22. Use of the present invention enables screening for a chemical which regulates excretion of a chemical and/or a waste. Furthermore, use of the present invention enables an arbitrary chemical to be tested for nephrotoxicity and/or hepatotoxicity. | 02-12-2009 |
20090042220 | Method for monitoring collagen type II degradation in cartilage - A method for improving the diagnostic assessment of cartilage degenerative processes, and to provide means of monitoring the effects of therapeutical measures taken towards arthritic diseases in most mammals utilizes an immunoassay to detect fragments of collagen type II resulting from collagenase activity comprising an antibody directed against an epitope comprised in the amino acid sequence HRGYPGLDG (SEQ ID NO:1), located in the helical region of collagen type II. | 02-12-2009 |
20090042221 | PRECISE EFFICACY ASSAY METHODS FOR ACTIVE AGENTS INCLUDING CHEMOTHERAPEUTIC AGENTS - An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying the best treatment or agent for the particular patient. Specific method innovations such as tissue sample preparation techniques render this method practically as well as theoretically useful. One particularly important tissue sample preparation technique is the initial preparation of cohesive multicellular particulates of the tissue sample, rather than enzymatically dissociated cell suspensions or preparations, for initial tissue culture monolayer preparation. With respect to the culturing of malignant cells, for example, it is believed (without any intention of being bound by the theory) that by maintaining the malignant cells within a multicellular particulate of the originating tissue, growth of the malignant cells themselves is facilitated versus the overgrowth of fibroblasts or other cells which tends to occur when suspended tumor cells are grown in culture. Practical monolayers of cells may thus be formed to enable meaningful screening of a plurality of treatments and/or agents. Growth of cells is monitored to ascertain the time to initiate the assay and to determine the growth rate of the cultured cells; sequence and timing of drug addition is also monitored and optimized. By subjecting uniform samples of cells to a wide variety of active agents (and concentrations thereof), the most promising agent and concentration for treatment of a particular patient can be determined. For assays concerning cancer treatment, a two-stage evaluation is contemplated in which both acute cytotoxic and longer term inhibitory effect of a given anti-cancer agent are investigated. | 02-12-2009 |
20090061461 | Phosphorylated or Non-Phosphorylated MPR as Diagnostic Marker or Therapeutic Target - A method of diagnosing diseases associated with aberrant biological phenotypes including contacting a sample to be tested with at least one isoform of membrane associated progesterone receptor component 1 (mPR) as a diagnostic marker, and determining or estimating the degree of phosphorylation of the membrane associated progresterone receptor component 1 (mPR). | 03-05-2009 |
20090061462 | Prion-specific peptide reagents - Peptide reagents that interact preferentially with the PrP | 03-05-2009 |
20090068683 | MARKERS FOR PREECLAMPSIA - This document provides methods and materials related to determining whether or not a pregnant mammal (e.g., a pregnant human) has preeclampsia. For example, methods and materials related to the use of urinary podocytes to determine whether or not a pregnant human has preeclampsia are provided. | 03-12-2009 |
20090081707 | Human trk receptors and neurotrophic factor inhibitors - The invention concerns human trkB and trkC receptors and their functional derivatives. The invention further concerns immunoadhesins comprising trk receptor sequences fused to immunoglobulin sequences. | 03-26-2009 |
20090087866 | HUMAN T2R RECEPTORS FOR RANITIDINE, STRYCHNINE AND DENATONIUM AND RELATED ASSAYS FOR IDENTIFYING HUMAN BITTER TASTE MODULATORS - The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter ligands, i.e., acetaminophen, ranitidine, strychnine and denatonium. The present invention further relates to the use of these receptors in assays for identifying ligands that modulate the activation of these taste receptors and which may be used as additives in foods, beverages and medicinals for modifying (blocking) T2R-associated bitter taste. | 04-02-2009 |
20090093002 | HUMANIZED ANTIBODY - The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. | 04-09-2009 |
20090093003 | PORCINE UMAMI TASTE RECEPTORS AND USES THEREFOR - The present invention provides nucleic acids encoding porcine taste receptors, polypeptides encoded by the nucleic acids, and methods of using the nucleic acids and polypeptides to identify compounds that enhance umami taste. | 04-09-2009 |
20090098579 | HUMAN T1R2 POLYPEPTIDE FUNCTIONAL ASSAYS - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular taste stimulus in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed. | 04-16-2009 |
20090098580 | MAMMALIAN SWEET TASTE RECEPTORS - The present invention provides isolated nucleic acid and amino acid sequences of sweet taste receptors comprising two heterologous G-protein coupled receptor polypeptides from the T1R family of sensory G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet taste receptors. | 04-16-2009 |
20090104630 | Semi-quantitative immunochromatographic device and method for the determination of HIV/AIDS immune-status via measurement of soluble CD40 ligand/CD 154, A CD4+T cell equivalent - A semi-quantitative, immunochromatographic device for the detection of HIV/AIDS immune status CD4+ T cell equivalents, such as soluble CD40 ligand/CD 154, includes one or more support materials capable of providing lateral flow. The one or more support materials include a first area for receiving a biological sample containing a target analyte, the analyte being a CD4+ T cell equivalent, such as soluble CD40 ligand/CD 154, a second area having a movably contained detector ligand, wherein the detector ligand is capable of forming a mobile complex with the soluble CD40 ligand/CD 154, and at least one capture area having a predetermined amount of an immobile capture reagent, the immobile capture reagent capable of specifically binding to the mobile complex formed by the soluble CD40 ligand/CD 154 protein and the detector ligand and providing a visible signal. | 04-23-2009 |
20090111125 | Method for detecting mycobacterial infection - A method of detecting a surrogate marker for active tuberculosis involves obtaining first, second and third samples from a subject suspected of having active tuberculosis, diluting the first sample and exposing part of it to an immobilized mycolic acid antigen in a test vessel and part of it to an immobilized mycolic antigen in a control vessel. The second sample is exposed to mycolic acid antigen-containing liposomes and the third sample is exposed to liposomes not containing mycolic acid antigens. The second sample is added to the test vessel and the third to the control vessel and binding of antibodies to the mycolic acid and antigen in both the test and control vessel is detected. The degree of binding between the test and control vessels is compared and lesser binding in the test vessel is an indicator of the presence of antibodies to the mycolic acid antigen. | 04-30-2009 |
20090111126 | MAMMALIAN CELL-BASED IMMUNOGLOBULIN DISPLAY LIBRARIES - Disclosed are mammalian cell surface display vectors for isolating and/or characterizing immunoglobulins and various uses thereof. | 04-30-2009 |
20090117593 | T. Cruzi-derived neurotrophic agents and methods of use therefor - The invention relates to | 05-07-2009 |
20090117594 | METHOD FOR MEASURING HUMAN MEGALIN - This invention provides a method for measuring human megalin that can be performed in a simpler manner within a shorter period of time than is possible with conventional techniques, and that can also quantify human megalin. This invention also provides a method that enables diagnosis of functional diseases, which are specific to cells, tissues, or organs, in a site-directed manner at an early stage. Measurement of human megalin enables detection of a disease in an organ in which megalin expression is observed. | 05-07-2009 |
20090123942 | Electrophysiological assays using oocytes that express human enac and the use of phenamil to improve the effect of enac enhancers in assays using membrane potential reporting dyes - In one aspect, the present invention relates to a mammalian cell-based high-throughput assay for the profiling and screening of human epithelial sodium channel (hENaC) cloned from a human kidney c-DNA library and is also expressed in other tissues including human taste tissue. The present invention further relates to amphibian oocyte-based medium-throughput electrophysiological assays for identifying human ENaC modulators, preferably ENaC enhancers. Compounds that modulate ENaC function in a cell-based ENaC assay are expected to affect salty taste in humans. The assays described herein have advantages over existing cellular expression systems. In the case of mammalian cells, such assays can be run in standard 96 or 384 well culture plates in high-throughput mode with enhanced assay results being achieved by the use of a compound that inhibits ENaC function, preferably an amiloride derivative such as Phenamil. In the case of the inventive oocyte electrophysiological assays (two-electrode voltage-clamp technique), these assays facilitate the identification of compounds which specifically modulate human ENaC. The assays of the invention provide a robust screen useful to detect compounds that facilitate (enhance) or inhibit hENaC function. Compounds that enhance or block human ENaC channel activity should thereby modulate salty taste in humans. | 05-14-2009 |
20090123943 | Characterization and Identification of Unique Human Adiponectin Isoforms and Antibodies - The invention pertains to methods for measuring different forms of human adiponectin that are present in human plasma/serum, and more specifically methods are based on an ELISA assay that utilizes different monoclonal antibodies directed against adiponectin, in combination with different polyclonal antibodies directed against different domains of human adiponectin. The invention also provides unique isoforms of adiponectin and antibodies thereto, including polyclonal and monoclonal antibodies. | 05-14-2009 |
20090123944 | Bioassays - The invention relates to vectors encoding bioassay receptors and in vitro bioassays using said bioassay receptors for assessing compounds of interest. In particular, the bioassays provide a generic platform for the comparison of binding of different ligands to their respective receptors or binding partners in the presence and/or absence of a compound of interest. | 05-14-2009 |
20090123945 | CHOLINERGIC/SEROTONINERGIC RECEPTOR AND USES THEREOF - The present invention describes new cholinergic/serotoninergic chimeric receptors and provides methods and compositions suitable for screening for ligands such as agonists, antagonists and allosteric modulators of α7 nicotinic acetylcholine receptors. | 05-14-2009 |
20090123946 | IMMUNOASSAYS AND KITS FOR THE DETECTION OF NGAL - The present invention relates to NGAL immunoassays and kits, and to methods of using glycosylated mammalian NGAL and antibodies that bind to mammalian NGAL in immunoassays and kits. Among other things, the methods and kits can be employed to determine the amount of human NGAL monomer in a test sample, as well as to determine the proportion of human NGAL monomer to human NGAL dimer contained in a test sample. | 05-14-2009 |
20090123947 | Analytical Sandwich Test for determining NT-proBNP - The present invention concerns an immunological test for determining NT-proBNP comprising at least two antibodies to NT-proBNP, wherein at least one of the antibodies to NT-proBNP is a monoclonal antibody. The epitopes recognized by the antibodies can slightly overlap. | 05-14-2009 |
20090130692 | Use of microproteins as tryptase - Disclosed are uses of microproteins preferably microproteins forming a cystine knot (i.e. belonging to the family of inhibitor cystine knot (ICK) polypeptides) or polynucleotides encoding said microproteins for the preparation of a pharmaceutical composition for treating or preventing a disease that can be treated or prevented by inhibiting the activity of tryptase as well as corresponding methods of treatment. Also disclosed are uses of the microproteins for inhibiting tryptase activity, for purifying tryptase, as a carrier molecule for tryptase and for deleting or quantifying tryptase in a sample, including corresponding diagnostic applications. Furthermore disclosed are fusion proteins comprising an inactive barnase as well as fusion proteins comprising barnase and a microprotein. Also encompassed are nucleic acid molecules encoding such a fusion protein, as well as corresponding vectors, host cells, preparation methods and uses of the fusion protein. Moreover, the present application discloses a crystal of a microprotein fused with barnase, preferably inactive barnase. The disclosure also refers to corresponding preparation methods for the crystal, structure analysis methods using the crystal data storage media comprising the structure data obtained, as well as to in silico methods using the structure data for characterizing the binding of microproteins to target molecules. Furthermore, disclosed are pharmaceutical compositions comprising the crystal and corresponding medical uses. | 05-21-2009 |
20090136970 | NOGO RECEPTOR HOMOLOGUES AND THEIR USE - This invention relates to gene polypeptides and polynucleotides that encode proteins of the Nogo-66 receptor (NgR) family and are therefore called NgR homologue 1 (NgRH1). The invention further relates to their use in identifying compounds that may be agonists or antagonists that are potentially useful in regeneration and protection of the nervous system, and to production of NgRH1 polypepfldes, derivatives, and antibodies. | 05-28-2009 |
20090142778 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE - Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD. | 06-04-2009 |
20090142779 | METHODS AND KITS FOR MEASURING VON WILLEBRAND FACTOR - Methods and kits for measuring levels of von Willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein Ibα having at least two of a G233V, D235Y and M239V mutations and an agent to detect a complex between the recombinant glycoprotein Ibα and von Willebrand factor. | 06-04-2009 |
20090142780 | METHODS OF DONOR SPECIFIC CROSSMATCHING - The detection of endothelial cell antibodies has been proven clinically important for successful organ transplantation. Disclosed are methods of isolating endothelial cell antibodies and methods for donor-specific crossmatching. | 06-04-2009 |
20090155818 | Measuring Receptor Homodimerization - The invention provides methods and kits for detecting and/or measuring receptor homodimers on a cell surface membrane. In one aspect, the methods employ pairs of probes comprising binding compounds and a cleaving probe, such that at least one binding compound binds specifically to the same epitope of a membrane-bound analyte as the cleaving probe. The binding compound includes one or more molecular tags attached through a cleavable linkage, and the cleaving probe includes a cleavage-inducing moiety that can cleave the linkage when within a defined proximity thereto. Binding of the two probes to a homodimer of a cell surface molecules results in release of molecular tags from the binding compounds, providing a measure of formation of the homodimeric complex. | 06-18-2009 |
20090155819 | Mammalian T1R3 Sweet Taste Receptors - The present invention provides isolated nucleic acid and amino acid sequences of sweet taste receptors, the receptors comprising consisting of a monomer or homodimer of a T1R3 G-protein coupled receptor polypeptide, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet and amino acid taste receptors. | 06-18-2009 |
20090162873 | GENE ENCODING A MULTIDRUG-RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7P15-21 AND USES THEREOF - The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell s susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance. | 06-25-2009 |
20090170129 | DETECTION OF CIRCULATING ENDOTHELIAL CELLS - Endothelial cells are detected in a blood sample by enriching the endothelial cells from the blood sample followed by performing on the enriched endothelial cells an immunoassay capable of detecting antigens expressed by the endothelial cells. The immunoassay is capable of detecting antigen expressed from 300 endothelial cells per milliliter of blood. The method can be used for assaying mature circulating endothelial cells or circulating endothelial progenitor cells. | 07-02-2009 |
20090176254 | MAMMALIAN GALANIN RECEPTORS - The present invention provides isolated mammalian GalR3 receptors, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the receptors using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptors and are useful for treating medical conditions caused or mediated by galanin. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian GalR3 receptors. | 07-09-2009 |
20090191574 | Methods, Products and Treatments for Diabetes - The invention involves assays, diagnostics, kits, and assay components for determining levels of K41-glycated CD59 in subjects. Treatments for subjects based upon levels of K41-glycated CD59 also are provided. | 07-30-2009 |
20090197284 | Analysis of Proteins from Biological Fluids Using Mass Spectrometric Immunoassay - Presented herein are methods, devices and kits for the mass spectrometric immunoassay (MSIA) of proteins present in complex biological fluids or extracts. Pipettor tips containing porous solid supports that are covalently derivatized with affinity ligand and used to extract specific proteins and their variants from various biological fluids. Nonspecifically bound compounds are rinsed from the extraction devices using a series of buffer and water rinses, after which the wild type protein (and/or its variants) are eluted directly onto a target in preparation for analysis such as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Mass spectrometry of the eluted sample then follows with the retained proteins identified via accurate molecular mass determination. Protein and variant levels can be determined using quantitative methods in which the protein/variant signals are normalized to signals of internal reference standard species (either doped into the samples prior to the MSIA analysis, or other endogenous protein co-extracted with the target proteins) and the values compared to a working curves constructed from samples containing known concentrations of the protein or variants. Such MSIA devices, kits and methods have significant application in the fields of; basic research and development, proteomics, protein structural characterization, drug discovery, drug-target discovery, therapeutic monitoring, clinical monitoring and diagnostics, as well as in the high throughput screening of large populations to establish and recognize protein/variant patterns that are able to differentiate healthy from diseased states. | 08-06-2009 |
20090203046 | METHODS FOR IDENTIFYING PURKINJE CELLS USING THE CORL2 GENE AS A TARGET - Total RNAs were prepared from the ventral and dorsal regions of embryonic day 12.5 mouse mesencephalon, and a cDNA fragment was obtained by the subtraction method (N-RDA). The full-length cDNA was cloned and the nucleotide sequence was determined. The gene was named Corl2. The result of homology search showed that about 850 residues of Corl2 exhibited homology to the XM_355050 sequence deposited in GenBank; however, the remaining ˜150 residues showed no homology. Thus, Corl2 was demonstrated to be a novel gene. The Corl2 expression in various mouse organs was analyzed by RT-PCR, and the result showed that Corl2 expression was specific to brain. The result of immunostaining day 12.5 embryos and postnatal day 12 brains demonstrated that Corl2 is useful as a Purkinje cell marker at any differentiation stages. | 08-13-2009 |
20090203047 | 88kDa tumorigenic growth factor and antagonists - This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expression or action. Antagonists to an 88 KDa autocrine growth and tumorigenicity stimulator are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies. | 08-13-2009 |
20090203048 | Screening Assays for Antioxidants and Antiproliferative Compounds - Provided are screening assays for identifying and evaluating compounds with antioxidant and/or antiproliferative activities. | 08-13-2009 |
20090203049 | BETA INTEGRIN GENE AND PROTEIN - Recombinant materials for the production of β integrin protein characteristic of | 08-13-2009 |
20090208976 | Regulation of F1-ATPase Beta Subunit Cellular Location - It has been discovered that the ability of analogues to affect binding of a labeled β-casomorphin (an enterostatin antagonist) to recombinant rat F | 08-20-2009 |
20090208978 | Panel Cell Used for Granulocyte Antibody Detection - A panel cell for detecting anti-HNA antibody is disclosed. The panel cell is obtained by introducing a DNA coding for an HNA antigen corresponding to the anti-HNA antibody into a cell so as to enable the expression of the DNA under the condition for use in the detection procedure, wherein the cell for DNA introduction exhibits no detectable reaction with anti-HLA-ABC antibody, anti-HLA-DR antibody, anti-HLA-DQ antibody, anti-HLA-DP antibody, anti-HNA-1 antibody, anti-HNA-2a antibody, anti-HNA-3a antibody, anti-HNA-4 antibody, anti-HNA-5 antibody, and serum from normal subject, in the detection procedure. The panel cell allows accurate and rapid detection of granulocyte antibody. | 08-20-2009 |
20090208979 | Method for identifying antipsychotic drug candidates - The present invention provides a method for identifying a compound or a combination of compounds having a pharmacological behavior that qualifies it as a candidate for clinical development of a drug for treatment of a psychiatric disease or disorder, preferably schizophrenia. According to this method, a candidate drug is assessed for its ability to produce a biochemical profile, in either or both in vitro and in vivo test systems, which is similar to a unique reference biochemical profile obtained following treatments with drugs or drug combinations effective against both positive and negative symptoms of psychiatric diseases or disorders. | 08-20-2009 |
20090215083 | SELECTING, CULTURING AND CREATING LINEAGE COMMITTED HEMATOPOIETIC STEM CELLS - The present invention provides a method for selecting hematopoietic stem cells (HSCs) comprising providing an agent which binds to α9β1 integrin on the cell surface to a population of cells including HSCs and separating HSCs by virtue of the binding agent. The invention also provides a method of culturing a population of HSCs in the presence of an agent which binds to α9β1, wherein the agent inhibits differentiation of the HSCs. The invention also provides a method of producing a population of lineage committed cells comprising culturing HSCs in the presence of an agent which inhibits or prevents binding to α9β1. | 08-27-2009 |
20090215084 | B7-H1 AND B7-H4 IN CANCER - Methods of determining prognosis of a subject with cancer or determining risk of cancer progression by assessing expression of B7-H4, or B7-H1 and B7-H4 in combination. | 08-27-2009 |
20090215085 | Proteomic Fingerprinting of Human IVF-Derived Embryos: Identification of Biomarkers of Developmental Potential - The present invention discloses biomarkers and biomarker combinations that have prognostic value as predictors of the developmental potential of individual IVF-derived human embryos. In particular, the biomarkers of this invention are useful to classify an embryo with implantation competence after uterine transfer or implantation incompetence. In addition, the biomarkers can be detected by non-invasive methods that do not harm the developing embryo. Also disclosed are kits for the prediction of developmental potential that detect the biomarkers of the invention, as well as methods using a plurality of classifiers to make a probable diagnosis of developmental potential. | 08-27-2009 |
20090220995 | MULTIPLE ADMINISTRATIONS OF UMBILICUS DERIVED CELLS - A method to determine the optimal administration protocol of allogeneic donor tissue to treat a disease in a human, using an animal model of human disease. | 09-03-2009 |
20090220996 | In vitro Assay Methods for Classifying Embryotoxicity of Compounds - The present disclosure provides methods useful for screening compounds and/or compositions, for example potential drug candidates. The results of the screening assays correlate to the effects of the compounds on the molecular and/or cellular level of the human body. Also disclosed are screening assays utilizing human embryonic stem cells RELICELL®hES of Indian origin. The methods disclosed herein correlate well with animal preclinical toxicity studies done in a clinical trial setup. | 09-03-2009 |
20090220997 | Stimulating G Protein-Coupled Receptors - This document provides methods and materials related to activating GPCRs. For example, methods and materials for activating GPCRs present on cells (e.g., human cell) as well as methods and materials for identifying GPCR agonists are provided. | 09-03-2009 |
20090220998 | Platelet Aggregation Assays - The present invention provides methods of determining platelet aggregation, methods of determining susceptibility to clotting upon administration of a CD40L-binding moiety, and kits related thereto. | 09-03-2009 |
20090220999 | Antibodies immunoreactive with mutant 5-enolpyruvlshikimate-3-phosphate synthase - Antibodies immunoreactive to double mutant EPSPS are provided, and in an embodiment the double mutant EPSPS is one in which the wild-type EPSPS is substituted at residue 102 with isoleucine and at residue 106 with serine. Also provided are hybridomas producing the antibodies, as well as methods of making and using the antibodies. | 09-03-2009 |
20090221000 | METHODS OF QUANTIFYING TASTE OF COMPOUNDS FOR FOOD OR BEVERAGES - Methods of quantifying the taste of compounds for food and beverages are provided. These methods comprise contacting the compounds with an isolated heteromeric receptor comprising at least one T1R2 polypeptide and at least one T1R3 polypeptide. | 09-03-2009 |
20090221001 | Methods for identifying compounds that modulate the T1R1/T1R3 umami taste receptor - Methods for identifying compounds that modulate the T1R1/T1R3 umami taste receptors are provided. These methods comprise screening for compounds that compete with lactisole for binding to and/or inhibiting the T1R1/T1R3 umami taste receptor. | 09-03-2009 |
20090221002 | Methods of quantifying taste of compounds for food or beverages - Methods of quantifying the taste of compounds for food and beverages are provided. These methods comprise contacting the compounds with an isolated heteromeric receptor comprising at least one T1R1 polypeptide and at least one T1R3 polypeptide. | 09-03-2009 |
20090221003 | PROCEDURE FOR THE GENERATION OF A HIGH PRODUCER CELL LINE FOR THE EXPRESSION OF A RECOMBINANT ANTI-CD34 ANTIBODY - The present invention relates to cell capture assay for the selection of a high producer cell line expressing anti-CD34 antibodies that recognize the CD34 membrane-protein in the cell membrane. The monoclonal antibody secreted by the hybridoma cell line 9C5/9069 binds to human CD34 and is used to isolate stem cells. The DNA sequences encoding for the antibody heavy and light chain have been identified, isolated from the hybridoma cells and cloned into appropriate expression vectors. After co-transfection of the heavy and light chain genes into HEK293T or in CHO cells either conditioned medium or purified antibody were assessed for binding to CD34 protein located in the cell membrane in different cell capture assays. The binding of the antibody to CD34-positive cells could be shown with these assays for several cell lines. | 09-03-2009 |
20090233317 | REPRESSOR OF SKELETAL MUSCLE DIFFERENTIATION, NUCLEIC ACIDS CODING THEREFOR AND THE USE THEREOF IN DIAGNOSIS AND THERAPY - Polypeptide sequences which play a part in the regulation of skeletal muscle differentiation, and nucleic acids coding therefor, and the use thereof in diagnosis and therapy are disclosed. Possible uses are also indicated for antibodies which are directed against corresponding epitopes of the GRIM1 polypeptide. | 09-17-2009 |
20090239246 | Biomarkers - The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring BNP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection. | 09-24-2009 |
20090253151 | Self-Renewing Master Adult Pluripotent Stem Cells - The present invention relates to a method for obtaining master adult pluripotent stem (MAPS) cells from adult human corneal epithelial tissues. The MAPS cells are obtained on the basis of pluripotent markers. Further the invention provides MAPS cells that are capable of self renewal and differentiation and have characteristics similar to that of human embryonic stem cells. The MAPS cells also retain the ability to differentiate into cells of different lineages. The composition comprising MAPS cells are useful for therapeutic purposes. Further, the invention provides a culture medium for proliferation of MAPS cells. | 10-08-2009 |
20090253152 | NOVEL MUTANT IGFBP-3 MOLECULES THAT DO NOT BIND TO IGFs, BUT RETAIN THEIR ABILITY TO FUNCTIONALLY BIND IGFBP-3 RECEPTOR - There is disclosed novel mutant IGFBP-3 polypeptides and fragments thereof that have either no binding, or diminished binding to IGFs, yet retain their ability to bind to the human IGFBP-3 receptor (“P4.33”). The present invention provides novel mutant IGFBP-3 nucleic acid sequences, and expression systems. Additional exemplary embodiments provide for screening assays for identifying IGFBP-3 receptor antagonists or agonists, methods for modulating IGF-independent IGFBP-3 responses of cells expressing IGFBP-3 receptors, methods for inducing or potentiating apoptosis of cells expressing IGFBP-3 receptors, methods for treating solid tumors having cells expressing IGFBP-3 receptors, and compositions comprising polypeptides having either no binding, or diminished binding to IGFs, yet retain their ability to bind to the IGFBP-3 receptor. | 10-08-2009 |
20090253153 | METHODS OF USING A G PROTEIN-COUPLED RECEPTOR TO IDENTIFY PEPTIDE YY (PYY) SECRETAGOGUES AND COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MODULATED BY PYY - The present invention relates to methods of using GPR119 receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY, such as conditions modulated by stimulation of NPY Y2 receptor (Y2R). Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition modulated by PYY, such as a condition modulated by stimulation of Y2R. Conditions modulated by PYY such as may be a condition modulated by stimulation of Y2R include bone-related conditions, metabolic disorders, angiogenesis-related conditions, ischemia-related conditions, convulsive disorders, malabsorptive disorders, cancers, and inflammatory disorders. | 10-08-2009 |
20090258376 | Protein isoforms and uses thereof - There is provided a method for screening for or, diagnosis or prognosis of a neurological disorder in a subject, for determining the stage or severity of such a neurological disorder in a subject, for identifying a subject at risk of developing such a neurological disorder, or for monitoring the effect of therapy administered to a subject having such a neurological disorder, said method comprising:
| 10-15-2009 |
20090263835 | Genes that are Up- or Down-Regulated During Differentiation of Human Embryonic Stem Cells - Genes that are up- or down-regulated during differentiation provide important leverage by which to characterize and manipulate early-stage pluripotent stem cells. Over 35,000 unique transcripts have been amplified and sequenced from undifferentiated human embryonic stem cells, and three types of differentiated progeny. Statistical analysis of the assembled transcripts identified genes that alter expression levels as differentiation proceeds. The expression profile provides a marker system that has been used to identify particular culture components for maintaining the undifferentiated phenotype. The gene products can also be used to promote differentiation; to assess other relatively undifferentiated cells (such as cancer cells); to control gene expression; or to separate cells having desirable characteristics. Manipulation of particular genes can be used to forestall or focus the differentiation process, en route to producing a specialized homogenous cell population suitable for human therapy. | 10-22-2009 |
20090269786 | RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies - This invention provides antibodies immunologically specific for ρ1-GABA | 10-29-2009 |
20090275055 | Monoclonal Antibodies Specific to Denatured Human Class I Leucocyte Antigens - [PROBLEMS] To provide a monoclonal antibody simultaneously detectable the expression of all three kinds of HLA-A, HLA-B and HLA-C heavy chain proteins composing human class I leukocyte antigens (HLA class I) in denatured human tissue samples fixed by formalin and the like. | 11-05-2009 |
20090275056 | Methods for obtaining antibodies - The invention is directed towards a method of enriching a population of cells in those cells that produce an antibody which recognises an antigen of interest. In particular, an untagged antigen is used in conjunction with a polyclonal antibody to isolate cells recognizing said antigen. | 11-05-2009 |
20090280508 | Methods and Reagents for Preparing and Using Immunological Agents Specific for P-Glycoprotein - This invention relates to immunological reagents and methods specific for a mammalian, transmembrane protein termed Pgp, having a non-specific efflux pump activity established in the art as being a component of clinically-important multidrug resistance in cancer patients undergoing chemotherapy. The invention provides methods for developing and using immunological reagents specific for certain mutant forms of Pgp and for wild-type Pgp in a conformation associated with substrate binding or in the presence of ATP depleting agents. The invention also provides improved methods for identifying and characterizing anticancer compounds. | 11-12-2009 |
20090280509 | SURFACE ACOUSTIC WAVE IMMUNOSENSOR FOR DIAGNOSING ALLERGY DISEASE AND METHOD FOR DIAGNOSING ALLERGY DISEASE USING THE SAME - A surface acoustic wave (SAW) immunosensor for diagnosing allergy disease includes one or more SAW devices on each of which allergens derived from one allergy-causing substance are fixed and an allergen derived from another allergy-causing substance is not included, that is, allergens derived from different allergy-causing substances being fixed on different SAW devices; and a signal detector which detects an output signal from the SAW device. Also a method for diagnosing allergy disease is capable of measuring levels of allergen-specific IgE and total IgE in blood or another sample taken from a subject of diagnosis using a SAW immunosensor, the allergens being derived from various allergy-causing substances, thereby capable of effectively diagnosing allergy disease for various allergy-causing substances. | 11-12-2009 |
20090280510 | Antibodies Specific to Heterodimers of Bcl-2 Family and Uses Thereof - Isolated antibodies specifically binding to heterodimers of the Bcl-2 family and uses thereof for detecting presence of Bcl-2 heterodimers in a patient. | 11-12-2009 |
20090286262 | NUCLEIC ACID, POLYPEPTIDE AND ITS USE - Novel chimeric proteins functional to screen for sweet taste modulators, the corresponding nucleic acid sequences, expression vectors, transfected host cells, and screening methods for modulators and enhancers of the sweet taste response employing the aforementioned are provided. | 11-19-2009 |
20090286263 | SKIN TAPE STRIPPING: A NON-INVASIVE DIAGNOSTIC STRATEGY FOR DERMAL EXPOSURE TO CYTOTOXIC COMPOUNDS - A non-invasive method for determining a subject's dermal exposure to an agent employing an immunohistochemical procedure on a skin strip applied to an exposed area on the subject's person and detecting agent adduct thereon. | 11-19-2009 |
20090286264 | IMAGING OF IMMUNOMAGNETICALLY ENRICHED RARE CELLS - A method for removing excess unbound ferrofluid and imaging immunomagnetically enriched circulating tumor cells is provided. A vessels having a preformed grooves in the viewing surface is optimally designed for cell alignment and imaging. After separating the unbound particles by centrifugation, an externally-applied force is applied to transport magnetically responsive particle-CTC complex toward the transparent collection wall. The grooved inner surface of the viewing face of the chamber provide uniform distribution of the particles for easy imaging. The invention is also useful in conducting quantitative analysis and sample preparation in conjunction with automated cell enumeration techniques as in quantitative analysis of CTC in disease. | 11-19-2009 |
20090291458 | Method for Determining the Status of an Individual - Methods of determining status of an individual based on the use of biological specimen and analysis of reference population of cells are described. | 11-26-2009 |
20090298095 | Immortalization of cells including neuronal cells - The instant invention provides methods for immortalizing cells. The invention further provides immortalized cell lines, e.g., neuronal cell lines, and methods of using these cell lines in screening assays. | 12-03-2009 |
20090298096 | Interleukin-1 alpha ABS and methods of use - Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors. | 12-03-2009 |
20090305307 | Methods for detecting targets - The present invention provides method and compositions for detecting target molecules present on cells and tissues. In particular, the methods involve adding primary antibodies such as scFv-targeted lactamase that are directed against a target of interest (e.g., cancer markers) to a tissue sample, followed by adding a lactam-containing compound and finally a lactamase reporter system. In some preferred embodiments, the lactamase reporters are fluorescent reporters that bind to the test tissue. In some particularly preferred embodiments, the test tissue contains at least once cancer cell and/or at least one cancer-associated marker. | 12-10-2009 |
20090305308 | METHOD FOR IDENTIFYING CELL-SPECIFIC PROTEIN COMBINATION PATTERNS - The present invention discloses a method for identifying cell-specific protein combination patterns of cell surfaces of circulating cells of the immune system of a human or animal for the identification of different stages of organ-specific chronic inflammatory diseases or tumour diseases comprising the following steps: a) providing a sample of circulating cells of the immune system of a human or animal showing an organ-specific chronic inflammatory disease or tumour disease and providing a sample of circulating cells of the same cell type of the immune system of a healthy human or animal; b) determining cell-specific protein combination patterns of the cell surfaces of said healthy and pathologically modified cells; c) comparing the resulting protein combination patterns of the cell surfaces of said healthy and pathologically modified cells and subtracting the coincident parts of the protein combination patterns of said healthy and pathologically modified cells, thereby determining a cell-specific protein combination patterns of the cell surfaces of said pathologically modified cells resulting therefrom; and d) identifying and characterizing the resulting cell-specific protein combination pattern of the cell surfaces of said pathologically modified circulating cells of the immune system in terms of molecules and its spatial arrangement within the cell as disease specific. The invention moreover relates to compositions and kits comprising antibodies and/or ligands which can be employed for the performance of the method. | 12-10-2009 |
20090305309 | Methods and Compositions for Detecting Neoplastic Cells - Methods and compositions for identifying neoplastic cells in a biological sample are provided. | 12-10-2009 |
20090305310 | Methods for Determining Notch Signaling and Uses Thereof - The invention relates, in part, to methods of determining Notch signaling in cells, tissues and/or subjects. The invention additionally relates, in part, to diagnostic assays for cell differentiation-associated diseases or conditions and for screening tools in research and clinical applications. | 12-10-2009 |
20090311720 | METHODS OF MODULATING AND IDENTIFYING AGENTS THAT MODULATE INTRACELLULAR CALCIUM - Methods are provided for identifying agents that modulate intracellular calcium. Also provided are methods of modulating calcium within cells and methods of identifying proteins involved in modulating intracellular calcium. | 12-17-2009 |
20090317831 | Sepsis Test - There is provided a method for determining whether a subject has a bacterial infection comprising: identifying an abnormal expression of one or more of CD49e, CD 14, CD11c, CD49f, and CD29 on leucocytes in a sample obtained from the subject; wherein an abnormal expression of CD49e, CD 14, CD11c, CD49f or CD29 is indicative of the subject having a bacterial infection. | 12-24-2009 |
20090317832 | Cell Classification System - The present invention involves the reaction of a CD4 immuno-conjugate with a sample of patient whole blood. The CD4 immuno-conjugate consists of one or more antibodies with specificity for the CD4 surface receptor coupled to a signal moiety, or “label”, that is detectable by a flow cytometer. Such labels may generate a signal by such means as fluorescence properties, light scatter properties, electronic properties, or magnetic properties. The CD4 immuno-conjugate binds to both the CD4 positive lymphocytes (Helper T cells) and all monocytes. Differential detection means are employed to count immuno-conjugate labeled Helper T cells. The present invention distinguishes itself by simultaneously measuring the signal level from monocytes as a means to verify sufficient activity of the anti-CD4 antibody. | 12-24-2009 |
20090317833 | Screening Method - The present invention provides a method of screening for a drug for the prophylaxis or treatment of at least one disease selected from the group consisting of cardiac disease, autoimmune disease, inflammatory disease, central nervous system disease, infectious disease, sepsis, severe sepsis and septic shock, which includes selecting a substance that binds to an intracellular region of TLR4, and inhibits signal transduction from said molecule, and a kit for this method, which contains (1) a cell that expresses wild-type TLR4 and (2) a cell that expresses a mutant TLR4, and which can detect a signal from TLR4 with expression of a reporter gene as an index. | 12-24-2009 |
20090317834 | NOVEL CELLULAR GLYCAN COMPOSITIONS - The invention describes novel compositions of glycans, glycomes, from human embryonic stem cells, and especially novel subcompositions of the glycomes with specific monosaccharide compositions and glycan structures. The invention is further directed to methods for modifying the glycomes and analysis of the glycomes and the modified glycomes. Furthermore, the invention is directed to stem cells carrying the modified glycomes on their surfaces. The glycomes are preferably analysed by profiling methods able to detect reproducibly and quantitatively numerous individual glycan structures at the same time. The most preferred type of the profile is a mass spectrometric profile. The invention specifically revealed novel target structures and is especially directed to the development of reagents recognizing the structures. | 12-24-2009 |
20090317835 | DEVICE FOR SAMPLING CELLS BY CONTACT - A microtechnological device ( | 12-24-2009 |
20090325196 | LEVELS OF BCMA PROTEIN EXPRESSION ON B CELLS AND USE IN DIAGNOSTIC METHODS - The present invention provides a method of measuring the levels of BCMA in a biological sample, specifically upon the B cell surface. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE, and for methods for treating an individual clinically diagnosed with an autoimmune disease. This diagnostic test serves to predict a patient's likelihood to respond to a specific drug treatment, in particular treatment with BLyS antagonists, either singly or in combination with other immune suppressive drugs | 12-31-2009 |
20090325197 | ASSAY FOR IMMUNOSUPPRESSANT DRUGS - The invention provides immunoassays for immunosuppressant drugs, wherein the assay is carried out under high salt conditions to achieve improved sensitivity. The invention also provides kits that are useful for performing the methods of the invention. | 12-31-2009 |
20090325198 | Non-Denaturing Lysis Reagent For Use With Capture-In-Solution Immunoassay - The invention provides a lysis reagent and method for preparing a test sample for use in an assay, wherein the method yields a homogeneous lysis mixture suitable for use in automated pipetting systems without the need for a centrifugation step. The lysis reagent includes a glycol and non-specific animal immunoglobulins. Other aspects of the invention include related immunoassays and test kits. | 12-31-2009 |
20100003703 | ASSAY SYSTEM FOR GLP-2 RECEPTOR LIGANDS - Disclosed herein is a method for measuring the contractility of intestinal tissue upon treatment with GLP-2 or a GLP-2 ligand. Also disclosed is an assay which directly measures the activity of GLP-2 or GLP-2 ligands ex vivo and permits the screening of putative GLP-2 ligands in native tissue. | 01-07-2010 |
20100003704 | IN SITU detection of early stages and late stages HPV infection - Embodiments of the invention provide methods, polyclonal antibodies, monoclonal antibodies, assays, and kits for detecting HPV infection, including infection by various HPV genotypes, early and/or late HPV-associated or HPV-specific proteins or antibodies. Mononoclonal antibodies are used to detect oncogenic high risk and low risk HPV types in a single assay, which is not limited to assay type or format. Useful tools for specific detection of invasive cervical cancer are provided. Cervical cancer biomarkers are identified and can be used in a detection method for early stage precancerous lesions as well as late stage cancer progression. | 01-07-2010 |
20100015638 | Method for production of antibody directed against cell membrane surface antigen epitope and assaying method - Disclosed are a method for determining the affinity of an antibody capable of binding to a cell membrane surface antigen for the antigen; and a method for assaying or screening an antibody capable of binding to a cell membrane surface antigen by utilizing the determination method. In the determination of the affinity of the antibody for the antigen, floating cells presenting the antigen on the surface of the cell membrane thereof are used and the B/F separation of the cells is made by centrifugation or on a filter through which the cells cannot pass. | 01-21-2010 |
20100015639 | Methods and Kits to Detect and Monitor Ovarian Cancer and Preeclampsia - The present invention provides methods and kits related to a prognostic, and, in certain embodiments, diagnostic indicator for ovarian cancer which comprises measuring the level of MUC16 bound to immune cells. The level of MUC16 bound to immune cells can by itself be an indicator of disease regression or recurrence, or this indicator can be used in conjunction with assays for serum CA125 and other diagnostic markers. The invention further provides methods and kits related to the detection of ovarian cancer by measuring levels of Siglec-9 expression on immune cells. As well, related methodologies are provided for the detection of preeclampsia in pregnant human subjects. | 01-21-2010 |
20100015640 | Nucleic Acid, Polypeptide and Its Use - Novel chimeric proteins functional to screen for umami taste modulators, the corresponding nucleic acid sequences, expression vectors, transfected host cells, and screening methods for modulators and enhancers of the umami taste response employing the aforementioned are provided. | 01-21-2010 |
20100028910 | ACTIVATED PROTEIN C VARIANTS WITH NORMAL CYTOPROTECTIVE ACTIVITY BUT REDUCED ANTICOAGULANT ACTIVITY - Variants (mutants) of recombinant activated protein C (APC) or recombinant protein C (prodrug, capable of being converted to APC) that have substantial reductions in anticoagulant activity but that retain normal levels of anti-apoptotic activity are provided. Two examples of such recombinant APC mutants are KKK191-193AAA-APC and RR229/230AA-APC. APC variants and prodrugs of the invention have the desirable property of being cytoprotective (anti-apoptotic effects), while having significantly reduced risk of bleeding. The invention also provides a method of using the APC variants or prodrugs of the invention to treat subjects who will benefit from APC's cytoprotective activities that are independent of APC's anticoagulant activity. These subjects include patients at risk of damage to blood vessels or tissue in various organs caused, at least in part, by apopotosis. At risk patients include, for example, those suffering (severe) sepsis, ischemia/reperfusion injury, ischemic stroke, acute myocardial infarction, acute or chronic neurodegenerative diseases, or those undergoing organ transplantation or chemotherapy, among other conditions. Methods of screening for variants of recombinant protein C or APC that are useful in accordance with the invention are also provided. | 02-04-2010 |
20100028911 | MULTICOLOR REAGENTS CONTAINING COMPENSATION CONTROLS - The present invention provides multicolor reagent formulations containing in a single container both fluorescently labeled detection reagents and single-color compensation control reagents, wherein the compensation control reagents consist of reagent-capture particles bound to a fluorescently labeled detection reagent included in the multicolor reagent formulation. The multicolor reagent formulations of the present invention simplify manufacture and commercial distribution of multicolor reagent kits. | 02-04-2010 |
20100028912 | IMAGING USING RADIOACTIVE MONOCATIONS IN COMBINATION WITH A RECEPTOR BINDING LIGAND THAT STIMULATES THE INFLUX OF CATIONS - A novel method of imaging, comprising administration of a radioactive mono-cation, such as, for example, | 02-04-2010 |
20100028913 | NOVEL CARBOHYDRATE FROM HUMAN CELLS AND METHODS FOR ANALYSIS AND MODIFICATION THEREOF - The invention describes reagents and methods for specific binders to glycan structures of stem cells. Furthermore the invention is directed to screening of additional binding reagents against specific glycan epitopes on the surfaces of the stem cells. The preferred binders of the glycans structures includes proteins such as enzymes, lectins and antibodies. | 02-04-2010 |
20100035279 | Fluorescent Substrates for Monoamine Transporters as Optical False Neurotransmitters - The present invention relates to compounds of the general structure: wherein Y is O, X is O, bond α is absent and bond β is present, or Y is H, X is CH, bond α is present, and bond β is absent; atom Z is a carbon and bonds χ, δ and γ are present, or is a nitrogen and bonds χ, δ and γ are absent; R | 02-11-2010 |
20100035280 | Chimeric Fc-gamma Receptor and Method for Determination of ADCC Activity by Using the Receptor - An objective of the present invention is to provide chimeric receptors containing a mouse Fcγ receptor extracellular domain and a human Fcγ receptor transmembrane domain, or chimeric receptors containing a mouse Fcγ receptor extracellular domain and a human γ chain transmembrane domain. Another objective of the present invention is to provide methods for measuring the ADCC activity of mouse antibodies and methods of screening for mouse antibodies having ADCC activity, using the chimeric receptors. | 02-11-2010 |
20100041072 | PROCESS FOR IDENTIFYING A LIGAND THAT BINDS TO THE NEP BINDING SITE FOR THE SMR1 PENTAPEPTIDE - The invention relates to the therapeutic use of a SMR1-peptide or a pharmaceutically active amount of said SMR1-peptide, for the preparation of a therapeutic composition for preventing or treating diseases wherein a modulation of the activity of a membrane metallopeptidase, notably a membrane-zinc metallopeptidase, is sought, in a mammal, specifically in a human. | 02-18-2010 |
20100047826 | Cell Into Which Protein, Which Can Serve as Polymerization Nucleus of Protein Polymer, or Polymer Thereof Is Introduced, and Method for Production of The Cell - The present invention has the object of providing a cell into which a protein, which can serve as a polymerization nucleus of a protein polymer, or polymer thereof is introduced, and a method for producing the cell. The invention relates to a cell into which a protein, which can serve as a polymerization nucleus of a protein polymer, or a polymer thereof is introduced, a method for producing the cell, and a method of screening for a compound inhibiting an intracellular accumulation of a protein containing fibril structures, wherein the method comprises bringing a candidate substance into contact with the cell. | 02-25-2010 |
20100047827 | NOVEL SPECIFIC CELL BINDERS - The invention describes reagents and methods for specific binders to glycan structures of stem cells. Furthermore the invention is directed to screening of additional binding reagents against specific glycan epitopes on the surfaces of the stem cells. The preferred binders of the glycans structures includes proteins such as enzymes, lectins and antibodies. | 02-25-2010 |
20100055718 | NANOPLATE DYE PLATFORM AND METHODS OF MAKING AND USING THE SAME - Embodiments disclosed herein relate to labeling reagents comprising a plurality of nanoplates attached to dye molecules. The nanoplates may be configured into stacks and/or at least partially surrounded by a surrounding layer. The reagent may then be used to label a target (e.g., structure or environment). | 03-04-2010 |
20100055719 | Screening method for identifying new aminoacyl-tRNA synthetase inhibitors - The method comprising: a) obtaining a gene sequence codifying a naturally occurring aminoacyl-tRNA synthetase; b) engineering the gene codifying for said aminoacyl-tRNA synthetase, resulting into an aminoacyl-tRNA synthetase with a defective activity, with the proviso that the engineering does not affect the functionality of the catalytic site of the enzyme; c) cloning the gene resulting from step (b) in an expression vector; d) transforming isolated mammalian cells with the expression vector resulting from step (c); e) growing the recombinant cells resulting from step (d) in a nutrient medium under conditions which allow the expression of the engineered aminoacyl-tRNA synthetase, resulting the expression into cell death or a decrease in the rate of cell division; f) providing a substance to be tested to the medium resulting from step (e); and g) analyzing the resulting cell growth, wherein if there is an increase in cell growth, then the substance selectively inhibits the activity of the engineered aminoacyl-tRNA synthetase and does not affect to its cellular ortholog, resulting in that said substance is a candidate to drug. | 03-04-2010 |
20100068731 | Use of N-Myristoyltransferase on Non-Tumor Tissue for Cancer Diagnosis - A diagnostic method and kit are disclosed for detection of cancer. Detection of elevated levels of N-myristoyltransferase (NMT) or NMT activity in blood or bone marrow, and specifically in peripheral blood mononuclear cells, can be used as a marker for cancer. The use of this method for detection of adenocarcinoma, such as colorectal cancer, is exemplified. | 03-18-2010 |
20100068732 | CLONED GLUCAGON-LIKE PEPTIDE-2 RECEPTORS - The invention relates to nucleotides and amino acid sequences encoding Glucagon-like peptide-2 receptors, recombinant host cells transformed with such nucleotides, and methods of using the same in drug screening and related applications. | 03-18-2010 |
20100068733 | pH-Sensitive Fluorescent Probe - A compound represented by the following general formula (I): | 03-18-2010 |
20100075343 | NOVEL PEPTIDES - The present invention provides novel peptides with energy-modulating activity or circulatory function-modulating activity. The peptides of the present invention have energy-modulating activity or circulatory function-modulating activity and thus are useful for treating food consumption disorders and diseases of the circulatory system. | 03-25-2010 |
20100081149 | NOVEL OXIDIZED LDL COMPLEX AND METHOD FOR DETECTION THEREOF - Serum amyloid P component, oxidized LDL and β2-glycoprotein I can together form a complex. The presence of a disease such as hyperlipemia and atherosclerosis can be determined by detecting the complex by using either one of an anti-serum amyloid P component antibody and an anti-β2-glycoprotein I antibody. | 04-01-2010 |
20100081150 | Methods for Generating Host Cells - The present disclosure provides compositions and methods comprising cells producing glycoproteins with variant glycosylation patterns. The methods and compositions may be used in producing antibodies and proteins of therapeutic value. | 04-01-2010 |
20100086946 | PLGF, FLT1 AND ENDOGLIN FOR DIAGNOSING ANGIOGENIC STATUS IN CORONARY ARTERY DISEASE - Described are methods for diagnosing the angiogenic status of a subject suffering from coronary heart disease comprising determining the amounts of placental growth factor or a variant thereof, endoglin or a variant thereof and soluble FLT1 or a variant thereof in a sample of a subject suffering from coronary heart disease and comparing the amounts determined with reference amounts, whereby the angiogenic status is diagnosed. Also disclosed are diagnostic devices and kits for carrying out the aforementioned methods | 04-08-2010 |
20100086947 | USE OF FLOW-CYTROMETRIC ANALYSIS TO OPTIMIZE CELL BANKING STRATEGIES FOR CHO CELLS - Production of biopharmaceuticals from CHO cells requires generation of master-, working- and post-production cell banks of high quality, partly under GMP conditions. An optimal cryopreservation strategy is needed for each new production cell line, particularly with regard to the desire to establish production processes that are completely devoid of serum or even any animal components and to ensure robust thaw performance for reliable production. Here we describe a novel strategy employing flow cytometric (FC) analysis of Annexin V-stained cells for high-throughput characterization of CHO cell banks. Our data show that this method enables evaluation of a cryopreservation procedure just 6 h after thaw. | 04-08-2010 |
20100086948 | Ovarian Cancer Biomarkers and Uses Thereof - The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of ovarian cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose ovarian cancer or permit the differential diagnosis of a pelvic mass as benign or malignant. In another aspect, methods are provided for diagnosing ovarian cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having ovarian cancer, or the likelihood of the individual having ovarian cancer is determined, based on the at least one biomarker value. | 04-08-2010 |
20100093001 | Means and methods for the production of amyloid oligomers - The present invention relates to the field of amyloid disorders, more particularly to the field of diseases where protein misfolding leads to the generation of insoluble amyloid fibers in tissues and organs. The invention provides methods for the production of soluble, toxic amyloid oligomers. The invention further provides assays using the amyloid oligomers to screen for molecules that interfere with the toxicity of the oligomers. | 04-15-2010 |
20100099121 | METHOD FOR THE DIAGNOSIS OF CANCERS BY MEASURING THE CHANGES OF GLYCOSYLATION OF PROTEINS RELATED TO TUMORIGENESIS AND METASTASIS AND KIT FOR DIAGNOSIS OF CANCERS USING THE SAME - The present invention relates to a method for diagnosing cancers by measuring proteins associated with tumorigenesis and metastasis, and a diagnostic kit using the same, particularly relates to the method for diagnosing cancers by measuring the changes of glycosylation of proteins and the kit for diagnosis of cancers using the said method. The method and kit of the present invention can effectively be used for the sensitive diagnosis of cancers comprising colon cancer, stomach cancer, lung cancer and liver cancer. | 04-22-2010 |
20100105080 | Methods For Determining The Bioactivity Of TGF-Beta In A Composition - A novel method for determining the bioactivity of TGF-β in a sample of milk, raw protein source, or nutritional composition is provided. The method includes particular reconstitution steps, centrifugation steps, incubation steps, and activation steps. The bioactivity of the TGF-β in the sample may be measured in a HT-2 cell bioassay or a cellomics bioassay. | 04-29-2010 |
20100112600 | Methods and compositions for modulating synapse formation - The invention provides methods of modulating synapse formation. Methods for identifying agents to modulate synapse formation are also disclosed. | 05-06-2010 |
20100112601 | NOVEL MONOCLONAL ANTIBODY AND USE OF THE SAME - The present invention provides an anti-PAC1 monoclonal antibody capable of recognizing a PAC1 having a native structure, a PAC1 activity regulator (in particular, activity inhibitor) containing the antibody, a prophylactic/therapeutic agent for a disease associated with accentuation of a bioactivity of PAC1, containing the antibody, a diagnostic reagent for a disease associated with an abnormality of PAC1 activity, containing the antibody, and a screening method for a substance that regulates the expression of PAC1, using the antibody and a PAC1-expressing cell. | 05-06-2010 |
20100112602 | Protein-Protein Interaction Biosensors and Methods of Use Thereof - The invention provides methods and reagents for identifying an agent, such as by screening a library of agents, that modulates the interaction of two or more polypeptides, the method comprising: introducing into a cell at least a first polypeptide, each comprising a binding domain, wherein the first polypeptide comprises a localization domain of the second polypeptide; and detecting the cellular location of the first polypeptide, the second polypeptide or a combination thereof, wherein a change in the cellular location of the first polypeptide, the second polypeptide or a combination thereof indicates that the agent modulates the interaction of the two or more polypeptides. The invention also provides methods and reagents for identifying the binding domains of one or more polypeptides. | 05-06-2010 |
20100112603 | METHOD FOR PREDICTING THE RESPONSE TO A TREATMENT - The invention is related to a method of predicting the response to a treatment with a HER inhibitor in a patient comprising the steps of assessing a biomarker or a combination of biomarkers selected from the group consisting of amphiregulin, an epidermal growth factor, a transforming growth factor alpha, and a HER2 biomarker in a biological sample from the patient and predicting the response to the treatment with the HER inhibitor in the patient by evaluating the results of the first step. Further uses and methods wherein these markers are used are disclosed. | 05-06-2010 |
20100120068 | G-protein-conjugated receptor having altered ligand affinity, and use thereof - A modified G-protein-coupled receptor (GPCR), having modified ligand affinity is provided by binding a G-protein-coupled receptor to a polypeptide consisting of an amino acid sequence of SEQ ID NO: 1. Furthermore, agonists for or antagonists against the modified GPCR are screened using a transformant in which the modified GPCR has been expressed. This makes it possible to provide a technique for analyzing the function of many putative GPCRs whose entities have not been clarified. | 05-13-2010 |
20100120069 | MULTIPOTENT/PLURIPOTENT CELLS AND METHODS - Described herein are multipotent stem cells, e.g., human and other mammalian pluripotent stem cells, and related methods. | 05-13-2010 |
20100120070 | PRECISE EFFICACY ASSAY METHODS FOR ACTIVE AGENTS INCLUDING CHEMOTHERAPEUTIC AGENTS - An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying. One particularly important tissue sample preparation technique is the initial preparation of cohesive multicellular particulates of the tissue sample. For assays concerning cancer treatment, a two-stage evaluation is contemplated in which both acute cytotoxic and longer term inhibitory effect of a given anti-cancer agent are investigated. The tissue sample technique of the present invention is also useful in assaying expression and/or secretion of various markers, factors or antigens present on or produced by the cultured cells for diagnostic purposes and for using such expression to monitor the applicability of certain candidate therapeutic or chemotherapeutic agents and the progress of treatment with those agents. | 05-13-2010 |
20100129833 | Methods to Identify Modulators - Sucralose-binding TAS2R bitter taste receptors have been identified. Novel methods to identify modulators and in particular inhibitors to the bitter taste of sucralose and an inhibitor, are provided. | 05-27-2010 |
20100136582 | METHOD FOR IDENTIFICATION OF SOMATIC STEM CELLS - The invention relates to a method for identification of somatic stem cells, wherein the spatial arrangement of epitopes in a sample is captured by MELC technology for identifying the phenotype specific to the somatic stem cells. The invention moreover relates to a composition, a kit and a biochip comprising at least one antibody and/or ligand which can be employed for the performance of the method. | 06-03-2010 |
20100143943 | DETECTION OF DYSPLASTIC OR NEOPLASTIC CELLS USING ANTI-MCM2 ANTIBODIES - Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, oesophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and pre-cancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma. | 06-10-2010 |
20100143944 | Systems and methods for rapidly changing the solution environment around sensors - The invention provides microfluidic systems for altering the solution environment around a nanoscopic or microscopic object, such as a sensor, and methods for using the same. The invention can be applied in any sensor technology in which the sensing element needs to be exposed rapidly, sequentially, and controllably, to a large number of different solution environments whose characteristics may be known or unknown. | 06-10-2010 |
20100143945 | DNA-DAMAGE-INDUCED PROTEOLYSIS - The present application provides methods for identifying compounds for inhibiting DNA damage-induced Htt proteolysis, and methods and compositions for protecting cells from DNA damage-induced cleavage of Htt. | 06-10-2010 |
20100143946 | ALPHA-SYNUCLEIN KINASE - The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 kinase. | 06-10-2010 |
20100151496 | ASSAYS FOR NUCLEAR HORMONE RECEPTOR BINDING - Methods and genetic constructs are provided for detecting the binding of nuclear hormone receptors to a coactivator/corepressor. The methods employ enzyme fragment complementation using fragments of β-galactosidase as the detection system. Cells are transformed to express the large fragment of β-galactosidase fused to a member of the complex with NHR for initiation of transcription and have it localized in the nucleus and to express the small fragment of β-galactosidase fused to the nuclear hormone receptor for binding to the member upon stimulation with a ligand. | 06-17-2010 |
20100151497 | FLUORESCENCE-BASED ASSAY FOR DETECTING COMPOUNDS FOR MODULATING THE SODIUM-CALCIUM EXCHANGER (NCX) IN "FORWARD MODE" - Transporters are an emerging target family with enormous potential, offering scientific and economic opportunities. The Sodium/Calcium exchanger is an important mechanism for removing Ca | 06-17-2010 |
20100151499 | PROTEOLYTIC RELEASE OF GLYCANS - The present disclosure provides strategies for analyzing protein-linked glycans, and particularly for analyzing glycans on cell surface glycoproteins. | 06-17-2010 |
20100159484 | Chemotaxis diagnostic - A method is described for determining the chemotactic activity of leukocytes in a sample, in which method the expression of a cell adhesion molecule is determined. | 06-24-2010 |
20100167314 | CONTROL OF INTRACELLULAR TARGET MOLECULE BY IP3 RECEPTOR-BINDING PROTEIN - The present invention provides a composition comprising an IP | 07-01-2010 |
20100167315 | METHOD FOR INVESTIGATING THE RESPONSE TO A TREATMENT WITH A MONOCLONAL ANTIBODY - The invention relates to steps for the development or the quality control of recombinant monoclonal antibodies (MoAbr) used as medicaments, and also to the selection of the patients liable to effectively respond to a treatment with a given monoclonal antibody. More specifically, the invention relates to a method for evaluating, in vitro, the effector functions of NK cells in response to a test monoclonal antibody, comprising at least the following steps: (i) the NK cells are brought into contact with said monoclonal antibody, which is fixed on a support, in the presence of an agent for inhibiting the secretion of cytokines by said cells; (ii) by way of positive control for the activation of the NK cells, the same experiment is carried out using, in place of the test monoclonal antibody, a monoclonal antibody directed against the Fc RIIIa receptor; (iii) after an incubation period of at least 1 hour, the response of the NK cells is observed by measuring the presence of the CD107 marker at the cell surface, and also the presence of intracellular IFN and/or of intracellular TNF. | 07-01-2010 |
20100167316 | Enrichment of Tissue-Derived Adult Stem Cells Based on Retained Extracellular Matrix Material - Methods for enriching, detecting, or using adult stem cells through the use of recognition ligands that specifically bind to ECM components retained to the surfaces of adult stem cells are described. An ECM component such as hyaluronan that is retained to the surfaces of adult stem cells when removed from animal tissues can be used to detect a diverse population of adult stem cells based on the nature of the ECM niche region in which the adult stem cells normally reside. For example, a separation method such as magnetic separation can be used to detect and isolate or enrich adult stem cells based on a recognition ligand that is specific for an ECM component that is retained to the surfaces of adult stem cells to a greater degree than to other cells in the population. | 07-01-2010 |
20100173332 | Method for the Fluorescent Detection of Nitroreductase Activity Using Nitro-Substituted Aromatic Compounds - A method utilising one or more fluorogenic probes, for the detection of nitroreductase activity. The non-fluorescent probes are reduced in the presence of nitroreductase to form fluorescent derivatives that may be detected using fluorescence spectroscopy. In particular, the method may be used to detect and/or identify a plurality of nitroreductase in a single test environment | 07-08-2010 |
20100173333 | METHOD OF SCREENING CANDIDATE COMPOUNDS FOR SUSCEPTIBILITY TO BILIARY EXCRETION - A method of screening a candidate compound for susceptibility to biliary excretion. The method includes the steps of providing a culture of hepatocytes, the culture having at least one bile canaliculus; exposing a candidate compound to the culture; and determining an amount of candidate compound in the at least one bile canaliculus, the amount of candidate compound in the at least one bile canaliculus indicating the susceptibility of the candidate compound to biliary excretion. Optionally, the culture of hepatocytes is a long-term culture in a sandwich configuration. The method is particularly applicable to the screening of multiple candidate compounds in a single effort. | 07-08-2010 |
20100178658 | SCREENING ASSAYS FOR INHIBITORS OF BETA AMYLOID PEPTIDE ION CHANNEL FORMATION - Screening assays and methods of employing the screening assays designed to identify potential inhibitors of amyloidal neurodegenerative disease. The screening assays comprises providing a membrane construct disposed on a substrate and contacting the membrane construct with Aβ peptide capable of forming an Aβ peptide ion channel in the construct. The membrane construct is then contacted with a test compound. Aβ peptide ion channel activity is determined after the construct has incubated with the Aβ peptide in the presence and in the absence of the test compound. A reduction in the Aβ peptide ion channel activity of the membrane construct contacted with the test compound in comparison to a different membrane construct contacted with the same Aβ peptide in the absence of said test compound indicates that the test compound is an inhibitor of amyloidal neurodegenerative disease. | 07-15-2010 |
20100184092 | Methods and Compositions for Detecting Receptor-Ligand Interactions in Single Cells - The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state. | 07-22-2010 |
20100184093 | Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition - Clinical information, molecular information and/or computer-generated morphometric information is used in a predictive model for predicting the occurrence of a medical condition. In an embodiment, a model predicts whether a patient is likely to have a favorable pathological stage of prostate cancer, where the model is based on features including one or more (e.g., all) of preoperative PSA, Gleason Score, a measurement of expression of androgen receptor (AR) in epithelial and stromal nuclei and/or a measurement of expression of Ki67-positive epithelial nuclei, a morphometric measurement of a ratio of area of epithelial nuclei outside gland units to area of epithelial nuclei within gland units, and a morphometric measurement of area of epithelial nuclei distributed away from gland units. In some embodiments, quantitative measurements of protein expression in cell lines are utilized to objectively assess assay (e.g., multiplex immunofluorescence (IF)) performance and/or to normalize features for use within a predictive model. | 07-22-2010 |
20100184094 | USE OF MDCK CELLS IN THE EVALUATION OF CHOLESTEROL MODULATORS - A novel use for MDCK cells in the evaluation of cholesterol modulators is provided. In particular, methods for detecting substances which bind to NPC1L1 and block intestinal cholesterol absorption are provided. Such substances are of use in the treatment of individuals with hypercholesterolemia. The various assays may additionally be employed for studying NPC1L1 function. | 07-22-2010 |
20100184095 | Steroid Hormone Assay Method - The level of a steroid hormone, including estrogen, in the stratum corneum of the skin is assayed by LC-MS analysis of a steroid hormone in the stratum corneum of the skin collected by a tape stripping method. This allows the concentration in the skin of the steroid hormone, including estrogen which has an important effect on the state of the skin, to be easily measured. | 07-22-2010 |
20100184096 | SCREENING METHODS USING SITOSTEROLEMIA SUSCEPTIBILITY GENE (SSG) POLYPEPTIDES - The present invention provides nucleic acids encoding a novel ABC family cholesterol transporter, SSG. The herein-disclosed sequences can be used for any of a number of purposes, including for the diagnosis and treatment of cholesterol-associated disorders, including sitosterolemia, and for the identification of molecules that associate with and/or modulate the activity of SSG. | 07-22-2010 |
20100184097 | 4,5-BIS(4-METHOXYPHENYL)IMIDAZOLE COMPOUND INDUCING DIFFERENTIATION OF MYOBLASTS OR MUSCLE FIBERS INTO NEURON CELLS, A PHARMACEUTICAL COMPOSITION INCLUDING SAID COMPOUND, A METHOD OF INDUCING NEURON CELLS DIFFERENTIATION AND A SCREENING METHOD FOR IDENTIFYING ADDITIONAL COMPOUND USEFUL FOR INDUCING NEURON CELLS DIFFERENTIATION - The present invention relates to 4,5-bis(4-methoxyphenyl)imidazole compound inducing differentiation of myoblasts or muscle fibers into neuron cells, a pharmaceutical composition including said compound, a method of inducing neuron cells differentiation and a screening method for identifying additional compound useful for inducing neuron cells differentiation. More specifically, it relates to 2-{2-[5-(3-chlorophenyl)]furanyl}-4,5-bis(4-methoxyphenyl)imidazole that induces differentiation of myoblasts or muscle fibers into neuron cells, all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug thereof, and a pharmaceutical composition including said compound, a method of inducing neuron cells differentiation and a screening method for identifying additional compound useful for inducing neuron cells differentiation. | 07-22-2010 |
20100184098 | METHODS FOR MEASURING ENZYME ACTIVITY - The invention relates to fluorescence methods for measuring enzyme activity, in particular enzyme cleaving and joining activities. The invention also relates to fluorogenic substrates which are useful for measuring enzyme activity and as in vitro and in vivo imaging probes. | 07-22-2010 |
20100196928 | Gene specific to cancer and diagnosis kit using the same - The present invention provides a new additional identification of a gene related to cancer expression and a diagnostic kit using the same. | 08-05-2010 |
20100196929 | STABILISATION OF THE PHENOTYPIC PROPERTIES OF ISOLATED PRIMARY CELLS - The invention provides a method for stabilisation of phenotypic properties of isolated primary cells comprising modulating at least two epigenetic modifications in said cells. | 08-05-2010 |
20100196930 | CELL BASED ASSAYS FOR THE TRIGLYCERIDE SYNTHESIS PATHWAY - A method for identifying a compound which modulates the activity of acyl-coA: diacylglycerol acyltransferase comprises the steps of contacting a stable isotope labeled fatty acid with cells in either presence or absence of the compound, extracting the cells with isopropyl alcohol, and determining the level of a stable isotope labeled triglyceride in the presence or absence of the compound; wherein a change in the level of the stable isotope labeled triglyceride indicates that the compound modulates the DGAT activity. | 08-05-2010 |
20100203556 | METHODS OF USING A G PROTEIN-COUPLED RECEPTOR TO IDENTIFY PEPTIDE YY (PYY) SECRETAGOGUES AND COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MODULATED BY PYY - The present invention relates to methods of using GPR119 receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY, such as conditions modulated by stimulation of NPY Y2 receptor (Y2R). Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition modulated by PYY, such as a condition modulated by stimulation of Y2R. Conditions modulated by PYY such as may be a condition modulated by stimulation of Y2R include bone-related conditions, metabolic disorders, angiogenesis-related conditions, ischemia-related conditions, convulsive disorders, malabsorptive disorders, cancers, and inflammatory disorders. | 08-12-2010 |
20100216164 | MAMMALIAN PRICKLE GENE - The present invention provides the mPrickle gene which encodes a protein present in mammalian PSD fractions. The mPrickle protein is localized in synapses, and binds to the scaffold protein PSD-95. Precipitation of endogenous mPrickle using an anti-mPrickle antibody results in the coprecipitation of NMDA receptors, and thus, mPrickle can be used in drug delivery systems that target NMDA receptors. NMDA receptors are closely related to learning and memory, and are also suggested to be involved in mental disorders. Thus, in the future, mPrickle is expected to be applicable to the diagnosis and/or treatment of neurodegenerative diseases associated with learning/memory, such as mental deterioration and dementia. | 08-26-2010 |
20100216165 | USE OF SOLUBLE FORMS OF THE DESMOGLEIN I PROTEIN FOR THE PURPOSES OF SCREENING FOR ANTI-AGEING ACTIVE AGENTS - The invention relates to the use of one or more complexed or noncomplexed, soluble peptide form(s) of Desmoglein I, as a marker for evaluating the effectiveness of active agents and/or of treatments, in particular anti-ageing active agents and/or treatments, with regard to an epidermis. | 08-26-2010 |
20100216166 | TARGET ACTIVATED MICROTRANSFER - A device for performing target activated transfer that includes a mounting surface for mounting a tissue sample; and a light source positioned to substantially uniformly irradiate both stained and unstained regions of the tissue sample with light energy that activates the reagent to selectively adhere the stained regions to a transfer surface. Also described is an automated system for transferring tissue from a tissue sample to a transfer substrate. The system includes means for holding a tissue section that includes targets specifically stained with an absorptive stain thereby resulting in a stained tissue surface, and a flexible transfer film that includes a lower thermoplastic layer in sufficient thermal contact with the stained tissue surface; an irradiating assembly configured to provide a predetermined uniform light dose to the entire tissue section; and means for applying a constant pressure to the transfer film during irradiation. | 08-26-2010 |
20100216167 | METHODS FOR RELIEVING NEUROPATHIC PAIN BY MODULATING ALPHA 1G T-TYPE CALCIUM CHANNELS AND MICE LACKING ALPHA 1G T-TYPE CALCIUM CHANNELS - The present invention relates to a novel use of a transgenic mouse deficient in α1G T-type calcium channel as an animal model for the study of neuropathic diseases, more precisely, a novel use of a transgenic mouse having resistance against neuripathic pain as an animal model for the development of a therapeutic agent and a treatment method for human neuropathic diseases. The transgenic mouse deficient in α1G T-type calcium channel having resistance against neuropathic pain, provided by the present invention, can be effectively used for the development of a therapeutic agent and a treatment method for human neuropathic diseases. | 08-26-2010 |
20100221751 | METHOD OF SCREENING ENDOTHELIAL CELLS FOR ANGIOGENIC CAPABILITY - Provided is a method of screening a primary endothelial cell population for angiogenesis capability comprising: (a) measuring the percentage of cells that are positive for VEGF R2 and CD34, the level of VEGF R2, or measuring the VEGF R2 to VEGF R1 ratio in the population; and (b) selecting those populations where the measured percentage or the measured ratio is over a threshold value. | 09-02-2010 |
20100221753 | Prostate Cancer-Related Compositions, Methods and Kits Based on DNA Macroarray Proteomics Platforms - The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue. | 09-02-2010 |
20100233730 | THERAPEUTIC MODULATION OF AUTOPHAGY - Methods for screening for modulators of autophagy are disclosed. Methods for identifying genes whose expression inhibits autophagy, as well as genes whose expression promotes autophagy, are disclosed. Also disclosed are methods for identifying compounds that stimulate autophagy, as well as compounds that inhibit autophagy. Cell lines that may be used in the methods of identification are also disclosed. | 09-16-2010 |
20100240071 | Assay for Detection of Transient Intracellular CA2+ - This invention relates to a simple end point assay for detection of transient intracellular Ca | 09-23-2010 |
20100240072 | Cancer Imaging and Treatment - A compound, or a pharmaceutically acceptable salt or ester thereof, comprises the structure: [(P1-S1 | 09-23-2010 |
20100255501 | METHOD OF IDENTIFYING A MHC CLASS I RESTRICTED T CELL RESPONSE - Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cytotoxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and polypeptides and therapeutic uses thereof. Moreover, indications for selecting appropriate minimal antigenic MUC-1 polypeptides with reference to the HLA-type of the patient to be treated or tested are described. | 10-07-2010 |
20100255502 | Methods for Detecting and Inhibiting Angiogenesis - The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds α5β1 integrin, and detecting specific binding of the agent to α5β1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual. The invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of α5β1 integrin to a ligand expressed in the tissue; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of α5β1 integrin to a ligand in a tissue associated with the pathological condition. The invention also provides methods of identifying an agent that reduces or inhibits angiogenesis associated with α5β1 integrin expression in a tissue by contacting a tissue exhibiting angiogenesis associated with α5β1 integrin expression with an agent, and detecting a reduction or inhibition of angiogenesis in the tissue. | 10-07-2010 |
20100255503 | MARKERS FOR DIAGNOSIS OF CANCER AND ITS USE - Disclosed herein are diagnostic markers CTHRC1, CANP and KIAA0101, which are overexpressed specifically in breast or colorectal cancer. A method for diagnosing the cancer by detecting the markers, and a method for preventing or treating by inhibiting the expression and activity of the markers are also disclosed. | 10-07-2010 |
20100255504 | Reactive Heterocycle-Substituted 7-Hydroxycoumarins and Their Conjugates - Chemically-reactive, water-soluble, heterocycle-substituted 7-hydroxycoumarin dyes, their bioconjugates and uses are described. The conjugates derived from reactive heterocycle-substituted 7-hydroxycoumarin dyes are used for analyzing biological compounds. These heterocycle-substituted 7-hydroxycoumarin dyes are particularly useful as fluorescent labels for biopolymer detection reagents, such as antibodies or nucleic acid probes. The dye-antibody conjugates of the invention are particularly useful for analyzing analytes using a flow cytometer equipped with a violet laser as an excitation source due to their strong absorption at 405 nm and high fluorescence quantum yield. | 10-07-2010 |
20100255505 | GENETICALLY MODIFIED STEM CELLS AND METHODS FOR IDENTIFYING TISSUES DIFFERENTIATED THEREFROM - Genetically modified stem cells and the selection of cells differentiated therefrom are disclosed. Particularly, the herein disclosed invention relates to stem cells or cells differentiated therefrom containing a copy of a stably inheritable expression construct that is suitable for the expression of transgenes in stem cells, wherein said construct comprises at least a double-feature constitutive promoter being operable both in stem cells and in differentiated tissues, the expression level thereof being subject to a tissue or cell type specific regulation in differentiated cells, and, optionally, under the control of said promoter, a transgene, wherein said transgene is expressed in the stem cell. Furthermore methods are disclosed to produce such stem cells, as well as specific uses of said stem cells in assay methods and in human therapy and in veterinary practice. | 10-07-2010 |
20100255506 | PROCESS OF USING A TETRAZOLIUM SALT - Thiazolyl tetrazolium salts with increased solubility in aqueous solutions have alkylammonium alkoxy substituents, preferably trimethyl ammonium propoxy groups substituents, on phenyl rings attached to the tetrazolium ring. | 10-07-2010 |
20100261201 | ASSAY FOR MONITORING ACTIVITY OF FRIZZLED RECEPTORS - The present invention relates to cell free assays for measuring receptor activity, especially for measuring a constitutive or a non-constitutive activity of frizzled receptors and uses thereof. The present invention further concerns a method for measuring a constitutive or non-constitutive activity of a frizzled receptor and a method for obtaining an active frizzled receptor ligand. | 10-14-2010 |
20100261202 | METHOD FOR EFFICIENT PRODUCTION OF MONOCYTE-DERIVED MULTIPOTENT CELL (MOMC) - It is to provide a practical method for producing efficiently a large amount of MOMC, which is a multipotent cell which is very suitable for cell transplantation for organ regeneration. It was found that by culturing peripheral blood monocytes in vitro on fibronectin in the presence of SDF-1, MOMC can be produced more efficiently, and the present invention has been completed. Specifically, it is a method for producing MOMC by culturing in vitro peripheral blood monocytes expressing CD14 on fibronectin, wherein the in vitro culture is performed in the presence of SDF-1. | 10-14-2010 |
20100261203 | Methods and kits for screening transplant recipients and candidates - Methods and kits are provided for determining of immunoglobulin isotypes and subclasses in a subject. In general the subject is a human who is a transplant candidate recipient or recipient, has allergies, or has an autoimmune disease. The method involves analyzing a sample of a body fluid of a transplant candidate or recipient, allergy patient or autoimmune disease sufferer and correlating the relative amounts of each immunoglobulin isotype and subtype, such that the distribution of isotypes and subtypes is an indication of success of the transplant in the candidate and recipient or the prognosis of the autoimmune disease. | 10-14-2010 |
20100267057 | Cell Surface Display, Screening and Production of Proteins of Interest - Aspects of the invention provide compositions and methods for displaying engineered polypeptides on a cell surface. According to aspects of the invention, immobilized polypeptides can be screened to identify one or more variants having one or more functional or structural properties of interest. Aspects of the invention provide composition and methods for producing engineered protein or protein variants having a functional or a structural property of interest. | 10-21-2010 |
20100279316 | Antibodies to Phosphorylated IRAK4 - The present invention relates to antibodies that bind phosphorylated forms of IRAK4, methods of using such antibodies to detect IRAK4 biological activity, and methods for the detection, diagnosis, and prognostication of pathological conditions related to IRAK4 biological activity. ERAK4 is one member of a small family of highly conserved cytoplasmic signal transduction proteins characterized by the presence of an N-terminal “death domain” and a C-terminal serine-threonine kinase domain. IRAK4 functions in cytoplasmic signal transduction pathways by interacting with membrane spanning proteins which play, inter alia, critical roles in vertebrate immune system function. | 11-04-2010 |
20100279317 | Method - The present invention provides a method for identifying a single or group of T cell receptors (TCR) protective and/or effective against a disease, having the following steps: i) obtaining T cells from a donor non-human animal; ii) adoptive transfer of the T cells into a plurality of T cell-deficient recipient non-human animals in a number such that at least one recipient animal is protected against the disease but at least one animal remains unprotected; and iii) determination of the TCR(s) present only in the protected animals. These TCR can be used to identify the determinants or antigens for inclusion in a vaccine or other treatment. | 11-04-2010 |
20100279318 | METHOD OF IDENTIFYING TRANSMEMBRANE PROTEIN-INTERACTING COMPOUNDS - A method for screening compounds for their ability to interact with transmembrane proteins is provided. Also provided is a method for determining whether proteins such as transmembrane proteins are able to oligomerise. The method uses a transmembrane protein that comprises a nuclear localization sequence (NLS) | 11-04-2010 |
20100285504 | MONOCLONAL ANTIBODY WHICH BINDS MET IN FORMALIN-FIXED AND PARAFFIN-EMBEDDED TISSUES AND RELATED METHODS - In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase Met. Disclosed herein are (a) a monoclonal antibody named Met4, which antibody is specific for Met, and (b) a hybridoma cell line that produces Met4. The Met4 antibody is particularly useful for detecting Met in formalin-fixed tissue. Methods of using the Met4 antibody for detection, diagnosis, prognosis, and evaluating therapeutic efficacy are provided. | 11-11-2010 |
20100297671 | Method and Device for the Quantitative Determination of Analytes in Liquid Samples - The invention relates to a method and a device for the highly sensitive parallel detection and quantitative determination of analytes in liquid samples. According to said method, total internal reflection fluorescence (TIRF) is used in combination with a binding inhibition test on a specially coated support. The inventive method makes it possible to quickly analyze different types of liquids, such as drinking water, fruit juices, milk, serum, blood plasma, urine, etc., while allowing samples to be analyzed simultaneously regarding several different analytes, including hormones, antibiotics, pesticides, pharmaceuticals, drugs, and other molecules or molecular complexes, for example. | 11-25-2010 |
20100297672 | HIGHLY SENSITIVE SYSTEM AND METHODS FOR ANALYSIS OF TROPONIN - The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin. | 11-25-2010 |
20100297673 | METHODS AND COMPOSITIONS FOR UPREGULATION OF PEROXIREDOXIN ACTIVITY - A novel method of identifying compounds capable of upregulating Peroxiredoxin activity is disclosed. The method includes providing a sample of cells that express Peroxiredoxin, providing a sample of a candidate compound, contacting the cell sample and the compound sample, and measuring a quantitative indicator of Peroxiredoxin activity within the cell sample after the contacting step. Peroxiredoxin inducers identified by the method and uses therefore to upregulate Peroxiredoxin activity in subjects and to reduce LDL and/or VLDL levels and to prevent or treat atherosclerosis and inflammatory disorders such as arthritis in subjects are also described. The invention also provides a method of treatment of inflammatory and cardiovascular diseases which comprises providing a patient in need of treatment with an effective amount of a composition that increases Peroxiredoxin protein or activity. | 11-25-2010 |
20100297674 | NOVEL CELL LINES EXPRESSING NaV AND METHODS USING THEM - Cells and cell lines that express voltage-gated sodium ion channels (NaV) and methods for using the cells and cell lines are disclosed herein. The NaV-expressing cells and cell lines are useful in high throughput screening assays. | 11-25-2010 |
20100304406 | Protein Phosphorylation by Serine/Threonine Kinases in Insulin Signaling Pathways - The invention discloses 137 novel phosphorylation sites identified in insulin signaling pathways, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 12-02-2010 |
20100311082 | Stable Cell Lines and Methods for Evaluating Gastrointestinal Absorption of Chemicals - Nucleic acids and vectors for interfering with the expression of membrane efflux transport proteins in cells that express such proteins are provided. Also provided are cells and cell lines comprising such nucleic acids and vectors. Methods for screening chemicals and biomolecules for gastrointestinal absorption in animals, and kits for practicing such methods are also provided. | 12-09-2010 |
20100317034 | PRIMATE T-LYMPHOTROPIC VIRUSES - Disclosed are compositions and methods related to the isolation and identification of the primate T-lymphotropic viruses, HTLV-3 and HTLV-4. The diversity of HTLVs was investigated among central Africans reporting contact with NHP blood and body fluids through hunting, butchering, and keeping primate pets. Herein it is shown that this population is infected with a variety of HTLVs, including two retroviruses; HTLV-4 is the first member of a novel phylogenetic lineage that is distinct from all known HTLVs and STLVs; HTLV-3 falls within the genetic diversity of STLV-3, a group that has not previously been seen in humans. The present disclosure also relates to vectors and vaccines for use in humans against infection and disease. The disclosure further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-3 and HTLV-4 and related viruses. | 12-16-2010 |
20100317035 | USE OF SPECIFIC T2R TASTE RECEPTORS TO IDENTIFY COMPOUNDS THAT BLOCK BITTER TASTE - Assays for identifying compounds that modulate, preferably inhibit bitter taste associated with the activation of hT2R4, hT2R44 and/or hT2R61 are provided. The compounds identified according to these assays should modulate, e.g., inhibit bitter taste associated with bitter tasting compounds including quinine, 6-nitrosaccharin, saccharin and/or denatonium. These compounds are useful additives for foods, beverages or medicinal preparations having a bitter taste. | 12-16-2010 |
20100330590 | ASSAYS USING CHIMERIC T1R3 TASTE RECEPTOR POLYPEPTIDES - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed. | 12-30-2010 |
20100330591 | GPCR Expressing Cell Lines and Antibodies - The present invention provides expression vectors that facilitate high levels of expression of GPCR proteins. Encompassed by the invention are methods and compositions for recombinant cell lines expressing GPCR proteins with the aid of the expression vectors of the instant invention. The recombinant cell lines of the instant invention express GPCR proteins at levels of at least about 150,000 copies of the protein per cell. The present invention also provides methods and compositions for raising antibodies against GPCR proteins using the high expressing recombinant cells of the instant invention. | 12-30-2010 |
20100330592 | METHOD FOR DETECTING TRUNCATED MOLECULES - Exemplary disclosed embodiments may comprise, for example, providing a sample potentially comprising a native molecule and/or a truncated molecule. The native molecule comprises at least first and second regions recognized by first and second specific binding moieties, and the truncated molecule includes only one of the first and second regions. A composition comprising first and second specific binding moieties is applied to the sample in a manner effective to form first and second specific binding pairs with the first and second regions. For example, if the molecule is a protein, such as HER2, the protein may have a first epitope and a second epitope. Once a specific binding pair is formed, the pair must be visualized. Certain disclosed embodiments comprise a direct detection method whereby primary antibodies are coupled to signal generating moieties. Alternatively, signal amplification techniques can be used to visualize a specific binding pair. | 12-30-2010 |
20110003315 | CHIMERIC PCSK9 PROTEINS, CELLS COMPRISING SAME, AND ASSAYS USING SAME - A chimera protein comprising in the following order: a signal peptide, a proprotein convertase subtilisin/kexin type 9 preproprotein (PCSK9) sequence consisting of amino acid residues at positions 35 to 696 of SEQ ID NO: 38, a transmembrane domain and a cytosolic domain, wherein said cytosolic (CT) domain comprises a sequence able to recycle the protein from the cellular membrane to endosomes. | 01-06-2011 |
20110003316 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY - The present invention provides methods, compositions, substrates, and kits useful for analyzing the metabolic activity in cells, tissue, and animals and for screening test compounds for their effect on cytochrome P450 activity. In particular, a one-step and two-step methods using luminogenic molecules, e.g. luciferin or coelenterazines, that are cytochrome P450 substrates and that are also bioluminescent enzyme, e.g., luciferase, pro-substrates are provided. Upon addition of the luciferin derivative or other luminogenic molecule into a P450 reaction, the P450 enzyme metabolizes the molecule into a bioluminescent enzyme substrate, e.g., luciferin and/or luciferin derivative metabolite, in a P450 reaction. The resulting metabolite(s) serves as a substrate of the bioluminescent enzyme, e.g., luciferase, in a second light-generating reaction. Luminescent cytochrome P450 assays with low background signals and high sensitivity are disclosed and isoform selectivity is demonstrated. The present invention also provides an improved method for performing luciferase reactions which employs added pyrophosphatase to remove inorganic pyrophosphate, a luciferase inhibitor which may be present in the reaction mixture as a contaminant or may be generated during the reaction. The present method further provides a method for stabilizing and prolonging the luminescent signal in a luciferase-based assay using luciferase stabilizing agents such as reversible luciferase inhibitors. | 01-06-2011 |
20110003317 | METHODS OF SCREENING COMPOUNDS FOR INSECT-CONTROL ACTIVITY INVOLVING THE TYRAMINE RECEPTOR - An exemplary method of screening compositions for insect control activity includes, providing an insect cell expressing a receptor of the insect olfactory cascade or fragment thereof, contacting a test composition to the insect cell, measuring at least one parameter selected from olfactory cascade receptor binding affinity, intracellular cAMP levels, and intracellular Ca | 01-06-2011 |
20110003318 | NUCLEOTIDE AND PROTEIN SEQUENCE OF MAMMASTATIN AND METHODS OF USE - A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated mammastatin. | 01-06-2011 |
20110003319 | Transgenic Trasnchromosomal Rodents for Making Human Antibodies - The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies. | 01-06-2011 |
20110003320 | IMMUNOASSAY METHOD AND KIT AND DEVELOPING SOLVENT THEREFOR - An immunoassay method and a kit which comprises a combination of a test piece for immunochromatography and a developing solvent, by which a target substance is detected accurately in a short period of time while a preventing a nonspecific reaction. | 01-06-2011 |
20110008801 | METHODS FOR MEASURING CELL-CELL OR CELL-MATRIX ADHESIVE FORCES AND COMPOUNDS FOR DISRUPTING ADHESIVE FORCES IN BIOLOGICAL SYSTEMS - The invention provides an atomic force microscope-based bioassay, assisted by thermodynamic characterizations to quickly and accurately screen for compounds that disrupt cell-cell or cell-substrate interactions. | 01-13-2011 |
20110008802 | TNFalpha GENE EXPRESSION AS A BIOMARKER OF SENSITIVITY TO ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS - TNFα gene expression can be used as a biomarker of a cell's sensitivity to antagonists of inhibitor of apoptosis proteins (IAPs). Methods of the invention are useful for screening patients to identify those who could benefit from administration of an IAP antagonist to treat various malignant or benign tumors, benign proliferative diseases, or autoimmune diseases. | 01-13-2011 |
20110014634 | NUCLEIC ACIDS ENCODING T2R, A NOVEL FAMILY OF TASTE RECEPTORS - The invention provides isolated nucleic acid and amino acid sequences of taste cell specific G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste cell specific G-protein coupled receptors. | 01-20-2011 |
20110014635 | MARKER PEPTIDE FOR ALZHEIMER'S DISEASE - To provide a peptide obtainable by cleaving an N-terminal region and a C-terminal region of Alcadein α, Alcadein β, or Alcadein γ; and capable of being a diagnostic marker for Alzheimer's disease. It is possible to detect Alzheimer's disease at an early stage without burdening subjects to be tested by using the peptide as a diagnostic marker. | 01-20-2011 |
20110020841 | CENTROSOME AMPLIFICATION AS A BIOSENSOR FOR DNA DAMAGE - The present invention provides an assay kit for identifying and/or monitoring genotoxic modulating agents comprising eukaryotic cells, characterised in that the cells stably express at least one labelled centrosome marker. | 01-27-2011 |
20110020842 | eEF2K Assays for Identifying Compounds that Inhibit eEF2K Activity - Assays for identifying novel compounds for inhibiting eEF2 kinase and consequence peptides employed therein. | 01-27-2011 |
20110020843 | LABEL-FREE METHODS RELATED TO PHOSPHODIESTERASES - 196. Disclosed are methods of incubating cells on biosensors, and methods using the disclosed incubation techniques to identify PDE4 modulators. | 01-27-2011 |
20110027804 | IMMUNE SYSTEM MODELING DEVICES AND METHODS - Devices and methods are provided for detecting an immune reaction to a test agent using an immune modeling system comprising a barrier component configured to culture a biological barrier, an immune component configured to culture immune cells, and one or more inter-component microfluidic connections between the barrier component and the immune component. The system provides for culturing a biological barrier in the barrier component of the system, culturing immune cells in the immune component of the system, applying the test agent to the biological barrier, and monitoring the immune cells to detect an immune reaction to the test agent. | 02-03-2011 |
20110027805 | ACPL-RELATED ASSAYS - The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. | 02-03-2011 |
20110027806 | FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING AND ATHEROSCLEROSIS - Although it can be farnesylated, the mutant lamin A protein expressed in Hutchinson Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression. Similarly, treatment with FTIs should improve disease status in progeria and other laminopathies. In addition, elements of atherosclerosis and aging in non-laminopathy individuals will improve after treatment with farnesyltransferase inhibitors. | 02-03-2011 |
20110027807 | PROTEIN SPECIFIC TO PANCREATIC BETA CELLS IN ISLETS OF LANGERHANS AND APPLICATIONS THEREOF - The invention relates to protein ZnT-8 which is specifically expressed in the pancreatic beta cells in islets of Langerhans, to a polynucleotide encoding said protein which is involved in the maturation and exocytosis of insulin, and to the applications thereof, for example, for sorting and studying beta cells and for screening medicine acting on diabetes and hyperinsulinism. | 02-03-2011 |
20110033874 | BIOMARKERS - The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring ANP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection. Also provided are antibodies useful in the methods of the invention. | 02-10-2011 |
20110039278 | DEVICE AND METHODS FOR THE IMMUNOLOGICAL IDENTIFICATION OF CEREBROSPINAL FLUID - The present disclosure relates to detection of the presence or absence of cerebrospinal fluid (CSF) in a sample by the detection of one or more antigens that are enriched in CSF compared to their levels in other bodily fluids. The devices and methods are suitable for the detection of the presence or absence of cerebrospinal fluid in samples of mixed bodily fluids from a wide variety of human populations crossing ethnicity, age, gender, health status and genetic variability. | 02-17-2011 |
20110039279 | METHODS AND COMPOSITIONS FOR DIAGNOSING BREAST CANCER - Mammastatin has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin. | 02-17-2011 |
20110045496 | GAL ALPHA 1-3GAL-CONTAINING N-GLYCANS IN GLYCOPROTEIN PRODUCTS DERIVED FROM CHO CELLS - The present invention provides methods of evaluating CHO cells. | 02-24-2011 |
20110045497 | NOVEL ACIDIC GLYCAN MARKERS OF HUMAN CELLS - The invention is directed to the analysis of novel acidic glycan markers of several types of human cells. The analysis is performed by mass spectrometry or specific binder molecules. | 02-24-2011 |
20110045498 | On-Site Liquid Production - A biological sample processing system for on-site liquid production comprises a processing apparatus for processing of biological samples arranged on microscope slides, and a production unit connected to the apparatus. The production unit comprises a first ingredient source, a second ingredient source, and a mixer station. The mixer station is configured to mix ingredients to produce a liquid product. Supply conduits are arranged to supply an amount of a first ingredient and an amount of a second ingredient from the first and second ingredient sources to the mixer station. A delivery conduit is provided for transportation of an amount of the liquid product from the mixer station. A production controller is arranged in communication with the production unit, and is configured to control the operation of the production unit. | 02-24-2011 |
20110045499 | Screening systems utilizing RTP801 - RTP801 represents a unique gene target for hypoxia-inducible factor-1 (HIF-1). Down-regulation of the mTOR pathway activity by hypoxia requires de novo mRNA synthesis and correlates with increased expression of RTP801. | 02-24-2011 |
20110045500 | CELL CULTURE METHOD AND SCREENING METHOD - Provided is a cell culture method whereby an in vivo function can be sustained over a long period of time and culture can be conducted using the minimum number of cells required. The cell culture method includes culturing undifferentiated cells in a layered state in a partitioned micro-space and obtains differentiated cells. When screening a pharmaceutical agent, undifferentiated cells capable of differentiating into liver cells, intestinal epithelial cells, nerve cells, myocardial cells and vascular endothelial cells are preferred. Particularly, in the prediction of pharmacokinetics or the like for humans, human cells are preferred. | 02-24-2011 |
20110053182 | DIAGNOSIS OF PRE-CANCEROUS CONDITIONS USING PCDGF AGENTS - The present invention relates to methods and compositions designed for the treatment or management of pre-cancerous conditions, especially in order to prevent, delay, or decrease the likelihood that the pre-cancerous condition will progress to malignant cancer. The methods of the invention comprise the administration of an effective amount of one or more agents that decrease/inhibit PCDGF expression, secretion, and/or activity. The invention also provides pharmaceutical compositions comprising one or more PCDGF agents. In some embodiments, the PCDGF agents can be administered with other therapeutic agents for treatment or management of a pre-cancerous condition that are not PCDGF-based. Diagnostic methods and methods for screening for therapeutically useful PCDGF agents are also provided. | 03-03-2011 |
20110053183 | METHOD OF CONCENTRATING HUMAN MESENCHYMAL STEM CELLS - The present invention is intended to provide methods for highly enriching human mesenchymal stem cells from a cell population containing the human mesenchymal stem cells. To highly enrich human mesenchymal stem cells, CD271 | 03-03-2011 |
20110053184 | Nucleic Acid Encoding A Haplotype of Human T2R Receptor hT2R50 - The present invention relates to the discovery of a novel haplotype of the human taste receptor hT2R50 in the T2R taste receptor family that responds to particular bitter ligands, i.e., 2-acetylpyrazine and ethylpyrazine. The present invention also relates to the use of this novel haplotype in assays for identifying ligands that modulate the activation of the hT250 taste receptor. These compounds potentially may be used as additives in foods, beverages and medicinals for modifying (blocking) hT2R50-associated bitter taste. | 03-03-2011 |
20110059467 | CONTROLLED MODIFICATION OF SEMICONDUCTOR NANOCRYSTALS - A controlled valency semiconductor nanocrystal can have a desired number of compounds associated with it. The semiconductor nanocrystal can have exactly one compound associated with it, and the compound can have exactly one binding site for an affinity target. The semiconductor nanocrystal can be used to image single copies of cell-surface proteins. | 03-10-2011 |
20110059468 | Magnetic separation device for cell sorting and analysis - A magnetic sifter is adapted for manipulation of biological cells by providing a greater pore density at the edge of the sifter than at the center. Application of an external magnetic field to the sifter causes high magnetic fields and field gradients at the sifter pores. These conditions are suitable for capturing magnetically tagged or labeled cells at the sifter pores. Altering the external magnetic field can provide controlled capture and/or release of magnetically labeled cells from the sifter pores. The purpose of having a greater pore density at the periphery of the sifter than at the center is to provide improved flow rate uniformity through the sifter. Such flow rate uniformity is advantageous for cell quantification. | 03-10-2011 |
20110065129 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION - This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation. | 03-17-2011 |
20110076696 | CARDIOVASCULAR SAFETY ASSAY - The present invention provides assays and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. Said assays and kits are based on the finding that the interaction of astemizole with the HERG potassium channel can be exploited to predict cardiotoxicity of compounds during the development of new therapeutics and other agents. | 03-31-2011 |
20110081661 | Modified photoproteins with increased affinity for calcium and enhanced bioluminescence and uses thereof - The present invention provides modified photoproteins, e.g., modified Clytin, having an increased affinity for calcium as well as an enhanced bioluminescence and their use as calcium indicators in reporter gene systems and in cell-based assays. | 04-07-2011 |
20110081662 | SCREENING METHODS FOR BONE MORPHOGENETIC MIMETICS - Disclosed are methods for identifying agents which modulate the activity of bone morphogenetic protein-7. These methods for identifying agents utilize bone morphogenetic protein receptors, specifically the daf-4 receptor, and more specifically the extracellular domain of the daf-4 receptor. Agents identified by the methods are also described as well as compositions comprising the agents and methods of treating a subject using the agents or compositions. | 04-07-2011 |
20110081663 | Molecular Probe for Imaging of Pancreatic Islets and Use of the Same - A molecular probe for imaging of pancreatic islets is provided. The molecular probe includes a polypeptide represented by the following formula (1), or a polypeptide that has a homology with the foregoing polypeptide. | 04-07-2011 |
20110086366 | METHODS FOR ASSESSING THE RISK OF ADVERSE EVENTS UPON TREATMENT WITH IGG4 ANTIBODIES - The invention relates to methods and kits for assessing the risk, for an individual, of developing an adverse event upon treatment with a therapeutic antibody which is capable of Fab-arm exchange, said method comprising the steps of: a) providing a sample from an individual who is a candidate for treatment with said therapeutic antibody, b) assaying said sample for the presence of circulating IgG4 antibodies that binds an antigen known or suspected to be associated with a causative agent of said adverse event, and c) assessing, on the basis of the outcome of the assay of step b), the risk that the individual will develop said adverse event upon treatment with the therapeutic antibody, wherein the risk of development of said adverse event increases with increased level of said circulating IgG4 antibodies. | 04-14-2011 |
20110097741 | PARTIAL T1R2 NUCLEIC ACID SEQUENCE, RECEPTOR PROTEIN AND ITS USE IN SCREENING ASSAYS - A novel sweet receptor protein, corresponding nucleic acid sequence, expression vectors, transfected host cells, and screening methods for modulators including ligands of the sweet taste response employing the aforementioned are provided. | 04-28-2011 |
20110097742 | CONTRAST AGENTS, METHODS FOR PREPARING CONTRAST AGENTS, AND METHODS OF IMAGING - Embodiments of the present disclosure provide for contrast agents, methods of making contrast agents, and methods of using contrast agents, and the like. | 04-28-2011 |
20110104715 | CYTOTOXIC PEPTIDES AND PEPTIDOMIMETICS BASED THEREON, AND METHODS FOR USE THEREOF - In accordance with the present invention, it has been discovered that the β-amyloid precursor protein (APP), and two APP-like proteins (APLP1 and APLP2) are proteolytically cleaved by caspases in the C terminus to generate an approximately 31 amino acid peptide. It has been further discovered that the resultant C-terminal peptide is a potent inducer of apoptosis. Both caspase-cleaved APP and activated caspase-9 is present in brains of Alzheimer's disease patients but not in control brains. These findings indicate that caspase cleavage of APP and APP-like proteins leads to the generation of apoptotic peptides, which may contribute to the neuronal death associated with Alzheimer's disease. Accordingly, there are provided compositions and methods for modulating apoptosis. | 05-05-2011 |
20110104716 | NOVEL METHOD FOR SCREENING BRAIN-ACTIVE COMPOUNDS - The invention relates to a novel screening method for brain-active substances and mixtures using hippocampal slices. | 05-05-2011 |
20110104717 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT - The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN. | 05-05-2011 |
20110111429 | FLUORESCENT CARBAZOLE COMPOUNDS FOR CANCER DIAGNOSIS - A compound of formula (I): | 05-12-2011 |
20110111430 | METHOD FOR DIAGNOSING LIVER FIBROSIS - Provided herein are methods and devices for nonsurgically predicting, diagnosing, and monitoring liver fibrosis in an individual. Methods utilize biomarkers, age and sex to determine a diagnostic score. The diagnostic score is then used to predict, diagnose, or assess liver fibrosis in the individual. | 05-12-2011 |
20110111431 | METHOD FOR IDENTIFYING PRE-NEOPLASTIC AND/OR NEOPLASTIC STATES IN MAMMALS - The present invention relates to methods of identifying pre-neoplastic and/or neoplastic states in mammals and in particular to a method for identifying pre-neoplastic and neoplastic cells in tissues and body fluids, based on differential expression of purinergic receptors in these cells. | 05-12-2011 |
20110111432 | DIAGNOSTIC METHOD FOR PEANUT ALLERGY - The present invention provides novel methods and tools to differentiate between true allergy and false positive allergy tests. In particular, parameters that can be statistically associated with true peanut allergy have been identified. These include wheal size in response to a skin prick test and total IgE. Further parameters may be measured for greater certainty. | 05-12-2011 |
20110111433 | PIEZOELECTRICAL CHARACTERIZATION OF MATERIALS - One aspect of the disclosure is a method of characterizing a surface. In an exemplary embodiment, the method includes: (a) positioning a piezoelectric sensor near the surface; (b) obtaining by the sensor a resonant acoustic profile (RAP) of the surface; and (c) analyzing the obtained RAP to characterize the surface. The piezoelectric sensor has an interacting layer, which is adapted for binding to the surface to be characterized. In one embodiment, the characterized surface and the interacting layer are of about the same size. | 05-12-2011 |
20110111434 | COLON STEM CELLS ASSOCIATED WITH COLITISAND COLORECTAL CANCER AND METHODS OF USE - The disclosure provides methods of isolating and propagating self-renewing colonic stem/progenitor cells (CS/PCs) that express aldehyde dehydrogenase (ALDH1), from colon cancer and colitis tissues, as well as from normal colon tissue, methods of identifying agents for modulating the proliferative status of such cells, an methods of screening patients having colitis for an increased risk of colorectal cancer. Novel methods of adherent cell culture propagation of CS/PC involving use of colon-specific fibroblastic stromal cells (CFSt) {i.e. the “niche” cells) as support cells (e.g., “feeder cells”). The present disclosure encompasses an isolated mammalian pluripotent colon epithelial stem/progenitor cell (CS/PC), or a population of said cells, where each CS/PC may comprise a detectable marker, where the detectable marker is aldehyde dehydrogenase 1 (ALDH1), and where the isolated population of mammalian pluripotent CS/PCs is substantially free of cells that do not have the detectable ALDH 1 marker. The disclosure encompasses further provides methods for determining the prognosis for a patient for developing a colon cancer, the method detecting the presence of at least one marker in a tissue section from a patient, the marker or plurality of markers indicating the presence of a pluripotent colon epithelial stem/progenitor cells and indicating the prognosis of the patient for developing a colon cancer. | 05-12-2011 |
20110117573 | CELL DIVISION MARKER - This application relates to a newly identified animal cell structure, the midbody scar. This structure is a remnant of the midbody that is retained by one daughter cell following cytokinesis and persists through multiple subsequent cell cycles. The midbody scar can be useful as a marker of dividing cells or of a cell's replicative age. | 05-19-2011 |
20110117574 | FLUORESCENCE BASED ASSAY TO DETECT SODIUM/CALCIUM EXCHANGER "FORWARD MODE" MODULATING COMPOUNDS - Transporters are an emerging target family with enormous potential, offering scientific and economic opportunities. The sodium/calcium exchanger is an important mechanism for removing Ca | 05-19-2011 |
20110117575 | ISOLATION AND/OR IDENTIFICATION OF STEM CELLS HAVING ADIPOCYTIC, CHONDROCYTIC AND PANCREATIC DIFFERENTIATION POTENTIAL - The present invention relates to a method for isolating and/or identifying stem cells having adipocytic, chondrocytic and pancreatic differentiation potential, wherein an antibody is used that binds to the antigen TNAP, alone or in combination with an antibody that binds to the cell surface antigen CD56. The invention also relates to stem cells isolated by the method according to the invention for treating defects or damages or diseases in bone or cartilage of a patient in need thereof. | 05-19-2011 |
20110129854 | ASSAY FOR DIAGNOSIS OF CARDIAC MYOCYTE DAMAGE - Assays are disclosed for diagnosing a clinical condition, assessing risk or predicting an outcome as a result of cardiac myocyte damage. Immunoassay methods and kits provide for the assessment of cardiac myocyte damage by determining the presence of multiple cardiac myocyte antigens in a test sample, and combining the multiple determinations in a single assay result. | 06-02-2011 |
20110129855 | Recombinant Anti-Epidermal Growth Factor Receptor Antibody Compositions - The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies shown synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody. | 06-02-2011 |
20110129856 | APPARATUS AND METHOD FOR SEPARATING COMPONENTS - An apparatus for separating components and a method of separating components using the apparatus are provided. The apparatus includes: a main chamber which contains a sample that is separated into a plurality of layers by a centrifugal force; a component separating chamber which is connected to the main chamber, and receives a specific layer including specific components among the plurality of layers; a first channel which connects the component separating chamber to the main chamber; and a first channel valve which is disposed in the first channel to control a liquid flowing through the first channel. | 06-02-2011 |
20110136144 | FIBROBLAST GROWTH PATTERNS FOR DIAGNOSIS OF ALZHEIMER'S DISEASE - Methods of diagnosing Alzheimer's disease are provided. At least five methods of diagnostic measurements are presented: Method 1: Integrated score; Method 2: Average aggregate area per number of aggregates; Method 3: Cell migration analysis; Method 4; Fractal analysis; Method 5: Lacunarity Analysis. In certain embodiments, a sample of a subject's skin provides a network of fibroblasts that is imaged and a fractal dimension of the image is calculated. The fractal dimension can be compared to an aged-matched control (non-Alzheimer's) database to determine if the subject has Alzheimer's disease. The network of fibroblasts may be cultured in a matrix, for example in a protein mixture. | 06-09-2011 |
20110136145 | METHODS FOR PROMOTING FUSION AND REPROGRAMMING OF SOMATIC CELLS - The invention features methods for reprogramming somatic cells by treating the cells with one or more agents to induce de-differentiation, in particular by targeting demethylase and methyltransferase genes. The invention also features methods of monitoring somatic cell fusion and reprogramming and methods of identifying agents that alter somatic cell fusion and reprogramming. The invention also features reprogrammed cells and kits. | 06-09-2011 |
20110136146 | BIOASSAY FOR POLYQ PROTEIN - The present invention relates to bioassays for mutated polyQ protein associated with disease and their use as diagnostic tools, for monitoring disease progression or for monitoring the efficacy of treatment of the disease. In a preferred embodiment the polyQ-protein is polyQ-huntingtin. | 06-09-2011 |
20110143372 | ANTIBODIES AGAINST HUMAN EPO RECEPTOR - An antibody binding to human EPO receptor, characterized in specifically binding EPO receptor fragment LDKWLLPRNPPSEDLPGPGGSVDIV (SEQ ID NO:1), CSSALASKPSPEGASAASFEY (SEQ ID NO:2), or GGLSDGPYSNPYENSLIPAAEP (SEQ ID NO:3) is useful for the analysis of EPO receptor in human tissue. | 06-16-2011 |
20110143373 | METHOD OF EVALUATING THE INTEGRITY OF THE PLASMA MEMBRANE OF CELLS BY DETECTING GLYCANS FOUND ONLY INTRACELLULARLY - The invention describes novel reagents that can be applied for analysis of the quality of human cells. The method evaluates the integrity of the plasma membrane of the cells by detecting novel glyco structures found only intracellularly. The method can be applied, for example, to demonstrate exposure of therapeutic cell preparation to potentially harmful conditions. It can also be used as a quality control tool in methods in which intact cell membrane is essential and it can be applied in separation of damaged cells from non- damaged. | 06-16-2011 |
20110143374 | Methods to Identify Modulators of the Interaction Between Dextromethorphan and the Bitter Taste Receptor TAS2R46 - TAS2R46 was identified as a dextromethorphan-binding bitter taste receptor. Novel methods to identify modulators and in particular inhibitors to the bitter taste of dextromethorphan are provided. | 06-16-2011 |
20110143375 | BIOMARKER DETECTION PROCESS AND ASSAY OF NEUROLOGICAL CONDITION - The subject invention provides a robust, quantitative, and reproducible process and assay for diagnosis of a neurological condition in a subject. The invention provides measurement of two or more biomarkers in a biological fluid such as CSF or serum resulting in a synergistic mechanism for determining the extent of neurological damage in a subject with an abnormal neurological condition and for discerning subtypes thereof or tissue types subjected to damage. | 06-16-2011 |
20110143376 | Methods to Identify Modulators - TAS2R7 was identified as a menthol-binding bitter taste receptor. Novel methods to identify modulators and in particular inhibitors to the bitter taste of menthol are provided. | 06-16-2011 |
20110151483 | Mammalian Sweet and Amino Acid Heterodimeric Taste Receptors Comprising T1R3 and T1R1 - The present invention provides isolated nucleic acid and amino acid sequences of sweet or amino acid taste receptors comprising T1R3 and T1R1, two heterologous G-protein coupled receptor polypeptides from the T1R family of sensory G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet and amino acid taste receptors. | 06-23-2011 |
20110151484 | hERG MUTANTS AND USES THEREOF - An isolated nucleic acid molecule capable of expressing an human ether-à-go-go related gene (hERG) mutant that enhances hERG inactivation, wherein the mutation is not located in the vicinity of the drug-binding pocket within the cavity of the ion conduction pore of the hERG protein. Use of the isolated nucleic acid molecule in an assay for screening potential drug binding to hERG protein. | 06-23-2011 |
20110151485 | METHOD FOR SCREENING FOR ANTIANGIOGENIC AGENT, AND METHOD FOR SCREENING FOR ANTIANGIOGENIC SIGNAL GENE - Disclosed are a method for screening for an antiangiogenic agent and a method for screening for an antiangiogenic gene, both of which are achieved by detecting an antiangiogenic signal within a short time by a simple means. The method for screening for an antiangiogenic agent comprises: a candidate compound administration step of administering a candidate compound for the antiangiogenic agent to a vascular endothelial cell or a cultured cell derived from a vascular endothelial cell; a cell-maintaining step of maintaining the vascular endothelial cell or the cultured cell derived from the vascular endothelial cell to which the candidate compound has been administered; and a signal detection step of detecting the phosphorylation of a protein phosphorylated by the administration of endostatin. | 06-23-2011 |
20110159522 | Three-Dimensional Microfluidic Platforms and Methods of Use Thereof - Provided are methods and devices for formation and study of three-dimensional biological systems, including prokaryotic and eukaryotic cell migration, proliferation, and differentiation. | 06-30-2011 |
20110165595 | APPARATUS AND METHODS FOR PROCESSING A WHOLE BLOOD SAMPLE - The present invention provides a device and method for heating a whole blood sample for use in an assay, comprising irradiating said whole blood sample with monochromatic visible light of between 380 nm and 740 nm to raise the temperature of said whole blood sample to a target temperature between about 35° C. and 40 ° C. An apparatus for heating whole blood samples stored in a cartridge is further described comprising a housing assembly disposed to receive the cartridge one or more visible light optical emitters disposed in the housing apparatus and configured to selectively illuminate a staging area of the cartridge a temperature sensor disposed in the housing apparatus and configured to sense a temperature of the cartridge and a control circuit coupled to the temperature sensor and the array of visible light optical emitters so as to control a heating profile of the whole blood sample. | 07-07-2011 |
20110171663 | MICROTRENCH AND TUMOUR PROLIFERATION ASSAY - There is provided a cell culture microtrench being defined on or in a surface of a substrate, wherein the ratio of the width of the microtrench to the maximum length of the short axis of a cell type of interest is about 6 or preferably less, the length of the short axis of the cell type being measured when a cell is in detached or suspended form. There is also provided an array comprising such a microtrench and uses of such microtrenches, including cell-based assays. | 07-14-2011 |
20110177528 | METHODS FOR DETECTING AND INHIBITING ANGIOGENESIS - The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds α5β1 integrin, and detecting specific binding of the agent to α5β1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual. The invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of α5β1 integrin to a ligand expressed in the tissue; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of α5β1 integrin to a ligand in a tissue associated with the pathological condition. The invention also provides methods of identifying an agent that reduces or inhibits angiogenesis associated with α5β1 integrin expression in a tissue by contacting a tissue exhibiting angiogenesis associated with α5β1 integrin expression with an agent, and detecting a reduction or inhibition of angiogenesis in the tissue. | 07-21-2011 |
20110183359 | METHODS FOR DETECTING MODULATORS OF CYTOKINE RECEPTOR ZALPHA11 - Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zalpha11, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zalpha11, are located on chromosome 16, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 07-28-2011 |
20110189702 | PHOTOLUMINESCENT MATERIALS FOR MULTIPHOTON IMAGING - Disclosed are nano-sized materials that can exhibit luminescence in a multi-photon imaging technique. The materials include a nano-sized particle or a carbon nanotube and a passivation agent bound to the surface of the nanoparticle or nanotube. The passivation agent can be, for instance, a polymeric material. The passivation agent can also be derivatized for particular applications. For example, the luminescent materials can be derivatized to recognize and bind to a target material, for instance a biologically active material, a pollutant, or a surface receptor on a tissue or cell surface, such as in a tagging or staining protocol. The materials exhibit strong luminescence with multi-photon excitation in the near infrared. | 08-04-2011 |
20110189703 | High Throughput Cell-Based Assays, Methods of Use and Kits - In the present invention cells are placed in a multiwell plate and grown. When the assay is to be performed, one uses gravity to wash away any unbound ligands rather than vacuum or centrifugation. The cells are then examined to detect the bound ligand. To perform the washing step(s) the plate is placed into a carrier plate having open wells in register with the wells of the filter plate or one may use a wicking device or an underdrain attached to the bottom of the filter plate. Sufficient wash liquid is added to allow for filtration by the effect of gravity to occur. Cells are retained within the wells at a rate of 4 times that of other rapid methods. | 08-04-2011 |
20110195434 | METHOD FOR THE ANALYSIS OF SOLID OBJECTS - A method of analysis or diagnosis of solid objects is based on real-time detection of how predefined probes interact with structures present on or in the solid object combined with the calculation of how the recorded binding curves of said probes are distributed in terms of interaction properties. The interaction properties are input to a classification algorithm which automatically determines statues of the solid object. The method is particularly advantageous for solid biological objects like tissue slices combined with antibody probes, said antibody recognizing receptors known to be over-expressed in disease states on said tissue slice. | 08-11-2011 |
20110201027 | BIOSENSOR FOR DETECTING A TRACE AMOUNT OF SAMPLE AND PRODUCTION METHOD THEREFOR - The present invention relates to a biosensor capable of a trace amount of sample and a fabrication method thereof. More specifically, the invention relates to a method for fabricating a biosensor, the method comprising: immobilizing a receptor molecule, which binds selectively to a target substance, on an electrically insulated nano-electrode chip; binding an enzyme to the receptor molecule; and treating the bound enzyme with metal ions and depositing the metal ions on the nano-electrode surface, and to a biosensor fabricated thereby. According to the invention, a precipitate is produced on the nano-electrode surface by a precipitation between the enzyme and the metal ions, and the produced precipitate electrically connects the nano-electrodes together, thereby increasing electrical conductivity. Thus, the invention is useful for quantitative analysis of trace amounts and/or various concentrations of target substances. | 08-18-2011 |
20110201028 | T1R HETERO-OLIGOMERIC TASTE RECEPTORS AND CELL LINES THAT EXPRESS SAID RECEPTORS AND USE THEREOF FOR IDENTIFICATION OF TASTE COMPOUNDS - The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners. | 08-18-2011 |
20110201029 | IL-13 RECEPTOR ANTIBODIES - This invention relates to monoclonal and polyclonal antibodies capable of specifically recognizing IL-13 receptor α and uses thereof. | 08-18-2011 |
20110201030 | Human G-Protein Chemokine Receptor (CCR5) HDGNR10 - Human G-protein chemokine receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host. | 08-18-2011 |
20110207147 | Compositions and Methods for Modification of Biomolecules - Provided are modified cycloalkyne compounds; and methods of use of such compounds in modifying biomolecules. Embodiments include a cycloaddition reaction that can be carried out under physiological conditions. The cycloaddition reaction involves reacting a modified cycloalkyne with an azide moiety on a target biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provide for its application in vivo and in vitro. | 08-25-2011 |
20110207148 | T1R HETERO-OLIGOMERIC TASTE RECEPTORS AND CELL LINES THAT EXPRESS SAID RECEPTORS AND USE THEREOF FOR IDENTIFICATION OF TASTE COMPOUNDS - The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners. | 08-25-2011 |
20110207149 | METHODS AND COMPOSITIONS FOR RISK STRATIFICATION - The present invention provides an approach for the simultaneous determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of potentiators of cellular activation allows for characterization of such pathways and cell populations. | 08-25-2011 |
20110212468 | BIOMARKERS AND METHODS FOR DETERMINING DISEASE PROGRESSION IN NONALCOHOLIC STEATOHEPATITIS (NASH) - Diets high in saturated fat and fructose have been implicated in the development of obesity and nonalcoholic steatohepatitis (NASH) in humans. Provided herein are biomarkers, methods, and animal models useful for the investigation and non-invasive detection of NASH, including a non-invasive biomarker that could be used to establish disease severity, follow progression, and evaluate response to treatment in clinical trials for this increasingly prevalent disease. | 09-01-2011 |
20110212469 | Simultaneous Assay of Target and Target-Drug Binding - Whole cell, simultaneous target and drug-target assay using differentially labeled antibodies and flow cytometry. First antibody binds to total target and second antibody binds to the drug binding site of the target, thus drug binding will competitively inhibit the second antibody allowing for a competitive inhibition assay of drug-target binding. The assay allows for whole cell analysis and even analysis of mixed populations of cells, yet provides detailed kinetic assessment of drug activity. | 09-01-2011 |
20110223618 | ASSAYS USING CHIMERIC T1R POLYPEPTIDE - This invention relates to chimeric taste receptors comprising the extracellular portion of one T1R or a variant or fragment thereof, either T1R1 or T1R2, and the transmembrane portion of another T1R or a variant or fragment thereof, either T1R1 or T1R2, preferably associated with a T1R3 polypeptide and a suitable G protein. These chimeric taste receptors and cells which express such chimeric taste receptors are useful in assays for identifying sweet and umami ligands as well in assays for identifying sweet and umami enhancers. Additionally, these chimeric taste receptors and cells which express same can be used to map and determine where specific sweet and umami ligands interact with their respective receptors and to elucidate the mechanism of receptor activation. | 09-15-2011 |
20110236909 | LASER SCANNING CYTOMETRY MEDIATED ANALYSIS OF THERAPEUTIC EFFICACY IN TUMORS - This invention describes the use of a laser scanning device, for example a laser scanning CYTOMETRY (LSC), with a double-fluorescent labeling technique as a quantitative method that can be used to objectively and accurately measure endothelial cell death, endothelial tumor cell death and blood vessel density of tumor tissue. These parameters can be used as markers of efficacy in tumors treated with anti-angiogenic or traditional therapies and can distinguish patients who respond to these drugs from those who do not. | 09-29-2011 |
20110244484 | METHOD OF DIAGNOSING ALZHEIMER'S DISEASE USING GIANT MAGNETORESISTANCE SENSOR AND MAGNETIC BEAD-POLYPROTEIN COMPLEX FOR DIAGNOSING ALZHEIMER'S DISEASE - Provided are a method of diagnosing Alzheimer's disease using a giant magnetoresistance sensor and a magnetic bead-polyprotein complex for diagnosing Alzheimer's disease. The method of diagnosing Alzheimer's disease using the giant magnetoresistance sensor may be applied to diagnose Alzheimer's disease more easily and simply using the giant magnetoresistance sensor than using conventional fluorescent materials or genetic analyses, and the magnetic bead-polyprotein complex may be mass-produced as a diagnostic biosensor for Alzheimer's disease, and thus to be useful to monitor and treat Alzheimer's disease. | 10-06-2011 |
20110244485 | ANTI-TUNA VASA ANTIBODY - An object of the present invention is to provide a means for distinguishing between a germ cell derived from a donor (tuna) and a germ cell derived from a recipient in a method for inducing differentiation of a tuna germ cell, wherein a primordial germ cell derived from the tuna is transplanted into an early embryo of the heterologous recipient fish. The present inventors compared a Vasa amino acid sequence of bluefin tuna with those of other fish (black skipjack, skipjack, chub mackerel, blue mackerel, round frigate mackerel and frigate mackerel), identified amino acid sequence regions specific to bluefin tuna, and, by using the amino acid sequences specific to bluefin tuna as antigens, successfully produced monoclonal antibodies specifically recognizing primordial germ cells, spermatogonia, oogonia or oocytes derived from bluefin tuna, thus accomplishing the present invention. | 10-06-2011 |
20110244486 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF DIABETES - Methods, assays and compositions for the diagnosis and treatment of diabetes, in which the glutamate transporters and/or receptors expressed in pancreatic islet cells are used as therapeutic targets or tools for the identification or treatment of individuals suffering from or susceptible to diabetes. | 10-06-2011 |
20110244487 | METHODS FOR TESTING BINDING OF A LIGAND TO A G PROTEIN-COUPLED RECEPTOR - The present invention relates to methods for testing for the binding of a ligand to a G Protein-Coupled Receptor. In particular, the methods of the invention are useful in high throughput screening for ligands which bind to G Protein-Coupled Receptors. | 10-06-2011 |
20110250618 | BIOMARKERS AND ASSAYS FOR DIABETES - The present invention is directed to novel biomarkers and combinations thereof. The present invention also provides assays and data evaluation methods related to the detection and monitoring of diseases, particularly, diabetes. In particular, the biomakers in accordance with the present invention include, but are not limited to, modified forms of nominally wild-type proteins, such as Gc-Globulin or GcG (also known as Vitamin D binding protein), beta-2-microglobulin (b2m), cystatin C (cysC), Albumin and Hem A&B. Particular forms of diabetes contemplated by the methods of the present invention include, but are not limited to, type 1 diabetes (T1D), type 2 diabetes (T2DM), pre-T1D and pre-T2DM. The present invention also provides methods of detecting multiple biomarkers in a single assay and to employ data evaluation methods that is able to accurately use these data in the determination and monitoring of diseases, such as diabetes. | 10-13-2011 |
20110256555 | USE OF CXCR4 PROTEIN EXPRESSION ON THE SURFACE OF STEM CELLS AS A MARKER FOR TUMOR TROPIC POTENTIAL - The present invention relates to tumor tropic stem cells, and particularly to neural stem cells, and their use as delivery vehicles for therapeutic gene products to neoplastic foci. The stem cells with tumor tropic potential are selected based on the stem cells exhibiting CXCR4 receptors or an affinity for the chemokine SDF-1. The stem cells may additionally exhibit markers characteristic of astrocytic progenitors. The stem cells may be administered as part of a treatment regimen including the chemokine SDF-1. | 10-20-2011 |
20110262937 | T1R HETERO-OLIGOMERIC TASTE RECEPTORS AND CELL LINES THAT EXPRESS SAID RECEPTORS AND USE THEREOF FOR IDENTIFICATION OF TASTE COMPOUNDS - The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners. | 10-27-2011 |
20110269152 | Anchoring/capturing system for selecting or analyzing a CHO cell according to a product secreted by the CHO cell - An anchoring/capturing system for selecting or analyzing a CHO cell according to a product secreted by the CHO cell is described. The anchoring/capturing system comprises a first antibody or a first antigen-binding fragment for anchoring to the extracellular surface of the CHO cell, and a second antibody or a second antigen-binding fragment for binding the secreted product. Uses and methods involving the anchoring/capturing system are provided. | 11-03-2011 |
20110269153 | Immunoassay Device with Improved Sample Closure - An apparatus and method for sealing a fluid sample collection device, comprising: loading a fluid sample collection device with a fluid sample, said device comprising a housing having at least one substantially planar surface that includes an orifice in fluid communication with an internal fluid sample holding chamber which terminates at an internal capillary stop; and slidably moving a sealing element over at least a portion of said substantially planar surface in a way that displaces any excess fluid sample away from the orifice, seals the fluid sample within said holding chamber, and inhibits the fluid sample from prematurely breaking through the internal capillary stop. | 11-03-2011 |
20110275096 | Detection of Activation of Endothelial Cells as Surrogate Marker for Angiogenesis - Methods, compositions and kits are provided for assessing angiogenesis through sensitive, direct detection of activation of endothelial cells at molecular levels. In general, activation of endothelial cells is detected by measuring the levels of cellular components and their protein complexes participating in a specific angiogenesis signaling pathway in endothelial cells. The methods can be used for assessing status of diseases associated with undesirable angiogenesis, such as the likelihood of developing the disease, presence or absence of the disease, prognosis of the disease and the likelihood of response or resistance to a particular anti-angiogenic therapy. The methods can also be used to guide the design of effective therapeutic regimens targeting a specific angiogenic signaling pathway, as well as in conjunction with therapeutic intervention of diseases or conditions associated with undesirable angiogenesis. | 11-10-2011 |
20110281281 | INTEGRATION-FREE HUMAN INDUCED PLURIPOTENT STEM CELLS FROM BLOOD - Provided herein are methods for generating human induced pluripotent stem cells free from genomic integration of exogenous transgenes by transfecting into nucleated blood cells one or more DNA expression vectors (e.g., plasmid vectors) that do not contain a mammalian origin of replication, and encode and permit expression of one or more reprogramming factors (e.g., Oct4, Sox2, Klf4, and c-Myc). Also provided herein are the integration-free human induced pluripotent stem cells obtained by the methods described herein. | 11-17-2011 |
20110281282 | SUBPOPULATIONS OF SPORE-LIKE CELLS AND USES THEREOF - Subpopulations of spore-like cells expressing specific cell surface and gene expression markers are provided. In one embodiment, the cells express at least one cell surface or gene expression marker selected from the group consisting of Oct4, nanog, Zfp296, cripto, Gdf3, UtF1, Ecat1, Esg1, Sox2, Pax6, nestin, SCA-1, CD29, CD34, CD90, B1 integrin, cKit, SP-C, CC10, SF1, DAX1, and SCG10. Also provided are methods for purifying a subpopulation of spore-like cells of interest from a population of spore-like cells, and methods for inducing differentiation of the isolated spore-like cells into cells of endodermal, mesodermal or ectodermal origin. The spore-like cells can be used to generate cells originating from all three germ layers and can be used to treat a patient who has a deficiency of functional cells in any of a wide variety of tissues, including the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system. | 11-17-2011 |
20110300559 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER AND NEURODEGENERATIVE DISEASES RELATED TO BECLIN-1 - The present invention relates to antibodies specific for human Beclin-1 protein phosphorylated at position Thr 119 and uses thereof. In particular, these antibodies are useful in diagnosing diseases associated with impaired autophagy including cancer and neurodegenerative diseases. The invention further relates to human Beclin-1 mutated at position 119 with a phospho-mimicking residue and uses thereof for treating cancer and neurodegenerative diseases. | 12-08-2011 |
20110300560 | NOVEL MEMBERS OF THE CAPSAICIN/VANILLOID RECEPTOR FAMILY OF PROTEINS AND USES THEREOF - The invention provides isolated nucleic acids molecules, designated hVR-1, hVR-2, and rVR-2 nucleic acid molecules, which encode novel members of the Capsaicin/Vanilloid receptor family. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing hVR-1, hVR-2, and rVR-2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an hVR-1, hVR-2, and rVR-2 gene has been introduced or disrupted. The invention still further provides isolated hVR-1, hVR-2, and rVR-2 proteins, fusion proteins, antigenic peptides and anti-hVR-1, anti-hVR-2, and anti-rVR-2 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. | 12-08-2011 |
20110306063 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Clusterin, Heart-type fatty acid binding protein, Hepatocyte growth factor, Interferon gamma, Interleukin-12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries. | 12-15-2011 |
20110306064 | Quantifiable Internal Reference Standards For Immunohistochemistry And Uses Thereof - Methods for identifying Quantifiable Internal Reference Standards (QIRS) for immunohistochemistry (IHC). Also disclosed are methods for using QIRS to quantify test antigens in IHC. | 12-15-2011 |
20110311991 | Methods of Identifying Modulators of the Bitter Taste Receptor TAS2R44 - Steviol glycosides have been discovered to bind the bitter taste receptor TAS2R44. Novel methods of identifying modulators and in particular inhibitors to the bitter taste of steviol glycosides and an inhibitor of steviol glycosides are provided. | 12-22-2011 |
20110318756 | SMALL SPECIMEN STAINING AND DIAGNOSING OF CELLS - An immunohistochemical staining of small specimen comprises using a plurality of antibodies and/or antigens to mark certain cells with particular colors of stains in order to distinguish target cells, such as carcinoma cells, in a stained small specimen. For example, antibodies CD44, cytokeratin 20 and p53 may be used for selectively staining a specimen of a urothelial mucosal biopsy on a single slide. Mouse monoclonal antibody CD44 is associated only with reactive urothelial cells, while rabbit monoclonal antibody p53 is associated only with carcinoma cells. Mouse monoclonal antibody cytokeratin 20 is associated with both “umbrella cells” and carcinoma cells, but antibody p53 is not associated with umbrella cells, which are the most superficial urothelial cells and are characterized morphologically from the other cells in a prepared specimen. Thus, diagnosis is facilitated by the staining of carcinoma cells in a contrasting color to normal urothelial cells and superficial urothelial cells. | 12-29-2011 |
20120003670 | Methods and Kits for Measuring Von Willebrand Factor - Methods and kits for measuring levels of von Willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein Ibα having at least two of a G233V, D235Y and M239V mutations and an agent to detect a complex between the recombinant glycoprotein Ibα and von Willebrand factor. | 01-05-2012 |
20120009596 | PROTEIN MARKERS FOR DETECTING LIVER CANCER AND METHOD FOR IDENTIFYING THE MARKERS THEREOF - The present invention relates to the diagnosis of liver cancer. It discloses the use of protein ERBB3 and protein IGFBP2 in the diagnosis of liver cancer. It relates to a method for diagnosis of liver cancer from a liquid sample, derived from an individual by measuring ERBB3 protein and IGFBP2 protein in the sample. Measurement of ERBB3 protein and IGFBP2 protein can, e.g., be used in the early detection or diagnosis of liver cancer. | 01-12-2012 |
20120009597 | Biomarker for Barrett's Oesophagus - The present invention relates to the use of TFF3 in the diagnosis and detection of Barrett's Oesophagus using non-invasive, non-endoscopic methods. | 01-12-2012 |
20120009598 | T2R, A NOVEL FAMILY OF TASTE RECEPTORS - The invention provides nucleic acid and amino acid sequences for a novel family of taste transduction G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste transduction G-protein coupled receptors. | 01-12-2012 |
20120009599 | METHOD FOR DETECTING MEMBRANE PROTEIN INTERNALIZATION - A method for detecting the internalization of a transmembrane protein of interest expressed at the surface of a cell, comprising the following steps:
| 01-12-2012 |
20120009600 | METHOD OF DIAGNOSING ADOLESCENT IDIOPATHIC SCOLIOSIS - A method for diagnosing an increased risk for developing adolescent idiopathic scoliosis (AIS) in a human subject, comprising detecting the presence or absence of at least one impairment in melatonin-signaling pathway in a cell sample of the subject in the presence and in the absence of a known melatonin-signaling pathway agonist, wherein the cell sample is selected from the group consisting of blood cell sample, osteoblast cell sample, osteoclast cell sample and myoblast cell sample, and wherein the presence of the at least one impairment in the melatonin-signaling pathway indicates that the subject possesses an increased risk for developing AIS. | 01-12-2012 |
20120009601 | METHODS AND COMPOSITIONS FOR REPROGRAMMING CELLS - The present invention is directed, in part, to methods and compositions comprising inhibitors of micro RNA-145 and activators of the TGF-β signaling pathway to permit reprogramming using only small molecule compounds. Also described herein are methods to distinguish cancer cells or cells having cancerous potential in human iPS cell populations, based on determining the balance of p21-p53 expression levels, or ratio thereof in reprogrammed cells. In further aspects, methods and compositions to cause redifferentiation of a hepatoma cell to a hepatocye-like cell using acyclic retinoid and inhibitors of AKR1B10 are provided. | 01-12-2012 |
20120015377 | METHOD AND APPARATUS FOR MEASURING BIOGENOUS BIOLOGICALLY ACTIVE SUBSTANCE - Provided is an assay method and an assay device whereby assay time can be largely shortened in the case of detecting a physiologically active substance of biological origin. The aggregation start time of a liquid mixture of an assay sample with LAL is determined. From this aggregation start time, the physiologically active substance is detected or the concentration thereof is measured. The liquid mixture of the assay sample with LAL is stirred with, for example, a magnetic stirrer to form gel particles. Next, the scattered light intensity of laser light scattered by these gel particles is measured. Then, the frequency distribution of the scattered light intensity fluctuation is obtained. Based on the temporal change in the frequency distribution shape, the aggregation start time of the liquid mixture of the assay sample with LAL is determined. | 01-19-2012 |
20120015378 | IDENTIFICATION OF BITTER LIGANDS THAT SPECIFICALLY ACTIVATE HUMAN T2R RECEPTORS AND RELATED ASSAYS FOR IDENTIFYING HUMAN BITTER TASTE MODULATORS - The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds. The invention further relates to the use of these receptors in assays for identifying ligands that modulate the activation of these taste receptors by these bitter ligands and related compounds and which may be used as additives and/or removed from foods, beverages, cosmetics and medicinals in order to modify (block) T2R-associated bitter taste. | 01-19-2012 |
20120021440 | METHODS FOR TESTING LIGAND BINDING TO G PROTEIN-COUPLED RECEPTORS - The present invention relates to methods for testing for the binding of a ligand to a G Protein-Coupled Receptor. In particular, the methods of the invention are useful in high throughput screening for ligands which bind to G Protein-Coupled Receptors. | 01-26-2012 |
20120028275 | BIOMIMETIC MEMBRANE FOR CELL EXPANSION - The invention relates to a membrane which can be used for cultivating adherent or suspension cells, in particular adherent cells, wherein said membrane allows for the adhesion and proliferation of the cells due to modification of the membrane surface with a combination of at least one extracellular matrix protein, at least one extracellular matrix (proteo-) glycan, and at least one heparin-binding growth factor. The invention further relates to a method for preparing said modified or coated membrane which can be used for the cultivation of cells, in particular adherent cells, and to methods of using such membrane for the cultivation of cells, in particular adherent cells. | 02-02-2012 |
20120034625 | Monoclonal Antibody Capable of Binding Integrin Alpha 10 Beta 1 - The present invention provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 and a hybridoma cell line deposited at the Deutsche Sammlung von Microorganismen and Zellkulturen GmbH under the accession number DSM ACC2583. Furthermore, the present invention also provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 produced by the hybridoma cell line deposited. Methods and uses of said antibody or a fragment thereof in identifying and selecting cells of a chondrogenic nature for treatment purposes, in particular for the identification and isolation of chondrocytes, mesenchymal progenitor cells and embryonic stem cells for tissue engineering of cartilage, or for identifying diagnostic and therapeutic tools in studying the biological role and the structural/functional relationships of the integrin alpha10beta1 with its various extracellular matrix ligands are also included. | 02-09-2012 |
20120040373 | Integrated Diagnosis of Heparin-Induced Thrombocytopenia - Disclosed are methods for the early detection of heparin-induced thrombocytopenia comprising the quantitative detection of chemokine platelet factor-heparin complexes, autoantibodies to such complexes, and platelet activation. Also disclosed are assays to detect the propensity of a subject to develop heparin-induced thrombocytopenia. | 02-16-2012 |
20120040374 | METHOD FOR DETECTING RENAL DISEASE COMPRISING MEASURING HUMAN MEGALIN IN URINE - This invention provides a diagnostic kit and a diagnostic marker used for diagnosing a renal disease. This invention also provides a method for detecting a renal disease comprising measuring at least one type of human megalin existing in urine selected from among full-length human megalin and human megalin fragments of (i) to (iii): (i) full-length human megalin; (ii) a human megalin endodomain fragment lacking a human megalin ectodomain; and (iii) a human megalin ectodomain fragment lacking a human megalin endodomain. | 02-16-2012 |
20120045777 | NOVEL GENES ENCODING PROTEINS HAVING PROGNOSTIC, DIAGNOSTIC, PREVENTIVE, THERAPEUTIC, AND OTHER USES - The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. | 02-23-2012 |
20120058491 | METHOD FOR INDUCTION OF DIFFERENTIATION OF ES CELL - It is an object of the present invention to establish a system for reliably differentiating an ES cell into a hepatic cell. The present invention provides a method for inducing the differentiation of an ES cell into a hepatic cell, which comprises, in the presence of an M15 cell, culturing a mammal-derived ES cell in the presence of activin and bFGF, and then culturing the ES cell in the presence of dexamethasone, HGF, and oncostatin M. | 03-08-2012 |
20120064545 | MOUSE MODEL FOR POMPE DISEASE AND METHODS OF USE THEREOF - The present invention provides mouse models for Pompe disease and methods of using the same to test agents that may be effective in the treatment of Pompe disease. | 03-15-2012 |
20120070846 | METHODS FOR DETECTING MOLECULE-MOLECULE INTERACTIONS WITH A SINGLE DETECTION CHANNEL - A single molecule or molecule complex detection method is disclosed in certain aspects, comprising nano- or micro-fluidic channels. | 03-22-2012 |
20120070847 | Method For Detecting And Purifying Pancreatic Beta Cells - The invention is based, in part, on the discovery that a polypeptide, referred to herein as Betacam, is selectively expressed on the surface of pancreatic islet cells, Thus, in one aspect, the invention is directed to compositions comprising Betacam or that can be used to detect Betacam. In another aspect, the invention provides methods of detecting (e.g., non-invasively) pancreatic beta cells from a mammalian cell source. Another aspect of the invention is directed to cellular purification of pancreatic beta cells from a heterogeneous cell source of multiple kinds. In another aspect, the invention provides methods of identifying agents that modulate activity of Betacam-In yet another aspect, the invention provides for improved treatment and diagnosis of diabetes. | 03-22-2012 |
20120077211 | STABLE COMPOSITIONS COMPRISING CHROMOGENIC COMPOUNDS AND METHODS OF USE - Compositions, assays, methods, and kits are disclosed for use in applications that utilize oxidation of a chromogenic electron donor such as diaminobenzidine (DAB) to generate a signal. Applications include, but are not limited to, immunohistochemistry, chromogenic in situ hybridization, Western blots, Northern blots, Southern blots, ELISA assays, and microarray detection. The compositions, assays, methods, and kits disclosed herein make use of a novel, stabilized formulation of DAB and a novel, stabilized formulation of hydrogen peroxide. | 03-29-2012 |
20120083000 | Neuropeptide Release Assay For Sodium Channels - Methods and compositions for using genetically modified non-human animals are provided, wherein the genetic modification comprises a humanization of the one or more extracellular pore loops of a Na | 04-05-2012 |
20120083001 | METHOD FOR TRANSPORTING POTASSIUM IONS FROM FRONT SIDE TO BACK SIDE OF LIPID BILAYER MEMBRANE - An object of the present invention is to detect a specific chemical substance with high sensitivity and high precision. By using a specific lipid bilayer membrane, a chemical substance is detected with high sensitivity and high precision. Here, the specific lipid bilayer membrane comprises a chemical substance receptor, a chimeric G protein, and a potassium ion channel. The chimeric G protein comprises a chimeric G | 04-05-2012 |
20120083002 | Methods For Modulating The Development Of Dopamine Neuron By The Dopamine D2 Receptor And Compositions Thereof - The present invention relates to a composition for modulating the activation of Nurr1, the composition comprising an agonist or an antagonist of a dopamine D2 receptor, methods for modulating the activation of Nurr1 by the dopamine D2 receptor, a method and composition for treating Nurr1-related diseases using the dopamine D2 receptor, and methods for screening a modulator of a dopamine D2 receptor of a test compound. Accordingly, the activation of Nurr1 can be modulated by treating the dopaminergic neurons with the agonist or the antagonist of the dopamine D2 receptor, thereby enhancing or inhibiting generation of the dopaminergic neurons. | 04-05-2012 |
20120083003 | PARKIN SUBSTRATE AND ASSAY - The invention provides in vitro, ex vivo, and in vivo assays for Parkin activity, in which Parkin-mediated ubiquitination of a Sept4 protein is measured. The assays may be used to screen for agents that modulate Parkin protein ligase activity. | 04-05-2012 |
20120083004 | Diagnostic Method for Celiac Sprue - Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue. | 04-05-2012 |
20120088252 | Device and Method for the Detection of Particles - The present invention relates to devices and methods for the qualitative and/or quantitative detection of particles. In particular, the invention relates to devices for the detection of particles, comprising a reaction chamber formed within a chamber body between a first surface and a second surface, wherein the second surface is located opposite to the first surface, and one or more displacers, wherein the distance between the first surface and the second surface is variable via the one or more displacers at least in one or more parts of the surface area of the first surface and/or second surface. The invention also relates to corresponding methods for the detection of particles. | 04-12-2012 |
20120094310 | METHOD FOR DETERMINING BIOLOGICALLY ACTIVE HGF - The present invention relates to a for determining the presence, absence or amount of biologically active or inactive HGF in a sample, comprising the steps: bringing the sample in contact with a gel comprising a HGF binding component of the extracellular matrix or cell membrane, adding toluidine blue to the gel, correlating the colour of the gel and/or a liquid in contact with the gel with the presence, absence or amount of biologically active HGF in the sample. It also relates to a kit of parts comprising toluidine blue and a gel comprising at least one HGF-binding component of the extracellular matrix or cell membrane, such as a proteoaminoglycan or a glucosaminoglycan, and optionally buffers, vials and sampling instruments and to a gel comprising at least one HGF-binding component of the extracellular matrix or cell membrane, such as a proteoaminoglycan or a glucosaminoglycan, toluidine blue and HGF. | 04-19-2012 |
20120100559 | NOVEL HYDROPHILIC AND LIPOPHILIC RHODAMINES FOR LABELLING AND IMAGING - The invention relates to novel and improved photostable rhodamine dyes of the general structural formulae I or II and their uses as fluorescent markers, e.g. for immunostainings and spectroscopic and microscopic applications, in particular in conventional and stimulated emission depletion (STED) microscopy and fluorescence correlation spectroscopy. The partially deuterated analogues are useful as molecular mass distribution tags in mass spectroscopic applications. wherein R | 04-26-2012 |
20120122119 | METHODS OF IDENTIFYING COMPOUNDS THAT BIND TO A TOLL-LIKE RECEPTOR - The present invention is directed to nucleic acid molecules and polypeptides encoding a dsRNA receptor (dsRNA-R). The dsRNA-R contains a THD, interacts with the MyD88 adapter protein, and may bind to dsRNA. The present invention is also directed to antibodies against dsRNA-R and to methods of modulating an immune response and the methods of identifying compounds which bind to and/or modulate dsRNA-R. | 05-17-2012 |
20120129189 | Methods of Controlling Cell Proliferation - The present disclosure provides methods for increasing self-renewal/expansion of stem cells. The present disclosure provides methods of reducing uncontrolled cell proliferation. The present disclosure provides methods of identifying agents that modulate Notch1/-catenin binding, and methods of identifying agents that inhibit enzyme-mediated cleavage of Notch1 intracellular domain from Notch1 transmembrane domain. | 05-24-2012 |
20120135423 | Methods for GPCR signaling pathway determination using biosensor-cell assays - A system and method for GPCR signaling pathway analysis and elucidation using a biosensor, a live-cell, and a pathway active compound, as defined herein. | 05-31-2012 |
20120142027 | Compositions and Methods for Modulating the Immune Response and Identifying Immunomodulators - The present invention provides compositions and methods for the identification of immunomodulators. The invention further provides an isolated complex comprising an UNC93B polypeptide and an UNC93B-dependent TLR polypeptide and methods of use thereof. The invention further provides methods of modulating immune system activity and methods of treating diseases characterized by aberrant immune system activity. | 06-07-2012 |
20120142028 | BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITORS - The present invention provides diagnostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. These methods are based on the surprising discovery that the effectiveness of treatment with an EGFR kinase inhibitor is predicted by whether a patient's tumor cells express a high or a low level of the biomarkers vimentin and E-cadherin, such that patients whose tumors express a high level of at least one of the biomarkers vimentin and E-cadherin have a longer overall survival and progression free survival than patients whose tumors express a low level of both vimentin and E-cadherin. The present invention further provides a method for treating tumors or tumor metastases in a patient, comprising the steps of diagnosing a patient's likely responsiveness to an EGFR kinase inhibitor by assessing whether tumor cells express a high level of at least one of the biomarkers vimentin and E-cadherin, and administering to said patient a therapeutically effective amount of an EGFR kinase inhibitor (e.g. erlotinib), particularly when effectiveness of the inhibitor is predicted. | 06-07-2012 |
20120142029 | NUCLEIC ACIDS ENCODING A G-PROTEIN COUPLED RECEPTOR INVOLVED IN SENSORY TRANSDUCTION - The invention provides isolated nucleic acid and amino acid sequences of sensory cell specific G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sensory cell specific G-protein coupled receptors. | 06-07-2012 |
20120149035 | MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF - The present invention provides devices and systems for use at the point of care. The methods devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device are modular to allow for flexibility and robustness of use with the disclosed methods for a variety of medical applications. | 06-14-2012 |
20120149036 | BIOASSAY METHOD FOR ANTIBODY AGAINST THYROID-STIMULATING HORMONE RECEPTOR, MEASUREMENT KIT FOR THE ANTIBODY, AND NOVEL GENETICALLY MODIFIED CELL FOR USE IN THE BIOASSAY METHOD OR THE MEASUREMENT KIT - The present invention provides a method and a kit for assaying a TSH receptor antibody, which are easy to manipulate and are safe. Specifically, the present invention provides a composition comprising a genetically modified cell forced to co-express a TSH receptor, a cyclic nucleotide responsive calcium channel, and a luminescent protein aequorin. Use of the composition enables the assay of a TSH receptor antibody contained in a sample. | 06-14-2012 |
20120156695 | MICROORGANISM FOR EXPRESSING A HUMAN MEMBRANE PROTEIN - The invention relates to an isolated, genetically modified, living non-mammal organism, having increased HMG-CoA-reductase activity compared to the wild type, and having reduced C24-methyltransferase and/or delta22-desaturase activity compared to the wild type. The invention is characterized in that the organism has increased dehydrocholesterol-delta70-reductase activity compared to the wild type. The invention further relates to different uses of such an organism, to a test kit comprising such an organism, and to a membrane extract of such an organism. | 06-21-2012 |
20120156696 | container for forming a cell aggregate and a method for forming a cell aggregate - A container for forming a cell aggregate is provided in which a group represented by a general formula of: | 06-21-2012 |
20120156697 | Method for Identifying an Agent that Inhibits Candida albicans-Mediated Host Cell Differentiation - The present invention features a method for identifying an agent that inhibits | 06-21-2012 |
20120164664 | T1R TASTE RECEPTORS AND GENES ENCODING SAME - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular taste stimulus in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed. | 06-28-2012 |
20120171699 | ANTIBODIES FOR THE DETECTION OF INTEGRIN COMPLEXES IN FFPE MATERIAL - The invention relates to antibodies that are capable to bind the extracellular domain of integrin. Another object of the invention concerns the use of said antibodies for detecting integrins in archival formalin fixed paraffin embedded (FFPE) tissue. The invention also relates to methods for preparing monoclonal rabbit antibodies, wherein the immunogen is an insect expression culture-derived recombinant extracellular integrin domain, and another method for screening anti-integrin antibodies that discriminate between closest integrin homologues and that are especially suited for immunohistochemistry in FFPE material. | 07-05-2012 |
20120178103 | DETECTION OF DYSPLASTIC OR NEOPLASTIC CELLS USING ANTI-MCM6 ANTIBODIES - Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, oesophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and pre-cancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma. | 07-12-2012 |
20120183975 | Taste Receptors Of The T1R Family From Domestic Dog - The present invention relates to the discovery of several genes of the domestic dog ( | 07-19-2012 |
20120190048 | METHOD FOR DETERMINING THE BINDING OF A GIVEN COMPOUND TO A MEMBRANE RECEPTOR - The invention relates to a method for determining whether a test compound binds preferentially to a membrane receptor R1 or to a membrane receptor R2, these receptors being known to be expressed on the surface of the cells in monomeric, homodimeric or heterodimeric form. This method is applied using one or two FRET partner pairs. | 07-26-2012 |
20120196301 | USE OF BINDING PARTNERS FOR 5-HT5 RECEPTORS FOR THE TREATMENT OF NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS - The present invention relates to the use of binding partners for 5-HT5 receptors for the treatment of neuropathological, in particular neurodegenerative and/or neuropsychiatric, disorders, which can occur, in particular, in cerebral ischemia, stroke, epilepsy and seizures in general, chronic schizophrenia, other psychotic disorders, dementia, in particular Alzheimer's dementia, demyelinizing disorders, in particular multiple sclerosis, and brain tumors. The invention also relates to processes for the identification and characterization of such binding partners, in particular in the form of screening processes. | 08-02-2012 |
20120202220 | MULTIVALENT FLUORESCENT PROBES - Multivalent fluorescent probes and methods of using these multivalent fluorescent probes for in vitro and in vivo imaging are described. | 08-09-2012 |
20120202221 | NATURAL PEPTIDE AND DERIVATIVES AS MODULATORS OF GPCR GPR1 AND USES THEREOF - The invention relates to the identification of Humanin and derivatives thereof as ligands of the GPR1 GPCR (G-protein coupled receptor). The invention encompasses the use of the interaction of GPR1 polypeptides and Humanin polypeptides as the basis of screening assays for agents that modulate the activity of the GPR1 receptor. The invention also encompasses diagnostic assays based upon the GPR1/Humanin polypeptide interaction, as well as kits for performing diagnostic and screening assays. | 08-09-2012 |
20120202222 | ENZYME FRAGMENT COMPLEMENTATION ASSAYS FOR MONITORING THE ACTIVATION OF THE VOLTAGE-GATED POTASSIUM ION CHANNEL HERG - The present invention provides methods and cell based assays for testing for the binding of a ligand to a human Ether-a-go-go-related (hERG) voltage-gated potassium ion channel protein in an enzyme complementation assay. The invention is of particular use in toxicological and drug screening, particularly for high throughput screening. | 08-09-2012 |
20120208210 | Post-Translational Modifications Indentified by Elemental Analysis - Methods and kits for enzymes involved in post-translational modifications are provided. The methods employ elemental analysis, including ICP-MS. The methods allow for the convenient and accurate analysis of post-translation modifications of substrates by enzymes involved in post-translational modifications, including kinase and phosphatase enyzmes | 08-16-2012 |
20120208211 | HUMANISED PSORIASIS MODEL - The present invention relates to a new humanised animal model of psoriasis. Said model is generated by grafting humanised skin equivalents in the animal, injecting T lymphocytes and cytokines involved in the generation of the disease in humans, and performing the tape-stripping technique in order to generate damage in said grafted equivalents. Said model may be used to study the disease, as well as for the identification and evaluation of the efficacy of compounds against said disease. | 08-16-2012 |
20120219967 | CHOLINERGIC/SEROTONINERGIC RECEPTOR AND USES THEREOF - The present invention describes new cholinergic/serotoninergic chimeric receptors and provides methods and compositions suitable for screening for ligands such as agonists, antagonists and allosteric modulators of α7 nicotinic acetylcholine receptors. | 08-30-2012 |
20120219968 | GPCR Expressing Cell Lines and Antibodies - The present invention provides expression vectors that facilitate high levels of expression of GPCR proteins. Encompassed by the invention are methods and compositions for recombinant cell lines expressing GPCR proteins with the aid of the expression vectors of the instant invention. The recombinant cell lines of the instant invention express GPCR proteins at levels of at least about 150,000 copies of the protein per cell. The present invention also provides methods and compositions for raising antibodies against GPCR proteins using the high expressing recombinant cells of the instant invention. | 08-30-2012 |
20120219969 | MARKER FOR NEUROMYELITIS OPTICA - The present invention provides for methods and materials for diagnosing and treating neuromyelitis optica (NMO). | 08-30-2012 |
20120231477 | Blood Biomarkers for Bone Fracture and Cartilage Injury - Blood biomarkers are described for use in methods and compositions to determine whether an individual has sustained a bone fracture or a cartilage injury. | 09-13-2012 |
20120252037 | STIMULATORY AUTO-ANTIBODIES TO THE PDGF RECEPTOR AS PATHOLOGY MARKER AND THERAPEUTIC TARGET - An in vitro method for detecting the presence in a body sample of auto-antibodies for the PDGF receptor suitable for the diagnosis and prognosis of autoimmune diseases, in particular the systemic sclerosis and related diagnostic kits. Use of an inhibitor of ROS and/or Ras-ERK1/2 for the preparation of a medicament for therapeutic treatment of autoimmune diseases or of treating the Graft-Versus-Host-Reaction (GVHR). Pharmaceutical composition comprising an effective amount of an inhibitor of ROS and/or Ras-ERK1/2, and proper diluents, and/or excipients, and/or adjuvants. | 10-04-2012 |
20120258474 | METHODS OF DETECTING DNA DAMAGE - The present invention relates to methods of detecting agents that cause or may potentiate DNA damage, and to assays that may be employed in such methods. In particular, the invention relates to methods of detecting DNA damage in in vitro cultures of human cells. | 10-11-2012 |
20120270236 | VOLTAGE-GATED PROTON CHANNEL, Hv1, AND USES THEREFOR - Nucleic acid and protein sequences relating to a proton channel (HvI) are disclosed. Nucleic acids, vectors, transformed cells, transgenic animals, polypeptides, and antibodies relating to the HvI gene and protein are disclosed. Also provided are methods of identifying modulators of HvI activity, methods of geno typing subjects with respect to HvI, and methods of diagnosing and treating HvI-mediated disorders. | 10-25-2012 |
20120276553 | MESENCHYMAL PRECURSOR CELL - A method of enriching mesenchymal precursor cells including the step of enriching for cells based on at least two markers. The markers may be either i) the presence of markers specific for mesenchymal precursor cells, ii) the absence of markers specific for differentiated mesenchymal cells, or iii) expression levels of markers specific for mesenchymal precursor cells. The method may include a first solid phase sorting step utilising MACS recognising expression of the antigen to the STRO-1 Mab, followed by a second sorting step utilising two colour FACS to screen for the presence of high level STRO-1 antigen expression as well as the expression of VCAM-1. | 11-01-2012 |
20120276554 | ISOLATION AND USE OF RYANODINE RECEPTORS - The genes encoding ryanodine receptor homologs have been characterized from multiple insect families. The genes and their corresponding polypeptides have a number of uses including but not limited to the development of screens to identify insecticidally active compounds. Methods are outlined for overcoming toxic effects of expressing recombinant proteins in host cells. | 11-01-2012 |
20120301899 | USE OF NOVEL MARKERS OF PLURIPOTENT STEM CELLS - The disclosure relates to novel markers of pluripotent stem cells and uses thereof, and particularly, though not exclusively, to antibody molecules based on fragments of mAb84 which bind to undifferentiated pluripotent stem cells via podocalyxin-like protein-1 (PODXL). | 11-29-2012 |
20120309026 | METHODS AND COMPOSITIONS FOR DETECTING THE ACTIVATION STATE OF MULTIPLE PROTEINS IN SINGLE CELLS - The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state. | 12-06-2012 |
20120309027 | QUANTITATIVE PEPTIDE ANALYSIS BY MASS SPECTROMETRY - A method for determining the concentration ratio in a sample of a target peptide to a reference peptide that is chemically identical with the target peptide, but labeled by isotopes, acquires mass spectra of the target and reference peptides. One of a plurality of families of superimposed bell-shaped curves which is a best fit to ion current peak groups of the target and reference peptides in the mass spectra is determined by varying parameters of the families. In each family, each bell-shaped curve has a predetermined height, the curves have fixed distances from each other and the relative curve heights and curve distances in the families are individually calculated from an elemental composition of the peptides and an isotope abundance distribution of elements composing the peptides, taking into account purity of the isotopes. The concentration ratio is then determined from the parameters of the best fit. | 12-06-2012 |
20120309028 | IMMUNOASSAY STANDARDS AND MEASUREMENT OF CLINICAL BIOMARKERS USING INTRA-ASSAY CALIBRATION STANDARDS - The present invention provides novel compositions and methods for creating quantitative standards to calibrate analytes. These compositions and methods enable the creation of standards and calibrators for analyzing analytes and measuring clinical biomarkers. Also provided are kits comprising the novel compositions for use in assays, for example sandwich immunoassays. | 12-06-2012 |
20120315651 | COMPOSITIONS AND METHODS FOR AUTOLOGOUS GERMLINE MITOCHONDRIAL ENERGY TRANSFER - Oogonial stem cell (OSC)-derived compositions, such as nuclear free cytoplasm or isolated mitochondria, and uses of OSC-derived compositions in autologous fertility-enhancing procedures are described. | 12-13-2012 |
20120315652 | SWEET TASTE RECEPTOR-EXPRESSING CONSTRUCT, CELL BODY EXPRESSING THE SAME, AND UTILIZATION THEREOF - [Object] An object of the present invention is to provide a sweet taste receptor-expressing construct which can functionally stably express both of a sweet taste receptor (T1R2+T1R3) and a G protein α subunit at a high expression efficacy, and a stable expression cell body expressing the construct. | 12-13-2012 |
20120322083 | ANTIBODY BINDING TO ABCA1 POLYPEPTIDE - The invention relates to an isolated antibody that binds to native ABCA1 polypeptide and its uses for the detection of ABCA1 polypeptides in tissue samples. | 12-20-2012 |
20120322084 | CELL LINES COMPRISING SOUR-TASTE RECEPTORS - The present invention relates to sour taste receptors and compositions and methods thereof. In particular, the present invention provides assays and methods of screening for ligands specific for sour taste receptors. Additionally, the present invention provides methods for screening for accessory proteins and mutations, polymorphisms and other potential sour taste receptor protein mutations that are associated with disease states, and therapeutic agents, ligands, and modulators of such proteins. The present invention also provides compositions and methods for modulating sour taste receptors in vitro and in vivo. | 12-20-2012 |
20120329075 | MONITORING PROTEIN TRAFFICKING USING BETA-GALACTOSIDASE REPORTER FRAGMENT COMPLEMENTATON - Methods and materials are disclosed for use in an enzyme fragment complementation assay using complementary fragments of β-galactosidase to study the trafficking of proteins in a cell. Compounds that bind to a target peptide have been found to affect protein folding and therefore trafficking. β-Galactosidase fragments, an enzyme donor (ED) and an enzyme acceptor (EA), are fused to a target peptide and to an intracellular compartment protein, wherein the compartment is involved in intracellular trafficking. Contacting the cell with a compound that binds to the target peptide results in enhanced movement of the protein through the cellular trafficking pathway comprised of the endoplasmic reticulum, Golgi apparatus, the plasma membrane, endosomes, etc. Using this approach, compounds that bind to a target peptide and alter its ability to traffic through the normal cellular pathway can be readily detected. | 12-27-2012 |
20130004969 | IL-17 Heteromeric Receptor Complex - The present invention relates to Interleukin-17 ligand and receptor family members and the discovery that IL-17 receptor A and IL-17 receptor C form a heteromeric receptor complex that is biologically active. | 01-03-2013 |
20130011861 | MODULATORS OF P-SELECTIN GLYCOPROTEIN LIGAND 1 - Compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as autoimmune diseases, transplant rejection, and allergic diseases. | 01-10-2013 |
20130022994 | REGULATION OF BACE DEGRADATION - The invention relates to methods and products for diagnosing, preventing, and treating Alzheimer's disease and abnormal production of amyloid β. | 01-24-2013 |
20130040315 | HUMAN AND MURINE STEM-CELL LINES: MODELS OF ENDOTHELIAL CELL PRECURSORS - The present invention relates to isolated human cells that are precursors of endothelial cells other than embryonic stem cells, to isolated murine cells that are precursors of endothelial cells, and to methods using same, In particular, the present invention relates to established cell lines of isolated human cells that are precursors of endothelial cells other than embryonic stem cells and established cell lines of isolated murine cells that are precursors of endothelial cells. The present invention can be used in particular in the medical and/or veterinary fields, in particular in the field of therapeutics and/or in the field of studies of cellular mechanisms. | 02-14-2013 |
20130040316 | CELL LINES COMPRISING ENDOGENOUS TASTE RECEPTORS AND THEIR USES - Provided herein are cell lines and assays that can be utilized to identify taste receptor modulators. | 02-14-2013 |
20130040317 | CELL LINES COMPRISING ENDOGENOUS TASTE RECEPTORS AND THEIR USES - Provided herein are cell lines and assays that can be utilized to identify taste receptor modulators. | 02-14-2013 |
20130040318 | INCREASE OF MYELOID MICROVESICLES IN THE CEREBROSPINAL FLUID AS BIOMARKER OF MICROGLIA/MACROPHAGE ACTIVATION IN NEUROLOGICAL DISORDERS - The present invention relates to a method for the diagnostic and/or prognostic of a neurological disease characterized by an inflammation process in a subject comprising measuring the amount of myeloid derived microvesicles in a cerebrospinal fluid sample obtained from the subject. The invention further relates to a method for predicting and/or monitoring the efficacy of a treatment for a neurological pathology or for monitoring a neurological disease progression. | 02-14-2013 |
20130045489 | NEURAL NANOPROBES - Neural nanoprobes are described, as well as methods for their use, including for use as a tagging system for neuronal pathway identification. The neural nanoprobes comprise metallic nanoparticles that are conjugated to both (i) a cationic polymer such as polyethylenimine and (ii) an antibody to a vesicular transporter protein. These methods allow retrograde characterization of glutamatergic neurons in a tissue slice preparation. Since the nanoparticles used are non-lipid-soluble and are specifically conjugated to enter and escape the synaptic vesicular machinery, these nanoparticles allow probing of a neuron's somatic origin, via the synapse, by diffusional means. | 02-21-2013 |
20130052661 | Methods for Biomolecule and Biomolecule Complex (BMC) Detection and Analysis and the Use of Such for Research and Medical Diagnosis - The present application pertains to improved methods of detecting biomolecules in a biological sample (or system), In particular, embodiments discussed herein allow for the detection of biomolecule complexes. The embodiments enable for the first time the elucidation of the significance of biomolecule complexes for certain disease states, which in turn enables the diagnosis of disease states based on the identity and complexing level of a biomolecule complex in a particular biological sample. | 02-28-2013 |
20130052662 | Method for Automated Autoantibody Detection and Identification - The present invention is a kit and method for detecting and identifying autoantibodies. The invention employs the use of indirect immunofluorescence, imaging flow cytometry and pattern recognition software to automatically identify autoantibodies associated with autoimmune disorders. | 02-28-2013 |
20130052663 | Chimeric Receptors and Methods for Identifying Agents Exhibiting an Activity on Type 1 Single Pass Transmembrane Receptors - The present invention provides novel chimeric receptors and methods of screening using the chimeric receptors. The chimeric receptors comprise an extracellular domain of a type 1 single pass transmembrane receptor (T1SPTR) and an intracellular domain with kinase activity stemming from a receptor tyrosine kinase. According to an embodiment, the chimeric receptor comprises a full-length T1SPTR. According to another embodiment the chimeric receptor comprises a full-length or truncated tumor necrosis factor receptor (TNFR) or interleukin receptors, or cytokine receptors, or transforming growth factor receptors. The present invention provides means for screening of modulators of TNFRs or interleukin receptors, or cytokine receptors, or transforming growth factor receptors. | 02-28-2013 |
20130059317 | Binding Partners for the Thyrotropin Receptor and Uses Thereof - A binding partner for the TSH receptor, which binding partner comprises, or is derived from, a human monoclonal or recombinant antibody, or one or more fragments thereof, reactive with the TSH receptor, uses thereof, methods of diagnosis and therapy employing the same, and anti-idiotypic antibodies thereto. | 03-07-2013 |
20130065252 | COMPOSITIONS AND METHODS FOR DETECTING AUTOANTIBODIES - The invention provides compositions and methods for detecting thyroid hormone blocking immunoglobulin (TBI). The invention's methods are sensitive and specific for TBI, and may be used for the dual detection of both TBI and TSI. The invention's compositions and methods are useful for the diagnosis of diseases that are associated with the presence of TBI and/or TSI, for monitoring the progress of disease and/or treatment regimens, therapeutics, vaccines, etc., and for assisting clinicians in making treatment decisions. | 03-14-2013 |
20130065253 | DETECTION SYSTEM AND USES THEREFOR - A system for the detection of molecular associations, the system comprising: i) a first agent, comprising a first interacting group coupled to a first reporter component; ii) a second agent, comprising a second interacting group coupled to a second reporter component; iii) a third agent, comprising a third interacting group; iv) a modulator; and v) a detector; wherein proximity of the first and second reporter components generates a signal capable of detection by the detector; and wherein the modulator modulates the association of the second interacting group with the third interacting group; such that monitoring the signal generated by proximity of the first and second reporter components by the detector constitutes monitoring the association of the first and third agents. | 03-14-2013 |
20130071858 | AUTOMATED STAINING SYSTEM AND REACTION CHAMBER - An apparatus including a reagent cartridge and a reaction chamber, the reagent cartridge having a reagent capsule removably positioned therein for dispensing of a reagent onto the reaction chamber. A system including a linearly translatable mounting assembly having a plurality of mounting stations dimensioned to receive at least one fluid dispensing cartridge, a linearly translatable bulk reagent dispensing assembly having a plurality of bulk reagent dispensing nozzles coupled thereto and a receiving assembly positioned beneath the mounting assembly and the bulk reagent dispensing assembly, the receiving assembly including a plurality of reaction stations. A method including determining an inventory of an automated sample processing system, downloading a processing protocol from a central controller to the automated sample processing system, operating the automated sample processing system based on the processing protocol and independently of the central controller and dispensing a reagent from the automated sample processing system. | 03-21-2013 |
20130078646 | ANTIBODIES, COMPOSITIONS, AND ASSAYS FOR DETECTION OF CARDIAC DISEASE - The present invention provides antibodies, devices, and immunoassays for detection of ischemic cardiac events (unstable angina and heart attack) in patients experiencing chest pain. The invention allows for rapid determination of the cause of chest pain, and allows for differentiation of chest pain due to ischemic cardiac events and other causes. The invention provides antibodies that specifically bind to the epitope f-MII and the epitope f-MLF. | 03-28-2013 |
20130078647 | Methods of Detection of Changes in Cells - Methods are provided to detect changes in cells without the use of detection labels. | 03-28-2013 |
20130078648 | DIRECT EXAMINATION OF BIOLOGICAL MATERIAL EX VIVO - The present invention relates to a method for the visual examination of biological material ex vivo and an apparatus for the sterical orientation of biological material which can be used in said method. | 03-28-2013 |
20130078649 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY AND DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL - The present invention concerns combination of an amount of a BRS-3 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the BRS-3 agonist alone and by the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing obesity and diabetes and conditions related thereto and conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues. | 03-28-2013 |
20130102010 | T1R Hetero-Oligomeric Taste Receptors and Cell Lines That Express Said Receptors and Use Thereof for Identification of Taste Compounds - The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners. | 04-25-2013 |
20130115623 | USE OF MARKERS OF UNDIFFERENTIATED PLURIPOTENT STEM CELLS - The disclosure relates to methods of binding and identifying undifferentiated pluripotent stem cells and particularly, although not exclusively, to use of binding moieties which bind to PHB on the surface of undifferentiated pluripotent stem cells, such as PHB-binding peptides, and to methods for depleting undifferentiated stem cells from a sample. | 05-09-2013 |
20130115624 | Methods To Identify Modulators - Disclosed are compounds that activate the human G-protein coupled receptor TAS2R41, and methods of using these compounds for identifying compounds that modulate the response of the TAS2R41 receptor. Compounds identified as modulators of the response of the receptor TAS2R41 may be used to decrease or mask the bitter taste of foods or drugs. | 05-09-2013 |
20130115625 | NOVEL PROTEIN AND USE THEREOF - A protein being the following (A), (B), or (C): (A) a protein represented by the amino acid sequence of SEQ ID NO: 1; (B) a protein represented by an amino acid sequence in which one or a plurality of amino acid is substituted, deleted, inserted or added in the amino acid sequence of SEQ ID NO: 1, the protein having binding activity specific for a mixture of a sphingolipid and cholesterol; or (C) a protein represented by an amino acid sequence being at least 70% identical to the amino acid sequence of SEQ ID NO: 1. | 05-09-2013 |
20130115626 | ANTI-NEUROPILIN ANTIBODIES AND METHODS OF USE - The invention provides anti-NRP1 antibodies and methods of using the same. | 05-09-2013 |
20130115627 | METHODS FOR IDENTIFYING CANDIDATE CYTOTOXIC ANTIBODY MOLECULES - The disclosure relates to methods for screening candidate antibody molecules which bind to podocalyxin-like protein (PODXL) and/or to undifferentiated pluripotent stem cells and particularly, although not exclusively, to methods for identifying candidate cytotoxic antibody molecules. | 05-09-2013 |
20130122520 | METHODS FOR PURIFYING ENDODERM AND PANCREATIC ENDODERM CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS - The present disclosure relates to compositions and methods comprising cell surface markers for hES-derived cells, in particular, endoderm lineage cells including pancreatic endoderm-type cells, derived from hES cells. | 05-16-2013 |
20130122521 | DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO FIBROBLASTS, COMPOSITIONS COMPRISING MESENCHYMAL STEM CELL-DERIVED FIBROBLASTS, AND METHODS OF USING THE SAME - Methods and compositions are provided for the differentiation and characterization of mammalian fibroblast from mesenchymal stem cells. The methods of the invention provide a means to obtain mesenchymal stem cell-derived fibroblast populations, e.g., seeded on a scaffold, which may be used in wound healing. | 05-16-2013 |
20130122522 | ASSESSING MAMMALS FOR VASCULAR DISEASES AND VALVULAR DISEASES - This document provides methods and materials related to assessing mammals for vascular disease. This document also provides methods and materials related to assessing mammals for valvular disease. For example, methods and materials for assessing mammals for vascular disease using elevated levels of endothelial progenitor cells expressing a bone-related polypeptide (e.g., an osteocalcin polypeptide) as markers are provided. | 05-16-2013 |
20130137118 | INTEGRIN HETERODIMER AND A SUBUNIT THEREOF - A recombinant or isolated integrin heterodimer comprising a novel subunit α10 in association with a subunit β is described. The α10 integrin may be purified from bovine chondrocytes on a collagen-type-II affinity column. The integrin or the subunit of α10 can be used as a marker or target of all types of cells, e.g. of chondrocytes, osteoblasts, and fibroblasts. The integrin or the subunit α10 thereof can be used as a marker or target in different physiological or therapeutic methods. They can also be used as active ingredients in pharmaceutical compositions and vaccines. | 05-30-2013 |
20130143235 | COMPARATIVE LIGAND MAPPING FROM MHC CLASS I POSITIVE CELLS - Compositions that include isolated, functionally active, recombinantly produced class I HLA trimolecular complexes that include epitopes unique to breast cancer cells are disclosed. | 06-06-2013 |
20130149715 | G-PROTEIN-CONJUGATED RECEPTOR HAVING ALTERED LIGAND AFFINITY, AND USE THEREOF - A modified G-protein-coupled receptor (GPCR), having modified ligand affinity is provided by binding a G-protein-coupled receptor to a polypeptide consisting of an amino acid sequence of SEQ ID NO: 1. Furthermore, agonists for or antagonists against the modified GPCR are screened using a transformant in which the modified GPCR has been expressed. This makes it possible to provide a technique for analyzing the function of many putative GPCRs whose entities have not been clarified. | 06-13-2013 |
20130149716 | METHODS AND KITS FOR MEASURING VON WILLEBRAND FACTOR - Methods and kits for measuring levels of von Willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein Ibα having at least two of a G233V, D235Y and M239V mutations and an agent to detect a complex between the recombinant glycoprotein Ibα and von Willebrand factor. | 06-13-2013 |
20130149717 | METHODS AND COMPOSITIONS RELATED TO DOPAMINERGIC NEURONAL CELLS - A method of differentiation stem cells cells by contacting stem cells with a dopaminergic differentiation agent is provided in certain aspects. For example, the agent may comprise substituted benzoxazole. These methods and compositions may be used in toxicological screens, e.g., to evaluate the neurotoxicity of a test compound or treatment of neurological disorders. | 06-13-2013 |
20130157289 | IMMUNO-PET IMAGING OF ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR - Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of detecting or determining the presence of STEAP-1 proteins are provided. | 06-20-2013 |
20130171664 | PH-RESPONSIVE FLUORESCENT FALSE NEUROTRANSMITTERS AND THEIR USE - This invention relates to compounds having the following structure: | 07-04-2013 |
20130171665 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISORDERS AND ALZHEIMER'S DISEASE AND IMPROVING NORMAL MEMORY - The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease. | 07-04-2013 |
20130177925 | DETECTION OF ANTIGEN-SPECIFIC PERIPHERAL BLOOD MONONUCLEAR CELLS AND METHODS FOR DIAGNOSING IMMUNE DISORDERS - The present invention relates to a method for detecting the presence or the absence, and optionally quantifying and/or isolating, antigen-specific peripheral blood mononuclear cells. This method, which involves flow cytometry, is based on the use of a fluorescently-labeled antibody specifically recognizing peripheral blood mononuclear cells, and of fluorescently-labeled beads coated with at least one antigen that is specifically recognized by antigen-specific peripheral blood mononuclear cells. The method according to the invention is for example useful for diagnosing immune disorders such as transplant rejections and autoimmune disorders. | 07-11-2013 |
20130177926 | Simultaneous Assay of Target and Target-Drug Binding - Whole cell, simultaneous target and drug-target assay using differentially labeled antibodies and flow cytometry. First antibody binds to total target and second antibody binds to the drug binding site of the target, thus drug binding will competitively inhibit the second antibody allowing for a competitive inhibition assay of drug-target binding. The assay allows for whole cell analysis and even analysis of mixed populations of cells, yet provides detailed kinetic assessment of drug activity. | 07-11-2013 |
20130189710 | Method And Assay Kit For Detection Of Toxicity Induced By Pyrrolizidine Alkaloids - An antibody, which specifically recognizes adducts between pyrrole and cellular macromolecules. Such adducts are likely to occur in mammals suffering an incident of pyrrolizidine alkaloid poisoning. The antibody can be produced using a synthetic immunogen conjugated with a pyrrole as a hapten and it can be used, for example in an assay kit and/or by itself, as a novel means for detecting or diagnosing pyrrolizidine alkaloid poisoning both clinics and research laboratories. | 07-25-2013 |
20130189711 | METHODS, PRODUCTS AND TREATMENTS FOR DIABETES - The invention involves assays, diagnostics, kits, and assay components for determining levels of K41-glycated CD59 in subjects. Treatments for subjects based upon levels of K41-glycated CD59 also are provided. | 07-25-2013 |
20130189712 | T2R, A NOVEL FAMILY OF TASTE RECEPTORS - The invention provides nucleic acid and amino acid sequences for a novel family of taste transduction G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste transduction G-protein coupled receptors. | 07-25-2013 |
20130189713 | PLATELET AGGREGATION ASSAYS - The present invention provides methods of determining platelet aggregation, methods of determining susceptibility to clotting upon administration of a CD40L-binding moiety, and kits related thereto. | 07-25-2013 |
20130189714 | METHOD FOR THE DETECTION AND/OR QUANTIFICATION OF THE INTERACTION OF PLATELETS WITH INTERACTION PARTNERS - The invention refers to methods for detecting and/or quantifying the interaction of platelets or platelet surface molecules with an interaction partner, methods for detecting and/or quantifying the capability of a test substance to modulate the interaction of platelets or platelet surface molecules with interaction partners and articles or manufacture. | 07-25-2013 |
20130196346 | METHODS FOR DIAGNOSIS OF MYELODYSPLASTIC SYNDROMES (MDS) - The present invention relates to methods and kits for diagnosing, ascertaining the clinical course of myelodysplastic syndrome (MDS) and ascertaining response to a therapy regimen of myelodysplastic syndrome. Specifically the invention provides methods and kits useful in the diagnosis and determination of clinical parameters associated with MDS based on surface markers unique to MDS. | 08-01-2013 |
20130196347 | METHOD AND DEVICE FOR ANALYSING MOLECULAR INTERACTIONS, AND USES THEREOF - The invention relates to a method for analysing an interaction between a first molecule and a second molecule bonded to a particle, including the following steps: contacting the first molecule with the second molecule bonded to the particle under conditions enabling the interaction thereof; applying a predetermined liquid flow to the particle bonded to the second molecule; observing a movement of the particle bonded to the second molecule caused by the applied flow; analysing the interaction according to the movement observed and the applied flow, the particle having a greater hydrodynamic resistance than the first and/or second molecule, and a mass Péclet number of greater than 1. The invention also relates to a device for analysing an interaction between a first molecule and at least one second molecule, as well as to the use of the method or of the device in screening a candidate molecule for developing a drug. | 08-01-2013 |
20130196348 | NEUROPEPTIDE Q AS MODULATOR OF GPCR GALR2 AND USES THEREOF - The invention relates to the identification of Neuropeptide Q as ligand of the GALR2 GPCR (G-protein coupled receptor). The invention encompasses the use of the interaction of GALR2 polypeptides and Neuropeptide Q polypeptides as the basis of screening assays for agents that modulate the activity of the GALR2 receptor. The invention also encompasses diagnostic assays based upon the GALR2/Neuropeptide Q polypeptide interaction, as well as kits for performing diagnostic and screening assays. | 08-01-2013 |
20130203078 | NOVEL ULTRASENSITIVE CELL BASED SENSORS AND USES THEREOF - The present invention relates to a novel cell based sensor useful for drug discovery that comprises a cell line with professional regulated exocytosis of secretory granules transfected with a protease as a reporter polypeptide stored in the regulated secretory granules of the cell line with professional regulated exocytosis and having either an endogenous or a heterologous molecule as a modulator of regulated secretory granules exocytosis, such said granule stored protease reporter having at least: a high resistance to conditions already present inside the granules such as low pH and proteolysis by other proteases; enzymatic activity after exocytosis; a highly specific cleavage sequence; a very low level of secretion under unstimulated or basal conditions; and a high signal to background activity in a media compatible with cell culture viability and granule exocytosis for a high throughput robust and sensitive detection. | 08-08-2013 |
20130203079 | ANTIBODIES FOR THE DETECTION OF INTEGRIN COMPLEXES IN FFPE MATERIAL - The invention relates to antibodies that are capable to bind the extracellular domain of integrin. Another object of the invention concerns the use of said antibodies for detecting integrins in archival formalin fixed paraffin embedded (FFPE) tissue. The invention also relates to methods for preparing monoclonal rabbit antibodies, wherein the immunogen is an insect expression culture-derived recombinant extracellular integrin domain, and another method for screening anti-integrin antibodies that discriminate between closest integrin homologues and that are especially suited for immunohistochemistry in FFPE material. | 08-08-2013 |
20130210032 | DEVICE, SYSTEM AND METHOD FOR DETECTING A SENSORY PERCEPTION - A device for detecting a sensory perception with regard to an analyte, having a sensor system and an organic receptor cell for detecting the sensory perception. The organic receptor cell is designed to assume a cellular state, which depends on the analyte in contact with the receptor cell. The sensor system is designed to determine the cellular state and to output it to the cellular state signal, which indicates the cellular state. | 08-15-2013 |
20130210033 | MARKER FOR AMYOTROPHIC LATERAL SCLEROSIS, AND USE THEREOF - An object is to provide a biomarker specific to amyotrophic lateral sclerosis and a use thereof. Provided are a marker for amyotrophic lateral sclerosis containing a transmembrane glycoprotein nmb, and a method for detecting amyotrophic lateral sclerosis, which utilizes the marker, and the like. | 08-15-2013 |
20130224766 | VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) PROTEIN AND GENE, MUTANTS THEREOF, AND USES THEREOF - Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors: polynucleotides encoding the polypeptides: vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides. Methods of inhibiting endothelial cell proliferation are also provided. | 08-29-2013 |
20130236911 | HEMOKININ-1 RECEPTOR AND HEMOKININ-1-DERIVED PEPTIDE - The present invention provides a peptide having antagonist activity against SP, pain control activity, anti-inflammation activity, and anti-pruritic activity. The present invention further provides a method for searching for a therapeutic agent for pain, a therapeutic agent for inflammation, and a therapeutic agent for pruritus using G protein coupled receptor (GPR) 83, which is an HK-1 specific receptor. | 09-12-2013 |
20130244254 | T1R HETERO-OLIGOMERIC TASTE RECEPTORS - Newly identified mammalian taste-cell-specific G protein-coupled receptors which function as hetero-oligomeric complexes in the sweet taste transduction pathway, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in sweet taste signaling as hetero-oligomeric complexes, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for identifying putative taste modulating compounds using such hetero-oligomeric complexes also described, as is a novel surface expression facilitating peptide useful for targeting integral plasma membrane proteins to the surface of a cell. | 09-19-2013 |
20130252257 | QUANTIFICATION OF CIRCULATING STEM AND PROGENITOR CELLS AS A MEANS OF ASSESSING EFFICACY OF NATUROPATHIC INTERVENTIONS - Disclosed are tests, correlations and “theranostic” interventions aimed at optimizing general health through quantification of cells with regenerative potential in circulation. Some embodiments include use of circulating endothelial progenitor cell (EPC) testing as a means of quantifying general health status in a patient. The combination of EPC testing together with a naturopathic intervention, wherein the selection and dosage of said naturopathic intervention is tailored based on said quantitative test is provided. In other embodiments, regenerative cells are selected from the group comprising of very small embryonic like cells (VSEL), CD34 cells with hematopoietic potential, and circulating mesenchymal stem cells (MSC). Naturopathic interventions include recommendations of lifestyle modification, dietary supplements, intravenous vitamins, detoxification, acupuncture, and guided imagery. | 09-26-2013 |
20130252258 | RAPID SCREENING OF MONOCLONAL ANTIBODIES - Methods and systems for rapid and efficient screening of monoclonal antibodies and antibody-secreting cells, and particularly of single antibody-secreting cells, for both primary and functional characteristics, and particularly cell to cell interactions, in a microfluidic system, in particular an inverted open microwell system, where the particle(s) is not bound to a substrate. | 09-26-2013 |
20130266964 | METHOD OF DETECTING ENDOTHELIAL PROGENITOR CELLS - A method of detecting endothelial progenitor cells is provided. The method involves contacting a population of cells with a composition comprising a conjugate or complex of the formula A | 10-10-2013 |
20130273566 | Serological Markers of Inflammatory Bowel Disease Phenotype and Disease Progression - Disclosed are novel biomarkers and methods related to diagnostic tests for the detection and characterization of inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. In particular, the instant invention relates to novel biomarkers and methods of using such biomarkers to predict disease behavior and severity, to differentiate among disease types, and to optimize selection of treatment options in individuals suspected of having an inflammatory bowel disease. | 10-17-2013 |
20130273567 | Screening Method for Candidate Agonist Compounds for Adiponectin Receptor I - A method of screening for candidate compounds for adiponectin receptor 1 agonist including a step of bringing test compounds into contact with cells to determine whether they cause intracellular influx of extracellular calcium ions and selecting, from the test compounds, compounds causing the intracellular influx of extracellular calcium ions as the candidate compounds for adiponectin receptor 1 agonist. | 10-17-2013 |
20130273568 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS - The invention relates to benzimidazole-carboxamide 5-HT | 10-17-2013 |
20130273569 | VIOLET LASER EXCITABLE DYES AND THEIR METHOD OF USE - The present invention provides dye compounds optimally excited at about 400 nm and have a Stokes shift of at least about 80 nm. These dyes find use in detection of analyte in a sample and the preparation of dye-conjugates. | 10-17-2013 |
20130273570 | METHOD FOR IDENTIFICATION AND CULTURE OF MULTIPOTENT MESENCHYMAL STEM CELLS WITH HIGH PROLIFERATION POTENTIAL - Variations in the differentiation and lineage potential of stem cells, including mesenchymal stem cells, currently limit their therapeutic use. The ability to identify, isolate, and specifically amplify stem cell populations with desired differentiation potential would contribute the use of stem cells in research and therapy. The present invention discloses a method of assessing differentiation potential of stem cells by measuring the differential expression of antigens CD146 and NG2 on the stem cells. The con elation between CD146 and NG2 expression and differentiation and trilineage potential is explored. The invention also discloses methods to specifically amplify or enrich stem cells with desired differentiation potential, monitor the differentiation potential of a heterogeneous stem cell population, quantify the heterogeneity in differentiation potential of a stem cell culture, and remove stem cells with specific differentiation potentials from a heterogeneous cell culture. | 10-17-2013 |
20130280734 | BIOASSAY METHOD FOR DETECTING PHYSIOLOGICALLY ACTIVE SUBSTANCE - Provided are a procedurally simple and safe method and kit for measuring the concentration in a biological sample of a physiologically active substance which binds to a receptor that causes a change in intracellular cAMP concentration. By providing a composition including genetically-modified cells which show co-expression of a receptor that causes a change in intracellular cAMP concentration, a cyclic nucleotide-responsive calcium channel, and aequorin luminescent protein, it is possible to measure how much of a physiologically active substance which binds to said receptor is included in a biological sample. | 10-24-2013 |
20130302823 | T1R HETERO-OLIGOMERIC TASTE RECEPTORS AND CELL LINES THAT EXPRESS SAID RECEPTORS AND USE THEREOF FOR IDENTIFICATION OF TASTE COMPOUNDS - The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R 1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners. | 11-14-2013 |
20130302824 | METHODS FOR DETECTION OF RARE SUBPOPULATIONS OF CELLS AND HIGHLY PURIFIED COMPOSITIONS OF CELLS - Methods are provided for detection of a target cell type within a cell population, and compositions are provided comprising cells and an indicator that indicates the number of cells of the target cell type in the cell population. Examples are provided in which these methods are used to detect human embryonic stem cells within a differentiated cell population with exquisite sensitivity. Differentiated cells produced from embryonic stem cells can be characterized by these methods before transplantation into a recipient, thereby providing further assurance of safety. | 11-14-2013 |
20130302825 | USES OF MACROPHAGE MANNOSE RECEPTOR TO SCREEN COMPOUNDS AND USES OF THESE COMPOUNDS - Methods and associated compositions of matter (e.g., kits, cell lines, etc.) for screening compounds that bind to macrophase mannose receptor (MMR). Compounds identified by these methods and drug conjugates that includes these compounds are also encompassed as are their uses in the manufacture of medicaments. | 11-14-2013 |
20130302826 | METHOD FOR QUANTIFICATION OF SOLUBLE LR 11 - Provided is a method for quantifying soluble LR11 in a biological sample such as serum by an immunological means conveniently and accurately without the need of carrying out any complicated separation manipulation. An immunological quantification method for soluble LR11 in a sample derived from a mammal, including a step of treating the sample with at least one surfactant selected from a group consisting of a polyoxyalkylene alkyl ether, a polyoxyalkylene alkyl phenyl ether, an alkyl glycoside, an alkylthio glycoside, an acyl-N-methylglucamide and a salt of cholic acid. | 11-14-2013 |
20130302827 | ANNEXIN-BASED APOPTOSIS MARKERS - The present invention describes an annexin derivative and a method of using the annexin derivative as a biosensor for real-time visualization of phosphatidylserine exposure, apoptosis, live-cell imaging and monitoring of cell health. | 11-14-2013 |
20130316373 | SEPARATION OF LIVING UNTOUCHED NEURONS - The present invention provides the use of the cell surface antigen CD51 as a negative selection marker for neuronal cells and a method for enrichment, isolation and/or detection of neuronal cells comprising the steps a) contacting a sample containing neuronal cells with an antigen-binding fragment specific for the CD51 antigen coupled to a solid phase, thereby labeling the CD51 positive cells of said sample and b) isolating the non-labeled cells of said sample. | 11-28-2013 |
20130323753 | METHODS AND KITS FOR IDENTIFICATION OF ANTI-EXCITOTOXIC COMPOUNDS - The instant invention provides methods and kits for screening for anti-excitotoxic compounds which increase the total amount of EAAT-1 protein or the surface amount of EAAT-1 protein. | 12-05-2013 |
20130323754 | Diagnostic Kit as Well as a Metho dfor the Examination of a Human Patient Sample for the Presence of Neuromyelitis Optica-Specific Antibodies - A diagnostic kit as well as a method for the examination of a human patient sample for the presence of neuromyelitis optica-specific antibodies are described, for which an initial substrate is incubated with human sample material, and said incubated initial substrate is examined using indirect immunofluorescence, whether neuromyelitis optica-specific antibodies have at least partially bound to said initial substrate. | 12-05-2013 |
20130330740 | NOVEL THERAPEUTIC AND DIAGNOSTIC PRODUCTS AND METHODS - The present invention relates to the use of p11 as a drug target as well as a tool for the diagnosis, treatment and development of p11/5-HT receptor related disorders. The invention further relates to p11 knock-out animals as well as p11 transgenic animals and their use as models for the development of novel psychotherapeutic agents, and to methods of diagnosis, prophylaxis and treatment of p11/5-HT receptor related disorders. | 12-12-2013 |
20130330741 | KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCs) - Described herein are compositions, a system, and kits for detection of endocrine disruptor chemicals (EDCs) in environmental samples, such as samples of water including but not limited to waste water treatment plant effluent, using a live-cell fluorescence-based nuclear translocation reporter system. Upon binding of a ligand to a fluorescent-labeled reporter protein, the protein (and therefore the fluorescence) is translocated in a ligand level-dependent manner from the cytoplasm to the nucleus of live mammalian cells; this translocation is detectable as diffuse (cytoplasmic) fluorescence converting to localized, brightly fluorescent nuclei. The described kits can be used to reliably detect very low levels of EDC contamination, including in high throughput analysis systems as described. | 12-12-2013 |
20130337470 | METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMadCAM LEVELS - Provided herein is a method of monitoring the change of the alpha-4 integrin activities in an individual by correlating with the soluble vascular cell adhesion molecule (sVCAM) and/or soluble mucosal addressin cell adhesion molecule (sMAd-CAM) levels. Particularly, this method can be used, for example, to evaluate the pharmacokinetics and pharmacodynamics (PK/PD) of an alpha-4 integrin inhibitor used to treat a disease associated with pathological or chronic inflammation. | 12-19-2013 |
20130344507 | SYSTEMS AND METHODS FOR SEPARATING COMPONENT MATERIALS OF A SUSPENSION USING IMMUNOMAGNETIC SEPARATION - This disclosure is directed to systems and methods for immunomagnetic separation of a target analyte of a suspension from the other component materials of the suspension. The system may be composed of a tube, a magnetizable float, and a magnet. The magnetizable float is configured to propagate or introduce a magnetic field. In one aspect, the magnet is included in the magnetizable float. In another aspect, the magnet is external to the magnetizable float. The system may also include a solution containing a particle to conjugate with the target analyte to form a target analyte-particle complex. The particle is capable of being attracted by the magnetic field or magnetic gradient introduced by the magnet. The target analyte-particle complex may be attracted to the magnetizable float. | 12-26-2013 |
20130344508 | Methods and/or Use of Oligonucleotide Conjugates for Suppressing Background Due to Cross-Hybridization - The present disclosure is directed to methods and/or uses of oligonucleotide conjugates for assays and detections and related systems and/or kits for suppressing background due to cross-hybridization. Certain methods are directed to a method for detecting one or more biological targets of a sample in a detection assay, comprising: providing a molecular probe, comprising a binding moiety and an oligonucleotide sequence, to a sample comprising one or more biological targets; binding the one or more biological targets with the binding moiety; providing a detectable component to the sample, wherein the detectable component comprises a signal generating moiety conjugated to an oligonucleotide sequence complementary to the oligonucleotide sequence of the molecular probe; hydridizing the oligonucleotide sequence of the target-bound molecular probe to the detectable component; and detecting a signal generated from the hydridized detectable component. Various other embodiments, applications etc. are disclosed herein. | 12-26-2013 |
20140004535 | MUTANT SMOOTHENED AND METHODS OF USING THE SAME | 01-02-2014 |
20140017708 | Subpopulations of Spore-Like Cells and Uses Thereof - Subpopulations of spore-like cells expressing specific cell surface and gene expression markers are provided. In one embodiment, the cells express at least one cell surface or gene expression marker selected from the group consisting of Oct4, nanog, Zfp296, cripto, Gdf3, UtF1, Ecat1, Esg1, Sox2, Pax6, nestin, SCA-1, CD29, CD34, CD90, B1 integrin, cKit, SP-C, CC10, SF1, DAX1, and SCG10. Also provided are methods for purifying a subpopulation of spore-like cells of interest from a population of spore-like cells, and methods for inducing differentiation of the isolated spore-like cells into cells of endodermal, mesodermal or ectodermal origin. The spore-like cells can be used to generate cells originating from all three germ layers and can be used to treat a patient who has a deficiency of functional cells in any of a wide variety of tissues, including the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system. | 01-16-2014 |
20140024043 | Mammalian Sweet and Amino Acid Heterodimeric Taste Receptors Comprising T1R3 and T1R1 - The present invention provides isolated nucleic acid and amino acid sequences of sweet or amino acid taste receptors comprising T1R3 and T1R1, two heterologous G-protein coupled receptor polypeptides from the T1R family of sensory G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet and amino acid taste receptors. | 01-23-2014 |
20140024044 | CELL CYCLE MEASURING METHOD BASED ON AN ELECTROCHEMICAL METHOD - A method for measuring cell cycles includes immobilizing a capture specifically binding to a cell membrane protein to a substrate, wherein the cell membrane protein is a counterpartner binding to the capture, binding a cell having the cell membrane protein as the counterpartner to the capture, and measuring a redox potential of the cell. A method for screening a substance affecting cell cycles includes immobilizing a capture specifically binding to a cell membrane protein to a substrate; wherein the cell membrane protein is a counterpartner binding to the capture, binding a cell having the cell membrane protein as the counterpartner to the capture, treating a test substance of interest for analysis to a cell, and measuring a redox potential of the cell. | 01-23-2014 |
20140024045 | USE OF MICROPATTERNED SOFT SUBSTRATE FOR MEASURING OF CELL TRACTION FORCES - The present invention relates to devices and methods for the measurement of cell traction forces. In particular, the invention is based on the use of a soft substrate with cell adhesive micropatterns. | 01-23-2014 |
20140024046 | Exosomal Biomarkers for Cardiovasular Events - The present invention relates to a method of predicting the risk of a subject developing a cardiovascular event, comprising determining the presence of a biomarker that is indicative of the risk of developing a cardiovascular event in an exosome sample from the subject. The exosomes are suitably isolated from a body fluid selected from serum, plasma, blood, urine, amniotic fluid, malignant ascites, bronchoalveolar lavage fluid, synovial fluid, breast milk, saliva, in particular serum. Alternatively, the exosomes are present in a body fluid, in particular serum. The biomarker is selected from the proteins Vitronectin, Serpin F2, CD14, Cystatin C, Plasminogen, Nidogen 2, Serpin G1 or any combination of two or more of these proteins. The invention further relates to a method of diagnosing the occurrence of acute coronary syndrome in a subject, comprising determining the presence of a biomarker that is indicative of the occurrence of acute coronary syndrome in an exosome sample from the subject. In this method the biomarker is selected from Serpin F2, CD14, Cystatin C or combinations thereof. | 01-23-2014 |
20140030735 | BIOMARKERS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE - The methods described herein are based on the discovery that the plasma level of a panel of specific proteins differs between two subject populations: 1) subjects at risk for chronic obstructive pulmonary disease (“COPD”) but not manifesting clinical symptoms of COPD; and 2) subjects having very severe COPD. The difference in plasma levels is statistically significant for each protein. The identification of these proteins thus facilitates susceptibility detection, early disease detection, disease severity assessment, disease progression monitoring, and therapy efficacy monitoring. | 01-30-2014 |
20140038206 | IMAGE ANALYSIS AND MEASUREMENT OF BIOLOGICAL SAMPLES - Methods, devices, systems, and apparatuses are provided for the image analysis of measurement of biological samples. | 02-06-2014 |
20140038207 | PLATELET ANALYSIS SYSTEM - A method for diagnosis of HIT (Heparin-induced thrombocytopenia) in a patient's serum or plasma sample and a system comprising kits for performing the method. | 02-06-2014 |
20140038208 | PREPARATION OF ANTI-PEG ANTIBODY EXPRESSING CELL AND APPLICATION THEREOF - The present invention provides a method for preparing an isolated eukaryotic cell which presents an anti-polyethylene glycol (PEG) antibody on a cell membrane. The present invention also provides a method for a quantitative analysis of a polyethylene glycol (PEG) by said anti-PEG antibody expressing cell. The cell-based quantitative analysis of the present prevention could sensitively quantify free PEG and PEG-modified macromolecules (proteins, nanoparticles and liposomes) as sensitive as nano-gram level. | 02-06-2014 |
20140045194 | MONITORING PROTEIN TRAFFICKING USING BETA-GALACTOSIDASE REPORTER FRAGMENT COMPLEMENTATION - Methods and materials are disclosed for use in an enzyme fragment complementation assay using complementary fragments of β-galactosidase to study the trafficking of proteins in a cell. Compounds that bind to a target peptide have been found to affect protein folding and therefore trafficking. β-Galactosidase fragments, an enzyme donor (ED) and an enzyme acceptor (EA), are fused to a target peptide and to an intracellular compartment protein, wherein the compartment is involved in intracellular trafficking. Contacting the cell with a compound that binds to the target peptide results in enhanced movement of the protein through the cellular trafficking pathway comprised of the endoplasmic reticulum, Golgi apparatus, the plasma membrane, endosomes, etc. Using this approach, compounds that bind to a target peptide and alter its ability to traffic through the normal cellular pathway can be readily detected. | 02-13-2014 |
20140057287 | NOVEL CARDIOMYOCYTE MARKER - The present invention provides a method for production or detection of a cardiomyocyte(s) and/or cardiac progenitor cell(s), comprises extracting a cardiomyocyte(s) and/or cardiac progenitor cell(s) from a cell population comprising cardiomyocytes and/or cardiac progenitor cells using as an index VCAM1 positivity. | 02-27-2014 |
20140065643 | NUCLEIC ACIDS ENCODING A G-PROTEIN COUPLED RECEPTOR INVOLVED IN SENSORY TRANSDUCTION - The invention provides isolated nucleic acid and amino acid sequences of sensory cell specific G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sensory cell specific G-protein coupled receptors. | 03-06-2014 |
20140072983 | Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies - An in vitro assay method is disclosed. This non-cell-based dual function target binding assay is useful for detecting both an IgG target antibody, such as a biologic drug, in a biological sample (e.g., a serum sample) and the presence of neutralizing antibodies (NAb) against the IgG target antibody. | 03-13-2014 |
20140072984 | SOLUBLE GP130 MUTEINS WITH IMPROVED BINDING ACTIVITY - Described are soluble gp130 polypeptide monomers and dimers, wherein, in a preferred embodiment, at least one of the three amino acid residues Thr | 03-13-2014 |
20140072985 | Bioassay Method for Antibody Against Thyroid-Stimulating Hormone Receptor, Measurement Kit for the Antibody, and Novel Genetically Modified Cell for Use in the Bioassay Method or the Measurement Kit - The present invention provides a method and a kit for assaying a TSH receptor antibody, which are easy to manipulate and are safe. Specifically, the present invention provides a composition comprising a genetically modified cell forced to co-express a TSH receptor, a cyclic nucleotide responsive calcium channel, and a luminescent protein aequorin. Use of the composition enables the assay of a TSH receptor antibody contained in a sample. | 03-13-2014 |
20140080146 | METHOD FOR DETECTING NEUROLOGICAL DISEASE ASSOCIATED WITH COGNITIVE IMPAIRMENT BY MEASURING EPHA4 EXTRACELLULAR DOMAIN - A method for detecting a neurological disease associated with cognitive impairment, wherein the extracellular domain of EphA4 is measured from a biological sample taken from a subject. | 03-20-2014 |
20140099652 | COMPOSITION FOR MONITORING VESICLE, KIT AND METHOD OF MONITORING VESICLE USING THE SAME - Provided is a method of monitoring a vesicle in a sample, including contacting a vesicle in a sample with a membrane permeable marker that is converted into a detectable marker in the vesicle, measuring a signal of the detectable marker, and monitoring the vesicle based on the measured signal. | 04-10-2014 |
20140106374 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 04-17-2014 |
20140113314 | Two Pore Channels as a Therapeutic Target to Protect Against Myocardial Ischemia and as an Adjuvant in Cardiac Surgery - The present invention relates to methods and compositions for modulating the activity of two-pore domain K+ channels (“K | 04-24-2014 |
20140120552 | Sensitive And Rapid Methods Of Using Chimeric Receptors To Identify Autoimmune Disease And Assess Disease Severity - The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays. Such improvements are based upon the superior performance of assays comprising a chimeric TSH receptor in the presence of a glucocorticoid including, but not limited to, dexamethasone. | 05-01-2014 |
20140120553 | T2R, A NOVEL FAMILY OF TASTE RECEPTORS - The invention provides nucleic acid and amino acid sequences for a novel family of taste transduction G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste transduction G-protein coupled receptors. | 05-01-2014 |
20140127716 | BENCHMARKS FOR NORMAL CELL IDENTIFICATION - Provided herein are methods, compositions, and kits for determining cell signaling profiles in normal cells and comparing the cell signaling profiles of normal cells to cell signaling profiles from a test sample. | 05-08-2014 |
20140134644 | METHODS AND KITS FOR DIAGNOSING SJOGREN'S SYNDROME - The invention features methods and kits for determining the presence of, or a predisposition to develop, Sjögren's syndrome in humans. The invention features methods to detect changes in the levels of one or more LMP-2 protein isoforms, in particular phosphorylated isoforms of LMP-2, and to detect changes in cellular protein phosphorylation and ubiquitination in samples from Sjögren's patients. | 05-15-2014 |
20140141452 | Method of Determining, Identifying or Isolating Cell-Penetrating Peptides - The present invention provides a method of determining or identifying or isolating a cell-penetrating peptide (CPP) or analog or derivative thereof having cell-type selectivity and/or at least capable of passing through a Blood Brain Barrier of an animal subject. This invention also provides CPPs and analogs and derivatives thereof, such as those set forth in SEQ ID NOs: 1-27 of the Sequence Listing, and compositions comprising one or more of the CPPs, including conjugates in which a CPP or analog or derivative thereof is linked to a cargo molecule. The invention also provides methods for transporting cargo molecules across cell membranes to specific locations within cells, and for treating, preventing and/or diagnosing diseases that are treatable by a cargo molecule to which a CPP or analog or derivative of the invention is attached. The invention also provides tailored peptide libraries for use in identifying or isolating CPPs. | 05-22-2014 |
20140141453 | CELL BINDING ASSAY - The present invention relates to a fluorescent cell binding assay combining pre-labeling and Western blotting. Intact cells are incubated with pre-labelled binders preferably followed by SDS PAGE (sodium dodecylsulphate polyacrylamide gel) separation and Western blotting. More closely, the invention relates to a cell binding assay in which the degree or amount of binding of one or more cell interacting protein or protein component to the cell surface is measured with the ability to correlate the degree of cell binding to the sample load/total number of cells. | 05-22-2014 |
20140147860 | Acoustic Cytometry Methods and Protocols - Various embodiments disclosed herein comprise acoustic cytometry based methods, kits, computer software methods and systems to analyze a variety of bioparticles. In one embodiment, a method for analyzing bioparticles comprises: acoustically focusing one or more bioparticles through an interrogation zone; optically exciting the one or more bioparticles in the interrogation zone with an excitation source; detecting an optical signal from the bioparticles; and analyzing the optical signal to characterize at least one quality or quantity parameter of the bioparticles. Properties of biomolecules that may be analyzed include but are not limited to cell proliferation analysis, live/dead cell discrimination, cell cycle analysis, basic phenotyping, immunophenotyping, rare-event detection, apoptosis, phagocytosis, pinocytosis, detection of phosphoproteins, detection of one or more cellular markers, detection of one or more intracellular marker, detection of cancer cells, detection of pathological markers on a cell, microbial cell analysis and/or picophytoplankton analysis. | 05-29-2014 |
20140154701 | HUMANIZED FC GAMMA R MICE - Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity FcγR locus, and wherein the mouse is capable of expressing a functional FcRγ-chain. Genetically modified mice are described, including mice that express low affinity human FcγR genes from the endogenous FcγR locus, and wherein the mice comprise a functional FcRγ-chain. Genetically modified mice that express up to five low affinity human FcγR genes on accessory cells of the host immune system are provided. | 06-05-2014 |
20140162289 | IDENTIFYING MOLECULES MODULATING PROTEIN-PROTEIN INTERACTIONS USING PROTEASE ACTIVATED REPORTERS - Assay methods and systems use enzymatic cleavage resulting from protein-protein interaction to modulate (activate or inactivate) a reporter. | 06-12-2014 |
20140162290 | PROBE FOR DETECTING DEAD CELL - Provided is a molecular imaging probe that accumulates specifically and highly sensitively at a tumor site in vivo, and enables quantitative analysis, e.g. a probe for detecting an apoptotic cell(s) and/or a necrotic cell(s), comprising a fusion protein of a Tim4 protein and a protein or polypeptide that forms a dimer, the protein or polypeptide being bound to the C-terminus of the Tim4 protein, wherein the mucin domain of the Tim4 protein and the C-terminal side domain thereof are replaced with a polypeptide consisting of the amino acid sequence of a) or b) below: a) an amino acid sequence having a length of 30 to 120 amino acid residues comprised in the amino acid sequence of the mucin domain of a wild-type Tim4 protein; b) an amino acid sequence having an identity of not less than 80% to the amino acid sequence of a). | 06-12-2014 |
20140162291 | IN VITRO METHOD USING HUMAN SKIN FOR EVALUATING THE INFLUENCE OF ABC TRANSPORTERS - An in vitro method is described that uses full-thickness human skin for evaluating the influence of ABC transporters (such as MDR1, MRP1, MRP2 or BCRP) on the absorption and distribution of topically applied medicinal substances. | 06-12-2014 |
20140178896 | Method Using A Nonlinear Optical Technique for Detection of Interactions Involving A Conformational Change - A nonlinear optical technique, such as second or third harmonic or sum or difference frequency generation, is used to detect binding interactions, or the degree or extent of binding, that comprise conformational change. In one aspect of the present invention, the nonlinear optical technique detects a conformational change in a probe due to target binding. In another aspect of the invention, the nonlinear optical technique screens candidate probes by detecting a conformational change due to a probe-target interaction. In another aspect of the invention, the nonlinear optical technique screens candidate modulators of a probe-target interaction by detecting a conformational change in the presence of the modulator. | 06-26-2014 |
20140178897 | METHODS USING A NONLINEAR OPTICAL TECHNIQUE FOR DETECTION OF INTERACTIONS INVOLVING A CONFORMATIONAL CHANGE - A nonlinear optical technique, such as second or third harmonic or sum or difference frequency generation, is used to detect binding interactions, or the degree or extent of binding, that comprise conformational change. In one aspect of the present invention, the nonlinear optical technique detects a conformational change in a probe due to target binding. In another aspect of the invention, the nonlinear optical technique screens candidate probes by detecting a conformational change due to a probe-target interaction. In another aspect of the invention, the nonlinear optical technique screens candidate modulators of a probe-target interaction by detecting a conformational change in the presence of the modulator. | 06-26-2014 |
20140178898 | Method for Detecting Fat-Reducing Compounds - A method for detecting fat-reducing compounds comprises four steps, the first step is to provide a clone of adipocytes cultured on a culture dish; the second step is to add a dilution of a test compound to the culture dish for a first time; the third step is to add an insulin-like growth factor to the culture dish for a second time; and the fourth step is to collect the adipocytes for detecting the expression level of at least one specific protein to be a reference value for reducing fat or for decreasing the glucose transport by the test compound. A further method for detecting fat-reducing compounds is disclosed by modifying the last step which detects the levels of a particular protein translocated from the cytosol to the cell membrane of the adipocytes for testing whether the compounds have the ability to regulate or reduce adipocyte glucose uptake. | 06-26-2014 |
20140178899 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER AND NEURODEGENERATIVE DISEASES RELATED TO BECLIN-1 - The present invention relates to antibodies specific for human Beclin-1 protein phosphorylated at position Thr 119 and uses thereof. In particular, these antibodies are useful in diagnosing diseases associated with impaired autophagy including cancer and neurodegenerative diseases. The invention further relates to human Beclin-1 mutated at position 119 with a phospho-mimicking residue and uses thereof for treating cancer and neurodegenerative diseases. | 06-26-2014 |
20140186854 | Method Using A Nonlinear Optical Technique for Detection of Interactions Involving A Conformational Change - A nonlinear optical technique, such as second or third harmonic or sum or difference frequency generation, is used to detect binding interactions, or the degree or extent of binding, that comprise conformational change. In one aspect of the present invention, the nonlinear optical technique detects a conformational change in a probe due to target binding. In another aspect of the invention, the nonlinear optical technique screens candidate probes by detecting a conformational change due to a probe-target interaction. In another aspect of the invention, the nonlinear optical technique screens candidate modulators of a probe-target interaction by detecting a conformational change in the presence of the modulator. | 07-03-2014 |
20140186855 | Method for Detection of Intestinal, and Blood-Brain Barrier Permeability and Testing Materials Thereto - Methods, assays, and apparatus are disclosed for testing of antigens associated with intestinal and/or blood-brain barrier permeability. For example, blood, saliva or other bodily fluid can be tested for binding (1) to a bacterial toxin (preferably a lipopolysaccharide), and (2) binding to tissue antigens selected from at least one of (a) a gut-related antigen and (b) a blood brain barrier-related antigen. Analysis of test results can be used to assist in detecting and diagnosing diseases associated with leaky gut syndrome (whether due to paracellular or transcellular pathways, and whether due to bacterial toxins or some other cause) and/or to diseases associated with excessive blood brain barrier permeability, which are contemplated herein to include both neuroinflammation and/or neuroautoimmunity conditions, and especially amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis, Alzheimer's, or peripheral neuropathy, and major depression. | 07-03-2014 |
20140186856 | OBSERVATION APPARATUS AND OBSERVATION METHOD - An observation apparatus and an observation method are provided. The observation apparatus includes a light source that emits illumination light used to observe a specimen to which a fluorescent substance that specifically binds to or is expressed in a stimulus target has been supplied, an illumination optical system that radiates the illumination light emitted from the light source | 07-03-2014 |
20140193835 | CELL-BASED DETECTION OF APF THROUGH ITS INTERACTION WITH CKAP4 FOR DIAGNOSIS OF INTERSTITIAL CYSTITIS - An assay system designed to detect a protein biomarker in urine that is diagnostic for interstitial cystitis (IC). The presence of a 9 amino acid glycopeptide, antiproliferative factor (APF), in urine is unique to patients with IC. Urine samples from patients who exhibit symptoms consistent with IC are added to the assay system. Binding of APF to the cytoskeletal associated protein 4 (CKAP4) is positive for the presence of APF in urine and diagnostic for IC. The diagnostic system is a significant and surprising advance in diagnosis of IC and has commercial applications relevant to women and men who suffer from symptoms consistent with IC. | 07-10-2014 |
20140193836 | NOVEL MARKERS FOR DOPAMINERGIC NEURON PROGENITOR CELLS - The present invention provides a method for selecting dopaminergic neuron progenitor cells, which comprises detecting any one or more of markers selected from the group consisting of CD15 (SSEA-1), CD24, CD46, CD47, CD49b, CD57, CD58, CD59, CD81, CD90, CD98, CD147, CD184, Disalogangliosid GD2, SSEA-4, CD49f, SERINC4, CCR9, PHEX, TMPRSS11E, HTR1E, SLC25A2, Ctxn3, Cc17, Chrnb4, Chrna3, Kcnv2, Grm2, Syt2, Lim2, Mboat1, St3ga16, Slc39a12, Tacr1, Lrtm1, Dscam and CD201. | 07-10-2014 |
20140199712 | COMPOSITIONS AND METHODS FOR CAPTURE OF CELLULAR TARGETS OF BIOACTIVE AGENTS - The present invention provides compositions and methods for capture and identification of the cellular targets of a bioactive agent. In particular, provided herein are bioactive agents tethered to capture ligand, cellular targets (optionally tagged with a reporter), capture proteins (optionally present as capture fusions), surfaces (e.g., displaying, capture ligands, capture proteins, or capture fusions), and methods of capturing and identifying the cellular targets of a bioactive agent therewith. | 07-17-2014 |
20140199713 | APPARATUS AND METHODS FOR CONDUCTING ASSAYS AND HIGH THROUGHPUT SCREENING - The present invention provides microfluidic devices and methods for using the same. In particular, microfluidic devices of the present invention are useful in conducting a variety of assays and high throughput screening. Microfluidic devices of the present invention include elastomeric components and comprise a main flow channel; a plurality of branch flow channels; a plurality of control channels; and a plurality of valves. Preferably, each of the valves comprises one of the control channels and an elastomeric segment that is deflectable into or retractable from the main or branch flow channel upon which the valve operates in response to an actuation force applied to the control channel. | 07-17-2014 |
20140212892 | Method For Automated Tissue Analysis - The invention provides an improved method for identifying and interpreting tissue specimens and/or cells derived from tissue specimens. A panel of cell-based reagents provides a number of readouts of cellular states or biomarkers that together define a profile of a diversity of cellular states or biomarkers in a tissue specimen representing the ‘systems” nature of biology. This cellular profile is interpreted using informatics tools, to identify similarities between specimens, in vivo medical conditions, and suggest options for treating medical conditions. | 07-31-2014 |
20140212893 | L-SERINE COMPOSITIONS, METHODS AND USES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS - L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD). | 07-31-2014 |
20140212894 | METHOD OF DIAGNOSING SURGICAL SITE INFECTIONS - A marker useful in diagnosing surgical site infections is provided. In the method of the present invention for detecting surgical site infections, sCD14-ST in a sample is measured. | 07-31-2014 |
20140234864 | MAGNETIC REMOVAL OR IDENTIFICATION OF DAMAGED OR COMPROMISED CELLS OR CELLULAR STRUCTURES - A method for magnetic cellular manipulation may include contacting a composition with a biological sample to form a mixture. The composition may include a plurality of particles. Each particle in the plurality of particles may include a magnetic substrate. The magnetic substrate may be characterized by a magnetic susceptibility greater than zero. The composition may also include a chargeable silicon-containing compound. The chargeable silicon-containing compound may coat at least a portion of the magnetic substrate. The biological sample may include cells and/or cellular structures. The method may also include applying a magnetic field to the mixture to manipulate the composition. | 08-21-2014 |
20140234865 | INSTRUMENT AND METHOD FOR OPTICAL PARTICLE SENSING - Devices for detecting particle sizes and distributions using focused light scattering techniques, by passing a sample through a focused beam of light, are disclosed. In one embodiment, the devices include one or more lasers, whose light is focused into a narrow beam and into a flow cell, and dispersions are passed through the flow cell using hydrodynamic sample injection. In another embodiment, a plurality of lasers is used, optionally with hydrodynamic sample injection. Particles pass through and scatter the light. The scattered light is then detected using scatter and extinction detectors, and, optionally, fluorescence detectors, and the number and size of the particles is determined. Particles in the size range of 0.1 to 10 μm can be measured. Using the device, significantly smaller particles can be detected than if techniques such as EQELS, flow cytometry, and other conventional devices for measuring biological particles. | 08-21-2014 |
20140242609 | Diagnosis and treatment of kidney stones, methods and compositions therefor - Methods of detecting, diagnosing, monitoring and treating kidney stones are disclosed. In some embodiments, methods of detecting, diagnosing or monitoring kidney stones comprise contacting a urine sample with anti-Claudin-14 antibody, and detecting quantity of a complex comprising Claudin-14 and the antibody, wherein an increase compared to control levels is diagnostic for kidney stones. In some embodiments, methods further comprise testing a second sample at a second time point to detect increased kidney stones. In some embodiments, methods of treating kidney stone disease comprise administering an miR-9 mimic or an miR-374 mimic. In some embodiments, methods comprise administering an inhibitor of CaSR signaling. In some embodiments, methods comprise administering a HDAC inhibitor. In some embodiments methods of treating hyperparathyroidism and hypercalcemia are disclosed, comprising administering an agonist of CaSR. Methods of abrogating CaSR-mediated regulation of claudin-14, microRNAs and urinary Ca++ excretion are disclosed, comprising administering a calcineurin inhibitor. | 08-28-2014 |
20140242610 | Methods and Compositions for Cytometric Detection of Rare Target Cells in a Sample - The present disclosure provides cytometric methods for the detection of rare target cells in a sample. In certain aspects, the methods and compositions may facilitate the detection of rare target cells, such as circulating tumor cells (CTCs), in a biological sample such as blood. Aspects of the methods include contacting the sample with first and second binding members that specifically bind to a marker of the rare target cell, and cytometrically assaying the sample for the presence of cells comprising bound first and second binding members to detect the rare target cell in the sample. Also provided are systems, compositions, and kits for practicing the subject methods. | 08-28-2014 |
20140248638 | OXMIF AS A DIAGNOSTIC MARKER - The present invention pertains to the recognition that a specific oxMIF form of MIF is useful as a diagnostic marker in (MIF-related) diseases, in particular for example monitoring of disease progression. The present invention also pertains to the respective use of a diagnostic kit and a respective diagnostic assay and pertains to advantageous respective antibodies. | 09-04-2014 |
20140248639 | ASSAYS FOR IDENTIFYING COMPOUNDS THAT MODULATE BITTER TASTE - The present invention is based on applicants' discovery, disclosed herein, of agonists for the TAS2R receptors TAS2R1, TAS2R4, TAS2R9, TAS2R13, TAS2R14, TAS2R16, TAS2R44, TAS2R46, and TAS2R60. The assignment of agonists to these receptors makes assays for identifying compounds that modulate bitter taste possible. For example, the present invention provides methods of identifying compounds that inhibit the bitter taste due to these agonists. The present invention also provides methods of identifying compounds that selectively inhibit the bitter taste due to these agonists. The present invention further provides methods of identifying compounds that mimic the bitter taste due these agonists. The present invention also provides methods of identifying compounds that enhance the bitter taste due to these agonists. | 09-04-2014 |
20140273015 | BINDING COMPOUNDS TO HUMAN Beta 1-ADRENORECEPTOR (Beta 1-AR) AND THEIR USE IN MEASUREMENT OF AUTO-ANTI- Beta 1-AR ANTIBODIES - The present disclosure relates to binding compounds/antibodies that bind to the second extracellular loop of the human β1-adrenoreceptor (β1-AR-ECII) that are produced by/obtainable from a host cell/hybridoma with a deposit number selected from the group consisting of DSM ACC3121, DSM ACC3174, DSM ACC3175, DSM ACC3176 and DSM AC-C3177. The binding compounds/antibodies are particularly useful in determination of auto-anti-β1-AR antibodies in an in vitro cell based assay system in order to characterize and to identify auto-antibodies directed against the β1-AR-ECII in a biological sample. Further aspects of the disclosure are nucleic acid molecules encoding said binding compounds/antibodies, vectors, host cells, methods for producing the binding compounds/antibodies of the disclosure as well as a kit comprising the binding compounds/antibodies of the present disclosure. | 09-18-2014 |
20140287435 | KITS, COMPOSITIONS AND METHODS FOR DETECTING A BIOLOGICAL - The present invention provides kits, apparatus and methods for determining a biological condition in a mammalian subject, the method includes incubating a specimen from a patient with at least one composition in a kit for a predetermined period of time to form at least one reaction product, when the subject has said biological condition, and receiving an indication of the at least one reaction product responsive to at least one reporter element in the kit thereby providing the indication of the biological condition in the subject. | 09-25-2014 |
20140295458 | METHOD OF REVERSIBLY STAINING A TARGET CELL - The present invention relates to methods of reversibly staining a target cell. The invention also relates to methods of isolating a target cell or a target cell population that is defined by the presence of at least one common specific receptor molecule. The invention also provides kits that can be used to carry out the methods of the invention. | 10-02-2014 |
20140302527 | TARGET-SPECIFIC PROBE COMPRISING FERRITIN PROTEIN AND DETECTION FOR BIOMARKER USING THE SAME - This invention relates to a target-specific probe containing a ferritin fusion protein and a targeting agent, a target-specific imaging probe containing a labeling agent coupled to the target-specific probe, and a detection method or detection kit of a biomarker using these probes. | 10-09-2014 |
20140302528 | IDENTIFICATION OF BITTER LIGANDS THAT SPECIFICALLY ACTIVATE HUMAN T2R RECEPTORS AND RELATED ASSAYS FOR IDENTIFYING HUMAN BITTER TASTE MODULATORS - The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds. Also, the invention relates to the discovery of specific hT2R9 alleles and their disparate activity in functional assays with the same biter ligands. The invention further relates to the use of these T2R receptors in assays for identifying ligands that modulate the activation of these taste receptors by specific bitter ligands and related compounds. These compounds may be used as additives and/or removed from foods, beverages, cosmetics and medicinals in order to modify (block) T2R-associated bitter taste. Also T2R ligands may be used as therapeutics to treat and modulate T2R associated gastrointestinal and metabolic functions as well as treat gastrointestinal and metabolic diseases such as eating disorders, food sensing, food absorption, obesity, diabetes, Crohn's disease, celiac disease, et al. | 10-09-2014 |
20140322730 | Botulinum Neurotoxin E Receptors and Uses Thereof - An isolated polypeptide comprising an amino acid sequence selected from amino acids 506-582 of SV2A, wherein position 573 is N and is glycosylated, or amino acids 449-525 of SV2B, wherein position 516 is N and is glycosylated. The present invention also provides an antibody that binds specifically to the polypeptide, an isolated nucleic acid comprising a polynucleotide that encodes the polypeptide; a method for reducing BoNT/E toxicity in an animal; a method for identifying an agent that blocks or inhibits binding between BoNT/E and an SV2A or SV2B protein; a method for monitoring synaptic vesicle endo- or exocytosis, a method for specifically delivering a chemical entity to a cell which has a specific receptor to a BoNT toxin. Also provided are a chimeric toxin for targeting a proteolytic domain of a toxin to a cell, the chimeric toxin comprising a catalytic or proteolytic domain of the BoNT toxin, and a ligand or a fragment thereof for a non-BoNT receptor on the cell; a method for targeting a proteolytic domain of a BoNT toxin to a cell, an isolated non-neuronal cell comprising a BoNT toxin receptor; and a method for screening for an inhibitor of a BoNT toxin. | 10-30-2014 |
20140329255 | METHODS OF SCREENING T1R1/T1R3 RECEPTORS FOR COMPOUNDS THAT MODULATE UMAMI TASTE SIGNALING - The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners. | 11-06-2014 |
20140349311 | THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES OR ALLERGY, AND METHOD FOR SCREENING FOR THE THERAPEUTIC AGENT - Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between Sema3A and a Neuropilin-1/Plexin-A1 heteroreceptor. The substance includes, for example, a Sema3A neutralizing antibody, a Neuropilin-1 neutralizing antibody, or a soluble Neuropilin-1 or derivative thereof. Also disclosed is a method for screening a therapeutic agent for treating a cellular immune disease utilizing a signal generated by the interactions of Neuropilin-1, Plexin-A1 and Sema3A as a marker. | 11-27-2014 |
20140356884 | Boundary Layer Suction for Cell Capture - Capturing particles includes introducing a fluid sample, which includes particles of a first type, into a first channel of a microfluidic device and flowing the fluid sample past a porous or partially porous membrane. The pores fluidly connect the first channel to a second channel, and the device further includes multiple binding moieties on a first side of the porous membrane adjacent to the first channel. The binding moieties are capable of binding to the first type of particles. Capturing particles also includes creating a pressure difference between the first and second channels to enable the fluid sample to flow from the first channel through the porous membrane into the second channel and to direct the particles toward the binding moieties, thereby capturing the first type of particles. In addition, by creating a modified capture surface that is impermeable near the walls of the channels, capture efficiencies and throughput can be increased. | 12-04-2014 |
20140370522 | DETECTION OF PROTEIN TRANSLOCATION BY BETA-GALACTOSIDASE REPORTER FRAGMENT COMPLEMENTATION - Methods and compositions are provided for detecting molecular translocations, particularly protein translocations within and between sub-cellular compartments, using at least two components that exhibit a localization-dependent difference in complementation activity. In particular, alpha-complementing β-galactosidase fragments are provided. These β-galactosidase reporter fragments display significantly enhanced enzymatic activity when one fragment is localized in a membrane. Methods for carrying out no-wash ELISA assays based on the reporter component system are also provided. | 12-18-2014 |
20140370523 | Methods of Determining Patient Response by Measurement of HER-2 Expression - Methods are provided for determining or otherwise assessing the response of a patient to treatment, in particular, to cancer treatment. The methods include the analysis of samples for the presence or the absence of HER2 markers alone or in conjunction with other biomarkers, such as HER3 markers. In certain examples, the probable time to progression can be determined by first determining HER2 positive patients and then further stratifying by using the presence or the absence of a second biomarker (e.g, HER3 markers). In addition, the data can be used to track a patient's response to a treatment regimen, assessing the expected success of treating a patient using a particular regiment, determining the effects of a treatment regiment or for categorizing a patient in order to create a homogenous group for a clinical trial. | 12-18-2014 |
20140377777 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Insulin-like growth factor-binding protein 7, Beta-2-glycoprotein 1, Metalloproteinase inhibitor 2, Alpha-1 Antitrypsin, Leukocyte elastase, Serum Amyloid P Component, C-X-C motif chemokine 6, Immunoglobulin A, Immunoglobulin G subclass I, C-C motif chemokine 24, Neutrophil collagenase, Cathepsin D, C-X-C motif chemokine 13, Involucrin, Interleukin-6 receptor subunit beta, Hepatocyte Growth Factor, CXCL-1, -2, -3, Immunoglobulin G subclass II, Metalloproteinase inhibitor 4, C-C motif chemokine 18, Matrilysin, C-X-C motif chemokine 11, and Antileukoproteinase as diagnostic and prognostic biomarker assays of renal injury in the sepsis patient. | 12-25-2014 |
20140377778 | Determination of sFlt-1:Angiogenic Factor Complex - Methods for determining the presence or amount of a complex comprising a first and second molecular entity are provided, preferably an sFlt-1:PlGF complex. A determination of the presence or amount of the complex can be used in methods for predicting, detecting, monitoring a disease, or guiding therapy in respect to a disease such as vascular, vascular-related disease, cardiac, cardiac-related disease, cancer, cancer-related disease, preeclampsia, and preeclampsia-related disease. Determining sFlt-1:angiogenic factor complex is particularly useful for predicting and detecting preeclampsia in early stages of gestation and in stages of the disease where clinical evaluation may be uninformative. | 12-25-2014 |
20150010922 | METHODS OF SELECTING RETINAL PIGMENTED EPITHELIAL CELLS - A method of selecting retinal pigmented epithelial (RPE) cells from a mixed population of cells is disclosed. The method comprises:
| 01-08-2015 |
20150017659 | PROFILING OF SIGNAL PATHWAY PROTEINS TO DETERMINE THERAPEUTIC EFFICACY - The present invention provides methods for detecting, measuring and quantitating the activation states of components of the PI3K signaling pathway in cells such as tumor cells. In particular embodiments, the present invention enable the determination of tumor adaptation to anticancer therapy. Accordingly, the present invention provides methods for improved cancer therapy selection/adjustment and disease monitoring. | 01-15-2015 |
20150024406 | INCREASED AQUAPORIN EXPRESSION ON CELLULAR MEMBRANE TO IMPROVE CRYOPRESERVATION EFFICIENCY - A method of storing mammalian cells or tissue (e.g., liver cells or hepatocytes) for subsequent use comprises the steps of: (a) contacting the cells or tissue in vitro to a choleretic agent in an effective amount; (b) combining said cells or tissue with a cryopreservative; (c) freezing said cells or tissue, and then (d) storing said frozen cells or tissue in frozen form for subsequent use. | 01-22-2015 |
20150024407 | T1R Hetero-Oligomeric Taste Receptors - Newly identified mammalian taste-cell-specific G protein-coupled receptors which function as hetero-oligomeric complexes in the sweet taste transduction pathway, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in sweet taste signaling as hetero-oligomeric complexes, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for identifying putative taste modulating compounds using such hetero-oligomeric complexes also described, as is a novel surface expression facilitating peptide useful for targeting integral plasma membrane proteins to the surface of a cell. | 01-22-2015 |
20150024408 | WATER SOLUBLE NANOCRYSTALLINE QUANTUM DOTS CAPABLE OF NEAR INFRARED EMISSIONS - A novel quantum dot capable of near infrared emissions at wavelengths of 750-1100 is made by forming solid solutions of metal sulfide, metal selenide or metal sulfide selenide by incorporating a suitable amount of an additional metallic element or elements to provide an emission wavelength in the range of 750 nm to 1100 nm. The quantum dots may be enabled for bioconjugation and may be used in a method for tissue imaging and analyte detection. | 01-22-2015 |
20150050667 | Cell-Surface Signatures for Isolating Neurons from Cell Cultures Derived from Pluripotent Stem Cells - The inventors disclose methods and systems that provide for the isolation and purification of neurons directly from heterogeneous cell cultures. The expression of various cell adhesion molecules was examined in pluripotent stem cells. Changes in the expression of one or more of these molecules correlates with the progression of cells from non-lineage committed to neural cells. Using one or more antibodies for these molecules in combination with antibodies specific for CD200 will enable one to identify and isolate neurons from a population cells. | 02-19-2015 |
20150050668 | ASSAY FOR ANTI-TR ANTIBODIES - The present invention relates to a method for determining the presence of anti-Tr antibodies in a subject comprising the steps of obtaining a sample from said subject testing the presence of said antibodies in said sample by addition of DNER protein or an antigenic part thereof and checking whether said DNER protein is bound by any antibodies in said sample Such an assay is useful for the diagnosis of paraneoplastic cerebellar degeneration that is associated with Hodgkin lymphoma, or, more generally, to type patients suffering from cerebellar ataxia. Also comprised in the invention is a kit for performing such an assay. | 02-19-2015 |
20150064720 | BIOMOLECULE-GRAPHENE QUANTUM DOT CONJUGATES AND USE THEREOF - The invention relates to biomolecules conjugated to graphene quantum dots, and in particular, to use of such biomolecule-graphene quantum dot conjugates as fluorophores for imaging applications. | 03-05-2015 |
20150072356 | APPLICATION OF INTEGRIN BETA SUBUNIT IN DIAGNOSING VENOUS THROMBOEMBOLISM - The present invention provides a method for diagnosing venous thromboembolism (VTE), comprising: detecting the level of an integrin β1 subunit, an integrin β2 subunit, and/or an integrin β3 subunit in a blood sample. Also provided is a reagent kit for diagnosing VTE, comprising a substance capable of specifically binding to the integrin β1 subunit, the integrin β2 subunit, and/or the integrin β3 subunit. | 03-12-2015 |
20150079609 | QUICK TEST FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE - The invention relates to method for the diagnosis of Alzheimer's disease or the early stages thereof or a predisposition to said disease. Said method is based on quantitative determination of a mitogenically expressible surface marker, in particular CD69, and peripherally accessible cells, e.g. skin cells or lymphocytes, (a) prior to and (b) after mitogenic stimulation. A specific stimulation index a:b is an indication of Alzheimer's disease or early stages thereof or of a predisposition to said disease. The invention also relates to kits which are suitable for carrying out the inventive method of diagnosis. | 03-19-2015 |
20150079610 | Chimeric Fc-gamma Receptor and Method for Determination of ADCC Activity by Using the Receptor - An objective of the present invention is to provide chimeric receptors containing a mouse Fcγ receptor extracellular domain and a human Fcγ receptor transmembrane domain, or chimeric receptors containing a mouse Fcγ receptor extracellular domain and a human γ chain transmembrane domain. Another objective of the present invention is to provide methods for measuring the ADCC activity of mouse antibodies and methods of screening for mouse antibodies having ADCC activity, using the chimeric receptors. | 03-19-2015 |
20150087000 | DIAGNOSTIC KITS TO DETECT SP22 AND SP22 ANTIBODIES - Oral, topical and injectable contraceptives, which are based on sperm protein 22 kDa (SP22) polypeptides and antibodies and infertility diagnostics and kits are provided. | 03-26-2015 |
20150093761 | Differentiation and amplification method for inducing human neuralstem/progenitor cells to differentiate into oligodendrocyte progenitor cells andapplication thereof - A Method for inducing human neural stem/progenitor cells to differentiate into oligodendrocyte progenitor cells and application thereof comprises following steps of: pre-treating neural stem cells derived from different resources in pre-treatment medium including bFGF and EGF for culturing; and inducing neural stem cells after pre-treating with inducing medium including PDGF-AA, bFGF and NT3, so as to differentiate into oligodendrocyte progenitor cells (OPCs). Main markers of the OPCs obtained by the method, such as NG2, O4, A2B5 and PDGFR, have a positive rate of 80˜90%. The OPCs obtained thereby is capable of proliferating steadily in the OPCs inducing medium for at least 10 generations and simultaneously maintaining biological characteristics thereof unchanged. The OPCs induced by the present invention can be applied in treating myelin-associated diseases or researching on drug screening. | 04-02-2015 |
20150093762 | HEPATIC STELLATE CELL PRECURSORS AND METHODS OF ISOLATING SAME - The present invention relates to precursor cells to hepatic stellate cells, compositions comprising same and methods of isolating same. The surface antigenic profile of the precursors is MHC class Ia negative, ICAM-1 | 04-02-2015 |
20150093763 | METHOD FOR DIAGNOSIS OF PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS - A method for the diagnosis and/or therapy control of systemic sclerosis is disclosed wherein soluble CD90 is detected in body fluids. By measuring the concentration of soluble CD90 certain forms of diseases can be differentiated by applying the ex vivo method. | 04-02-2015 |
20150093764 | BLOCKING REAGENT COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Blocking reagent compositions, as well as methods of making and using the same, are provided. Aspects of the composition include a blocking reagent that binds to the cell surface but does not specifically bind to a targeted first cell surface antigen. Also provided are system and kits that include the compositions. | 04-02-2015 |
20150093765 | METHOD OF PROGNOSIS - The present invention relates to the use of soluble CD163 as a prognostic marker for the assessment of the risk for contracting a disorder, in particular for contracting diabetes and/or a liver disorder. The invention also relates to the use of CD163 as a prognostic marker for assessing lifetime expectancy. | 04-02-2015 |
20150104811 | METHOD FOR PRETREATING BIOLOGICAL SAMPLE CONTAINING PROTEIN - The present invention provides a method for pretreatment of a biological sample in the immunoassay of a protein contained in the biological sample. The method includes the steps of: (1) freezing the biological sample at a temperature higher than −80° C., in particular at −70° C. or higher; (2) thawing the frozen biological sample; and (3) solubilizing the biological sample using a surfactant. | 04-16-2015 |
20150104812 | MICRO-ENGINEERED HYDROGELS - A polyacrylamide hydrogel includes co-polymerized acrylamide, bisacrylamide and N-hydroxyethylacrylamide | 04-16-2015 |
20150104813 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) - The invention provides prognostic methods for evaluating the severity of NMO and NMO-associated diseases as well as methods of treating NMO and NMO-associated diseases. | 04-16-2015 |
20150111224 | BIOMARKERS FOR ADVERSE CARDIAC REMODELING - The present invention provides for certain biomarkers for adverse cardiac remodeling. The biomarkers have predictive value in assessing the risk of a subject developing heart failure and other conditions related to adverse cardiac remodeling, as well as diagnosing adverse cardiac remodeling, and determining response to therapy addressing adverse cardiac remodeling. | 04-23-2015 |
20150111225 | METHOD FOR IN VITRO DIFFERENTIATION OF BLOOD CIRCULATING CELLS INTO NEURONAL-LIKE CELLS AND APPLICATIONS THEREOF - The present invention relates to a method for in vitro differentiation of a population of blood circulating cells, such as monocytes and preferably pluripotent macrophages derived therefrom, into cells displaying functional and phenotypic neuronal characteristics. The invention further encompasses neuronal-like cells obtainable according to the present method, compositions comprising said cells, and applications thereof. | 04-23-2015 |
20150118693 | METHOD OF HIGH-THROUGHPUT SORTING OF HIGH EXPRESSION CELL AND CELLS SORTED THEREFROM - The invention provides a method of high-throughput sorting of high expression protein-producing cell, which utilizes linking a protein and a transmembrane domain with a self-processing cleavage site and regulating the secretion of the protein or expression of protein on the cell membrane by adding self-processing cleavage enzyme inhibitor. Then, the high expression cell line can be high-throughput sorted by a detection technique. The invention also provides a recombinant nucleotide sequence and a vector used in the method and a cell sorted by the method. | 04-30-2015 |
20150132773 | IDENTIFICATION OF ATYPICAL ANTIBODIES IN HUMAN BLOOD AND BLOOD PRODUCTS - A method identifies atypical antibodies in blood or blood product manufacturing processes that may produce false positives in quality control testing on intermediate or final products. | 05-14-2015 |
20150132774 | FLUORESCENT PROTEIN VOLTAGE SENSORS FOR MEASURING MEMBRANE POTENTIAL AND IMAGING HIGH-FREQUENCY NEURONAL ELECTRICAL ACTIVITY - Fluorescent protein voltage sensors for measuring membrane potential and imaging high-frequency neuronal electrical activity are disclosed. In particular, the invention relates to engineered protein voltage sensors that comprise a voltage-sensing domain comprising four transmembrane domains linked to a circularly permuted fluorescent protein, which is inserted into the extracellular loop between the third (S3) and fourth (S4) transmembrane segments of the voltage-sensing domain. Such fluorescent protein voltage sensors can be used for measuring the electrical activity of neurons, including single action potentials, trains of action potentials, and subthreshold potential changes and, in particular, for imaging high-frequency neuronal electrical activity. Additionally, fluorescent protein voltage sensors can be used for a variety of other purposes, including measuring the membrane potential of any cell, including other excitable cells such as cardiac cells and endocrine cells, and for screening agents that target ion channels for their effects on membrane potential. | 05-14-2015 |
20150301024 | METHOD OF SCREENING MODULATOR OF XKR8 - The disclosure relates to a method of screening a modulator of Xkr8, comprising the steps of:
| 10-22-2015 |
20150301042 | Methods Of Using Chimeric Receptors To Identify Autoimmune Disease - The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays. | 10-22-2015 |
20150307916 | QUINONE-MASKED PROBES AS LABELING REAGENTS FOR CELL UPTAKE MEASUREMENTS - Provided are labeling reagents and methods of using the reagents for cell uptake measurements. The labeling reagents can be quinone-masked probes including fluorophores and/or luminophores. | 10-29-2015 |
20150323533 | Detection Device for In Vivo and/or In Vitro Enrichment of Sample Material - The invention relates to a detection device for in vivo and/or in vitro enrichment of sample material, including a functional surface equipped with detection receptors, in which the functional surface is located directly or indirectly on a measuring structure that includes optically conductive material for optical measurement of target molecules enriched on the detection receptors. | 11-12-2015 |
20150346208 | PD-L1 Antibodies and Uses Thereof - Provided herein are novel PD-L1 antibodies and methods for using the same for diagnosing a medical condition associated with elevated PD-L1 levels (e.g., cancer) in subjects in need thereof and antigen binding fragments thereof. The PD-L1 antibodies and antigen binding fragments are also useful in evaluating the efficacy of a particular therapeutic regime in a subject diagnosed as having a PD-L1-related medical condition. | 12-03-2015 |
20150355184 | ANTIBODIES THAT BIND TO HUMAN PROGRAMMED DEATH LIGAND 1 (PD-L1) - The present disclosure provides isolated antibodies that specifically bind to human PD-L1, as well as antigen binding fragments of such antibodies, and kits comprising the anti-PD-L1 antibodies or binding fragments and a set of reagents for detecting a complex of the antibody, or antigen binding fragment thereof, bound to human PD-L1. The antibodies and antigen binding fragments of this disclosure are useful for immunohistochemical detection of human PD-L1 expression in tissue samples. Nucleic acid molecules encoding the antibodies and antigen binding fragments of this disclosure, as well as expression vectors and host cells for expression thereof, are also provided. | 12-10-2015 |
20150355191 | Cell-Based Assay for Neutralizing Antibodies - The present disclosure relates to a method for detecting the presence of PDGF neutralizing antibodies in a serum sample, comprising contacting a population of cells with i) a serum sample, and ii) PDGF, wherein the cells comprise a PDGF receptor; and detecting an amount of a biomarker in the population of cells, wherein the biomarker indicates binding of the PDGF with the PDGF receptor. The present disclosure also relates to a method of determining the presence of PDGF neutralizing antibodies in a subject who has received or is currently receiving a treatment comprising PDGF. | 12-10-2015 |
20150355204 | MARKER FOR DEPRESSION, ASSAY METHOD, METHOD FOR DETERMINING DEPRESSION, SCREENING METHOD FOR ANTIDEPRESSANTS, AND KIT - Disclosed herein are a method and a kit using a novel marker associated with depression. The marker for depression includes one or more selected from a noradrenaline transporter and a dopamine transporter. The method for determining depression includes a step of examining an expression level of the marker for depression in a blood sample collected from a subject. | 12-10-2015 |
20150362484 | CHROMOPHORE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Chromophore compositions and methods of making and using the same are provided. Aspects of the chromophore compositions include a chromophore component having a chromophore, such as a fluorescent dye moiety, stably associated with a prosthetic group binding cavity of a metalloprotein. Also provided are methods of making, methods of use, systems and kits related to the subject fluorescent compositions. | 12-17-2015 |
20150362489 | RECEPTORS OF RSPO2 AND RSPO3 - The present invention relates to the finding that Syndecans (Sdc) are receptors of Rspondin-2 (Rspo2) and Rspondin-3 (Rspo3). Thus, the present invention relates to the identification of Rspo2, Rspo3 and/or Sdc activity modulators by determining if a test compound has the ability to modulate the binding of an Rspo2 and/or Rspo3 polypeptide to an Sdc polypeptide. Further, the invention refers to novel uses for antagonists of Rspo2 and/or Rspo3 in the treatment of Sdc-associated disorders and for Sdc antagonists in the treatment of Rspo2- and/or Rspo3-associated disorders. | 12-17-2015 |
20150376261 | NOVEL CHIMERIC POLYPEPTIDES FOR SCREENING AND DRUG DISCOVERY PURPOSES - Described are polypeptides and their use for screening and drug discovery. More specifically, the disclosure provides chimeric polypeptides comprising a membrane protein, in particular a GPCR, fused to a binding domain, wherein the binding domain is directed against and/or specifically binds to the membrane protein. In particular, the chimeric polypeptides are single proteins wherein, in an intramolecular reaction, the binding domain stabilizes the membrane protein in a conformation of interest. Also provided are nucleic acid sequences encoding such chimeric polypeptides, cells capable of expressing such chimeric polypeptides as well as cellular compositions derived thereof. Also screening methods for compounds using the chimeric polypeptides. | 12-31-2015 |
20150376576 | Subpopulations of Spore-Like Cells and Uses Thereof - Subpopulations of spore-like cells expressing specific cell surface and gene expression markers are provided. In one embodiment, the cells express at least one cell surface or gene expression marker selected from the group consisting of Oct4, nanog, Zfp296, cripto, Gdf3, UtF1, Ecat1, Esg1, Sox2, Pax6, nestin, SCA-1, CD29, CD34, CD90, B1 integrin, cKit, SP-C, CC10, SF1, DAX1, and SCG10. Also provided are methods for purifying a subpopulation of spore-like cells of interest from a population of spore-like cells, and methods for inducing differentiation of the isolated spore-like cells into cells of endodermal, mesodermal or ectodermal origin. The spore-like cells can be used to generate cells originating from all three germ layers and can be used to treat a patient who has a deficiency of functional cells in any of a wide variety of tissues, including the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system. | 12-31-2015 |
20150377887 | IN SITU AFFINITY MATURATION OF ANTIBODIES - This disclosure relates to a method to mimicking the germinal center reaction to generate antibodies with altered binding properties or increased affinity directly in hybridomas. To allow convenient and rapid affinity maturation of antibodies, a controllable activation-induced cytidine deaminase (AID) expression system to induce somatic hypermutation in hybridomas is developed. Selection of high affinity antibodies is achieved by fluorescence-activated cell sorting of hybridomas that preferentially bind fluorescence-labeled antigens. The disclosure also relates to de novo generation of hybridomas with tunable antibody affinity by generating myeloma fusion partners with controllable AID expression. | 12-31-2015 |
20160002322 | ANTIBODIES AGAINST TM4SF5 AND ANTICANCER COMPOSITIONS COMPRISING THE SAME - The present invention provides an antibody or antigen binding fragment thereof, that binds to TM4SF5, and uses thereof. The antibody of this invention inhibits the growth, metastasis and invasion of cancer cells expressing TM4SF5 by binding to a tumor-specific antigen, TM4SF5, with high affinity, and therefore can be used to diagnose, prevent or treat various cancers expressing TM4SF5. | 01-07-2016 |
20160002603 | SELECTIVE CELL THERAPY FOR THE TREATMENT OF RENAL FAILURE - Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein cells have been expanded in vitro. The kidney cells may include peritubular interstitial cells of the kidney, and preferably produce erythropoietin (EPO). The kidney cells may also be selected based upon EPO production. Methods of producing an isolated population of EPO producing cells are also provided, and methods of treating a kidney disease resulting in decreased EPO production in a patient in need thereof are provided, including administering the population to the patient, whereby the cells produce EPO in vivo. | 01-07-2016 |
20160002668 | COMPOSITIONS AND METHODS OF USE THEREOF FOR IDENTIFYING ANTI-VIRAL AGENTS - The present disclosure provides a recombinant expression vector comprising a nucleotide sequence encoding a herpesvirus transactivator, where the nucleotide sequence is operably linked to a herpesvirus control element. The present disclosure provides cell lines genetically modified to express a herpesvirus transactivator under the control of a herpesvirus control element. The present disclosure provides methods of identifying agents that disrupt feedback regulation of a herpesvirus transcriptional control element by a herpesvirus transactivator. | 01-07-2016 |
20160003824 | METHOD OF DETECTING CLEAVED SNAP25 IN TISSUE SAMPLES - Methods and compositions for detecting BoNT/A enzymatic activity in tissues or a tissue sample are described herein. The invention encompasses antibodies that bind preferentially to BoNT/A cleaved SNAP25 and is able to preferentially detect BoNT/A cleaved SNAP25, as compared to intact (non-cleaved) SNAP25, in a tissue sample. | 01-07-2016 |
20160003852 | FELINE BITTER TASTE RECEPTORS AND METHODS - A family of novel feline bitter taste receptors, referred to as feline TAS2R (fTAS2R), are disclosed herein. Isolated polynucleotides encoding the novel feline bitter taste receptors and chimeric polypeptides are also disclosed, as are expression vectors and host cells for expression of the novel feline bitter taste receptors. Methods of identifying compounds that bind to the novel feline bitter taste receptors and modulate their activity are disclosed. | 01-07-2016 |
20160011114 | PHOTOMETRIC ANALYSIS METHOD AND PHOTOMETRIC ANALYSIS DEVICE USING MICROCHIP, MICROCHIP FOR PHOTOMETRIC ANALYSIS DEVICE, AND PROCESSING DEVICE FOR PHOTOMETRIC ANALYSIS | 01-14-2016 |
20160011191 | DETECTION KIT AND DETECTION METHOD | 01-14-2016 |
20160018395 | POLYMER DOT COMPOSITIONS AND RELATED METHODS - Lyophilized chromophoric polymer dot compositions are provided. Also disclosed are methods of making and using the lyophilized compositions, methods of dispersing the lyophilized compositions in aqueous solutions and kits supplying the compositions. | 01-21-2016 |
20160018416 | NEW DUAL BIOMARKER OF NEURODEGENERATION AND OF NEUROREGENERATION - A new dual biomarker of neurodegeneration and of neuroregeneration | 01-21-2016 |
20160024215 | LLT-1 ANTIBODIES WITH NEW FUNCTIONAL PROPERTIES - The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies, and to cells that express such antibodies. antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis. | 01-28-2016 |
20160033524 | Methods of Detecting Donor-Specific Antibodies and Systems for Practicing the Same - Provided are methods for determining the presence or absence of donor specific antibodies in a biological sample. The methods include mixing a cellular sample from a donor with a biological sample from a recipient under conditions sufficient for recipient immune antibodies, if present, to bind to donor cell surface antigen (Ag) to form an immune antibody-Ag complex, contacting the mixture with beads comprising an antibody that specifically binds the immune antibody-Ag complex (e.g., the Ag or immune antibody) on a surface thereof, adding under lysis conditions a detectably-labeled antibody that specifically binds the immune antibody-Ag complex bound to the beads, and detecting the presence or absence of the detectably-labeled antibody bound to the immune antibody-Ag complex to determine the presence or absence of donor specific antibodies in the biological sample from the recipient. Systems and kits for practicing the subject methods are also provided. | 02-04-2016 |
20160033530 | ISOLATING CELLS EXPRESSING SECRETED PROTEINS - A method of detecting and isolating cells that produce a secreted protein of interest (POI), for example, an antibody, comprising: a) providing a eukaryotic cell comprising (i) a nucleic acid encoding the POI, and (ii) a nucleic acid encoding a cell surface capture molecule, which comprises a membrane anchor and is capable of binding the POI; (b) culturing the cell under conditions in which the POI and cell surface capture molecule are expressed, and a POI-cell surface capture molecule complex is formed intracellularly and displayed on the cell surface; c) detecting the surface-displayed POI by contacting the cells with a detection molecule, which binds the POI; and d) isolating cells based on the detection molecule. | 02-04-2016 |
20160046905 | PLURIPOTENT STEM CELL FOR NEURONAL DIFFERENTIATION INDUCTION - The present invention aims to provide a method of producing motor neurons/neurons that sufficiently reproduce intrinsic properties of motor neurons/neurons, especially of the motor neurons/neurons in patients, from pluripotent stem cells promptly and synchronically, and a pluripotent stem cell capable of differentiating into a neuron or a motor neuron promptly and synchronically after a drug treatment. | 02-18-2016 |
20160047808 | DEPLETION OF MOUSE CELLS FOR ISOLATION OF HUMAN CELLS - Object of the invention is a process for depleting host cells from a xenograft of human cells on a murine host characterized in
| 02-18-2016 |
20160054338 | Methods for Predicting Cardiovascular Mortality Risk - The present invention relates to a method for predicting cardiovascular mortality risk in a patient, comprising determining the level of endothelial microparticles in a blood sample obtained from said patient. | 02-25-2016 |
20160060589 | PARTICLE TRANSPORTING SYSTEM AND METHOD OF OPERATING THE SAME - The present invention provides a particle transporting system including a holder, a vibrator and a tube. The vibrator connects the holder to provide vibration to the holder. The tube spirally surrounds the holder. A method of operating a particle transporting system is provided. The method includes the following steps: (a) providing a particle transporting system as shown above; (b) injecting a sample fluid with plural particles into the tube; and (c) transporting the sample fluid with the particles to a target apparatus with vibration provided by the vibrator. | 03-03-2016 |
20160068818 | A METHOD FOR GENERATING INDUCED PLURIPOTENT STEM CELLS - The invention relates to a method for generating induced pluripotent stem cells, wherein the method comprises: step a) of inducing non-pluripotent cells to produce a mixture comprising induced pluripotent stem cells and non-pluripotent cells; step b) of contacting the mixture comprising induced pluripotent stem cells and non-pluripotent cells obtainable from step a) with a binding agent, wherein the binding agent is capable of binding an epitope consisting of the non-reducing terminal saccharide structure according to formula (Fucα1-2) | 03-10-2016 |
20160069874 | ASSAY DEVICE - The disclosure relates to a method and device for detecting and quantifying biological molecules such as cell surface or intracellular ligands/receptors in a dynamic system with high sensitivity and specificity; the method of using such platform optionally in combination with an optical detection system and kits comprising the optical platform. | 03-10-2016 |
20160069876 | SYSTEMS, METHODS, AND WORKFLOWS FOR OPTOGENETICS ANALYSIS - The invention provides methods for characterizing cellular physiology by incorporating into an electrically excitable cell an optical reporter of, and an optical actuator of, electrical activity. A signal is obtained from the optical reporter in response to a stimulation of the cell. Either or both of the optical reporter and actuator may be based on genetically-encoded rhodopsins incorporated into the cell. The invention provides all optical methods that may be used instead of, or as a complement to, traditional patch clamp technologies and that can provide rapid, accurate, and flexible assays of cellular physiology. | 03-10-2016 |
20160069900 | IMMUNOASSAY FOR SOLUBLE PD-L1 - The present disclosure describes two matched antibody pairs for use in a sandwich immunoassay for detecting and quantifying soluble PD-L1 in liquid samples, as well as an electrochemiluminescence sandwich immunoassay that has been optimized and validated with one of the matched pairs. | 03-10-2016 |
20160069912 | DNA-based molecular switches and uses thereof - Disclosed are nucleic acid-based molecular switches that respond to changes in pH. The switches may be used in DNA nanodevices. The switches may also act as sensors for measuring the pH of a sample, including cells, regions thereof, and whole organisms. The switch includes an A-motif that forms at acidic pH. Also disclosed are compositions and methods for measuring the pH of cells or regions thereof, such as vesicles, the nucleus, mitochondrial matrix, or the Golgi lumen. | 03-10-2016 |
20160076056 | METHOD OF INACTIVATING A GLUCOCORTICOID RECEPTOR GENE IN AN ISOLATED CELL - Disclosed herein are methods and compositions for inactivation of the human glucocorticoid receptor (GR) gene by targeted cleavage of genomic DNA encoding the GR. Such methods and compositions are useful, for example, in therapeutic applications which require retention of immune function during glucocorticoid treatment. | 03-17-2016 |
20160084820 | METHODS OF TREATING OR PREVENTING PERIODONTITIS AND DISEASES ASSOCIATED WITH PERIODONTITIS - The present disclosure describes methods for preventing or treating periodontitis or diseases associated with periodontitis. The present disclosure also describes methods of screening for compounds that can be used to prevent or treat periodontitis or diseases associated with periodontitis. | 03-24-2016 |
20160084825 | STABILIZED LOW AFFINITY CONFORMATION OF INTEGRINS FOR DRUG DISCOVERY - The methods and compositions described herein are based, in part, on the discovery that the introduction of a disulfide bond into an integrin polypeptide by the substitution of at least one cysteine residue in the polypeptide permits stabilization of the integrin in a “closed/inactive” state. This stabilizing disulfide bond permits integrins to be screened for a candidate molecule that can bind to the closed state. In particular, this approach can be used to screen for agents that bind to the closed state of an integrin polypeptide, and are useful as therapeutic treatments to prevent integrin activation. | 03-24-2016 |
20160084834 | TASTE RECEPTOR INTERNALIZATION ASSAY - This disclosure provides a taste receptor internalization assay useful for identifying taste modulators. | 03-24-2016 |
20160084847 | STABILIZED LIQUID FORMULATIONS CONTAINING RECEPTORS - Methods and reagents are disclosed for preparing a liquid solution of a receptor. The methods comprise combining in a liquid medium the receptor, a chelating agent and a C2-C6 polyol. An amount of the chelating agent and the C2-C6 polyol is sufficient to achieve a stable and active receptor in the liquid solution, which is maintained at a temperature of about 2° C. to about 40° C. The compositions may be employed in assays for the determination of analytes that include receptor-binding analytes. | 03-24-2016 |
20160102130 | WATER SOLUBLE G-PROTEIN COUPLED RECEPTOR - Described herein are recombinant integral membrane proteins having multiple transmembrane domains that have been engineered to be less hydrophobic, through alteration of the amino acid sequence of the native protein, but retain the ability to bind their natural ligand. The decreased hydrophobicity of the described proteins makes them more water soluble than the native protein, which allows the described proteins to be expressed in bacteria in large quantities and isolated in the absence of membranes, all while retaining the ability to interact with known ligands. | 04-14-2016 |
20160109445 | IDENTIFICATION OF BITTER LIGANDS THAT SPECIFICALLY ACTIVATE HUMAN T2R RECEPTORS AND RELATED ASSAYS FOR IDENTIFYING HUMAN BITTER TASTE MODULATORS - The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds. Also, the invention relates to the discovery of specific hT2R9 alleles and their disparate activity in functional assays with the same biter ligands. The invention further relates to the use of these T2R receptors in assays for identifying ligands that modulate the activation of these taste receptors by specific bitter ligands and related compounds. These comounds may be used as additives and/or removed from foods, beverages, cosmetics and medicinals in order to modify (block) T2R-associated bitter taste. Also T2R ligands may be used as therapeutics to treat and modulate T2R associated gastrointestinal and metabolic functions as well as treat gastrointestinal and metabolic diseases such as eating disorders, food sensing, fod absorption, obesity, diabetes, Crohn's disease, celiac disease, et al. | 04-21-2016 |
20160123962 | IL-34 RECEPTOR ASSAYS AND USES THEREOF - Methods are disclosed for identifying activators and inhibitors of actions of interleukin-34 (IL-34) that are independent of the colony stimulating factor-1 (CSF-1) receptor (CSF-1R) and play a role in development, homeostasis and disease. | 05-05-2016 |
20160124000 | DETECTION OF PROTEIN TO PROTEIN INTERACTIONS - The present invention relates to methods and kits for detecting the interaction between a first membrane protein and a second protein in mammalian cells as well as to identify molecules that can disrupt protein to protein interactions. The invention relies on the functional reconstitution of an active human ubiquitin by two inactive fragments upon the interaction of two proteins attached through a linker to the inactive fragments. The reconstituted ubiquitin is then cleaved by human ubiquitin proteases resulting in the release of an artificial transcription factor, which in turn activates a reporter gene transcription. Activation of the reporter gene is indicative of the interaction between the two proteins. | 05-05-2016 |
20160131635 | CELL ANALYSIS BY MASS CYTOMETRY - A combination of mutually exclusive cell-based analytical techniques can be applied to the same group of cells for analysis. The same group of cells can be prepared for analysis by each technique resulting with candidate cells targeted for mass cytometry analysis. This configuration allows for the correlation of the information between each technique to produce a matrix of multi dimension of cellular information with the same group of cells. | 05-12-2016 |
20160131639 | NOVEL ANTIGEN BINDING PROTEIN AND ITS USE AS ADDRESSING PRODUCT FOR THE TREATMENT OF CANCER - The present invention relates to a novel antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to a novel antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers. | 05-12-2016 |
20160139155 | Method for determining mutateable ligand-GPCR binding at single amino acid resolution and pairs of mutated ligand and GPCR - Method of determining GPCR and mutatable ligand binding ability, includes providing a well microtiter plate with well array having rows and columns, GPCR or rhodopsin in wells, and parent ligand mutant binding to GPCR when GPCR resides in conformation, contacting parent ligand mutants in wells with GPCR, coupling parent ligand to GPCR, and determining mutant ligand binding strength compared to standard parent ligand and GPCR by determining coupled mutant-GPCR complex in wells. Rhodopsin binding 403 mutants covering arrestin sequence provides functional 4th dimension arrestin crystal structures. Resulting single amino acid resolution functional maps reveal critical interactions in arrestin polar core and C-tail interrupted during activation. Amino acid patches reduce binding and act as direct binding rhodopsin interfaces. This and computational molecular docking active arrestin4 and light-activated rhodopsin develop arrestin-rhodopsin complex model. Combined mutants allow binding affinity modification and GPCR-ligand complex stability for diagnostics or intervention. | 05-19-2016 |
20160153970 | SYNTHETIC MICROFLUIDIC SYSTEMS FOR HYPOXIA | 06-02-2016 |
20160153976 | POLYARGININE-COATED MAGNETIC NANOVECTOR AND METHODS OF USE THEREOF | 06-02-2016 |
20160161507 | Method and Prognostic Kit for Monitoring Multiple Sclerosis (MS) - A method and prognostic kit for assessing severity of MS in a subject suffering from MS, or for monitoring progression of MS in a subject suffering from MS, or for monitoring the effect of therapy administered to a subject suffering from MS. In both the method and prognostic kit, the level of one or more kynurenine pathway compounds in a tissue or body fluid of the subject suffering from MS are compared with a reference value for the one or more kynurenine pathway compounds. | 06-09-2016 |
20160168533 | ISOLATION, EXPANSION AND USE OF CLONOGENIC ENDOTHELIAL PROGENITOR CELLS | 06-16-2016 |
20160177273 | STEM CELLS FOR MODELING TYPE 2 DIABETES | 06-23-2016 |
20160186209 | RECOMBINANT CELLS AND METHODS OF USING SUCH CELLS TO IDENTIFY CIRCADIAN RHYTHM MODULATORS - The invention provides recombinant cells comprising detectable reporters useful in identifying agents, genes, and other modulators of circadian period length and amplitude. Such modulators are useful for resetting the circadian clock in a variety of contexts (e.g., jet lag, shift work). Such cells are also useful in selecting an administration regimen for a therapeutic agent, where the agent's efficacy and/or adverse side effects show circadian effects. | 06-30-2016 |
20160187322 | FELINE BITTER TASTE RECEPTORS AND METHODS - A family of novel feline bitter taste receptors, referred to as feline TAS2R (fTAS2R), are disclosed herein. Isolated polynucleotides encoding the novel feline bitter taste receptors and chimeric polypeptides are also disclosed, as are expression vectors and host cells for expression of the novel feline bitter taste receptors. Methods of identifying compounds that bind to the novel feline bitter taste receptors and modulate their activity are disclosed. | 06-30-2016 |
20160195513 | EVALUATION METHOD AND SCREENING METHOD FOR S1P1 RECEPTOR AGONIST | 07-07-2016 |
20160195522 | METHOD OF AGGLUTINATION IMMUNOASSAY | 07-07-2016 |
20160195541 | In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s) | 07-07-2016 |
20160195548 | ANTIBODY, KIT AND METHOD FOR DETERMINATION OF AMYLOID PEPTIDES | 07-07-2016 |
20170234857 | Methods and Test Kits for Determining Male Fertility Status | 08-17-2017 |
20170234874 | INTEGRATED VISUAL MORPHOLOGY AND CELL PROTEIN EXPRESSION USING RESONANCE-LIGHT SCATTERING | 08-17-2017 |
20080248531 | Preparation of fully human antibodies - The present invention provides a method of preparing fully human antibodies that recognize a pre-determined antigen without relying on human donors that have already been exposed to the antigen. To this end, lymphocytes from naive human donors are immunized in vitro with the antigen of interest, and cells that produce antibodies against the antigen are identified. Since the lymphocytes are immunized in vitro rather than in vivo, it is possible to control which antigen, or which part of the antigen, would be recognized by the antibody. A preferred antigen is gp120 of HIV, particularly the co-receptor binding region of gp120. | 10-09-2008 |
20090075341 | IL-21 ANTAGONISTS - Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, graft versous host disease, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases. | 03-19-2009 |
20090142807 | FUSION PARTNER FOR PRODUCTION OF MONOCLONAL RABBIT ANTIBODIES - The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications. | 06-04-2009 |
20110195456 | Methods and compositions for the production of monoclonal antibodies - The present invention comprises compositions and methods for making monoclonal antibodies. The present invention further comprises vectors that replicate the immune system components, particularly an antigen-presenting cell (APC) element of the immune synapse. Additionally, the present invention may further comprise synthetic T-cells. | 08-11-2011 |
20110236931 | CHEMICAL AND BIOCHEMICAL ADDUCTS AS BIOMARKERS FOR ORGANOPHOSPHATE EXPOSURE - Provided is a method to identify OP-adducted biomarkers of OP exposure as well as compounds containing OPs that can provide OP adducts. | 09-29-2011 |
20120301923 | DIALYSIS FERMENTER-BIOREACTOR WITH DIALYSIS DEVICE - The present disclosure provides systems and methods of using a semipermeable membrane in a dialysis fermenter as a separation layer between a cell-containing liquid culture medium and a non-cell-containing dialysis medium. In some embodiments, the semipermeable membrane may have a molecular cut-off of 15 kDa to 50 kDa. The instant disclosure also provides a dialysis fermenter with compartments for cell-containing culture medium, non-cell-containing nutrient solution as well as an exchange unit having a semipermeable membrane, wherein mass transfer takes place between the culture medium and the dialysis medium by means of diffusion and/or ultrafiltration. Methods for culturing cells are also disclosed. | 11-29-2012 |
20140004566 | Fusion Partner for Production of Monoclonal Rabbit Antibodies | 01-02-2014 |
20150147784 | Reagents and Methods for Detecting Influenza Virus Proteins - Two universally conserved sequences from influenza type A neuraminidases were identified by large scale sequence analysis then chemically modified and conjugated to carrier proteins to generate mono-specific and monoclonal antibodies. The two antibodies, one targeting the N-terminus of the type A neuraminidase and the other sequence close to enzymatic active site, were capable of binding to all 9 subtypes of neuraminidase while demonstrating remarkable specificity against the viral neuraminidase sequences since no cross-reactivity against allantoic proteins was observed. Quantitative analyses of NA using slot blot suggest that the antibodies can be used for NA antigen quantitation in vaccines. These represent the first time the antibody-based immunoassay can be used for NA quantitative determination. | 05-28-2015 |
20150353883 | Medium Supplements for Improved Process Performance - The present invention pertains to a cell culture medium comprising dextran sulfate or a mixture of dextran sulfate and ferric citrate, and methods of using thereof. The present invention further pertains to a method of producing a protein of interest in a large scale cell culture, comprising supplementing the cell culture with dextran sulfate or a mixture of dextran sulfate and ferric citrate. | 12-10-2015 |
20160017027 | Hybridoma Clones and Monoclonal Antibodies to Fibroblast Growth Factor 4 - The present invention is directed to a monoclonal antibody that recognizes human FGFR4 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody and methods of use thereof. | 01-21-2016 |
20160046712 | KIR-BINDING AGENTS AND METHODS OF USE THEREOF - The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided. | 02-18-2016 |
20160176975 | GENERATION OF A CANCER-SPECIFIC IMMUNE RESPONSE TOWARD MUC1 AND CANCER SPECIFIC MUC1 ANTIBODIES | 06-23-2016 |
435700300 | Animal tissue cell culture | 42 |
20080206819 | Intensified Perfusion Production Method - The invention comprises a process for producing a protein of interest in a perfusion system using induction agents without a substantial loss of cell viability. The invention also comprises methods of growing cells in a perfusion system using induction agents without a substantial loss of cell viability. | 08-28-2008 |
20090023186 | USE OF VALPROIC ACID FOR ENHANCING PRODUCTION OF RECOMBINANT PROTEINS IN MAMMALIAN CELLS - Culturing cells for the commercial production of proteins for diagnosis and therapy is a costly and time consuming process. The equipment required is expensive, and production cost are high. In order to provide commercially viable processes it is desirable to use cell lines which produce large quantities of product with each production run. However, most cells do not produce large quantities of desired product per se either because they do not produce a large quantity of product per unit of time (specific productivity) or because they do not survive long enough in the culture medium (time). Here, we identified that addition of a valproic acid compound to the culture medium increases overall (batch) yield and titer. More importantly, compared to the widely used sodium butyrate, batch yields using a valproic acid compound as a medium additive are significantly higher. | 01-22-2009 |
20090042253 | USE OF PERFUSION TO ENHANCE PRODUCTION OF FED-BATCH CELL CULTURE IN BIOREACTORS - The invention relates to methods of improving protein production, e.g., large-scale commercial protein production, e.g., antibody production, utilizing a modified fed-batch cell culture method comprising a cell growth phase and a polypeptide production phase. The modified fed-batch cell culture method combines both cell culture perfusion and fed-batch methods to achieve higher titers of polypeptide products. Because the modified fed-batch cell culture method of the invention produces higher polypeptide product titers than fed-batch culture alone, it will substantially improve commercial-scale protein production. The invention also relates to a perfusion bioreactor apparatus comprising a fresh medium reservoir connected to a bioreactor by a feed pump, a recirculation loop connected to the bioreactor, wherein the recirculation loop comprises a filtration device, e.g., ultrafiltration or microfiltration, and a permeate pump connecting the filtration device to a permeate collection container. | 02-12-2009 |
20090123975 | FEED MEDIA - The invention provides stable feed media containing pyruvate and methods for stabilizing feed media by adding pyruvate. The invention further provides methods for producing proteins using such media and proteins produced through the use of such methods. | 05-14-2009 |
20090258395 | IRX-2 MODIFIED MANUFACTURING PROCESS - A highly efficient method of making a primary cell derived biologic by purifying mononuclear cells (MNCs) in a automated cell processor to remove contaminating cells by loading leukocytes onto lymphocyte separation medium (LSM) and centrifuging the medium to obtain purified MNCs, storing the MNCs overnight in a closed sterile bag system, stimulating an induction mixture of the MNCs with phytohemagglutinin (PHA) or other mitogen and ciprofloxacin in a scalable cell culture device and producing a primary cell derived biologic from the MNCs, removing the mitogen from the induction mixture by filtering, incubating the induction mixture, clarifying the induction mixture by filtering to obtain a primary cell derived biologic supernatant, and clearing the primary cell derived biologic supernatant from adventitious agents by anion exchange chromatography, filtration. A closed system prevents contamination of the resulting primary cell derived biologic. An automated method of purifying cells. A method of scalably inducing cells. | 10-15-2009 |
20100120093 | Method of Producing Serum-Free Insulin-Free Factor VII - The invention provides methods and compositions for the serum-free, insulin-free production of recombinant Factor VII. | 05-13-2010 |
20100184148 | IN VITRO GERMINAL CENTERS - The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days. | 07-22-2010 |
20100196963 | CONDITIONED MEDIUM AND EXTRACELLULAR MATRIX COMPOSITIONS FROM CELLS CULTURED UNDER HYPOXIC CONDITIONS - The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications. | 08-05-2010 |
20110081682 | PRODUCTION OF BONE MORPHOGENIC PROTEINS (BMPS) USING A NOVEL TISSUE CULTURE PLATFORM - The present disclosure provides methods for producing Bone Morphogenetic Proteins (BMPs). The BMPs are produced using ex vivo-derived mineralized three-dimensional bone constructs of varying degrees of maturity and mineralization. The bone constructs are obtained by culturing osteoblasts and osteoclast precursors under randomized gravity vector conditions whereupon the bone constructs secrete BMPs into the culture medium. Culture medium is periodically removed from the bone construct culture, and the BMPs are purified from the removed culture medium. | 04-07-2011 |
20110117603 | ENHANCEMENT OF CELLULAR PRODUCTION THROUGH MECHANOTRANSDUCTION - Disclosed herein are methods of modulating protein production via the application of tensegrity forces on cells and cell cultures. The methods of the invention increase production of protein from cells and cell culture. The tensegrity forces can be stress that is applied to the cells, and can include one or more of the following: mechanical stress, shear stress, stretch effects, and pressure induced stress. | 05-19-2011 |
20110143397 | RNA PREPARATIONS COMPRISING PURIFIED MODIFIED RNA FOR REPROGRAMMING CELLS - The present invention provides compositions and methods for reprogramming somatic cells using purified RNA preparations comprising single-strand mRNA encoding an iPS cell induction factor. The purified RNA preparations are preferably substantially free of RNA contaminant molecules that: i) would activate an immune response in the somatic cells, ii) would decrease expression of the single-stranded mRNA in the somatic cells, and/or iii) active RNA sensors in the somatic cells. In certain embodiments, the purified RNA preparations are substantially free of partial mRNAs, double-stranded RNAs, un-capped RNA molecules, and/or single-stranded run-on mRNAs. | 06-16-2011 |
20110207175 | MULTI-CULTURE BIOREACTOR SYSTEM - There is provided co-culture bioreactor systems that can maintain stem cells and differentiated cell types in physically isolated environments but can allow biochemical communication between these cells. For instance, a co-culture bioreactor system of the present invention can include a first culture chamber that defines a first inlet and a first outlet such that fluid can flow through the culture chamber. The system can also include a second culture chamber defining a second inlet and a second outlet allowing a second fluid flow through this second chamber. The system can also include a semi-permeable membrane. The semi-permeable membrane can be located between the first culture chamber and the second culture chamber. | 08-25-2011 |
20110250644 | FEED SUPPLEMENT FOR MAMMALIAN CELL CULTURE AND METHODS OF USE - An improved feed supplement for culture of mammalian cells used to produce proteins is provided. The improved supplement is devoid of animal-derived components and protein hydrolysates. The invention also provides methods of using the supplement in production of a therapeutic proteins, such as an antibody. In some embodiments, the antibody is an anti-human IL-23p19 antibody. | 10-13-2011 |
20110300580 | Selection of host cells expressing protein at high levels - Described is a DNA molecule comprising an open reading frame sequence that encodes a selectable marker polypeptide, wherein the DNA molecule in the coding strand comprises a translation start sequence for the selectable marker polypeptide having a GTG start codon or a TTG start codon, and wherein the ORF sequence that encodes the selectable marker protein has been mutated to replace at least half of its CpG dinucleotides as compared to the native ORF sequence that encodes the selectable marker protein. Further provided are such DNA molecules wherein the ORF sequence that encodes a selectable marker polypeptide is part of a multicistronic transcription unit that further comprises an open reading frame sequence encoding a polypeptide of interest. Also described are methods for obtaining host cells expressing a polypeptide of interest, wherein the host cells comprise the DNA molecules described herein. Further provided is the production of polypeptides of interest, comprising culturing host cells comprising the DNA molecules described herein. | 12-08-2011 |
20120021459 | FEED MEDIA - The invention provides stable feed media containing pyruvate and methods for stabilizing feed media by adding pyruvate. The invention further provides methods for producing proteins using such media and proteins produced through the use of such methods. | 01-26-2012 |
20120149063 | PROCESS FOR THE CULTURING OF CELLS - The invention relates to a process for the culturing of cells, preferably E1-immortalized HER cells, more preferably PER.C6 cells in a reactor in suspension in a cell culture medium, wherein the cells produce a biological substance, preferably an antibody, wherein at least one cell culture medium component is fed to the cell culture and wherein the cell culture comprising the cells, the biological substance and cell culture medium is circulated over a separation system and wherein the separation system separates the biological substance from substances having a lower molecular weight than the biological substance and wherein the biological substance is retained in or fed back into the reactor. Preferably part of the substances of lower molecular weight is continuously removed from the cell culture. | 06-14-2012 |
20120171724 | High yield suspension cell line, system, and method for making same - A system and method of adapting host cells to suspension cell culture and a suspension cell line produced thereby are disclosed. The method includes the serial replating of substantially undiluted culture cells onto a surface area until cell clumps are visualized and then, upon cell clumping, moving the cells into a suspension culture system. | 07-05-2012 |
20120214204 | CELL CULTURE MEDIA FOR UVC EXPOSURE AND METHODS RELATED THERETO - The invention relates to cell culture media optimized for exposure to ultraviolet C (UVC) light exposure and related methods. | 08-23-2012 |
20130183714 | MYELOMA CELL CULTURE IN TRANSFERRIN-FREE LOW IRON MEDIUM - The present invention relates to a method for culturing mammalian cells in a culture medium which is transferrin free and which contains no lipophilic or synthetic nitrogen-containing chelators. Also provided is the use of the medium and a process for providing a mammalian product by culturing cells capable of producing the product in the medium. | 07-18-2013 |
20130196380 | IN VITRO PROCESS FOR THE PREPARATION OF ANTIBODIES OF THE IGG TYPE - An in vitro process for the preparation of antibodies of the IgG type, comprising the steps of: i. challenging dendritic cells obtained from a donor with an antigen against which the antibodies to be prepared are directed; ii. challenging CD4+ T cells obtained from the same donor with fragments of the antigen presented by the dendritic cells from step L, with the proviso that the dendritic cells are ones essentially not secreting interferon-γ (IFN-γ) and interleukin 12 (IL-12), to generate antigen-specific CD4+ Th2 cells; iii. challenging with the antigen a B cell population obtained from the same donor and including a sufficient proportion of naive B cells; and iv. contacting the antigen-specific CD4+ Th2 cells according to ii. with at least a fraction of the B cell population from iii. to form an antigen-specific plasma cell; v. immortalizing said antigen-specific plasma cell; and vi. isolating the IgG antibodies formed by said antigen-specific plasma cell. | 08-01-2013 |
20130210076 | CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE - Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium. | 08-15-2013 |
20130217069 | CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE - Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium. | 08-22-2013 |
20130244283 | Process for Protein Production - The present invention relates to a process for the production of a haemostasis protein by continuous perfusion culturing of a cell culture in suspension, said cell culture expressing said haemostasis protein into said culture suspension, wherein the cell culture flows across a filter module, which filter module leads to a harvest port, the filter module having a mesh size of from 0.1 to 2.9 μm allowing passage across of the haemostasis protein and wherein the flow across the filter module is an alternating tangential flow. The invention also relates to a protein produced by the process of the invention. | 09-19-2013 |
20130266985 | Process for Cell Culturing by Continuous Perfusion - The invention relates to a process for the culturing of cells by continuous perfusion culturing of a cell culture comprising cell culture medium and cells, wherein cell culture medium is added to the cell culture, the cell culture is circulated over a filter module comprising hollow fibers resulting in an outflow of liquid having a lower cell density than the cell culture and the flow within the filter module is an alternating tangential flow. Preferably, culture medium is added at a particular perfusion rate and/or biomass is removed form the culture at least once. The method is especially suitable for the culturing of aggregating cells. The invention also relates to such a process wherein a biological substance, preferably an antibody, is produced by the cells, which biological substance may be further purified in downstream processing. | 10-10-2013 |
20140004565 | CELL-BASED BIOPROCESSING | 01-02-2014 |
20140030762 | BIOREACTOR FOR CELL CULTURE ON A THREE-DIMENSIONAL SUBSTRATE - The invention relates to a bioreactor ( | 01-30-2014 |
20140051124 | METHODS FOR REDUCING ACCUMULATION OF LACTATE DURING CULTURING AND METHOD FOR PRODUCING POLYPEPTIDE - The present disclosure relates to methods of decreasing lactate production in cell culture using divalent transitional metallic salts. The present disclosure also relates to a method of producing polypeptide by adding divalent transitional metallic salt to the cell culture medium for reducing lactate accumulation followed by fermenting and recovering the polypeptide. | 02-20-2014 |
20140087424 | Process for Cell Culturing by Continuous Perfusion - The invention relates to a process for the culturing of cells by continuous perfusion culturing of a cell culture comprising cell culture medium and cells, wherein cell culture medium is added to the cell culture, the cell culture is circulated over a filter module comprising hollow fibers resulting in an outflow of liquid having a lower cell density than the cell culture and the flow within the filter module is an alternating tangential flow. Preferably, culture medium is added at a particular perfusion rate and/or biomass is removed form the culture at least once. The method is especially suitable for the culturing of aggregating cells. The invention also relates to such a process wherein a biological substance, preferably an antibody, is produced by the cells, which biological substance may be further purified in downstream processing. | 03-27-2014 |
20140106405 | MAMMALIAN CELL CULTURE PROCESSES FOR PROTEIN PRODUCTION - The present invention describes methods and processes for the production of proteins by animal cell or mammalian cell culture. In one aspect, the methods comprise the growth of cells in a growth factor/protein/peptide free medium. In another aspect, the methods comprise the addition of growth factors during the production phase. The methods sustain a high viability of the cultured cells, and can yield an increased end titer of protein product, and a high quality of protein product. | 04-17-2014 |
20140162318 | ENHANCING INGREDIENTS FOR PROTEIN PRODUCTION FROM VARIOUS CELLS - [Summary] The present invention relates to a protein production accelerating agent that has enabled to largely increase the produced amount of a desired protein by adding polysaccharides to a medium for animal cells containing a serum or serum alternative, and a production method of a protein using a medium containing the protein production accelerating agent. | 06-12-2014 |
20140308707 | METHOD FOR PRODUCTION OF FACTOR VIII - The present invention relates to methods of producing a Factor VIII polypeptide in mammalian cell cultures. | 10-16-2014 |
20140322758 | ADDITION OF IRON TO IMPROVE CELL CULTURE - The present invention provides, among other things methods of increasing cell density, viability and/or titer in a cell culture including steps of adding a composition comprising iron to the cell culture. | 10-30-2014 |
20150111252 | METHOD AND APPARATUS FOR ANTIBODY PRODUCTION AND PURIFICATION - The subject invention pertains to methods and apparatus for the production and purification of cell products, such as immunoglobulins. One aspect of the invention is an integrated cell culture and purification apparatus for the growth and maintenance of cells and the harvest and purification of cell products, such as immunoglobulins. Thus, the apparatus integrates a cell culture function with a purification function. Other aspects of the invention pertain to an automated method for producing immunogenic compositions such as vaccines. | 04-23-2015 |
20160060591 | FEED MEDIA - The invention provides stable feed media containing pyruvate and methods for stabilizing feed media by adding pyruvate. The invention further provides methods for producing proteins using such media and proteins produced through the use of such methods. | 03-03-2016 |
20160097074 | DEFINED GLYCOPROTEIN PRODUCTS AND RELATED METHODS - The invention provides methods, databases and systems for making glycoprotein products having defined properties. | 04-07-2016 |
20160097109 | ENGINEERED LEATHER AND METHODS OF MANUFACTURE THEREOF - Engineered animal skin, hide, and leather comprising a plurality of layers of collagen formed by cultured animal collagen-producing (e.g., skin) cells. Layers may be formed by elongate multicellular bodies comprising a plurality of cultured animal cells that are adhered and/or cohered to one another; wherein the elongate multicellular bodies are arranged to form a substantially planar layer for use in formation of engineered animal skin, hide, and leather. Further described herein are methods of forming engineered animal skin, hide, and leather utilizing said layers of animal collagen-producing cells. | 04-07-2016 |
20190144958 | CULTURED LEATHER AND PRODUCTS MADE THEREFROM | 05-16-2019 |
435700400 | Blood (lymphoid) cell culture | 5 |
20080206787 | Process to determine enzyme activity - The present invention provides for various processes for determining enzyme activity. In one embodiment, a process for detecting an enzyme activity includes contacting a blood component with a substrate comprising a cleavage site of the enzyme and a tag moiety to produce a sample comprising a cleavage product having a known mass, and placing the sample in contact with a SELDI sample chip which has surface moieties which bind to the cleavage product. In another embodiment, the process further includes subjecting the SELDI sample chip to SELDI mass spectrometry to identify the cleavage product. The present invention also provides for a kit which includes a SELDI sample chip having surface moieties capable of binding to an enzyme cleavage product. | 08-28-2008 |
20080213800 | Method for Examing Interstitital Cystitis - It has been found that the urine from an IC patient shows a high value in amount and the existence of activity of an azurophilic granular substance, thereby to establish a method for examining IC. The present invention relates to a method for examining interstitial cystitis using the kinetics of an azurophilic granular substance in urine as a marker. Also, the present invention relates to a kit for examining interstitial cystitis for use in the examination method, a use of an azurophilic granular substance as a test marker for examining interstitial cystitis or evaluating pharmacological effects of a drug, and a method for examining therapeutic effects on a patient with interstitial cystitis using an azurophilic granular substance as a marker. | 09-04-2008 |
20080227115 | Inhibition of cancer metastasis - The present invention relates to compositions and methods for cancer diagnosis, treatment and drug screening. In particular, the present invention provides compositions and methods for targeting the nuclear translocation of IkB kinase-α (IKKα) and the IKKα-mediated suppression of Maspin expression observed in metastatic prostate cancer cells. | 09-18-2008 |
20080227116 | Histaminase Determination - Disclosed is a method for determining histaminase (DAO; EC 1.4.3.6) activity in a sample. Said method comprises the following steps: an aqueous solution is supplied which contains a predefined amount of a diamine; the aqueous solution is mixed and incubated with the sample for a given period of time in conditions in which the diamine can be reacted with a DAO possibly present in the sample; the diamine is derivatized; the amount of derivatized diamine is determined; the predefined amount of diamine is compared to the amount of derivatized diamine; and the activity of histaminase possibly present is determined. | 09-18-2008 |
20080254485 | Methods And Compositions For Monitoring And Risk Prediction In Cardiorenal Syndrome - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function. | 10-16-2008 |
20080261238 | Method for Differentiation of Factor XIII Deficiency States in Relation to Fibrinogen Deficiency States Using Thrombelastographic Techniques - The invention relates to a method for determining a factor XIII deficiency, a method for determining a fibrinogen deficiency, and a method for differentiating between a factor XIII deficiency and a fibrinogen deficiency by means of thrombelastographic techniques. On the basis of the evaluation of the thrombelastographic parameters, a rapid and a selective substitution of factor XIII and/or of fibrinogen in deficiency states is possible. | 10-23-2008 |
20080261239 | DETECTING MOLECULAR INTERACTIONS - The present disclosure features a variety of compositions, kits, and methods that are useful for, inter alia, detecting and/or analyzing an interaction between two molecules, a target molecule and a target-specific binding agent which can be, e.g., proteins, nucleic acids, saccharides or polysaccharides, small molecules, or combinations of any of the foregoing. The compositions, kits, and methods can also be used, e.g., to detect the presence or absence of an enzymatic activity (e.g., a kinase activity, a protease activity, or a phosphatase activity) in a sample; to identify a compound that modulates an interaction between two molecules; or to identify compounds that modulate the activity of an enzyme. | 10-23-2008 |
20080261240 | METHOD - A method for attenuating a microorganism which comprises inhibiting in the microorganism a metabolic pathway essential for viability, by promoting use of the substrate of the pathway in a different metabolic pathway which is non-essential to the microorganism whereby the substrate is unavailable to the essential pathway and the micro organism is attenuated. | 10-23-2008 |
20080274476 | Assay Method - There is disclosed a method for determining the activity of gamma-secretase in a text subject, using a biological sample from the subject. | 11-06-2008 |
20080274477 | Forms of Factor Xiia - A 53 Kd novel form of factor XIIa and related products, including nucleic acid molecules, monoclonal and polyclonal antibodies and hybridoma cell lines. Also assays for a 53 Kd form of factor XIIa and uses of said assays in diagnostic and prognostic methods, for example in the prediction of survival following myocardial infarction. | 11-06-2008 |
20080274478 | NOVEL AROMATIC PRENYLTRANSFERASES, NUCLEIC ACIDS ENCODING SAME AND USES THEREFOR - In accordance with the present invention, a novel aromatic prenyltransferase, Orf2 from | 11-06-2008 |
20080293078 | Method For the Detection of Atp in a Sample With the Aid of Luminescene and a Computer Programme For That Purpose - The present invention relates to a method for detecting ATP in a sample by using luminescence, wherein a luminescence reagent is added to the sample that has not undergone any pre-treatment with an extractant in order to effect the formation of an ATP complex, wherein the luminescence of the ATP com lex thus formed is measured. | 11-27-2008 |
20080299584 | ONCOPROTEIN PROTEIN KINASE ANTIBODY KIT - An isolated polypeptide (JNK) characterized by having a molecular weight of 46 kD as determined by reducing SDS-PAGE, having serine and threonine kinase activity, phosphorylating the c-Jun N-terminal activation domain and polynucleotide sequences and method of detection of JNK are provided herein. JNK phosphorylates c-Jun N-terminal activation domain which affects gene expression from AP-1 sites. | 12-04-2008 |
20080299585 | METHODS FOR DETECTION AND MEASUREMENT OF SECRETORY PHOSPHOLIPASE A2 LEVELS (sPLA2) IN BIOLOGICAL FLUIDS - Elevated levels of secretory phospholipase A | 12-04-2008 |
20080311591 | Differential Immunoassay - The invention provides assay methods and kits that in general measure the level of a first analyte in a sample reduced by the level of a second analyte present in the same sample. In one embodiment, where levels of a first analyte from a first source is desirably determined and first analyte in the sample released from a second source is accompanied by proportional co-release of a second analyte, the assay identifies the level of first analyte released only from the first source. For analytes within bodily fluids, the assay can differentiate between elevated levels of analyte specific to the particular physiological or pathological state and elevated levels not specific to the particular state, providing single tests with diagnostic utility. | 12-18-2008 |
20090004675 | Method of Identifying Compounds for Bacterial Growth Modulation - The present invention relates to a method of identifying a candidate compound for modulating bacterial growth. This the method involves providing a β clamp peptide from a bacterial replicase, providing a second peptide that binds to at least one amino acid of SEQ ID NO:9 that is not designated X, wherein the second peptide does not exhibit polymerase activity, and providing a test compound. The β clamp peptide and the second peptide are contacted with the test compound, and the level of binding between the β clamp peptide and the second peptide in the presence of the test compound is determined. The level of binding between the β clamp peptide and the second peptide in the presence of the test compound is then compared to a control that does not contain the test compound. A test compound that alters the level of binding between the β clamp peptide and the second peptide compared to the control is a candidate compound for modulating bacterial growth. | 01-01-2009 |
20090011431 | Diagnosis of Sepsis by the Selective Determination of the Concentration of Cu/Zn Superoxide Dismutase (Cu/Zn Sod) in Patient Samples - The present invention relates to a method for the early determination of the risk of mortality of patients in intensive care units or emergency care units during which the concentration of Cu/Zn superoxide dismutase (Cu/Zn SOD) in a serum sample or plasma sample of the patient is selectively determined, and quantitatively or semi-quantitatively measured concentrations, which exceed a predetermined threshold value are correlated with a high risk of mortality. | 01-08-2009 |
20090011432 | Detecting and Profiling Molecular Complexes - Methods are provided for detecting the formation of complexes of molecules, especially proteins, in a sample, such as a cell or tissue lysate. In one aspect, a cleaving probe specific for a first protein in a complex and one or more binding compounds specific for one or more second proteins in a complex are provided. Upon binding, the cleaving probe is induced to generate an active species, such as singlet oxygen, that cleaves molecular tags attached to the binding compounds only in the local region of the cleaving probe. The released molecular tags are separated from the assay mixture and from one another to provide a readout that is related to the number and types of proteins present in the complex. | 01-08-2009 |
20090017467 | COMPOSITION EXHIBITING A VON WILLEBRAND FACTOR (vWF) PROTEASE ACTIVITY COMPRISING A POLYPEPTIDE CHAIN WITH THE AMINO ACID SEQUENCE AAGGILHLELLV - The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production. | 01-15-2009 |
20090035789 | MONITORING ENZYME MIXTURES - This invention provides a method for simultaneously detecting the presence of at least two enzymes in a sample, said method comprising the steps of; i) providing a first substrate for a first enzyme, said first substrate being labeled with a first fluorophore, ii) providing a second substrate for a second enzyme, said second substrate being labeled with a second fluorophore, iii) exposing the labeled substrates to the sample to allow the first and second enzymes present in the sample to interact with respective first and second fluorophore-labeled substrates to form respective first and second fluorophore-labeled substrate fragments; and, detecting the presence of said fluorophore-labeled substrate fragments. | 02-05-2009 |
20090053735 | Vector expressing n-deacetylase/n-sulfotransferase 2 - An object of the present invention is to provide an expression vector that allows for stable production of N-deacetylase/N-sulfotransferase 2 in large amounts and a process for production of N-deacetylase/N-sulfotransferase 2 using the same. The present invention provides a recombinant baculovirus expression vector obtained by incorporating into baculovirus DNA, a DNA fragment having lobster L21 DNA, DNA encoding gp67 signal peptide and DNA encoding the 79th to 883rd amino acids of human N-deacetylase/N-sulfotransferase 2 in this order in the 5′ to 3′ direction. | 02-26-2009 |
20090053736 | Homogeneous Chemiluminescent Immunoassay for Analysis of Iron Metalloproteins - The present invention relates to assays and kits for detecting or quantifying iron metalloprotein in test samples. | 02-26-2009 |
20090053737 | Monoclonal Antibody Which Binds Met In Formalin-Fixed and Paraffin-Embedded Tissues and Related Methods - In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase Met. Disclosed herein are (a) a monoclonal antibody named Met4, which antibody is specific for Met, and (b) a hybridoma cell line that produces Met4. The Met4 antibody is particularly useful for detecting Met in formalin-fixed tissue. Methods of using the Met4 antibody for detection, diagnosis, prognosis, and evaluating therapeutic efficacy are provided. | 02-26-2009 |
20090053738 | PROTEASE DETECTION - A method of detecting a protease in a sample. The method comprises providing an analyte degradable by the protease. The analyte is contacted with the sample. The degradation products of the analyte or the residual undegraded analyte is detected in a binding assay. | 02-26-2009 |
20090075298 | METHOD OF ANALYZING ENZYME - A method of analyzing an enzyme, comprising (1) bringing a sample suspected of containing an enzyme to be analyzed into contact with an enzyme substrate which is immobilized on an insoluble carrier and can be cleaved by the enzyme, in a liquid, (2) separating the insoluble carrier from the liquid, and (3) analyzing a substrate or a fragment thereof which remains on the insoluble carrier and/or a fragment of the substrate which is released from the insoluble carrier into the liquid; and a kit for analyzing an enzyme, comprising at least an enzyme substrate which is immobilized on an insoluble carrier and can be cleaved by the enzyme, are disclosed. | 03-19-2009 |
20090075299 | Diagnostic Methods - The present invention relates to methods of diagnosing cancerous conditions in a patient, as well as methods of monitoring the progression of a cancerous condition and/or methods of monitoring a treatment protocol of a therapeutic agent or a chemotherapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein. | 03-19-2009 |
20090081702 | DISCRIMINATON OF CARDIAC DYSFUNCTION IN PREGNANT FEMALES - The present invention relates to a method for diagnosing if a pregnant woman suffers from a cardiac dysfunction, comprising the steps of a) measuring the level of a natriuretic peptide in a sample b) measuring the level of placental growth factor and/or sFlt-1 or a variant thereof in a sample, wherein an increased level of a natriuretic peptide and a decreased level of placental growth factor and/or an increased level of sFlt-1 or a variant thereof indicates the presence of a placenta-associated cardiac dysfunction, and wherein an increased level of a natriuretic peptide and a not decreased level of placental growth factor and/or a not increased level of sFlt-1 or a variant thereof indicates the presence of a cardiac dysfunction related to heart disease. The present invention also relates to an array, to an immunological rapid test, to the use of corresponding kits, and to methods for a decision support for the possible treatment of a pregnant woman suffering from a cardiac dysfunction. | 03-26-2009 |
20090081703 | METHOD FOR DETECTING DEEP VENOUS THROMBOSIS - A method for detecting deep vein thrombosis (DVT) in humans includes the steps of assaying a collected blood sample and measuring the amount of Lp-PLA | 03-26-2009 |
20090081704 | COMPOSITIONS, METHODS AND KITS FOR REAL-TIME ENZYME ASSAYS USING CHARGED MOLECULES - Compositions, methods and kits useful for, among other things, detecting, quantifying and/or characterizing enzymes. | 03-26-2009 |
20090087864 | Procedure for the determination of the activity of the protease which activates factor VII from protein solutions - A procedure for the determination of the activity of the protease which activates blood clotting factor VII from protein solutions is describes, in which
| 04-02-2009 |
20090098575 | The Human E3alpha Ubiquitin Ligase Family - The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3α ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products. | 04-16-2009 |
20090098576 | Feline Pancreatic Lipase - Isolated nucleic acid molecules having a nucleotide sequence encoding feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Isolated feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Host cells comprising a vector containing the polynucleotide sequences and methods for expressing the polypeptides. The generation of monoclonal antibodies that specifically binds to the feline pancreatic lipase polypeptides, and cell lines secreting the monoclonal antibodies. Methods for determining the presence or amount of feline pancreatic lipase in a biological sample. The methods include using standards or calibrators of recombinant feline pancreatic lipase to quantify the lipase in a sample. Devices and kits for performing methods for detecting feline pancreatic lipase in biological samples. | 04-16-2009 |
20090098577 | METHOD OF IDENTIFYING COMPOUNDS THAT MODULATE CASPASE 9 ACTIVITY VIA USE OF A KOSMOTROPIC SALT - The present invention discloses methods for activating Caspase 9 in such a way that it can be used in assays to discover modulators of Caspase 9. | 04-16-2009 |
20090104627 | METHOD FOR DETERMINATION OF ENZYMATIC ACTIVITY - A novel modified polysaccharide, a solid phase to which the polysaccharide is adhered, methods for detecting N-deacetylase activity, N-sulfotransferase activity and N-deacetylase/N-sulfotransferase activity in a sample which utilizes said solid phase, and detection kits thereof. | 04-23-2009 |
20090104628 | Method for quantifying phosphokinase activity on proteins - The invention involves a method for measuring phosphorylation of proteins at specific sites and, as such, is an indicator of the protein kinase activity of enzymes capable of phosphorylating those sites. The method involves the in vitro or in vivo phosphorylation of a target protein at a specific serine, threonine or tyrosine residue, subjecting that protein (non-phosphorylated) to reaction mixture containing all reagents, including phosphokinase which allow the creation of a phosphorylated form of protein. The phosphorylated protein is measured by contacting it with an antibody specific for the phosphorylation site(s). The invention includes antibodies useful in practicing the methods of the invention. The invention particularly relates to all proteins modified by phosphorylation and dephosphorylation as illustrated by Tau, Rb and EGFR proteins and antibodies specific for the site of phosphorylation of the Tau, Rb or EGFR proteins. | 04-23-2009 |
20090111124 | Kinase peptides and antibodies - The invention relates to novel kinase peptides and antibodies, as well as nucleic acids related to them. The peptides, antibodies and the nucleic acids are useful for the detection, staging and monitoring of the progression of a kinase-mediated disease, as well as for determining or monitoring the efficacy of treatment. | 04-30-2009 |
20090117591 | Fibrosis Markers - The invention relates to the use of a combination of at least two markers that are selected from among Uromodulin, MAC2BP, AGP1 and Cathepsin A, for the in vitro detection of fibrotic alterations. In addition, the invention relates to a kit for determining the levels of said markers in a biological sample. | 05-07-2009 |
20090117592 | Altered Intracellular Localization of BRK/Sik Protein Tyrosine Kinase in Human Prostate Tumors - The invention provides methods for detecting abnormal prostate conditions, such as benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), and adenocarcinoma, in an animal by comparing the amount of the Breast Tumor Kinase (BRK) tyrosine kinase in the nuclei of prostate luminal epithelial cells in a test sample with an amount of nuclear BRK protein in epithelial cells of normal prostate glands. | 05-07-2009 |
20090123941 | METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY - A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents. | 05-14-2009 |
20090136969 | Lipoprotein Associated Phospholipase A2, Inhibitors Thereof and Use of the Same in Diagnosis and Therapy - The enzyme Lp-PLA | 05-28-2009 |
20090142776 | ANTIBODY FOR ASSAYING ADAMTS13 ACTIVITY AND METHOD FOR ASSAYING THE ACTIVITY - The subject of the present invention is to provide a useful antibody for measuring ADAMTS13 activity, in particular, a monoclonal antibody and a method for measuring ADAMTS13 activity. Further, another subject of the present invention also is to provide a monoclonal antibody which has specific reactivity to an antigenic determinant site produced by reacting ADAMTS13 with VWF that is a substrate or a partial peptide of VWF that is a potential substrate, but has no specific reactivity to the complete VWF molecule, and a use of the antibody of interest. Those subjects were achieved by succeeding in obtaining a monoclonal antibody (anti-N-10 monoclonal antibody) which has specific reactivity to a cleavage site that is cleavable by ADAMTS13 in the partial peptide of VWF, and further by finding a method for measuring ADAMTS13 activity using the monoclonal antibody of interest. | 06-04-2009 |
20090142777 | Reagents for the detection of protein phosphorylation in leukemia signaling pathways - The invention discloses 424 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Adaptor/Scaffold proteins, Cytoskeletal proteins, Cellular Metabolism enzymes, G Protein/GTPase Activating/Guanine Nucleotide Exchange Factor proteins, Immunoglobulin Superfamily proteins, Inhibitor proteins, Lipid Kinases, Nuclear DNA Repair/RNA Binding/Transcription proteins, Serine/Threonine Protein Kinases, Tyrosine Kinases, Protein Phosphatases, and Translation/Transporter proteins. | 06-04-2009 |
20090148866 | Antibodies and Improved Test Sample Handling Methods for Use in Assays for Myeloperoxidase - The present disclosure relates to isolated antibodies that can be used in an assay to determine the concentration levels of myeloperoxidase (MPO) in a test sample. Additionally, the present disclosure also relates to the use of improved test sample handling methods in assays in order to preserve the original MPO levels in the test sample. | 06-11-2009 |
20090155814 | PROTEINS IN TYPE 2 DIABETES - The present invention relates to the use of naturally occurring compounds and derivatives thereof as markers for predisposition of diabetes related diseases. The invention also relates to a pharmaceutical composition for treatment of diabetes related diseases. | 06-18-2009 |
20090162870 | FATTY ACID SYNTHASE IN LIVER DISEASE - Methods and compositions for detecting elevated fatty acid synthase (FAS) expression in the liver of a subject are disclosed. The detection may be of expression in liver cells per se or in a bodily fluid of a subject. Also disclosed are methods for identifying the presence or absence of liver disease or pathology in relation to elevated FAS. The disclosed methods may be practiced with various compositions comprising reagents for detecting FAS expression as described herein. | 06-25-2009 |
20090162871 | Mutants of the factor VII-activating protease and detection methods using specific antibodies - Mutants of the DNA sequence coding for the protease (FSAP) which activates blood clotting factor VII and single-chain plasminogen activators, the mutants comprising a G/C base exchange at nucleotide position 1177 and/or a G/A base exchange at nucleotide position 1601, are described. The corresponding protease has a Glu/Gln exchange at amino acid position 393 and/or a Gly/Glu exchange at amino acid position 534. Diagnostic methods which are used for detecting FSAP in body fluids or tissue cells and also for identifying patients with genetic heterozygous or homozygous FSAP expression are also described. In addition, antibodies against FSAP and its mutants are disclosed and diagnostic methods which can be used to detect antibodies against FSAP and its mutants are specified. | 06-25-2009 |
20090170125 | Cellular assay method for identifying pkc-0 inhibitors - The invention relates to a method for investigating the modulating effect of a test substance on a PKCθ-dependent signal transduction pathway or for finding a PKCθ modulator in a human or animal cell, including the steps
| 07-02-2009 |
20090170126 | Prostasin Partial Peptide and Anti-Prostasin Antibody - An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen. | 07-02-2009 |
20090186367 | DIAGNOSIS OF FERTILITY CONDITIONS USING A SERINE PROTEASE - The present invention relates to a method of diagnosing an infertility condition in a human female subject, the method comprising detecting pregnancy-related serine protease (PRSP) protein in a test sample taken from said subject at between 7 and 20 weeks into pregnancy; detecting PRSP protein in a test sample from a fertile control mammal taken within the same period; and comparing the PRSP protein in the test sample with the PRSP protein detected in the control sample, wherein a change in PRSP protein in the sample compared to the control sample is indicative of an infertility condition. | 07-23-2009 |
20090203043 | Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways - The invention discloses 142 novel phosphorylation sites identified in insulin signaling pathways, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 08-13-2009 |
20090203044 | SPHINGOSINE-1-PHOSPHATE LYASE POLYPEPTIDES, POLYNUCLEOTIDES AND MODULATING AGENTS AND METHODS OF USE THEREFOR - Compositions, methods and kits for diagnosing and treating cancer are provided. Therapeutic compositions may comprise agents that modulate the expression or activity of a sphingosine-1-phosphate lyase (SPL). Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous SPL. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. SPL polypeptides, polynucleotides and antibodies are also provided. | 08-13-2009 |
20090215080 | METHODS FOR IDENTIFICATION OF INHIBITORS OF ENZYME ACTIVITY - The invention discloses compositions and methods of synthesis to create novel ligands and drugs and identifying such compounds as inhibitors of enzyme targets for use in the treatment of clinical disorders, including cancer, infectious diseases, parasitic infestations, neurological disorders, reproductive disorders, inflammatory disorders, circulatory disorders, and metabolic disorders. | 08-27-2009 |
20090220990 | METHOD AND KIT FOR DETECTING CONDITION IN PATIENT WITH DISTURBANCE OF CONSCIOUSNESS - A method for detecting a condition in a patient with disturbance of consciousness, by analyzing an amount and/or activity of a von Willebrand factor-cleaving protease, and a kit for detecting a condition in a patient with disturbance of consciousness, comprising an antibody or a fragment thereof which specifically binds to a von Willebrand factor-cleaving protease, or a von Willebrand factor or a fragment thereof, are disclosed. Examples of the detection of a condition include a detection of cerebrovascular disease, a detection of arteriosclerotic vascular disease, and a detection or prediction of severity. | 09-03-2009 |
20090233316 | Protein, An Antibody and Measurement of the Protein - A novel mammalian protein related to human hypothetical protein FLJ22662 (SEQ ID NO: 1) and homologous hypothetical proteins from mammal species other than | 09-17-2009 |
20090239242 | Method for the early identification and prediction of kidney injury - A method for the early identification and prediction of elevated blood creatinine levels resulting from a reduction in kidney function in a subject, comprises contacting a urine sample from the subject with a capture molecule for a biomarker specific for the distal region of the renal tubule and which biomarker is released from said region when there is damage to said region indicative and predictive of elevated blood creatinine levels resulting from a reduction in kidney function. The method can be used to detect Acute Kidney Injury (AKI) caused by many conditions or diseases or through the administration of drugs. The method can indicate and/or predict a reduction in kidney function significantly earlier than the current standard creatinine test. Methods for predicting a need for renal replacement therapy (RRT) are also disclosed. | 09-24-2009 |
20090253149 | Novel Chemistry Used in Biosensors - The invention relates to novel compositions and methods for the detection of analytes using the nuclear reorganization energy, λ, of an electron transfer process. | 10-08-2009 |
20090258374 | Multisignal Labeling Reagents, and Processes and Uses Therefor - The present invention provides multisignal labeling reagents and these are useful in a number of biochemical applications, including the manufacture of biomolecular probes and their use in detecting or amplifying analyte-specific moieties. | 10-15-2009 |
20090258375 | ASSAYS FOR DETECTING PREGNANCY-ASSOCIATED GLYCOPROTEINS - Disclosed are methods and compositions for detecting pregnancy in an animal by means of assaying peptidase activity of one or more Pregnancy Associated Glycoproteins (PAGs). In certain aspects, methods also comprising use of an antibody that binds immunologically to a PAG that displays proteolytic activity are provided. Substrates of proteolytic PAGs are also provided, as are kits, and methods of use. Further, methods of purifying PAGs based on their proteolytic activity are also provided. | 10-15-2009 |
20090263829 | ALZHEIMER'S DISEASE BIOMARKERS AND METHODS OF USE - The invention encompasses biomarkers for AD, a method for detecting AD, a method of monitoring AD, and a kit for quantifying biomarkers for AD. | 10-22-2009 |
20090263830 | VISUALIZATION AND QUANTITIATION OF CELLULAR CYTOTOXICITY USING CELL-PERMEABLE FLUOROGENIC PROTEASE SUBSTRATES AND CASPASE ACTIVITY INDICATOR MARKERS - This invention provides a non-radioactive assay to monitor and quantify the target-cell killing activities mediated by cytotoxic T lymphocytes (CTLs). This assay is predicated on the discovery that apoptosis pathway activation and, in particular, caspase activity, provides a measure of cytotoxic effector cell activity. In one embodiment, measurement of CTL-induced caspase activation in target cells is achieved through detection of the specific cleavage of fluorogenic caspase substrates. This assay reliably detects antigen-specific CTL killing of target cells, and provides a more sensitive, more informative and safer alternative to the standard | 10-22-2009 |
20090269784 | PROTEIN ENGINEERING OF MONOACYLGLYCEROL LIPASE (MGLL) - A number of soluble engineered forms of MGLL that are suitable for high-throughput screening and protein crystallization, as well as a crystallized form of monoacylglycerol lipase protein (MGLL) and descriptions of the X-ray diffraction patterns are disclosed. The engineered constructs of MGLL permit the expression and purification of protein suitable for crystallography or high-throughput screening and identification of ligands, which can function as active agents to MGLL. The X-ray diffraction patterns allow the three dimensional structure of MGLL to be determined at atomic resolution so that ligand binding sites on MGLL can be identified and the interactions of ligands with MGLL amino acid residues can be modeled. Models prepared using such maps permit the design of ligands which can function as active agents which include, but are not limited to, those that function as inhibitors of MGLL. | 10-29-2009 |
20090286260 | MYELOPEROXIDASE DETECTION IN DIAGNOSIS AND PROGNOSIS OF HEMATOPOIETIC DISORDERS - The present invention relates to the diagnosis of hematopoietic disorders and to determining the prognosis of patients affected by such disorders. The methods generally comprise determining a level of myeloperoxidase in a body fluid sample from the individual and using the level as a factor for diagnosing the disorder in the mammal or as a factor for determining the prognosis of a patient diagnosed with such a disorder. Myelodysplastic syndrome, acute myeloid leukemia and chronic myeloid leukemia are exemplary disorders. Also provided are method of cancer therapy involving reducing the level of myeloperoxidase in the body fluid of the individual. | 11-19-2009 |
20090311719 | IN VITRO METHOD FOR DIAGNOSING NEURODEGENERATIVE DISEASES - Disclosed is an in vitro method for the detection, for the determination of the severity and for the assessment of the progress and prediction of neurodegenerative diseases, in which the presence and/or concentration of carbamoyl phosphate synthetase 1 (CPS 1) is determined in a biological fluid of a patient who suffers from a neurodegenerative disease or is suspected of suffering from such a disease, and conclusions about the presence, progression, severity or success of a treatment of the neurodegenerative disease are drawn on the basis of the determined presence and/or concentration of CPS 1 or the non-detectability of a CPS 1 immune reactivity. | 12-17-2009 |
20090317830 | HEPATITIS C VIRUS NS2/3 ASSAY - The present invention provides an assay for the detection of the NS2/3 cleavage products NS2 or NS3 in the presence of uncleaved NS2/3. Following self-cleavage of NS2/3 to generate NS2 and NS3 cleavage products, a sample is incubated with a ligand specific for the recognition of NS2 or NS3 cleavage product in the presence of uncleaved NS2/3. There is provided a method for detecting a NS2/3 autocleavage product in a sample containing NS2/3 protease, whereby the amount of bound ligand detected correlates with the NS2/3 autocleavage activity. A further aspect of the present invention concerns ligands selectively recognizing one of the NS2 cleavage product or the NS3 cleavage product with minimal cross-reactivity with the uncleaved NS2/3 and the other cleaved product. The present invention provides antibodies that selectively recognize one of cleaved NS2 product or cleaved NS3 product with minimal cross-reactivity with the uncleaved NS2/3 and the other cleaved product. | 12-24-2009 |
20090325193 | Diagnostic Test For The Detection Of A Molecule Or Drug In Whole Blood - The invention provides methods of preparing a test sample for use in an assay for detecting an analyte bound by an intracellular ligand. The methods typically involve contacting the test sample with an assay reagent comprising: a lysis reagent; and a protease that has proteolytic activity for said intracellular ligand; to form a mixture compatible for use in an immunoassay without subsequent extraction steps. Other aspects of the invention include related immunoassays and test kits. | 12-31-2009 |
20100015635 | IMMOBILISATION OF FLUORESCENT PROTEINS - The present invention concerns a method of detection of an analyte in which a protein capable of binding the analyte and comprising a fluorescent energy label and an energy acceptor moiety capable of accepting energy emitted by the label or protein by Forster energy transfer (FRET), is exposed to incident electromagnetic energy to excite the protein or label, and the fluorescent emission of the label is measured; characterised in that the protein is encapsulated in a biocompatible, optically transparent matrix which is permeable to the analyte, and in that the protein undergoes no substantial conformational change during the method; further characterised in that the energy acceptor moiety has a more active and less active state, which is determined by the presence of analyte, and the emission from the label is indicative of the presence of analyte. A biocompatible optically transparent matrix in which a protein capable of binding an analyte is also provided. | 01-21-2010 |
20100021939 | PROCESS FOR DETECTING ENZYME ACTIVITY IN AN IMMUNOASSAY - The invention relates to a process for detecting enzyme activity in an immunoassay comprising the following steps: | 01-28-2010 |
20100028907 | Novel Antigens and Antibodies Associated to Pancreatic Ductal Adenocarcinoma - The present invention provides novel human protein antigens and related antibodies that have been identified as being specifically expressed in association to human Pancreatic Ductal Adenocarcinoma (PDA). In particular, novel phosphorylated isoforms of alpha-enolase have been identified in transformed cell lines of pancreatic origin and antibodies binding such isoforms are specifically present in the sera of PDA patients. These proteins and antibodies can be useful for the diagnosis and the treatment of PDA and other cancers having common molecular features. | 02-04-2010 |
20100028908 | NOVEL DETECTION SYSTEM - The present invention relates to methods of making nanoarrays for use in detecting species formed on the surface of the array using SE(R)RS. The methods can involve nanolithographic printing of a compound by dip pen nanolithographic printing. A SE(R)RS substrate can be used for the array and which can be selected from surfaces roughened by the oxidation-reduction cycle (ORC), island films, colloidal nanoparticles and surface-confined nanostructures. A coating or intermediate layer, such as a layer formed of nitrocellulose, can be provided between the compound and the SE(R)RS substrate. There are also provided arrays themselves and methods of using such arrays. | 02-04-2010 |
20100041068 | DEEPLY QUENCHED ENZYME SENSORS AND BINDING SENSORS - Sensors for detecting enzyme activity are provided that include a substrate module comprising a substrate for the enzyme of interest and a fluorescent label, a quencher, and a detection module. The detection module binds to the substrate module either before or after the enzyme acts on the substrate and sequesters the label from the quencher, resulting in an increased signal from the label. Sensors for detecting protein-protein interactions are also provided that include a quencher and a labeled first polypeptide. Binding of the first polypeptide to a second polypeptide sequesters the label from the quencher, resulting in an increased signal from the label. Methods using the sensors to detect enzyme activity and to screen for compounds affecting enzyme activity or to detect protein-protein interactions and to screen for compounds affecting protein-protein interactions, respectively, are also described. | 02-18-2010 |
20100041069 | METHODS FOR DIAGNOSING AND MONITORING LIVER DISEASES - A method of diagnosing a liver disorder in a subject is disclosed. The method comprises determining a level of sH2A and at least one additional liver marker in a sample of the subject wherein a change beyond a predetermined threshold in both the sH2A and the at least one additional marker with respect to a sample from a healthy individual is indicative of the liver disorder. Kits for diagnosing a liver disorder are also disclosed. | 02-18-2010 |
20100047824 | CITRUS FRUIT PEELING PROCESS - An efficient process for enzymatically peeling citrus fruit applies a vacuum to perforated fruit and, while maintaining that vacuum, introduces an enzyme solution to the perforated fruit. The fruit is infused with the enzyme by releasing the vacuum pressure. After incubating the enzyme, the albedo of the fruit is weakened and the citrus peel can be readily removed. The peeled fruit may be divided into sections and the encompassing membrane removed. | 02-25-2010 |
20100055715 | Nucleic and amino acid sequences of prokaryotic ubiquitin-like protein and methods of use thereof - The present invention relates to prokaryotic ubiquitin-like protein (Pup) nucleic acid sequences and Pup amino acid sequences encoded therefrom. Also encompassed are antibodies that are immunologically specific for Pup. Methods directed to isolation and identification of pupylated substrates that utilize the conjugated Pup as an affinity tag are also included. Pupylated substrates that are identified using the method and reagents of the present invention provide tools useful for the identification of additional components of prokaryotic proteasomal machinery. Modulators of Pup activity and methods for identifying such modulators are also encompassed herein. | 03-04-2010 |
20100075342 | Biomarker for ovarian cancer CTAP3-related proteins - The present invention provides a protein-based biomarker that is useful in qualifying ovarian cancer status in a patient. In particular, the biomarker of this invention is useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarker can be detected by SELDI mass spectrometry. | 03-25-2010 |
20100081147 | HUMAN CATECHOL-O-METHYLTRANSFERASE (COMT) ASSAY - Disclosed is an assay (method) to quantify the amounts of catecholamine-O-methyltransferase (COMT) protein in samples, such as extracts from cell cultures, body fluids, tissues, and environmental samples. It uses novel agents (anti-NE, COMT-NE, or COMT-epitope-NE) in combination with two previously described agents (anti-COMT and COMT) in a competitive ELISA system to achieve this aim. | 04-01-2010 |
20100086944 | Methods and Compositions for Diagnosis and Prognosis of Renal Artery Stenosis - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects in the context of renal artery stenosis (RAS). In particular, the invention relates to using assays that detect NGAL, their use to diagnose RAS in subjects suffering from hypertension, and their use in prognosis, particularly of mortality and worsening renal function. | 04-08-2010 |
20100099118 | METHODS OF DETERMINING TOTAL PON1 LEVEL - A method of determining an amount of total PON1 in a sample of a subject is disclosed. The method comprises:
| 04-22-2010 |
20100099119 | Detecting a Bacterial Process in Chronic Rhinosinusitis - The present invention provides a method for identifying bacterial induced rhinosinusitis. The method comprises obtaining a nasal or paranasal mucus sample and detecting the presence of neutrophil degranulation in the mucus sample. Degranulation of neutrophils can be determined by morphological analysis of the cells in the mucus or by detection of released (i.e., “free”) granule content markers such as neutrophil elastase or myeloperoxidase. Based on an accurate determination of the cause of sinusitis as described herein, an appropriate treatment can be instituted. | 04-22-2010 |
20100105076 | ANALYSIS KIT COMPRISING AT LEAST TWO MOLECULARLY IMPRINTED POLYMERS AND AT LEAST ONE MARKER, AND METHOD OF ANALYSIS USING SAME - The present invention relates to a kit for analysing at least one target molecule comprising at least a first molecularly imprinted polymer and a second molecularly imprinted polymer which are chemically identical or different, capable of interacting with the target molecule(s), and at least one marker, wherein said marker is either a competitive marker or marker capable of (i) of interacting with all or part of the recognition sites for the target molecule(s) of the second molecularly imprinted polymer and (ii) of being displaced from said recognition site(s) by the target molecule(s) when said molecularly imprinted polymer is placed in the presence of said target molecule(s), or an intrinsic marker or a constitutive unit of the second molecularly imprinted polymer, capable (i′) of interacting with all or part of the target molecule(s) when the latter interact(s) with all or part of its recognition sites for said target molecule(s) and (ii″) of consequently emitting a detectable signal. | 04-29-2010 |
20100112598 | Novel Assay for Inositol Phosphorylceramide Synthase Activity - Disclosed is a simple and reproducible method for assaying inositol phosphorylceramide synthase activity that employs a fluorescence resonance energy transfer pair for measuring enzyme activity. The invention also includes a novel method for identifying IPC synthase inhibitors. | 05-06-2010 |
20100120064 | ANTIBODY SPECIFIC TO INTACT HUMAN AUTOTAXIN, METHOD OF SCREENING THE SAME AND METHOD AND REAGENT FOR EXAMINING MALIGNANT LYMPHOMA BY ASSAYING AUTOTAXIN - A screening method is provided for antibody specifically recognizing naturally-occurring form of human autotaxin in a state in which it is present in the body without being denatured, comprising the steps of: binding a binding factor capable of capturing a candidate antibody of the antibody to a solid phase; binding the candidate antibody of the antibody to the binding factor; allowing naturally-occurring form of human autotaxin to react on a system in which the candidate antibody has reacted; and selecting an antibody that specifically recognizes the naturally-occurring form of human autotaxin by using as an indicator thereof the binding strength of the naturally-occurring form of human autotaxin to the antibody. Moreover, a detecting method for malignant lymphoma is provided comprising: measuring the concentration of autotaxin in a human specimen, and judging to be a malignant lymphoma in the case that value exhibits a significantly higher value than normal values comprised of measured values from normal healthy subjects. | 05-13-2010 |
20100120065 | METHOD FOR DETERMINING ENDOGLYCOSIDASE (HEPARANASE) ENZYME ACTIVITY - The present invention provides a method for determining endoglycosidase activity, and in particular of the heparanase type, in a sample, and also a method for detecting compounds that modulate the activity of endoglycosidases and in particular endoglycosidases of the heparanase type. | 05-13-2010 |
20100120066 | METHOD FOR DETECTING INTERACTIONS BETWEEN TWO AND MORE BIOLOGICAL MACROMOLECULES - Methods for detecting interactions of biomolecules include (a) preparing a cell comprising (i) a first construct comprising a bait, a first labeling material and a translocation module; and (ii) a second construct comprising a prey and a second labeling material; (b) detecting the distribution of the first construct and the second construct in the cell. The methods are simplified and show significantly high accuracy. | 05-13-2010 |
20100129832 | DETECTION METHOD AND DETECTION REAGENT FOR AUTOIMMUNE PANCREATITIS OR FULMINANT TYPE-1 DIABETES - By detecting an antibody which immunologically reacts with amylase α2-A in a sample, AIP or FT1DM is examined or the possibility of developing FT1DM is determined. Detection of this antibody is for instance carried out by an immunological method using an antigen which immunologically reacts with this antibody. The antigen is preferably a partial fragment containing the amino acid sequence of amino acid numbers 299 to 512 of human amylase α2-A. | 05-27-2010 |
20100136576 | In Vitro Method for Diagnosing Prostate Cancer - The invention relates to an in vitro method for diagnosing prostate cancer and to antibodies and fragments thereof directed against CK2-α and their use for the diagnosis and prognosis of prostate cancer. | 06-03-2010 |
20100136577 | COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF PROLIFERATIVE ABNORMALITIES ASSOCIATED WITH OVEREXPRESSION OF HUMAN TRANSKETOLASE LIKE-1 GENE - Methods for in vitro diagnosis of carcinoma are disclosed. In one aspect the invention relates to methods such as detecting the level of transketolase like-1 polypeptide, which are especially useful for the detection of tumors and their precursory stages based on the detection of overexpression of human transketolase like-1 gene in biological samples. In another aspect the invention relates to methods for treatment of disorders associated with the overexpression of human transketolase like-1 gene. Methods for treatment may include gene therapeutic approaches as well as methods for inhibiting or reducing the activity of transketolase like-1 polypeptides. | 06-03-2010 |
20100136578 | METHOD OF MEASURING THE ACTIVITY OF LIPID-MODIFIED ENZYME - It is intended to provide an assay method whereby the activity of a lipid-modifying enzyme can be conveniently measured over a wide range and a drug capable of controlling a lipid-modifying enzyme with the use of this assay method. The above problem can be solved by, for example, a method of measuring the activity of a lipid-modifying enzyme which comprises the steps of (I) preparing a lipid micelle containing a biotinylated lipid and a substrate for the lipid-modifying enzyme; (II) bringing the lipid micelle prepared in the above step (I) into contact with the lipid-modifying enzyme; and (III) evaluating the activity of the lipid-modifying enzyme by applying an evaluation method using the proximity effect to the product obtained in the above step (II). | 06-03-2010 |
20100136579 | BIOMARKERS USEFUL IN LIVER FIBROSIS DIAGNOSIS - Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and β-2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing liver fibrosis. | 06-03-2010 |
20100143940 | (3R)-HYDROXYACYL-ACP DEHYDRATASE ENZYMES USED IN THE BIOSYNTHESIS OF MYCOLIC ACIDS AND USE OF SAME FOR SCREENING ANTIBIOTICS - The invention relates to (3R)-hydroxyacyl-ACP dehydratase enzymes involved in the biosynthesis of mycolic acids, and to the use of same for screening antibiotics, medicaments that can be used to treat infections in humans or in animals, caused by | 06-10-2010 |
20100151494 | FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS - The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor. | 06-17-2010 |
20100159477 | Reagents for the detection of protein phosphorylation in signaling pathways - The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, adhesion/extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding/repair/replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G/regulator proteins, inhibitor proteins, motor/contractile proteins, phosphatase, protease, Ser/Thr protein kinases, Protein kinase (Tyr)s, receptor/channel/cell suface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function. | 06-24-2010 |
20100159478 | BIOMARKERS FOR CHRONIC VASCULAR DYSFUNCTION - Materials and methods for using biomarkers to determine prognosis and response to treatment in subjects having chronic vascular dysfunction. | 06-24-2010 |
20100159479 | TIMP-1 AS A MARKER FOR COLORECTAL CANCER - The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein TIMP-1 (tissue inhibitor of metalloproteinase 1) as a marker molecule in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual, the method involving measuring TIMP-1 in the sample. Measurement of TIMP-1 can, e.g., be used in the early detection or diagnosis of colorectal cancer. | 06-24-2010 |
20100159480 | BIOSENSORS, METHOD FOR OBTAINING THE SAME AND USES THEREOF - The invention relates to biosensors, methods for obtaining them and their use for detecting, assaying or locating, in direct immunofluorescence, a ligand such as an antigen or hapten, in a heterogeneous population. The biosensor includes (i) at least one fragment of a receptor which is protein in nature, capable of binding to a ligand via an active site, where at least one amino acid residues of the fragment located in the proximity of the active site is naturally present in the form of a cystein (Cys) residue, or is substituted with a Cys residue, and (ii) a fluorophore coupled to the Cys residue. | 06-24-2010 |
20100159481 | DETECTION OF HYPERTENSION USING GLUCURONIDATED METABOLIC PRODUCTS - A method of assessing arachidonic acid (AA) metabolites-dependent hypertension by measuring glucuronidated dihydroxyeicosatrienoic acids (DHETs) and DHET metabolites in a biological sample which contains the epitopes unique to DHET (using any methods including GC/MS, LC/MS or ELISA). An example of the glucuronidated DHET metabolite is DHET-alcohols such as omega or omega-1 oxidated DHET and DHET esterified glycerol. The method further includes determining the amount of glucuronidated molecules containing a DHET-specific epitope which is immunoreactive with antibodies produced against DHETs. | 06-24-2010 |
20100167310 | Reagent for Measuring Agglutination and Method of Measuring Agglutination - [PROBLEMS] To provide a reagent for measuring agglutination by using a reaction accelerator, which causes no spontaneous agglutination of receptor-sensitized carrier particles in the coexistence of these carrier particles, and a measurement method. | 07-01-2010 |
20100167311 | Oxidoreductases and Processes Utilising Such Enzymes - In Cu-containing nitrite reductase from | 07-01-2010 |
20100167312 | METHOD FOR ASSAYING A TARGET ANALYTE WHILE REDUCING INTERFERENCE IN AN IMMUNOSENSOR SYSTEM - An electrochemical immunosensor system with reduced interference, comprising: a first immunosensor that generates an electrochemical signal based on the formation of a sandwich between an immobilized antibody, a target analyte and a labeled antibody, wherein a portion of the signal arises from non-specific binding of the labeled antibody in the region of the first immunosensor, and
| 07-01-2010 |
20100184088 | METHODS OF IDENTIFYING AGENTS THAT MODULATE METHYLATION OF VEGFR1 BY SMYD3 - The present invention relates to methods for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of VEGFR1 by SMYD3. The invention further provides methods and pharmaceutical compositions for treating and preventing colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified. | 07-22-2010 |
20100184089 | DIAGNOSIS AND MONITORING OF CHRONIC RENAL DISEASE USING NGAL - A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF. | 07-22-2010 |
20100196926 | Combined Method And Kit For The Sequential Measurement of (1) The Enzymatically Active Fraction And (2) The Total Amount Of An Enzyme - The present invention is related to a combined method and kit (or device) for the sequential measurement of the enzymatically active fraction and the total amount of an enzyme [(such as myeloperoxidase (MPO)] in a sample, and that find improved applications in veterinary and human health fields. | 08-05-2010 |
20100203553 | Histochemical and biomarker for liver fibrosis - The histochemical and biomarker for liver fibrosis is a technique for determining the existence and extent of liver fibrosis by evaluating the extent of peptidylarginine deiminase (PAD) activity by immunological methods. The method is illustrated using liver biopsy. A small section of tissue from a liver biopsy is incubated overnight with a monoclonal antibody specific to PAD, stained, and examined microscopically. The number of hepatocytes that positively express PAD activity per one hundred hepatocytes is counted and expressed as a percentage. The percentage of PAD activity is then correlated with a METAVIR fibrosis score according to results from a statistically significant reference population. The degree of liver fibrosis and an appropriate treatment regimen may then be determined. | 08-12-2010 |
20100203554 | GENERIC KINASE/PHOSPHATASE ASSAY WITH SINGLE READOUT - The present invention relates to a generic method for detecting a kinase or phosphatase activity. The method comprises the following steps: incubating a kinase or phosphatase activity sample with a kinase or phosphatase substrate molecule comprising either a fluorophore having a detectable readout or molecule with an aromatic group which serves as a quencher of the fluorophore, incubating the mixture of step a) with a detection entity comprising either a fluorophore or a molecule with an aromatic group and a binding partner, wherein the substrate molecule and the detection entity are capable of binding to the binding partner and the binding of the substrate molecule and the detection entity to the binding partner lead to an altered readout of the fluorophore, and measuring the readout of the fluorophore in the mixture of step b), wherein an altered readout of the fluorophore compared to a blank is indicative for the presence of a kinase or phosphatase activity in the sample. | 08-12-2010 |
20100203555 | Wild-Type Receptor Assays - A method for determining ligand activation of receptors using cells expressing genetic constructs of a fusion protein of at least a binding domain of an auxiliary protein and a fragment of β-galactosidase, a fusion protein of an endosome-associated protein and a complementary fragment of β-galactosidase, and a wild-type receptor. The receptors are characterized by binding to the auxiliary protein-binding domain upon activation by an agonist and then endocytosing associated with an endosome to which the endosome-associated protein binds. Cells are incubated with a candidate ligand followed by lysis with a lysing medium comprising a substrate for the β-galactosidase. The enzyme product is then detected as a measure of the activation of the receptor. | 08-12-2010 |
20100209941 | METHOD, DEVICE AND KIT FOR DETERMINING CONDITIONS RELATED TO A DYSFUNCTION OF THE RENAL PROXIMAL TUBULE - A method, device and kit are disclosed for determining a condition related to dysfunction of the Renal Proximal Tubule (RPT) by detecting the presence of type III Carbonic Anhydrase, CAIII, in a urine sample of a subject. The method is used for diagnosis and to monitor the progress of a condition, and to determine the efficacy of a treatment. | 08-19-2010 |
20100209942 | NEW BIOMARKER FOR MONITORING DEVELOPMENT OF DISEASES AND ASSESSING THE EFFICACY OF THERAPIES - The invention concerns a method for monitoring the development of a disease in a patient, or for assessing the efficacy of a cytokine therapy or a statin therapy in a patient, in which methods CD73 in a tissue fluid drawn from said patient is used as a biomarker. The invention concerns also methods for determining of CD73 protein in a sample drawn from an individual's tissue fluid. | 08-19-2010 |
20100209943 | Measurement Of Protease Activity In Post-Mortem Meat Samples - The present methods and systems relate to the placement on meat surfaces of a dye-linked protease substrate bonded in a defined location to a solid, porous support. Proteases in the meat hydrolyze the substrate, which then releases the dye, which diffuses away so that the extent of diffusion can be determined by imaging. Alternatively, the amount of dye released can be determined by its mobilization into a liquid medium. The present methods and systems also relates to determining the amount of hydrolyzed protein that is present in post-mortem meat samples. Agents which bond to hydrolyzed proteins, but not to unhydrolyzed proteins, are generated, wherein such agents comprise antibodies or aptamers. Such agents are then used in quantitative assays comprising ELISA tests or lateral flow tests. | 08-19-2010 |
20100216160 | METHOD FOR THE SCREENING PROTEASOME OF ACTIVITY-MODULATING AGENTS AND MEANS FOR CARRYIING OUT SAID METHOD - An in cellulo method for the screening of proteasome activity-modulating agents, includes the following steps of:
| 08-26-2010 |
20100216161 | Method for identifying protease inhibitors - The invention describes a method for assaying HCV NS3 protease activity using an NS3•4A protease molecule. The invention also provides a method for screening and identifying modulators of NS3 protease. | 08-26-2010 |
20100221747 | IMMUNOCHROMATOGRAPHY DETECTION OF MULTIDRUG-RESISTANT STAPHYLOCOCCUS AND DIAGNOSTIC KIT - It is intended to provide an immunochromatographic detection device which detects PBP2′ specifically produced by a multidrug-resistant | 09-02-2010 |
20100221748 | AMPK modulation as a method of regulating stem cell and cancer stem cell proliferation, self-renewal and differentiation - Methods are disclosed for decreasing stem cell proliferation, including cancer stem cell proliferation. These methods comprise administering to stem cells inhibitors of AMP activated protein kinase (AMPK). Methods for promoting stem cell growth by increasing stem cell proliferation, self-renewal and/or differentiation are also disclosed. These methods comprise administering AMPK activators to stem cells. Methods of achieving selective differentiation of stem cells are also disclosed. These methods comprise administering small molecules to stem cells that modulate AMPK activity. Applications of these methods are also disclosed, such as methods of increasing numbers of neuronal progenitor cells. These methods can be used therapeutically, such as for repair of spinal cord injuries, or for stimulating neurogenesis in the hippocampus, and other cell-based therapies. The methods can also be used for screening of compounds that can be activators or inhibitors of AMPK activity. | 09-02-2010 |
20100221749 | THREE-FUNCTIONAL PSEUDO-PEPTIDIC REAGENT, AND USES AND APPLICATIONS THEREOF - The invention relates to a three-functional pseudo-peptidic reagent, to the various uses thereof, in particular for preparing bioluminescent reagents or optionally luminescent bio-conjugates, to the use of said reagents and bio-conjugates for functionalising solid substrates, and to the use of solid substrates thus functionalised in the detection of molecules of interest. | 09-02-2010 |
20100227335 | MATRIX METALLOPROTEINASE-7 (MMP-7) MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE IN THE DETECTION OF OVARIAN CANCER - Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MMP-7. Monoclonal antibodies having the binding characteristics of an MMP-7 antibody of the invention and monoclonal antibodies that bind to an MMP-7 epitope of a disclosed antibody are further provided. Hybridoma cell lines that produce an MMP-7 monoclonal antibody of the invention are also disclosed herein. The compositions find use in diagnostic methods as well as in screening methods for identifying patients having an increased likelihood of having ovarian cancer. Kits comprising one or more of the disclosed MMP-7 monoclonal antibodies and for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MMP-7 epitope of a disclosed monoclonal MMP-7 antibody and methods of using these polypeptides in the production of MMP-7 antibodies are also encompassed by the present invention. | 09-09-2010 |
20100233729 | DETECTING INTERACTIONS AT BIOMIMETIC INTERFACES WITH LIQUID CRYSTALS - A method of forming a liquid crystal device, includes: contacting an aqueous solution comprising a surfactant and a receptor molecule with a top surface of a liquid crystal. The liquid crystal is in a holding compartment of a substrate, and the receptor molecule is adsorbed on the top surface of the liquid crystal forming an interface between the liquid crystal and the aqueous solution. The receptor molecule is different than the surfactant. A method of detecting a compound in a flowing stream includes passing an aqueous solution over a top surface of a liquid crystal in a holding compartment of a substrate. The method also includes determining whether a change in the orientation of the liquid crystal occurs as the aqueous solution is passed over the top surface of the liquid crystal. A change in the orientation of the liquid crystal indicates the presence of the compound in the flowing stream. | 09-16-2010 |
20100240067 | APPARATUS AND METHOD FOR ASSAYING COAGULATION IN FLUID SAMPLES - This invention is a disposable cartridge for use at the patient side to perform traditional coagulation assays on fresh whole blood or blood derivative samples. The cartridge, in use with an electronic analyzer allows a fluid sample to be metered and quantitatively mixed with reagents which activate the coagulation cascade. An artificial substrate for thrombin, the enzyme whose action results in clot formation is also provided. Clot formation is subsequently detected using a microfabricated sensor also housed within the cartridge which detects electrochemically the product of the thrombin reaction upon the synthetic substrate. | 09-23-2010 |
20100240068 | MARKER PANEL FOR COLORECTAL CANCER - The present invention relates to a method for assessing colorectal cancer (CRC) in vitro including measuring in a sample the concentration and/or activity of a seprase polypeptide and/or fragments thereof and of either anti-p53 and/or osteopontin and/or ferritin, of optionally one or more other marker of CRC, and using the combined measurement result in the assessment of CRC. Furthermore, it especially relates to a method for assessing CRC from a liquid sample, derived from an individual by measuring seprase and at least anti-p53, ferritin and/or osteopontin in the sample. The method according to the present invention can, e.g., be used in the early detection of cancer by screening of asymptomatic individuals or in the surveillance of patients who undergo surgery. | 09-23-2010 |
20100248263 | BIOMARKERS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION - The invention relates to proteins associated with age-related macular degeneration (AMD). These proteins, which are present in blood, are expressed in individuals with AMD at either elevated or reduced levels compared to healthy individuals. The invention provides methods for diagnosing AMD. The invention provides methods for assessing the efficacy of treatment of AMD. The invention provides methods for monitoring the progression of AMD. | 09-30-2010 |
20100248264 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions - Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the proteome. The compounds are multifunctional reagents that provide for the separation and isolation of complex protein mixtures. Automated systems for performing the methods also are provided. | 09-30-2010 |
20100261198 | METHODS OF DETECTION OF FACTOR XIA AND TISSUE FACTOR - The invention provides compositions and methods for the detection of Factor XIa or Tissue Factor (TF) activity in a sample using an antibody based clotting time prolongation assay. The invention provides methods for detection of FXIa or TF activity in a sample using a fluorogenic substrate. Further provided herein is a correlation between elevated levels of FXIa and/or TF with inflammation, acute coronary syndrome (ACS), myocardial infarction, coronary artery disease (CAD), heart failure, aortic stenosis, stroke, or transient ischemic attack. The frequency of FXIa and TF activity was substantially lower in individuals with stable coronary artery disease and no history of myocardial infarction. No FXIa or TF activity was observed in healthy individuals. | 10-14-2010 |
20100267054 | Measuring The Activity Of Proteases - A method and apparatuses for determining the total content of proteases by means of measuring their enzyme activity after previous deinhibition is disclosed. In biological samples, lysosomal proteases are completely (e.g. in blood serum) or partly (e.g. in tissue homogenates) inhibited. A method proposed for the deinhibition entails immersing a solid support material (e.g. nylon or nitrocellulose) as plastic strip to which is linked, covalently or by adsorption, an inhibitor-binding substance which binds the inhibitor corresponding to the protease more strongly than the protease in the sample for measurement. After the deinhibition has taken place, the plastic strip is removed from the liquid sample for measurement, and the sample for measurement is passed on for measurement of the enzyme activity. Fluorogenic substrates from which the fluorogen 7-amino-4-trifluoromethylcoumarin is eliminated proved to be particularly advantageous for the activity measurement. These substrates make it possible for the sensitivity on measurement in microtitre plates with a fluorescence reader to be at least 10 times higher compared with conventional AMC substrates in blood serum, and thus for the fluorimetric determination of such enzyme activities in blood serum to be efficient with this measuring arrangement which is widely used in clinical laboratories. | 10-21-2010 |
20100273186 | SPLIT MUTANT HYDROLASE FUSION REPORTER AND USES THEREOF - The invention provides polynucleotides encoding and polypeptides corresponding to split hydrolase fusion proteins, wherein the hydrolase sequence may include at least one substitution, and use of the split hydrolase fusion proteins. | 10-28-2010 |
20100273187 | ANTIBODIES AGAINST DELTA-5 DESATURASE AND USES THEREOF - Disclosed are antibodies that specifically recognize Δ5-desaturase, methods of producing the antibodies, nucleotides and polypeptides for producing the antibodies, and methods of using the antibodies. The Δ5-desaturase-specific antibodies provide improved methods of detecting Δ5-desaturase in a sample. | 10-28-2010 |
20100285502 | NOVEL AROMATIC PRENYLTRANSFERASES, NUCLEIC ACIDS ENCODING SAME AND USES THEREFOR - In accordance with the present invention, a novel aromatic prenyltransferase, Orf2 from | 11-11-2010 |
20100291590 | METHODS FOR THE DIAGNOSIS AND THE PROGNOSIS OF A BRAIN TUMOR - The present invention relates to methods for the diagnosis of a brain tumor and for the estimation of a prognosis for patients having a brain tumor using the presence/absence of a particular IDH1 mutation as a marker. | 11-18-2010 |
20100291591 | NOVEL PLATING MEDIA - Plating media contains enzyme substrates (ES) used to detect enzyme activity associated with a target organism and that include a binding motif (BM) that serves to bind detectable enzymes (DE) (also called marker enzymes in this disclosure). A signalogenic substructure (SG) produces detectable signals and an enzyme labile group (ELG) is labile to the action of a marker enzyme and it typically includes the binding motif. The enzyme labile group links to the signalogenic substructure via a labile bond (LB) which is cleaved by the action of the marker enzyme separating the signalogenic substructure and the enzyme labile group. In some embodiments a linker is inserted between the signalogenic substructure and the enzyme labile group. Presence of the enzyme and thus the organism is detected by presence of a fluorogenic, precipitate that can be detected in single colonies. | 11-18-2010 |
20100297665 | METHOD FOR TESTING AND SCREENING P38 MAP KINASE MODIFIERS - This invention provides methods for treating diseases associated with elevated p38 mitogen-activated protein kinase activity. Moreover, the invention provides methods for testing a candidate compound for a p38 mitogen-activated protein kinase modifying activity by calculating the level of relocalization of an SMN complex component from the cytoplasm to the nucleus of a cell. Additionally, the invention provides a kit and a system for calculating the same. | 11-25-2010 |
20100297666 | METHODS FOR DETERMINATION OF PROTEIN PHOSPHATASE ACTIVITY, AND USES IN PREDICTING THERAPEUTIC OUTCOMES - One aspect of the present disclosure encompasses methods for determining a protein kinase or phosphatase activity in a biological sample, comprising: contacting in a reaction mix a first test sample and a fluorescently-labeled peptide substrate capable of being modified by a protein phosphatase or a protein kinase, contacting the reaction mix with a TiO | 11-25-2010 |
20100297667 | METHOD FOR DIAGNOSIS OF DISEASE USING QUANTITATIVE MONITORING OF PROTEIN TYROSINE PHOSPHATASE - The present invention relates to a method for quantifying protein tyrosine phosphatase (referred as PTP hereinafter) in biosamples, precisely a diagnostic method for disease by quantifying PTP using mass spectrometry and profiling of comparative PTP levels. By quantifying PTP in biosamples and profiling thereof according to the method of the present invention, disease can be diagnosed and diverse disease conditions and health conditions can be confirmed via profiling. | 11-25-2010 |
20100297668 | HUMAN E3ALPHA UBIQUITIN LIGASE FAMILY - The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3α ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products. | 11-25-2010 |
20100304404 | MOLECULAR MODIFICATION ASSAYS - Systems for detecting molecular modifications and the presence and/or activity of enzymes and/or other agents involved in facilitating or otherwise regulating such modifications. | 12-02-2010 |
20100304405 | COMBINATORIAL DISCOVERY OF ENZYMES WITH UTILITY IN BIOMASS TRANSFORMATION - Methods for the cell-free identification of polypeptide and polypeptide combinations with utility in biomass transformation, as well as specific novel polypeptides and cell-free systems containing polypeptide combinations discovered by such methods are disclosed. | 12-02-2010 |
20100311081 | PREDICTING CANCER PROGRESSION - A method of predicting the likelihood of cancer relapse in a patient undergoing treatment for cancer is provided. The binding response level of an immunoreactive material (IM) comprising thymidine kinase 1 (TK1) protein is determined in a body fluid sample of a patient and the likelihood of relapse of the cancer disease is predicted based on this determined IM binding response level. Those patients that run a risk of cancer progress and relapse 1-15 years after the cancer treatment may be identified directly by the IM binding response level within a few months following initiation of the treatment. | 12-09-2010 |
20100317029 | Nasopharyngeal cancer malingancy biomarker and method thereof - The present invention discloses a nasopharyngeal cancer malignancy biomarker and a method thereof, wherein relative TP expression is used to evaluate the malignancy of nasopharyngeal cancer. The biomarker of the present invention assists the currently-existing inspections to find out cancer in the early stage and achieve early diagnosis and early therapy. The present invention also functions as an effective indicator to monitor the metastasis and relapse of nasopharyngeal cancer. | 12-16-2010 |
20100317030 | METHODS AND COMPOSITIONS FOR DETERMINING ENZYMATIC ACTIVITY - The present invention comprises crystalline polyketide synthases, isolated non-native polyketide synthases having the structural coordinates of said crystalline polyketide synthases, and nucleic acids encoding such non-native polyketide synthases. Also disclosed are methods of predicting the activity and/or substrated specificity of putative polyketide synthase, methods of identifying potential polyketide synthase substrates, and methods of identifying potential polyketide synthase inhibitors. | 12-16-2010 |
20100317031 | ULTRA-SENSITIVE CHEMILUMINESCENT SUBSTRATES FOR ENZYMES AND THEIR CONJUGATES - New chemiluminescent compounds, stable in aqueous buffers, for use in biological assaying include acridane-based compounds and 1,2-dioxetanes. Among the new acridane-based compounds are water-soluble acridanes, enhancer coupled acridanes, bis and tris-acridanes as well as acridane-1,2-dioxetanes. Among the new 1,2-dioxetanes are electron deficient group-containing dioxetanes and tethered bis-1,2-dioxetanes. The 1,2-dioxetanes are useful as substrates for various enzymes. The acridanes can be admixed with an oxidizing agent an aqueous buffer and, optionally, a stabilizer to form a substrate or reagent formulation useful for assaying, inter alia, HRP. | 12-16-2010 |
20100330588 | METHOD TO QUANTIFY METHYLTRANSFERASE ACTIVITY - The related disclosure pertains to a method to quantify methyltransferase activity. In an exemplar embodiment, the method may be carried out by the following steps: i) incubating a mixture comprising a methyltransferase, a substrate, and radiolabeled S-adenosylmethionine for a period of time sufficient for the protein methyltransferase to methylate and transform at least some of the substrate into a methylated product of the substrate, then ii) at one or more times removing an aliquot of the mixture, then iii) contacting the aliquot of the mixture to a resin capable of binding the methylated product of the substrate, followed by iv) a washing step to remove the unreacted radiolabeled S-adenosylmethionine, followed by v) an elution step to elute and isolate the methylated product, then vi) measuring the amount of radiolabel in the methylated product. | 12-30-2010 |
20110003312 | LINKED PEPTIDE FLUOROGENIC BIOSENSORS - Biosensors, compositions comprising biosensors, methods of producing biosensors, and methods of using biosensors are disclosed. The biosensors comprise a fluorogen-activating peptide and a blocking peptide. The fluorogen-activating peptide and blocking peptide are covalently linked through a peptide linker. The blocking peptide associates with the fluorogen-activating peptide thereby blocking an active domain of the fluorogen-activating peptide when the linker is in an unmodified state. The peptide linker may contain an amino acid sequence that is specifically recognized as a modification substrate by a cognate enzyme. The fluorogen-activating peptide and the blocking peptide at least partially disassociate when the linker is modified by an enzyme, thereby allowing the fluorogen-activating peptide to bind a cognate fluorogen and modulate a fluorescence signal. | 01-06-2011 |
20110014631 | METHOD FOR DIAGNOSING ACUTE CORONARY SYNDROME - This invention concerns a bioaffinity assay for quantitative determination in a sample of free PAPP-A, defined as the pregnancy associated plasma protein A (PAPP-A) that is not complexed to the proform of major basic protein (proMBP), wherein
| 01-20-2011 |
20110020839 | METHODS AND COMPOSITIONS FOR DETECTING THE ACTIVATION STATE OF MULTIPLE PROTEINS IN SINGLE CELLS - The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state. | 01-27-2011 |
20110027801 | EphA KINASE CANCER DIAGNOSTIC - A method of detecting malignant progression of neoplastic cells in an animal includes obtaining a sample of neoplastic cells from the animal, determining a level of S897-EphA2 phosphorylation in the neoplastic cells of the samplem, and comparing the determined level of S897-EphA2 phosphorylation in the sample to a control value, wherein an increased level of S897-EphA2 phosphorylation compared to the control value is indicative of malignant progression of the neoplastic cell in the animal. | 02-03-2011 |
20110045494 | CANCER DETECTION METHODS AND TECHNIQUES - A method is provided for detecting and/or measuring the occurrence of an enzyme in the form of CYP1B1 in a patient for the detection of cancer in said patient. The method includes the steps of administering a reporter substrate to a patient; taking a bodily fluid and/or tissue sample from the patient after one or more pre-determined periods of time; and analyzing the bodily fluid and/or tissue sample in vitro for the occurrence and/or measurement of a metabolite of the reporter substrate caused as a result of metabolism of the reporter substrate by said enzyme in said patient during said pre-determined period of time. | 02-24-2011 |
20110053178 | Methods and Compositions for Detection of Lethal Cell and Uses Thereof - The present invention relates to methods and compositions for identifying and detecting lethal cell useful for monitoring disease status and therapy response in various types of cancer patients regardless of the etiological origin of the cancer and uses thereof. | 03-03-2011 |
20110053179 | Biomarkers For Prediction Of Major Adverse Cardiac Events And Uses Thereof - The present invention relates to combinations of biomarkers and levels thereof that may be used, for example, in the determination of risk associated with the occurrence of a major adverse cardiac event (MACE) in a patient. | 03-03-2011 |
20110053180 | KINASE SENSORS - The present invention generally relates to compositions and methods for determining kinase activity. In some cases, the compositions comprise a triazole heterocycle. In some embodiments, the compositions comprise a quinoline moiety. In one aspect, the present invention is directed to compositions that undergo chelation-enhanced fluorescence (CHEF). In some cases, the compositions may have fluorescence emission spectra with peak maxima greater than 490 nm. The compositions of the present invention can be used, in certain embodiments, to detect phosphorylated substrates and biological processes such as phosphorylation events. | 03-03-2011 |
20110059465 | SCREENING ASSAYS FOR AGENTS THAT ALTER INHIBITOR OF APOPTOSIS (IAP) PROTEIN REGULATION OF CASPASE ACTIVITY - The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7. The invention also provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a pro-caspase such as pro-caspase-9. In addition, the invention also provides methods for identifying agents that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP. The invention further provides methods of reducing the severity of a pathologic condition in an individual by administering to the individual an agent that alters the caspase inhibitory activity of an IAP. In addition, the invention provides methods of modulating the ability of a population of cells to survive ex vivo by contacting the cells with an agent that alters the caspase inhibitory activity of an IAP in the cells. | 03-10-2011 |
20110065127 | Detection of Degradative Enzymes and Biomolecules in Bodily Fluids - Provided herein are methods, kits and compositions useful in detecting degradative enzymes and biomolecules in bodily fluid samples. | 03-17-2011 |
20110070594 | Method for Detecting Escherichia coli - Described herein are methods of detecting an infection and for detecting the presence or absence of microorganisms, for example, wound pathogens in a sample, by contacting a sample with an enzyme produced and/or secreted by the bacteria, and detecting modification or the absence of modification of the substrate, as an indicator of the presence or absence of the enzyme in the sample. The present invention also features a biosensor for detecting the presence or absence of bacteria in a sample. | 03-24-2011 |
20110070595 | METHODS FOR THE IDENTIFICATION OF PARP INTERACTING MOLECULES AND FOR PURIFICATION OF PARP PROTEINS - The present invention relates to immobilization compounds and methods useful for the identification of PARP interacting compounds or for the purification or identification of PARP proteins. | 03-24-2011 |
20110076692 | Detection of Cardiac Markers on a Droplet Actuator - The present invention provides for the detection of cardiac markers on a droplet actuator. An aspect provides a method of assaying a cardiac marker in a biological sample from a subject, the method including providing a droplet actuator, loading the biological sample and assay reagents on the droplet actuator, executing droplet operations to create sample droplets from the sample and reagent droplets from the reagents on the droplet actuator, and executing droplet operations using the sample droplets and reagent droplets to produce a detectable signal indicative of the quantity of the cardiac marker in the biological sample. Still other aspects are provided. | 03-31-2011 |
20110076693 | METHOD FOR DETECTION AND QUANTIFICATION OF PLK1 EXPRESSION AND ACTIVITY - Isolated peptide substrates of Plk1 and nucleic acids encoding these peptides are disclosed. The peptides include two to ten repeats of the amino acid sequence set forth as X | 03-31-2011 |
20110081659 | SUBSTRATES FOR GLYCOGEN SYNTHASE KINASE 3 ENZYMES AND METHODS OF USE - Methods and compositions for glycogen synthase kinase 3 assays continue to be required for detection of glycogen synthase 3 kinase, assessment of glycogen synthase 3 kinase activity and identification of modulators of glycogen synthase 3 kinase. Methods and compositions for glycogen synthase kinase 3 assays are provided herein based on the discovery of a previously unknown interaction between glycogen synthase 3 kinase and eukaryotic translation initiation factor 4E-binding protein 1 which serves as a substrate for glycogen synthase kinase 3-alpha and glycogen synthase kinase 3-beta. | 04-07-2011 |
20110097736 | METHODS OF DETERMINING LEVELS OF FREE AMINO ACID AND DIPEPTIDES AND DIAGNOSING ALZHEIMER'S DISEASES - Provided herein are methods of diagnosing Alzheimer's disease (“AD”) based on characteristic changes of the levels of certain free amino acids or dipeptides (collectively termed as “AD diagnosis markers”) in the body fluid sample of an individual, carnosine synthesis activities in the plasma, and dopamine synthesis activities in the plasma. Also provided are methods of simultaneously determining the levels of at least two free amino acids or dipeptides in the biological fluid sample of an individual. | 04-28-2011 |
20110097737 | Methods and Compositions for Targeting Proteins of Interest to the Host Cell Envelope - Methods and compositions are provided for producing membrane proteins or toxic proteins from recombinant DNA introduced into a prokaryotic host cell by targeting the expressed proteins to the envelope of the host cell. The methods and compositions utilize a protein vehicle fused to a protein of interest. The fusion protein may contain one or more protease cleavage sites to separate the protein of interest from the protein vehicle either in vivo or in vitro. The protein vehicle is characterized by a membrane-tar peptide and a trans-membrane segment separated by a cytoplasmic amino acid sequence that includes a cytoplasmic affinity-binding domain. | 04-28-2011 |
20110097738 | PLASMA BIOMARKER TOOL FOR THE DIAGNOSIS OF LIVER CANCER COMPRISING LIVER CARBOXYLESTERASE 1 AND LIVER CANCER SCREENING METHOD - The present invention relates to a plasma biomarker for diagnosing hepatocellular carcinoma (HCC), in particular to the discovery of a protein in plasma using 2-D fluorescence differential gel electrophoresis (2-D DIGE), immunoprecipitation and Nano-liquid chromatography mass spectrometry (Nano-LC-MS/MS) system that was unknown on the basis of conventional techniques. By demonstrating the presence of liver carboxylesterase 1 (hCE1) in human plasma and confirming that its secretion level is higher in patients with HCC than in healthy volunteers, this invention may be used as a screening method to diagnose HCC at an early stage. | 04-28-2011 |
20110104712 | Method for Assaying Plasma Enzymes in Whole Blood - The present invention relates to a method for assaying catalytic plasma enzymes, such as transaminases and NADH-dependent enzymes, in a sample of whole blood, by measuring, in a microfluidic chamber, the decrease in the fluorescence of NADH consumed during the enzymatic reactions catalyzed by the NADH-dependent enzymes. | 05-05-2011 |
20110111427 | BIOMARKER FOR THE ESTIMATION OF ACUTE RENAL DISORDER AND PROGNOSIS OF THE DISORDER, AND USE OF THE BIOMARKER - To provide a novel biomarker that is useful for prediction of early onset of acute kidney injury, estimation of prognosis associated with a renal function, and differentiation of acute kidney injury. Furthermore, to provide use of the novel biomarker. Midkine is used as a biomarker. The determination of a possibility of the onset of acute kidney injury, estimation of prognosis associated with a renal function or differentiation of an acute kidney injury are carried out based on the detection result of the urinary midkine. | 05-12-2011 |
20110124009 | COMPOSITION, KIT AND METHOD FOR ASSAYING NEUROPATHY - The present invention relates to a method for detecting a disease accompanied with neuropathy such as glaucoma, comprising measuring and/or detecting one or more of polypeptides shown in SEQ ID NOS: 1 to 15, mutants thereof, or fragments thereof in a biological sample from a subject, and also to a composition or kit for diagnosis of a disease accompanied with neuropathy such as glaucoma. | 05-26-2011 |
20110136137 | SERUM PROTEOMIC FOR FINDING DIAGNOSTIC MARKERS AND FOR MONITORING THERAPEUTICAL INTERVENTION IN TREATMENT OF HEPATOCELLULAR CARCINOMA - The invention is directed to biomarkers for determining the EGFR kinase activity in a subject, and the use thereof for predicting and monitoring therapeutic intervention in cancer patients. Areas of application are the life sciences: biology, biochemistry, biotechnology, medicine and medical technology. | 06-09-2011 |
20110136138 | METHOD FOR PREDICTING A NEED FOR RENAL REPLACEMENT THERAPY (RRT) - A method for predicting a need for Renal Replacement Therapy (RRT) in a patient comprises: determining a concentration of pi glutathione S transferase-(πGST) in a first urine sample from the patient; and wherein a need for RRT is predicted when the πGST concentration is determined to be elevated in comparison to a patient without kidney injury. The method according to the invention can further comprise detecting for the presence of risk factors for RRT in a patient, the risk factors including elevated serum creatinine concentration, type I diabetes, type II diabetes, hypertension, dyslipidemia, hyperglycaemia, proteinuria and hypoalbuminemia. | 06-09-2011 |
20110143368 | Tyrosine phosphorylation sites - The invention discloses 142 novel phosphorylation sites identified in carcinoma, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 06-16-2011 |
20110143369 | METHOD FOR DETERMINING TREATMENT OF DISSEMINATED INTRAVASCULAR COAGULATION - A method for determining an appropriate treatment option for a patient who has been diagnosed with disseminated intravascular coagulation (DIC) but who may have thrombotic thrombocytopenic purpura (TTP), by analyzing the amount and/or enzyme activity of a von Willebrand factor (vWF)-cleaving protease (ADAMTS13) and the amount of vWF in a patient that has been diagnosed with DIC is disclosed. Using the method of the present invention, a differential diagnosis of patients with thrombotic thrombocytopenic purpura (TTP) can be made from among patients diagnosed with DIC, which could not previously be distinguished on the basis of only clinical findings or known markers. Also disclosed is a kit for determining an appropriate treatment option, the kit comprising an antibody or a fragment thereof which specifically binds to ADAMTS13. | 06-16-2011 |
20110151481 | BETA-2 MICROGLOBULIN AS A BIOMARKER FOR PERIPHERAL ARTERY DISEASE - The present invention provides β2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject. | 06-23-2011 |
20110159521 | METHODS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME - The invention provides an ELISA assay for the determination of serum mast cell β-tryptase levels using rabbit anti-tryptase as the capture antibody and alkaline phosphatase conjugated G3 as the detecting antibody. Luminescent substrate CPSD was used to enhance the assay sensitivity. Also provided are methods for aiding in the diagnosis of irritable bowel syndrome by detecting the serum level of β-tryptase, histamine and/or prostaglandin E | 06-30-2011 |
20110165593 | Mutants of 06-Alkylguanine-DNA Alkyltransferase - The invention relates to AGT mutants showing, when compared to the wild type human AGT, two or more advantageous properties selected from (a) reduced DNA interaction; (b) localisation of the expressed protein in eukaryotic cells that is no longer restricted to the nucleus; (c) improved expression yield as soluble protein and improved stability in various hosts; (d) improved stability under oxidising conditions; (e) improved stability within cells after reaction with a substrate; (f) improved stability outside cells before and after reaction with a substrate; (g) improved in vitro solubility; (h) improved reactivity against O | 07-07-2011 |
20110165594 | SYSTEMIC MARKERS FOR ASTHMA AND ANALOGOUS DISEASES - Provided herein are diagnostic and prognostic methods, diagnostic and prognositic markers, and methods for evaluating anti-inflammatory agents or drugs in subjects with asthma and/or an analogous disease associated with high oxidative and nitrative stress at the disease site. In certain embodiments, the methods comprise a step of assaying for decreased levels of superoxide dismutase activity in the blood, serum, or plasma of the subject. In certain embodiments, the methods comprise a step of assaying for elevated levels of one or more oxidatively-modified SOD isoforms or species in the blood, serum or plasma of the subject. Also provided are diagnostic kits for use in the present invention. In certain embodiments, such kits comprise at least one binding reagent that specifically binds to at least one oxidatively-modified SOD species. | 07-07-2011 |
20110183357 | DEVICE AND METHODS FOR LIQUID CRYSTAL-BASED BIOAGENT DETECTION - The present invention provides liquid crystal-based devices and methods for bioagent detection. In certain aspects, the present invention is directed to devices and methods utilizing liquid crystals and membranes containing polymerized targets that can report the presence of bioagents including, but not limited to, enzymes, antibodies, and toxins. | 07-28-2011 |
20110189697 | RECOMBINANT CELLS AND PLANTS FOR SYNTHESIS OF VERY LONG CHAINS FATTY ACID (VLCFA) - The present disclosure is relative to a method for the production of Very-Long-Chain Fatty Acids (VLCFA) into a plant cell, including culturing a recombinant plant cell in an appropriate medium, wherein said plant cell is transformed with an heterologous gene encoding for an hydroxyacyl-CoA dehydratase. The disclosure is also relative to a method for producing vegetable oil including high levels of VLCFA. | 08-04-2011 |
20110189698 | Protein Biomarkers and Methods for Diagnosing Kawasaki Disease - A method, kit and device for diagnosing Kawasaki Disease are provided. The invention provides detecting an expression level of at least two Kawasaki Disease diagnostic biomarkers in a biological sample from a patient with a capture agent and diagnosing the patient as having Kawasaki Disease when the expression levels of the at least two diagnostic biomarkers in the patient biological sample are higher than the normal expression levels of the same biomarkers in a biological sample from a control subject. The first Kawasaki Disease diagnostic biomarker disclosed in the present invention is a cardiomyocyte biomarker, and the second Kawasaki Disease diagnostic biomarker is an inflammatory biomarker. The invention further provides detecting an expression level of a third biomarker, interferon type-I biomarker, in the patient biological sample with a capture agent and diagnosing the patient as having Kawasaki Disease when the expression level of interferon type-I biomarker is lower than the expression level in a control subject. | 08-04-2011 |
20110195432 | METHODS FOR THE SELECTION OF THERAPEUTIC TREATMENTS FOR CANCER - Methods are disclosed for identifying subjects that would benefit from treatment with an inhibitor of HDAC6 deacetylase activity. The methods can include contacting a sample obtained from the subject with an of HDAC6 deacetylase activity detecting the amount of HDAC6 protein present in the tumor sample in comparison with a control. Such methods can be used to determine if a tumor in a subject is sensitive to treatment with an inhibitor of HDAC6 deacetylase activity. Also disclosed are methods for monitoring a response to a cancer treatment. Such methods are particularly useful in selecting a compound or multiple compounds for the treatment of cancer in a subject. Methods are also disclosed for identifying agents that inhibit cancer. The methods can include contacting at least one cell with a test agent and detecting an amount of HDAC6 protein in the cell in comparison to a control. | 08-11-2011 |
20110201021 | USE OF THE IRAP PROTEIN FOR IMPLEMENTING METHODS OF DIAGNOSIS AND OF PROGNOSIS - The use of the IRAP protein for implementing methods of diagnosis and of prognosis. | 08-18-2011 |
20110201022 | ASSAYS FOR DETECTION OF PHENYLALANINE AMMONIA-LYASE AND ANTIBODIES TO PHENYLALANINE AMMONIA-LYASE - Provided herein are methods of detecting the presence of a pegylated enzyme, an enzyme-specific antibody (e.g., a neutralizing antibody or of a particular isotype), or a polyethylene glycol (PEG)-specific antibody in a sample, such as a bodily fluid or tissue of a patient. In certain embodiments, the enzyme is phenylalanine ammonia-lyase (PAL), such as | 08-18-2011 |
20110201023 | MANNOSE 6-PHOSPHATE-BINDING ANTIBODIES AND THEIR USES - The present invention relates to an isolated antibody or antigen-binding fragment thereof which specifically binds to mannose 6-phosphate and methods for preparing such antibody or antigen-binding fragment thereof. The invention further relates to a nucleic acid molecule encoding such antibody or antibody fragment, an expression vector comprising such nucleic acid molecule and a host cell comprising such nucleic acid molecule or expression vector. The invention also relates to a method for purifying or concentrating a target molecule comprising at least one mannose 6-phosphate residue from a sample. In another aspect, the invention relates to a method for diagnosing a disease which is characterized by an absent or reduced modification of molecules with mannose 6-phosphate residues. Finally, the invention relates to the use of an antibody or antibody fragment of the invention for use in medicine, in particular for the diagnosis of a disease which is characterized by an absent or reduced modification of molecules with mannose 6-phosphate residues. | 08-18-2011 |
20110212465 | ARMET AS A MARKER FOR CANCER - Disclosed is a method aiding in the assessment of cancer. More specifically disclosed is the use of the arginine-rich metastasized in early tumors protein (=ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., breast, ovary, cervix, head and neck, endometrium, melanoma, bladder, kidney, pancreas, prostate, esophagus, stomach or bile duct cancer. Further disclosed is a method for assessing cancer from a liquid sample, derived from an individual by measuring ARMET in the sample. Measurement of ARMET can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery. | 09-01-2011 |
20110217719 | METHODS AND KITS FOR DIAGNOSING OBSTRUCTIVE SLEEP APNEA - The presently-disclosed subject matter provides methods and kits for diagnosing obstructive sleep apnea (OSA) in a subject, such as a human child, wherein a biological sample is provided from the subject and the amount of a Urocortin III peptide is determined from the sample. Further provided are methods for diagnosing OSA in a subject wherein the amount of a Urocortin III peptide and one or more peptides selected from a Uromodulin peptide, an Orosomucoid 1 peptide, and a Kallikrein 1 peptide are determined in a biological sample from a subject. | 09-08-2011 |
20110223616 | HuR-Associated Biomarkers - The present invention relates to methods of identifying gene targets, including methods of using ribonucleoprotein (RNP) immunoprecipitation-microarrays to identify cancer gene targets, such as subsets of RNP-associated mRNAs in breast cancer cell lines. Also presented, are ribonucleotide binding protein-associated biomarkers, panels or sets of ribonucleotide binding protein-associated biomarkers, methods and compositions comprising ribonucleotide-binding protein, associated nucleotides, nucleotide arrays, and kits to facilitate the diagnosis of and monitoring the disease status or progression of treatment of breast cancers, including drug-resistant breast cancers. | 09-15-2011 |
20110229911 | AZUROPHILIC GRANULE PROTEASES AS MARKERS IN CARDIOLOGICAL DISEASES - The present invention is concerned with an assay for detecting and/or determining the level of a protease from azurophilic granules of polymorphonuclear neutrophils or a complex thereof with an endogenous inhibitor for risk stratification and/or prognosis and/or therapy control and/or monitoring of a patient having a cardiological disease or condition. | 09-22-2011 |
20110236908 | TOTAL PLASMA FVII/FVIIA LEVELS AS INDICATORS OF PRE-ECLAMPSIA OF PREGNANT FEMALES - Raised total plasma FVII protein, including activated FVII (FVIIa) in pregnant females, compared with total plasma FVII protein in normal pregnancy, has been found to be an indicator of the pregnancy complication of pre-eclampsia. | 09-29-2011 |
20110269150 | Compositions and methods for predicting cardiovascular events - The present invention provides compositions, devices, kits, and methods for determining the risk of peri-operative cardiovascular events or predicting cardiovascular events associated with angioplasty. In certain embodiments, the present invention provides methods, compositions, kits, and devices configured for determining the value of at least two markers selected from myeloperoxidase (MPO), an F2-isoprostane (F2-IsoP), C-reactive protein (CRP), urinary micro-albumin (UMA), and lipoprotein-associated phospholipase A2 (Lp-PLAZ), such that a subject's risk of experiencing a cardiovascular event is determined. | 11-03-2011 |
20110281279 | CIRCULATING Epha2 RECEPTOR - Provided are compositions, methods, and kits relating to the detection of a circulating or soluble form of the EphA2 receptor tyrosine kinase. | 11-17-2011 |
20110281280 | Methods and Compositions for Monitoring and Risk Prediction in Cardiorenal Syndrome - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function. | 11-17-2011 |
20110287449 | MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE - Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a predetermined value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from healthy controls. Such comparison characterizes the test subject's risk of developing CVD. | 11-24-2011 |
20110294141 | METHOD FOR ANALYZING PSA AND METHOD FOR DISTINGUISHING PROSTATE CANCER FROM PROSTATIC HYPERTROPHY USING THAT METHOD FOR ANALYZING PSA - A method for distinguishing prostate cancer from prostatic hypertrophy using the method for analyzing PSA and an analysis kit of PSA are provided. | 12-01-2011 |
20110300556 | MONOCLONAL ANTIBODIES DETECTION METHODS FOR ENZYMES THAT CONFER RESISTANCE TO 2,4-DICHLOROPHENOXYACETIC ACID IN PLANTS - Described herein are monoclonal antibodies and methods useful for determining and quantitating the presence of an aryloxyalkanoate dioxygenase enzyme. | 12-08-2011 |
20110306058 | METHOD FOR THE FUNCTIONAL MEASUREMENT OF PLASMATIC THROMBODULINE ACTIVITY - A method for the in vitro measurement of the thromboduline functional activity, includes dosing in a biological medium, and from a biological sample, the thrombine-activation of C protein into activated C protein (PCa) in the presence of its co-factor or the thromboduline, the method including adding to the sample plasma the agents necessary for activating the C protein system, adding purified C protein and also adding a fibrin polymerisation inhibitor. Also described is application of the method in the detection of coagulation pathologies. | 12-15-2011 |
20110306059 | COMPOSITIONS AND METHODS FOR MEASURING 3,6-L-AHG TRANSFERASE ACTIVITY AND 3,6-L-AHG - Provided herein are a composition for measuring 3,6-anhydro-L-galactose (3,6-L-AHG) transferase activity by reduction of NADP to NADPH, and a method of measuring 3,6-L-AHG transferase activity using the same. The composition and method are useful for determining 3,6-L-AHG in a material containing 3,6-L-AHG such as algae biomass and industrial applications. | 12-15-2011 |
20110306060 | PCSK9 IMMUNOASSAY - Methods of using PCSK | 12-15-2011 |
20120003665 | Dissolved Protein Arthritis Markers - Methods and kits for diagnosing arthritis are provided. The methods may involve detection of 14-3-3 eta or gamma proteins in a sera or synovial fluid sample. | 01-05-2012 |
20120009592 | ENPP1 (PC-1) GENE HAPLOTYPE ASSOCIATED WITH THE RISK OF OBESITY AND TYPE 2 DIABETES AND THEIR APPLICATIONS - The present invention is directed to a method for determining if a subject is at increased risk to develop obesity or pathology related to obesity by determining the presence of a haplotype comprising three specific SNPs in a DNA or RNA sample of this subject and/or an elevated serum ENPP1 protein concentration. The present invention also relates to a kit and to an isolated nucleic sequence, vector or recombinant cell comprises said ENPP1 gene haplotype. The invention further comprises a method for selecting a compound for the treatment or the prevention of obesity or pathology related to obesity and a method for determining the efficacy of a drug to reduce the risk of obesity or pathology related to obesity in a patient. | 01-12-2012 |
20120009593 | ANALYSIS METHOD FOR THE IN VITRO DIAGNOSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN DOGS BY ASSAYING CANINE PROSTATE SPECIFIC ESTERASE, AND BPH TREATMENT FOLLOW UP - The invention relates to an analysis method for the in vitro diagnosis of benign prostatic hyperplasia (BPH) in a dog, using the CPSE contained in biological fluid samples collected from the dog as well as biological molecules specifically binding CPSE. The invention is characterised in that it includes the following steps: a. collecting a biological fluid sample from a dog; b. measuring the canine prostate specific esterase (CPSE) of said sample; c. comparing said measured CPSE concentration with a reference value, said value being from around 34 ng/ml to around 102.4 ng/ml for serum or plasma, preferably around 61 ng/ml; d. using the CPSE concentration as a BPH marker; and e. diagnosing BPH in a dog when measured CPSE concentrations in said sample exceed said reference value. | 01-12-2012 |
20120009594 | METHOD FOR MEASURING BETA-GLUCAN, AND BETA-GLUCAN-BINDING PROTEIN FOR USE IN THE METHOD - Disclosed are a method for measuring βG comprising the steps of bringing a sample into contact with a βG-binding protein 1 and a βG-binding protein 2, each comprising an amino acid sequence which is identical or substantially identical to an amino acid sequence shown in any one of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20, and having the β-glucan binding activity, to form a complex of the βG-binding protein 1, βG in the sample and the βG-binding protein 2, measuring quantity of the complex, and determining βG concentration in the sample based on the quantity of the complex; a reagent and a kit for use in said method; a novel βG-binding protein; a nucleic acid molecule encoding the βG-binding protein; and a method for producing the aforementioned βG-binding protein. | 01-12-2012 |
20120028274 | PROTEIN KINASE C GAMMA AS A BIOMARKER FOR NEUROPSYCHOLOGICAL AND COGNITIVE FUNCTIONS IN THE CENTRAL NERVOUS SYSTEM - Embodiments of the present invention are directed to a biological marker, the gamma isoform of protein kinase C (PKCg), which surprisingly allows rapid identification of compromised cognitive, behavioral, and neuropsychological functions under conditions associated with acute, transient hypoxia in humans. It was surprisingly discovered that PKCg is released from neural cells and can be detected in peripheral blood after hypoxic events unrelated to the reduction or elimination of blood flow through affected tissues. Embodiments of this invention are also directed to a broad range of clinical applications, particularly in emergency medicine. Other embodiments are related to compositions and methods for distinguishing between hypoxic encephalopathies and conditions arising from neuroanatomical/structural anomalies and/or incidental pathologies, for example, alcohol intoxication. | 02-02-2012 |
20120034624 | OSCILLATING IMMUNOASSAY METHOD AND DEVICE - The present invention provides apparatus and methods for the rapid determination of analytes in liquid samples by immunoassays incorporating magnetic capture of beads on a sensor capable of being used in the point-of-care diagnostic field. | 02-09-2012 |
20120040371 | DIAGNOSIS OF PREECLAMPSIA - The present invention provides methods and compositions related to the detection and/or monitoring of the levels of angiogenic factors, specifically VEGF, PlGF and sFlt-1, in urine samples obtained from pregnant women and the effects of such levels on the risk of developing complications of pregnancy, including hypertensive disorders such as preeclampsia, in the first, second, and/or third trimester of pregnancy. The present invention also provides kits for identifying and screening patients at risk of developing a complication of pregnancy, such as preeclampsia. | 02-16-2012 |
20120040372 | RECEPTOR TYROSINE KINASE ASSAYS - Methods for detecting phosphorylation of receptor tyrosine kinases (“RTKs”) upon activation and the modulation of activation by a candidate compound are provided. The method employs cells comprising two fusion products: (1) an RTK fused to a small fragment of β-galactosidase and (2) a phosphotyrosine binding peptide fused to the large fragment of β-galactosidase, where the 2 fragments weakly complex to form an active enzyme, and optionally a construct for a cytosolic RTK phosphorylating kinase, when the RTK does not autophosphoryate. To detect phosphorylation a β-galactosidase substrate is added to the cells, whereby product formation indicates the occurrence of phosphorylation. | 02-16-2012 |
20120045774 | Lipoprotein Associated Phospholipase A2, Inhibitors Thereof and Use of the Same in Diagnosis and Therapy - The enzyme Lp-PLA | 02-23-2012 |
20120045775 | PHOSPHOSPECIFIC PAK ANTIBODIES AND DIAGNOSTIC KITS - The present invention relates to the use of phosphorylated p21-activated protein kinases (PAK), especially PAK4, as biomarkers of tumorogenesis. The present invention contemplates the use of phosphospecific antibodies for detecting phosphorylated PAK from mammalian biopsies, as well as screening assays for identifying compounds that modulate PAK activity. Also contemplated is a method for determining a subset of a given population that is amenable to treatment with a compound that modulates PAK activity. | 02-23-2012 |
20120064542 | MONOCLONAL ANTIBODIES AND DETECTION METHODS FOR ENZYMES THAT CONFER RESISTANCE TO 2,4-DICHLOROPHENOXYACETIC ACID - Described herein are monoclonal antibodies and methods useful for determining and quantitating the presence of AAD-1 (aryloxyalkanoate dioxygenase) enzyme. These monoclonal antibodies are surprisingly well suited for detecting AAD-1 transgenic event gene products in a variety of plants and plant tissues. The invention further provides quantitative and qualitative immunoassays using the immunoglobulins of the invention. | 03-15-2012 |
20120077208 | USE OF CARBAMOYL PHOSPHATE SYNTHETASE 1 (CPS) AS A HUMORAL BIOMARKER FOR THE DIAGNOSIS OF TUMOUR DISEASES AND CHRONIC INFLAMMATORY INTESTINAL DISEASES - The invention relates to the use of carbamoyl synthetase 1 (CPS 1) as a humoral biomarker in in vitro methods for early diagnosis and detection, progress prognosis, the evaluation of the severity, and the progress evaluation of tumor diseases and chronic inflammatory intestinal diseases. | 03-29-2012 |
20120077209 | PROTEIN BIOMARKERS AND THERAPEUTIC TARGETS FOR AUTOIMMUNE AND ALLOIMMUNE DISEAES - A method for characterizing the risk a subject will develop an autoimmune and/or alloimmune disease following tissue transplant includes obtaining a biological sample from the subject, wherein the subject has received the tissue transplant determining in the biological sample a level of at least one protein selected from Tables 1-4, comparing the measured level of the at least one protein to a control value, and characterizing a subject as at greater risk of developing an autoimmune disease and/or alloimmune disease if the level of at least one protein determined is increased or decreased compared to the control value. | 03-29-2012 |
20120082999 | NEW ANTIBODY COCKTAIL - The present invention relates to a composition comprising at least three primary antibodies or fragments thereof, wherein the at least three antibodies or fragments thereof binds specifically to at least three different proteins, and wherein the at least three different proteins are AMCAR, CK 5/6, and HMWC. Methods for using the composition in diagnosis, prognosis, and assessing efficacy of treatment is further included as well as kits comprising said composition, and optionally, instructions of its use. | 04-05-2012 |
20120094307 | TUBE FOR MEASURING BIO-RELATED SUBSTANCE AND QUANTIFYING SYSTEM - A bio-related substance assay tube | 04-19-2012 |
20120107833 | Antibody specific for a mammalian sphingosine kinase type 2 isoform protein and methods of use thereof - Polyclonal or monoclonal antibodies which are specific for a mammalian sphingosine kinase type 2 isoform protein and methods for detecting the presence of sphingosine kinase type 2 isoform using the antibodies. | 05-03-2012 |
20120115165 | BIOMARKERS FOR DETECTION AND DIAGNOSIS OF HEAD AND NECK SQUAMOUS CELL CARCINOMA - Novel, sensitive and specific markers and methods for diagnostics and monitoring of head and neck squamous cell carcinoma (HNSCC) are provided. Kits and methods for the use of hyaluronic acid, hyaluronidase and CD44 to diagnose HNSCC are described. | 05-10-2012 |
20120122116 | USE OF LYMPHOCYTES TO MEASURE ANTHRAX LETHAL TOXIN ACTIVITY - It is disclosed herein that isolated lymphocytes, such as human B-cells and CD4 | 05-17-2012 |
20120122117 | SECRETED PHOSPHOLIPASE A2 BIOMARKERS FOR ARTHRITIS - The present invention relates to the use of protein expression profiles of sPLA2 isoforms with clinical relevance to osteoarthritis (OA). In particular, the invention provides methods for diagnosing OA or determining risk factors for development of OA based on expression of sPLA2-IIA. | 05-17-2012 |
20120129185 | METHODS AND COMPOSITIONS FOR DIAGNOSING ANKYLOSING SPONDYLITIS USING BIOMARKERS - The invention provides a method for determining the efficacy of a TNFα inhibitor, such as a TNFα antibody, or an antigen-binding portion thereof, for treating ankylosing spondylitis (AS), using a collagen degradation biomarker and/or a synovitis biomarker. | 05-24-2012 |
20120129186 | DEVICES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF WOUNDS USING BIOMARKERS - The present invention provides for devices and methods for determining the healing phase of a wound. In some aspects, the present invention provides a wound diagnosis device comprising a surface and at least one agent that is specific to a desired biomarker. In another aspect, the present invention provides a method of determining the phase of wound healing. In still other aspects, the present invention provides methods of determining the phase of wound healing using the disclosed devices. | 05-24-2012 |
20120129187 | DIAGNOSTICAL USE OF PEROXIREDOXIN 4 - The present invention relates to a method for the diagnosis or prognosis of a disease or clinical condition in a subject comprising the steps of: (i) providing a sample of bodily fluid of a subject, (ii) determining the level of peroxiredoxin 4 (PRX4) or a fragment thereof having at least 20 amino acids residues in length in said sample, and (iii) correlating the level of PRX4 or a fragment thereof with a disease or clinical condition. | 05-24-2012 |
20120135421 | METHODS FOR THE IDENTIFICATION OF PHOSPHATIDYLINOSITOL KINASE INTERACTING MOLECULES AND FOR THE PURIFICATION OF PHOSPHATIDYLINOSITOL KINASE PROTEINS - The present invention relates to immobilization compounds of formula (I), immobilization products and preparations thereof as well as methods and uses for the identification of phosphatidylinositol kinase interacting compounds or for the purification or identification of phosphatidylinositol kinase proteins. | 05-31-2012 |
20120149030 | IMMUNOASSAY FOR THROMBIN DETECTION - The invention relates to an in vitro immunoassay for quantifying thrombin in a sample comprising anti-thrombin III (AT-III) and thrombin. The method comprises the following steps: contacting the sample with a small molecule that recognizes the substrate binding site of thrombin; contacting the thrombin with a thrombin specific antibody raised against a thrombin blocked in the active site; and measuring the level of bound antibody. | 06-14-2012 |
20120149031 | ANTI-CMET ANTIBODY AND ITS USE FOR THE DETECTION AND THE DIAGNOSIS OF CANCER - The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to antibodies capable of binding to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of said antibodies, and corresponding processes, for detecting and diagnosing pathological hyperproliterative oncogenic disorders associated with expression of cMet. In certain embodiments, the disorders are oncogenic disorders associated with increased expression of cMet polypeptide relative to normal or any other pathology connected with the overexpression of cMet. The invention finally comprises products and/or compositions or kits comprising at least such antibodies for the prognosis or diagnostic of certain cancers. | 06-14-2012 |
20120156690 | METHOD FOR DIAGNOSING HEMANGIOSARCOMA IN CANINE USING DETECTION OF THYMIDINE KINASE ACTIVITY - The disclosure relates to a method for detecting hemangiosarcoma in canines. The method includes the steps of: (1) obtaining a quantity of blood from the subject canine; (2) separating the quantity of blood into a serum portion and a non-serum portion; (3) contacting the serum portion of the blood with a detector to detect presence of an amount of Thymidine Kinase (TK); and (4) detecting the level of TK in serum and determining whether TK is present in amounts of about 8 units/L or greater. | 06-21-2012 |
20120156691 | COMPOUND - Alternative methods for the detection and measurement of proteases in biological samples and compounds which allow for such detection are required to allow for rapid and selective identification of these enzymes. Compounds which allow for selective identification of these enzymes are provided with assays and kits for their use. | 06-21-2012 |
20120156692 | METHOD FOR SELECTING MARKER FOR DIAGNOSIS OF NUTRITIONAL STATUS OF PLANT, METHOD FOR DIAGNOSING NUTRITIONAL STATUS OF PLANT, AND METHOD FOR DETERMINING GROWTH STATUS - The present invention provides a method for selecting a marker for diagnosis of the nutritional status capable of reflecting the status of a particular nutrient in a plant without being influenced by various stresses in environmental factors, etc., and a method for diagnosing the status of a particular nutrient in a plant using a marker for diagnosis of the nutritional status selected by the method. A metabolite quantitatively changed depending on only the amount of a particular nutrient in a plant is selected as a marker for diagnosis of the nutritional status reflecting the status of the nutrient in the plant. | 06-21-2012 |
20120171696 | Gene Defects And Mutant ALK Kinase In Human Solid Tumors - In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides. | 07-05-2012 |
20120178100 | Serum Markers Predicting Clinical Response to Anti-TNF Alpha Antibodies in Patients with Psoriatic Arthritis - The invention provides tools for management of patients diagnosed with psoriatic arthritis, specifically, prior to the initiation of therapy with an anti-TNFα agent. The tools are specific markers and algorithms of predicting response to therapy based on standard clinical primary and secondary endpoints using serum marker concentrations. In one embodiment the baseline levels of VEGF, prostatic acid phosphatase, and adiponectin are used to predict the response at Week 14 after the initiation of therapy. In another embodiment, the change in a serum protein biomarker after 4 weeks of therapy is used such as MDC, lipoprotein a, and beta2-microglobulin. | 07-12-2012 |
20120178101 | DEVICE, METHOD, AND SYSTEM FOR QUANTITATIVELY MEASURING A SPECIMEN USING A CAMERA - The present invention relates to a device and method for quantitatively measuring an analyte using a camera. More particularly, to capture the identification code required for obtaining an accurate analysis result for the analyte to be analyzed, to capture the result of the reaction of the analyte using a camera without additional equipment, and to read the identification code and the result of the reaction of the analyte, the device of the present invention comprises: a camera for capturing a camera recognition area of an analyte kit, which contains an analyte reaction result obtained by the reaction of the analyte and an identification code for the analyte kit; an image-processing unit for separating the analyte reaction result image and the identification code image from images of the camera recognition area of the analyte kit captured by the camera; a reading unit for reading the analyte reaction result image and the identification code image; and a control unit for enabling the read result of the analyte reaction result image to be processed using the read result of the identification code image. | 07-12-2012 |
20120183973 | BIOMARKER COMPOSITION FOR DETECTING DIABETIC RETINOPATHY AND DIAGNOSTIC KIT THEREFOR - Provided is a biomarker composition for detecting diabetic retinopathy, comprising at least one protein selected from the group consisting of proteins as set forth in SEQ ID NOS: 1 to 169, a method and a kit for diagnosing diabetic retinopathy using the same. The biomarker can provide fundamental information in researching vitreoretinal disorders, such as, diabetic retinopathy and the protein may be used in a method and a kit for diagnosing diabetic retinopathy with a molecule specifically binding thereto. | 07-19-2012 |
20120190042 | PROTEIN BIOMARKERS AND THERAPEUTIC TARGETS FOR OSTEOARTHRITIS - The present invention relates to the identification and use of protein expression profiles with clinical relevance to osteoarthritis. In particular, the invention provides the identity of marker proteins whose expressions are correlated with OA, and/or OA progression. Methods and kits are described for using these protein expression profiles in the study and/or diagnosis of OA, in the determination of the degree of advancement of OA, and in the selection and/or monitoring of treatment regimens. The invention also relates to the screening of drugs that modulate expression of these proteins or nucleic acid molecules encoding these proteins, in particular for the development of disease-modifying OA agents. | 07-26-2012 |
20120190043 | ENZYMATIC SUBSTRATES FOR MULTIPLE DETECTION SYSTEMS - An inventive substrate is provided which includes a substrate compound of formula A-B | 07-26-2012 |
20120190044 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of metalloproteinase inhibitor 2, soluble oxidized low-density lipoprotein receptor 1, interleukin-2, von Willebrand factor, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor receptor superfamily member 11B, neutrophil elastase, interleukin-1 beta, heart-type fatty acid-binding protein, beta-2-glycoprotein 1, soluble CD40 ligand, coagulation factor VII, C—C motif chemokine 2, IgM, CA 19-9, IL-10, TNF-α, and myoglobin as diagnostic and prognostic biomarkers in renal injuries. | 07-26-2012 |
20120196299 | METHOD FOR DETECTION OF INTESTINAL, AND BLOOD-BRAIN BARRIER PERMEABILITY AND TESTING MATERIALS THERETO - Methods, assays, and apparatus are disclosed for testing of antigens associated with intestinal and/or blood-brain barrier permeability. For example, blood, saliva or other bodily fluid can be tested for binding (1) to a bacterial toxin (preferably a lipopolysaccharide), and (2) binding to tissue antigens selected from at least one of (a) a gut-related antigen and (b) a blood brain barrier-related antigen. Analysis of test results can be used to assist in detecting and diagnosing diseases associated with leaky gut syndrome (whether due to paracellular or transcellular pathways, and whether due to bacterial toxins or some other cause) and/or to diseases associated with excessive blood brain barrier permeability, which are contemplated herein to include both neuroinflammation and/or neuroautoimmunity conditions, and especially amyotrophic lateral sclerosis, Parkinsons disease, multiple sclerosis, Alzheimer's, or peripheral neuropathy, and major depression. | 08-02-2012 |
20120202218 | DETECTION METHOD AND DEVICE BASED ON NANOPARTICLE AGGREGATION - A method for determining the presence of a compound in a liquid solution, by admixing the liquid solution with a plurality of nanoparticles; providing conditions effective to cause aggregation of the nanoparticles in the liquid solution in the absence of said compound in the liquid solution; and observing a detectable signal reflecting the amount of aggregation of nanoparticles in the liquid solution, wherein the presence of the compound in the liquid solution results in a detectable signal reflecting a reduced amount of aggregation of nanoparticles in the liquid solution, in comparison to the amount of aggregation of nanoparticles obtained in the liquid solution in the absence of the compound therein. A nanoparticle, a composition, a kit and a for multi-well plate for use in the method are also disclosed. In some embodiments the association is cation-, anion and/or PH induced e.g. by using helix-loop-helix polypeptides as first and second molecules attached to the nanoparticles. The first molecules are directed to the target compound, the second molecules allow for aggregation of the nanoparticles. | 08-09-2012 |
20120202219 | PSA CAPTURE AGENTS, COMPOSITIONS, METHODS AND PREPARATION THEREOF - Disclosed herein are novel synthetic prostate specific antigen (PSA)-targeted capture agents that specifically bind PSA. In certain embodiments, these PSA capture agents are biligand or triligand capture agents containing two or three target-binding moieties, respectively. | 08-09-2012 |
20120208208 | PCSK9 IMMUNOASSAY - Methods of using PCSK9 antagonists. More specifically, methods for measuring circulating PCSK9 levels in a biological sample by means of an immunoassay. | 08-16-2012 |
20120208209 | PCSK9 IMMUNOASSAY - Methods of using PCSK9 antagonists. More specifically, methods for measuring circulating PCSK9 levels in a biological sample by means of an immunoassay. | 08-16-2012 |
20120219963 | DERIVATIVES OF URIDINE PHOSPHATE AND THEIR USES IN PROTEIN BINDING ASSAYS - The present invention relates to compounds and their use in competitive protein binding assays, for example for use with glycosyl transferase and/or glycoprocessing proteins. The present application also provides kits and apparatuses for use in the assays. In particular, the present invention provides a compound of the formula (I): wherein n is 1, 2 or 3; R | 08-30-2012 |
20120237947 | Glutathione S-Transferase Omega 1 Wild Type Specific Antibody - The invention relates to a novel antibody which binds to wild type (wt) Glutathione S-transferase Omega 1 (wtGSTO1) but not to mutant (mut) GSTO1 and methods and uses based on the antibody. The antibody is based on novel haptens and immunogens. | 09-20-2012 |
20120237948 | COLLAGEN NEOEPITOPE ANTIBODY - The present invention provides a novel monoclonal antibody that is specific for a C-terminal neoepitope of a collagen fragment and has substantially equal binding affinity whether proline contained in the neoepitope is in a non-hydroxylated form or in a hydroxylated form, and an immunoassay, a measurement method, a kit and the like using the antibody. The antibody allows for quantification of a collagen fragment generated by digestion of a biological sample with a collagenase present in the sample, regardless of the presence or absence of a hydroxylated form of proline in the neoepitope. | 09-20-2012 |
20120244553 | BIOMARKER OF ALLERGIC DISEASE AND USE OF THE SAME - A biomarker is provided for an allergic disease caused by an allergic reaction that is caused not exclusively by histamine release, such as pruritus, and use of the same. Use of Granzyme A as a biomarker makes it possible to provide an indication for chronic itching skin disease, for which existing antiallergic drugs have little effect, and easily and adequately allow diagnosis of the disease. It is possible to, for example, make a diagnosis of an allergic disease with an IV type allergy-like reaction not depending on the antigen-antibody reaction system. Screening with the use of Granzyme A enables the development of novel remedies for allergic diseases. Moreover, a drug capable of specifically controlling the action of a granzyme enables treatment of allergic disease with little side effect. | 09-27-2012 |
20120244554 | METHOD FOR THE DIRECT MEASURE OF MOLECULAR INTERACTIONS BY DETECTION OF LIGHT REFLECTED FROM MULTILAYERED FUNCTIONALIZED DIELECTRICS - Method and apparatus for the quantitative determination of molecular interactions between ligands in solution and receptors immobilized on the surface of a solid transparent material coated by one or more antireflective dielectric layers, through direct measurement of the light reflected by the interface between the surface and the solution. | 09-27-2012 |
20120258468 | INDICATOR AGENT FOR NONINFLAMMATORY STRESS RESPONSE AND USE THEREOF - A system enabling the molecular biological visualization and quantitative detection of events in a stress-exposed living organism and a means enabling the management of stress are provided. An indicator agent for non-inflammatory stress responses mediated by superoxide, which comprises IL-18, a visualizing agent for non-inflammatory stress responses for detecting the aforementioned indicator agent, a method of measuring the degree of non-inflammatory stress, which comprises using the aforementioned visualizing agent, a method of preventing, ameliorating or predicting a change in immune status based on a non-inflammatory stress response, which comprises applying the aforementioned visualizing agent to an animal, and a therapeutic agent for a change in immune status based on a non-inflammatory stress response for reducing the amount or activity of the aforementioned indicator agent. | 10-11-2012 |
20120258469 | Methods And Devices For Using Mucolytic Agents Including N-Acetyl Cysteine (NAC) - Devices and methods incorporate mucolytic agents into a point-of-care testing device. The sample is loaded, and then the sample travels until it encounters one or more lysis agents and/or mucolytic agents. The mucolytic agent is preferably pre-loaded onto the collection device. In a preferred embodiment, the mucolytic agent is localized between the sample application zone and the conjugate zone. In embodiments with a sample compressor, one or more mucolytic agents may be pre-loaded and dried on the sample compressor, the sample collector, in various locations on the test strip, or in the running buffer. | 10-11-2012 |
20120264138 | METHOD FOR DIAGNOSING AND MONITORING CARDIAC ISCHEMIA IN PATIENTS WITH ACUTE CHEST PAIN AND WITHOUT MYOCARDIAL INFARCTION - The present disclosure relates to a method for diagnosing the ischemic state in a subject suffering from acute coronary syndrome who does not fulfilling the diagnostic criteria for a myocardial infarction. The present disclosure also relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome but does not fulfill the diagnostic criteria for a myocardial infarction. The methods of the present disclosure are based on the determination of fms-like tyrosine kinase-1 (sFLT-1) and, optionally, hepatocyte growth factor (HGF) in a sample of said subject. The present disclosure also relates to kits and/or devices for carrying out the methods disclosed herein. | 10-18-2012 |
20120264139 | METHOD FOR DIAGNOSING ACUTE CORONARY SYNDROME - This invention concerns a bioaffinity assay for quantitative determination in a sample of free PAPP-A, defined as the pregnancy associated plasma protein A (PAPP-A) that is not complexed to the proform of major basic protein (proMBP), wherein | 10-18-2012 |
20120270233 | ASSOCIATION OF BIOMARKERS WITH PATIENT OUTCOME - The present method relates to quantification of prognostic and predictive biomarkers of the PDK/AKT/mTOR pathway, such as GSK3β, S6, CREB, PTEN, AKT and mTOR, using AQUA® analysis to estimate both patient risk and benefit of treatment to patients diagnosed with glioblastoma. Unlike traditional IHC, the AQUA® system is objective and produces quantitative in situ protein expression data on a continuous scale. Taking advantage of the power of the AQUA system, the present method provides a highly robust and standardized diagnostic assays that can be used in the clinical setting to provide physicians with reliable prognostic and predictive information. Glioblastoma multiform (GBM) remains one of the most aggressive human cancers, and biomarkers that provide prognostic and predictive information would be extremely valuable to both the physician and the patient. A patient's risk may be determined using the prognostic biomarkers of the present method. Such a prognostic determination will allow physicians to identify patients with a relatively ‘good’ or a relatively ‘poor’ prognosis. The benefit of treating specific patients with a specific therapy, may be determined usin̂ the predictive markers of the present method. Treatment with the AGC-family kinase inhibitor enzastaurin, for example, identifies patients that will likely benefit from treatment or not. | 10-25-2012 |
20120270234 | DDR2 PROTEIN WITH ACTIVATED KINASE ACTIVITY AND PREPARATION METHOD THEREOF - The present invention relates to a protein containing a modified DDR (Discoidin Domain Receptor) 2 cytosolic tyrosine kinase domain having an increased autophosphorylation and tyrosine kinase activity; a method for preparing a large amount of a protein containing DDR2 cytosolic tyrosine kinase domain, having an increased autophosphorylation and tyrosine kinase activity by inducing phosphorylations of tyrosines by a co-expression with Src or Src related proteins in host cells, or by H2O2 processing of host cells, or a site directed mutation modifying at least one of tyrosines to other amino acid; and a use thereof as a target material in developing medical drugs for treating a disease caused by an excessively activated DDR2 autophosphorylation and tyrosine kinase activity. | 10-25-2012 |
20120276551 | METHODS PREDICTING RISK OF AN ADVERSE CLINICAL OUTCOME - Provided are methods for evaluating the risk of an adverse clinical outcome in a subject, deciding whether to discharge or continue treating a subject (e.g., on an inpatient basis), or to initiate or terminate treatment, selecting a subject for participation 5 in a clinical study, and selecting a therapeutic treatment for a subject that include determining a level of ST2 and a level of galectin-3 in a biological sample from the subject. Kits are also provided that contain an antibody that specifically binds to ST2, an antibody that specifically binds to galectin-3, and instructions for using the in the methods described. | 11-01-2012 |
20120276552 | SERUM SPLA2-IIA AS DIAGNOSIS MARKER FOR PROSTATE AND LUNG CANCER - Methods for diagnosing prostate cancer and lung cancer are disclosed. The methods include obtaining a biological sample from a subject, determining a level of serum secretory phospholipase A | 11-01-2012 |
20120282627 | CRYSTAL OF HYPOXIA INDUCIBLE FACTOR 1 ALPHA PROLYL HYDROXYLASE - The crystal structure of ligand-bound EGLN1 catalytic domain of prolyl hydroxylase is disclosed. These coordinates are useful in computer aided drug design for identifying compounds that regulate EGLN1 prolyl hydroxylase and thereby regulate HIF-regulated disorders. | 11-08-2012 |
20120288872 | GENE DEFECTS AND MUTANT ALK KINASE IN HUMAN SOLID TUMORS - Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant polypeptides, probes for detecting it, isolated mutant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The invention also provides methods for determining the presence of these mutant polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides. | 11-15-2012 |
20120288873 | BIOMARKERS FOR THE DETECTION AND SCREENING OF DOWN SYNDROME - The disclosure includes assays and methods for screening for risk of Down syndrome and/or trisomy 21 in a fetus. The assays and methods comprise determining the level of at least one biomarker selected from mucin 13 (MUC13), bile salt-activated lipase (CEL), dipeptidyl peptidase 4 (DPP4), carboxypeptidase A1 (CPA1), amyloid precursor protein (APP) and tenascin-C (TNC-C) polypeptides in a test biological sample from a pregnant subject, wherein a decreased level of MUC13, CEL, DPP4, and/or CPA1 polypeptide and/or an increased level of APP and/or TNC-C polypeptide in the test biological sample compared to a corresponding reference biomarker polypeptide level indicates an increased risk of Down syndrome or trisomy 21 in the fetus. The disclosure also includes assays, compositions, immunoassays, and kits for performing the methods disclosed herein. | 11-15-2012 |
20120288874 | ENZYMATIC ACTIVITY-BASED DETECTION - Disclosed herein are methods and kits which are useful for detecting presence of an enzyme in a test sample based upon the intrinsic enzymatic activity of such test sample. The present invention provides the ability to evaluate cell culture conditions and optimize the desired glycoform content of recombinantly prepared enzymes. | 11-15-2012 |
20120295280 | CITRULLINATED PEPTIDES FOR DIAGNOSING AND PROGNOSING RHEUMATOID ARTHRITIS - The present invention provides novel citrullinated peptides, their use in methods for aiding, assisting, improving, or facilitating the diagnosis or prognosis of rheumatic diseases such as rheumatoid arthritis (RA), and methods for identifying novel citrullinated peptides that are immunoreactive with anti-citrullinated protein antibodies (ACPAs). The present invention also provides methods for detecting rheumatoid factor (RF) using novel RF detection reagents as a means to aid, assist, improve, or facilitate the diagnosis or prognosis of rheumatic diseases such as RA. Kits comprising at least one of the novel citrullinated peptides and/or RF detection reagents of the present invention are also provided. | 11-22-2012 |
20120295281 | SPECIFIC SALIVARY BIOMARKERS FOR RISK DETECTION, EARLY DIAGNOSIS, PROGNOSIS AND MONITORING OF ALZHEIMER'S AND PARKINSON'S DISEASES - Methods by which specific biomarkers in saliva are used for risk detection, early diagnosis, prognosis and monitoring of Alzheimer's and Parkinson's diseases. | 11-22-2012 |
20120295282 | METHODS OF DIAGNOSING OR TREATING PROSTATE CANCER USING THE ERG GENE, ALONE OR IN COMBINATION WITH OTHER OVER OR UNDER EXPRESSED GENES IN PROSTATE CANCER - The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene. | 11-22-2012 |
20120309018 | CANCER DETECTION MARKERS - Methods and compositions involving molecular markers for the detection and characterization of cancer in a patient are provided. | 12-06-2012 |
20120309019 | DETECTION OF UNHEALTHY BONE MARROW-DERIVED CELL FOR DISEASE PREDISPOSITIONS - Provided herein is a method for detecting the presence of a unique subset of unhealthy bone marrow-derived cell (BMDC) by co-staining the cytoplasmic and/or nuclear expression of PDPK F | 12-06-2012 |
20120309020 | LYSYL OXIDASE-LIKE 2 ASSAY AND METHODS OF USE THEREOF - The present disclosure provides an assay to detect and/or quantify circulating lysyl oxidase-like 2 (LOXL2) polypeptides in an individual. The assay is useful in diagnostic and prognostic applications, which are also provided. | 12-06-2012 |
20120309021 | DETECTION OF ANTIBODY THAT BINDS TO WATER SOLUBLE POLYMER-MODIFIED POLYPEPTIDES - The present invention provides analytical methods for detecting anti-polymer antibody in an individual. The methods involve contacting a sample from the individual with a water soluble polymer-modified carrier and detecting binding of antibody to the water soluble polymer on the water soluble polymer-modified carrier wherein binding is indicative of the presence of antibody to the water polymer-modified polypeptide. Antibody may be detected to water soluble polymers such as polyethylene glycol, polysialic acid, dextran, hydroxyalkyl starch, or hydroxyethyl starch. When antibody to the water soluble polymer polyethylene glycol is to be detected, the carrier is modified with a non-linear polyethylene glycol derivative. | 12-06-2012 |
20120315649 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 10B, Cadherin-16, Caspase-9, Bcl2 antagonist of cell death, Caspase-1, Cadherin-1, Poly [ADP-ribose] polymerase 1, Cyclin-dependent kinase inhibitor 1, Cadherin-5, Myoglobin, Apolipoprotein A-II, Mucin-16, Carcinoembryonic antigen-related cell adhesion molecule 5, and Cellular tumor antigen p53 as diagnostic and prognostic biomarker assays in renal injuries. | 12-13-2012 |
20120315650 | DETECTION OF CIRCULATING ADAMTS13-ANTIBODY COMPLEXES - The present invention relates to methods and means for detecting ADAMTS13 immune complexes in a sample. The methods include the steps of capturing and labelling immune complexes of anti-ADAMTS13 antibodies. Capturing and labelling may be achieved by two different binding units targeting the immune complexes. The invention further relates to diagnosing diseases associated with immunologic ADAMTS13 dysfunction like TTP (thrombotic thrombocytopenic purpura). | 12-13-2012 |
20120322080 | Measurement of PKA for Cancer Detection - The present invention relates to a method of detecting the presence of cancer by measuring the level of enzyme activity and autoantibodies in the blood of an individual. In particular the present invention relates to methods for measurement of activated cAMP-dependent protein kinase A (PKA) activity and antibodies to PKA, a kit for activated PKA activity measurement, and the use of the measured levels of these analytes for determining the presence of cancer. | 12-20-2012 |
20120322081 | METHODS FOR DETECTION OF BOTULINUM NEUROTOXIN - Provided herein is a large immuno-sorbent surface area assay (ALISSA) for rapid and sensitive detection of toxin or enzyme activity. This assay is designed to capture a low number of toxin or enzyme molecules and to measure their intrinsic protease activity via conversion of a fluorigenic or luminescent substrate. The ALISSA is significantly faster and more sensitive than methods routinely utilized in the art. This assay is applicable for use for detection of a variety of toxins or enzymes having proteolytic activity, such as | 12-20-2012 |
20120329070 | BIOMARKER PANELS FOR ASSESSING RADIATION INJURY AND EXPOSURE - Methods and kits are provided for assessing radiation injury and exposure in a subject. The methods comprise measuring the levels of at least two (2) protein biomarkers from different biological pathways and correlating the levels with an assessment of radiation injury and exposure. Additional use of peripheral blood cell counts and serum enzyme biomarkers, evaluated in the early time frame after a suspected radiation exposure, and use of integrated multiple parameter triage tools to enhance radiation exposure discrimination and assessment are also provided. The information obtained from such methods can be used by a clinician to accurately assess the extent of radiation injury/exposure in the subject, and thus will provide a valuable tool for determining treatment protocols on a subject by subject basis. | 12-27-2012 |
20120329071 | PROTEIN BIOMARKERS AND THERAPEUTIC TARGETS FOR RENAL DISORDERS - The present invention relates to a method of diagnosing a renal disorder. The method includes the steps of: (1) obtaining a biological sample from a subject; and (2) determining, in the biological sample, a level of one or more proteins whose abundance in urine change due to the renal disorder, wherein an increase or decrease in the level of one or more of the proteins compared to a control level is indicative of a renal disorder. | 12-27-2012 |
20130004963 | Tyrosine, serine and threonine phosphorylation sites - The invention discloses 155 novel phosphorylation sites identified in carcinoma and leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 01-03-2013 |
20130004964 | METHOD FOR CARRYING OUT REACTIONS IN AN ANALYTICAL DEVICE - Method and system for carrying out heterogeneous chemical or biological reactions are disclosed. The method comprising providing an analytical device having at least one liquid processing unit having at least one reaction chamber and a first inlet channel in fluid communication with the reaction chamber. The method further comprises supplying to the reaction chamber via the first inlet channel or a second inlet channel analyte capturing particles, supplying to the reaction chamber via the first inlet channel or the second inlet channel a liquid sample containing an analyte of interest, and confining by an equilibrium of forces the analyte capturing particles in a particle rearrangement zone within the reaction chamber. The forces comprise a drag force Fd generated by flowing liquids and a counter-oriented force Fg. The method also comprises capturing analytes present in the liquid sample with the particles in the particle rearrangement zone. | 01-03-2013 |
20130004965 | DETECTING AND COUNTING TISSUE - SPECIFIC STEM CELLS AND USES THEREOF - This invention provides methods of determining the number and percent of tissue specific stem cells (TSSCs) in a sample of cells, a population of cells or a sample of tissue. The methods rely on detecting the pattern-specific asymmetric localization of asymmetric self-renewal associated (ASRA) proteins or cell cycle specific proteins (CSSP) in cell undergoing asymmetrical self-renewal, which is a characteristic of TSSCs. The methods can be applied to any situations in which the percent of TSSC is desired such as laboratory research on adult stem cells, in drug development tests, prognostic indicator and therapeutic index, as a diagnostic and prognostic indicator and in monitoring TSSC expansion, e.g., in cell manufacturing processes. | 01-03-2013 |
20130011857 | COMPLEMENT FACTOR H FOR OXIDATIVE STRESS DISEASE CONDITIONS - The invention relates to complement Factor H for use in the prevention and treatment of oxidative stress disease conditions in a patient, the use of Factor H in the preparation of a pharmaceutical preparation, and methods of determining the specific binding of Factor H to MDA and/or MAA in a sample. | 01-10-2013 |
20130017556 | ASSAYS FOR HDL BIOMOLECULAR INTERACTIONS - The invention relates to methods, compositions and kits for detecting molecular interactions. In one embodiment, the invention relates to methods for quantifying HDL interactions with biomolecules. In still another embodiment, the invention relates to methods for determining HDL function. | 01-17-2013 |
20130017557 | COMBINATION OF sPLA2 TYPE IIA MASS AND OXPL/APOB CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENTAANM Mallat; ZiadAACI ParisAACO FRAAGP Mallat; Ziad Paris FRAANM Tedgui; AlainAACI ParisAACO FRAAGP Tedgui; Alain Paris FRAANM Tsimikas; SotiriosAACI La JollaAAST CAAACO USAAGP Tsimikas; Sotirios La Jolla CA USAANM Witztum; JosephAACI La JollaAAST CAAACO USAAGP Witztum; Joseph La Jolla CA US - The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: —measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) sPLA2 type HA mass and b) oxidized phospholipids on apolipoprotein B-IOO particles (OxPL/apoB), —combining said measurements, the combined value of sPLA2 type HA mass and OxPL/apoB being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event. | 01-17-2013 |
20130017558 | ADAM12 AS A BIOMARKER FOR BLADDER CANCER - The invention generally relates to isolated human or humanized antibodies or functional fragments thereof that include an antigen binding region that specifically binds a form of a disintegrin and metalloprotease 12 (ADAM12) present in a tissue or body fluid that is indicative of a cancer. | 01-17-2013 |
20130022992 | IN VITRO ASSAY FOR QUANTIFYING CLOSTRIDIAL NEUROTOXIN ACTIVITY - Novel methods for determining the unknown biological activity of a clostridial neurotoxin in a sample with respect to the known biological activity of a clostridial neurotoxin in a reference sample, comprising the step of comparing the biological activity of a clostridial neurotoxin preparation with the biological activity of a standard preparation of a reference clostridial neurotoxin in certain in vitro systems. | 01-24-2013 |
20130022993 | COMPOUND, PHOSPHORYLATION INHIBITOR, INSULIN RESISTANCE IMPROVING AGENT, PREVENTIVE OR THERAPEUTIC AGENT FOR DIABETES, AND SCREENING METHOD - A new compound inhibiting phosphorylation of Ser727 of STAT3, a phosphorylation inhibitor containing the new compound, an insulin resistance improving agent and a preventive or therapeutic agent for diabetes; and a screening method for at least one of the insulin resistance improving agent and the preventive or therapeutic agent for diabetes. | 01-24-2013 |
20130029351 | A25 BACTERIOPHAGE LYSIN - The invention relates to the identification, sequencing, and isolation of an A25 bacteriophage lysin gene that expresses a protein involved in the lysis of bacterial cells during the phage life cycle. The invention further relates to methods for lysing certain bacteria using lysin, which are useful for example in a diagnostic procedure designed to detect these bacteria. | 01-31-2013 |
20130029352 | METHODS FOR DIAGNOSING AND MONITORING THE PROGRESSION OF CANCER - Methods for measuring c-Met levels in urine and blood samples are provided. Methods for diagnosis and prognosis evaluation for cancer are also provided. | 01-31-2013 |
20130029353 | AUTOANTIBODY ENHANCED IMMUNOASSAYS AND KITS - The present disclosure provides immunoassays and kits for detection or quantification of an analyte of interest in a test sample that potentially contains endogenously produced autoantibodies reactive with the analyte | 01-31-2013 |
20130034863 | Apparatus and Methods for Detecting Inflammation Using Quantum Dots - Apparatus and methods for detecting an a biomarker indicative of an inflammatory condition, including a capillary tube adapted for one or more biomarkers to adhere to an interior surface thereof, a light source for energizing quantum dots conjugated with the biomarkers within the capillary tube, and a detection system for detecting and quantifying fluorescent energy emitted by the quantum dots in one or more predetermined wavelength ranges, each wavelength range being correlated to one and only one of the biomarkers. A method of stabilizing the fluorescence intensity of quantum dots is also disclosed. | 02-07-2013 |
20130034864 | Protein, An Antibody and Measurement of the Protein - Methods for determining the occurrence or level of a mammalian protein in a sample and methods for determining the capability of a compound to transform or to inhibit the transformation of a selected mammalian protein in pro-phospholipase B form to an enzyme active phospholipase B form employ a pro-phospholipase B (PLB-II) mammalian protein which comprises at least one SU2 subunit comprising SEQ ID NO: 3 and having a molecular weight within the range of 30-60 kDa. Methods for determining the capability of a compound to enhance or inhibit the enzymatic activity of a selected protein having phospholipase B enzyme activity employ a protein comprising an activated form of such a pro-phospholipase B (PLB-II) mammalian protein. | 02-07-2013 |
20130040309 | Methods and Compositions for In-Vivo Enzyme Capture - The invention includes compositions, methods and kits for the in vivo identification of an enzyme that binds to a substrate. The invention comprises, in part, a photoreactive moiety to aid in identification of such an enzyme. | 02-14-2013 |
20130040310 | ULK1 COMPOSITIONS, INHIBITORS, SCREENING AND METHODS OF USE - This disclosure relates to methods and compositions useful for the treatment of cancer and diseases and disorders associated with autophagy. | 02-14-2013 |
20130040311 | MONOCLONAL ANTIBODY AGAINST NECROSIS MARKER ERP29 AND USE THEREOF - [PROBLEM] To provide a monoclonal antibody against a biomarker which shows high specificity and can be effectively used in detection and diagnosis of various lesions relevant to various kinds of carcinomas and foci of necrosis, and so forth. | 02-14-2013 |
20130040312 | DETECTION OF NGAL IN CHRONIC RENAL DISEASE - Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF. | 02-14-2013 |
20130052659 | METHOD FOR MEASURING IgG-MEDIATED COMPLEMENT ACTIVATION - A method for measuring immunoglobulin G-mediated complement activation, includes the following steps:
| 02-28-2013 |
20130059314 | FRET-BASED METHOD FOR THE DETERMINATION OF PROTEIN PHOSPHATASE AND KINASE ACTIVITY - This disclosure relates to methods of determining activities of protein phosphatases and kinases. The disclosure further relates to methods of clinical monitoring of calcineurin activity and immunosuppression in patients and which may be used to predict transplant acceptance in patients. | 03-07-2013 |
20130059315 | Alpha-Amylase Mutants - The present invention relates to a method of constructing a variant of a parent Termamyl-like alpha-amylase, which variant has alpha-amylase activity and at least one altered property as compared to the parent alpha-amylase, comprises
| 03-07-2013 |
20130065246 | METHOD FOR DIAGNOSING MELANOCYTIC PROLIFERATIONS - The invention provides a method for diagnosing a melanocytic proliferation in a subject comprising staining a sample of lesional melanocytes with an antibody against soluble adenylyl cyclase (sAC) and interpreting the sAC staining pattern, which is associated with a diagnosis of a melanocytic proliferation. The sAC staining pattern, which is complex, is discriminatory and distinctive according to the nature of the melanocytic proliferation. The sAC staining pattern comprises one or more of dot-like Golgi staining, broad granular Golgi staining, diffuse cytoplasmic staining, nucleolar staining, incomplete granular nuclear staining, and pan-nuclear staining. The method of the invention is particularly useful in confirming or disaffirming a diagnosis reached through conventional histologic examination of a sample. Additionally, the invention provides a kit for use in interpreting melanocytic proliferations. | 03-14-2013 |
20130065247 | METHODS OF DIAGNOSING LATENT AND ACTIVE MALIGNANCIES - Disclosed are procedures and methods for diagnosing latent and active cancers in a subject. The described methods include the use of sandwich ELISA assays containing antibodies specific for certain epitopes on the A-protein. This enables the assay to discriminate between the monomelic and homopolymeric forms of A-protein. | 03-14-2013 |
20130065248 | REAGENTS AND METHODS FOR SIRTUIN CAPTURE - The invention provides a method of preparing a sirtuin complex. The invention also provides a method of detecting a sirtuin in a sample comprising use of the aforesaid sirtuin complex. | 03-14-2013 |
20130071854 | METHODS FOR THE IDENTIFICATION AND CHARACTERIZATION OF HDAC INTERACTING COMPOUNDS - The present invention relates to methods for the identification and characterization (e.g. selectivity profiling) of HDAC interacting compounds using protein preparations derived from cells endogenously expressing HDACs or cell preparations containing said HDACs. | 03-21-2013 |
20130071855 | FLC AS BIOMARKER - The invention provides a method of identifying a subject likely to have liver disease, or for determining the prognosis of a subject previously identified as having a liver disease comprising detecting an amount of free light chains in a sample from the subject, wherein a higher amount of FLC is associated with an increased likelihood of the subject having a liver disease or an increased likelihood of having a poor prognosis of a liver disease. Assay kits for use in such methods are also provided. | 03-21-2013 |
20130078645 | BIOMARKERS - The invention relates to a method of diagnosing or monitoring schizophrenia or other psychotic disorder. The biomarkers used are selected from cyclophilin A, cytosalic non-specific dipepditase, Caoctosin-like protein, Glucose-6-phosphate isomerase, uncharacterized protein KIAA0423, myosin 14, myosin 15, nicotinamide phosphoribosyltransferase, pyruvate kinase isozyme R/L, phosphoglyterate mutase 4. | 03-28-2013 |
20130084582 | SEROLOGICAL MARKERS FOR DETECTING COLORECTAL CANCER AND THEIR APPLICATION FOR INHIBITING COLORECTAL CANCER CELLS - Embodiments relate to serological markers for detecting the colorectal cancer and applications of the serological markers. A phospholipid scramblase1 (PLSCR1), a stomatin-like protein 2 (STOML2) or a transport protein Sec61β (SEC61β) increases expression in the blood at the earlier stage of the colorectal cancer. Detecting the expression of the PLSCR1, STOML2 or SEC61β protein or an induced autoantibody of each protein in a blood sample is used to diagnose the colorectal cancer. Moreover, the serological marker improves the detection efficiency and the sensitivity in detecting the colorectal cancer and is used to predict the prognosis. The serological markers are applied in preparing a detection device or inhibiting the growth of the colorectal cancer cells. | 04-04-2013 |
20130089871 | MARKER FOR DETECTION AND/OR DISCRIMINATION OF NON-ALCOHOLIC STEATOHEPATITIS, METHOD FOR DETECTION AND/OR DISCRIMINATION OF NON-ALCOHOLIC STEATOHEPATITIS, AND KIT FOR USE IN THE METHOD - The detection of a non-alcoholic steatohepatitis patient and the accurate discrimination between a normal person and a non-alcoholic steatohepatitis patient can be achieved by measuring alanine-glyoxylate amino transferase in a sample. | 04-11-2013 |
20130095502 | REAGENTS AND METHODS FOR PHOSPHORYLATION/DEPHOSPHORYLATION ANALYSES - Disclosed herein are reagents that include a moiety that includes a metal such as titanium and that readily binds to phosphorylated molecules the reagents also include at least one moiety that produces a signal or that binds to a molecule that produces a signal. The reagent may also include a moiety that binds to a larger molecule or to a surface. Some forms of the reagent include a dendrimer that can simultaneously bind to multiple metal moieties that include a metal such as titanium and multiple moieties that can be used to detected bound molecules. These reagents can be used in detection and/or measurement and/or at least partial purification of phosphorylated molecules. These reagents and methods using them are used to analyze proteins, polypeptides, nucleic acids, phospholipids and the like. They are readily adapted for use in gels, blots, plate based high through put assays and for mass spectrometry. | 04-18-2013 |
20130095503 | SERUM SPLA2-IIA AS DIAGNOSIS MARKER FOR PROSTATE AND LUNG CANCER - Kits for assessing lung cancer in patients with solitary pulmonary nodules and methods for assessing lung cancer. The kit includes reagents for detection and/or quantification of serum secretory phospholipase A | 04-18-2013 |
20130095504 | DISEASE MARKER DETECTION KIT AND DISEASE MARKER DETECTION METHOD - Provided is a detection kit, which a disease detection kit used together with a secondary ion mass spectrometer in order to detect a disease marker contained in a biological sample, the detection kit including: a base including a noble metal thin film formed thereon; a reactant containing peptide specifically reacting with the disease marker; a first storage unit filled with the reactant; a test substance containing a biological sample of a possible disease carrier; a second storage unit filled with the test substance; a mixing unit mixing the reactant and the test substance with each other to prepare a detection substance containing the specific reactant, which is the peptide specifically reacted with the disease marker contained in the biological sample; and a contact unit contacting the detection substance prepared by the mixing unit with the base to bond the specific reactant to the noble metal film of the base. | 04-18-2013 |
20130102009 | SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS - Provided are methods and compositions for detecting a compound that activates a sirtuin deacetylase activity on a fluorescent-free activation substrate in vitro. Further provided are sirtuin modulating compounds of the formulas (I)-(XXI), and related compounds (XXXI), (XXXII), (XXXIII), and (XXXIV), including the fluorescent free-substrate SIRT1 activator compounds of formulas (XL), (XI), (XII), and (XIII). | 04-25-2013 |
20130122518 | WELLNESS PANEL - A panel for monitoring levels of biomarkers, including an assay having at least one inflammation monitoring test, at least one oxidative stress monitoring test, and at least one antioxidant activity monitoring test. A method of monitoring an individual's health, by collecting a sample from the individual, applying the sample to an assay panel, performing at least one inflammation monitoring test, at least one oxidative stress monitoring test, and at least one antioxidant activity monitoring test in the panel, and determining levels of biomarkers related to inflammation, oxidative stress, and antioxidant activity and therefore providing information regarding the individual's relative health and/or risk of developing one or more diseases. | 05-16-2013 |
20130130275 | IMMUNOASSAY METHODS AND REAGENTS FOR DECREASING NONSPECIFIC BINDING - Methods and kits for reducing non-specific binding in an immunoassay for PIVKA-II in a test sample are described, in which the test sample is reacted with an anti-prothrombin antibody in the presence of one or more of the following additives: skim milk, saponin, CaCl | 05-23-2013 |
20130130276 | METHOD FOR DETECTING GASTRIC CANCER - The object of the present invention is to provide a method for detecting gastric cancer, and a kit for detecting gastric cancer. The object can be solved by a method for detecting gastric cancer characterized by analyzing β1,4-N-acetylgalactosamine transferase 1. According to the present invention, gastric cancer patients can be detected at high rates, even early stage gastric cancer patients without a subjective symptom. | 05-23-2013 |
20130130277 | REMEDY FOR DIABETES - A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the β subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the β subunit of a trimeric GTP-binding protein, as the active ingredient, etc. | 05-23-2013 |
20130137116 | METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY - A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance of NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents. | 05-30-2013 |
20130143232 | METHODS FOR THE DETECTION AND MONITORING OF ACUTE MYOCARDIAL INFARCTION - Disclosed herein are methods of detecting and/or prognosing myocardial infarction by detecting a proteolytic fragment of caspase-3 such as the p17 fragment or the p12 fragment. The myocardial infarction can be STEMI or NSTEMI. | 06-06-2013 |
20130149713 | BIOMARKERS OF HEMORRHAGIC SHOCK - Methods for the use of keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) (KC/GRO), apolipoprotein A2 (APOA2), angiotensinogen r (AGT), thyroglobulin (TG), disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), anionic trypsin-1 (PRSS1), complement C4 (C4A), zona pellucida sperm-binding protein 1 (ZP1), neuropilin-2 (NRP2), solute carrier family 13 member 2 (SLC13A2), glucagon-like peptide 2 receptor (GLP2R), lipoma high mobility group protein isoform I-C (HMGIC) fusion partner-like protein 4 (LHFPL4), and claudin-3 (CLDN3) as biomarkers for diagnosis and prognosis, and for monitoring the efficacy of treatment, in hemorrhagic shock (HS). | 06-13-2013 |
20130149714 | BIO-DIAGNOSTIC TESTING SYSTEM AND METHODS - An implantable diagnostic device in accordance with the present disclosure includes a probe assembly that can be implemented in a variety of ways. A few example implementations include: a needle inside which is located a bio-sensor chip (the needle being insertable into a human being); a compact package containing the bio-sensor chip (the compact package configured for placement inside a catheter); or a silicon-based bio-sensor package configured for insertion into a vein. | 06-13-2013 |
20130157288 | IMMOBILISED-BEAD IMMUNOMULTIPLEX ASSAY - Embodiments of this invention include image-based systems and methods for detection of one or more analytes. A surface has identifiable analyte-specific capture particle(s) immobilised thereto at any point of an assay, to which different analytes attach due to the affinity of analyte-specific capture molecule(s) linked to the surface of the capture particle(s) for the analyte. Analyte-specific detector molecules with conjugated detection moieties are then attached to the analyte, and a computer assisted, image-based detection system captures images of the capture particles with or without attached analytes and detector molecules. By using different subsets of analyte-specific capture molecules, each subset having a characteristic identifiable feature; it is now possible to perform capture particle-based, rapid multiplex assays of biological and non-biological analytes without flow. These image-based systems can be used to aid in diagnosis of disease, evaluation of therapy for disease, or laboratory investigation. | 06-20-2013 |
20130171659 | METHODS OF PROGNOSIS AND DIAGNOSIS OF RHEUMATOID ARTHRITIS - Provided are methods of diagnosing rheumatoid arthritis in a patient by detecting the presence and/or amount of a biomarker of rheumatoid arthritis in a sample from the patient. The methods and biomarkers may be used to develop an accurate prognosis for a patient having rheumatoid arthritis or suspected of having rheumatoid arthritis, or to accurately diagnose a patient having, or suspected of having rheumatoid arthritis. The methods and biomarkers may be used to identify and/or classify a patient as a candidate for a rheumatoid arthritis therapy. | 07-04-2013 |
20130171660 | BLOOD MARKER FOR RENAL CANCER - The present invention provides a blood marker for renal cancer, more specifically, a blood marker that can be practically used for clinical diagnosis of renal cancer. The present invention also provides a blood marker that can be practically used for follow-up after treatment such as surgery and during treatment such as medication for renal cancer. A blood marker for renal cancer selected from the group consisting of Galectin-1, Galectin-3, and α-enolase. Galectin-1 and/or Galectin-3 as a blood marker for renal cancer for use in an examination performed before diagnostic imaging. α-Enolase as a blood marker for renal cancer for use in monitoring during and/or after treatment for renal cancer. | 07-04-2013 |
20130171661 | Assay for Identification of LRRK2 Inhibitors - A method for assessing the effect of a test compound on LRRK2 in a cell-based system, the method comprising the steps of a) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the phosphorylation state of Ser910 and/or Ser935 of the LRRK2; and/or b) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the binding of the LRRK2 to a 14-3-3 polypeptide. The method may comprise or further comprise the step of assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the subcellular location of LRRK2. The method is considered to be useful in assessing the effect of putative LRRK2 inhibitors in cell based systems, including in vivo systems. | 07-04-2013 |
20130177923 | DIAGNOSTIC USE OF INDIVIDUAL MOLECULAR FORMS OF A BIOMARKER - Methods are provided of diagnosing, monitoring or determining the severity of disease or injury by measuring individual molecular forms of neutrophil gelatinase-associated lipocalin (NGAL) in bodily fluids, including the diagnosis and monitoring of acute renal injury leading to acute renal failure in a human or mammalian subject by determining the concentration of the free monomer form of NGAL. | 07-11-2013 |
20130177924 | LINKED PEPTIDE FLUOROGENIC BIOSENSORS - Biosensors, compositions comprising biosensors, methods of producing biosensors, and methods of using biosensors are disclosed. The biosensors comprise a fluorogen-activating peptide and a blocking peptide. The fluorogen-activating peptide and blocking peptide are covalently linked through a peptide linker. The blocking peptide associates with the fluorogen-activating peptide thereby blocking an active domain of the fluorogen-activating peptide when the linker is in an unmodified state. The peptide linker may contain an amino acid sequence that is specifically recognized as a modification substrate by a cognate enzyme. The fluorogen-activating peptide and the blocking peptide at least partially disassociate when the linker is modified by an enzyme, thereby allowing the fluorogen-activating peptide to bind a cognate fluorogen and modulate a fluorescence signal. | 07-11-2013 |
20130183683 | METHODS OF DIAGNOSING ACUTE CARDIAC DISORDERS USING BNP-SP - The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring BNP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection. | 07-18-2013 |
20130183684 | PROTEIN BIOMARKERS FOR OBSTRUCTIVE AIRWAYS DISEASES - Provided herein are methods for the diagnosis of obstructive airways diseases such as asthma and chronic obstructive pulmonary disease, and the discrimination between such diseases based on the expression profiles of biomarker proteins and combinations of biomarker proteins. In particular embodiments the biomarker proteins are selected from ceruloplasmin, haptoglobin, hemopexin, - | 07-18-2013 |
20130183685 | METHOD OF RECOMBINANT MACROMOLECULAR PRODUCTION - A method for recombinantly expressing a macromolecule in a host cell is disclosed which involves culturing a host cell which contains two nucleic acid sequences, i.e., a first nucleic acid sequence encoding a membrane-permeabilizing agent and a second nucleic acid sequence encoding a desired macromolecule under the operative control of an inducible promoter, to a selected cell density that permits accumulation of the agent. Thereafter the host cell is exposed to an environmental condition that induces the agent to disrupt the integrity of the cell membrane without complete lysis of the cell membrane. The host cell thereby allows transport through the membrane of small molecular weight compounds. These resulting host cells are cultured in the presence of a nutrient cocktail that contains components that can transport through the disrupted cell membrane, e.g., an inducing agent that induces the tightly regulated promoter and metabolic requirements that permit expression of the macromolecule. | 07-18-2013 |
20130189706 | BIOSENSOR USING WHISPERING GALLERY MODES IN MICROSPHERES - A biosensor for detecting the presence of a target analyte is disclosed. The biosensor is formed from microspheroidal particles which have had a binding partner for the target analyte immobilized on their surfaces. The binding partners may be nucleotides; peptides, proteins, enzymes, antibodies and so on. When the analyte binds to its partner, the whispering gallery mode (WGM) profiles of the micro spheroidal particles change such that the profile peaks undergo a red- or blue-shift. The immobilized binding partners may include fluorophores and the like so that they emit fluorescence, phosphorescence, incandescence and the like. These fluorophores may take the form of a nanocrystal or quantum dot. | 07-25-2013 |
20130196342 | Compositions And Methods For Modulating S-Nitrosogluthione Reductase - Disclosed herein are methods and compositions for modulating the levels and/or activity of S-nitrosoglutathione reductase (GSNOR) in vivo or in vitro. Specifically disclosed are GSNOR deletion constructs, host cells and non-human mammals comprising GSNOR deletions, and methods of screening employing GSNOR deletion mutants. Also specifically disclosed are reagents and procedures for measuring, monitoring, or altering GSNOR levels or activity (as well as nitric oxide and S-nitrosothiol levels) in connection with various medical conditions. | 08-01-2013 |
20130196343 | SIGNAL LOCKING LABEL FREE BIOSENSING - A biosensor can include a fluid flow channel ( | 08-01-2013 |
20130203073 | ASSAY FOR ANALYTES BASED ON AGGREGATION - The present invention relates to compositions, assay devices, kits and methods for detecting the presence, amount and/or activity of an analyte in a sample. In particular, the present invention relates to the detection of enzymes. The present invention also relates to methods of diagnosing diseases associated with dysregulation of enzymes, screening for modulators of enzymatic activity, candidate antimicrobial peptides and toxins. | 08-08-2013 |
20130203074 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 as diagnostic and prognostic biomarkers in renal injuries. | 08-08-2013 |
20130210029 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE IN A NON-SURGICAL ICU POPULATION - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects admitted to a hospital critical care setting for other than a post-surgical or trauma indication. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Insulin-like growth factor IA, soluble Epidermal growth factor receptor, and Leukocyte elastase as diagnostic and prognostic biomarkers in renal injuries. | 08-15-2013 |
20130210030 | IN VIVO METHOD FOR THE EVALUATION OF A COMPOUND-TARGET INTERACTION - The invention relates to a method for evaluation of a compound-target interaction in vivo, comprising the steps of administering the compound to an animal, taking a body fluid sample of the animal, determining the concentration of the compound in the body fluid sample, taking a cellular sample of the animal containing the target, preparing a protein preparation of said cellular sample, providing an immobilised ligand capable of binding to the target, contacting the protein preparation with the immobilised ligand under conditions allowing the formation of a complex between the immobilised ligand and the target, determining the amount of complexes formed in step, and correlating the amount of complexes with the concentration of the compound in the body fluid sample. | 08-15-2013 |
20130210031 | DETECTION OF ADENYLATE CYCLASE - One major problem in diagnosis methods presently available for anthrax is that these methods require several days to produce a result, are rendered unusable after antibiotic use, or are not quantifiable. The only existing treatment for anthrax requires administration soon after infection at a time when patients are exhibiting only mild flu-like symptoms. Thus, by the time a diagnosis is made a patient may be days beyond the time when treatment would be effective. The present invention reduces diagnosis time to as little as four hours providing same day identification of anthrax radically increasing the odds of delivering proper treatment and patient recovery. The rapid identification of anthrax edema factor activity exhibited by the invention is also amenable to in vivo screening protocols for the discovery and development of anthrax vaccines, anti-toxins and edema factor inhibitors. The invention isolates and concentrates edema factor and edema toxin from nearly any sample. By capitalizing on the adenylate cyclase activity of edema factor the invention amplifies output signals producing reliable detection of low concentrations of edema factor previously unachievable. The invention involves novel purification and detection techniques and substrates for rapid, reproducible, and quantitative measurements of anthrax edema factor, and other adenylate cyclases in biological samples. | 08-15-2013 |
20130217033 | BIOMARKER FOR MONITORING DEVELOPMENT OF DISEASES AND ASSESSING THE EFFICACY OF THERAPIES - The invention concerns a method for monitoring the development of a disease in a patient, and for assessing the efficacy of a therapy influencing on the CD73 level or activity in the patient, in particular a cytokine therapy or a statin therapy. CD73 in a tissue fluid drawn from the patient is used as a biomarker. The invention concerns also methods for determining of CD73 protein in a sample drawn from an individual's tissue fluid. | 08-22-2013 |
20130217034 | PROCESS FOR AVOIDING FALSE POSITIVE RESULTS IN A DETECTING PROCESS OF AN INFLAMMATION INDICATOR IN A RINSE SOLUTION FOR TAKING UP GINGIVAL CREVICULAR FLUID - A process for avoiding false positive results in a detecting process of an inflammation indicator from the matrix metalloproteinase (MMP) family in a gingival crevicular fluid (GCF), wherein said GCF, which is obtained from a mouthrinse or saliva, is filtered before said inflammation indicator from the MMP family is assayed. | 08-22-2013 |
20130217035 | BIOLOGICAL MOLECULE DETECTING APPARATUS AND BIOLOGICAL MOLECULE DETECTING METHOD - A configuration was adopted, in which the orientations of free molecules and binding molecules within a solution are switched by switching the vibration direction of orientation controlling light, thereby switching the amount of light emitted by each free molecule and each binding molecule. There is a difference in the amounts of time required for the orientations of the free molecules and the binding molecules to switch accompanying the switch in the emission direction of the orientation controlling light. Therefore, the timings at which the amounts of light emitted by each type of molecule increase differ. Accordingly, the fluorescence contributed by fluorescent molecules associated with free molecules and the fluorescent molecules associated with binding molecules can be respectively calculated, even if all of the fluorescent molecules within the solution emit fluorescence. Thereby, the concentration of a detection target substance can be accurately measured with a simple structure. | 08-22-2013 |
20130224763 | BIOLOGICAL MOLECULE DETECTING APPARATUS AND BIOLOGICAL MOLECULE DETECTING METHOD - A biological molecule detecting apparatus capable of highly sensitive measurements is provided. A laser was emitted onto a solution, to impart external force onto free molecules and binding molecules within the solution. The external force inhibited Brownian motion of the free molecules and the binding molecules. The concentration of a detection target substance which is associated the binding molecules can be measured with high sensitivity, by measuring the Brownian motion of the free molecules and the binding molecules within the solution irradiated with the laser. | 08-29-2013 |
20130224764 | BIOLOGICAL MOLECULE DETECTING APPARATUS AND BIOLOGICAL MOLECULE DETECTING METHOD - A biological molecule detecting apparatus capable of highly sensitive measurements is provided. The emission direction of an orientation controlling light beam was periodically switched, to periodically switch the orientation direction of binding molecules | 08-29-2013 |
20130224765 | NANO-POROUS MEMBRANE BASED SENSORS - Sensors include nano-porous alumina membranes that are sensitized by immobilization of antibodies in the nano-pores. The nano-membranes can be sensitized to respond to a single target compound, or different portions of the nano-membrane can be differently sensitized. Capture of the target compound can be detected based on a spectral signature associated with electrical conductance in the nano-pores. | 08-29-2013 |
20130230865 | Methods for Monitoring Methotrexate Therapy - The present invention provides methods for assessing efficacy of a methotrexate (MTX) dosing regimen in a patient. | 09-05-2013 |
20130236908 | METHOD FOR PREDICTING A NEED FOR RENAL REPLACEMENT THERAPY (RRT) - A method for predicting a need for Renal Replacement Therapy (RRT) in a patient comprises: determining a concentration of pi glutathione S transferase-(πGST) in a first urine sample from the patient; and wherein a need for RRT is predicted when the πGST concentration is determined to be elevated in comparison to a patient without kidney injury. The method according to the invention can further comprise detecting for the presence of risk factors for RRT in a patient, the risk factors including elevated serum creatinine concentration, type I diabetes, type II diabetes, hypertension, dyslipidemia, hyperglycaemia, proteinuria and hypoalbuminemia. | 09-12-2013 |
20130252254 | Procalcitonin gene expression as a precise biomarker of aging process - The invention relates to a method for diagnosis and/or complications and/or risk assessment of aging, in particular of aging process, wherein a determination of the marker procalcitonin (PCT: SEQ ID No. 1) or a partial peptide or fragment thereof or if contained in a marker combination (Panel, Cluster) is carried out on a patient within normal value ranges of leucocytes under investigation. The invention further relates to invent new drugs, a diagnostic device and a kit for carrying out said method. | 09-26-2013 |
20130252255 | BLADDER CANCER DIAGNOSIS COMPOSITION CONTAINING APE1/REF-1 AND BLADDER CANCER DIAGNOSTIC KIT USING SAME - Provided are a bladder cancer diagnosis composition containing APE1/Ref-1, a bladder cancer diagnostic kit containing an antibody which specifically binds to the APE1/Ref-1, and a method of measuring APE1/Ref-1 concentration in biological samples through an antigen-antibody binding reaction using the antibody which specifically binds to the APE1/Ref-1. According to the invention, the APE1/Ref-1 protein concentration in serum of bladder cancer patients is significantly higher than in healthy subjects, and more particularly, it significantly increases in the serum of patients with stage 2 or later bladder cancer. | 09-26-2013 |
20130260389 | BETA-2 MICROGLOBULIN AS A BIOMARKER FOR PERIPHERAL ARTERY DISEASE - The present invention provides β2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject. | 10-03-2013 |
20130260390 | Methods and Compositions for Highly Sensitive Detection of Molecules - The present invention discloses methods for the detection and monitoring of a condition in a subject using highly sensitive detection of molecules. The invention provides a method for detecting or monitoring a condition in a subject, comprising detecting a first marker in a first sample from the subject and detecting a second marker, wherein the first marker comprises a biomarker, e.g., Cardiac Troponin-I (cTnI) or Vascular Endothelial Growth Factor (VEGF), and wherein the limit of detection of the first marker is less than about 10 pg/ml. The second marker can be a biomarker, physiological marker, a molecular marker or a genetic marker. | 10-03-2013 |
20130260391 | Method Of Determining The Protease Cathepsin B In A Biological Sample - A method for determination of the potentially available activity of cathepsin B in a biological sample, including the activity of the active form of cathepsin B, the form of cathepsin B which can be activated from the pro-form procathepsin B being present in the sample, and the form of cathepsin B which can be activated and which is inhibited in the sample in its activity by protease inhibitor, whereby the procathepsin B being present in the sample is converted into the active form of cathepsin B, the free protease inhibitor for cathepsin B being present in the sample is depleted from the sample or its inhibitor function is suppressed, and the protease inhibitor is withdrawn from the inhibited form of cathepsin B, and subsequently the activity of the active cathepsin B in the sample is determined. | 10-03-2013 |
20130266961 | DIAGNOSIS AND RISK STRATIFICATION BY MEANS OF THE NOVEL MARKER CT-PROADM - The invention relates to a novel diagnostic marker CT-proADM (C-terminal fragment of preproADM, SEQ ID No. 1) for diagnosing and/or stratifying the risk of diseases. Also disclosed is a method for diagnosing and/or stratifying the risk of diseases, particularly cardiovascular diseases, cardiac insufficiency, and infections and/or inflammations of the lungs and respiratory tract. In said method, the CT-proADM (SEQ ID No. 1) marker, or a partial peptide of fragment thereof, or said marker contained in a marker combination (panel, cluster) is determined in a patient who is to be examined. The invention further relates to a diagnostic apparatus as well as a kit for carrying out said method. | 10-10-2013 |
20130266962 | MEANS AND METHODS FOR DIAGNOSING CANCER USING AN ANTIBODY WHICH SPECIFICALLY BINDS TO BRAF V600E - The present invention relates to the field of diagnostic tests and diagnostic tools. Specifically, contemplated is to a method for diagnosing cancer in a sample of a subject suspected to suffer from cancer comprising contacting the sample with an antibody which specifically binds to the epitope characterized by SEQ ID NO 1 on a BRAF polypeptide under conditions which allow for binding of said antibody to the epitope and determining binding of the antibody to the epitope, whereby cancer is diagnosed. Further contemplated are antibodies which specifically bind to the epitope characterized by SEQ ID NO 1 on a BRAF polypeptide and a device or kit comprising such antibodies. | 10-10-2013 |
20130273562 | 1L1RL-1 as a Cardiovascular Disease Marker and Therapeutic Target - This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure. | 10-17-2013 |
20130273563 | DEVICE FOR PERFORMING AN ENZYME-BASED DIAGNOSTIC TEST AND METHODS FOR USE THEREOF - Enzyme-based diagnostic testing systems for detecting and quantifying at least one of the activity level or the concentration of an enzyme or a biochemical analyte in a biological sample. Such enzyme-based diagnostic testing systems can provide rapid, accurate, affordable laboratory-quality testing at the point of care. An enzyme-based diagnostic testing system may include a lateral-flow chromatographic assay cassette that is configured for assaying an amount or activity of an enzyme in a sample or for enzymatically determining the concentration of an enzyme substrate in a sample. Additionally, the enzyme-based diagnostic testing systems may include testing devices (e.g., a smartphone or a similar remote computing device) having data collection and data analysis capabilities. Such testing devices may also include automated data reporting and decision support. | 10-17-2013 |
20130288269 | Biomarkers For Prediction Of Major Adverse Cardiac Events And Uses Thereof - The present invention relates to combinations of biomarkers and levels thereof that may be used, for example, in the determination of risk associated with the occurrence of a major adverse cardiac event (MACE) in a patient. | 10-31-2013 |
20130288270 | CHEMILUMINESCENT ENZYME ASSAY METHOD AND APPARATUS - A chemiluminescent enzyme immunoassay method for quantifying antigen or antibody using 1,1′-oxalyldiimidazole (ODI) derivative or 1,1′-oxalyldisodium benzoate (ODB) derivative chemiluminescence (CL) detection was developed. Also, various enzymes were quantified using ODI derivative or DOB derivative CL detection. Fluorescent compound formed from a substrate (non-fluorescent compound) through the enzyme assay methods emitted CL when the fluorescent compound received energy from high-energy intermediate formed in ODI derivative or ODB derivative CL reaction. | 10-31-2013 |
20130302819 | METHOD FOR THE EARLY IDENTIFICATION AND PREDICTION OF AN ABRUPT REDUCTION IN KIDNEY FUNCTION IN A PATIENT UNDERGOING CARDIOTHORACIC SURGERY - A method for the early identification and prediction of abrupt reduction in kidney function in a patient undergoing cardiothoracic (CT) surgery, including Cardio-Pulmonary Bypass (CPB), comprises contacting a urine sample from the patient with a capture molecule for a biomarker, especially πGST specific for the distal region of the renal tubule and which biomarker is released from said region when there is damage to said region indicative and predictive of an abrupt reduction in kidney function, the biomarker being detectable as early as intraoperatively or in the recovery stage post CT surgery, for example prior to transfer of the patient to the Intensive Care Unit (ICU), allowing for immediate corrective medical intervention. The method can be used to detect Acute Kidney Injury (AKI) and a requirement for Renal Replacement Therapy (RRT) namely dialysis, earlier than two hours post CT surgery and as early as zero hours post or during CT surgery or CPB. | 11-14-2013 |
20130302820 | Methods and Compositions for Treating Bleeding Disorders - Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described. | 11-14-2013 |
20130302821 | Method For Evaluating Atherosclerotic Lesion, And Kit - The present invention provides a method and a means for evaluating atherosclerotic lesions by identifying a protein (marker protein) group, the expression level of which varies according to the progression of the atherosclerotic lesion, and using the proteins. Specifically, the present invention relates to a method for evaluating atherosclerotic lesions, comprising the steps of detecting a marker protein exhibiting an expression pattern (expression variation) characteristic at a specific disease stage of atherosclerotic lesions in a subject, and evaluating the atherosclerotic lesions in the subject based on the detection result. | 11-14-2013 |
20130316369 | METHOD FOR DETECTING ESCHERICHIA COLI - Described herein are methods of detecting an infection and for detecting the presence or absence of microorganisms, for example, wound pathogens in a sample, by contacting a sample with an enzyme produced and/or secreted by the bacteria, and detecting modification or the absence of modification or the substrate, as an indicator of the presence or absence of the enzyme in the sample. The present invention also features a biosensor for detecting the presence or absence of bacteria in a sample. | 11-28-2013 |
20130316370 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Beta-nerve growth factor, Interleukin-17A, Follitropin subunit beta, Collagenase 3, Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1/Keratin-10, Type II cytoskeletal Keratin-6A/6B/6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite-regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha as diagnostic and prognostic biomarker assays in renal injuries. | 11-28-2013 |
20130323748 | METHOD OF JUDGING RISK OF CANCER RECURRENCE AND COMPUTER PROGRAM - There is provided a method of judging a risk of cancer recurrence based on the activity value and expression level of the first CDK, the activity value and expression level of the second CDK, and the expression levels of uPA and PAI-1 and a computer program. | 12-05-2013 |
20130323749 | GRANZYME A AND GRANZYME B DIAGNOSTICS - A method for identifying a subject being at risk for or having a chronic Inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease is provided. The method may include determining the concentration of GrA and/or GrB in a blood or serum sample from said subject; and comparing the concentrations to the corresponding concentration in a control sample, wherein an elevated concentration of GrA and/or GrB may be indicative of a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease. The method may further include identifying concentrations of fibrinogen, elastin and/or fibrillin. | 12-05-2013 |
20130323750 | Method for Analyzing Apoptosis Inducing Factor-2 - A method for analyzing apoptosis inducing factor-2 (AIF-2) is disclosed, which has not been found in urine samples of human patients with chronic kidney disease, to establish AIF-2 as a non-invasive biomarker for chronic kidney disease. The method includes: collecting a plurality of urine samples; conducting western blot for each urine sample for detecting the AIF-2 protein content in each urine sample; and conducting statistical analysis of the AIF-2 protein content in each urine sample to establish AIF-2 as a biological marker for chronic kidney disease. | 12-05-2013 |
20130323751 | Urine Biomarkers For Prediction Of Recovery After Acute Kidney Injury: Proteomics - This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal to recovery and/or renal non-recovery. | 12-05-2013 |
20130344503 | METHODS FOR DETERMINING THE RISK OF PRENATAL COMPLICATIONS - The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. | 12-26-2013 |
20130344504 | NNMT AS A MARKER FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) - An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein NNMT in said sample in vitro. | 12-26-2013 |
20130344505 | APEX1 AS A MARKER FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) - An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein APEX1 in said sample in vitro. | 12-26-2013 |
20130344506 | SEPRASE AS A MARKER FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) - An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein Seprase in said sample in vitro. | 12-26-2013 |
20140004530 | METHOD FOR THE EVALUATION OF COMPOUND-TARGET INTERACTIONS ACROSS SPECIES | 01-02-2014 |
20140004531 | Secretory Protein Biomarkers For High Efficiency Protein Expression | 01-02-2014 |
20140011211 | METHOD OF DIAGNOSING THE PRESENCE AND/OR SEVERITY OF A HEPATIC PATHOLOGY IN AN INDIVIDUAL AND/OR OF MONITORING THE EFFECTIVENESS OF A TREATMENT FOR ONE SUCH PATHOLOGY - A method pertains to a diagnosing the presence and/or severity of a hepatic pathology and/or of monitoring the effectiveness of a curative treatment against a hepatic pathology in an individual, comprising the establishment of at least one non-invasive diagnostic score, in particular a diagnostic score for portal and septal fibrosis and/or an estimate score for the fibrosis area and/or an estimate score for the fractal dimension. | 01-09-2014 |
20140017700 | SENSITIVE INTRACAVITY BIOSENSING PLATFORM AND METHODS FOR DETECTION THEREWITH - The present disclosure provides a method of detecting a target analyte, by binding the target analyte and a probe with at least one fluorophore to form a fluid composition. The fluid composition is excited within a laser cavity. The method comprises measuring a laser emission from the fluid composition based on an interaction between the target analyte and the probe. In certain aspects, the method provides hybridizing the target analyte and the probe, prior to the exciting. In certain variations, the methods comprise detecting a target analyte by measuring a laser emission from the fluid composition based on an interaction between the target analyte, where the interaction is probe energy transfer, intercalation, hybridization of the target analyte and the probe, or combinations thereof. The energy transfer can include fluorescence resonance energy transfer (FRET), FRET with a molecular-beacon, or cavity-assisted radiative energy transfer, by way of non-limiting example. | 01-16-2014 |
20140017701 | CHIMERIC PDK1 KINASES - The invention provides chimeric 3-phosphoinositide-dependent protein kinase 1 (PDK1), the PIF-binding pocket of which has mutations to mimic a second protein kinase, its production and use. The invention further provides a method for screening for compounds interacting with the PIF-pocket of an AGC kinase. | 01-16-2014 |
20140017702 | BIOMARKERS FOR ACUTE KIDNEY INJURY - Disclosed is an animal model that can be used, among other things, to generate biomarkers for the prognosis and/or diagnosis of acute kidney injury, more specifically sepsis-induced acute kidney injury. Disclosed are three such biomarkers. The disclosure specifically relates to human chitinase 3-like protein 1 for use as a biomarker. | 01-16-2014 |
20140017703 | BAD PHOSPHORYLATION DETERMINES OVARIAN CANCER CHEMO-SENSITIVITY AND PATIENT SURVIVAL - Despite initial sensitivity BAD-protein phosphorylation were evaluated in patient samples and cell lines as determinants of chemo-sensitivity and/or clinical outcome, and as therapeutic targets. Induced in-vitro OVCA cisplatin-resistance was associated with BAD-pathway expression. Expression of the pathway was also associated with resistance of 7 different cancers cell-types to 8 chemotherapeutic agents. Phosphorylation of the BAD-protein was associated with platinum-resistance in OVCA cells and primary OVCA specimens, and also overall patient survival. Targeted modulation of BAD-phosphorylation levels influenced cisplatin-sensitivity. A 47-gene BAD-pathway signature was associated in-vitro phospho-BAD levels and with survival of 838 patients with ovarian, breast, colon, and brain cancer. The survival advantage associated with both BAD-phosphorylation and also the BAD-pathway signature was independent of surgical cytoreductive status. The BAD apoptosis pathway influences human cancer chemo-sensitivity and overall survival. The pathway is useful as a biomarker of therapeutic response, patient survival, and therapeutic target. | 01-16-2014 |
20140024042 | BIOMARKERS FOR DETECTION AND DIAGNOSIS OF HEAD AND NECK SQUAMOUS CELL CARCINOMA - Novel, sensitive and specific markers and methods for diagnostics and monitoring of head and neck squamous cell carcinoma (HNSCC) are provided. Kits and methods for the use of hyaluronic acid, hyaluronidase and CD44 to diagnose HNSCC are described. | 01-23-2014 |
20140030732 | MICROFLUIDIC HPLC-CHIP FOR GLYCOPEPTIDE ANALYSIS WITH INTEGRATED HILIC ENRICHMENT - A microfluidic device for glycopeptide analysis includes an enrichment column capable of binding carbohydrates; a trapping column capable of binding peptides, wherein the trapping column is configured to be connected downstream of the enrichment column; a separation column, wherein the separation column is configured to be connected downstream of the trapping column; and a plurality of ports configured to work with a switching device to form a plurality of flow paths, wherein one of the plurality of flow paths allows the trapping column to be in fluid communication with the separation column. A method for glycopeptide analysis using a microfluidic device comprising a trapping column and a separation column, the method includes applying a sample of peptides to the microfluidic device; trapping the peptides on the trapping column; eluting the peptides from the trapping column into the separation column; and separating the peptides on the separation column. | 01-30-2014 |
20140030733 | Method for Diagnosing Neurodegenerative Diseases - The present invention relates to a method for diagnosing, in vitro, a neurodegenerative disease in an individual, in which:—the level of the double-stranded RNA-dependent protein kinase (PKR) in a sample of cerebrospinal fluid from the individual is determined,—it is deduced therefrom whether the individual is suffering from a neurodegenerative disease. | 01-30-2014 |
20140030734 | Biomarkers for Diseases of the Central Nervous System - The present invention describes a method of diagnosis and/or progression of a disease based on the detection and quantification of the expression levels of biomarkers preferably selected from the group comprising gelsolin isoforms (SEQ. ID 1 and 2) and Vitamin D binding protein isoforms (SEQ. ID 3 and 4). Said method is applied to central nervous system diseases, preferably to Multiple Sclerosis. | 01-30-2014 |
20140038203 | METHODS FOR DETECTING OR PREDICTING KIDNEY DISEASE - Methods of detecting or predicting the onset or magnitude of kidney diseases such as acute kidney disease (AKI), previously called acute renal failure (ARF), are provided. In various aspects, methods and kits are provided to detect specific urinary proteins associated with AKI diagnosis or prognosis such as, e.g., angiotensinogen. | 02-06-2014 |
20140038204 | SELECTIVE MEASUREMENT OF ACTIVE HUMAN PROTEASE COAGULATION FACTORS - The present invention relates to a method for the selective determination of the concentration of an active human protease coagulation factor in a sample, comprising the steps of binding a specific inhibitor of the human protease coagulation factor to a solid phase, letting the human protease coagulation factor contained in the sample bind to the solid phase-bound inhibitor, and detecting the human protease coagulation factor bound to the solid phase-bound inhibitor with a detection reagent. | 02-06-2014 |
20140051093 | HIGH LEVEL EXPRESSION OF RECOMBINANT TOXIN PROTEINS - The present invention relates to the field of recombinant toxin protein production in bacterial hosts. In particular, the present invention relates to production processes for obtaining high levels of a recombinant CRM197, Diphtheria Toxin, Pertussis Toxin, Tetanus Toxoid Fragment C, Cholera Toxin B, Cholera holotoxin, and | 02-20-2014 |
20140051094 | Method and Compositions for Specifically Detecting Physiologically Acceptable Polymer Molecules - The present invention relates to a method for determining the amount of a physiologically acceptable polymer molecule bound to a protein, an antibody or other composition being capable of specifically binding to a physiologically acceptable polymer molecule, and a kit containing said antibody or composition. | 02-20-2014 |
20140057285 | COMPOSITIONS AND METHODS TARGETING FORCE GENERATION IN KINESIN - In some aspects, the invention provides chimeric kinesin proteins. In other aspects the invention provides nucleic acids encoding chimeric kinesin proteins. Compositions and kits are provided that comprise chimeric kinesin proteins and nucleic acids encoding the same. Antibodies and antigen binding fragments that selectively bind kinesin proteins are also provided. | 02-27-2014 |
20140065641 | METHOD OF MEASURING THE DEGREE OF NON-INFLAMMATORY STRESS RESPONSE - A system enabling the molecular biological visualization and quantitative detection of events in a stress-exposed living organism and a means enabling the management of stress are provided. An indicator agent for non-inflammatory stress responses mediated by superoxide, which comprises IL-18, a visualizing agent for non-inflammatory stress responses for detecting the aforementioned indicator agent, a method of measuring the degree of non-inflammatory stress, which comprises using the aforementioned visualizing agent, a method of preventing, ameliorating or predicting a change in immune status based on a non-inflammatory stress response, which comprises applying the aforementioned visualizing agent to an animal, and a therapeutic agent for a change in immune status based on a non-inflammatory stress response for reducing the amount or activity of the aforementioned indicator agent. | 03-06-2014 |
20140065642 | SYSTEMS AND METHODS FOR CHARACTERIZATION OF MOLECULES - The present invention generally provides systems and methods for the detection, identification, or characterization of differences between properties or behavior of corresponding species in two or more mixtures comprised of molecules, including biomolecules and/or molecules able to interact with biomolecules, using techniques such as partitioning. The experimental conditions established as distinguishing between the mixtures of the molecules using the systems and methods of the invention can also be used, in some cases, for further fractionation and/or characterization of the biomolecules and/or other molecules, using techniques such as single-step or multiple-step extraction, and/or by liquid-liquid partition chromatography. The methods could also be used for discovering and identifying markers associated with specific diagnostics, and can be used for screening for such markers once discovered and identified during diagnostics screening. | 03-06-2014 |
20140072982 | SPECIFIC SALIVARY BIOMARKERS FOR RISK DETECTION, EARLY DIAGNOSIS, PROGNOSIS AND MONITORING OF ALZHEIMER'S AND PARKINSON'S DISEASES - Methods by which specific biomarkers in saliva are used for risk detection, early diagnosis, prognosis and monitoring of Alzheimer's and Parkinson's diseases. | 03-13-2014 |
20140080142 | Compositions and Methods of Using Differentiated Cells Sensitized to Botulinum Neurotoxin - Differentiated cholinergic cells having motor neuron-like morphology and increased sensitivity to botulinum neurotoxin are provided herein. Methods of using such differentiated cells for detecting neurotoxin are also provided. | 03-20-2014 |
20140080143 | PSA ASSAY AND REAGENT THEREFOR - Provided is a method for the simple and highly accurate assay of PSA by a one-step reaction that does not use carriers having different average grain sizes. Also provided is a reagent therefor. The PSA assay method comprises sensitizing insoluble carriers having the same average grain size within a range of greater than 0.20 μm but 0.40 μm or less using two types of anti-PSA monoclonal antibodies having different epitopes that are anti-PSA monoclonal antibodies that will react with both free PSA and PSA-ACT, which is a complex of free PSA and α1-antichymotrypsin, and bringing the carriers into contact with a sample in the presence of an aggregation promoter. | 03-20-2014 |
20140080144 | METHOD FOR DETERMINING PLATELET-ASSOCIATED ANALYTES - The present invention relates to a routine in vitro method for determining platelet-associated analytes, for example VWF, factor XIII, fibrinogen or D-dimer, in a sample of platelet-rich plasma. | 03-20-2014 |
20140087392 | GLYCOSYL TRANSFERASE FROM CHINESE HAMSTER AND RELATED METHODS - A glycosyl transferase from Chinese hamster and related methods are described. | 03-27-2014 |
20140093888 | HIGHLY PURE PLASMID DNA PREPARATIONS - The present disclosure generally relates to highly pure plasmid compositions having low, or undetectable, levels of colanic acid and other contaminants made by a process that includes the steps of obtaining a crude lysate of a plasmid DNA from a bacteria that makes colanic acid; treating the partially purified or purified plasmid DNA with a polypeptide that digests colanic acid under conditions that digest the colanic acid; and purifying the plasmid DNA from the digested colanic acid and the colanic acid degrading enzyme by one or more chromatography steps. | 04-03-2014 |
20140099650 | MONOCLONAL ANTIBODIES AND DETECTION METHODS FOR ENZYMES THAT CONFER RESISTANCE TO PHOSPHINOTHRICIN-N-ACETYL-TRANSFERASE - Described herein are monoclonal antibodies and methods useful for determining and quantitating the presence of a phosphinothricin-N-acetyl-transferase enzyme. The claimed antibodies and methods are particularly useful for identifying and quantitating the presence of phosphinothricin-N-acetyl-transferase expressed in trangenic plants. | 04-10-2014 |
20140106369 | BIOMARKERS FOR AGGRESSIVE PROSTATE CANCER - The present invention relates to the field of biomarkers and, more specifically, to biomarkers useful in diagnosing aggressive prostate cancer. In specific embodiments, a method for diagnosing aggressive prostate cancer in a patient comprises (a) measuring the levels of one or more biomarkers in a sample collected from the patient; and (b) comparing the levels of the one or more biomarkers with predefined levels of the same biomarkers that correlate to a patient having aggressive prostate cancer and predefined levels of the same biomarkers that correlate to a patient not having aggressive prostate cancer, wherein a correlation to one of the predefined levels provides the diagnosis. In a specific embodiment, the one or more biomarkers may comprise cathepsin-L (CTSL), periostin, microfibrillar-associated protein 4 (MFAP4), collagen XII, neprilysin, clusterin, neutrophil gelatinase associated lipocalin (NGAL), epithelial cell activating molecule (EpCAM), prostate specific antigen (PSA), membrane metallo-endopeptidase (MME) and asporin (ASPN). | 04-17-2014 |
20140106370 | BIOMAKERS USEFUL IN LIVER FIBROSIS DIAGNOSIS - Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and β-2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing liver fibrosis. | 04-17-2014 |
20140113310 | CANCER DETECTION MARKERS - Methods and compositions involving molecular markers for the detection and characterization of cancer in a patient are provided. | 04-24-2014 |
20140113311 | AGGLUTINATION ENHANCER - The purpose of the present invention is to provide an agglutination enhancer which shows superior agglutination enhancing effect to those of conventional immunoagglutination enhancers, and the present invention relates to an agglutination enhancer for an immunoagglutination measurement method which comprises a polymer having a monomer unit shown by the following general formula [1]: | 04-24-2014 |
20140120551 | METHODS OF DIAGNOSING, PREDICTING AND TREATING CARDIOVASCULAR DISEASE - Methods for determining an increased risk of developing a cardiovascular event excluding stable angina in a subject are disclosed. Also disclosed are methods for diagnosing a human subject's myocardial infarction (MI) and/or acute coronary syndrome (ACS) state or identifying a human subject's risk of MI and/or ACS. | 05-01-2014 |
20140127711 | Method And System For Detecting Lymphosarcoma in Cats Using Biomarkers - The invention provides a method and system for developing and using diagnoses of lymphosarcoma in feline subjects using Thymidine kinase (TK) and haptoglobin (HP) as biomarkers. The invention provides a method for obtaining the level of each biomarker and computing an index for a feline subject. The invention provides predefined index ranges to which the index value may be matched in order to determine whether the subject has a high probability of being affected by lymphosarcoma, even when the subject shows apparent symptoms that may be common with inflammatory bowel disease. | 05-08-2014 |
20140127712 | USE OF BACTERIAL BETA-LACTAMASE FOR IN VITRO DIAGNOSTICS AND IN VIVO IMAGING, DIAGNOSTICS AND THERAPEUTICS - Provided herein are assays and in vitro methods to determine susceptibility to a drug effective against a pathogenic bacteria, for example, a pathogenic Mycobacteria, that has a beta-lactamase activity. An excitation wavelength is delivered to a biological sample obtained from a subject having an infection from the pathogenic bacteria in the presence of a beta-lactamase substrate. The intensity of a signal, such as a fluorescent, luminescent or colorimetric signal, at an emission wavelength of a product of the beta-lactamase on the subject is correlated to drug susceptibility. Also provided is an assay system for monitoring drug susceptibility of a pathogenic bacteria comprising color-producing substrates for a beta-lactamase of the pathogenic bacteria, an assay device for visibly detecting a product of the beta-lactamase on the substrate thereof and a reader configured to quantify the visibly detected product. | 05-08-2014 |
20140127713 | MEANS FOR THE EXAMINATION OF BODY FLUIDS - The invention provides means for making examinations on a sample of body fluid, particularly a sample of blood. The presence of at least one characteristic protein is additionally detected, and the intended examinations are only executed and/or evaluated if said characteristic protein is present. The characteristic protein may for example be human serum albumin or hemoglobin if the body fluid is blood. Preferably, the characteristic protein is quantitatively detected in a competitive assay performed in a cartridge ( | 05-08-2014 |
20140127714 | METHOD AND ASSAY FOR DETERMINING FAS EXPRESSION - Methods and immunoassays for the determination of fatty acid synthase (FAS) expression in patients having or suspected of having a proliferative disorder, especially prostate cancer, are disclosed. The sensitive method and assay detect the level of expression of FAS in a biological sample using antibodies that are highly specific for FAS. The method and assay can be used to monitor the progression of cancer, and/or to predict the efficacy of certain treatments or the likelihood of recurrence of the cancer. | 05-08-2014 |
20140134640 | Gene Defects And Mutant ALK Kinase In Human Solid Tumors - Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant polypeptides, probes for detecting it, isolated mutant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The invention also provides methods for determining the presence of these mutant polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides. | 05-15-2014 |
20140141450 | Assays for Detecting Enzymatic Activity - The present invention relates to method of detecting activity of a sample. Some methods involve detecting a neo-binding-site created by the activity such as detecting an activity of a protease by detecting a neo-binding-site created by cleavage of a substrate by the protease. | 05-22-2014 |
20140141451 | ASSAY TO DETERMINE LRRK2 ACTIVITY IN PARKINSON'S DISEASE - Disclosed are novel phosphorylation sites identified in LRRK2 and associated with Parkinson's Disease, antibodies that specifically bind to said novel phosphorylation sites, and laboratory and clinical uses thereof. | 05-22-2014 |
20140154698 | METHODS FOR MEASURING CARCINOEMBRYONIC ANTIGEN - Disclosed herein are methods of accurately measuring carcinoembryonic antigen in a biological sample and methods of identifying and treating a mucinous cyst in a subject. | 06-05-2014 |
20140154699 | Monoclonal Antibodies which Specifically Recognize Human Liver-Carboxylesterase 1, Hybridoma Cell Lines which Produce Monoclonal Antibodies, and Uses Thereof - The present invention relates to monoclonal antibodies which specifically recognize human liver-carboxylesterase 1, hybridoma cell lines which produce monoclonal antibodies, and uses thereof. The invention can be used for the objective analysis of the expression amount of human liver-carboxylesterase 1 in tissues and blood, and the like, by being specifically bound to the human liver-carboxylesterase 1. Therefore, liver cancer can be conveniently and quickly diagnosed from urine or blood. | 06-05-2014 |
20140162285 | Methods of Modulating Vesicular Trafficking - Described are methods of identifying compounds useful for modulating vesicular trafficking, particularly those that disrupt the interactions between ARNO and the V-ATPase a2-subunit. Also described are peptides that modulate vesicular trafficking. | 06-12-2014 |
20140162286 | METHOD FOR THE DETECTION OF ENZYMATIC ACTIVITY WITH MAGNETICALLY FUNCTIONALIZED SUBSTRATES - The present invention provides methods for detecting an enzymatic activity, the method including combining at least one magnetic particle to an enzyme substrate to form a magnetically modified substrate, reacting the magnetically modified substrate with at least one enzyme; and detecting a change in a magnetic property of the magnetically modified substrate or its cleavage products, thereby detecting an activity of said at least one enzyme, wherein the method may be applied to a human subject to detect a disease selected from the group consisting of rheumatitis, arthritis, an injury, Dupuytren's disease, Peyronie's disease, a collagen related disease, steatosis, fibrosis, cirrhosis, metastasis, tissue regeneration, cancer, coronary disease, a liver disease, a metabolic condition, an infection and an inflammatory disease. | 06-12-2014 |
20140170674 | Membraine-Based Assay Devices Utilizing Time-Resolved Up-Converting Luminescence - This invention discloses an immunochromatographic assay device to detect and quantify analytes. The device utilizes up-converting luminescent probes to detect time-resolved luminescence signals. Because the unconverting luminescent probes can have relatively long emission lifetime, background interference from sample autofluorescence and light scattering from excitation source can be easily eliminated through delayed luminescence detection. Furthermore, the up-converting luminescent probes can be excited by near Infrared (IR) or IR light sources. In comparing with UV and visible lights, the near IR and IR lights can penetrate deeper into sample matrices and more effectively excite the probes, but not the sample matrices, resulting in less background and higher detection sensitivity. A simple and low cost reader can be designed to measure the delayed up-converting luminescence of long lifetime that does not use expensive optical filters and mirrors. | 06-19-2014 |
20140170675 | PROTEIN DETECTOR BASED ON MOLECULAR CONTROLLED SEMICONDUCTOR RESISTOR - The invention provides a semiconductor device for the detection of an active site-containing protein or a ligand thereof in a solution, said device comprising at least one insulating or semi-insulating layer; at least one conducting semiconductor layer, two conducting pads on top of the upper layer making electrical contact with said at least one conducting semi-conductor layer, such that electrical current can flow between them at a finite distance from the surface of the device; a protective molecular layer fabricated on top of said upper layer and protecting said layer from corrosion; and said ligand or active site-containing protein linked to said protective molecular layer. Exposure of said ligand or active site-containing protein to a solution containing said active site-containing protein or ligand, respectively, causes a current change through the device when a constant electric potential is applied between the two conducting pads. The semi-conductor device can be seen as a molecularly controlled semiconductor resistor (MOCSER) protein sensor based on doped and undoped GaAs stack structure. The GaAs is protected against etching in aqueous environments by the protective molecular layer. | 06-19-2014 |
20140178893 | NON-INVASIVE ENZYME SCREEN FOR TISSUE REMODELLING-ASSOCIATED CONDITIONS - Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzymes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of cancer, metastatic cancer, and obstructive and degenerative conditions. | 06-26-2014 |
20140178894 | CULTURE MEDIUM SUITABLE FOR THE CULTURE OF UNDIFFERENTIATED CELLS - The present application relates to a composition comprising the components listed in Table I in an amount that will lead to the respective concentration specified in Table I for each of said component when said composition is diluted with water into 1× medium, said composition being particularly suitable to generate a chemically-defined medium suitable for culturing cells, especially primary cells, maintaining their proliferation and differentiation potential. | 06-26-2014 |
20140186852 | BIOMARKERS FOR MYOCARDIAL ISCHEMIA - This invention relates, e.g., to a method for determining if a subject has myocardial ischemia, comprising (a) providing a blood sample obtained from a subject suspected of having myocardial ischemia; (b) determining in the sample the amount of one or more of the following proteins: (i) Lumican and/or (ii) Extracellular matrix protein 1 and/or (iii) Carboxypeptidase N; and (c) comparing the amount(s) of the protein(s) to a baseline value that is indicative of the amount of the protein in a subject that does not have myocardial ischemia, wherein a statistically significantly increased amount of the protein(s) compared to the baseline value is indicative of myocardial ischemia. Other proteins indicative of myocardial ischemia are also described, as are methods for treating a subject based on a diagnostic procedure of the invention, and kits for carrying out a method of the invention. | 07-03-2014 |
20140193831 | SEED TRAIT PREDICTION BY ACTIVITY-BASED PROTEIN PROFILING - The present invention relates to a method of predicting a plant seed trait, such as germination rate, vigour, aging and priming, by determining the presence of a target protein, i.e. diagnostic marker, in its active state in a protein sample derived from a plant seed or plant seed lot. Thereby, the quality of a plant seed or a plant seed lot can be predicted and/or diagnosed and seeds may be distinguished on basis of their characteristics and with respect to the traits described herein. Inter alia, seeds and seed lots having high germination quality may be distinguished from seeds and seed lots having low germination quality. In particular, the method comprises contacting the protein sample or the plant seed or plant seed lot with a chemical probe comprising a warhead being able to attach to an amino acid residue in or nearby an active site of the target protein under conditions allowing the formation of a conjugate of the target protein and the chemical probe, wherein the chemical probe further comprises a reporter tag which is used to detect the conjugate, and wherein detection of the conjugate indicates the presence of the target protein in the protein sample and is used to predict or diagnose the plant seed trait. The present invention further relates to the use of such chemical probes for the prediction of plant seed traits. | 07-10-2014 |
20140193832 | DETECTION OF PROSTATE CANCER USING PSA GLYCOSYLATION PATTERNS - The present invention features novel methods for determining if a subject has prostate cancer. The present invention is based on the development of lectin immunosorbant assays which analyze α2,6-linked sialylation of total serum PSA by | 07-10-2014 |
20140193833 | ISOLATION AND DETECTION OF CANCER CELLS - Provided are methods of using polycarbonate filters to isolate and detect cancer cells in a biological fluid, particularly biological fluids, such as urine, that contain very low concentrations of cancer cells. The characterization of the isolated cells for the presence or absence of cancer specific proteins is useful for cancer diagnosis and prognosis. | 07-10-2014 |
20140199705 | GLUCANASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM - The invention relates to polypeptides having glucanase, e.g., endoglucanase, mannanase, xylanase activity or a combination of these activities, and polynucleotides encoding them. In one aspect, the glucanase activity is an endoglucanase activity (e.g., endo-1,4-beta-D-glucan 4-glucano hydrolase activity) and comprises hydrolysis of 1,4-beta-D-glycosidic linkages in cellulose, cellulose derivatives (e.g., carboxy methyl cellulose and hydroxy ethyl cellulose) lichenin, beta-1,4 bonds in mixed beta-1,3 glucans, such as cereal beta-D-glucans or xyloglucans and other plant material containing cellulosic parts. In addition, methods of designing new enzymes and methods of use thereof are also provided. In alternative aspects, the new glucanases e.g., endoglucanases, mannanases, xylanases have increased activity and stability at increased pH and temperature. | 07-17-2014 |
20140199706 | Methods and Compositions for Enhancing Proteasome Activity - This invention relates to methods and compositions for enhancing proteasome activity in a cell. The methods and compositions for enhancing the activity of the proteasome in cells modulate the activity of Ubp6 (yeast) or Usp14 (human), an endogenous inhibitor of the proteasome. The methods and compositions partially or completely reduce the inhibitory activity of Usp14 on a proteasome, thereby specifically enhancing the protein-degradation activity of the proteasome. The invention also provides methods of screening to identify inhibitors of Ubp6, Usp14, and/or both Ubp6 and Usp14. | 07-17-2014 |
20140199707 | METHOD FOR IDENTIFYING INHIBITORS OF STAPHYLOCOCCUS AUREUS - Provided are methods for identifying and/or designing inhibitors of | 07-17-2014 |
20140199708 | CELL-BASED METHODS FOR MEASURING ACTIVITY OF A PROTEIN INHIBITOR - The invention provides a method for determining the activity of an inhibitor of a target protein that has a deleterious effect on cell growth. The principle of the claimed method is that a compound that inhibits the function of an overexpressed protein will relieve the detrimental effect of such overexpression in a concentration-dependent manner, thereby allowing the determination of the activity of the compound in inhibiting its target protein in live cells. | 07-17-2014 |
20140199709 | METHODS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME - The invention provides an ELISA assay for the determination of serum mast cell β-tryptase levels using rabbit anti-tryptase as the capture antibody and alkaline phosphatase conjugated G3 as the detecting antibody. Luminescent substrate CPSD was used to enhance the assay sensitivity. Also provided are methods for aiding in the diagnosis of irritable bowel syndrome by detecting the serum level of β-tryptase, histamine and/or prostaglandin E | 07-17-2014 |
20140206017 | LYSYL OXIDASE-LIKE 2 ASSAY AND METHODS OF USE THEREOF - The present disclosure provides an assay to detect and/or quantify circulating lysyl oxidase-like 2 (LOXL2) poly-peptides in an individual. The assay is useful in diagnostic and prognostic applications, which are also provided. | 07-24-2014 |
20140206018 | ANTIBODIES AGAINST FATTY ACID SYNTHASE - The present invention relates to antibodies that immunospecifically bind to FAS and certain FAS related proteins. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to FAS-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed. | 07-24-2014 |
20140212890 | METHODS, APPARATUSES, AND SYSTEMS FOR DETECTING AND QUANTIFYING PHOSPHOPROTEINS - Embodiments herein provide methods, apparatuses, and systems for detecting, monitoring, measuring, and/or characterizing the activity of phosphoproteins, such as tyrosine kinases (TKs) and downstream proteins in TK signal transduction pathways (e.g., TK pathway proteins). In various embodiments, the methods, apparatuses, and systems may use nanoparticles, such as quantum dots (QD), to detect and/or characterize the abnormally overactive TK signaling pathways that underlie tumorgenesis and tumor progression. In various embodiments, the QD-based methods, apparatuses, and systems may have a sufficiently high degree of sensitivity to enable the identification of new TK signaling pathway markers, for example for use in diagnosing, staging, monitoring, and/or prognosing cancers, or in evaluating the efficacy of cancer therapeutics. | 07-31-2014 |
20140212891 | Compositions and Methods Using NOX5 - Certain embodiments include methods of assessing male fertility. | 07-31-2014 |
20140220593 | INHIBITION OF PEROXIDASE ENZYMATIC ACTIVITY - The present invention deals with reagents and compositions capable of effectively inhibiting peroxidase activity. According to the invention, peroxidase enzymatic activity is blocked with an acidic aqueous solution of a protein denaturing agent. Preferred protein denaturing agents are detergents and chaotropic substances. | 08-07-2014 |
20140220594 | NMR METHODS FOR ENDOTOXIN ANALYSIS - The invention features a method of monitoring a clotting process by measuring a signal characteristic of the NMR relaxation of water in a sample undergoing endotoxi-induced clotting to produce NMR relaxation data and determining from the NMR relaxation data a magnetic resonance parameter of water in the sample characteristic of the level of endotoxin present in the sample. | 08-07-2014 |
20140234860 | MEASUREMENT OF PKA FOR CANCER CHARACTERIZATION - A method for characterizing a carcinoma in a subject. The method comprises assaying a sample of a bodily fluid derived from the subject for extracellular PKA activity and comparing the activity to a reference value. In the assay, a reaction mixture is prepared comprising the previously unfrozen sample, a PKA peptide substrate, a phosphorylation agent, the prepared mixture is incubated, and phosphorylated substrate formed in the incubated mixture is detected. The reference value is the amount of phosphorylated substrate formed in a mixture under equivalent redox conditions for a sample of bodily fluid derived from a population of normal subjects of the same species. | 08-21-2014 |
20140234861 | METHOD FOR DIAGNOSIS, PROGNOSIS OR TREATMENT OF ACUTE CORONARY SYNDROME (ACS) COMPRISING MEASUREMENT OF PLASMA CONCENTRATION OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) - A method for diagnosing acute coronary syndrome (ACS) in a subject, the method comprising measuring plasma macrophage migration inhibitory factor (MIF) concentration in a sample from the subject, and diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, wherein the sample is taken less than 4 hours after symptom onset. The invention also relates to a method for prognosing ACS in a subject, the method comprising measuring plasma MIF concentration in a sample from the subject, diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, and prognosing the magnitude of ACS from the subject plasma MIF concentration. Also provided is a method of treating ACS in a subject, a device, a kit, and a cardiac biomarker related to the methods of diagnosing and prognosing ACS. | 08-21-2014 |
20140242606 | PROBE FOR iFRET AND USE THEREOF - The present invention relates to a probe for iFRET and use thereof. Specifically, the present invention relates to a novel probe for iFRET, a method for preparing the probe for iFRET, a method for searching a target protein-specific binding site or a molecule having the binding site using the probe for iFRET, and a method for imaging the target protein using the probe for iFRET. The probe for iFRET according to the present invention utilizes an amino acid in a protein as a fluorescent donor, unlike the conventional FRET method. Therefore, only one fluorescent material is used, and its emission wavelength is distinct from the intrinsic fluorescence of the protein. Thus, high specificity and sensitivity are ensured, and the quantity, activity and mechanism of various proteins can be analyzed in an easy and accurate manner. | 08-28-2014 |
20140242607 | ANTIBODY FOR DETECTING EPITHELIAL OVARIAN CANCER MARKER AND METHOD FOR DIAGNOSING EPITHELIAL OVARIAN CANCER - It is intended to find a highly specific epithelial ovarian cancer marker and to provide an antibody capable of specifically recognizing and detecting the marker or a fragment of the antibody. The present invention provides an anti-β1,6-N-acetylglucosaminyltransferase 5B antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase β1,6-N-acetylglucosaminyltransferase 5B as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1. | 08-28-2014 |
20140248635 | ALPHA-TUBULIN ACETYLTRANSFERASE - Polypeptides with tubulin acetyltransferase activity are described, as are nucleic acids encoding said polypeptides, and methods of use. The invention further provides enhancers and inhibitors of tubulin acetyltransferase activity, as well as cells having altered tubulin transferase activity. | 09-04-2014 |
20140248636 | ASSAY FOR HISTIDINYL HYDROXYLASE ACTIVITY - The present invention relates to assays for monitoring activity of Mina53 and NO66 activities, in particular, to assays for identifying modulators of Mina53 and NO66 activities. The invention also relates to assays to monitor the histidinyl hydroxylase activity of Mina53 and NO66 on their substrates, the human ribosomal protein Rpl27a and Rpl8 respectively. The invention also enables the introduction of S-3-hydroxyhistidinyl residues into peptides and proteins. | 09-04-2014 |
20140248637 | COMPOSITION FOR DIAGNOSIS OF LUNG CANCER AND DIAGNOSIS KIT OF LUNG CANCER - Disclosed is as a biomarker useful in early diagnosis of lung cancer, at least one protein selected from the group including Quescin-sulfhydryl oxidase 1, Fibrillin-1, Isoform A of Lamin-A/C, Latent-transforming growth factor beta-binding protein 2, Galectin-1, highly similar to Dickkopf-related protein 3, Isoform A1-B of Heterogeneous nuclear ribonucleoprotein A1, 14-3-3 protein epsilon, Stanniocalcin-2, Cystatin-C, Isoform 1 of Connective tissue growth factor, Profilin-1, Isoform 1 of Extracellular matrix protein 1, Histone H2B type 2-E, Kinesin-like protein KIF26A, Zinc finger protein 516, and Isoform 1 of A-kinase anchor protein 9. | 09-04-2014 |
20140255951 | ANTIBODIES THAT BIND TO LYSYL OXIDASE-LIKE 2 (LOXL2) AND METHODS OF USE THEREFOR - The present disclosure provides lysyl oxidase-like-2 (LOXL2) polypeptide binding agents, including, for example, antibodies that specifically bind a LOXL2 polypeptide; and further provides compositions comprising same. The binding agents can be used in various treatment and diagnostic methods, which are also provided. | 09-11-2014 |
20140255952 | DEGRADABLE CARBON NANOTUBE-CONTAINING BIOSENSORS AND METHODS FOR TARGET CLINICAL MARKER DETECTION - The invention relates to carbon nanotube-containing composites as biosensors to detect the presence of target clinical markers, methods of their preparation and uses in the medical field. The invention is particularly suitable for the detection in patient biological specimens of bone markers and tissue markers. The biosensors of the invention include carbon nanotubes deposited on a substrate, gold nanoparticles deposited on the carbon nanotubes and, binder material and biomolecule deposited on the gold-coated carbon nanotubes. The biomolecule is selected to interact with the target clinical markers. The biosensor can be used as an in-situ or an ex-situ device to detect and measure the presence of the target clinical markers. | 09-11-2014 |
20140255953 | GRANZYME A AND GRANZYME B DIAGNOSTICS - A method for identifying a subject being at risk for or having a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease is provided. The method may include determining the concentration of GrA and/or GrB in a blood or serum sample from said subject; and comparing the concentrations to the corresponding concentration in a control sample, wherein an elevated concentration of GrA and/or GrB may be indicative of a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease. The method may further include identifying concentrations of fibrinogen, elastin and/or fibrillin. | 09-11-2014 |
20140273007 | DEVICES AND METHODS FOR SCREENING NIPPLE ASPIRATE FOR MARKERS INDICATIVE OF RISK OF DEVELOPING BREAST CANCER - A diagnostic test system, apparatus and method for identifying individuals at risk for developing or having breast cancer by detection of at least one marker associated with increased breast cancer risk in nipple aspirate fluid is provided. A testing device for screening nipple aspirate fluid for the presence of biomarkers associated with breast cancer and methods of identifying individual biomarkers and biomarker panels for evaluating the risk that an individual has developed or will develop breast cancer by assaying nipple aspirate fluid is described. | 09-18-2014 |
20140273008 | METHODS TO ASSESS ENZYME ACTIVITY USING MASS SPECTROMETRIC IMMUNOASSAY - Methods to assess biological enzyme activity directly in a complex clinical sample. To such a sample, e.g., plasma, an exogenous synthetic peptide substrate for an enzyme present in the sample and to be assessed is added. The sample then undergoes mass spectrometric immunoassay (MSIA) to monitor the mass spectral profile of the immuno-purified exogenous synthetic peptide substrate directly from the sample. Using the resulting profile, parameters such as enzyme activity and effect of enzyme modulators, including therapeutics administered to an individual for a condition involving the enzyme, may be determined. | 09-18-2014 |
20140287432 | Diagnosis, Prevention and Treatment of Disorders Characterized by Undesirable Cell Proliferation - The present invention relates to methods for the diagnosis, prevention and treatment of heart disease or heart failure in a subject. The present invention also relates to methods for the diagnosis, prevention and treatment of atherosclerosis with vulnerable plaque in a subject. Furthermore, the present invention relates to methods for the diagnosis, prevention and treatment of cardiomyopathies resulting from Chagas disease. | 09-25-2014 |
20140287433 | MEANS AND METHODS FOR DETERMINING CLOSTRIDIAL NEUROTOXINS - This invention relates to a method of determining presence, amount and/or activity of a clostridial neurotoxin in a sample, the method comprising or consisting of the following steps: (a) bringing said sample into contact with a liposome, said liposome comprising (aa) at least one receptor on its outer surface, said receptor being capable of binding said neurotoxin and comprising or consisting of (i) a glycolipid and (ii) a peptide or protein; and (ab) a substrate in its interior, said substrate (i) being cleavable by the peptidase comprised in said neurotoxin and (ii) generating a detectable signal upon cleavage, said detectable signal preferably being generated by (1) the donor of a FRET pair, said donor exhibiting increased fluorescence upon cleavage by said peptidase, (2) a luminescent compound formed upon said cleavage, or (3) an enzyme formed upon said cleavage; and (b) determining whether an increase in signal occurs as compared to the absence of said sample, wherein such increase is indicative of the presence of said neurotoxin and/or the degree of such increase is indicative of the amount and/or activity of said neurotoxin in said sample. | 09-25-2014 |
20140287434 | METHODS OF SCREENING FOR AND IDENTIFYING COMPOSITIONS WHICH MODULATE CELLULAR KINASE ACTIVITIES - The present invention relates to drug screening assays, therapeutic protocols and pharmaceutical compositions designed to target non-receptor tyrosine family kinases and components of the tyrosine kinase family signal transduction pathways. This includes primarily diseases or conditions associated with immune responses and can include treatment for cancers as well as various immune disorders. The invention reports a novel substrate SH2 domain docking mechanism apart from the kinase active site that is required for appropriate tyrosine phosphorylation by these tyrosine kinases. | 09-25-2014 |
20140295455 | ANTIBODY FOR DETECTING EPITHELIAL OVARIAN CANCER MARKER AND METHOD FOR DIAGNOSING EPITHELIAL OVARIAN CANCER - The present invention provides an antibody capable of specifically recognizing and detecting the highly specific cancer marker with respect to the epithelial ovarian cancer, or a fragment of the antibody. The present invention provides an anti-β1,3-N-acetylglucosaminyltransferase 3 antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase β1,3-N-acetylglucosaminyltransferase 3 as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1. | 10-02-2014 |
20140295456 | RENAL CELL CARCINOMA BIOMARKERS - Disclosed herein is a method of identifying a tumor biomarker. In one example, a tumor biomarker is identified by obtaining a peripheral biological fluid sample from a subject with a tumor as well as a tumor sample and an adjacent non-tumor sample from such subject. A protein expression profile is detected in the peripheral biological fluid sample, tumor sample and adjacent non-tumor sample. The protein expression profiles of the peripheral biological fluid sample, tumor sample and adjacent non-tumor sample are then compared, wherein an increase in expression of a specific protein in the tumor sample and peripheral biological fluid sample but not in the adjacent non-tumor sample indicates that the specific protein is a biomarker of the tumor. Also disclosed herein is a gene profiling signature that can be used to diagnosis a subject with renal cell carcinoma (RCC) or to identify agents with therapeutic potential to treat RCC. Thus, methods of diagnosing a subject with RCC are disclosed. Methods are also provided for identifying agents that alter an activity of a RCC biomarker. | 10-02-2014 |
20140295457 | GENE CLUSTER FOR BIOSYNTHESIS OF GRISELIMYCIN AND METHYLGRISELIMYCIN - The present invention refers to the gene cluster and genes comprised by the gene cluster which are involved in the biosynthesis of griselimycin and methylgriselimycin and to the use of the gene cluster, genes comprised thereby and proteins encoded thereby for the production of antibiotic agents. | 10-02-2014 |
20140302524 | ANTIBODIES THAT BIND TO LYSYL OXIDASE-LIKE 2 (LOXL2) AND METHODS OF USE THEREFOR - The present disclosure provides lysyl oxidase-like-2 (LOXL2) polypeptide binding agents, including, for example, antibodies that specifically bind a LOXL2 polypeptide; and further provides compositions comprising same. The binding agents can be used in various treatment and diagnostic methods, which are also provided. | 10-09-2014 |
20140302525 | METHODS OF IDENTIFYING SENP1 INHIBITORS - Provided herein are methods of detecting binding of an SENP1 polypeptide to a compound and methods for screening for inhibitors of SENP1. Further provided are aqueous compositions comprising SENP1 polypeptides and NMR apparatuses comprising the compositions for NMR analysis. | 10-09-2014 |
20140302526 | ZAP-70 DETECTION IN CHRONIC LYMPHOCYTIC LEUKEMIA - Detection of ZAP-70 expression provides important information about disease progression and overall survival in patients with chronic lymphocytic leukemia (CLL). The invention provides methods for diagnosing CLL in a subject, as well as methods for clearly distinguishing CLL patients with aggressive form of the disease. A consistent number of B cells from patient blood is isolated and lysed to release all of the intracellular ZAP-70 protein. The released ZAP-70 protein is subsequently extracted by immunomagnetic separation followed by detection with fluorescence immunosandwich assay. The ZAP-70 fluorescence signal is measured with Signalyte™-II spectrofluorometer. The VeriZAP™ assay is a simple, reliable, and reproducible method for quantitative detection of ZAP-70 in patient leukemic cells, and can be used as a prognostic test to distinguish indolent versus aggressive CLL patients. | 10-09-2014 |
20140308679 | Fluorometry - The invention relates to fluorometry, and in particular to methods and apparatus for time-delayed detection of fluorescence in a sample, for example for use in a clinical setting. Exemplary embodiments disclosed relate to a fluorometer ( | 10-16-2014 |
20140308680 | METHOD FOR DETECTION OF COAGULATION ACTIVITY AND BIOMARKERS - The present invention relates to a method for simultaneous detection of the coagulation activity of a blood sample and of the presence and/or amount of at least one target molecule within said blood sample, comprising the steps of: i) introducing a blood sample into a sample container comprising magnetic particles and a sensor surface, wherein said magnetic particles are functionalized with a first binding molecule, wherein said first binding molecule is attached to said magnetic particles, wherein the first binding molecule is capable of specifically binding to the at least one target molecule within said blood sample, and wherein a second binding molecule is attached to a sensor surface at the bottom of said sample container, and wherein said second binding molecule of the sensor surface is capable of specifically binding to the at least one target molecule within said blood sample; ii) measuring the presence and/or amount of said target molecule by detecting the number of magnetic particles bound to said sensor surface; wherein the number of bound magnetic particles is directly or inversely related to the amount of said at least one target molecule present in the sample; iii) at the same time or at different times measuring the co-agulation activity of said blood sample, wherein said magnetic particles are magnetically actuated; and wherein the loss of mobility of said magnetic particles is detected by measuring the light reflected from said immobilized magnetic particles near or at said sensor surface; and wherein the change of detected light signal is indicative of an increase of viscosity and/or a clotting of the blood sample; and wherein the magnetic particles in steps i) to iii) are magnetically actuated using a magnetic field generator. | 10-16-2014 |
20140315214 | CHAPERONE INTERACTION ASSAYS AND USES THEREOF - In some aspects, the invention provides methods of identifying, detecting, and/or measuring protein-protein interactions. In some aspects, the invention provides methods of identifying and/or characterizing modulators of protein-protein interactions. In some aspects, the invention provides methods of identifying and/or characterizing modulators of protein activity, wherein the methods are based at least in part on measuring interaction between a chaperone and client protein. In some aspects, the invention provides methods for identifying and/or characterizing compounds and/or for assessing compound specificity, wherein the methods are based at least in part on measuring interaction between a chaperone and client protein. In some embodiments, a client protein is a kinase. In some embodiments, a compound is a kinase inhibitor. In some aspects, the invention provides methods of profiling kinase inhibitor specificity. In some aspects, the invention provides assay systems and/or reagents useful for performing one or more of the inventive methods. In some aspects, the invention provides newly identified targets of a variety of kinase inhibitors. In some aspect, the invention provides methods of inhibiting kinases identified herein as targets of certain kinase inhibitors. In some aspects, the invention provides methods of treating a disease, e.g., cancer, by inhibiting one or more kinase(s) newly identified as targets of certain kinase inhibitors. | 10-23-2014 |
20140315215 | THERMOSTABLE ASSAY REAGENTS - There is provided a single-chain fusion protein comprising: (i) a thermostable kinase and (ii) a single-domain antibody or single-domain antibody fragment. There is also provided a method of preparing a single-domain antibody or single-domain antibody fragment, the method comprising: (i) expressing the single-domain antibody or antibody fragment as a single-chain fusion protein with a thermostable kinase, in a host cell such as | 10-23-2014 |
20140315216 | Immunoassay Test Slide - An immunoassay test slide for use in a dry chemistry analytical instrument includes a slide housing or case formed from two matable sections—a slide cover piece and a slide bottom piece. The slide housing defines an interior cavity in which is situated a sheet-like porous carrier matrix. The slide cover piece has an opening formed through the thickness thereof to expose a central portion of the fluid flow matrix so that a precise volume of fluid sample of blood, serum or the like, preferably pre-mixed with a conjugate reagent, and precise volumes of a wash reagent and a substrate (detector reagent), may be deposited on the matrix through the cover opening by a metering device of the analytical instrument. The bottom piece of the immunoassay test slide is transparent, and the slide is moved by a transport mechanism of the analytical instrument over a reflectometer or a fluorometer for performing reflectance or fluorescence measurements. | 10-23-2014 |
20140322725 | SENSORS AND ASSAYS FOR UBIQUITIN OR UBIQUITIN-LIKE PROTEINS - The present invention provides compositions comprising chimeric polypeptides that bind to free ubiquitin proteins or free ubiquitin-like proteins with high affinity, as well as chimeric polypeptides that bind to both free and conjugated ubiquitin proteins or free and conjugated ubiquitin-like proteins, and methods of using the chimeric polypeptides to determine the amount of free or total ubiquitin or free or total ubiquitin-like proteins in various types of samples. | 10-30-2014 |
20140322726 | MONOCLONAL ANTIBODY SPECIFICALLY RECOGNIZING ASPARAGINE SYNTHETASE - It is an object of the present invention to provide a monoclonal antibody, which is suitable for the quantitative analysis of asparagine synthetase in a cell. The present invention provides a monoclonal antibody which specifically recognizes asparagine synthetase that is present in a cell. | 10-30-2014 |
20140329252 | METHODS AND KITS FOR DIAGNOSING AND/OR PROGNOSING OSTEOARTHRITIS - A method of determining whether a subject is at risk of developing osteoarthritis (OA), said method comprising: determining the cellular localization of a Prohibitin-1 (PHB1) polypeptide and/or Small Ubiquitin-like Modifier (SUMO) polypeptide and/or UBC9, in a cell sample from said subject; and determining whether said subject is at risk of developing OA based on the cellular localization of a PHB1 polypeptide and/or SUMO and/or UBC9 polypeptide, is described. | 11-06-2014 |
20140329253 | Monoclonal Antibody For The Detection of SNAP/CLIP Tag - A monoclonal antibody that binds specifically to the SNAP motif and to the CLIP tag comprising CDRs with the amino acid sequences SEQ ID Nos. 3, 4, 5, and 8, 9, 10. | 11-06-2014 |
20140335537 | DEVICES FOR PERFORMING COLORIMETRIC ASSAY WITH PLUCKED HUMAN HAIR - Apparatuses are disclosed for performing calorimetric assays with plucked human hair using a device adapted for that purpose. This device may include a transparent reaction vessel connected via a capillary tube to a burst pack, and connected via another capillary tube to a funnel, into which a plucked human hair may be placed. | 11-13-2014 |
20140335538 | METHODS OF DIAGNOSING ALS - The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof. | 11-13-2014 |
20140342373 | MICROFLUIDIC SYSTEM - The present invention concerns a microfluidic system comprising: a microchannel containing several elements of two non-miscible fluids, the microchannel comprising a droplet ( | 11-20-2014 |
20140349309 | METHODS AND COMPOSITIONS FOR TREATMENT AND DIAGNOSIS OF FIBROSIS, TUMOR INVASION, ANGIOGENESIS, AND METASTASIS - The present disclosure provides innovative methodology and related compositions and kits for preventing and treating various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using an inhibitor of processed forms of lysyl oxidase or lysyl oxidase-like proteins, an inhibitor of LOX and an inhibitor of a LOXL, or a synergistic combination of an inhibitor of LOX or LOXL combined with other therapeutic agents. Also provided are innovative methods for selecting agents that prevent or inhibit tumor invasion, angiogenesis and metastasis, by contacting cells that are in an epithelial-mesenchymal transition (EMT) state with a candidate agent and detecting a change in the EMT state of the cells. Methods and related compositions and kits for diagnosing or monitoring various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using molecules or agents that specifically recognize processed forms of LOX or LOXL are also provided. Also provided herein are methods and related compositions, medical devices, systems and kits for preventing or treating various diseases and conditions associated with fibrosis with compositions comprising inhibitors of LOX or LOXL. Such diseases or conditions include pathological cardiovascular conditions and diseases such as hypertension, hypertensive heart disease, myocardial infarction, atherosclerosis, and restenosis, liver fibrosis, kidney fibrosis, lung fibrosis, dermal scaring, keloid formation, and Alzheimer's disease. | 11-27-2014 |
20140349310 | Anti-c-Met Antibodies - Provided is a monoclonal antibody, or antigen-binding fragment thereof that binds to c-Met. Such antibodies, or antigen-binding fragments thereof, are useful in in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting cell surface c-Met receptor levels for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens in patients harboring tumors in which c-Met is implicated in pathogenesis. | 11-27-2014 |
20140356882 | NON-INVASIVE ENZYME SCREEN FOR TISSUE REMODELLING-ASSOCIATED CONDITIONS - Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzyme complexes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of metastatic cancer by the identification of high molecular weight enzyme complexes comprising MMPs. | 12-04-2014 |
20140356883 | METHOD FOR EVALUATING THE SENSITIVITY AND SPECIFICITY OF FAST MALARIA- DIAGNOSIS TEST KITS - The invention relates to a method for evaluating kits for rapid diagnosis of malaria, in order to determine or to test the sensitivity and specificity thereof. To that end, the reactive strips of the diagnostic kits are exposed to different concentrations of the malaria parasite in a method that allows data on sensitivity and specificity indicated on the technical sheet of the kit to be ascertained. | 12-04-2014 |
20140370520 | METHODS AND COMPOUNDS FOR DETECTING CANCER - The invention relates to a method for diagnosing cancer, particularly bladder or prostate cancer using compounds of general formula (I): | 12-18-2014 |
20140370521 | IDENTIFICATION OF TWO NOVEL BIOMARKERS FOR NIEMANN-PICK DISEASE TYPE C - This invention provides novel biomarkers for Niemann-Pick disease, type C (NPC). In an exemplary embodiment, the invention provides methods for identifying a subject as having NPC. In embodiments, the methods involve detecting the level of biomarker selected from the group comprising i) galectin-3 (LGALS3); ii) cathepsin D (CTSD); iii) LGALS3 and CTSD; and iv) LGALS3 and/or CTSD in combination at least one additional NPC associated biomarker in a sample obtained from the subject. In embodiments, the methods involve comparing the level of biomarker to a reference. | 12-18-2014 |
20140377773 | Detection Marker for Anticancer Effects by Selenomethionine as an Inhibitor of Environmental Toxicity - The present invention relates to specific markers capable of detecting the development of colorectal cancer and the colorectal cancer inhibitory effect of SeMet (selenomethionine) having a chemopreventive effect against colorectal cancer. When the expressions of the biomarkers according to the present invention are measured and the expression levels thereof are analyzed in combination, whether SeMet (selenomethionine) is to be administered to prevent colorectal cancer can be determined and the development of colorectal cancer and the inhibitory effect of SeMet (selenomethionine) against the development of colorectal cancer can be monitored. Thus, these markers can be effectively used to observe the colorectal cancer inhibitory effect of SeMet (selenomethionine) and the prognosis of colorectal cancer resulting from the intake of SeMet (selenomethionine). | 12-25-2014 |
20140377774 | PAS KINASE ASSAYS - The present invention is directed towards methods for measuring and assaying PAS Kinase activity. The methods are useful, for example, for detecting PASK activity in a cell, and for screening for small molecule regulators of PAS kinase activity, as well as characterizing endogenous factors and stimuli that modulate PAS kinase activity, and identifying and optimizing the activity of potential PAS kinase inhibitors. | 12-25-2014 |
20150010920 | Enzyme Sensors, Methods For Preparing And Using Such Sensors, And Methods Of Detecting Protease Activity - Embodiments of the present disclosure provide for enzyme sensors, protease sensors, methods for producing and using the enzyme and protease sensors, methods of detecting and/or measuring protease activity, methods for characterizing protease cellular activity, fusion proteins, polynucleotides, and vectors corresponding to the enzyme and protease sensors, kits, and the like. | 01-08-2015 |
20150017656 | Rapid Lateral Flow Assay Method for Detecting Low Quantity Liquid or Dry Samples - This invention describes a design of a lateral flow assay device that detects dried chemicals or trice volume aqueous sample solutions, applicable for detecting body fluids and dried or liquid chemicals. The dried or aqueous samples on the sample loading area will contact with a secondary aqueous solution in described manner and flow to the reaction area. This invention enables a complete lateral flow assay while the sample volume itself is too small to accomplish a complete lateral flow test. | 01-15-2015 |
20150024403 | METHOD FOR DETECTING REPLICATION OR COLONIZATION OF A BIOLOGICAL THERAPEUTIC - Methods for detecting replication in or colonization of a host by a biological therapeutic, such as an oncolytic virus, cells administered for cell therapy and gene therapy vectors, are provided. In the methods, a product produced by the biological therapeutic is detected in a sample of tissue or body fluid distinct from the administered therapy or locus thereof, thereby permitting assessment of the therapy and/or monitoring its progress. | 01-22-2015 |
20150031047 | Methods and Systems For the Rapid Characterization of Functional Biological Molecules - In one non-limiting aspect, the invention provides a method for detecting the quality of a biological molecule comprising forming a first mixture of ingredients comprising: (i) a first binding agent that specifically binds to a tag, wherein the first binding agent is attached to a solid support; (ii) a decoy comprising a first portion comprising the tag attached to a second portion comprising an anchor; (iii) a sensor attached to a second binding agent that specifically binds to the anchor; and (iv) a sample suspected of containing a high quality biological molecule comprising a tag, wherein the tag of the high quality biological molecule is accessible; allowing interaction of the ingredients such that the sensor provides an output signal | 01-29-2015 |
20150031048 | CITRULLINATED BRAIN AND NEUROLOGICAL PROTEINS AS BIOMARKERS OF BRAIN INJURY OR NEURODEGENERATION - The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing brain injury or neurodegeneration. In one embodiment, a method for diagnosing brain injury in a patient comprises the steps of (a) obtaining a sample from the patient; (b) determining the ratio of citrullinated to unmodified arginine residues at one or more arginine residues of one or more brain injury biomarker proteins; and (c) correlating the ratio to a patient having brain injury or to a patient not having brain injury, thereby providing the diagnosis. | 01-29-2015 |
20150031049 | METHOD OF PREDICTING ACUTE APPENDICITIS - Embodiments of the invention provide method and devices for predicting the likelihood of acute appendicitis without invasive exploratory medical procedures. Several protein biomarkers: leucine-rich α-2-glycoprotein (LRG); S100-A8 (calgranulin); α-1-acid glycoprotein 1 (ORM); plasminogen (PLG); mannan-binding lectin serine protease 2 (MASP2); zinc-α-2-glycoprotein (AZGP1); Apolipoprotein D (ApoD); and α-1-antichymotrypsin (SERPINA3); are increased in the urine of patients with appendicitis. The method and devices comprise detecting the levels of these biomarkers and comparing with reference levels found in healthy individuals. | 01-29-2015 |
20150037814 | NON-INVASIVE ENZYME SCREEN FOR TISSUE REMODELLING-ASSOCIATED CONDITIONS - Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzymes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of cancer, metastatic cancer, and obstructive and degenerative conditions. | 02-05-2015 |
20150037815 | METHOD FOR THE TOPOGRAPHICALLY-SELECTIVE PASSIVATION OF MICRO- AND NANOSCALE DEVICES - Disclosed is a method of preparing a biosensor that involves providing a substrate including a surface having a topographical pattern formed at one or more sites on or in the surface, coating the substrate with a solution including hydrogel particles, wherein the hydrogel particles self-assemble on the surface to mask the surface except at the one or more sites, and binding one or more capture molecules to the one or more sites to form the biosensor. Systems that include the biosensor, as well as methods of using the biosensor, are also disclosed. | 02-05-2015 |
20150037816 | PCSK9 Function Assay - Methods and apparatuses for measuring the concentration of functional proprotein convertase subtilisin/kexin type 9 (PCSK9). A method of measuring functional PCSK9 in a sample is provided, by contacting the sample with a PCSK9-binding agent capable of binding to the LDL-R-binding region of a PCSK9; and measuring the amount of functional PCSK9 from the sample bound to the binding agent. Diagnostic methods, kits, and reagents for using the method are also provided. | 02-05-2015 |
20150044691 | BLOOD MARKER FOR RENAL CANCER - The present invention provides a blood marker for renal cancer, more specifically, a blood marker that can be practically used for clinical diagnosis of renal cancer. The present invention also provides a blood marker that can be practically used for follow-up after treatment such as surgery and during treatment such as medication for renal cancer. A blood marker for renal cancer selected from the group consisting of Galectin-1, Galectin-3, and α-enolase. Galectin-1 and/or Galectin-3 as a blood marker for renal cancer for use in an examination performed before diagnostic imaging. α-Enolase as a blood marker for renal cancer for use in monitoring during and/or after treatment for renal cancer. | 02-12-2015 |
20150050664 | ENZYME CONCENTRATION AND ASSAYS - A method of preparing a sample for conducting an assay, the method including: providing an input sample including glycoproteins; capturing glycoproteins from the input sample on a solid support; and washing the sample support to remove unbound portions of the input sample. | 02-19-2015 |
20150050665 | PREDICTIVE BIOMARKERS FOR BREAST CANCER - The invention relates to compositions and methods for detecting, screening, diagnosing or determining the progression of, regression of and/or survival from a proliferative disease or condition, specifically breast cancer. The invention also provides new assays and kits for the staging or stratifying breast cancer patients or patients suspected of having breast cancer. | 02-19-2015 |
20150050666 | NON-SPECIFIC REACTION INHIBITOR - Disclosed is a non-specific reaction inhibitor for use in an immunological measurement, comprising a complex of an antibody or a fragment of the antibody capable of specifically binding to a non-specific reaction factor, and a polymer. The non-specific reaction inhibitor can inhibit a non-specific reaction which may interfere with the accurate detection or quantification of a trace substance in an immunological measurement method. | 02-19-2015 |
20150056633 | DETECTION OF GLUTATHIONYLATED PROTEINS - The present invention, in some aspects, relates to systems and methods for determining oxidized proteins, including glutathionylated proteins such as S-glutathionylated proteins. The systems and methods of the invention can be used in vitro (e.g., in cell or tissue culture) or in vivo, for example, to diagnose a person having an oxidative stress condition. For instance, in some cases, the invention can be used to spatially determine the location and/or concentration of oxidized proteins within cells and/or tissues (e.g., through visual detection). In one set of embodiments, a glutathionylated or otherwise oxidized moiety on a protein may be reacted with a detection entity, which may be, for example, fluorescent, radioactive, electron-dense, able to bind to a signaling entity or a binding partner in order to produce a signal, etc. As a specific example, a glutathionylated moiety on a glutathionylated protein may be reacted with an alkylating agent to form an alkylthio moiety; the alkylthio moiety may include a detection entity or otherwise be able to interact with a signaling entity. In some embodiments, other moieties on the protein may be altered or blocked before reaction of the protein with the detection entity. Such moieties on the protein may be, for instance, non-oxidized or non-glutathionylated moieties able to react with the detection entity. As a particular example, in a protein containing a glutathionylated moiety and non-glutathionylated thiol moieties, the thiol moieties may first be altered or blocked prior to reaction of the protein with the detection entity. Also provided in certain aspects of the present invention are kits for determining oxidized proteins, which may include components such as detection entities, alkylating agents, blocking agents, reducing agents, signaling entities, binding partners, antibodies, instructions, and the like. | 02-26-2015 |
20150064714 | Polypeptides containing a modified fragment of the peptide IF1 - Labelled polypeptide constituted by:
| 03-05-2015 |
20150064716 | Goodpasture Antigen Binding Protein and Its Detection - The present invention provides native Goodpasture antigen binding protein isoforms, monoclonal antibodies directed against such proteins, and methods for their use. | 03-05-2015 |
20150072355 | FLAP ENDONUCLEASE-1 AS A MARKER FOR CANCER - Methods aiding in the assessment of cancer comprising use of the Flap endonuclease-1 protein (=FEN1) as a universal marker of different cancer types are provided. In particular, methods for assessing cancer from a liquid sample derived from an individual, which comprise measuring FEN1 in the sample are disclosed. Measurement of FEN1 is useful for the early detection of cancer or in the monitoring of patients who undergo surgery for tumor removal. | 03-12-2015 |
20150079607 | METHODS FOR MONITORING NEUROINFLAMMATORY DESTRUCTION OF NEURONS AND FOR TREATING DISEASES HAVING AN INFLAMMATORY COMPONENT RELATED TO PHOSPHOLIPASE A2 - The present invention relates to methods useful to monitor central and peripheral nervous system neuron/axon destruction resulting from an increase in acute phase inflammatory enzymes. The methods have applicability to monitoring the progress of neurological diseases, including multiple sclerosis and Alzheimer's disease, as well as neuroinflammatory damage that results from sports injuries, vigorous physical activity or any form of physical abuse. The invention further relates to methods of treating multiple sclerosis or other diseases with an inflammatory component related to phospholipase A2. | 03-19-2015 |
20150086998 | VALUE-ASSIGNED SOLUTIONS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 HAVING A LONG SHELF-LIFE - Value-assigned solutions having predetermined concentrations of recombinant Lp-PLA2 are described herein. In particular, described herein are solutions of rLp-PLA2 that are stable for an extended period of time. Kits and assays include these calibration solutions, as well as methods of making and using them are described. | 03-26-2015 |
20150086999 | LONG SHELF-LIFE KITS AND METHODS FOR STANDARDIZING, VERIFYING, CALIBRATING OR RECALIBRATING DETECTION OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 - Long shelf-life kits, value-assigned solutions, and methods for standardizing, verifying, calibrating or recalibrating detection of lipoprotein-associated phospholipase A2 having using them are described herein. In particular, described herein are methods of using solutions of rLp-PLA2 that are stable for an extended period of time to standardize, verify, calibrate or recalibrate assays for Lp-PLA2. | 03-26-2015 |
20150093758 | PSA CAPTURE AGENTS, COMPOSITIONS, METHODS AND PREPARATION THEREOF - Disclosed herein are novel synthetic prostate specific antigen (PSA)-targeted capture agents that specifically bind PSA. In certain embodiments, these PSA capture agents are biligand or triligand capture agents containing two or three target-binding moieties, respectively. | 04-02-2015 |
20150093759 | COMPOSITIONS AND METHODS FOR DETECTING NITRATION OF PKG-1a AND METHODS OF USE THEREOF - Antibodies for detecting nitration of nitrotyrosine 247 PKG-1α and antibodies for detecting nitrotyrosine 425 of PKG-1α are disclosed. Methods of detecting nitrotyrosine 247 PKG-1α and nitrotyrosine 425 of PKG-1α, and uses thereof are also disclosed for identification and diagnosis or phenotypes, pathologies, diseases and disorders associated with protein nitration of PKG-1α are also disclosed. In a preferred embodiment, one or more of the disclosed antibodies is used in the disclosed methods. | 04-02-2015 |
20150099270 | METHOD OF SCREENING PHARMACEUTICALS FOR DRUG INTERACTIONS AND NEPHROTOXICITY - A method of determining nephrotoxicity of pharmaceuticals by conducting a metabolite formation study in cells using PAH in a control group; measuring metabolite formation; exposing cells to pharmaceuticals in the treatment group; conducting the metabolite formation study using PAH; measuring the metabolite formation in the treatment group; comparing the metabolite formation in the control and treatment group, and making a determination as to the nephrotoxicity of pharmaceutical. | 04-09-2015 |
20150104806 | Parkinson's Disease Biomarker - The present invention relates to a biomarker for Parkinson's disease. The biomarker and products associated with the biomarker may be used to assist diagnosis or to assess onset and/or development of Parkinson's disease. The invention also relates to use of the biomarker in clinical screening, assessment of prognosis, evaluation of drug treatments, drug screening or drug development in the field of Parkinson's disease and Parkinson's disease related disorders. | 04-16-2015 |
20150104807 | KITS FOR DIAGNOSTIC AND THERAPEUTIC USES OF AUGMENTER OF LIVER REGENERATION IN INFLAMMATORY CONDITIONS - The present invention provides for methods and kits for detecting sepsis, trauma/hemorrhage or inflammation in a subject. It is based, at least in part, on the discovery that Augmenter of Liver Regeneration (“ALR”) is an early marker of these conditions. Accordingly, in other embodiments, the present invention provides for a method of treating sepsis, traumatic/hemorrhagic shock and inflammation by inhibiting ALR. | 04-16-2015 |
20150111223 | METHOD FOR EVALUATION OF PRESENCE OF OR RISK OF COLON TUMORS - The disclosed methods are used to predict or assess colon tumor status in a patient. They can be used to determine nature of tumor, recurrence, or patient response to treatments. Some embodiments of the methods include generating a report for clinical management. The methodology provided herein is intended to detect technical variations and to allow for data normalization and enhance signal detection and build predictive proteins profiles of disease status and response. | 04-23-2015 |
20150118690 | BIOLOGICAL ASSAY SAMPLE ANALYZER - A sample analyzer has an illuminator for illuminating an assay sample to cause luminescence, and a support for a sample vessel containing the assay sample. The support is adapted to position the assay sample proximate the illuminator. A detector is positioned along an optical axis extending from the illuminator, through the positioned assay sample, to the detector, so as to detect the luminescence from the assay sample. A reflector is removably disposed between the illuminator and the assay sample so as to reflect a portion of the luminescence back through the positioned assay sample toward the detector. | 04-30-2015 |
20150118691 | SIMULTANEOUS MEASUREMENT OF THROMBIN GENERATION AND CLOT STRENGTH IN PLASMA AND WHOLE BLOOD - A method for the simultaneous measurement of proteolylic enzyme generation and clot strength in plasma or whole blood or any appropriate biological sample derived from blood. The measurement method encompasses the use of a detectable substrate which includes a moiety that can be released upon reaction with the targeted proteolytic enzyme, and elements for measurement of an increase in viscosity of clot strength. | 04-30-2015 |
20150125876 | BIOMARKER FOR COGNITIVE DYSFUNCTION DISEASES, AND METHOD FOR DETECTION OF COGNITIVE DYSFUNCTION DISEASES USING THE BIOMARKER - The present invention aims to provide methods to detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence, or in quantity between non-cognitive impairment and patients with cognitive impairment and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect cognitive impairment including Alzheimer disease or mild cognitive impairment. Specifically, a biomarker for diagnosis of psychiatry disease or cognitive impairment comprising protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of amino acid sequence expressed by SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25 and selected from the group of partial peptide in these proteins consisting of amino acid sequence expressed by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 27. And further aims to provide diagnostic method using these biomarker. | 05-07-2015 |
20150132769 | BIOMARKER FOR DETERMINING MITOCHONDRIAL DAMAGE IN FRIEDREICH'S ATAXIA - Compositions and methods for screening for a disease or a disorder associated with a deficiency in frataxin in a subject using biomarkers for diseases or disorders associated with a deficiency in frataxin are disclosed. The compositions and methods include determining the acetylation status of mito-chondrial proteins. Also disclosed are methods of detecting progression of a disease or a disorder associated with a deficiency in frataxin in a subject and methods of monitoring effectiveness of a therapy for diseases or disorders associated with a deficiency in frataxin. | 05-14-2015 |
20150132770 | PREGNANCY-ASSOCIATED PLASMA PROTEIN-A2 (PAPP-A2) POLYNUCLEOTIDES - The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences, antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described. | 05-14-2015 |
20150132771 | COMBINATION OF SPLA2 ACTIVITY AND LP(A) CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT - The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: —measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) s PLA2 activity and b) Lipoprotein(a), —combining said measurements, the combined value of s PLA2 activity and Lp(a) being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event. | 05-14-2015 |
20150132772 | Determination of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Diagnostic Marker for Renal Disorders - Methods for diagnosing renal disorders by measuring human neutrophil gelatinase-associated lipocalin (NGAL) are provided. | 05-14-2015 |
20150140573 | ASSAYS FOR DETECTING GLUCOSIDASE ACTIVITY - The present invention relates to a method of detecting α-(1→6)-glucosidase activity in a sample. The method is for example useful for determining the limit dextrinase activity in a sample. The method involves use of an oligosaccharide substrate of the formula X-(glucoside)n-*(glucoside)m-Z—Y, where X is a blocking group, -* is a α-(1→6)-glucosidic linkage and Y is a detectable label. Upon cleavage of the α-(1→6)-glucosidic linkage, the detectable label is released and thus the α-(1→6)-glucosidase activity can be determined. The invention also relates to the oligosaccharide substrate per se. | 05-21-2015 |
20150147762 | METHOD FOR DETECTING CANCER, AND ANTIBODY CAPABLE OF RECOGNIZING PANCREATIC RIBONUCLEASE 1 - Pancreatic cancer can be detected using a monoclonal antibody which binds to pancreatic RNase 1 when a site in pancreatic RNase 1 capable of being modified with an N-glycan chain is not linked to a glycan chain, but which does not bind to pancreatic RNase 1 when an N-glycan chain is linked to the site. Also provided is a monoclonal antibody which can bind to pancreatic RNase 1 simultaneously with the binding of the aforementioned antibody to pancreatic RNase 1, and determining the ratio of A to B using the antibodies, wherein A represents the amount of the site located in the pancreatic RNase 1 capable of being modified with an N-glycan chain, wherein an N-glycan chain is linked or not linked to the site; and B represents the amount of the site located in the pancreatic RNase 1 capable of being modified with an N-glycan chain. | 05-28-2015 |
20150293104 | EPITHELIAL OVARIAN CANCER DIFFERENTIATION MARKER - An object of the present invention is to develop and provide an epithelial ovarian cancer diagnosis marker with which epithelial ovarian cancer can be detected inexpensively, conveniently, and low invasively with high accuracy, and a method for determining the presence or absence of epithelial ovarian cancer using the marker. The present invention provides a glycoprotein having a glycan-linked asparagine residue at a particular site of the glycoprotein secreted from an epithelial ovarian cancer cell, or a fragment thereof having the glycan as an epithelial ovarian cancer diagnosis marker. The present invention also provides a method for determining the presence or absence of epithelial ovarian cancer using the glycoprotein. | 10-15-2015 |
20150301050 | IMMUNO-BASED RETARGETED ENDOPEPTIDASE ACTIVITY ASSAYS - The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed. | 10-22-2015 |
20150323535 | METHOD FOR DIAGNOSING NEURODEGENERATIVE DISEASES - The present invention relates to a method for diagnosing, in vitro, a neurodegenerative disease in an individual, in which: the level of the double-stranded RNA-dependent protein kinase (PKR) in a sample of cerebrospinal fluid from the individual is determined; it is deduced therefrom whether the individual is suffering from a neurodegenerative disease. | 11-12-2015 |
20150329896 | N-END RULE PROTEASE ACTIVITY INDICATION METHODS AND USES THEREOF - A cell based assay for detection for protease activity is disclosed. In the assay a cell is engineered to express a protease substrate with at least one label, preferably on its C-terminus. Cleavage of the substrate by the protease that recognizes it results in a C-terminal fragment and a N-terminal fragment, where the fragment having the label is subject to ubiquitin proteasome degradation. The assay measures the disappearance of the label due to degradation of the fragment to which it is attached. A cell free assay is also described for detection of protease activity. In the cell free assay, the protease substrate is expressed in a solution that includes the elements of the ubiquitin proteasome pathway for degradation of the fragment. The assay measures the disappearance of the label attached to the fragment that results from cleavage by the protease. | 11-19-2015 |
20150330976 | METHOD FOR THE DETECTION AND QUANTITATION OF BIOMARKERS - The invention provides a method for detecting the presence or absence of a biomarker in a biological sample at a very low concentration comprising the steps of (a) contacting the biological sample with a capture binding sequence immobilized on a surface, (b) providing a conjugate comprising a detection binding sequence-glucose oxidase, (c) contacting the surface with the detection binding sequence-glucose oxidase conjugate, (d) separating any unbound detection binding sequence-glucose oxidase conjugate from the surface, (e) incubating the resulting surface with a glucose solution and a mixture comprising gold nanoparticles and a gold salt, wherein the gold nanoparticles have an initial particle size of about 5 nm, and (f) observing any change in color of the mixture. The invention also provides a method for diagnosing the presence of a prostate cancer biomarker in a subject and a kit for detecting or quantifying a biomarker in a biological sample. | 11-19-2015 |
20150338409 | Markers for Abnormal Cells - The present invention relates to methods of determining the presence or absence of abnormal lymphoid cells or abnormal myeloid cells in a cell sample, with the methods comprising subjecting the cell sample to conditions that will activate any inactive matriptase present in the cell sample and measuring the levels of activated matriptase in the cell sample. Once measured, these levels can then be compared to control levels of active matriptase to determine if the cell sample has elevated levels of activated matriptase over control levels of active matriptase. An elevation in the levels of activated matriptase in the cell sample is indicative that the cell sample contains abnormal lymphoid cells or abnormal myeloid cells. | 11-26-2015 |
20150355176 | IMMUNOASSAY METHOD LESS AFFECTED BY IMPURITIES - An object of the present invention is to provide a method of measuring the amount of a compound containing a sugar chain in a biological sample by a sandwich immunoassay method using a labeled lectin, which method is suitable for reduction of noise originating from impurities and determination of the exact amount of a target compound. | 12-10-2015 |
20150361405 | HIGH LEVEL EXPRESSION OF RECOMBINANT TOXIN PROTEINS - The present invention relates to the field of recombinant toxin protein production in bacterial hosts. In particular, the present invention relates to production processes for obtaining high levels of a recombinant CRM197, Diphtheria Toxin, Pertussis Toxin, Tetanus Toxoid Fragment C, Cholera Toxin B, Cholera holotoxin, and | 12-17-2015 |
20150369809 | TARGETING PHOSPHOFRUCTOKINASE AND ITS GLYCOSYLATION FORM FOR CANCER - The present invention relates to methods of treating cancer, suppressing or inhibiting tumorigenesis, tumor growth or cancer progression, and suppressing or inhibiting cancer cells from altering cellular metabolism in favor of cancerous growth. Also provided are compositions comprising an agent that decreases glycosylation of phosphofructokinase 1 or increases phosphofructokinase 1 expression or activity. | 12-24-2015 |
20160011196 | ASSAY TO DETERMINE LRRK2 ACTIVITY IN PARKINSON'S DISEASE | 01-14-2016 |
20160018411 | USE OF SEPRASE FOR DIFFERENTIAL DIAGNOSIS OF ACUTE DYSPNEA - The present invention relates to a method for differentiating in a patient who suffers from acute shortness of breath (acute dyspnea) between pulmonary disease and cardiac disease. The method is based on measuring the levels of seprase and of a cardiac marker in a sample from said patient. Further envisaged are kits and devices adapted to carry out the method of the present invention. | 01-21-2016 |
20160032264 | PREPARATIONS AND METHODS FOR TREATING MALIGNANCIES - Disclosed are therapeutic formulations comprising antibodies against the PEKRAEKIWK (SEQ ID NO:1) epitope of the monomeric isoform of A-protein and a physiologically acceptable carrier. Methods for the treatment of subjects using these therapeutic formulations are also disclosed. | 02-04-2016 |
20160033490 | Linked Peptide Fluorogenic Biosensors - Biosensors, compositions comprising biosensors, methods of producing biosensors, and methods of using biosensors are disclosed. The biosensors comprise a fluorogen-activating peptide and a blocking peptide. The blocking peptide associates with the fluorogen-activating peptide thereby blocking an active domain of the fluorogen-activating peptide. The fluorogen-activating peptide and blocking peptide are covalently linked in certain embodiments through a peptide linker. The peptide linker may contain an amino acid sequence that is specifically recognized as a modification substrate by a cognate enzyme. The fluorogen-activating peptide and the blocking peptide at least partially disassociate when the linker is modified by a cognate enzyme, thereby allowing the fluorogen-activating peptide to bind a cognate fluorogen and modulate a fluorescence signal. | 02-04-2016 |
20160047810 | METHODS TO OBTAIN A NOVEL CLASS OF GRAM NEGATIVE BACTERIA ANTIBIOTICS WHICH TARGET AN UNKNOWN CELL DIVISION ASSOCIATED PROTEIN LOP1 - The present invention relates to methods to identify substances which affect bacterial cell division by interfering with the function of LOP1, comprising bringing into contact a purified protein selected from the group: FtsZ, FtsQ, FtsL, FtsI and FtsN; with purified LOP1 protein and then assaying the formation of complexes between LOP1 and the selected purified protein in the presence and absence of a substance to be tested and then selecting substances from step b) which affect the formation of complexes when present. The present invention also relates to inhibitors of the activity and expression of LOP 1. | 02-18-2016 |
20160053283 | Methods and Compositions for Generating Stable Transfected Cells - Methods and compositions are provided involving high producing cell lines. Embodiments concern efficient methods for screening for such cell lines and for creating such cell lines. These cell lines can be used to create large amounts of protein. To quickly generate large quantity of recombinant proteins or vaccines for both pre-clinical study and clinical trials, almost all drug development will face the same challenging obstacle of rapidly generating a high stable producer. Developing and identifying a stable cell line is a critical part of biopharmaceutical development. | 02-25-2016 |
20160054319 | METHOD FOR DETECTING TRICHOPHYTONS AND ASSOCIATED DISEASES - A method is described for detecting the presence of at least one | 02-25-2016 |
20160077098 | RECOVERY OF ASPARTYL (ASPARAGINYL) BETA HYDROXYLASE (HAAH) FROM AN EXOSOMAL FRACTION OF HUMAN SERA FROM CANCER PATIENTS - The present invention encompasses methods of detecting exosomes comprising Aspartyl-[Asparaginyl]-β-hydroxylase (HAAH). The present invention contemplates is further directed to methods diagnosing cancer by identifying exosomes comprising HAAH. | 03-17-2016 |
20160077099 | NONLINEAR OPTICAL DETECTION OF MOLECULES COMPRISING AN UNNATURAL AMINO ACID POSSESSING A HYPERPOLARIZABILITY - A system for making molecules, and proteins in particular, suitable for detection by a surface-selective nonlinear optical technique. A first use of the invention is for determining a protein's structure in real space and real time. A second use of the invention is to detect a protein or its activity (conformational change). A third use of the invention is for drug screening. A further aspect of the present invention is measuring probe tilt angle orientation in an oriented protein. | 03-17-2016 |
20160083712 | CSN5 POLYPEPTIDES AND USES THEREOF FOR SCREENING THERAPEUTIC AGENTS - The present invention relates to mutated CSN5 polypeptides and their use in a method of screening modulators of CSN5 activity that could be used as therapeutic agents. | 03-24-2016 |
20160097775 | METHODS AND KITS FOR DETECTING MISFOLDED PROTEINS - Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia. | 04-07-2016 |
20160103133 | METHOD FOR DETERMINING PROGNOSIS OF CANCER - The present invention relates to a method for determining prognosis of cancer in a subject, which comprises the step of detecting phosphorylation of a tyrosine residue at position 2681 of TRIO in a sample obtained from the subject. | 04-14-2016 |
20160109430 | METHODS FOR DRUG DISCOVERY - The present invention provides assays for identifying drug candidates that regulate cellular senescence. In particular, the present invention relates to the use of ATRX foci as a biomarker for determining whether one or more drug candidates regulate senescence in a cell line. In one non-limiting embodiment, the present invention provides assays to identify compounds that can be used in a combinatorial cancer treatment. The present invention is based, at least in part, on the discovery that the number of ATRX foci increases in cells that undergo senescence. Accordingly, in non-limiting embodiments, the present invention provides for assays and kits for identifying drug combinations that may be useful in treating subject that have cancer and for identifying compounds that may be useful in treating age-related diseases. | 04-21-2016 |
20160116472 | BIOMARKERS FOR STROKE DIAGNOSIS - Disclosed herein are assays and methods of diagnosing strokes using glycogen phosphorylase-BB (GPBB) as the biomarker. Specifically, assays and methods are described herein for distinguishing an ischemic brain condition from myocardial infarction, or distinguishing an ischemic brain condition from stroke mimics, or distinguishing an ischemic stroke from a hemorrhagic stroke. The diagnostic results offered by these assays and methods allow early and appropriate treatment for the specific condition. Also disclosed is a method to identify whether a subject having an ischemic stroke exhibits salvageable brain tissue. | 04-28-2016 |
20160123982 | METHODS FOR ASSAYING JAK2 ACTIVITY IN RED BLOOD CELLS AND USES THEREOF - The present invention relates to methods for assaying JAK2 activity in a red blood cell. The present invention also relates to methods for diagnosing myeloproliferative neoplasm. | 05-05-2016 |
20160131666 | BIOMARKERS FOR INFLAMMATORY RESPONSE - An in-vitro method for the prediction, prognosis and/or diagnosis of an inflammatory response associated with a condition or disease such as schizophrenia in a subject, the method comprising determining in a sample of a subject the level of 25-hydroxy vitamin D3, preferably in combination with the level of least one biomarker wherein the at least one biomarker is selected from innate chemokine (IL-8) and matrix metalloproteinase (MMP-9); and comparing the levels of said 25-hydroxy vitamin D3 and at least one biomarker to a control level of 25-hydroxy vitamin D3 and the at least one biomarker respectively in order to determine a positive or negative prediction, prognosis and/or diagnosis of said inflammatory response indicating an associated condition or disease, such as schizophrenia. | 05-12-2016 |
20160146817 | DOT1L PROBES - The present invention relates to compound that bind Histone H3-lysine79 (H3K79) methyl transferase (DOTIL). The disclosed compounds are useful as for assessing the activity of DOTIL and for identifying inhibitors of DOTIL. Described herein are probes useful for both assessing the activity of DOTIL and identifying inhibitors of DOTIL. These probes can be used in various assays, including Amplified Luminescent Proximity Homogeneous Assays (“ALPHA” assays), Differential Scanning Fluorimetry (DFS) Assay, and Fluorescence Polarization (FP) assays used for high-throughput screening (HTS) for small molecule drug discovery. The compounds can also be used as a pull down agent for target identification. | 05-26-2016 |
20160153878 | Device and Methods | 06-02-2016 |
20160165878 | SEMINAL PLASMA COMPLEX QUALITY CONTROL MATERIAL, PREPARATION METHOD AND KIT THEREOF | 06-16-2016 |
20160169892 | MONOCLONAL ANTIBODIES, HYBRIDOMA CELL LINES, METHODS AND ASSAYS FOR DETECTING FUNGAL PHYTASE | 06-16-2016 |
20160169893 | PCSK9 Function Assay | 06-16-2016 |
20160178627 | System and Method for Identification and Characterization of Transglutaminase Species | 06-23-2016 |
20160195534 | Enzyme Detection Device | 07-07-2016 |
20160200832 | ASSAY TO DETECT HUMAN DPP-4 | 07-14-2016 |
20160377617 | DETECTION OF THE DEGREE OF EXPOSURE TO CHEMICAL WARFARE NERVE AGENTS AND ORGANOPHOSPHATE PESTICIDES WITH LATERAL FLOW ASSAYS - A sample analysis device used to detect a level of exposure of organophosphorus within a sample comprising a sample collection pad, at least one conjugate zone comprising an anti-analyte antibody that is conjugated with a reporter label, and a control antibody that is conjugated with a reporter label, a blocking and/or test zone comprising an immobilized nanoparticle or other molecule that captures the Organophosphate-bound analyte, a second blocking and/or test zone comprising an immobilized antibody that binds to the unbound analyte and an optional third blocking and/or control zone comprising an immobilized antibody that binds to the control molecule wherein, when the analyte is bound by the Organophosphate in the sample it will bind to the first test line, and if the analyte is “free’ from the Organophosphate it will bind to the second test line, and the control antibody will bind to the control line. | 12-29-2016 |
20160377618 | PCSK9 QUANTIFICATION BY IMMUNODETECTION - The present disclosure relates to, among other things, systems for detecting the level of specific lipoprotein-bound level of PCSK9, and optionally free PCSK9, lipoprotein or portions thereof and/or PCSK9 unbound lipoproteins present in a biological sample. The present invention also relates to methods of assessing the level of specific lipoprotein-bound level of PCSK9, and optionally free PCSK9, Apo B and/or PCSK9 unbound lipoproteins present in a biological sample, determining whether a subject is at increased risk for cardiovascular disease and monitoring the risk for developing cardiovascular disease. | 12-29-2016 |
20160377619 | ANTI-KRS MONOCLONAL ANTIBODY AND USE THEREOF - The present invention relates to an anti-lysyl-tRNA synthetase (KRS) antibody selectively binding to KRS, and a use thereof and, more specifically, to an antibody binding to human KRS or a fragment thereof, a method for producing the same, and a composition containing the same for diagnosing cancer, autoimmune diseases or inflammatory diseases. The antibody or fragment thereof of the present invention specifically binds to human KRS, and enables KRS detection and inhibition due to the absence of cross-linkage reactivity with the other proteins including the same ARS family, and thus the antibody or fragment thereof can be used to detect KRS and diagnose KRS-related diseases, i.e., cancer, autoimmune diseases or inflammatory diseases. | 12-29-2016 |
20170234894 | Noninvasive Body Fluid Stress Sensing | 08-17-2017 |
20190145974 | COMPOSITIONS AND METHODS FOR IMPROVED CELL-BASED BOTULINUM NEUROTOXIN ASSAYS | 05-16-2019 |
20090263866 | Industrial-scale Serum-free Production of Recombinant Factor VII in Mammalian Cells - The invention provides a method for industrial-scale production of FVII polypeptides in mammalian cell culture free of animal-derived components. | 10-22-2009 |
20110171689 | ARTIFICIAL IMMUNE SYSTEM: METHODS FOR MAKING AND USE - The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system. | 07-14-2011 |
20150376293 | Methods of Producing Antibodies Specific for p95 - The invention provides methods of measuring and/or quantifying the presence and/or amount of p95 and/or p95 complex in a sample. The invention also provides antibodies specific for p95, and methods of making such antibodies. | 12-31-2015 |
20160039925 | CELL CULTURE METHODS TO REDUCE ACIDIC SPECIES - The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of acidic species expressed by host cells, as well as to compositions and processes for controlling the amount of acidic species present in purified preparations. | 02-11-2016 |
20160160258 | MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS - A method for producing a clone of an immortalised human B memory lymphocyte, comprising the step of transforming human B memory lymphocytes using Epstein Barr virus (EBV) in the presence of a polyclonal B cell activator. The method is particularly useful in a method for producing a clone of an immortalised human B memory lymphocyte capable of producing a human monoclonal antibody with a desired antigen specificity, comprising the steps of: (i) selecting and isolating a human memory B lymphocyte subpopulation; (ii) transforming the subpopulation with Epstein Barr virus (EBV) in the presence of a polyclonal B cell activator; (iii) screening the culture supernatant for antigen specificity; and (iv) isolating an immortalised human B memory lymphocyte clone capable of producing a human monoclonal antibody having the desired antigen specificity. | 06-09-2016 |